0001826667
false
--12-31
0001826667
2023-08-10
2023-08-10
0001826667
dei:FormerAddressMember
2023-08-10
2023-08-10
0001826667
us-gaap:CommonStockMember
2023-08-10
2023-08-10
0001826667
us-gaap:WarrantMember
2023-08-10
2023-08-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 10, 2023
TRISALUS
LIFE SCIENCES, INC.
(Exact name of registrant as specified in its
charter)
Delaware |
|
001-39813 |
|
85-3009869 |
(State or Other Jurisdiction of
Incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification
No.) |
|
|
|
6272
W. 91st Ave., Westminster,
Colorado |
|
80031 |
|
(Address of principal executive offices) |
|
(Zip Code) |
|
|
|
|
|
|
|
(888)
321-5212
(Registrant’s telephone number, including
area code)
MedTech
Acquisition Corporation
48
Maple Avenue
Greenwich,
CT
06830
(Former name or former address, if changed since
last report.)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
symbol(s) |
|
Name of each exchange
on which registered |
Common
Stock, $0.0001 par value per share |
|
TLSI |
|
Nasdaq
Global Market |
Warrants,
each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 per share |
|
TLSIW |
|
Nasdaq
Global Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
INTRODUCTORY NOTE
Merger
TriSalus Life Sciences, Inc. (formerly known
as MedTech Acquisition Corporation (“MTAC”)), a Delaware corporation (“New TriSalus” or the “Company”),
previously entered into that certain Agreement and Plan of Merger, dated as of November 11, 2022, as amended by that certain First
Amendment to Agreement and Plan of Merger, dated as of April 4, 2023, the Second Amendment to Agreement and Plan of Merger, dated
as of May 13, 2023, and the Third Amendment to Agreement and Plan of Merger, dated as of July 5, 2023 (as amended, the “Merger
Agreement”), with MTAC Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of MTAC (“Merger Sub”)
and TriSalus Operating Life Sciences, Inc. (formerly known as TriSalus Life Sciences, Inc.), a Delaware corporation (“Legacy
TriSalus”). In connection with the business combination contemplated by the Merger Agreement,
MTAC filed a registration statement on Form S-4 (File No. 333-269138) (as amended, the “Registration Statement”)
with the U.S. Securities and Exchange Commission (the “SEC”). On July 18, 2023, the Registration Statement was declared
effective by the SEC and on July 18, 2023, MTAC filed a Definitive Proxy Statement/Prospectus (the “Proxy Statement/Prospectus”).
On August 10, 2023 (the “Closing Date”),
as contemplated in the Merger Agreement and described in the section titled “Proposal 1 – The Business Combination Proposal”
beginning on page 133 of the Proxy Statement/Prospectus, New TriSalus consummated the merger transactions contemplated by the Merger
Agreement, following the approval by MTAC’s stockholders at a special meeting of stockholders held on August 8, 2023 (the “MTAC
Stockholder Meeting”), whereby Merger Sub merged with and into Legacy TriSalus with the separate corporate existence of Merger Sub
ceasing (the “Merger” and, together with the other transactions contemplated by the Merger Agreement, the “Business
Combination”). The closing of the Business Combination is herein referred to as “the Closing.” In connection with the
consummation of the Merger on the Closing Date, MTAC changed its name from MedTech Acquisition Corporation
to TriSalus Life Sciences, Inc. and Legacy TriSalus changed its name from TriSalus Life Sciences, Inc. to TriSalus Operating
Life Sciences, Inc.
Immediately prior to the effective time of the
Merger, each share of preferred stock of Legacy TriSalus (“Legacy TriSalus Preferred Stock”) converted into shares of common
stock of Legacy TriSalus (“Legacy TriSalus Common Stock”) in accordance with the Amended and Restated Certificate of Incorporation
of Legacy TriSalus (such conversion, the “Legacy TriSalus Preferred Stock Conversion”) and each warrant of Legacy TriSalus
that was unexercised and unexpired was net exercised into Legacy TriSalus Common Stock (the “Legacy TriSalus Warrant Exercise”).
As a result of the Merger and upon the Closing,
among other things, (1) all outstanding shares of Legacy TriSalus Common Stock as of immediately prior to the Closing (including
Legacy TriSalus Common Stock resulting from the Legacy TriSalus Preferred Stock Conversion and Legacy TriSalus Warrant Exercise), were
exchanged at an exchange ratio of 0.02471853 (the “Exchange Ratio”) for an aggregate of 21,999,886 shares of common stock,
par value $0.0001 per share, of New TriSalus (“New TriSalus Common Stock”), (2) each option to purchase shares of Legacy
TriSalus Common Stock, whether vested or unvested, converted into an option to purchase shares of New TriSalus Common Stock (“New
TriSalus Assumed Option”), with each New TriSalus Assumed Option subject to the same terms and conditions as were applicable to
the original Legacy TriSalus option and with the resulting exercise price and number of shares of New TriSalus Common Stock purchasable
based on the Exchange Ratio and other terms contained in the Merger Agreement and (3) each Legacy TriSalus restricted stock unit
award converted into a restricted stock unit award to receive shares of New TriSalus Common Stock (“New TriSalus Assumed RSU Award”),
with each New TriSalus Assumed RSU Award subject to the same terms and conditions as were applicable to the original Legacy TriSalus
restricted stock unit award, and with the number of shares of New TriSalus Common Stock to which the New TriSalus Assumed RSU Award relates
being based on the Exchange Ratio and other terms contained in the Merger Agreement.
Unless the context otherwise requires, “we,”
“us,” “our” and the “Company” refer to New TriSalus and its consolidated subsidiaries following the
Closing and references to “MTAC” refer to MedTech Acquisition Corporation at or prior to the Closing. All references herein
to the “New TriSalus Board” refer to the board of directors of the Company after giving effect to the Business Combination.
In connection with the MTAC Stockholder Meeting
and the Business Combination, the holders of 890,499 shares of MTAC’s Class A common stock, par value $0.0001 per share (the “Class
A Common Stock”), exercised their right to redeem their shares for cash at a redemption price of approximately $10.58 per share,
for an aggregate redemption amount of approximately $9.4 million. Upon the Closing, the Company received approximately $42.9 million
in gross proceeds, comprising approximately $2.7 million from the MTAC trust account and $40,150,020 from the PIPE Financing (as defined
below).
At the Closing, MTAC’s
public units were automatically separated into their component securities upon consummation of the Business Combination and, as a result,
no longer trade as a separate security and were delisted from The Nasdaq Stock Market LLC (“Nasdaq”). On the business day
following the Closing, there were 26,316,681 issued and outstanding shares of New TriSalus Common Stock.
The foregoing description of the Merger Agreement
is a summary only and is qualified in its entirety by the full text of the Merger Agreement (including amendments), copies of which are
attached hereto as Exhibits 2.1, 2.2, 2.3 and 2.4, which are incorporated herein by reference.
Capitalized terms used in this Current Report
on Form 8-K but not otherwise defined herein shall have the meanings ascribed to those terms in the Proxy Statement/Prospectus.
PIPE Financing
On June 7, 2023 and July 4, 2023, MTAC
entered into separate subscription agreements (each, a “Subscription Agreement”) with certain investors (the “Preferred
Stock PIPE Investors”) pursuant to which MTAC agreed to issue and sell to the Preferred Stock PIPE Investors, in private placements
to close concurrently with the Closing Date, an aggregate of 4,015,002 shares of Series A Convertible Preferred Stock of the Company
(the “PIPE Shares”), for a purchase price of $10.00 per share and an aggregate purchase price of $40,150,020. Pursuant to
the Subscription Agreements, the Company gave certain registration rights to the Preferred Stock PIPE Investors with respect to the shares
of common stock that are issuable upon conversion of the PIPE Shares and agreed to file, not later than 30 days after the Closing Date,
a registration statement to register the resale of the PIPE Shares. The sale of PIPE Shares was consummated concurrently with the Closing
(the “PIPE Financing”). A description of the Subscription Agreements is included in the Proxy Statement/Prospectus in the
section entitled “Proposal 1 – The Business Combination Proposal – Certain Related Agreements – Subscription
Agreements” beginning on page 153 of the Proxy Statement/Prospectus.
The foregoing description of the Subscription
Agreements is a summary only and is qualified in its entirety by the full text of the forms of the Subscription Agreements, copies of
which are attached hereto as Exhibit 10.2 and Exhibit 10.3, and are incorporated herein by reference.
Item 1.01. Entry into a Material Definitive Agreement.
Amended and Restated Registration Rights Agreement
On the Closing Date, in connection with the consummation
of the Business Combination and as contemplated by the Merger Agreement, New TriSalus, MedTech Acquisition Sponsor LLC (the “Sponsor”),
the members of the Sponsor, and certain former stockholders of Legacy TriSalus entered into an amended and restated registration rights
agreement (the “Amended and Restated Registration Rights Agreement”). Pursuant to the Amended and Restated Registration Rights
Agreement, the Company agreed to file, not later than 45 days after the Closing Date, a registration statement to register for resale,
pursuant to Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”), certain New TriSalus securities
that are held by the parties thereto (the “Registrable Securities”). Pursuant to the Amended and Restated Registration Rights
Agreement, subject to certain requirements and customary conditions, the Company also grants piggyback registration rights and demand
registration rights to the parties thereto, will pay certain expenses related to such registration and will indemnify the parties thereto
against certain liabilities related to such registration. The Amended and Restated Registration Rights Agreement will terminate with respect
to any party thereto, on the date that such party no longer holds any Registrable Securities. The terms of the Amended and Restated Registration
Rights Agreement are described in the Proxy Statement/Prospectus in the section entitled “Proposal 1 – The Business Combination
Proposal – Certain Related Agreements – Amended and Restated Registration Rights Agreement” on page 152 of
the Proxy Statement/Prospectus.
The foregoing description of the Amended and Restated
Registration Rights Agreement is qualified in its entirety by the full text of the Amended and Restated Registration Rights Agreement,
a copy of which is attached hereto as Exhibit 10.1 and incorporated herein by reference.
Indemnification Agreements
On the Closing Date, the Company entered into
indemnification agreements with all of the Company’s directors and executive officers. These indemnification agreements require the Company
to indemnify its directors and executive officers for certain expenses, including attorneys’ fees, judgments, fines and settlement amounts
incurred by a director or executive officer in any action or proceeding arising out of their services
as one of the Company’s directors or executive officers or any other company or enterprise to which the person provides services
at the Company’s request.
The foregoing description of the indemnification
agreements is not complete and is subject to and qualified in its entirety by reference to the form of indemnification agreement, a copy
of which is attached hereto as Exhibit 10.25 and the terms of which are incorporated by reference herein.
Sponsor Support Agreement
In connection with the execution of the Merger
Agreement, MTAC entered into a sponsor support agreement (the “Sponsor Support Agreement”) with the Sponsor, Legacy TriSalus
and MTAC’s directors and officers. Pursuant to the Sponsor Support Agreement, the Sponsor and MTAC’s directors and officers
(the “Sponsor Holders”), among other things, agreed to vote all of their shares of capital stock in favor of the approval
of the Business Combination. In addition, the Sponsor Support Agreement provides that 3,125,000 of the shares of New TriSalus Common Stock
held by the Sponsor immediately after the Closing Date (such shares, the “Sponsor Earnout Shares”) became unvested and subject
to potential forfeiture if certain triggering events are not achieved prior to the fifth anniversary of the Closing Date (the “Earnout
Period”). Pursuant to the Sponsor Support Agreement, (i) 25% of the shares of New TriSalus Common Stock held by the Sponsor
Holders will only vest if, during the five year period following the Closing, the volume weighted average price of New TriSalus Common
Stock equals or exceeds $15.00 for any twenty trading days within a period of thirty consecutive trading days, (ii) 25% of the shares
of New TriSalus Common Stock held by the Sponsor Holders will only vest if, during the five year period following the Closing, the volume
weighted average price of New TriSalus Common Stock equals or exceeds $20.00 for any twenty trading days within a period of thirty consecutive
trading days, (iii) 25% of the shares of New TriSalus Common Stock held by the Sponsor Holders will only vest if, during the five
year period following the Closing, the volume weighted average price of New TriSalus Common Stock equals or exceeds $25.00 for any twenty
trading days within a period of thirty consecutive trading days; and (iv) 25% of the shares of New TriSalus Common Stock held by
the Sponsor Holders will only vest if, during the five year period following the Closing, the volume weighted average price of New TriSalus
Common Stock equals or exceeds $30.00 for any twenty trading days within a period of thirty consecutive trading days. Any such shares
held by the Sponsor Holders that remain unvested after the fifth anniversary of the Closing will be forfeited.
The foregoing description of the Sponsor Support
Agreement does not purport to be complete and is qualified in its entirety by the terms and conditions of the Sponsor Support Agreement,
the form of which is attached as Exhibit 10.4 to this Current Report on Form 8-K and is incorporated herein by reference.
TriSalus Support Agreements
In connection with the execution of the Merger
Agreement, certain of Legacy TriSalus’ stockholders entered into support agreements (collectively, the “TriSalus Support Agreements”)
with MTAC and Legacy TriSalus, pursuant to which the such Legacy TriSalus stockholders each agreed, among other things, to (i) consent
to, and vote to approve and adopt, the Merger Agreement and the Business Combination, subject to certain customary exceptions, (ii) waive
any dissenters’ or approval rights under applicable law in connection with the Business Combination, and (iii) not transfer,
subject to certain permitted exceptions, any of such stockholders’ shares of TriSalus capital stock prior to the Closing Date.
The foregoing description of the TriSalus Support
Agreements does not purport to be complete and is qualified in its entirety by the terms and conditions of the TriSalus Support Agreements,
the form of which is attached as Exhibit 10.5 to this Current Report on Form 8-K and is incorporated herein by reference.
Lock-Up Agreements
In connection with the Business Combination, MTAC,
the Sponsor and certain stockholders of Legacy TriSalus entered into lockup agreements pursuant to which such stockholders
agreed, subject to certain customary exceptions, to not transfer any shares of New TriSalus Common Stock held by them prior to the earliest
of (x) the date that is 365 days after the Closing Date, (y) the date following the Closing Date on which the last sales
price of New TriSalus Common Stock equals or exceeds $12.00 per share, subject to adjustment as provided therein, for any 20 trading
days within any 30-consecutive-day trading period commencing at least 150 days after the Closing Date, and (z) the date following
the Closing Date on which the New TriSalus consummates a liquidation, merger, tender offer, or similar transaction resulting in all of
its stockholders having the right to exchange their shares of New TriSalus Common Stock for cash, securities, or other property. The
Sponsor and its members are subject to a lockup on substantially similar terms pursuant to the terms of a letter Agreement with
MTAC, dated December 17, 2020 (the “Letter Agreement”).
The foregoing descriptions of the Letter Agreement
and the Lock-Up Agreements do not purport to be complete and are qualified in its entirety by the terms and conditions of the Letter
Agreement and Lock-Up Agreements, the forms of which are attached as Exhibits 10.6 and 10.7 to this Current Report on Form 8-K, respectively
and are incorporated herein by reference.
Item 2.01. Completion of Acquisition or Disposition of Assets.
The disclosure set forth in the “Introductory
Note” above is incorporated by reference into this Item 2.01.
FORM 10 INFORMATION
Prior to the Closing, the Company was a shell
company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) with no operations,
formed as a vehicle to effect a business combination with one or more operating businesses. Item 2.01(f) of Form 8-K states
that if the registrant was a shell company, as the Company was immediately before the Merger, then the registrant must disclose the information
that would be required if the registrant were filing a general form for registration of securities on Form 10. Accordingly, the Company
is providing below the information that would be included in a Form 10 if it were to file a Form 10. Please note that the information
provided below relates to the combined company after the consummation of the Business Combination, unless otherwise specifically indicated
or the context otherwise requires.
Cautionary Note Regarding Forward-Looking Statements
This Current Report on Form 8-K and documents
incorporated herein by reference may contain “forward-looking statements” within the meaning of Section 27A of the Securities
Act and Section 21E of the Exchange Act. The Company’s forward-looking statements include, but are not limited to, statements
regarding the Company’s or its management team’s expectations, hopes, beliefs, intentions or strategies regarding the future,
including the Company’s expectations regarding the timing of Phase 1 more mature efficacy data for its PERIO-01 clinical trial,
the size of any additional study to generate additional efficacy data for the PERIO-01 program, the planned timing for the initiation
of Phase 2 trial for its PERIO-01 program, the timing for any potential new drug application submission and any anticipated study with
respect to its development plan for hepatocellular carcinoma. In addition, any statements that refer to projections, forecasts or other
characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,”
“believe,” “continue,” “could,” “estimate,” “expect,” “intends,”
“may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,”
“should,” “would,” “goal” and similar expressions may identify forward-looking statements, but the
absence of these words does not mean that a statement is not forward-looking.
The forward-looking statements contained in this
Current Report on Form 8-K and in documents incorporated herein are based on the Company’s current expectations and beliefs
concerning future developments and their potential effects on us taking into account information currently available to the Company. There
can be no assurance that future developments affecting the Company will be those that the Company has anticipated. These forward-looking
statements involve a number of risks, uncertainties (many of which are difficult to predict and beyond the Company’s control) or
other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking
statements.
As a result of a number of known and unknown risks
and uncertainties, the Company’s actual results or performance may be materially different from those expressed or implied by these
forward-looking statements. Some factors that could cause actual results to differ include:
|
• |
the ability to recognize the anticipated benefits of the Business Combination; |
|
• |
the Company’s projected financial information, business and operating metrics, anticipated growth rate and market opportunity; |
|
• |
the ability to maintain the listing of the New TriSalus Common Stock and the warrants on the Nasdaq Global Market, and the potential liquidity
and trading of such securities; |
|
• |
the risk that the Business Combination disrupts current plans and operations of the Company as a result of the consummation of the Business
Combination; |
|
• |
costs related to the Business Combination; |
|
• |
changes in applicable laws or regulations; |
|
• |
the Company’s ability to raise financing in the future; |
|
• |
the Company’s success in retaining or recruiting, or changes required in, our officers, key employees or directors after the Business
Combination; |
|
• |
the Company’s ability to successfully commercialize any product candidates that it successfully develops and that are approved by
applicable regulatory authorities; |
|
• |
the Company’s expectations for the timing and results of data from clinical trials and regulatory approval applications; |
|
• |
the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; |
|
• |
the Company’s business, operations and financial performance including: |
|
o |
the Company’s history of operating losses and expectations of significant expenses and continuing losses for the foreseeable future; |
|
o |
the Company’s ability to execute its business strategy, including the growth potential of the markets for the Company’s products
and the Company’s ability to serve those markets; |
|
o |
the Company’s ability to grow market share in its existing markets or any new markets it may enter; |
|
o |
the Company’s ability to develop and maintain its brand and reputation; |
|
• |
the Company’s ability to partner with other companies; |
|
• |
the size of the addressable markets for the Company’s product candidates; |
|
• |
the Company’s expectations regarding its ability to obtain and maintain intellectual property protection and not infringe on the
rights of others; |
|
• |
the ability of the Company to manage its growth effectively; |
|
• |
the outcome of any legal proceedings that may be instituted against the Company; and |
|
• |
unfavorable conditions in the Company’s industry, the global economy or global supply chain, including financial and credit market
fluctuations, international trade relations, pandemics, political turmoil, natural catastrophes, warfare (such as the war between Russia
and Ukraine), and terrorist attacks. |
These forward-looking statements are based on
information available as of the date of this Current Report on Form 8-K, and current expectations, forecasts and assumptions, and
involve a number of risks and uncertainties. Accordingly, forward-looking statements in this Current Report on Form 8-K and in any
document incorporated herein by reference should not be relied upon as representing the Company’s views as of any subsequent date,
and the Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date
they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities
laws.
Business and Properties
The business and properties of MTAC and Legacy
TriSalus prior to the Business Combination are described in the Proxy Statement/Prospectus in the sections entitled “MTAC’s
Business” beginning on page 221 and “TriSalus’ Business” beginning on page 236 of the Proxy
Statement/Prospectus, which are incorporated herein by reference.
The following supplemental information supplements
and updates the information set forth in the section entitled “TriSalus’ Business” beginning on page 236
of the Proxy Statement/Prospectus and should be read in conjunction with the Proxy Statement/Prospectus. To the extent the following information
differs from or conflicts with the information contained in the Proxy Statement/Prospectus, the information set forth below shall be deemed
to supersede the respective information in the Proxy Statement/Prospectus.
On July 31, 2023, Legacy TriSalus received written responses (“FDA
Responses”) from the U.S. Food and Drug Administration (the “FDA”) in reference to a Type B meeting request for the
Company’s PERIO-01 clinical program. The FDA acknowledged that preliminary data from the PERIO-01 program suggests a tolerable safety
profile of SD-101 delivered by the Company’s pressure-enabled drug delivery (“PEDD”) method in combination with systemic
checkpoint inhibition in metastatic uveal melanoma patients, and that there were no concerns raised with respect to delivery of SD-101
via PEDD with the TriNav device. The FDA has asked for additional exploration of the optimal SD-101 dose, in a smaller study prior to
proceeding with a registrational trial. The Company currently expects to have Phase 1 more mature efficacy data at the multiple SD-101
doses for its PERIO-01 clinical trial in the second half of 2023. Based on the FDA’s feedback, the Company will move forward with
a 40-50 patient study to generate additional efficacy data to determine the optimal SD-101 dose for the PERIO-01 program. The Company
plans to initiate the Phase 2 trial for its PERIO-01 program to generate the additional efficacy and dose optimization data in 2023; however,
the initiation and timing of such Phase 2 trials and related data milestones are subject to change and dependent on multiple factors,
including interactions with regulatory authorities, enrollment rates, and external events which may impact operations at clinical sites.
As a further result of the FDA Responses, the Company anticipates that a potential new drug application submission with respect
to SD-101 in uveal melanoma with liver metastases is likely to occur beyond 2025, pending Phase 2 efficacy and dose optimization data.
In connection with its development plan for hepatocellular
carcinoma (“HCC”), the Company is also considering a separate study for advanced second line and beyond HCC with SD-101 in
combination with Y90 radioembolization. HCC study prioritization will be based on data expected to be available in the second half of
2023.
Risk Factors
The risks associated with the Company’s
business are described in the Proxy Statement/Prospectus in the section entitled “Risk Factors” beginning on page 50
of the Proxy Statement/Prospectus, which is incorporated herein by reference.
Financial Information
The information set forth in Item 9.01 of this
Current Report on Form 8-K concerning the financial information of MTAC and Legacy TriSalus is incorporated herein by reference.
The unaudited pro forma condensed combined financial information of MTAC and Legacy TriSalus as of and for the six months ended June 30,
2023 and for year ended December 31, 2022 is set forth in Exhibit 99.3 hereto and is incorporated herein by reference.
Management’s Discussion and Analysis of Financial Condition
and Results of Operations
The Management’s Discussion and Analysis
of Financial Condition and Results of Operations of MTAC for the fiscal years ended December 31, 2022 and 2021 is set forth
in the Proxy Statement/Prospectus in the sections entitled “Management’s Discussion and Analysis of Financial Condition
and Results of Operations of MTAC” beginning on page 227 of the Proxy Statement/Prospectus, and are incorporated herein
by reference.
The Management’s Discussion and Analysis
of Financial Condition and Results of Operations of MTAC for the three and six months ended June 30, 2023 and 2022 is set forth in
the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations”
beginning on page 27 of MTAC’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023, filed
with the SEC on August 2, 2023 (“MTAC Q2 Report”), and is incorporated herein by reference.
The Management’s
Discussion and Analysis of Financial Condition and Results of Operations of Legacy TriSalus for the fiscal years ended December 31,
2022 and 2021 is set forth in the Proxy Statement/Prospectus in the sections entitled “Management’s Discussion and Analysis
of Financial Condition and Results of Operations of TriSalus” beginning on page 279 of the Proxy Statement/Prospectus,
and are incorporated herein by reference.
The Management’s
Discussion and Analysis of Financial Condition and Results of Operations of Legacy TriSalus for the three and six months ended June 30,
2023 and 2022 is set forth in Exhibit 99.2 to this Current Report on Form 8-K, and is incorporated herein by reference.
Directors and Executive Officers
Information with respect to the Company’s
directors and executive officers after the Closing is set forth in the Proxy Statement/Prospectus in the section entitled “Directors
and Executive Officers After the Business Combination” beginning on page 344 of the Proxy Statement/Prospectus, which is
incorporated herein by reference. Additionally, interlocks and insider participation information regarding New TriSalus’ executive
officers is described in the Proxy Statement/Prospectus in the section titled “Directors and Executive Officers After the Business
Combination – Compensation Committee Interlocks and Insider Participation” beginning on page 354 and that information
is incorporated herein by reference.
Directors
Immediately following the Closing, the size of
the board of directors of the Company (the “New TriSalus Board”) was set at nine members. Upon the Closing, each of Mary Szela,
Sean Murphy, Mats Wahlström, Andrew von Eschenbach, George Kelly Martin, David J. Matlin, Arjun Desai, Kerry Hicks and Anil Singhal
were elected to serve as directors on the New TriSalus Board. The New TriSalus Board appointed Mr. Wahlström as Chairman of
the New TriSalus Board.
Drs. Singhal and Messrs. Hicks and Murphy
were appointed to serve as Class I directors, with terms expiring at the Company’s first annual meeting of stockholders following
the Closing; Messrs. Matlin and Wahlström and Dr. von Eschenbach were appointed to
serve as Class II directors, with terms expiring at the Company’s second annual meeting of stockholders following the Closing;
and Dr. Desai, Mr. Martin and Ms. Szela were appointed to serve as Class III directors, with terms expiring at the
Company’s third annual meeting of stockholders following the Closing. Biographical information for these individuals is set forth
in the Proxy Statement/Prospectus in the section entitled “Directors and Executive Officers After the Business Combination”
beginning on page 344 of the Proxy Statement/Prospectus, which is incorporated herein by reference.
Independence of Directors
The New TriSalus Board has determined that each
of Mats Wahlström, Andrew von Eschenbach, George Kelly Martin, David J. Matlin, Arjun Desai, Kerry Hicks and Anil Singhal qualify
as “independent directors,” as defined under the listing rules of Nasdaq (the “Nasdaq listing rules”), and
that the Board consists of a majority of “independent directors,” as defined under the rules of the SEC and Nasdaq listing
rules relating to director independence requirements.
Information with respect to the Company’s
directors after the Closing is set forth in the Proxy Statement/Prospectus in the sections entitled “Directors and Executive
Officers After the Business Combination” beginning on page 344 of the Proxy Statement/Prospectus, which is incorporated
herein by reference.
Committees of the Board of Directors
Immediately following the Closing, the standing
committees of the New TriSalus Board consist of an audit committee (the “Audit Committee”), a compensation committee (the
“Compensation Committee”), a nominating and corporate governance committee (the “Nominating and Corporate Governance
Committee”) and a science and technology committee (the “Science and Technology Committee”). Each of the committees
reports to the New TriSalus Board.
Immediately following the Closing, the New TriSalus
Board (i) appointed Messrs. Matlin, Hicks and Martin to serve on the Audit Committee, with
Mr. Matlin as chair of the Audit Committee, (ii) Mr. Martin and Drs. Desai and Singhal to serve on the Compensation
Committee, with Mr. Martin as chair of the Compensation Committee, (iii) Messrs. Hicks, Wahlström
and Matlin and Dr. von Eschenbach to serve on the Nominating and Corporate Governance Committee, with Mr. Hicks as chair
of the Nominating and Corporate Governance Committee, and (iv) Drs. von Eschenbach, Singhal and Desai to serve on the Science
and Technology Committee, with Dr. von Eschenbach as chair of the Science and Technology Committee.
Information with respect to the Committees of
the New TriSalus Board after the Closing is set forth in the Proxy Statement/Prospectus in the section entitled “Directors and
Executive Officers After the Business Combination” beginning on page 344 of the Proxy Statement/Prospectus, which is incorporated
herein by reference.
Executive Officers
Immediately following Closing, the New TriSalus
Board appointed the following individuals as the Company’s executive officers: Mary Szela to serve as Chief Executive Officer and
President, Sean Murphy to serve as Chief Financial Officer, James Alecxih to serve as President, Device Technology,
Steven Katz to serve as Chief Medical Officer, Bryan Cox to serve as Chief Scientific and Manufacturing Officer,
Jennifer Stevens to serve as Chief Regulatory Officer, and Richard Marshak to serve as Senior Vice President, Corporate Development &
Strategy. The biographical information for the new executive officers is set forth in the Proxy Statement/Prospectus in the section
entitled “Directors and Executive Officers After the Business Combination” beginning on page 344 of the Proxy
Statement/Prospectus, which is incorporated herein by reference.
Executive Compensation
Information with respect to the compensation of Legacy TriSalus’
executive officers prior to the Closing is set forth in the Proxy Statement/Prospectus in the section entitled “Executive Compensation
of TriSalus” beginning on page 356 of the Proxy Statement/Prospectus, which is incorporated herein by reference. In addition,
the board of directors of Legacy TriSalus approved bonuses in an aggregate amount of approximately $2.8 million to executive officers
and other employees of the Company, including bonuses of $338,485, $324,461 and $188,005 to Ms. Szela, Dr. Katz and Ms. Stevens,
respectively. These bonuses relate to the Company’s non-equity incentive plan described in the section entitled “Executive
Compensation of TriSalus–Narrative Disclosure to Summary Compensation Table–Non-Equity Incentive Plan Compensation”
beginning on page 357 of the Proxy Statement/Prospectus. Following the Closing, the New TriSalus Board approved adjustments to the
annual base salary of, and the grant of additional equity awards to, certain of New TriSalus’ officers. The annual base salary for
each of Ms. Szela, Dr. Katz and Ms. Stevens has been adjusted to $600,000, $515,000 and $412,000, respectively. Ms. Szela,
Dr. Katz and Ms. Stevens also received option grants of 172,500, 62,500 and 40,000 shares, respectively.
The foregoing description of the compensation
of the Company’s executive officers is qualified in its entirety by the full text of the employment agreements of Ms. Szela,
Dr. Katz and Ms. Stevens, copies of which are attached hereto as Exhibit 10.8, Exhibit 10.9 and Exhibit 10.12,
respectively, and incorporated herein by reference.
At the MTAC Stockholder Meeting, MTAC stockholders
approved the TriSalus Life Sciences, Inc. 2023 Equity Incentive Plan (the “2023 Plan”). The 2023 Plan was previously
approved, subject to stockholder approval, by the board of directors of MTAC on June 29, 2023. The description of the 2023 Plan is
set forth beginning on page 195 of the Proxy Statement/Prospectus section entitled “Proposal 4 – The Stock Plan Proposal,”
which is incorporated herein by reference. The description of the 2023 Plan is not complete and is subject to and qualified in its entirety
by reference to the 2023 Plan, a copy of which is attached hereto as Exhibit 10.21 and the terms of which are incorporated by reference
herein.
At the MTAC Stockholder Meeting, MTAC stockholders
approved the TriSalus Life Sciences, Inc. 2023 Employee Stock Purchase Plan (the “2023 ESPP”). The 2023 Plan was previously
approved, subject to stockholder approval, by the board of directors of MTAC on June 29, 2023. The description of the 2023 ESPP is
set forth beginning on page 203 of the Proxy Statement/Prospectus section entitled “Proposal 5 – The ESPP Proposal,”
which is incorporated herein by reference. The description of the 2023 ESPP is not complete and is subject to and qualified in its entirety
by reference to the 2023 ESPP, a copy of which is attached hereto as Exhibit 10.24 and the terms of which are incorporated by reference
herein.
Director Compensation
Information with respect to the compensation of
the Company’s directors is set forth in the Proxy Statement/Prospectus in the section entitled “Executive Compensation
of TriSalus – Director Compensation” beginning on page 362 of the Proxy Statement/Prospectus, which is incorporated
herein by reference.
Following the Closing, the New TriSalus Board
approved a non-employee director compensation policy consisting of annual cash retainers of $50,000 for each non-employee director and
an additional $30,000 for the chairperson of the New TriSalus Board; an additional $20,000 and $7,500 for the chairperson and each other
member of the audit committee of the New TriSalus Board, respectively; an additional $15,000 and $7,500 for the chairperson and each other
member of the compensation committee of the New TriSalus Board, respectively; an additional $15,000 and $7,500 for the chairperson and
each other member of the nominating and corporate governance committee of the New TriSalus Board, respectively; and an additional $25,000
and $7,500 for the chairperson and each other member of the science and technology committee of the New TriSalus Board, respectively.
The policy also provides for an initial grant of a stock option for 35,000 shares on the date an eligible director is first elected or
appointed to the New TriSalus Board after the Closing and an annual stock option grant for 15,000 shares on the date of each annual stockholder
meeting held after the Closing Date for each eligible director who continues to serve as a non-employee member of the New TriSalus Board
as of such date.
The foregoing does not constitute a complete summary
of the terms of the Non-Employee Director Compensation Policy. A copy of the Non-Employee Director Compensation Policy is attached hereto
as Exhibit 10.26 and the terms of which are incorporated by reference herein.
Security Ownership of Certain Beneficial Owners and Management
The following table sets forth information known
to the Company regarding the actual beneficial ownership of New TriSalus Common Stock as of the Closing Date, after giving effect to the
Closing, by:
|
• |
each person known by the Company to be the beneficial owner of more than 5% of the Company’s outstanding shares New TriSalus Common
Stock; |
|
• |
each of the Company’s executive officers and directors; and |
|
• |
all executive officers and directors of the Company as a group. |
Beneficial ownership is determined in accordance
with SEC rules, which generally provides that a person has beneficial ownership of a security if he, she or it possesses sole or shared
voting or investment power with respect to the security. Under SEC rules, beneficial ownership includes securities that the individual
or entity has the right to acquire, such as through exercise of stock options or warrants, within 60 days and are deemed to be outstanding
and beneficially owned by the persons holding those options or warrants for the purpose of computing the number of shares beneficially
owned and the percentage ownership of that person. They are not, however, deemed to be outstanding and beneficially owned for the
purpose of computing the percentage ownership of any other person.
The beneficial ownership percentages set forth
in the table below are based on 26,316,681 shares of New TriSalus Common Stock issued and outstanding as of the Closing Date and other
than as noted below, do not take into account the issuance of any shares of New TriSalus Common Stock upon the exercise of 8,333,272
public warrants, each exercisable for one share of New TriSalus Common Stock at a price of $11.50 per share (the “Public Warrants”)
to purchase an aggregate of 8,333,272 shares of New TriSalus Common Stock, the 5,933,333 private warrants, each exercisable for one share
of New TriSalus Common Stock at a price of $11.50 per share to purchase an aggregate of 5,933,333 shares of New TriSalus Common Stock
or the unexercised stock options and unvested RSUs held by the individuals except as noted below. Unless otherwise noted in the footnotes
to the following table, and subject to applicable community property laws, the persons and entities named in the table have sole voting
and investment power with respect to their beneficially owned New TriSalus Common Stock.
Name of Beneficial Owner(1) |
|
Number of
Shares of
New TriSalus
Common
Stock
Beneficially
Owned |
|
|
Percentage of
Outstanding
New TriSalus
Common
Stock |
|
Directors and Executive Officers |
|
|
|
|
|
|
|
Mary Szela(2) |
|
|
652,639 |
|
|
2.4 |
% |
Sean Murphy(3) |
|
|
580,305 |
|
|
2.2 |
% |
James Alecxih |
|
|
94,754 |
|
|
* |
|
Steven Katz, MD, FACS(4) |
|
|
132,386 |
|
|
* |
|
Bryan Cox, Ph.D.(5) |
|
|
72,384 |
|
|
* |
|
Richard Marshak, VMD(6) |
|
|
44,163 |
|
|
* |
|
Jennifer Stevens(7) |
|
|
32,958 |
|
|
* |
|
Mats Wahlström(8) |
|
|
2,744,542 |
|
|
10.4 |
% |
Andrew von Eschenbach |
|
|
— |
|
|
— |
|
George Kelly Martin |
|
|
— |
|
|
— |
|
David J. Matlin(9) |
|
|
2,272,421 |
|
|
8.2 |
% |
Arjun “JJ” Desai(10) |
|
|
449,794 |
|
|
1.7 |
% |
Anil Singhal |
|
|
19,278 |
|
|
* |
|
Kerry Hicks(11) |
|
|
2,310,022 |
|
|
8.8 |
% |
All executive officers and directors after the business combination as a group (14 individuals) |
|
|
9,405,646 |
|
|
35.2 |
% |
|
|
|
|
|
|
|
|
Five Percent Holders |
|
|
|
|
|
|
|
Frankenius Equity AB(12) |
|
|
6,397,776 |
|
|
24.1 |
% |
Christopher Dewey(13) |
|
|
1,555,289 |
|
|
5.7 |
% |
Unique Diamond Investments Limited |
|
|
1,546,569 |
|
|
5.9 |
% |
Michael Stansky(14) |
|
|
1,449,129 |
|
|
5.3 |
% |
Gene R. McGrevin(15) |
|
|
1,403,130 |
|
|
5.3 |
% |
HW Investment Partners, LLC(16) |
|
|
1,370,028 |
|
|
5.2 |
% |
Lombard International(17) |
|
|
1,358,013 |
|
|
5.1 |
% |
* |
|
Less than 1% |
|
(1) |
Unless otherwise noted, the business address of each of the following entities
or individuals is c/o TriSalus Life Sciences, Inc., 6272 W. 91st Avenue, Westminster, Colorado 80031. |
|
(2) |
Consists of (i) 243,189 shares held directly by Ms. Szela and (ii) 409,450 shares of New TriSalus Common Stock issuable
pursuant to New TriSalus Assumed Options that are exercisable within 60 days. |
|
(3) |
Consists of (i) 357,535 shares held by Murphy Family Trust 2012, (ii) 167,732 shares held by Sean E Murphy TTEE U/A 2/4/2004
(“Sean Murphy Trust”) and (iii) 55,038 shares of New TriSalus Common Stock issuable pursuant to New TriSalus Assumed
Options that are exercisable within 60 days. Lisa Murphy, Mr. Murphy’s spouse, has voting and investment discretion with respect
to the shares held directly by Murphy Family Trust 2012 and thus Mr. Murphy may be deemed to have beneficial ownership of the shares
held directly by Murphy Family Trust 2012. Mr. Murphy is the trustee of the Sean Murphy Trust and thus Mr. Murphy may be deemed
to have beneficial ownership of the shares held directly by the Sean Murphy Trust. |
|
(4) |
Consists of (i) 17,799 shares held directly by Mr. Katz and (ii) 114,587 shares of New TriSalus Common Stock issuable pursuant
to New TriSalus Assumed Options that are exercisable within 60 days. |
|
(5) |
Consists of (i) 67,817 shares held directly by Mr. Cox and (ii) 4,567 shares of New TriSalus Common Stock issuable pursuant
to New TriSalus Assumed Options that are exercisable within 60 days. |
|
(6) |
Consists of (i) 8,372 shares held directly by Mr. Marshak and (ii) 35,791 shares of New TriSalus Common Stock issuable
pursuant to New TriSalus Assumed Options that are exercisable within 60 days. |
|
(7) |
Consists of (i) 13,904 shares held directly by Ms. Stevens and (ii) 19,054 shares of New TriSalus Common Stock issuable
pursuant to New TriSalus Assumed Options that are exercisable within 60 days. |
|
(8) |
Consists of (i) 1,254,259 shares held by Leonard Capital LLC, (ii) 50,000 shares of New TriSalus Common Stock issuable upon
conversion of shares of Series A Convertible Preferred Stock held by Leonard Capital LLC as a Preferred Stock PIPE Investor, (iii) 1,370,028
shares held by HW Investment Partners, LLC (“HW Investment”), and (iv) 70,255 shares of New TriSalus Common Stock issuable
pursuant to New TriSalus Assumed Options that are exercisable within 60 days. Mr. Wahlström has sole voting and investment discretion
with respect to the shares held directly by Leonard Capital LLC and shared voting and investment discretion with respect to the shares
held directly by HW Investment and may be deemed to have beneficial ownership of the shares held by each of them. |
|
(9) |
Consists of (i) 931,903 shares held directly by Mr. Matlin of which 215,055 shares are vested and 716,848 shares are subject to vesting and forfeiture pursuant to the Sponsor Support Agreement, (ii) 1,240,518 shares underlying private warrants, which are exercisable for shares of New TriSalus Common Stock commencing 30 days after the closing of the Business Combination and (iii) 100,000 shares of New TriSalus Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by Mr. Matlin as a Preferred Stock PIPE Investor. |
|
(10) |
Consists of (i) 203,127 shares held directly by Dr. Desai of which 46,875 shares are vested and 156,252 shares are subject to vesting and forfeiture pursuant to the Sponsor Support Agreement and (ii) 246,667 shares underlying private warrants, which are exercisable for shares of New TriSalus Common Stock commencing 30 days after the closing of the Business Combination. |
|
(11) |
Consists of (i) 514,589 shares held directly by Mr. Hicks, (ii) 1,370,028 shares held by HW Investment, (iii) 81,845 shares held by the Millennium Trust Company, LLC, as custodian FBO Kerry Hicks IRAT, (iv) 322,737 shares held by The Kerry Raymond Hicks Dynasty Trust, for which Mr. Hicks serves as trustee, and (v) 20,823 shares of New TriSalus Common Stock issuable pursuant to New TriSalus Assumed Options that are exercisable within 60 days. Mr. Hicks has shared voting and investment discretion with respect to the shares held directly by HW Investment and may be deemed to have beneficial ownership of the shares held by each of them. |
|
(12) |
Consists of (i) 6,167,776 shares held by Frankenius Equity AB (“Frankenius Equity”) and (ii) 230,000 shares of New TriSalus Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by Frankenius Equity as a Preferred Stock PIPE Investor. Frankenius Equity’s principal place of business is Box 984, 501 10 Boras, Sweden. Paul Frankenius has sole voting and investment discretion with respect to the shares held directly by Frankenius Equity and may be deemed to have beneficial ownership of the shares held by Frankenius Equity. |
|
(13) |
Consists of (i) 573,690 shares held directly by the Christopher C Dewey Trust DTD 5/3/18, (ii) 881,599 shares underlying private warrants, which are exercisable for shares of New TriSalus Common Stock commencing 30 days after the closing of the Business Combination held by the Christopher C Dewey Trust DTD 5/3/18, (iii) 67,500 shares of New TriSalus Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by the Christopher C Dewey Trust DTD 5/3/18, (iv) 23,500 shares of New TriSalus Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by Dewey Family Properties LLC, and (v) 9,000 shares of New TriSalus Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by the Christopher C Dewey Family Trust, as Preferred Stock PIPE Investors. Mr. Dewey is the trustee of the Christopher C Dewey Trust DTD 5/3/18 and thus Mr. Dewey may be deemed to have beneficial ownership of the shares held directly by the Christopher C Dewey Trust DTD 5/3/18. Christina Dewey, Mr. Dewey’s spouse, has voting and investment discretion with respect to the shares held directly by Dewey Family Properties LLC and the Christopher C Dewey Family Trust and thus Mr. Dewey may be deemed to have beneficial ownership of the shares held by each of them. |
|
(14) |
Consists of (i) 521,539 shares held directly by Mr. Stansky, (ii) 827,590 shares underlying private warrants, which are exercisable for shares of New TriSalus Common Stock commencing 30 days after the closing of the Business Combination, (iii) 75,000 shares of New TriSalus Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by Mr. Stansky as a Preferred Stock PIPE Investor and (iv) 25,000 shares of Series A Convertible Preferred Stock held by Skyview Investments LLC (“Skyview”) as a Preferred Stock PIPE Investor. Mr. Stansky is the managing member of Skyview, has voting and investment discretion with respect to the shares held directly by Skyview and, as result, may be deemed to have beneficial ownership of the shares held by each of them. |
|
(15) |
Consists of (i) 1,390,474 shares held directly by Mr. McGrevin and (ii) 12,656 shares of New TriSalus Common Stock issuable pursuant to New TriSalus Assumed Options that are exercisable within 60 days. |
|
(16) |
Consists of 1,370,028 shares held by HW Investment. Messrs. Wahlström and Hicks have shared voting and investment discretion with respect to the shares held directly by HW Investment and may be deemed to have beneficial ownership of the shares held by each of them. |
|
(17) |
Consists of (i) 41,197 shares held directly by Lombard International Assurance S.A. – P47082 and 33,000 shares of New TriSalus Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by Lombard International Assurance S.A. – P47082 as a Preferred Stock PIPE Investor, (ii) 360,478 shares held directly by Lombard International Assurance S.A. – P47083 and 365,000 shares of New TriSalus Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by Lombard International Assurance S.A. – P47083 as a Preferred Stock PIPE Investor, (iii) 113,293 shares held directly by Lombard International Assurance S.A. – P47084 and 110,000 shares of New TriSalus Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by Lombard International Assurance S.A. – P47084 as a Preferred Stock PIPE Investor; (iv) 237,389 shares held directly by Lombard International Assurance S.A. – P47472, (v) 28,000 shares of New TriSalus Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by Lombard International Assurance S.A. – P47473 as a Preferred Stock PIPE Investor, (vi) 52,000 shares of New TriSalus Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by Lombard International Assurance S.A. – P69562 as a Preferred Stock PIPE Investor and (vii) 17,656 shares held directly by Lombard International Assurance S.A., policy number 2304-150035. |
Certain Relationships and Related Transactions
The certain relationships and related party transactions
of the Company are described in the Proxy Statement/Prospectus in the section entitled “Certain Relationships and Related Party
Transactions” beginning on page 372 of the Proxy Statement/Prospectus, which is incorporated herein by reference.
Legal Proceedings
Information about legal proceedings is set forth
in MTAC’s Annual Report on Form 10-K, filed with the SEC on March 22, 2023 and in the Proxy Statement/Prospectus in the
sections entitled “MTAC’s Business – Legal Proceedings” and “TriSalus’ Business –
Legal Proceedings” on pages 226 and 278, respectively, of the Proxy Statement/Prospectus, which are incorporated herein
by reference.
Market Price of and Dividends on the Registrant’s Common Equity
and Related Stockholder Matters
Market Information and Holders
Prior to the Business Combination, MTAC’s
units, Class A Common Stock and Public Warrants were historically quoted on the Nasdaq Capital Market under the symbols “MTACU,”
“MTAC” and “MTACW,” respectively. On August 10, 2023, the New TriSalus Common Stock and the Public Warrants
began trading on the Nasdaq Global Market under the new trading symbols “TSLI” and “TSLIW”, respectively. On the
Closing Date, the CUSIP numbers relating to the New TriSalus Common Stock and Public Warrants changed to 89680M 101 and 89680M 119, respectively.
As of the Closing Date and following the consummation of the Business
Combination, the Company had 26,316,681 shares of New TriSalus Common Stock issued and outstanding held of record by 271 holders
and 8,333,272 Public Warrants outstanding and held of record by 1 holder. As of the Closing Date and following the consummation
of the Business Combination, MTAC’s units ceased trading on the Nasdaq Capital Market and were separated into their component securities
upon consummation of the Business Combination and no fractional warrants were issued upon the separation.
Dividends
The Company has not paid any cash dividends on
the MTAC Common Stock or New TriSalus Common Stock to date. Subject to the rights of holders of the Series A Convertible Preferred
Stock or any other series of preferred stock of New TriSalus that may be issued and the provisions of the Company’s Second Amended
and Restated Certificate of Incorporation (the “Certificate of Incorporation”) holders of New TriSalus Common Stock will be
entitled to receive such dividends and other distributions in cash, stock or property of New TriSalus when, as and if declared thereon
by the New TriSalus Board, in its discretion, from time to time out of assets or funds of New TriSalus legally available therefor. The
Company does not anticipate declaring any cash dividends to holders of New TriSalus Common Stock in the foreseeable future.
Recent Sales of Unregistered Securities
The information set forth below under Item 3.02
of this Current Report on Form 8-K concerning the issuance and sale by the Company of certain unregistered securities is incorporated
herein by reference.
Description of Registrant’s Securities to be Registered
Common Stock
A description of the New TriSalus Common Stock
is included in Exhibit 4.4 to this Current Report on Form 8-K in the section entitled “Description of Securities –
Common Stock”, which is incorporated herein by reference.
Preferred Stock
A description of the New TriSalus Preferred Stock
is included in the Proxy Statement/Prospectus in the section entitled “Description of MTAC’s Securities – Preferred
Stock” beginning on page 321 of the Proxy Statement/Prospectus, which is incorporated herein by reference.
Warrants
A description of the Public Warrants is included
in the Proxy Statement/Prospectus in the section entitled “Description of MTAC’s Securities – Warrants ”
beginning on page 324 of the Proxy Statement/Prospectus, which is incorporated herein by reference.
Indemnification of Directors and Officers
Information about indemnification of the Company’s
directors and officers is set forth in the Proxy Statement/Prospectus in the section entitled “Directors and Executive Officers
After the Business Combination – Limitation on Liability and Indemnification of Directors and Officers” on page 354
of the Proxy Statement/Prospectus, which is incorporated herein by reference. On the Closing Date, the Company entered into indemnification
agreements with the Company’s directors and executive officers, a form of which is attached hereto as Exhibit 10.25 and incorporated
herein by reference. The information set forth under the heading “Indemnification Agreements” in Item 1.01 of this Current
Report on Form 8-K is incorporated herein by reference.
Financial Statements and Supplementary Data
The information set forth in Item 9.01 of this
Current Report on Form 8-K is incorporated herein by reference.
Changes in and Disagreements with Accountants on Accounting and
Financial Disclosure
The information set forth under Item 4.01 of this
Current Report on Form 8-K is incorporated herein by reference.
Financial Statements and Exhibits
The information set forth in Item 9.01 of this
Current Report on Form 8-K is incorporated herein by reference.
Item 3.02. Unregistered Sales of Equity Securities.
The disclosure set forth in the “Introductory
Note–PIPE Financing” above is incorporated by reference into this Item 3.02.
In connection with the Business Combination,
on August 10, 2023, the Sponsor elected to convert the entire unpaid $1,500,000 balance under the Convertible Sponsor Note into MTAC
Warrants at a price of $1.50 per warrant. Following such conversion, Sponsor received 1,000,000 MTAC Warrants, which are exercisable
into 1,000,000 shares of New TriSalus Common Stock. A description of the Convertible Sponsor Note is included in the Proxy Statement/Prospectus
in the section entitled “Certain Relationships and Related Party Transactions — MTAC Related Party Transactions — Promissory
Note — Related Party” beginning on page 372 of the Proxy Statement/Prospectus, which is incorporated
herein by reference.
The securities issued in connection with the
Subscription Agreements and the conversion of the Convertible Sponsor Note have not been registered under the Securities Act in reliance
on the exemption from registration provided by Section 4(a)(2) of the Securities Act and/or Rule 506(c) promulgated thereunder.
Item 3.03. Material Modification to Rights of Security Holders.
In connection with the Business Combination, on
August 10, 2023, the Company filed the Certificate of Incorporation with the Delaware Secretary of State, and also adopted
Amended and Restated Bylaws on August 10, 2023 (the “Bylaws”), which replaced MTAC’s Amended and Restated
Certificate of Incorporation and bylaws in effect as of such time. The material terms of the Certificate of Incorporation and the Bylaws
and the general effect upon the rights of holders of the New TriSalus Common Stock are discussed in the Proxy Statement/Prospectus in
the sections entitled “Proposal 2 – The Charter Approval Proposal” and “Proposals 3A-3E The Governance
Proposal” beginning on page 190 of the Proxy Statement/Prospectus, which is incorporated herein by reference.
In connection with the Business Combination,
on August 10, 2023, the Company filed the Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock
(the “Certificate of Designations) specifying the rights, powers, preferences, and privileges of the PIPE Shares that were issued
and sold pursuant to the Subscription Agreements. The Certificate of Designations became effective with the Secretary of State of the
State of Delaware upon filing. Pursuant to the Certificate of Designations, the Series A Convertible Preferred Stock will rank senior
to the New TriSalus Common Stock with respect to dividends and distributions on liquidation, dissolution, or winding up the affairs of
the Company. The Series A Convertible Preferred Stock will participate equally in any dividends declared to holders of New TriSalus Common
Stock and also carry an additional dividend at a rate per annum of 8.0% of $10.00 per share of Series A Convertible Preferred Stock (as
adjusted upon the occurrence of certain events), which shall accumulate on a daily basis (the “Annual Dividends”). The Annual
Dividends are payable, at the option of the Company, in cash, by issuing shares of New TriSalus Common Stock, or any combination of cash
and shares of New TriSalus Common Stock. The holder of Series A Convertible Preferred Stock will be entitled to vote with the holders
of New TriSalus Common Stock on all stockholder matters, with each share of Series A Convertible Preferred Stock entitling the holder
thereof to 1.07 votes per share. Holders of Series A Convertible Preferred Stock will also be entitled to a separate class vote on any
modification to the Company’s Certificate of Incorporation or the Certificate of Designations that adversely affects the powers,
preferences, or rights of the Series A Convertible Preferred Stock.
A description of the Certificate of Designations
and the Series A Convertible Preferred Stock is included in the Proxy Statement/Prospectus in the sections entitled “Proposal
1 – The Business Combination Proposal – Certain Related Agreements – Subscription Agreements” beginning on
page 153 of the Proxy Statement/Prospectus and “Description of MTAC’s Securities – Preferred Stock –
Series A Convertible Preferred Stock” beginning on page 321 of the Proxy Statement/Prospectus, each of which is incorporated
herein by reference.
The New TriSalus Common Stock and Public Warrants
are listed for trading on the Nasdaq Global Market under the symbols “TSLI” and “TSLIW,” respectively. On the
date of the Closing, the CUSIP numbers relating to New TriSalus Common Stock and Public Warrants changed to 89680M 101 and 89680M 119,
respectively.
Copies of the Certificate of Incorporation, the
Bylaws and the Certificate of Designations are included as Exhibit 3.1, Exhibit 3.2 and Exhibit 3.3, respectively, to this Current Report
on Form 8-K and incorporated herein by reference.
Item 4.01 Changes in Registrant’s Certifying Accountant.
On August 10, 2023, the New TriSalus Board
approved the engagement of KPMG LLP (“KPMG”) as the Company’s independent registered public accounting firm to audit
the Company’s consolidated financial statements for the year ending December 31, 2023. KPMG served as the independent registered
public accounting firm of Legacy TriSalus prior to the Business Combination. Accordingly, WithumSmith+Brown, PC (“Withum”),
the Company’s independent registered public accounting firm prior to the Business Combination, was informed on the Closing Date
that it would be dismissed and replaced by KPMG as the Company’s independent registered public accounting firm.
Withum’s report on the Company’s consolidated
balance sheets as of December 31, 2022 and 2021, the related consolidated statements of operations, stockholders’ equity and
cash flows for the years ended December 31, 2022 and 2021 and the related notes to the financial statements (collectively, the “financial
statements”) did not contain any adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty,
audit scope or accounting principles, except for the substantial doubt about the Company’s ability to continue as a going concern.
During the period from September 11, 2020
(inception) through December 31, 2022 and the subsequent interim period through August 10, 2023, there were no: (i) disagreements
with Withum on any matter of accounting principles or practices, financial statement disclosures or audited scope or procedures, which
disagreements if not resolved to Withum’s satisfaction would have caused Withum to make reference to the subject matter of the disagreement
in connection with its report or (ii) reportable events as defined in Item 304(a)(1)(v) of Regulation S-K under the Exchange
Act.
During the period from September 11, 2020
(inception) through December 31, 2022, and the interim period through August 10, 2023, the Company did not consult KPMG with
respect to either (i) the application of accounting principles to a specified transaction, either completed or proposed; or the type
of audit opinion that might be rendered on the Company’s financial statements, and no written report or oral advice was provided
to the Company by KPMG that KPMG concluded was an important factor considered by the Company in reaching a decision as to the accounting,
auditing or financial reporting issue; or (ii) any matter that was either the subject of a disagreement, as that term is described
in Item 304(a)(1)(iv) of Regulation S-K under the Exchange Act and the related instructions to Item 304 of Regulation S-K under the
Exchange Act, or a reportable event, as that term is defined in Item 304(a)(1)(v) of Regulation S-K under the Exchange Act.
The Company has provided Withum with a copy of
the disclosures made by the Company in response to this Item 4.01 and has requested that Withum furnish the Company with a letter addressed
to the SEC stating whether it agrees with the statements made by the Company in response to this Item 4.01 and, if not, stating the respects
in which it does not agree. A letter from Withum is attached to this Current Report on Form 8-K as Exhibit 16.1.
Item 5.01. Changes in Control of the Registrant.
Reference is made to the disclosure beginning
on page 133 of the Proxy Statement/Prospectus in the section entitled “Proposal No. 1—The Business Combination
Proposal—The Merger Agreement,” which is incorporated herein by reference. Further reference is made to the information
contained in the “Introductory Note” above and Item 2.01 to this Current Report, which is incorporated herein by reference.
As a result of the consummation of the Business
Combination, a change of control of MTAC has occurred, and the stockholders of MTAC as of immediately prior to the Closing held 9.7% of
the outstanding shares of New TriSalus Common Stock immediately following the Closing.
Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
The information set forth in the sections entitled
“Directors and Executive Officers”, “Certain Relationships and Related Transactions”, and “Indemnification
of Directors and Officers” in Item 2.01 of this Current Report on Form 8-K is incorporated herein by reference.
TriSalus Life Sciences, Inc. 2023 Equity Incentive Plan
At the MTAC Stockholder Meeting, the stockholders
of MTAC considered and approved the 2023 Plan. The 2023 Plan was previously approved, subject to stockholder approval, by the board of
directors of MTAC on June 29, 2023, and on the Closing Date, the New TriSalus Board ratified the approval of the 2023 Plan. The 2023
Plan became effective immediately upon the Closing.
The 2023 Plan initially makes available a maximum number of 5,585,008 shares of New
TriSalus Common Stock. Additionally, the number of shares reserved for issuance under the 2023 Plan will automatically increase on January 1 of each year,
starting on January 1, 2024 and ending on January 1, 2033, in an amount equal to (i) five percent (5%) of the number of
shares of New TriSalus Common Stock outstanding (or issuable upon conversion or exercise of outstanding instruments) on the final day
of the immediately preceding calendar year, or (ii) such lesser number of shares of New TriSalus Common Stock determined by the New
TriSalus Board prior to the date of the increase.
A description of the 2023 Plan is included in
the Proxy Statement/Prospectus in the section entitled “Proposal 4 – The Stock Plan Proposal” beginning on page 195
of the Proxy Statement/Prospectus, which is incorporated herein by reference. The foregoing description of the 2023 Plan is qualified
in its entirety by the full text of the 2023 Plan, which is attached hereto as Exhibit 10.21 and incorporated herein by reference.
TriSalus Life Sciences, Inc. 2023 Employee Stock Purchase Plan
At the MTAC Stockholder Meeting, the stockholders
of MTAC considered and approved the 2023 ESPP. The 2023 ESPP was previously approved, subject to the stockholder approval, by the board
of directors of MTAC on June 29, 2023, and on the Closing Date, the New TriSalus Board ratified the approval of the 2023 ESPP. The
2023 ESPP became effective immediately upon the Closing.
The 2023 ESPP initially makes available a maximum number of 1,396,252 shares of New
TriSalus Common Stock. Additionally, the number of shares reserved for issuance under the 2023 ESPP will automatically increase on January 1 of each year,
starting on January 1, 2024 and ending on January 1, 2033, in an amount equal to (i) three percent (3%) of the number of
shares of New TriSalus Common Stock outstanding (or issuable upon conversion or exercise of outstanding instruments) on the final day
of the immediately preceding calendar year, (ii) 2,792,503 shares or (iii) such lesser number of shares of New TriSalus Common
Stock determined by the New TriSalus Board prior to the date of the increase.
A description of the 2023 ESPP is included in
the Proxy Statement/Prospectus in the section entitled “Proposal 5 – The ESPP Proposal” beginning on page 203
of the Proxy Statement/Prospectus, which is incorporated herein by reference. The foregoing description of the 2023 ESPP is qualified
in its entirety by the full text of the 2023 ESPP, which is attached hereto as Exhibit 10.24 and incorporated herein by reference.
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change
in Fiscal Year.
At the MTAC Stockholder Meeting, MTAC’s
stockholders considered and approved, among other items, “Proposal 2 – The Charter Approval Proposal” (“Charter
Proposal”), which is described in greater detail beginning on page 190 in the Proxy Statement/Prospectus. The Certificate of
Incorporation, which became effective upon filing with the Secretary of State of the State of Delaware on August 10, 2023 includes
the amendments proposed by the Charter Proposal.
On August 10, 2023, the New TriSalus Board
adopted the Bylaws, which became effective on that date. The Certificate of Incorporation included the amendments proposed by the Charter
Proposal. The material terms of the Certificate of Incorporation and the Bylaws and the general effect upon the rights of holders of MTAC’s
capital stock are discussed in Exhibit 4.4 to this Current Report on Form 8-K in the section entitled “Description
of Securities – Common Stock”, the Proxy Statement/Prospectus in the sections entitled “Description of MTAC’s
Securities—Preferred Stock” beginning on page 321, the Proxy Statement/Prospectus in the sections entitled “Description
of MTAC’s Securities—Warrants” beginning on page 324 and “Comparison of Corporate Governance and Stockholders’
Rights” beginning on page 333, which are incorporated herein by reference.
In addition, the disclosure set forth under Item
3.03 in this Current Report on Form 8-K is incorporated herein by reference. Copies of the Certificate of Incorporation and the Bylaws
are included as Exhibit 3.1 and Exhibit 3.2, respectively, to this Current Report on Form 8-K and incorporated herein by
reference.
Item 5.05. Amendments to the Registrant’s Code of Ethics,
or Waiver of a Provision of the Code of Ethics.
In connection with the Business Combination,
on August 10, 2023, the New TriSalus Board approved and adopted a new Code of Business Conduct and Ethics applicable to all employees,
officers and directors of the Company. A copy of the Code of Business Conduct and Ethics can be found in the Investors section of the
Company’s website at www.trisaluslifesci.com.
Item 5.06. Change in Shell Company Status.
On August 10, 2023, as a result of the Business
Combination, MTAC ceased to be a shell company (as defined in Rule 12b-2 of the Exchange Act) as of the Closing. A description of
the Business Combination and the terms of the Merger Agreement are included in the Proxy Statement/Prospectus in the section entitled
“Proposal 1 – The Business Combination Proposal” beginning on page 133 of the Proxy Statement/Prospectus,
which are incorporated herein by reference. Further, the information set forth in the “Introductory Note” and under
Item 2.01 of this Current Report on Form 8-K is incorporated herein by reference.
Item 7.01. Regulation FD.
On August 10, 2023, the Company issued a press
release announcing the closing of the Business Combination. A copy of the press release is filed hereto as Exhibit 99.4 and incorporated
by reference herein.
The information in this Item 7.01, including Exhibit 99.4,
is furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to
liabilities under that section, and shall not be deemed to be incorporated by reference into the filings of the registrant under the Securities
Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings. This Current Report on
8-K will not be deemed an admission as to the materiality of any information contained in this Item 7.01, including Exhibit 99.4.
Item 9.01. Financial Statements and Exhibits.
(a) Financial Statements of Businesses Acquired.
The historical
unaudited condensed consolidated financial statements of Legacy TriSalus as of and for the three
and six months ended June 30, 2023, and for the three and six months ended June 30, 2022 and the related notes are included
in Exhibit 99.1 to this Current Report on Form 8-K and are incorporated herein by reference.
The historical
audited consolidated financial statements of Legacy TriSalus as of and for the years ended December 31,
2022, and 2021 and the related notes are included in the Proxy Statement/Prospectus beginning on page F-66 of the Proxy Statement/Prospectus.
and are incorporated herein by reference.
The historical unaudited condensed consolidated
financial statements of MTAC as of and for the three and six months ended June 30, 2023 and the three and six months ended June 30,
2022 and the related notes are included in the MTAC Q2 Report and incorporated herein by reference.
The historical audited consolidated financial
statements of MTAC as of and for the years ended December 31, 2022, and 2021 and the related notes are included in the Proxy Statement/Prospectus
beginning on page F-26 of the Proxy Statement/Prospectus and are incorporated herein by reference.
(b) Pro Forma Financial Information.
The unaudited pro forma condensed combined financial
information of Legacy TriSalus and MTAC as of June 30, 2023 and for year ended December 31, 2022 is set forth in Exhibit 99.3
hereto and is incorporated herein by reference.
|
|
|
|
Incorporated by Reference |
Exhibit No. |
|
Description |
|
Schedule/
Form |
|
File No. |
|
Exhibit |
|
Filing
Date |
|
|
|
|
|
|
2.1+ |
|
Agreement
and Plan of Merger, dated as of November 11, 2022, by and among MedTech Acquisition Corporation, MTAC Merger Sub, Inc., and
TriSalus Life Sciences, Inc. |
|
8-K |
|
001-39813 |
|
2.1 |
|
November 14,
2022 |
|
|
|
|
|
|
2.2 |
|
First
Amendment to Agreement and Plan of Merger, dated as of April 4, 2023, by and among MedTech Acquisition Corporation, MTAC Merger Sub, Inc.,
and TriSalus Life Sciences, Inc. |
|
8-K |
|
001-39813 |
|
10.1 |
|
April 5,
2023 |
|
|
|
|
|
|
2.3 |
|
Second
Amendment to Agreement and Plan of Merger, dated as of May 13, 2023, by and among MedTech Acquisition Corporation, MTAC Merger Sub, Inc.,
and TriSalus Life Sciences, Inc. |
|
8-K |
|
001-39813 |
|
10.1 |
|
May 13,
2023 |
|
|
|
|
|
|
|
|
|
|
|
2.4 |
|
Third
Amendment to Agreement and Plan of Merger, dated as of July 5, 2023, by and among MedTech Acquisition Corporation, MTAC Merger Sub, Inc.,
and TriSalus Life Sciences, Inc. |
|
8-K |
|
001-39813 |
|
10.1 |
|
July 6,
2023 |
|
|
|
|
|
|
3.1 |
|
Second Amended and Restated Certificate of Incorporation of TriSalus Life Sciences, Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.2 |
|
Amended and Restated Bylaws of TriSalus Life Sciences, Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.3 |
|
Certificate of Designations, Preferences and Rights of Series A Convertible
Preferred Stock of TriSalus Life Sciences, Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4.1 |
|
Specimen Common Stock Certificate. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4.2 |
|
Specimen Warrant Certificate. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4.3 |
|
Warrant
Agreement, dated December 17, 2020, by and between MedTech Acquisition Corporation and Continental Stock Transfer & Trust
Company. |
|
8-K |
|
001-39813 |
|
4.1 |
|
December 23,
2020 |
|
|
|
|
|
|
|
|
|
|
|
4.4 |
|
Description of Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Incorporated by Reference |
Exhibit No. |
|
Description |
|
Schedule/
Form |
|
File No. |
|
Exhibit |
|
Filing
Date |
|
|
|
|
|
|
|
|
|
|
|
10.1 |
|
Amended and Restated Registration Rights Agreement,
dated August 10, 2023, by and among TriSalus Life Sciences, Inc., members of MedTech Acquisition Sponsor LLC, and certain former
stockholders of TriSalus Life Sciences, Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.2 |
|
Form of
Subscription Agreement for PIPE Financing (Initial). |
|
8-K |
|
001-39813 |
|
10.1 |
|
June 8,
2023 |
|
|
|
|
|
|
|
|
|
|
|
10.3 |
|
Form of
Subscription Agreement for PIPE Financing (Subsequent). |
|
8-K |
|
001-39813 |
|
10.2 |
|
July 6,
2023 |
|
|
|
|
|
|
10.4 |
|
Sponsor
Support Agreement, dated as of November 11, 2022, by and among MedTech Acquisition Corporation, TriSalus Life Sciences, Inc.,
and MedTech Acquisition Sponsor LLC. |
|
8-K |
|
001-39813 |
|
10.3 |
|
November 14,
2022 |
|
|
|
|
|
|
10.5 |
|
Form of
Stockholder Support Agreement, by and among MedTech Acquisition Corporation, TriSalus Life Sciences, Inc. and certain stockholders
of TriSalus Life Sciences, Inc. |
|
8-K |
|
001-39813 |
|
10.4 |
|
November 14,
2022 |
|
|
|
|
|
|
10.6 |
|
Letter
Agreement, dated December 17, 2020, by and among MedTech Acquisition Corporation, its officers and directors and MedTech Acquisition
Sponsor LLC. |
|
8-K |
|
001-39813 |
|
10.1 |
|
December 23,
2020 |
|
|
|
|
|
|
|
|
|
|
|
|
10.7 |
|
Form of
Lock-up Agreement, by and among certain stockholders of TriSalus Life Sciences, Inc. and MedTech Acquisition Corporation. |
|
8-K |
|
001-39813 |
|
10.2 |
|
November 14,
2022 |
|
|
|
|
Incorporated by Reference |
Exhibit No. |
|
Description |
|
Schedule/ Form |
|
File No. |
|
Exhibit |
|
Filing Date |
|
|
|
|
|
|
|
|
|
|
|
10.8*# |
|
Amended
and Restated Employment Agreement, dated November 11, 2022, by and between TriSalus Life Sciences, Inc. and Mary Szela. |
|
S-4/A |
333-269138 |
|
10.14 |
|
April 21,
2023 |
|
|
|
|
|
10.9*# |
|
Amended
and Restated Employment Agreement, dated November 12, 2022, by and between TriSalus Life Sciences, Inc. and Steven C. Katz,
MD. |
|
S-4/A |
333-269138 |
|
10.15 |
|
April 21,
2023 |
|
|
|
|
|
10.10*# |
|
Executive
Employment Agreement, dated July 9, 2022, by and between TriSalus Life Sciences, Inc. and Sean Murphy. |
|
S-4/A |
333-269138 |
|
10.16 |
|
April 21,
2023 |
|
|
|
|
|
10.11*# |
|
Amended
and Restated Executive Employment Agreement, dated October 11, 2022, by and between TriSalus Life Sciences, Inc. and Richard
Marshak. |
|
S-4/A |
333-269138 |
|
10.17 |
|
April 21,
2023 |
|
|
|
|
|
|
|
|
|
|
10.12*# |
|
Executive
Employment Agreement, dated November 11, 2022, by and between TriSalus Life Sciences, Inc. and Jennifer L. Stevens. |
|
S-4/A |
333-269138 |
|
10.18 |
|
April 21,
2023 |
|
|
|
|
|
|
|
|
|
|
10.13*# |
|
Executive
Employment Agreement, dated November 4, 2022, by and between TriSalus Life Sciences, Inc. and Bryan F. Cox, Ph.D. |
|
S-4/A |
333-269138 |
|
10.19 |
|
April 21,
2023 |
|
|
|
|
|
|
|
|
|
|
10.14*# |
|
Executive Employment Agreement, dated November 4,
2022, by and between TriSalus Life Sciences, Inc. and James Alecxih. |
|
|
|
|
|
|
|
|
|
|
|
|
10.15* |
|
Surefire Medical, Inc. 2009 Amended and Restated Equity Incentive Plan. |
|
|
|
|
|
|
|
|
|
|
|
|
10.16* |
|
Form of Stock Option Grant Notice and
Form of Stock Option Agreement under Surefire Medical, Inc. 2009 Amended and Restated Equity Incentive Plan (Pre-2020). |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.17* |
|
Form of Early Exercise Stock Option Grant
Notice and Form of Stock Option Agreement under Surefire Medical, Inc. 2009 Amended and Restated Equity Incentive Plan (for
grants prior to 2020). |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.18* |
|
Form of Stock Option Grant Notice and
Form of Stock Option Agreement under Surefire Medical, Inc. 2009 Amended and Restated Equity Incentive Plan (for grants after
2020). |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.19* |
|
Form of Early Exercise Stock Option Grant Notice and Form of Stock Option Agreement under Surefire
Medical, Inc. 2009 Amended and Restated Equity Incentive Plan (for grants after 2020). |
|
|
|
|
|
|
|
|
|
|
|
|
10.20* |
|
Form of Restricted Stock Unit Grant Notice and Form of Restricted Stock Unit Agreement under Surefire
Medical, Inc. 2009 Amended and Restated Equity Incentive Plan. |
|
|
|
|
|
|
|
|
|
|
|
|
10.21* |
|
TriSalus Life Sciences, Inc. 2023 Equity
Incentive Plan. |
|
|
|
|
|
|
|
|
|
|
|
|
10.22* |
|
Form of Stock Option Grant Notice and
Form of Stock Option Agreement under 2023 Equity Incentive Plan. |
|
|
|
|
|
|
|
|
|
|
|
|
10.23* |
|
Form of Restricted Stock Unit Grant Notice
and Form of Restricted Stock Unit Agreement under 2023 Equity Incentive Plan. |
|
|
|
|
|
|
|
|
|
|
|
Incorporated by Reference |
Exhibit No. |
|
Description |
|
Schedule/ Form |
|
File No. |
|
Exhibit |
|
Filing Date |
|
|
|
|
|
|
|
|
|
|
10.24* |
|
TriSalus Life Sciences, Inc. 2023 Employee Stock
Purchase Plan. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.25* |
|
Form of Indemnification Agreement by and between the Company and
its directors and executive officers. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.26* |
|
Non-Employee Director Compensation Policy. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.27+ |
|
Office/Warehouse
Lease, dated February 4, 2014 between Colorado Industrial Portfolio LLC and Surefire Medical, Inc., as amended. |
|
S-4/A |
333-269138 |
|
10.25 |
|
July 6,
2023 |
|
|
|
|
|
|
|
|
10.28# |
|
Asset
Purchase Agreement, dated as of July 31, 2020, by and between Dynavax Technologies Corporation and Surefire Medical Inc. d/b/a TriSalus
Life Sciences. |
|
S-4/A |
333-269138 |
|
10.13 |
|
April 21,
2023 |
|
|
|
|
|
|
|
|
10.29# |
|
Strategic
Collaboration Agreement, dated March 2, 2021, by and between Surefire Medical Inc. d/b/a TriSalus Life Sciences and The University
of Texas M.D. Anderson Cancer Center. |
|
S-4/A |
333-269138 |
|
10.20 |
|
April 21,
2023 |
|
|
|
|
|
|
|
10.30# |
|
Distribution
and Collaboration Agreement, dated May 7, 2019, between Hangzhou Ruizhen Therapeutics Co., Ltd. and Surefire Medical, Inc.
d/b/a TriSalus Life Sciences. |
|
S-4/A |
333-269138 |
|
10.24 |
|
June 8,
2023 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16.1 |
|
Letter from WithumSmith+Brown, PC to the SEC. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21.1 |
|
List of Subsidiaries of TriSalus Life Sciences, Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.1 |
|
Unaudited Condensed Consolidated Financial Statements of Legacy TriSalus as of and for the three and six months
ended June 30, 2023 and for the three and six months ended June 30, 2022. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.2 |
|
Management’s Discussion and Analysis of Financial Condition
and Results of Operations of Legacy TriSalus for the three and six months ended June 30, 2023 and 2022. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.3 |
|
Unaudited Pro Forma Condensed Combined
Financial information of TriSalus Life Sciences, Inc. as of and for the six months ended June 30, 2023 and the year ended December 31,
2022.
|
|
|
|
|
|
|
|
|
99.4 |
|
Press release dated August 10, 2023. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
104 |
|
Cover page Interactive data file (embedded within the inline XBRL document). |
|
|
|
|
|
|
|
|
+ |
The schedules and exhibits to this agreement have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A
copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request. |
# |
Certain portions of this Exhibit have been omitted in accordance with Regulation S-K Item 601(b)(10)(iv) because they
are not material and are the type of information that the Registrant treats as private or confidential. The Registrant agrees to furnish
supplementally an unredacted copy of the Exhibit, or any section thereof, to the SEC upon request |
* |
Indicates management contract or compensatory plan or arrangement. |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: August 16, 2023
|
TRISALUS LIFE SCIENCES, INC. |
|
|
|
|
By: |
/s/ Mary Szela |
|
|
Mary Szela |
|
|
Chief Executive Officer |
Exhibit 3.1
SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
OF
MEDTECH ACQUISITION CORPORATION
MedTech Acquisition Corporation, a corporation organized
and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), DOES
HEREBY CERTIFY AS FOLLOWS:
1. The name of the Corporation
is “MedTech Acquisition Corporation” (the “Corporation”). The original
certificate of incorporation of the Corporation was filed with the Secretary of State of the State of Delaware on September 11, 2020,
and was most recently amended and restated on December 17, 2020 (the “Existing Certificate”).
2. This Second Amended and Restated
Certificate of Incorporation (the “Restated Certificate”), which both restates and amends the provisions of
the Existing Certificate, was duly adopted in accordance with the provisions of Sections 242 and 245 of the DGCL, as amended from
time to time.
3. This Restated Certificate shall
become effective on the date of filing with the Secretary of State of Delaware.
4. Pursuant to Sections 242
and 245 of the DGCL, the text of the Existing Certificate is hereby restated and amended in its entirety to read as follows:
Article I
Name
The name of this Corporation is TriSalus Life Sciences, Inc.
Article II
Registered Agent
The address of the registered office of the Corporation
in the State of Delaware is 251 Little Falls Drive, City of Wilmington, County of New Castle, Zip Code 19808, and the name of the registered
agent of the Corporation in the State of Delaware at such address is Corporation Service Company.
Article III
Purpose
The purpose of the Corporation is to engage in any
lawful act or activity for which a corporation may be organized under the DGCL.
Article IV
Capitalization
A. The Corporation is authorized
to issue two classes of stock to be designated, respectively, “Common Stock” and “Preferred Stock.” The total
number of shares which the Corporation is authorized to issue is 410,000,000 shares. 400,000,000 shares shall be common stock of the Corporation,
par value $0.0001 per share (the “Common Stock”). 10,000,000 shares shall be preferred stock of the Corporation,
par value $0.0001 (the “Preferred Stock”).
B. Effective immediately
upon the filing and effectiveness of this Restated Certificate with the Office of the Secretary of State of the State of Delaware (the
“Effective Time”), each one share of the Corporation’s Class A Common Stock, par value $0.0001 per
share (the “Class A Common Stock”), and each one share of the Corporation’s Class B Common Stock,
par value $0.0001 per share (the “Class B Common Stock”) that was issued and outstanding immediately prior
to the Effective Time shall automatically be reclassified, redesignated and changed into one validly issued, fully paid and non-assessable
share of Common Stock without any further action by the Corporation or any stockholder thereof. Each certificate that immediately prior
to the Effective Time represented shares of Class A Common Stock or Class B Common Stock (each, a “Prior Certificate”)
shall, until surrendered to the Corporation in exchange for a certificate representing the same number of shares of Common Stock, automatically
represent that number of shares of Common Stock into which the shares of Class A Common Stock or Class B Common Stock represented
by the Prior Certificate shall have been reclassified and redesignated.
C. The Preferred Stock may
be issued from time to time in one or more series. The Board of Directors of the Corporation (the “Board of Directors”)
is hereby expressly authorized to provide for the issue of all or any of the remaining shares of the Preferred Stock, in one or more series,
and to fix the number of shares of such series and to determine or alter for each such series, such voting powers, full or limited, or
no voting powers, and such designation, preferences, and relative, participating, optional, or other rights and such qualifications, limitations,
or restrictions thereof, as shall be stated and expressed in the resolution or resolutions adopted by the Board of Directors and filed
in accordance with the DGCL.
D. Each outstanding share
of Common Stock shall entitle the holder thereof to one vote on each matter properly submitted to the stockholders of the Corporation
for their vote; provided, however, that, except as otherwise required by law or as otherwise provided herein, holders of Common
Stock shall not be entitled to vote on any amendment to this Restated Certificate (including any certificate of designation filed with
respect to any series of Preferred Stock) that relates solely to the terms of one or more outstanding series of Preferred Stock if the
holders of such affected series of Preferred Stock are entitled, either separately or together as a class with the holders of one or more
other such series of Preferred Stock, to vote thereon pursuant to law or this Restated Certificate (including any certificate of designation
filed with respect to any series of Preferred Stock).
E. The number of authorized
shares of Common Stock and/or Preferred Stock, or any series thereof, may be increased or decreased (but not below the number of shares
thereof then outstanding plus, if applicable, the number of shares of Common Stock or Preferred Stock or such series, as applicable, reserved
for issuance) by the affirmative vote of the holders of a majority of the voting power of all of the outstanding shares of stock of the
Corporation entitled to vote thereon, irrespective of the provisions of Section 242(b)(2) of the DGCL (or any successor provision
thereto) and without a separate vote of the holders of the Preferred Stock, or of any series thereof, unless a vote of any such holders
is required pursuant to the terms of any certificate of designation filed with respect to any series of Preferred Stock.
Article V
Board of Directors
For the management of the business and for the conduct
of the affairs of the Corporation, and in further definition, limitation and regulation of the powers of the Corporation, of its directors
and stockholders, or any class thereof, as the case may be, it is further provided that:
A. MANAGEMENT OF THE BUSINESS.
Except as otherwise provided by the DGCL or this
Restated Certificate, the management of the business and the conduct of the affairs of the Corporation shall be vested in its Board of
Directors. Subject to any rights of the holders of shares of any series of Preferred Stock then outstanding to elect additional directors
under specified circumstances, the number of directors which shall constitute the Board of Directors shall be fixed exclusively by resolutions
adopted by a majority of the authorized number of directors constituting the Board of Directors.
B. BOARD OF DIRECTORS
Subject to the rights of the holders of any series
of Preferred Stock to elect additional directors under specified circumstances, the directors shall be divided into three classes designated
as Class I, Class II and Class III, respectively. Each class will consist, as nearly as possible, of a number of directors
equal to one-third of the number of members of the Board of Directors authorized as provided in Section A of this Article V.
The Board of Directors is authorized to assign members of the Board of Directors already in office to such classes at the time the classification
becomes effective. At the first annual meeting of stockholders held after the effectiveness of this Restated Certificate, the initial
term of office of the Class I directors shall expire and Class I directors shall be elected for a full term expiring at the
third annual meeting of stockholders held thereafter. At the second annual meeting of stockholders held after the effectiveness of this
Restated Certificate, the initial term of office of the Class II directors shall expire and Class II directors shall be elected
for a full term expiring at the third annual meeting of stockholders held thereafter. At the third annual meeting of stockholders held
after the effectiveness of this Restated Certificate, the initial term of office of the Class III directors shall expire and Class III
directors shall be elected for a full term expiring at the third annual meeting of stockholders held thereafter. At each succeeding annual
meeting of stockholders, directors shall be elected for a full term expiring at the third annual meeting of stockholders held thereafter,
to succeed the directors of the class whose terms expire at such annual meeting.
Notwithstanding the foregoing provisions of this
section, each director shall serve until such director’s successor is duly elected and qualified or until such director’s
earlier death, resignation or removal. No decrease in the number of directors constituting the Board of Directors shall shorten the term
of any incumbent director.
C. REMOVAL OF DIRECTORS
1. Subject to the rights
of any series of Preferred Stock to remove directors elected by such series of Preferred Stock, neither the entire Board of Directors
nor any individual director may be removed from office without cause.
2. Subject to any limitations
imposed by applicable law and the rights of any series of Preferred Stock to remove directors elected by such series of Preferred Stock,
any individual director or the entire Board of Directors may be removed from office with cause by the affirmative vote of the holders
of at least 66⅔% of the voting power of all the then-outstanding shares of the capital stock of the Corporation entitled to vote
generally at an election of directors.
D. VACANCIES.
Subject to any limitations imposed by applicable
law and subject to the rights of the holders of any series of Preferred Stock to elect additional directors or fill vacancies in respect
of such directors, any vacancies on the Board of Directors resulting from death, resignation, disqualification, removal or other causes
and any newly created directorships resulting from any increase in the number of directors, shall, unless the Board of Directors determines
by resolution that any such vacancies or newly created directorships shall be filled by the stockholders, be filled only by the affirmative
vote of a majority of the directors then in office, even though less than a quorum of the Board of Directors or by the sole remaining
director, and not by the stockholders. Any director elected to fill a newly created directorship or vacancy in accordance with the preceding
sentence shall hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until
such director’s successor shall have been elected and qualified or such director’s earlier death, resignation or removal.
E. PREFERRED STOCKHOLDERS ELECTION RIGHTS
Whenever the holders of any one or more series of
Preferred Stock shall have the right, voting separately as a series or separately as a class with one or more such other series, to elect
directors at an annual or special meeting of stockholders, the election, term of office, removal and other features of such directorships
shall be governed by the terms of this Restated Certificate (including any certificate of designation relating to any series of Preferred
Stock) applicable thereto. The number of directors that may be elected by the holders of any such series of Preferred Stock shall be in
addition to the number fixed pursuant to Article V hereof, and the total number of directors constituting the whole Board shall be
automatically adjusted accordingly. Except as otherwise provided by the Board in the resolution or resolutions establishing such series,
whenever the holders of any series of Preferred Stock having such right to elect additional directors are divested of such right pursuant
to the provisions of such stock, the terms of office of all such additional directors elected by the holders of such stock, or elected
to fill any vacancies resulting from the death, resignation, disqualification or removal of such additional directors, shall forthwith
terminate (in which case each such director thereupon shall cease to be qualified as, and shall cease to be, a director) and the total
authorized number of directors of the Corporation shall automatically be reduced accordingly.
F. BYLAW AMENDMENTS.
The Board of Directors is expressly authorized and
empowered to adopt, amend or repeal any provisions of the Bylaws of the Corporation without the assent or vote of the stockholders in
any manner not inconsistent with the laws of the State of Delaware or this Restated Certificate. Any adoption, amendment or repeal of
the Bylaws of the Corporation by the Board of Directors shall require the approval of a majority of the authorized number of directors.
The stockholders shall also have power to adopt, amend or repeal the Bylaws of the Corporation; provided, however, that, in addition
to any vote of the holders of any class or series of stock of the Corporation required by law or by this Restated Certificate, such action
by stockholders shall require the affirmative vote of the holders of at least 66⅔% of the voting power of all of the then-outstanding
shares of the capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class.
G. STOCKHOLDER ACTIONS.
1. The directors of the
Corporation need not be elected by written ballot unless the Bylaws so provide.
2. No action shall be taken
by the stockholders of the Corporation except at an annual or special meeting of stockholders called in accordance with the Bylaws and
no action shall be taken by the stockholders by written consent.
Advance notice of stockholder nominations for the
election of directors and of business to be brought by stockholders before any meeting of the stockholders of the Corporation shall be
given in the manner provided in the Bylaws of the Corporation.
Article VI
Limited Liability; Indemnification
A. The liability of the
directors and officers for monetary damages shall be eliminated to the fullest extent permitted under applicable law. In furtherance thereof,
a director or officer of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for
breach of fiduciary duty as a director or officer, except to the extent such exemption from liability or limitation thereof is not permitted
under the DGCL as the same exists or may hereafter be amended. Any repeal or modification of the foregoing two sentences shall not adversely
affect any right or protection of a director or officer of the Corporation existing hereunder with respect to any act or omission occurring
prior to such repeal or modification. If applicable law is amended after approval by the stockholders of this Article VI to authorize
corporate action further eliminating or limiting the personal liability of directors or officers, then the liability of a director or
officer to the Corporation shall be eliminated or limited to the fullest extent permitted by applicable law as so amended.
B. To the fullest extent
permitted by applicable law, the Corporation is authorized to provide indemnification of (and advancement of expenses to) directors, officers
and agents of the Corporation (and any other persons to which applicable law permits the Corporation to provide indemnification) through
Bylaw provisions, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise.
C. Any repeal or modification
of this Article VI shall only be prospective and shall not adversely affect the rights or protections or increase the liability of
any officer or director under this Article VI as in effect at the time of the alleged occurrence of any act or omission to act giving
rise to liability or indemnification.
Article VII
Forum
A. Unless the Corporation
consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court
of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and
only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) and any appellate
court therefrom shall be the sole and exclusive forum for the following claims or causes of action under the Delaware statutory or common
law: (A) any derivative claim or cause of action brought on behalf of the Corporation; (B) any claim or cause of action for
breach of a fiduciary duty owed by any current or former director, officer or other employee or stockholder of the Corporation, to the
Corporation or the Corporation’s stockholders; (C) any claim or cause of action against the Corporation or any current or former
director, officer or other employee of the Corporation, arising out of or pursuant to any provision of the DGCL, this Restated Certificate
or the Bylaws of the Corporation (as each may be amended from time to time); (D) any claim or cause of action seeking to interpret,
apply, enforce or determine the validity of this Restated Certificate or the Bylaws of the Corporation (as each may be amended from time
to time, including any right, obligation, or remedy thereunder); (E) any claim or cause of action as to which the DGCL confers jurisdiction
on the Court of Chancery of the State of Delaware; and (F) any claim or cause of action against the Corporation or any current or
former director, officer or other employee of the Corporation, governed by the internal-affairs doctrine or otherwise related to the Corporation’s
internal affairs, in all cases to the fullest extent permitted by applicable law and subject to the court having personal jurisdiction
over the indispensable parties named as defendants. This Section A of Article VII shall not apply to claims or causes of action
brought to enforce a duty or liability created by the Securities Act of 1933, as amended (the “1933 Act”), or the Securities
Exchange Act of 1934, as amended, or any other claim for which the federal courts have exclusive jurisdiction.
B. Unless the Corporation
consents in writing to the selection of an alternative forum, to the fullest extent permitted by applicable law, the federal district
courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising
under the 1933 Act, including all causes of action asserted against any defendant named in such complaint.
Article VIII
Corporate Opportunity
The Corporation renounces, to the fullest extent
permitted by law, any interest or expectancy of the Corporation in, or in being offered an opportunity to participate in, any Excluded
Opportunity pursuant to Section 122(17) of the DGCL. An “Excluded Opportunity” is any matter, transaction or interest
that is presented to, or acquired, created or developed by, or which otherwise comes into the possession of (i) any director of the
Corporation who is not an employee of the Corporation or any of its subsidiaries, or (ii) any holder of Common Stock or Preferred
Stock or any partner, member, director, stockholder, employee or agent of any such holder, other than someone who is an employee of the
Corporation or any of its subsidiaries (collectively, “Covered Persons”), unless such matter, transaction or interest is presented
to, or acquired, created or developed by, or otherwise comes into the possession of, a Covered Person solely in such Covered Person’s
capacity as a director of the Corporation, such opportunity is one the Corporation is legally and contractually permitted to undertake,
and to the extent the director is permitted to refer that opportunity to the Corporation without violating any legal obligation. Any amendment,
repeal or modification of the foregoing provisions of this Article VIII shall not adversely affect any right or protection of any
director of the Corporation existing at the time of such amendment, repeal or modification.
Article IX
Miscellaneous
A. Any person or entity
holding, owning, or otherwise acquiring any interest in any security of the Corporation shall be deemed to have notice of and consented
to the provisions of this Restated Certificate.
B. Subject to Sections A
and C of Article VI and the last sentence of Article VIII, the Corporation reserves the right to amend, alter, change or repeal,
at any time and from time to time, any provision contained in this Restated Certificate, in the manner now or hereafter prescribed by
statute, except as provided in paragraph C. of this Article IX, and all rights, preferences and privileges of whatsoever nature conferred
upon the stockholders, directors or any other persons whomsoever by and pursuant to this Restated Certificate in its present form or as
hereafter amended herein are granted subject to this reservation.
C. Notwithstanding any other
provisions of this Restated Certificate or any provision of law that might otherwise permit a lesser vote or no vote, but in addition
to any affirmative vote of the holders of any particular class or series of capital stock of the Corporation required by applicable law
or by this Restated Certificate or any certificate of designation filed with respect to a series of Preferred Stock, the affirmative vote
of the holders of at least 66⅔% of the voting power of all of the then-outstanding shares of capital stock of the Corporation entitled
to vote generally in the election of directors, voting together as a single class, shall be required to alter, amend or repeal (whether
by merger, consolidation or otherwise) or adopt any provision inconsistent with, Articles V, VI, VII, VIII and IX.
IN WITNESS WHEREOF, the Corporation has caused
this Second Amended and Restated Certificate of Incorporation to be executed by a duly authorized officer of this Corporation on August
10, 2023.
|
By: |
/s/ Christopher C. Dewey |
|
|
Name: Christopher C. Dewey |
|
|
Title: Chief Executive Officer |
Exhibit 3.2
AMENDED AND RESTATED
BYLAWS
OF
Trisalus life sciences,
inc.
__________________________________________________
(A DELAWARE CORPORATION)
August 10, 2023
ARTICLE
I
Offices
Section 1.
Registered Office. The registered office of TriSalus Life Sciences, Inc. (the “corporation”) in the State
of Delaware and the name of the corporation’s registered agent at such address shall be as set forth in the Amended and Restated
Certificate of Incorporation of the corporation (as the same may be amended and/or restated from time to time, the “Certificate
of Incorporation”).
Section 2.
Other Offices. The corporation may also have and maintain an office or principal place of business at such place as may be fixed by
the Board of Directors of the corporation (the “Board of Directors”), and may also have offices at such other
places, both within and without the State of Delaware as the Board of Directors may from time to time determine or the business of the
corporation may require.
ARTICLE
II
Corporate Seal
Section 3.
Corporate Seal. The Board of Directors may adopt a corporate seal. Said seal may be used by causing it or a facsimile thereof to be
impressed, affixed or reproduced or otherwise.
ARTICLE
III
Stockholders’ Meetings
Section 4.
Place of Meetings. Meetings of the stockholders of the corporation may be held at such place, if any, either within or without the
State of Delaware, as may be determined from time to time by the Board of Directors. The Board of Directors may, in its sole discretion,
determine that the meeting shall not be held at any place, but may instead be held solely by means of remote communication as provided
under the General Corporation Law of the State of Delaware (“DGCL”) and Section 14 below.
Section 5.
Annual Meetings.
(a) The
annual meeting of the stockholders of the corporation, for the purpose of election of directors and for such other business as may
properly come before it, shall be held on such date, time and place, if any, as may be determined from time to time by the Board of
Directors. Subject to applicable law, the Board of Directors, or any director or officer of the corporation to whom the Board of
Directors delegated such authority, may postpone, reschedule or cancel any annual meeting of stockholders previously scheduled by
the Board of Directors at any time before or after notice of such meeting has been given to stockholders. Nominations of persons for
election to the Board of Directors and proposals of other business to be considered by the stockholders may be made at an annual
meeting of stockholders: (i) pursuant to the corporation’s notice of meeting of stockholders (or any supplement thereto); (ii)
by or at the direction of the Board of Directors or a duly authorized committee thereof; (iii) as may be provided in the certificate
of designation for any class or series of preferred stock; or (iv) by any stockholder of the corporation who was a stockholder of
record at the time of giving the stockholder’s notice provided for in Section 5(b) of these amended and restated bylaws (as
may be amended and/or restated from time to time, the “Bylaws”) and who is a stockholder of record at the
time of the annual meeting of stockholders, who is entitled to vote at the meeting and who complied with the notice procedures set
forth in this Section 5. For the avoidance of doubt, clause (iv) above shall be the exclusive means for a stockholder to make
nominations and submit other business (other than matters properly included in the corporation’s notice of meeting of
stockholders and proxy statement under Rule 14a-8 under the Securities Exchange Act of 1934, as amended, and the rules and
regulations thereunder (the “1934 Act”)) before an annual meeting of stockholders.
(b)
At an annual meeting of the stockholders, only such business shall be conducted as is a proper matter for stockholder action under
the DGCL, the Certificate of Incorporation, the Bylaws, and only such nominations shall be made and such business shall be conducted as
shall have been properly brought before the meeting in accordance with the procedures below.
(i) For
nominations for the election to the Board of Directors to be properly brought before an annual meeting by a stockholder pursuant to
clause (iv) of Section 5(a), the stockholder must deliver written notice to the Secretary at the principal executive offices of
the corporation on a timely basis as set forth in Section 5(b)(iii) and must update and supplement the information contained in such
written notice on a timely basis as set forth in Section 5(c). Such stockholder’s notice shall include: (A) as to each nominee
such stockholder proposes to nominate at the meeting: (1) the name, age, business address and residence address of such nominee, (2)
the principal occupation or employment of such nominee, (3) the class or series and number of shares of each class or series of
capital stock of the corporation that are owned of record and beneficially by such nominee and a list of any pledges of or
encumbrances on such shares, (4) the date or dates on which such shares were acquired and the investment intent of such acquisition,
(5) the questionnaire, representation and agreement required by Section 5(e), completed and signed by such nominee; and (6) all
other information concerning such nominee as would be required to be disclosed or provided to the corporation in a proxy statement
soliciting proxies for the election of such nominee as a director in an election contest (even if an election contest is not
involved and whether or not proxies are being or will be solicited), or that is otherwise required to be disclosed pursuant to
applicable requirements of state and federal law, including Section 14 of the 1934 Act and the rules and regulations promulgated
thereunder, the Certificate of Incorporation, and these Bylaws (including such person’s written consent to being named in the
corporation’s proxy statement and associated proxy card and other filings as a nominee of the stockholder and to serving as a
director if elected); and (B) all of the information required by Section 5(b)(iv). The corporation may require any proposed nominee
to furnish such other information as it may reasonably require to determine the eligibility of such proposed nominee to serve as a
director of the corporation and to determine the independence (as such term is used in any applicable stock exchange listing
requirements or applicable law) of such proposed nominee or to determine the eligibility of such proposed nominee to serve on any
committee or sub-committee of the Board of Directors under any applicable stock exchange listing requirements or applicable law, or
that the Board of Directors determines, in its sole discretion, could be material to a reasonable stockholder’s understanding
of the background, qualifications, experience, independence, or lack thereof, of such proposed nominee. The
number of nominees a stockholder may nominate for election at the annual meeting of stockholders (or in the case of a stockholder
giving the notice on behalf of a beneficial owner, the number of nominees a stockholder may nominate for election at the annual
meeting of stockholders on behalf of such beneficial owner) shall not exceed the number of directors to be elected at such annual
meeting. A stockholder may not designate any substitute nominees unless the stockholder provides timely notice of such substitute
nominee(s) in accordance with this Section 5, in the case of an annual meeting, or Section 6, in the case of a special meeting (and
such notice contains all of the information, representations, questionnaires and certifications with respect to such substitute
nominee(s) that are required by the Bylaws with respect to nominees for director).
(ii)
For business other than nominations for the election to the Board of Directors to be properly brought before an annual meeting by
a stockholder pursuant to clause (iv) of Section 5(a), the Proposing Person must deliver written notice to the Secretary at the principal
executive offices of the corporation on a timely basis as set forth in Section 5(b)(iii), and must update and supplement such written
notice on a timely basis as set forth in Section 5(c). The Proposing Person’s notice shall set forth: (A) as to each matter the
Proposing Person proposes to bring before the meeting, a brief description of the business desired to be brought before the meeting, the
text of the proposal or business (including the text of any resolutions proposed for consideration and in the event that such business
includes a proposal to amend the Bylaws, the language of the proposed amendment), the reasons for conducting such business at the meeting,
and any material interest (including any anticipated benefit of such business to any Proposing Person (as defined below) other than solely
as a result of its ownership of the corporation’s capital stock, that is material to any Proposing Person individually, or to the
Proposing Persons in the aggregate) in such business of any Proposing Person; and (B) the information required by Section 5(b)(iv).
(iii)
To be timely, the written notice required by Section 5(b)(i) or 5(b)(ii) must be received by the Secretary at the principal executive
offices of the corporation not later than the close of business on the 90th day, nor earlier than the close of business on
the 120th day, prior to the first anniversary of the date (as stated in the corporation’s proxy materials) the definitive
proxy statement was first sent to stockholders in connection with the preceding year’s annual meeting of stockholders (for purposes
of notice required for action to be taken at the corporation’s annual meeting of stockholders for the 2024 calendar year, the date
of the 2023 annual meeting shall be deemed to have occurred on August 8, 2023); provided, however, that, subject to the last sentence
of this Section 5(b)(iii), in the event that the date of the annual meeting is advanced more than 30 days prior to or delayed by more
than 70 days after the anniversary of the preceding year’s annual meeting, or if no annual meeting was held (or deemed to have been
held), notice by the stockholder to be timely must be so received not earlier than the close of business on the 120th day prior
to such annual meeting and not later than the close of business on the later of the 90th day prior to such annual meeting or,
if later than the 90th day prior to such annual meeting, the tenth day following the day on which public announcement of the
date of such meeting is first made by the corporation. In no event shall an adjournment or postponement of an annual meeting (or the public
announcement thereof) for which notice has been given, or for which a public announcement of the date of the meeting has been made by
the corporation, commence a new time period (or extend any time period) for the giving of a stockholder’s notice as described above.
(iv) The
written notice required by Sections 5(b)(i) or 5(b)(ii) shall also set forth, as of the date of the notice and as to the Proposing
Person: (A) the name and address of each Proposing Person, including, if applicable, such name and address as they appear on the
corporation’s books and records; (B) the class, series and number of shares of each class or series of the capital stock of
the corporation that are, directly or indirectly, owned of record or beneficially (within the meaning of Rule 13d-3 under the 1934
Act) by each Proposing Person (provided, that for purposes of this Section 5(b)(iv), such Proposing Person shall in all events be
deemed to beneficially own all shares of any class or series of capital stock of the corporation as to which such Proposing Person
or any of its affiliates or associates has a right to acquire beneficial ownership at any time in the future); (C) a description of
any agreement, arrangement or understanding (whether oral or in writing) with respect to such nomination or proposal (and/or the
voting of shares of any class or series of capital stock of the corporation) between or among any Proposing Person and any of its
affiliates or associates, and/or any other persons (including their names), including without limitation, any agreements,
arrangements or understandings required to be disclosed pursuant to Item 5 or Item 6 of Schedule 13D under the 1934 Act, regardless
of whether the requirement to file a Schedule 13D is applicable; (D) a representation that the Proposing Persons are holders of
record or beneficial owners, as the case may be, of shares of the corporation at the time of giving notice, will be entitled to vote
at the meeting, and that such stockholder (or a qualified representative thereof) intends to appear in person or by proxy at the
meeting to nominate the person or persons specified in the notice (with respect to a notice under Section 5(b)(i)) or to propose the
business that is specified in the notice (with respect to a notice under Section 5(b)(ii)); (E) a representation as to whether the
Proposing Persons or any other participant (as defined in Item 4 of Schedule 14A under the 1934 Act) intend to solicit proxies from
the required number of the corporation’s voting shares in support of any proposed nominee, as promulgated under Rule 14a-19 of
the 1934 Act (with respect to a notice under Section 5(b)(i)), and, if so, the name of each participant in such solicitation and the
amount of the cost of solicitation that has been and will be borne, directly or indirectly, by each participant in such
solicitation, and a representation as to whether the Proposing Persons intend or are part of a group which intends to (x) deliver,
or make available, a proxy statement and/or form of proxy to holders of at least such percentage of the corporation’s voting
shares that would be required to approve or adopt the proposal or elect the nominee or (y) otherwise solicit proxies or votes from
stockholders in support of such proposal (with respect to a notice under Section 5(b)(ii)); (F) to the extent known by any Proposing
Person, the name and address of any other stockholder supporting the proposal on the date of such stockholder’s notice; (G) a
description of all Derivative Transactions (as defined below) by each Proposing Person during the previous 12 month period,
including the date of the transactions and the class, series and number of securities involved in, and the material economic or
voting terms of, such Derivative Transactions; (H) a certification regarding whether each Proposing Person has complied with all
applicable federal, state and other legal requirements in connection with such Proposing Person’s acquisition of shares of
capital stock or other securities of the corporation and/or such Proposing Person’s acts or omissions as a stockholder or
beneficial owner of the corporation; and (I) any other information relating to each Proposing Person required to be disclosed in a
proxy statement or other filings required to be made in connection with solicitations of proxies for, as applicable, the proposal
and/or for the election of directors in an election contest pursuant to and in accordance with Section 14 of the 1934 Act and the
rules and regulations promulgated thereunder.
(c) A
Proposing Person providing the written notice required by Section 5(b)(i) or (ii) shall update and supplement such notice in
writing, if necessary, so that the information (other than the representations required by Section 5(b)(iv)(E)) provided or required
to be provided in such notice is true and correct in all material respects as of (i) the record date for the determination of
stockholders entitled to notice of the meeting and (ii) the date that is five Business Days (as defined below) prior to the meeting
and, in the event of any adjournment or postponement thereof, five Business Days prior to such adjourned or postponed meeting;
provided, that no such update or supplement shall cure or affect the accuracy (or inaccuracy) of any representations made by any
Proposing Person, any of its affiliates or associates or a nominee, or the validity (or invalidity) of any nomination or proposal
that failed to comply with this Section 5 or is rendered invalid as a result of any inaccuracy therein. In the case of an update and
supplement pursuant to clause (i) of this Section 5(c), such update and supplement shall be received by the Secretary at the
principal executive offices of the corporation not later than five Business Days after the public announcement of the record date
for the determination of stockholders entitled to notice of the meeting. In the case of an update and supplement pursuant to clause
(ii) of this Section 5(c), such update and supplement shall be received by the Secretary at the principal executive offices of the
corporation not later than two Business Days prior to the date for the meeting, and, in the event of any adjournment or postponement
thereof, two Business Days prior to such adjourned or postponed meeting.
(d)
Notwithstanding anything in Section 5(b)(iii) to the contrary, in the event that the number of directors to be elected to the Board
of Directors at the next annual meeting is increased effective after the time period for which nominations would otherwise be due under
Section 5(b)(iii) and there is no public announcement by the corporation naming all of the nominees for the new positions created by such
increase at least 100 days before the first anniversary of the preceding year’s annual meeting, a Proposing Person’s notice
required by this Section 5 and that complies with the requirements in Section 5(b)(i), other than the timing requirements in Section
5(b)(iii), shall also be considered timely, but only with respect to nominees for the new positions created by such increase, if it shall
be received by the Secretary at the principal executive offices of the corporation not later than the close of business on the tenth day
following the day on which such public announcement is first made by the corporation.
(e)
To be eligible to be a nominee for election or re-election as a director of the corporation pursuant to a nomination under Section
5 or Section 6, each Proposing Person must deliver (in accordance with the time periods prescribed for delivery of notice under Section
5(b)(iii) to the Secretary at the principal executive offices of the corporation a written questionnaire with respect to the background,
qualifications, stock ownership and independence of such proposed nominee and the background of any other person or entity on whose behalf
the nomination is being made (in the form provided by the Secretary within 10 days following a written request therefor by a stockholder
of record) and a written representation and agreement (in the form provided by the Secretary within 10 days following written request
therefor by a stockholder of record) that such person (i) is not and will not become a party to (A) any agreement, arrangement or understanding
(whether oral or in writing) with, and has not given any commitment or assurance to, any person or entity as to how such person, if elected
as a director of the corporation, will act or vote on any issue or question (a “Voting Commitment”) that has
not been disclosed to the corporation in the questionnaire or (B) any Voting Commitment that could limit or interfere with such person’s
ability to comply, if elected as a director of the corporation, with such person’s fiduciary duties under applicable law; (ii) is
not and will not become a party to any agreement, arrangement or understanding (whether oral or in writing) with any person or entity
other than the corporation with respect to any direct or indirect compensation, reimbursement or indemnification in connection with service
or action as a director of the corporation or a nominee that has not been disclosed in such questionnaire; (iii) would be in compliance,
if elected as a director of the corporation, and will comply with, all applicable publicly disclosed corporate governance, conflict of
interest, confidentiality and stock ownership and trading policies and guidelines of the corporation; and (iv) if elected as a director
of the corporation, intends to serve the entire term until the next meeting at which such candidate would face re-election.
(f) A
person shall not be eligible for election or re-election as a director at an annual meeting, unless the person is nominated, in the
case of an annual meeting, in accordance with either clause (ii), (iii) or (iv) of Section 5(a) and in accordance with the
procedures set forth in Section 5(b), Section 5(c), Section 5(d) and Section 5(e), as applicable, or in the case of a special
meeting, in accordance with Section 6(c). Only such business shall be conducted at any annual meeting of the stockholders of the
corporation as shall have been brought before the meeting in accordance with clauses (i), (ii), (iii) or (iv) of Section 5(a) and in
accordance with the procedures set forth in Section 5(b), Section 5(c), Section 5(d) and Section 5(e), as applicable.
Notwithstanding anything to the contrary in the Bylaws, unless otherwise required by applicable law, if any Proposing Person (i)
provides notice pursuant to Rule 14a-19(b) promulgated under the 1934 Act with respect to any proposed nominee and (ii) subsequently
(x) fails to comply with the requirements of Rule 14a-19 promulgated under the 1934 Act (or fails to timely provide reasonable
evidence sufficient to satisfy the corporation that such Proposing Person has met the requirements of Rule 14a-19(a)(3) promulgated
under the 1934 Act in accordance with the following sentence) or (y) fails to inform the corporation that they no longer plan to
solicit proxies in accordance with the requirements of Rule 14a-19 under the 1934 Act by delivering a written notice to the
Secretary at the principal executive offices of the corporation within two Business Days after the occurrence of such change, then
the nomination of each such proposed nominee shall be disregarded (and such nominee disqualified from standing for election or
re-election), notwithstanding that the nominee is included (as applicable) as a nominee in the corporation’s proxy statement,
notice of meeting or other proxy materials for any stockholder meeting (or any supplement thereto) and notwithstanding that proxies
or votes in respect of the election of such proposed nominees may have been received by the corporation (which proxies and votes
shall be disregarded). Upon request by the corporation, if any Proposing Person provides notice pursuant to Rule 14a-19(b)
promulgated under the 1934 Act, such Proposing Person shall deliver to the corporation, no later than five Business Days prior to
the applicable meeting, reasonable evidence that it has met the requirements of Rule 14a-19(a)(3) promulgated under the 1934 Act.
Notwithstanding anything to the contrary set forth herein, and for the avoidance of doubt, the nomination of any person whose name
is included (as applicable) as a nominee in the corporation’s proxy statement, notice of meeting or other proxy materials for
any stockholder meeting (or any supplement thereto) as a result of any notice provided by any Proposing Person pursuant to Rule
14a-19(b) promulgated under the Exchange Act with respect to such proposed nominee and whose nomination is not made by or at the
direction of the Board of Directors or any authorized committee thereof shall not be deemed (for purposes of clause (i) of Section
5(a) or otherwise) to have been made pursuant to the corporation’s notice of meeting (or any supplement thereto) and any such
nominee may only be nominated by a Proposing Person pursuant to clause (b) of Section 5 and, in the case of a special meeting of
stockholders, pursuant to and to the extent permitted under Section 6(c) of these Bylaws. Except as otherwise required by applicable
law, the chairperson of the meeting shall have the power and duty to determine whether a nomination or any business proposed to be
brought before the meeting was made, or proposed, as the case may be, in accordance with the procedures and requirements set forth
in the Bylaws (including, without limitation, compliance with Rule 14a-19 promulgated under the 1934 Act) and, if any proposed
nomination or business is not in compliance with the Bylaws, or the Proposing Person does not act in accordance with the
representations in Sections 5(b)(iv)(D), 5(b)(iv)(E) and 5(e), to declare that such proposal or nomination shall not be presented
for stockholder action at the meeting and shall be disregarded (and such nominee disqualified from standing for election or
re-election), or that such business shall not be transacted, notwithstanding such proposal or nomination is set forth in (as
applicable) the corporation’s proxy statement, notice of meeting or other proxy materials and notwithstanding that proxies or
votes in respect of such nomination or such business may have been solicited or received.
Notwithstanding the foregoing provisions of this Section 5(f), unless otherwise required by applicable law, if the stockholder (or a
qualified representative of the stockholder) does not appear at the annual meeting of stockholders of the corporation to present a
nomination or proposed business, such nomination shall be disregarded (and such nominee disqualified from standing for election or
re-election) and such proposed business shall not be transacted, notwithstanding such nomination or proposed business is set forth
in (as applicable) the corporation’s proxy statement, notice of meeting or other proxy materials and notwithstanding that
proxies in respect of such vote may have been received by the corporation. For purposes of this Section 5(f), to be considered a
qualified representative of the stockholder, a person must be a duly authorized officer, manager or partner of such stockholder or
must be authorized by a writing executed by such stockholder or an electronic transmission delivered by such stockholder to act for
such stockholder as proxy at the meeting of stockholders and such person must produce such writing or electronic transmission, or a
reliable reproduction of the writing or electronic transmission, at the meeting of stockholders.
(g)
For purposes of Sections 5 and 6,
(i)
“affiliates” and “associates” shall have the meanings set forth in Rule 405 under
the Securities Act of 1933, as amended (the “1933 Act”);
(ii)
“Business Day” means any day other than Saturday, Sunday or a day on which banks are closed in New York
City, New York;
(iii)
“close of business” means 6:00 p.m. local time at the principal executive offices of the corporation on
any calendar day, whether or not the day is a Business Day;
(iv)
“Derivative Transaction” means any agreement, arrangement, interest or understanding entered into by, or
on behalf or for the benefit of, any Proposing Person or any of its affiliates or associates, whether record or beneficial:
(A) the value of which
is derived in whole or in part from the value of any class or series of shares or other securities of the corporation;
(B) that otherwise
provides any direct or indirect opportunity to gain or share in any gain derived from a change in the value of securities of the corporation;
(C) the effect or
intent of which is to mitigate loss, manage risk or benefit from changes in value or price with respect to any securities of the corporation;
or
(D) that provides
the right to vote or increase or decrease the voting power of, such Proposing Person, or any of its affiliates or associates, directly
or indirectly, with respect to any securities of the corporation,
which agreement, arrangement,
interest or understanding may include, without limitation, any option, warrant, debt position, note, bond, convertible security, swap,
stock appreciation or similar right, short position, profit interest, hedge, right to dividends, voting agreement, performance-related
fee or arrangement to borrow or lend shares (whether or not subject to payment, settlement, exercise or conversion in any such class or
series), and any proportionate interest of such Proposing Person in the securities of the corporation held by any general or limited partnership,
or any limited liability company, of which such Proposing Person is, directly or indirectly, a general partner or managing member; and
(v) “Proposing
Person” includes each of the stockholders giving the notice, the beneficial owner or beneficial owners, if different,
on whose behalf the nomination or proposal for other business subject to Section 5 of Article III is made, any of their respective
affiliates or associates (including, if such stockholder or beneficial owner is an entity, each director, executive, managing member
or control person of such entity), and any others acting in concert.
(vi)
“public announcement” shall mean disclosure in a press release reported by the Dow Jones News Service, Associated
Press or comparable national news service or in a document publicly filed by the corporation with the Securities and Exchange Commission
pursuant to Section 13, 14 or 15(d) of the 1934 Act or by such other means reasonably designed to inform the public or security holders
in general of such information, including, without limitation, posting on the corporation’s investor relations website.
Section 6.
Special Meetings.
(a)
Special meetings of the stockholders of the corporation may be called, for any purpose as is a proper matter for stockholder action
under Delaware law, by (i) the Chairperson of the Board of Directors, (ii) the Chief Executive Officer, or (iii) the Board
of Directors pursuant to a resolution adopted by the Board of Directors.
(b)
The Board of Directors shall determine the date, time and place, if any, of such special meeting. Upon determination of the date,
time and place, if any, of the meeting, the Secretary shall cause a notice of meeting to be given to the stockholders entitled to vote,
in accordance with the provisions of Section 7. No business may be transacted at such special meeting otherwise than specified in
the notice of meeting.
(c) Only
such business (including the election of specific individuals to fill vacancies or newly created directorships on the Board of
Directors) shall be conducted at a special meeting of stockholders as shall have been brought before the meeting pursuant to the
corporation’s notice of meeting. Nominations of persons for election to the Board of Directors may be made at a special
meeting of stockholders at which directors are to be elected (i) by or at the direction of the Board of Directors or a duly
authorized committee thereof or (ii) by any stockholder of the corporation who is a stockholder of record (and, with respect to any
beneficial owner, if different, on whose behalf such nomination or nominations are made, only if such beneficial owner was the
beneficial owner of shares of the corporation) at the time of giving notice provided for in this paragraph and who is a stockholder
of record at the time of the special meeting, who is entitled to vote at the meeting and who delivers written notice to the
Secretary of the corporation setting forth the information required by Sections 5(b)(i), 5(b)(iv) and 5(e). The number of nominees a
stockholder may nominate for election at a special meeting on its own behalf (or in the case of a stockholder giving the notice on
behalf of a beneficial owner, the number of nominees a stockholder may nominate for election at the special meeting on behalf of
such beneficial owner) shall not exceed the number of directors to be elected at such special meeting. In the event the corporation
calls a special meeting of stockholders for the purpose of electing one or more directors to the Board of Directors, any such
stockholder of record may nominate a person or persons (as the case may be), for election to such position(s) as specified in the
corporation’s notice of meeting, if written notice setting forth the information required by Sections 5(b)(i), 5(b)(iv) and
5(e) shall be received by the Secretary at the principal executive offices of the corporation not earlier than 120 days prior to
such special meeting and not later than the close of business on the later of the 90th day prior to such meeting or the
tenth day following the day on which the corporation first makes a public announcement of the date of the special meeting and of the
nominees proposed by the Board of Directors to be elected at such meeting. The stockholder shall also update and supplement such
information as required under Section 5(c). In no event shall an adjournment or a postponement of a special meeting for which notice
has been given, or the public announcement thereof has been made, commence a new time period (or
extend any time period) for the giving of a stockholder’s notice as described above.
(d)
A person shall not be eligible for election or re-election as a director at the special meeting unless the person is nominated either
in accordance with clause (i) or clause (ii) of Section 6(c). Except as otherwise required by applicable law, the chairperson of the meeting
shall have the power and duty to determine whether a nomination was made in accordance with the procedures and requirements set forth
in the Bylaws and, if any proposed nomination or business is not in compliance with the Bylaws (including, without limitation, compliance
with Rule 14a-19 under the 1934 Act), or if the Proposing Person does not act in accordance with the representations in Sections 5(b)(iv)(D),
5(b)(iv)(E) and 5(e), to declare that such nomination shall not be presented for stockholder action at the meeting and shall be disregarded
(and such nominee disqualified from standing for election or re-election), notwithstanding that such nomination is set forth in (as applicable)
the corporation’s proxy statement, notice of meeting or other proxy materials and notwithstanding that proxies in respect of such
nomination may have been solicited or received. Notwithstanding the foregoing provisions of this Section 6(d), unless otherwise required
by applicable law, if the stockholder or a qualified representative of the stockholder does not appear at the special meeting of stockholders
of the corporation to present a nomination, such nomination shall be disregarded (and such nominee disqualified from standing for election
or re-election), notwithstanding that the nomination is set forth (as applicable) in the corporation’s proxy statement, notice of
meeting or other proxy materials and notwithstanding that proxies or votes in respect of such nomination may have been solicited or received
by the corporation.
(e)
Notwithstanding the foregoing provisions of Sections 5 and 6, a stockholder must also comply with all applicable requirements
of the 1934 Act and the rules and regulations promulgated thereunder with respect to matters set forth in Sections 5 and 6, and any failure
to comply with such requirements shall be deemed a failure to comply with Section 5 or 6, as applicable, provided, however, that
to the fullest extent not prohibited by applicable law, any references in these Bylaws to the 1934 Act or the rules and regulations promulgated
thereunder are not intended to and shall not limit the requirements applicable to proposals and/or nominations for the election to the
Board of Directors to be considered pursuant to Sections 5 or 6. Nothing in the Bylaws shall be deemed to affect any rights of holders
of any class or series of preferred stock to nominate and elect directors pursuant to and to the extent provided in any applicable provision
of the Certificate of Incorporation.
Section
7. Notice of Meetings. Except as otherwise provided by applicable
law or the Certificate of Incorporation or the Bylaws, notice, given in writing or by electronic transmission, of each meeting of
stockholders shall be given not less than ten nor more than 60 days before the date of the meeting to each stockholder entitled to
vote at such meeting. Such notice shall be given in the manner provided in Section 232 of the DGCL and shall specify the date, time,
place, if any, in the case of special meetings, the purpose or purposes of the meeting, the record date for determining stockholders
entitled to vote at the meeting, if such record date is different from the record date for determining stockholders entitled to
notice of the meeting, and the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be
present in person and vote at any such meeting. If mailed, notice is given when deposited in the United States mail, postage
prepaid, directed to the stockholder at such stockholder’s address as it appears on the records of the corporation. If sent
via electronic transmission, notice is given when directed to such stockholder’s electronic mail address unless (a) the
stockholder has notified the corporation in writing or by electronic transmission of an objection to receiving notice by electronic
mail or (b) electronic transmission of such notice is prohibited by applicable law. Notice of the time, place, if any, and purpose
of any meeting of stockholders (to the extent required) may be waived in writing, signed by the person entitled to notice thereof,
or by electronic transmission by such person, either before or after such meeting, and will be waived by any stockholder by his or
her attendance thereat in person, by remote communication, if applicable, or by proxy, except when the stockholder attends a meeting
for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not
lawfully called or convened. Any stockholder so waiving notice of such meeting shall be bound by the proceedings of any such meeting
in all respects as if due notice thereof had been given.
Section 8.
Quorum and Vote Required. At all meetings of stockholders, except where otherwise provided by statute or by the Certificate of Incorporation,
or by the Bylaws, the presence, in person, by remote communication, if applicable, or by proxy duly authorized, of the holders of a majority
of the voting power of the outstanding shares of stock entitled to vote at the meeting shall constitute a quorum for the transaction of
business. In the absence of a quorum, any meeting of stockholders may be adjourned, with or without notice, other than announcement at
the meeting or in a manner otherwise permitted by DGCL, from time to time, either by the chairperson of the meeting or by vote of the
holders of a majority of the voting power of the shares represented thereat and entitled to vote thereon, but no other business shall
be transacted at such meeting. The stockholders present at a duly called or convened meeting, at which a quorum is present, may continue
to transact business until adjournment, notwithstanding the withdrawal of enough stockholders to leave less than a quorum.
Unless a different or minimum vote is required
by statute or by applicable stock exchange rules, or by the Certificate of Incorporation or the Bylaws, in which case such different or
minimum vote shall be the applicable vote on the matter, in all matters other than the election of directors, the affirmative vote of
the holders of a majority of the voting power of the shares present in person, by remote communication, if applicable, or represented
by proxy duly authorized at the meeting and voting affirmatively or negatively (excluding abstentions and broker non-votes) on such matter
shall be the act of the stockholders. Except as otherwise provided by statute or by applicable stock exchange rules, the Certificate of
Incorporation or the Bylaws, directors shall be elected by a plurality of the votes of the shares present in person, by remote communication,
if applicable, or represented by proxy duly authorized at the meeting and entitled to vote generally on the election of directors. Where
a separate vote by a class or classes or series is required, except where otherwise provided by statute or by the Certificate of Incorporation
or the Bylaws or any applicable stock exchange rules, the holders of a majority of the voting power of the outstanding shares of such
class or classes or series, present in person, by remote communication, if applicable, or represented by proxy duly authorized, shall
constitute a quorum entitled to take action with respect to that vote on that matter. Unless a different or minimum vote is required by
statute or by the Certificate of Incorporation or the Bylaws or any applicable stock exchange rules, in which case such different or minimum
vote shall be the applicable vote on the matter, the affirmative vote of the holders of a majority (plurality, in the case of the election
of directors) of the voting power of the shares of such class or classes or series present in person, by remote communication, if applicable,
or represented by proxy duly authorized at the meeting and voting affirmatively or negatively (excluding abstention and broker non-votes)
on such matter shall be the act of such class or classes or series.
Section
9. Adjournment and Notice of Adjourned Meetings. Any
meeting of stockholders, whether annual or special, may be adjourned from time to time either by the chairperson of the meeting or
by the vote of the holders of a majority of the voting power of the shares present in person, by remote communication, if
applicable, or represented by proxy duly authorized at the meeting and entitled to vote thereon. When a meeting is adjourned to
another time or place, if any, (including an adjournment taken to address a technical failure to convene or continue a meeting using
remote communication) notice need not be given of the adjourned meeting if the time and place, if any, thereof and the means of
remote communication, if any, by which stockholders and proxyholders may be deemed present in person and may vote at such meeting
are announced at the meeting at which the adjournment is taken. or are (i) displayed, during the time scheduled for the meeting, on
the same electronic network used to enable stockholders and proxy holders to participate in the meeting by means of remote
communication or (ii) set forth in the notice of meeting given in accordance with Section 7. At the adjourned meeting, the
corporation may transact any business that might have been transacted at the original meeting. If the adjournment is for more than
30 days or if after the adjournment a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be
given to each stockholder of record entitled to vote at the meeting. If after the adjournment a new record date for determination of
stockholders entitled to vote is fixed for the adjourned meeting, the Board of Directors shall fix as the record date for
determining stockholders entitled to notice of such adjourned meeting the same or an earlier date as that fixed for determination of
stockholders entitled to vote at the adjourned meeting, and shall give notice of the adjourned meeting to each stockholder of record
as of the record date so fixed for notice of such adjourned meeting.
Section 10.
Voting Rights. For the purpose of determining those stockholders entitled to vote at any meeting of the stockholders or adjournment
thereof, except as otherwise provided by applicable law, only persons in whose names shares stand on the stock records of the corporation
on the record date shall be entitled to vote at any meeting of stockholders. Every person entitled to vote shall have the right to do
so either in person, by remote communication, if applicable, or by an agent or agents authorized by a proxy granted in accordance with
Delaware law. An agent so appointed need not be a stockholder. Every proxy must be authorized by an instrument in writing or by a transmission
permitted by law, including Rule 14a-19 promulgated under the 1934 Act, filed in accordance with the procedure established for the meeting
and signed by the stockholder or by such stockholder’s attorney-in-fact. No proxy shall be voted after three years from its date
of creation unless the proxy provides for a longer period. A proxy shall be irrevocable if it states that it is irrevocable and if, and
only as long as, it is coupled with an interest sufficient in law to support an irrevocable power. A stockholder may revoke any proxy
which is not irrevocable by attending the meeting and voting in person or by delivering to the Secretary of the corporation a revocation
of the proxy or a new proxy bearing a later date. Voting at meetings of stockholders need not be by written ballot. Any stockholder directly
or indirectly soliciting proxies from other stockholders must use a proxy card color other than white, which shall be reserved for the
exclusive use of the Board of Directors.
Section 11.
Joint Owners of Stock. If shares or other securities having voting power stand of record in the names of two or more persons, whether
fiduciaries, members of a partnership, joint tenants, tenants in common, tenants by the entirety, or otherwise, or if two or more persons
have the same fiduciary relationship respecting the same shares, unless the Secretary is given written notice to the contrary and is furnished
with a copy of the instrument or order appointing them or creating the relationship wherein it is so provided, their acts with respect
to voting shall have the following effect: (a) if only one votes, his or her act binds all; (b) if more than one votes, the
act of the majority so voting binds all; (c) if more than one votes, but the vote is evenly split on any particular matter, each
faction may vote the securities in question proportionally, or may apply to the Delaware Court of Chancery for relief as provided in Section 217(b)
of the DGCL. If the instrument filed with the Secretary shows that any such tenancy is held in unequal interests, a majority or even-split
for the purpose of subsection (c) shall be a majority or even-split in interest.
Section 12.
List of Stockholders. The corporation shall prepare, no
later than the tenth day before each meeting of stockholders, a complete list of the stockholders entitled to vote at said meeting, arranged
in alphabetical order, showing the address of each stockholder and the number and class of shares registered in the name of each stockholder;
provided, however, if the record date for determining the stockholders entitled to vote is less than ten days before the meeting date,
the list shall reflect all of the stockholders entitled to vote as of the tenth day before the meeting date. Such list shall be open
to the examination of any stockholder, for any purpose germane to the meeting, (a) on a reasonably accessible electronic network,
provided that the information required to gain access to such list is provided with the notice of the meeting, or (b) during ordinary
business hours, at the principal place of business of the corporation. In the event that the corporation determines to make the list
available on an electronic network, the corporation may take reasonable steps to ensure that such information is available only to stockholders
of the corporation.
Section 13.
Action without Meeting.
No action shall be taken by
the stockholders of the corporation except at an annual or special meeting of stockholders duly called in accordance with the Bylaws,
and no action shall be taken by the stockholders by written consent.
Section 14.
Remote Communication. For the purposes of the Bylaws, if authorized by the Board of Directors in its sole discretion, and subject
to such guidelines and procedures as the Board of Directors may adopt, stockholders and proxyholders may, by means of remote communication:
(a)
participate in a meeting of stockholders; and
(b)
be deemed present in person and vote at a meeting of stockholders whether such meeting is to be held at a designated place or solely
by means of remote communication, provided that (i) the corporation shall implement reasonable measures to verify that each person deemed
present and permitted to vote at the meeting by means of remote communication is a stockholder or proxyholder, (ii) the corporation shall
implement reasonable measures to provide such stockholders and proxyholders a reasonable opportunity to participate in the meeting and
to vote on matters submitted to the stockholders, including an opportunity to read or hear the proceedings of the meeting substantially
concurrently with such proceedings, and (iii) if any stockholder or proxyholder votes or takes other action at the meeting by means of
remote communication, a record of such vote or other action shall be maintained by the corporation.
Section 15.
Organization.
(a)
At every meeting of stockholders, the Chairperson of the Board of Directors, or, if a Chairperson has not been appointed, is absent
or refuses to act, the Chief Executive Officer, or if no Chief Executive Officer is then serving or the Chief Executive Officer is absent
or refuses to act, the President, or, if the President is absent or refuses to act, a chairperson of the meeting designated by the Board
of Directors, or, if the Board of Directors does not designate such chairperson, a chairperson of the meeting chosen by a majority of
the voting power of the stockholders entitled to vote, present in person or by proxy duly authorized, shall act as chairperson of the
meeting of stockholders. The Chairperson of the Board of Directors may appoint the Chief Executive Officer as chairperson of the meeting.
The Secretary, or, in his or her absence, an Assistant Secretary or other officer or other person directed to do so by the chairperson
of the meeting, shall act as secretary of the meeting.
(b)
The Board of Directors shall be entitled to make such rules or regulations for the conduct of meetings of stockholders as it shall
deem necessary, appropriate or convenient. Subject to such rules and regulations of the Board of Directors, if any, the chairperson of
the meeting shall have the right and authority to convene and (for any or no reason) to recess and/or adjourn the meeting, to prescribe
such rules, regulations and procedures and to do all such acts as, in the judgment of such chairperson, are necessary, appropriate or
convenient for the proper conduct of the meeting, including, without limitation, establishing an agenda or order of business for the meeting,
rules and procedures for maintaining order at the meeting and the safety of those present, limitations on participation in such meeting
to stockholders of record of the corporation and their duly authorized and constituted proxies and such other persons as the chairperson
shall permit, restrictions on entry to the meeting after the time fixed for the commencement thereof, limitations on the time allotted
to questions or comments by participants and regulation of the opening and closing of the polls for balloting on matters that are to be
voted on by ballot. The date and time of the opening and closing of the polls for each matter upon which the stockholders will vote at
the meeting shall be announced at the meeting. Unless and to the extent determined by the Board of Directors or the chairperson of the
meeting, meetings of stockholders shall not be required to be held in accordance with rules of parliamentary procedure.
(c)
The corporation may and shall, if required by applicable law, in advance of any meeting of stockholders, appoint one or more inspectors
to act at the meeting and make a written report thereof. The corporation may designate one or more persons as alternate inspectors to
replace any inspector who fails to act. If no inspector or alternate is able to act at a meeting of stockholders, the chairperson of the
meeting shall appoint one or more inspectors to act at the meeting. Each inspector, before entering upon the discharge of the duties of
inspector, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best
of such inspector’s ability. The inspectors shall: (1) ascertain the number of shares outstanding and the voting power of each;
(2) determine the shares represented at a meeting and the validity of proxies and ballots; (3) count all votes and ballots; (4) determine
and retain for a reasonable period a record of the disposition of any challenges made to any determination by the inspectors; and (5)
certify their determination of the number of shares represented at the meeting, and their count of all votes and ballots. The inspectors
may appoint or retain other persons or entities to assist the inspectors in the performance of the duties of the inspectors. In determining
the validity and counting of proxies and ballots, the inspectors shall be limited to an examination of the proxies, any envelopes submitted
with those proxies, any information provided in accordance with Sections 211(e) or 212(c)(2) of the DGCL or any information provided pursuant
to Sections 211(a)(2)b.(i) or (iii) of the DGCL, ballots and the regular books and records of the corporation, except that the inspectors
may consider other reliable information for the limited purpose of reconciling proxies and ballots submitted by or on behalf of banks,
brokers, their nominees or similar persons which represent more votes than the holder of a proxy is authorized by the record owner to
cast or more votes than the stockholder holds of record. If the inspectors consider other reliable information for the limited purpose
permitted herein, the inspectors at the time they make their certification pursuant to Section 231(b)(5) of the DGCL shall specify the
precise information considered by them including the person or persons from whom they obtained the information, when the information was
obtained, the means by which the information was obtained and the basis for the inspectors’ belief that such information is accurate
and reliable.
ARTICLE
IV
Directors
Section 16.
Number and Term of Office. The authorized number of directors
of the corporation shall be fixed in accordance with the Certificate of Incorporation. Directors need not be stockholders unless so required
by the Certificate of Incorporation.
Section 17.
Powers. The business and affairs of the corporation shall be managed by or under the direction of the Board of Directors, except as
may be otherwise provided by the Certificate of Incorporation or the DGCL.
Section 18.
Classes of Directors. The directors shall be divided into classes as and to the extent provided in the Certificate of Incorporation,
except as otherwise required by applicable law.
Section 19.
Vacancies. Vacancies or newly created directorships on the Board of Directors shall be filled as provided in the Certificate of Incorporation,
except as otherwise required by applicable law.
Section 20.
Resignation. Any director may resign at any time by delivering his or her notice in writing or by electronic transmission to the Board
of Directors or the Secretary. Such resignation shall take effect at the time of delivery of the notice or at any later time specified
therein. Acceptance of such resignation shall not be necessary to make it effective. When one or more directors shall resign from the
Board of Directors, effective at a future date, a majority of the directors then in office, including those who have so resigned, shall
have power to fill such vacancy or vacancies, the vote thereon to take effect when such resignation or resignations shall become effective,
and each director so chosen shall hold office for the unexpired portion of the term of the director whose place shall be vacated and until
his or her successor shall have been duly elected and qualified or until his or her earlier death, resignation or removal.
Section 21.
Removal.
(a)
Subject to any rights of any series of preferred stock to remove directors elected by such series of
preferred stock, neither the Board of Directors nor any individual director may be removed from office without cause.
(b)
Subject to any limitation imposed by applicable law and any rights of any series of preferred stock to
remove directors elected by such series of preferred stock, any individual director or the entire Board of Directors may be removed
from office with cause by the affirmative vote of the holders of 662/3% of the voting power of all the
then-outstanding shares of capital stock of the corporation entitled to vote generally at an election of directors.
Section 22.
Meetings.
(a)
Regular Meetings. Unless otherwise restricted by the Certificate of Incorporation, regular meetings of the Board of Directors may
be held at any time or date and at any place within or without the State of Delaware that has been designated by the Board of Directors
and publicized among all directors, either orally or in writing, by telephone, including a voice-messaging system or other system designed
to record and communicate messages, or by electronic mail or other electronic means. No further notice shall be required for regular meetings
of the Board of Directors.
(b)
Special Meetings. Unless otherwise restricted by the Certificate of Incorporation, special meetings of the Board of Directors
may be held at any time and place within or without the State of Delaware as designated and called by the Chairperson of the Board
of Directors, the Chief Executive Officer or the Board of Directors.
(c)
Meetings by Electronic Communications Equipment. Any member of the Board of Directors, or of any committee thereof, may participate
in a meeting by means of conference telephone or other communications equipment by means of which all persons participating in the meeting
can hear each other, and participation in a meeting by such means shall constitute presence in person at such meeting.
(d)
Notice of Special Meetings. Notice of the time and place, if any, of all special meetings of the Board of Directors shall be transmitted
orally or in writing, by telephone, including a voice messaging system or other system or technology designed to record and communicate
messages, or by electronic mail or other electronic means, during normal business hours, at least 24 hours before the date and time of
the meeting. If notice is sent by U.S. mail, it shall be sent by first class mail, postage prepaid, at least three days before the date
of the meeting.
(e)
Waiver of Notice. Notice of any meeting of the Board of Directors may be waived in writing, or by electronic transmission, at any
time before or after the meeting and will be waived by any director by attendance thereat, except when the director attends the meeting
for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully
called or convened. The transaction of all business at any meeting of the Board of Directors, or any committee thereof, however called
or noticed, or wherever held, shall be as valid as though it had been transacted at a meeting duly held after regular call and notice,
if a quorum be present and if, either before or after the meeting, each of the directors not present who did not receive notice shall
sign a written waiver of notice or shall waive notice by electronic transmission. All such waivers shall be filed with the corporate records
or made a part of the minutes of the meeting.
Section 23.
Quorum and Voting.
(a)
Unless the Certificate of Incorporation requires a greater number, and except with respect to questions related to indemnification
arising under Section 47 for which a quorum shall be one-third of the exact number of directors fixed from time to time by the Board of
Directors in accordance with the Certificate of Incorporation, a quorum of the Board of Directors shall consist of a majority of the total
number of directors then serving on the Board of Directors or, if greater, one-third of the exact number of directors fixed from time
to time by the Board of Directors in accordance with the Certificate of Incorporation. At any meeting whether a quorum be present or otherwise,
a majority of the directors present may adjourn from time to time until the time fixed for the next regular meeting of the Board of Directors,
without notice other than by announcement at the meeting.
(b)
At each meeting of the Board of Directors at which a quorum is present, all questions and business shall be determined by the affirmative
vote of a majority of the directors present, unless a different vote be required by applicable law, the Certificate of Incorporation or
the Bylaws.
Section
24. Action without Meeting. Unless otherwise restricted by the Certificate of
Incorporation or the Bylaws, any action required or permitted to be taken at any meeting of the Board of Directors or of any
committee thereof may be taken without a meeting, if all members of the Board of Directors or committee, as the case may be, consent
thereto in writing or by electronic transmission. Such consent or consents shall be filed with the minutes of proceedings of the
Board of Directors or committee. After an action is taken, such filing shall be in paper form if the minutes are maintained in paper
form and shall be in electronic form if the minutes are maintained in electronic form.
Section 25.
Fees and Compensation. Directors shall be entitled to such compensation for their services as may be approved by the Board of Directors,
or a committee thereof to which the Board of Directors has delegated such responsibility and authority, including, if so approved, by
resolution of the Board of Directors or a committee thereof to which the Board of Directors has delegated such responsibility and authority,
a fixed sum and reimbursement of expenses incurred, if any, for attendance at each regular or special meeting of the Board of Directors
and at any meeting of a committee of the Board of Directors, as well as reimbursement for other reasonable expenses incurred with respect
to duties as a member of the Board of Directors or any committee thereof. Nothing herein contained shall be construed to preclude any
director from serving the corporation in any other capacity as an officer, agent, employee, or otherwise and receiving compensation therefor.
Section 26.
Committees.
(a)
Executive Committee. The Board of Directors may appoint an Executive Committee to consist of one or more members of the Board of Directors.
The Executive Committee, to the extent permitted by applicable law and provided in the resolution of the Board of Directors shall have
and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the corporation,
and may authorize the seal of the corporation to be affixed to all papers that may require it; but no such committee shall have the power
or authority in reference to (i) approving or adopting, or recommending to the stockholders, any action or matter (other than the
election or removal of directors) expressly required by the DGCL to be submitted to stockholders for approval, or (ii) adopting,
amending or repealing any Bylaw of the corporation.
(b)
Other Committees. The Board of Directors may, from time to time, appoint such other committees as may be permitted by applicable law.
Such other committees appointed by the Board of Directors shall consist of one or more members of the Board of Directors and shall have
such powers and perform such duties as may be prescribed by the resolution or resolutions creating such committees, but in no event shall
any such committee have the powers denied to the Executive Committee in the Bylaws.
(c)
Term. The Board of Directors, subject to any requirements of any outstanding series of preferred stock and the provisions of subsections (a)
or (b) of this Section 26, may at any time increase or decrease the number of members of a committee or terminate the existence of
a committee. The membership of a committee member shall terminate on the date of such committee member’s death, such person’s
resignation from the committee or on such date that the committee member, for any reason, is no longer a member of the Board of Directors.
The Board of Directors may at any time for any reason remove any individual committee member and the Board of Directors may fill any committee
vacancy created by death, resignation, removal or increase in the number of members of the committee. The Board of Directors may designate
one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee,
and, in addition, in the absence or disqualification of any member of a committee, the member or members thereof present at any meeting
and not disqualified from voting, whether or not such member or members constitute a quorum, may unanimously appoint another member of
the Board of Directors to act at the meeting in the place of any such absent or disqualified member.
(d)
Meetings. Unless the Board of Directors shall otherwise provide, regular meetings of the Executive Committee or any other committee
appointed pursuant to this Section 26 shall be held at such times and places, if any, as are determined by the Board of Directors,
or by any such committee, and when notice thereof has been given to each member of such committee, no further notice of such regular meetings
need be given thereafter. Special meetings of any such committee may be held at such place, if any, that has been determined from time
to time by such committee, and may be called by any director who is a member of such committee, upon notice to the members of such committee
of the time and place, if any, of such special meeting given in the manner provided for the giving of notice to members of the Board of
Directors of the time and place, if any, of special meetings of the Board of Directors. Notice of any meeting of any committee may be
waived in writing or by electronic transmission at any time before or after the meeting and will be waived by any director by attendance
thereat, except when the director attends such meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction
of any business because the meeting is not lawfully called or convened. Unless otherwise provided by the Board of Directors in the resolutions
authorizing the creation of the committee, a majority of the authorized number of members of any such committee shall constitute a quorum
for the transaction of business, and the act of a majority of those present at any meeting at which a quorum is present shall be the act
of such committee.
Section 27.
Duties of Chairperson of the Board of Directors and Lead Independent Director.
(a)
The Chairperson of the Board of Directors, when present, shall preside at all meetings of the stockholders and the Board of Directors.
The Chairperson of the Board of Directors shall perform such other duties customarily associated with the office and shall also perform
such other duties and have such other powers, as the Board of Directors shall designate from time to time.
(b)
The Chairperson of the Board of Directors, or if the Chairperson is not an independent director, one of the independent directors,
may be designated by the Board of Directors as lead independent director to serve until replaced by the Board of Directors (“Lead
Independent Director”). The Lead Independent Director will preside over meetings of the independent directors and perform such other
duties as may be established or delegated by the Board of Directors.
Section 28.
Interested Directors. No contract or transaction between the corporation and one or more of its directors or officers, or between
the corporation and any other corporation, partnership, association or other organization in which one or more of the corporation’s
directors or officers are directors or officers or have a financial interest, shall be void or voidable solely for this reason, or solely
because the director or officer is present at or participates in the meeting of the Board of Directors or committee thereof that authorizes
the contract or transaction, or solely because any such director’s or officer’s vote is counted for such purpose if: (a) the
material facts as to the director’s or officer’s relationship or interest and as to the contract or transaction are disclosed
or are known to the Board of Directors or the committee and the Board of Directors or committee in good faith authorizes the contract
or transaction by the affirmative vote of a majority of the disinterested directors, even though the disinterested directors be less than
a quorum; (b) the material facts as to the director’s or officer’s relationship or interest and as to the contract or transaction
are disclosed or are known to the stockholders entitled to vote thereon and the contract or transaction is specifically approved in good
faith by vote of the stockholders; or (c) the contract or transaction is fair as to the corporation as of the time it is authorized, approved
or ratified by the Board of Directors, a committee thereof or the stockholders. Common or interested directors may be counted in determining
the presence of a quorum at a meeting of the Board of Directors or of a committee that authorizes the contract or transaction.
Section 29.
Organization. At every meeting of the directors, the Chairperson
of the Board of Directors, or, if a Chairperson has not been appointed or is absent, the Lead Independent Director, or if a Lead Independent
Director has not been appointed or is absent, the Chief Executive Officer (if a director), or, if a Chief Executive Officer is
absent, the President (if a director), or if the President is absent, the most senior Vice President (if a director), or, in the absence
of any such person, a chairperson of the meeting chosen by a majority of the directors present, shall preside over the meeting. The Secretary,
or in his or her absence, any Assistant Secretary or other officer, director or other person directed to do so by the person presiding
over the meeting, shall act as secretary of the meeting.
ARTICLE
V
Officers
Section 30.
Officers Designated. The officers of the corporation shall include, if and when designated by the Board of Directors, the Chief Executive
Officer, the President, one or more Vice Presidents, the Secretary, the Chief Financial Officer and the Treasurer. The Board of Directors
may also appoint one or more Assistant Secretaries and Assistant Treasurers and such other officers and agents with such powers and duties
as it shall deem appropriate or necessary. The Board of Directors may assign such additional titles to one or more of the officers as
it shall deem appropriate. Any one person may hold any number of offices of the corporation at any one time unless specifically prohibited
therefrom by applicable law, the Certificate of Incorporation or the Bylaws. The salaries and other compensation of the officers of the
corporation shall be fixed by or in the manner designated by the Board of Directors or by a committee thereof to which the Board of Directors
has delegated such responsibility.
Section 31.
Tenure and Duties of Officers.
(a)
General. All officers shall hold office at the pleasure of the Board of Directors and until their successors shall have been duly
elected and qualified, subject to the officer’s earlier death, resignation or removal. If the office of any officer becomes vacant
for any reason, the vacancy may be filled by the Board of Directors or by a committee thereof to which the Board of Directors has delegated
such responsibility or, if so authorized by the Board of Directors, by the Chief Executive Officer or another officer of the corporation.
(b)
Duties of Chief Executive Officer. The Chief Executive Officer shall preside at all meetings of the stockholders and, if a director,
at all meetings of the Board of Directors, unless a Chairperson of the Board of Directors or Lead Independent Director has been appointed
and is present. The Chief Executive Officer shall be the chief executive officer of the corporation and, subject to the supervision, direction
and control of the Board of Directors, shall have the general powers and duties of supervision, direction, management and control of the
business and officers of the corporation as are customarily associated with the position of Chief Executive Officer. To the extent that
a Chief Executive Officer has been appointed and no President has been appointed, all references in the Bylaws to the President shall
be deemed references to the Chief Executive Officer. The Chief Executive Officer shall perform other duties customarily associated with
the office and shall also perform such other duties and have such other powers, as the Board of Directors shall designate from time to
time.
(c)
Duties of President. The President shall preside at all meetings of the stockholders and, if a director, at all meetings of the
Board of Directors, unless a Chairperson of the Board of Directors, Lead Independent Director, or Chief Executive Officer has been
appointed and is present. Unless another officer has been appointed Chief Executive Officer of the corporation, the President shall
be the chief executive officer of the corporation and, subject to the supervision, direction and control of the Board of Directors,
shall have the general powers and duties of supervision, direction, management and control of the business and officers of the
corporation as are customarily associated with the position of President. The President shall perform other duties customarily
associated with the office and shall also perform such other duties and have such other powers, as the Board of Directors (or the
Chief Executive Officer, if the Chief Executive Officer and President are not the same person and the Board of Directors has
delegated the designation of the President’s duties to the Chief Executive Officer) shall designate from time to time.
(d)
Duties of Vice Presidents. A Vice President may assume and perform the duties of the President in the absence or disability of the
President or whenever the office of President is vacant (unless the duties of the President are being filled by the Chief Executive Officer).
A Vice President shall perform other duties customarily associated with the office and shall also perform such other duties and have such
other powers as the Board of Directors or the Chief Executive Officer, or, if the Chief Executive Officer has not been appointed or is
absent, the President shall designate from time to time.
(e)
Duties of Secretary and Assistant Secretary. The Secretary shall attend all meetings of the stockholders and of the Board of Directors
and shall record all acts, votes and proceedings thereof in the minute books of the corporation. The Secretary shall give notice in conformity
with the Bylaws of all meetings of the stockholders and of all meetings of the Board of Directors and any committee thereof requiring
notice. The Secretary shall perform all other duties provided for in the Bylaws and other duties customarily associated with the office
and shall also perform such other duties and have such other powers, as the Board of Directors or the Chief Executive Officer, or if no
Chief Executive Officer is then serving, the President shall designate from time to time. The Chief Executive Officer, or if no Chief
Executive Officer is then serving, the President may direct any Assistant Secretary or other officer to assume and perform the duties
of the Secretary in the absence or disability of the Secretary, and each Assistant Secretary shall perform other duties customarily associated
with the office and shall also perform such other duties and have such other powers as the Board of Directors or the Chief Executive Officer,
or if no Chief Executive Officer is then serving, the President shall designate from time to time.
(f)
Duties of Chief Financial Officer. The Chief Financial Officer shall keep or cause to be kept the books of account of the corporation
in a thorough and proper manner and shall render statements of the financial affairs of the corporation in such form and as often as required
by the Board of Directors, the Chief Executive Officer, or the President. The Chief Financial Officer, subject to the order of the Board
of Directors, shall have the custody of all funds and securities of the corporation. The Chief Financial Officer shall perform other duties
customarily associated with the office and shall also perform such other duties and have such other powers as the Board of Directors or
the Chief Executive Officer, or if no Chief Executive Officer is then serving, the President shall designate from time to time. To the
extent that a Chief Financial Officer has been appointed and no Treasurer has been appointed, all references in the Bylaws to the Treasurer
shall be deemed references to the Chief Financial Officer. The President may direct the Treasurer, if any, or any Assistant Treasurer
to assume and perform the duties of the Chief Financial Officer in the absence or disability of the Chief Financial Officer.
(g)
Duties of Treasurer and Assistant Treasurer. Unless another officer has been appointed Chief Financial Officer of the
corporation, the Treasurer shall be the chief financial officer of the corporation, shall keep or cause to be kept the books of
account of the corporation in a thorough and proper manner and shall render statements of the financial affairs of the corporation
in such form and as often as required by the Board of Directors, the Chief Executive Officer or the President. Unless another
officer has been appointed Chief Financial Officer of the corporation, the Treasurer, subject to the order of the Board of
Directors, shall have the custody of all funds and securities of the corporation. The Treasurer shall perform other duties
customarily associated with the office and shall also perform such other duties and have such other powers as the Board of Directors
or the Chief Executive Officer, or if no Chief Executive Officer is then serving, the President shall designate from time to time.
The Chief Executive Officer, or if no Chief Executive Officer is then serving, the President may direct any Assistant Treasurer or
other officer to assume and perform the duties of the Treasurer in the absence or disability of the Treasurer, and each Assistant
Treasurer shall perform other duties commonly incident to the office and shall also perform such other duties and have such other
powers as the Board of Directors or the Chief Executive Officer, or if no Chief Executive Officer is then serving, the President
shall designate from time to time.
Section 32.
Delegation of Authority. The Board of Directors may from time to time delegate the powers or duties of any officer to any other officer
or agent, notwithstanding any provision hereof.
Section 33.
Resignations. Any officer may resign at any time by giving notice in writing or by electronic transmission to the Board of Directors,
the Chairperson of the Board of Directors, the Chief Executive Officer, the President or the Secretary. Any such resignation shall be
effective when received by the person or persons to whom such notice is given, unless a later time is specified therein, in which event
the resignation shall become effective at such later time. Unless otherwise specified in such notice, the acceptance of any such resignation
shall not be necessary to make it effective. Any resignation shall be without prejudice to the rights, if any, of the corporation under
any contract with the resigning officer.
Section 34.
Removal. Any officer may be removed from office at any time, either with or without cause, by the Board of Directors, or by any committee
thereof or any superior officer upon whom such power of removal may have been conferred by the Board of Directors.
ARTICLE
VI
Execution Of Corporate Instruments And Voting Of Securities Owned By The Corporation
Section 35.
Execution of Corporate Instruments. The Board of Directors may, in its discretion, determine the method and designate the signatory
officer or officers, or other person or persons, to execute, sign or endorse on behalf of the corporation any corporate instrument or
document, or to sign on behalf of the corporation the corporate name without limitation, or to enter into contracts on behalf of the corporation,
except where otherwise provided by applicable law or the Bylaws, and such execution or signature shall be binding upon the corporation.
All checks and drafts drawn
on banks or other depositaries on funds to the credit of the corporation or in special accounts of the corporation shall be signed by
such person or persons as the Board of Directors shall from time to time authorize so to do.
Unless otherwise specifically
determined by the Board of Directors or otherwise required by applicable law, the execution, signing or endorsement of any corporate instrument
or document may be effected manually, by facsimile or (to the extent permitted by applicable law and subject to such policies and procedures
as the corporation may have in effect from time to time) by electronic signature.
Unless authorized or ratified
by the Board of Directors or within the agency power of an officer, no officer, agent or employee shall have any power or authority to
bind the corporation by any contract or engagement or to pledge its credit or to render it liable for any purpose or for any amount.
Section 36.
Voting of Securities Owned by the Corporation. All stock and other securities of or interests in other corporations or entities owned
or held by the corporation for itself, or for other parties in any capacity, shall be voted, and all proxies with respect thereto shall
be executed, by the person authorized so to do by resolution of the Board of Directors, or, in the absence of such authorization, by the
Chairperson of the Board of Directors, the Chief Executive Officer, the President, or any Vice President.
ARTICLE
VII
Shares Of Stock
Section 37.
Form and Execution of Certificates. The shares of the corporation shall be represented by certificates, or shall be uncertificated
if so provided by resolution or resolutions of the Board of Directors. Certificates for the shares of stock, if any, shall be in such
form as is consistent with the Certificate of Incorporation and applicable law. Every holder of stock in the corporation represented by
certificates shall be entitled to have a certificate signed by or in the name of the corporation by any two authorized officers of the
corporation, certifying the number, and the class or series, of shares owned by such holder in the corporation. Any or all of the signatures
on the certificate may be facsimiles. In case any officer, transfer agent, or registrar who has signed or whose facsimile signature has
been placed upon a certificate shall have ceased to be such officer, transfer agent, or registrar before such certificate is issued, it
may be issued with the same effect as if he were such officer, transfer agent, or registrar at the date of issue.
Section 38.
Lost Certificates. A new certificate or certificates shall be issued in place of any certificate or certificates theretofore issued
by the corporation alleged to have been lost, stolen, or destroyed, upon the making of an affidavit of that fact by the person claiming
the certificate of stock to be lost, stolen, or destroyed. The corporation may require, as a condition precedent to the issuance of a
new certificate or certificates, the owner of such lost, stolen, or destroyed certificate or certificates, or the owner’s legal
representative, to agree to indemnify the corporation in such manner as it shall require or to give the corporation a surety bond in such
form and amount as it may direct as indemnity against any claim that may be made against the corporation with respect to the certificate
alleged to have been lost, stolen, or destroyed.
Section 39.
Transfers.
(a)
Transfers of record of shares of stock of the corporation shall be made only upon its books by the holders thereof, in person or by
attorney duly authorized, and, in the case of stock represented by certificate, upon the surrender of a properly endorsed certificate
or certificates for a like number of shares.
(b)
The corporation shall have power to enter into and perform any agreement with any number of stockholders of any one or more classes
or series of stock of the corporation to restrict the transfer of shares of stock of the corporation of any one or more classes or series
owned by such stockholders in any manner not prohibited by the DGCL.
Section 40.
Fixing Record Dates.
(a)
In order that the corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any
adjournment thereof, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution
fixing the record date is adopted by the Board of Directors, and which record date shall, subject to applicable law, not be more than
60 nor less than ten days before the date of such meeting. If the Board of Directors so fixes a record date for determining the stockholders
entitled to notice of any meeting of stockholders, such date shall also be the record date for determining the stockholders entitled to
vote at such meeting, unless the Board of Directors determines, at the time it fixes the record date for determining the stockholders
entitled to notice of such meeting, that a later date on or before the date of the meeting shall be the record date for determining the
stockholders entitled to vote at such meeting. If no record date is fixed by the Board of Directors, the record date for determining stockholders
entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day immediately preceding the day
on which notice is given, or if notice is waived, at the close of business on the day immediately preceding the day on which the meeting
is held. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment
of the meeting; provided, however, that the Board of Directors may fix a new record date for the adjourned meeting in accordance
with the provisions of this Section 40(a).
(b)
In order that the corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or
allotment of any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock,
or for the purpose of any other lawful action, the Board of Directors may fix, in advance, a record date, which record date shall not
precede the date upon which the resolution fixing the record date is adopted, and which record date shall be not more than 60 days prior
to such action. If no record date is fixed, the record date for determining stockholders for any such purpose shall be at the close of
business on the day on which the Board of Directors adopts the resolution relating thereto.
Section 41.
Registered Stockholders. The corporation shall be entitled to recognize the exclusive right of a person registered on its books as
the owner of shares to receive dividends, and to vote as such owner, and shall not be bound to recognize any equitable or other claim
to or interest in such share or shares on the part of any other person whether or not it shall have express or other notice thereof, except
as otherwise provided by the laws of Delaware.
Section 42.
Additional Powers of the Board. In addition to, and without limiting, the powers set forth in the Bylaws, the Board of Directors shall
have power and authority to make all such rules and regulations as it shall deem expedient concerning the issue, transfer, and registration
of certificates for shares of stock of the corporation, including the use of uncertificated shares of stock, subject to the provisions
of the DGCL, other applicable law, the Certificate of Incorporation and the Bylaws. The Board of Directors may appoint and remove transfer
agents and registrars of transfers, and may require all stock certificates to bear the signature of any such transfer agent and/or any
such registrar of transfers.
ARTICLE
VIII
Other Securities Of The Corporation
Section 43.
Execution of Other Securities. All bonds, debentures and other corporate securities of the corporation, other than stock certificates
(covered in Section 37), may be signed by the Chairperson of the Board of Directors, the Chief Executive Officer, the President or
any Vice President, or such other person as may be authorized by the Board of Directors; provided, however, that where any such
bond, debenture or other corporate security shall be authenticated by the manual signature, or where permissible facsimile signature,
of a trustee under an indenture pursuant to which such bond, debenture or other corporate security shall be issued, the signatures of
the persons signing and attesting the corporate seal on such bond, debenture or other corporate security may be the imprinted facsimile
of the signatures of such persons. Interest coupons appertaining to any such bond, debenture or other corporate security, authenticated
by a trustee as aforesaid, shall be signed by the Treasurer or an Assistant Treasurer of the corporation or such other person as may be
authorized by the Board of Directors, or bear imprinted thereon the facsimile signature of such person. In case any officer who shall
have signed or attested any bond, debenture or other corporate security, or whose facsimile signature shall appear thereon or on any such
interest coupon, shall have ceased to be such officer before the bond, debenture or other corporate security so signed or attested shall
have been delivered, such bond, debenture or other corporate security nevertheless may be adopted by the corporation and issued and delivered
as though the person who signed the same or whose facsimile signature shall have been used thereon had not ceased to be such officer of
the corporation.
ARTICLE
IX
Dividends
Section 44.
Declaration of Dividends. Dividends upon the capital stock of the corporation, subject to the provisions of the Certificate of Incorporation
and applicable law, if any, may be declared by the Board of Directors. Dividends may be paid in cash, in property, or in shares of the
capital stock, or other securities of the corporation, subject to the provisions of the Certificate of Incorporation and applicable law.
Section 45.
Dividend Reserve. Before payment of any dividend, there may be set aside out of any funds of the corporation available for dividends
such sum or sums as the Board of Directors from time to time, in its absolute discretion, determines proper as a reserve or reserves to
meet contingencies, or for equalizing dividends, or for repairing or maintaining any property of the corporation, or for such other purpose
or purposes as the Board of Directors shall determine to be conducive to the interests of the corporation, and the Board of Directors
may modify or abolish any such reserve in the manner in which it was created.
ARTICLE
X
Fiscal Year
Section 46.
Fiscal Year. The fiscal year of the corporation shall be fixed by resolution of the Board of Directors.
ARTICLE
XI
Indemnification
Section 47.
Indemnification of Directors, Executive Officers, Employees and Other Agents.
(a)
Directors and Executive Officers. The corporation shall indemnify to the full extent
permitted under and in any manner permitted under the DGCL or any other applicable law, any person who was or is made or threatened to
be made a party to or is otherwise involved (as a witness or otherwise) in any threatened, pending, or completed action, suit, or proceeding,
whether civil, criminal, administrative, or investigative (hereinafter, a “Proceeding”), by reason of the fact
that such person is or was a director or executive officer (for the purposes of this Article XI, “executive officers”
shall be those persons designated by the corporation as (a) executive officers for purposes of the disclosures required in the corporation’s
proxy and periodic reports or (b) officers for purposes of Section 16 of the 1934 Act) of the corporation, or while serving as a director
or executive officer of the corporation, is or was serving at the request of the corporation as a director, officer, employee, or agent
of another corporation, partnership, joint venture, trust, or other enterprise, including service with respect to an employee benefit
plan (collectively, “Another Enterprise”), against expenses (including attorneys’ fees), judgments, fines
(including ERISA excise taxes or penalties) and amounts paid in settlement actually and reasonably incurred by him or her in connection
with such Proceeding if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best
interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct
was unlawful; provided, however, that the corporation may modify the extent of such indemnification by individual contracts with
its directors and executive officers; and, provided, further, that the corporation shall not be required to indemnify or advance
expenses to any director or executive officer in connection with any proceeding (or part thereof) initiated by such person unless (i)
such indemnification is expressly required to be made by applicable law, (ii) the proceeding was authorized by the Board of Directors
of the corporation, (iii) such indemnification is provided by the corporation, in its sole discretion, pursuant to the powers vested
in the corporation under the DGCL or any other applicable law or (iv) such indemnification is required to be made under subsection (d)
of this Section 47.
(b)
Other Officers, Employees and Other Agents. The corporation shall have power to indemnify (including the power to advance expenses
in a manner consistent with subsection (c) of this Section 47) its other officers, employees
and other agents as set forth in the DGCL or any other applicable law. The Board of Directors shall have the power to delegate the determination
of whether indemnification shall be given to any such person (except executive officers) to such officers or other persons as the Board
of Directors shall determine.
(c)
Expenses. The corporation shall advance to any person who was or is a party or is threatened to be made a party to any
threatened, pending or completed Proceeding, by reason of the fact that such person is or was a director or executive officer, of
the corporation, or is or was serving at the request of the corporation as a director or executive officer of Another Enterprise,
prior to the final disposition of the Proceeding, promptly following request therefor, all expenses (including attorneys’
fees) incurred by any director or executive officer in connection with such Proceeding provided, however, that if the DGCL requires,
an advancement of expenses incurred by a director or executive officer in his or her capacity as a director or executive officer
(and not in any other capacity in which service was or is rendered by such indemnitee, including, without limitation, service to an
employee benefit plan) shall be made only upon delivery to the corporation of an undertaking (hereinafter an
“undertaking”), by or on behalf of such indemnitee, to repay all amounts so advanced if it shall
ultimately be determined by final judicial decision from which there is no further right to appeal (hereinafter a “final
adjudication”) that such indemnitee is not entitled to be indemnified or entitled to advancement for such expenses
under this Section 47 or otherwise.
Notwithstanding the foregoing,
unless otherwise determined pursuant to paragraph (d) of this Section 47, no advance shall be made by the corporation to an executive
officer of the corporation (except by reason of the fact that such executive officer is or was a director of the corporation in which
event this paragraph shall not apply) in any Proceeding, if a determination is reasonably and promptly made (i) by a majority vote
of directors who were not parties to the Proceeding, even if not a quorum, or (ii) by a committee of such directors designated by
a majority vote of such directors, even though less than a quorum, or (iii) if there are no such directors, or such directors so direct,
by independent legal counsel in a written opinion, that the facts known to the decision-making party at the time such determination is
made demonstrate clearly and convincingly that such person acted in bad faith or in a manner that such person did not believe to be in
or not opposed to the best interests of the corporation.
(d)
Enforcement. Without the necessity of entering into an express contract, all rights to indemnification and advances to directors and
executive officers under this Section 47 shall be deemed to be contractual rights, shall vest when the person becomes a director or executive
officer of the corporation, shall continue as vested contract rights even if such person ceases to be a director or executive officer
of the corporation, and shall be effective to the same extent and as if provided for in a contract between the corporation and the director
or executive officer. Any right to indemnification or advancement of expenses granted by this Section 47 to a director or executive officer
shall be enforceable by or on behalf of the person holding such right in any court of competent jurisdiction if (i) the claim for
indemnification or advancement of expenses is denied, in whole or in part, or (ii) no disposition of a claim for indemnification
is made within 90 days of request therefor. To the fullest extent permitted by applicable law, the claimant in such enforcement action,
if successful in whole or in part, shall be entitled to be paid also the expense of prosecuting the claim. In connection with any claim
for indemnification, the corporation shall be entitled to raise as a defense to any such action that the claimant has not met the standards
of conduct that make it permissible under the DGCL or any other applicable law for the corporation to indemnify the claimant for the amount
claimed. In connection with any claim by an executive officer of the corporation (except in any Proceeding, by reason of the fact that
such executive officer is or was a director of the corporation) for advances, the corporation shall be entitled to raise a defense as
to any such action clear and convincing evidence that such person acted in bad faith or in a manner that such person did not believe to
be in or not opposed to the best interests of the corporation, or with respect to any criminal action or proceeding that such person acted
without reasonable cause to believe that his or her conduct was lawful. Neither the failure of the corporation (including its Board of
Directors, independent legal counsel or its stockholders) to have made a determination prior to the commencement of such action that indemnification
of the claimant is proper in the circumstances because he or she has met the applicable standard of conduct set forth in the DGCL or any
other applicable law, nor an actual determination by the corporation (including its Board of Directors, independent legal counsel or its
stockholders) that the claimant has not met such applicable standard of conduct, shall be a defense to the action or create a presumption
that claimant has not met the applicable standard of conduct. In any suit brought by a director or executive officer to enforce a right
to indemnification or to an advancement of expenses hereunder, or brought by the corporation to recover an advancement of expenses pursuant
to the terms of an undertaking, the burden of proving that the director or executive officer is not entitled to be indemnified, or to
such advancement of expenses, under this Section 47 or otherwise shall be on the corporation.
(e)
Non-Exclusivity of Rights. The rights conferred on any person by this Section 47 shall not be exclusive of any other right that such
person may have or hereafter acquire under any applicable statute, provision of the Certificate of Incorporation, Bylaws, agreement, vote
of stockholders or disinterested directors or otherwise, both as to action in his or her official capacity and as to action in another
capacity while holding office. The corporation is specifically authorized to enter into individual contracts with any or all of its directors,
officers, employees or agents respecting indemnification and advances, to the fullest extent not prohibited by the DGCL, or by any other
applicable law.
(f)
Survival of Rights. The rights conferred on any person by this Section 47 shall continue as to a person who has ceased to be a
director, executive officer, other officer, employee or other agent and shall inure to the benefit of the heirs, executors and
administrators of such a person.
(g)
Insurance. To the fullest extent permitted by the DGCL or any other applicable law, the corporation, upon approval by the Board of
Directors, may purchase and maintain insurance on behalf of any person required or permitted to be indemnified pursuant to this Section
47.
(h)
Amendments. Any repeal or modification of this Section 47 shall only be prospective and shall not affect the rights under this Section
47 as in effect at the time of the alleged occurrence of any action or omission to act that is the cause of any Proceeding against any
current or former director or executive officer of the corporation.
(i)
Saving Clause. If this Article XI or any portion hereof shall be invalidated on any ground by any court of competent
jurisdiction, then the corporation shall nevertheless indemnify and advance expenses to each director and executive officer to the
full extent not prohibited by any applicable portion of this Article XI that shall not have been invalidated, or by any other
applicable law. If this Article XI shall be invalid due to the application of the indemnification and advancement provisions of
another jurisdiction, then the corporation shall indemnify and advance expenses to each director and executive officer to the full
extent under any other applicable law.
(j)
Certain Definitions and Construction of Terms. For the purposes of Article XI of the
Bylaws, the following definitions and rules of construction shall apply:
(i)
The term “Proceeding” shall be broadly construed and shall include, without limitation, the investigation,
preparation, prosecution, defense, settlement, arbitration and appeal of, and the giving of testimony in, any threatened, pending or completed
action, suit or proceeding, whether civil, criminal, administrative or investigative.
(ii)
The term “expenses” shall be broadly construed and shall include, without limitation, court costs, attorneys’
fees, witness fees, fines, amounts paid in settlement or judgment and any other costs and expenses of any nature or kind incurred in connection
with any Proceeding.
(iii) The
term the “corporation” shall include, in addition to the resulting corporation, any constituent
corporation (including any constituent of a constituent) absorbed in a consolidation or merger that, if its separate existence had
continued, would have had power and authority to indemnify its directors, officers, and employees or agents, so that any person who
is or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request of such
constituent corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust,
employee benefit plan or other enterprise, shall stand in the same position under the provisions of this Section 47 with respect to
the resulting or surviving corporation as he would have with respect to such constituent corporation if its separate existence had
continued.
(iv)
References to a “director,” “executive officer,” “officer,”
“employee,” or “agent” of the corporation shall include, without limitation, situations
where such person is serving at the request of the corporation as, respectively, a director, executive officer, officer, employee, trustee
or agent of another corporation, partnership, joint venture, trust or other enterprise.
(v)
References to “Another Enterprise” shall include employee benefit plans; references to “fines”
shall include any excise taxes assessed on a person with respect to an employee benefit plan; and references to “serving at
the request of the corporation” shall include any service as a director, officer, employee or agent of the corporation that
imposes duties on, or involves services by, such director, officer, employee, or agent with respect to an employee benefit plan, its participants,
or beneficiaries; and a person who acted in good faith and in a manner such person reasonably believed to be in the interest of the participants
and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner “not opposed to the best interests
of the corporation” as referred to in this Section 47.
Notices
Section 48.
Notices.
(a)
Notice to Stockholders. Notice to stockholders of stockholder meetings shall be given as provided in Section 7. Without limiting the
manner by which notice may otherwise be given effectively to stockholders under any agreement or contract with such stockholder, and except
as otherwise required by applicable law, written notice to stockholders for purposes other than stockholder meetings may be sent by U.S.
mail or nationally recognized overnight courier, or by electronic mail or other electronic means in accordance with Section 232 of the
DGCL.
(b)
Notice to Directors. Any notice required to be given to any director may be given by the method stated in subsection (a), as
otherwise provided in the Bylaws (including by any of the means specified in Section 22(d)), or by overnight delivery service. Any notice
sent by overnight delivery service or U.S. mail shall be sent to such address as such director shall have filed in writing with the Secretary,
or, in the absence of such filing, to the last known post office address of such director.
(c)
Affidavit of Mailing. An affidavit of mailing, executed by a duly authorized and competent employee of the corporation or its transfer
agent appointed with respect to the class of stock affected, or other agent, specifying the name and address or the names and addresses
of the stockholder or stockholders, or director or directors, to whom any such notice or notices was or were given, and the time and method
of giving the same, shall in the absence of fraud, be prima facie evidence of the facts therein contained.
(d)
Methods of Notice. It shall not be necessary that the same method of giving notice be employed in respect of all recipients of notice,
but one permissible method may be employed in respect of any one or more, and any other permissible method or methods may be employed
in respect of any other or others.
(e)
Notice to Person with Whom Communication is Unlawful. Whenever notice is required to be given, under applicable law or any provision
of the Certificate of Incorporation or Bylaws of the corporation, to any person with whom communication is unlawful, the giving of such
notice to such person shall not be required and there shall be no duty to apply to any governmental authority or agency for a license
or permit to give such notice to such person. Any action or meeting which shall be taken or held without notice to any such person with
whom communication is unlawful shall have the same force and effect as if such notice had been duly given. In the event that the action
taken by the corporation is such as to require the filing of a certificate under any provision of the DGCL, the certificate shall state,
if such is the fact and if notice is required, that notice was given to all persons entitled to receive notice except such persons with
whom communication is unlawful.
(f)
Notice to Stockholders Sharing an Address. Except as otherwise prohibited under the DGCL, any notice given under the provisions
of the DGCL, the Certificate of Incorporation or the Bylaws shall be effective if given by a single written notice to stockholders
who share an address if consented to by the stockholders at that address to whom such notice is given. Such consent shall have been
deemed to have been given if such stockholder fails to object in writing to the corporation within 60 days of having been given
notice by the corporation of its intention to send the single notice. Any consent shall be revocable by the stockholder by written
notice to the corporation.
ARTICLE
XII
Amendments
Section 49.
Amendments. Subject to the limitations set forth in Section 47(h) or the provisions of the Certificate of Incorporation, the Board
of Directors is expressly empowered to adopt, amend or repeal the Bylaws of the corporation. Any adoption, amendment or repeal of the
Bylaws of the corporation by the Board of Directors shall require the approval of a majority of the authorized number of directors.
The stockholders also shall have power to adopt, amend or repeal the Bylaws of the corporation; provided, however, that, in addition
to any vote of the holders of any class or series of stock of the corporation required by applicable law or by the Certificate of Incorporation,
such action by stockholders shall require the affirmative vote of the holders of at least 662/3%
of the voting power of all of the then-outstanding shares of the capital stock of the corporation entitled to vote generally in the election
of directors, voting together as a single class.
Exhibit 3.3
CERTIFICATE OF DESIGNATIONS, PREFERENCES AND
RIGHTS OF
SERIES A CONVERTIBLE PREFERRED STOCK
OF TRISALUS LIFE SCIENCES, INC.
Pursuant to Section 151 of the
General Corporation Law of the State of Delaware
The undersigned, pursuant to the provisions of
Section 151 of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that, pursuant
to the authority expressly vested in the Board of Directors of TriSalus Life Sciences, Inc., a Delaware corporation (the “Corporation”),
by the Second Amended and Restated Certificate of Incorporation of the Corporation, the Board of Directors has by resolution duly provided
for the issuance of and created a series of preferred stock of the Corporation, par value $0.0001 per share, and in order to fix the designation
and amount and the voting powers, preferences and relative, participating, optional and other special rights, and the qualifications,
limitations and restrictions, of such series of preferred stock, has duly adopted resolutions setting forth such rights, powers and preferences,
and the qualifications, limitations and restrictions thereof, of such series of preferred stock as set forth in this Certificate of Designations,
Preferences and Rights of Series A Convertible Preferred Stock (this “Certificate of Designations”). This Certificate
of Designations will be effective as of August 10, 2023.
Section 1. Number of Shares and Designation.
5,000,000 shares of preferred stock of the Corporation shall constitute a series of preferred stock designated as Series A Convertible
Preferred Stock (the “Preferred Stock”). The number of shares of Preferred Stock may be increased (to the extent of
the Corporation’s authorized and unissued preferred stock) by further resolution duly adopted by the Board of Directors and the
filing of a certificate of increase with the Secretary of State of the State of Delaware.
Section 2. Rank. Each share of Preferred
Stock shall rank equally in all respects and shall be subject to the provisions herein. The Preferred Stock shall, with respect to payment
of dividends, rights (including as to the distribution of assets) upon liquidation, dissolution or winding up of the affairs of the Corporation,
or otherwise (i) rank senior to the Corporation’s common stock, par value $0.0001 per share (the “Common Stock”),
and any other class or series of equity securities of the Corporation, hereafter created, that by its terms does not expressly rank senior
to, or on parity with, the Preferred Stock as to payment of dividends or rights (including as to the distribution of assets) upon liquidation,
dissolution or winding up of the affairs of the Corporation, or otherwise (all of such equity securities, including the Common Stock,
are collectively referred to herein as “Junior Securities”), (ii) rank junior to any class or series of equity
securities of the Corporation, hereafter created without violation of this Certificate of Designations, that by its terms expressly ranks
senior to the Preferred Stock as to payment of dividends or rights (including as to the distribution of assets) upon liquidation, dissolution
or winding up of the affairs of the Corporation, or otherwise (all of such equity securities are collectively referred to herein as “Senior
Securities”), and (iii) rank on parity with any class or series of equity securities of the Corporation, hereafter created
without violation of this Certificate of Designations, that expressly provides that it ranks pari passu with the Preferred Stock
as to payment of dividends or rights (including as to the distribution of assets) upon liquidation, dissolution or winding up of the affairs
of the Corporation (all of such equity securities are collectively referred to herein as “Parity Securities”). The
respective definitions of Junior Securities, Senior Securities and Parity Securities shall also include any securities, rights or options
exercisable or exchangeable for or convertible into any of the Junior Securities, Senior Securities or Parity Securities, as the case
may be.
Section 3. Definitions.
(a) As used herein, the following terms shall
have the meanings set forth below or in the section cross-referenced below, as applicable, whether used in the singular or the plural:
“10-Day VWAP” means the average
of the daily VWAP of the Common Stock for each Trading Day in the ten (10)-Trading Day period immediately prior to, but excluding, the
applicable determination date.
“Accrued Dividend Fundamental Transaction
Shares” has the meaning set forth in Section 7(g)(i).
“Accrued Dividends” means,
as of any date, with respect to any share of Preferred Stock, all dividends that have accrued pursuant to Section 4(a)(ii) but
that have not been paid as of such date.
“Actual Dividend PIK Payment Shares”
has the meaning set forth in Section 4(a)(iii).
“Affiliate” means, with respect
to any Person, any other Person directly or indirectly controlling, controlled by or under common control with, such Person.
“Alternate
Consideration” has the meaning set forth in Section 7(g).
“Annual Dividend Payment Date”
means August 10 of each year (each, an “Anniversary Date”), commencing on the first Anniversary Date immediately following
the Original Issuance Date; provided, that if any such Anniversary Date is not a Business Day then the “Annual Dividend Payment
Date” shall be the next Business Day immediately following such Anniversary Date.
“Annual Dividend Payment Record Date”
has the meaning set forth in Section 4(a)(iv).
“Annual Dividends” has the
meaning set forth in Section 4(a)(ii).
“Beneficially Own” and “Beneficial
Ownership” has the meaning given such term in Rule 13d-3 under the Exchange Act, and a Person’s beneficial ownership of
Capital Stock shall be calculated in accordance with the provisions of such rule, but without taking into account any contractual restrictions
or limitations on voting or other rights; provided, however, that for purposes of determining beneficial ownership, a Person
shall be deemed to be the beneficial owner of any security which may be acquired by such Person, whether within sixty (60) days or thereafter,
upon the conversion, exchange or exercise of any warrants, options, rights or other securities.
“Board of Directors” means
the board of directors of the Corporation or any committee thereof duly authorized to act on behalf of such board of directors for the
purposes in question.
“Business Day” means any day
that is not a Saturday, a Sunday or any other day on which commercial banks are generally required or authorized by law to be closed in
New York City, New York.
“Buy-In” has the meaning set
forth in Section 6(b)(vi).
“By-laws” means the Amended
and Restated By-Laws of the Corporation, as amended from time to time.
“Capital Stock” of any Person
means any and all shares, interests (including partnership interests), rights to purchase, warrants, options, participations or other
equivalents of or interests in (however designated) equity of such Person, including any preferred stock, but excluding any debt securities
convertible into such equity.
“Certificate of Designations”
has the meaning set forth in the preamble.
“Certificate of Incorporation”
means the Second Amended and Restated Certificate of Incorporation of the Corporation, as amended from time to time.
“Close of Business” means 5:00
p.m., New York City time.
“Common Stock” has the meaning
set forth in Section 2.
“Common Stock Dividend Record Date”
has the meaning set forth in Section 4(a)(iv).
“control” (including the terms
“controlling”, “controlled by” and “under common control with”), with respect
to the relationship between or among two or more Persons, means the possession, directly or indirectly, of the power to direct or cause
the direction of the affairs or management of a Person, whether through the ownership of voting securities, as trustee or executor, by
contract or otherwise.
“Conversion Date” has the meaning
set forth in Section 6(b)(iii).
“Conversion Notice” has the
meaning set forth in Section 6(b)(i).
“Conversion Price” means, as
of any date, the Initial Conversion Price, as adjusted pursuant to Section 7.
“Conversion Right” has the
meaning set forth in Section 6(a)(i).
“Convertible Securities” means
indebtedness or shares of Capital Stock convertible into or exchangeable for Common Stock.
“Corporation” has the meaning
set forth in the preamble.
“DGCL” has the meaning set
forth in the preamble.
“Dividend PIK Amount” has the
meaning set forth in Section 4(a)(iii).
“Dividend Rate” has the meaning
set forth in Section 4(a)(ii).
“Exchange Act” means the Securities
Exchange Act of 1934, as amended from time to time, and the rules and regulations promulgated thereunder.
“Ex-Date” means, when used
with respect to any distribution, the first date on which the Common Stock or other securities in question do not have the right to receive
the distribution giving rise to an adjustment to the Conversion Price.
“Floor Price” means an amount equal to $2.10, as
adjusted for any stock dividend, stock split, reverse stock split, combination or similar event
affecting the Common Stock.
“Fundamental Transaction” means,
at any time while the Preferred Stock is outstanding, any transaction whereby:
(i) the
Corporation, directly or indirectly, in one or more related transactions effects any merger or consolidation or other similar business
combination of the Corporation with or into another Person, in each case, pursuant to which the Common Stock will be converted
into, or exchanged for, cash, securities or other property of the Corporation or another Person;
(ii) the
Corporation, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition (including
in connection with any Liquidation) of all or substantially all of its assets in one or a series
of related transactions;
(iii) any,
direct or indirect, purchase offer, tender offer or exchange offer (whether by the Corporation or another Person) is completed pursuant
to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has
been accepted by the holders of 50% or more of the outstanding Common Stock;
(iv) the
Corporation, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization
of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for
other securities, cash or property; or
(v) the
Corporation, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business
combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another
Person whereby such other Person acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common
Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party
to, such stock or share purchase agreement or other business combination).
“Fundamental Transaction Date”
has the meaning set forth in Section 7(g).
“Holder” means, at any time,
any Person in whose name shares of Preferred Stock are registered, which may be treated by the Corporation as the absolute owner of such
shares of Preferred Stock for the purpose of making payment and settling the related conversions and for all other purposes.
“Initial Conversion Price”
means with respect to each share of Preferred Stock, $10.00 per share.
“Issuance Date” means, with
respect to a share of Preferred Stock, the date of issuance of such share of Preferred Stock.
“Junior Securities” has the
meaning set forth in Section 2.
“Liquidation” means the voluntary
or involuntary liquidation, dissolution or winding up of the Corporation.
“Liquidation Preference” means,
with respect to each share of Preferred Stock, $10.00 per share, as adjusted for any stock dividend,
stock split, reverse stock split, combination or similar event affecting the Preferred Stock.
“NASDAQ” means The Nasdaq Stock
Market LLC (or its successor).
“Options” means rights, options
or warrants to subscribe for, purchase or otherwise acquire Common Stock or Convertible Securities.
“Original Issuance Date” means
August 10, 2023.
“Parity Securities” has the
meaning set forth in Section 2.
“Participating Dividends” has
the meaning set forth in Section 4(a)(i).
“Payment Period” means, with
respect to a share of Preferred Stock, the period beginning on the day after the preceding Annual Dividend Payment Date (or if no Annual
Dividend Payment Date has occurred since the Issuance Date of such share of Preferred Stock, the Issuance Date) to and including the next
Annual Dividend Payment Date; provided that, for the purpose of determining the amount of Accrued Dividends for any Payment Period,
the Payment Period shall be calculated based on the actual number of days elapsed during such Payment Period on either an actual 365-or
366-day year, as applicable.
“Person” means an individual,
entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act).
“Preferred Stock” has the meaning
set forth in Section 1.
“Register” means the securities
register maintained in respect of the Preferred Stock by the Transfer Agent.
“Securities Act” means the
Securities Act of 1933, as amended.
“Senior Securities” has the
meaning set forth in Section 2.
“Share Delivery Date” has the
meaning set forth in Section 6(b)(ii).
“Subsidiary” or
“Subsidiaries” means, with respect to any Person, any other Person of which (i) if a corporation, a
majority of the total voting power of shares of capital stock entitled (without regard to the occurrence of any contingency) to vote
in the election of directors thereof is at the time owned or controlled, directly or indirectly, by that Person or one or more of
the other Subsidiaries of that Person or a combination thereof, or (ii) if a limited liability company, partnership,
association or other business entity (other than a corporation), a majority of partnership or other similar ownership interest
thereof is at the time owned or controlled, directly or indirectly, by that Person or one or more other Subsidiaries of that Person
or a combination thereof and for this purpose, a Person or Persons owns a majority ownership interest in such a business entity
(other than a corporation) if such Person or Persons shall be allocated a majority of such business entity’s gains or losses
or shall be or control any managing director or general partner of such business entity (other than a corporation). For the purposes
hereof, the term “Subsidiary” shall include all Subsidiaries of such Subsidiary.
“Threshold Amount” means 19.90%
of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock pursuant
to an applicable Conversion Notice.
“Trading Day” means a day on
which the NASDAQ is open for the transaction of business.
“Transfer Agent” means, Continental
Stock Transfer & Trust Company, the current transfer agent of the Corporation, with a mailing address of 1 State Street 30th Floor,
New York, NY 10004 and an email address of cstmail@continentalstock.com and any successor transfer agent of the Corporation.
“VWAP” means, for any date,
if the Common Stock is then listed or quoted on the NASDAQ (or its successor) or another U.S. national securities exchange, the per share
daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the NASDAQ (or its successor)
or another U.S. national securities exchange on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (or, if
Bloomberg ceases to publish such price, any successor service reasonably chosen by the Corporation) (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)) (or if such volume weighted average price is unavailable, the market price
of one share of the Common Stock on such Trading Day determined, using a volume-weighted average method, by a nationally recognized investment
banking firm retained for this purpose by the Corporation).
(b) In addition to the above definitions, unless
the context requires otherwise:
(i) any reference to any statute, regulation,
rule or form as of any time shall mean such statute, regulation, rule or form as amended or modified and shall also include any successor
statute, regulation, rule or form from time to time;
(ii) the word “including”
shall be deemed to be followed by the words “without limitation”;
(iii) references to “$”
or “dollars” means the lawful coin or currency the United States of America; and
(iv) references to “Section”
are references to Sections of this Certificate of Designations.
Section 4. Dividends.
(a) Holders of the issued and outstanding shares
of Preferred Stock shall be entitled to receive, out of the assets of the Corporation legally available for the payment of dividends,
dividends on the terms described below:
(i) Holders of shares of Preferred
Stock shall be entitled to participate equally and ratably with the holders of shares of Common Stock in all dividends paid on the shares
of Common Stock (other than dividends paid in the form of Common Stock, Convertible Securities or Options) as if immediately prior to
each Common Stock Dividend Record Date, all shares of Preferred Stock then outstanding were converted into shares of Common Stock. Dividends
payable pursuant to this Section 4(a)(i) (the “Participating Dividends”) shall be payable on the same date that
such dividends are payable to holders of shares of Common Stock, and no dividends shall be payable to holders of shares of Common Stock
unless the full dividends contemplated by this Section 4(a)(i) are paid at the same time to the Holders of the Preferred Stock.
(ii) In addition to any dividends
pursuant to Section 4(a)(i), the Corporation shall pay, subject to Section 4(c), if, as and when declared by the Board
of Directors, out of funds of the Corporation legally available therefor, on each Annual Dividend Payment Date for the applicable Payment
Period or Payment Periods dividends on each outstanding share of Preferred Stock (the “Annual Dividends”) at a rate
per annum (calculated on the basis of an actual 365- or 366-day year, as applicable) equal to 8.00% of the Liquidation Preference
per share of Preferred Stock (the “Dividend Rate”), payable in accordance with Section 4(a)(iii) below. Subject
to Section 4(c), Annual Dividends shall accrue and accumulate on a daily basis from the Issuance Date of such share, whether or
not declared and whether or not the Corporation has funds legally available for the payment of such dividends and shall be payable annually
in arrears, if, as and when so authorized and declared by the Board of Directors, on each Annual Dividend Payment Date, commencing on
the first Annual Dividend Payment Date following the Issuance Date of such share. Accrued Dividends, to the extent unpaid, shall in all
cases be payable upon a Liquidation pursuant to Section 5, upon a conversion of the Preferred Stock following a Fundamental Transaction
pursuant to Section 7(g)(i), or upon any conversion of the Preferred Stock pursuant to Section 6(a)(i) or Section 6(a)(ii).
Annual Dividend payments shall be aggregated per Holder and shall be made to the nearest cent (with $0.005
being rounded upward).
(iii) The Annual Dividends
may, at the option of the Corporation in its sole discretion, be paid (A) in cash, (B) by delivery of shares of Common Stock, or (C) by
delivery of any combination of cash and shares of Common Stock; provided that, if the Corporation elects to pay all or any part
of the total amount of an Annual Dividend in shares of Common Stock (such amount with respect to any Annual Dividend Payment Date, the
“Dividend PIK Amount”), the number of shares of Common Stock to be delivered shall be determined by dividing the Dividend
PIK Amount by the 10-Day VWAP with respect to such Annual Dividend Payment Date; provided that, where the Corporation has determined
in its sole discretion to pay a Dividend PIK Amount, if the 10-Day VWAP with respect to such Annual Dividend Payment Date is less
than the Floor Price, (A) the number of shares of Common Stock that are permitted to be delivered in partial payment of the Dividend PIK
Amount (the “Actual Dividend PIK Payment Shares”) shall be calculated by dividing (v) the Dividend PIK Amount by (w)
the Floor Price and (B) the portion of the Annual Dividend that is not paid by delivery of the Actual Dividend PIK Payment Shares shall
be payable in cash, which amount shall be calculated as (x) the total Dividend PIK Amount less (y)(i) the product of the Actual Dividend
PIK Payment Shares multiplied by (ii) the 10-Day VWAP.
(iv) Each Participating Dividend
or Annual Dividend shall be paid pro rata to the Holders of shares of Preferred Stock entitled thereto. Each Participating Dividend or
Annual Dividend shall be payable to the Holders of Preferred Stock as they appear on the Register at the Close of Business on the record
date designated by the Board of Directors for such dividends, which (i) with respect to Participating Dividends, shall be the same
day as the record date for the payment of dividends to the holders of shares of Common Stock (the “Common Stock Dividend Record
Date”), and (ii) with respect to Annual Dividends, shall be not more than thirty (30) days nor less than ten (10) days
preceding the applicable Annual Dividend Payment Date (such date, an “Annual Dividend Payment Record Date”).
(b) Without the consent of the Holders representing
at least a majority of the then-issued and outstanding shares of Preferred Stock, the Corporation shall not (i) declare, pay or
set aside for payment any dividends or distributions upon any Junior Securities or (ii) repurchase, redeem or otherwise acquire
any Junior Securities (other than repurchases, redemptions or acquisitions of shares of Junior Securities with respect to equity awards
(including in connection with “cashless” or “net” exercises of Options, payment of the exercise or purchase price
of Options, or to satisfy tax withholding obligations due as a result of the exercise of Options or delivery of equity awards) under any
equity incentive plan or similar arrangements of the Corporation or its Subsidiaries) for any consideration or pay any moneys or make
available for a sinking fund for the redemption of any shares of such Junior Securities, unless, in each case, (A) immediately
before and after the taking of such action, the fair value of the Corporation’s assets would exceed the sum of its debts (including
for this purpose the aggregate Liquidation Preference and the aggregate Accrued Dividends of the Preferred Stock), (B) immediately
after the taking of such action, the Corporation, in its good faith judgment, would be able to pay all of its debts (including the aggregate
Liquidation Preference and the aggregate Accrued Dividends of the Preferred Stock) as they are reasonably expected to come due and (C)
such action is otherwise in compliance with applicable law.
(c) If the Fundamental Transaction Date or Conversion
Date of any share of Preferred Stock is after an Annual Dividend Payment Record Date for a declared Annual Dividend on the Preferred Stock
but occurs on or prior to the next Annual Dividend Payment Date, then the Holder of such share at the Close of Business on such Annual
Dividend Payment Record Date will be entitled, notwithstanding the related Fundamental Transaction or conversion, as applicable, to receive,
on or, at the Corporation’s election, before such Annual Dividend Payment Date, such declared Annual Dividend on such share. Except
as provided in this Section 4(c), Annual Dividends on any share of Preferred Stock will cease to accumulate from and after the
Fundamental Transaction Date or Conversion Date, as applicable.
Section 5. Liquidation Rights.
(a) In the event of any Liquidation, each
Holder shall be entitled to receive liquidating distributions out of the assets of the Corporation legally available for
distribution to stockholders of the Corporation, before any payment or distribution of any assets of the Corporation shall be made
or set apart for holders of any Junior Securities, including the Common Stock, for such Holder’s shares of Preferred Stock in
an amount equal to the greater of (i) the sum of (A) the aggregate Liquidation Preference and (B) the aggregate
Accrued Dividends of such shares as of the date of the Liquidation, and (ii) the amount such Holder would have received had
such shares of Preferred Stock, immediately prior to such Liquidation, been converted into shares of Common Stock pursuant to Section
6, without regard to any of the limitations on conversion or convertibility contained therein.
(b) In the event the assets of the Corporation
available for distribution to stockholders of the Corporation upon a Liquidation shall be insufficient to pay in full the amounts payable
with respect to all outstanding shares of Preferred Stock pursuant to Section 5(a), such assets, or the proceeds thereof, shall
be distributed among the Holders ratably in proportion to the full respective liquidating distributions to which they would otherwise
be respectively entitled upon such Liquidation.
(c) Neither the sale, conveyance, exchange or
transfer (for cash, shares of stock, securities or other consideration) of all or substantially all of the assets, capital stock or business
of the Corporation (other than in connection with the liquidation, dissolution or winding up of the Corporation) nor the merger, consolidation,
share exchange, statutory exchange or any other business combination transaction of the Corporation into or with any other Person shall
by itself be deemed to be a Liquidation for purposes of this Section 5.
Section 6. Conversion.
(a) Conversion of Preferred Stock.
(i) Optional Conversion.
Subject to and in accordance with the provisions of this Section 6, each Holder of shares of Preferred Stock shall have the right,
at any time and from time to time, at such Holder’s option, to convert all or any portion of such Holder’s shares of Preferred
Stock into fully paid and non-assessable shares of Common Stock (the “Conversion Right” and such shares of Common Stock
are sometimes referred to hereinafter as, the “Conversion Shares”) by providing the Corporation, with the Conversion
Notice (as defined in Section 6(b)(i) below). Upon a Holder’s election to exercise its Conversion Right pursuant to the Conversion
Notice, each share of Preferred Stock for which the Conversion Right is exercised shall be converted into such number of Conversion Shares
equal to the quotient of (A) the sum of (1) the Liquidation Preference and (2) if the Corporation has not otherwise
paid the Accrued Dividends to the Holder, the Accrued Dividends on such share as of the Conversion Date, divided by (B)
the Conversion Price of such share in effect at the time of conversion.
(ii) Automatic Conversion.
On the four year anniversary of the Original Issuance Date, all then outstanding shares of Preferred Stock shall automatically convert
into fully paid and non-assessable shares of Common Stock, with each share of Preferred Stock automatically converted into such number
of shares of Common Stock equal to the quotient of (A) the sum of (1) the Liquidation Preference and (2) if the Corporation
has not otherwise paid the Accrued Dividends to the Holder, the Accrued Dividends on such share as of the Conversion Date, divided
by (B) the Conversion Price of such share in effect at the time of conversion.
(iii) Fractional Shares.
No fractional shares of Common Stock shall be issued upon the conversion of any shares of Preferred Stock. If more than one share of Preferred
Stock subject to conversion is held by the same Holder, the number of full shares of Common Stock issuable upon conversion thereof shall
be computed on the basis of the sum of (A) the aggregate Liquidation Preference and (B) the aggregate Accrued Dividends
as of the Conversion Date on all shares of Preferred Stock so subject for which the Corporation has not otherwise paid such Accrued Dividends.
If the conversion of any share or shares of Preferred Stock results in a fractional share of Common Stock issuable after application of
the immediately preceding sentence, the Corporation shall pay a cash amount in lieu of issuing such fractional share in an amount equal
to the value of such fractional interest multiplied by the 10-Day VWAP of a share of Common Stock determined on the Conversion Date.
(iv) Reservation of
Shares. The Corporation will at all times reserve and keep available out of its authorized and unissued Common Stock, solely for
the purpose of effecting conversions of the Preferred Stock into shares of Common Stock, a number of shares of Common Stock equal to
100% of the number of shares of Common Stock then issuable upon conversion of all then outstanding shares of Preferred Stock. The
Corporation shall take all action permitted by applicable law, including calling meetings of stockholders of the Corporation and
soliciting proxies for any necessary vote of the stockholders of the Corporation, to amend the Certificate of Incorporation to
increase the number of authorized and unissued shares of Common Stock, if at any time there shall be insufficient authorized and
unissued shares of Common Stock to permit such reservation or to permit the conversion of all outstanding shares of Preferred Stock.
The Corporation covenants that the Preferred Stock and all Common Stock that may be issued upon conversion of Preferred Stock shall
upon issuance be duly authorized, fully paid and non-assessable and will not be subject to preemptive rights or subscription rights
of any other stockholder of the Corporation. The Corporation further covenants that the Corporation shall, if permitted by the rules
of the NASDAQ, at its sole expense, cause to be authorized for listing or quotation on the NASDAQ, all Common Stock issuable upon
conversion of the Preferred Stock, subject to official notice of issuance. The Corporation will use its reasonable best efforts to
ensure that such Common Stock may be issued without violation of any applicable law or regulation.
(b) Mechanics of Conversion.
(i) The Conversion Right of
a Holder of Preferred Stock shall be exercised by the Holder by delivering written notice to the Corporation, substantially in the form
attached hereto as Annex A, that the Holder elects to convert all or a portion of the shares of Preferred Stock held by such Holder
(a “Conversion Notice”) and specifying the name or names (with address or addresses) in which shares of Common Stock
are to be issued and (if so required by the Corporation or the Corporation’s Transfer Agent) by a written instrument or instruments
of transfer in form reasonably satisfactory to the Corporation or the Transfer Agent, duly executed by the Holder or its legal representative.
(ii) As promptly as practicable
after the receipt of the Conversion Notice, and the payment of required taxes or duties pursuant to Section 10(a), if applicable, and
in no event later than three (3) Trading Days thereafter (the “Share Delivery Date”), the Corporation shall instruct
the Transfer Agent to update the Register to reflect the shares of Common Stock held by such Holder as a result of such conversion and
shall issue and shall deliver or cause to be issued and delivered to such Holder, or to such other Person on such Holder’s written
order (A) evidence of such issuance reasonably satisfactory to such Holder, and (B) cash for any fractional interest in respect of a share
of Common Stock arising upon such conversion settled as provided in Section 6(a)(iii).
(iii) The conversion of any
share of Preferred Stock shall be deemed to have been made in connection with any exercise of the Conversion Right at the Close of Business
on the date of giving the Conversion Notice (the “Conversion Date”). Until the Conversion Date with respect to any
share of Preferred Stock has occurred, such share of Preferred Stock will remain outstanding and will be entitled to all of the powers,
designations, preferences and other rights provided herein, including that such share shall (A) accrue and accumulate Annual Dividends
and participate in Participating Dividends pursuant to Section 4 and (B) entitle the Holder thereof to the voting rights provided
in Section 8.
(iv) Corporation’s
Obligations to Issue Common Stock. Subject to Section 6(c), the Corporation’s obligations to issue and deliver shares of Common
Stock upon conversion of shares of Preferred Stock in accordance with the terms hereof are absolute and unconditional, irrespective of
any action or inaction by any Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of
any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination,
or any breach or alleged breach by any Holder or any other Person of any obligation to the Corporation or any violation or alleged violation
of law by any Holder or any other Person, and irrespective of any other circumstance which might otherwise limit such obligation of the
Corporation to any Holder in connection with the issuance of such shares of Common Stock.
(v) Failure to Deliver
Shares of Common Stock upon Conversion of Shares of Preferred Stock. If, in the case of any Conversion Notice, the Conversion Shares
to be issued in connection with the Conversion Right are not delivered to the applicable Holder by the Share Delivery Date, in addition
to any other rights herein, the Holder shall be entitled to elect by written notice to the Transfer Agent, on behalf of the Corporation,
at any time on or before its receipt of such Conversion Shares, to rescind such Conversion Notice, in which event the Corporation shall
promptly return to the Holder any certificated Preferred Stock delivered to the Corporation and the Holder shall promptly return to the
Corporation any Conversion Shares issued to such Holder pursuant to the rescinded Conversion Notice.
(vi) Compensation for
Buy-In on Failure to Timely Deliver Conversion Shares Upon Conversion. In addition to any other rights available to the Holder,
if the Corporation fails for any reason to deliver to a Holder the applicable Conversion Shares by the Share Delivery Date pursuant
to Section 6(b)(ii) (other than a failure caused by incorrect or incomplete information provided by the Holder to the
Corporation and which the Corporation promptly provides written notice to the Holder of), and if after such Share Delivery Date such
Holder is required by its brokerage firm to purchase (in an open market transaction or otherwise), or the Holder’s brokerage
firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by such Holder of the Conversion Shares which
such Holder was entitled to receive upon the conversion relating to such Share Delivery Date (a “Buy-In”), then
the Corporation shall (A) pay in cash to such Holder (in addition to any other remedies available to or elected by such Holder) the
amount, if any, by which (x) such Holder’s total purchase price (including any brokerage commissions) for the Common Stock so
purchased exceeds (y) the product of (1) the aggregate number of shares of Common Stock that such Holder was entitled to receive
from the conversion at issue multiplied by (2) the actual sale price at which the sell order giving rise to such purchase obligation
was executed (including any brokerage commissions) and (B) at the option of such Holder, either reissue (if surrendered) the shares
of Preferred Stock equal to the number of shares of Preferred Stock submitted for conversion (in which case, such conversion shall
be deemed rescinded) or deliver to such Holder the number of shares of Common Stock that would have been issued if the Corporation
had timely complied with its delivery requirements under Section 6(b)(ii). For example, if a Holder purchases shares of
Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted conversion of shares of
Preferred Stock with respect to which the actual sale price of the Conversion Shares (including any brokerage commissions) giving
rise to such purchase obligation was a total of $10,000, under clause (A) of the immediately preceding sentence, the Corporation
shall be required to pay such Holder $1,000. The Holder shall provide the Corporation written notice indicating the amounts payable
to such Holder in respect of the Buy-In and, upon request of the Corporation, evidence of the amount of such loss. Nothing herein
shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief with respect to the Corporation’s failure to timely
deliver the Conversion Shares upon conversion of the shares of Preferred Stock as required pursuant to the terms hereof.
(c) NASDAQ Conversion Limits; Solicitation
of Stockholder Approval. Notwithstanding Section 6(a) of this Certificate of Designations, the Corporation shall not be required
to issue any shares of Common Stock to a given Holder upon conversion by such Holder (or its assigns) of any shares of Preferred Stock
to the extent (and only to the extent) that such conversion would result in a given Holder (including its predecessors-in-interest) beneficially
owning a number of shares of Common Stock in excess of the applicable Threshold Amount that has not been approved by the Corporation’s
stockholders (including at any special meeting of the Corporation’s stockholders) in accordance with the stockholder approval
requirements of NASDAQ Marketplace Rule 5635 (or any equivalent rule or requirement of the applicable exchange or automated quotation
system on which the Common Stock is then listed or quoted). In the event that any proposed conversion would be restricted by the foregoing
limitation, the Corporation shall use reasonable best efforts to take any and all actions which may be necessary, including obtaining
regulatory, NASDAQ (or such exchange or automated quotation system on which the Common Stock is then listed) or stockholder approvals,
in order that the Corporation may thereafter validly and legally issue such shares of Common Stock to the given Holder or Holder(s) in
compliance with the applicable listing standards of NASDAQ (or such exchange or automated quotation system on which the Common Stock is
then listed).
Section 7. Adjustments to Conversion Price.
(a) Adjustments to Conversion Price. Except
as provided in Section 7(d), the Conversion Price shall be subject to the following adjustments:
(i) Stock Dividends and
Distributions. If the Corporation declares a dividend or makes a distribution on the Common Stock payable in shares of Common Stock,
then the Conversion Price in effect at the opening of business on the Ex-Date for such dividend or distribution shall be adjusted to the
price determined by multiplying the Conversion Price at the opening of business on such Ex-Date by the following fraction:
OS0
OS1
Where,
OS0 = the number of shares of Common Stock outstanding
at the Close of Business on the Business Day immediately preceding the Ex-Date for such dividend or distribution.
OS1 = the sum of the number of shares of Common
Stock outstanding at the Close of Business on the Business Day immediately preceding the Ex-Date for such dividend or distribution plus
the total number of shares of Common Stock constituting such dividend or distribution.
If any dividend or distribution described in this
Section 7(a)(i) is declared but not so paid or made, the Conversion Price shall be readjusted, effective as of the date and time
the Board of Directors determines not to make such dividend or distribution, to such Conversion Price that would be in effect if such
dividend or distribution had not been declared.
(ii) Subdivisions, Splits
and Combination of the Common Stock. If the Corporation subdivides, splits or combines the shares of Common Stock, then the Conversion
Price in effect immediately prior to the effective date of such share subdivision, split or combination shall be adjusted to the price
determined by multiplying the Conversion Price in effect immediately prior to the effective date of such share subdivision, split or combination
by the following fraction:
OS0
OS1
Where,
OS0 = the number of shares of Common Stock outstanding
immediately prior to the effective date of such share subdivision, split or combination.
OS1 = the number of shares of Common Stock outstanding
immediately after the opening of business on the effective date of such share subdivision, split or combination.
If any subdivision, split or combination described
in this Section 7(a)(ii) is announced but the outstanding shares of Common Stock are not subdivided, split or combined, the Conversion
Price shall be readjusted, effective as of the date the Board of Directors determines not to subdivide, split or combine the outstanding
shares of Common Stock, to such Conversion Price that would be in effect if such subdivision, split or combination had not been announced.
(iii) Other Distributions.
If the Corporation distributes to all holders of shares of Common Stock, any Convertible Securities or Options or any other assets for
which there is no corresponding distribution in respect of the Preferred Stock pursuant to Section 4(a)(i) (which excludes, for
the avoidance of doubt, any distribution of cash or non-cash property for which there is a corresponding distribution in respect of the
Preferred Stock pursuant to Section 4(a)(i)), then the Conversion Price in effect immediately prior to the Ex-Date for such distribution
shall be adjusted to the price determined by multiplying the Conversion Price in effect immediately prior to the Ex-Date for such distribution
by the following fraction:
SP0 – FMV
SP0
Where,
SP0 = the 10-Day VWAP of a share of Common Stock
determined on the Ex-Date for such distribution.
FMV = the fair market value of the portion of
the distribution applicable to one share of Common Stock on the Ex-Date for such distribution, in the case of a non-cash distribution
or with respect to the non-cash portion of a distribution, if any, as determined (i) by the good faith determination of the Board
of Directors or (ii) if, within five (5) Business Days following notice from the Corporation of the value determined by the Board
of Directors pursuant to clause (i), the Holders of a majority of the outstanding shares of Preferred Stock object in good faith
to such determination, then the fair market value will be determined by a nationally recognized independent investment banking firm that
has for this purpose (x) been selected by the Board of Directors, and (y) is reasonably acceptable to Holders of a majority
of the outstanding shares of Preferred Stock; provided, that such value, whether determined pursuant to the foregoing clause (i)
or (ii), shall not for the purposes hereof in any event be equal to or greater than the 10-Day VWAP of a share of Common Stock
determined on such date.
In a “spin-off,” where the Corporation
makes a distribution to all holders of shares of Common Stock consisting of capital stock of any class or series, or similar equity interests
of, or relating to, a Subsidiary of the Corporation or other business unit, the Conversion Price will be adjusted on the fifteenth (15th)
Trading Day after the effective date of the distribution by multiplying such Conversion Price in effect immediately prior to such fifteenth
(15th) Trading Day by the following fraction:
MP0
MP0 + MPs
Where,
MP0 = (i) if the Common Stock is listed
or quoted on a principal U.S. national or regional securities exchange or traded on an over-the-counter market, the 10-Day VWAP of a share
of Common Stock determined on the eleventh (11th) Trading Day following the effective date of such distribution, or (ii)
if the Common Stock is not listed or quoted on a principal U.S. national or regional securities exchange or traded on an over-the-counter
market, the 10-Day VWAP of a share of Common Stock on the effective date of such distribution.
MPs = (i) if the capital stock or equity interests
distributed to the holders of shares of Common Stock are listed or quoted on a principal U.S. national or regional securities exchange
or traded on an over-the-counter market, an amount equal to the product of (x) the number of shares of such capital stock or equity
interests representing the portion of the distribution applicable to one share of Common Stock and (y) the 10-Day VWAP of such
capital stock or equity interests on the eleventh (11th) Trading Day following the effective date of such distribution, or
(ii) if such capital stock or equity interests are not listed or quoted on a principal U.S. national or regional securities exchange
or traded on an over-the-counter market, the 10-Day VWAP of the capital stock or equity interests representing the portion of the distribution
applicable to one share of Common Stock on the effective date of such distribution (after giving effect to such distribution).
In the event that such distribution described
in this Section 7(a)(iii) is not so paid or made, the Conversion Price shall be readjusted, effective as of the date the Board
of Directors publicly announces its decision not to pay or make such distribution, to the Conversion Price that would then be in effect
if such distribution had not been declared.
(iv) Automatic Adjustment
Upon Reset Dates. The Conversion Price will automatically reset upon each of the eighteen (18) month and forty-seven (47) month anniversaries
of the Original Issuance Date to be equal to the lower of (x) the then-current Conversion Price and (y) the higher of (A) the Floor Price
or (B) the 10-Day VWAP of the Common Stock determined as of the date of such reset. Notwithstanding the foregoing, there shall be no automatic
resets of the Conversion Price pursuant to this Section 7(a)(iv) following a Fundamental Transaction Date.
(b) Other Adjustments.
(i) The Corporation may make
decreases in the Conversion Price, in addition to any other decreases required by this Section 7, if the Board of Directors deems
it advisable to avoid or diminish any income tax to holders of the Common Stock resulting from any dividend or distribution of shares
of Common Stock (or issuance of Options for Common Stock) or from any event treated as such for income tax purposes.
(ii) If the Corporation takes
any action affecting the Common Stock, other than an action described in Section 7(a), which upon a determination by the Board
of Directors, in its good faith discretion (such determination intended to be a “fact” for purposes of Section 151(a) of the
DGCL), would materially adversely affect the conversion rights of the Holders of shares of Preferred Stock, the Conversion Price shall
be adjusted, to the extent permitted by applicable law, in such manner, if any, and at such time, as the Board of Directors determines
in good faith to be equitable in the circumstances.
(c) Successive Adjustments. Successive
adjustments in the Conversion Price shall be made, without duplication, whenever any event specified in Section 7(a) or Section
7(b) shall occur.
(d) Rounding of Calculations; Minimum Adjustments.
All adjustments to the Conversion Price shall be calculated to the nearest one-tenth (1/10th) of a cent. No adjustment in the Conversion
Price shall be required if such adjustment would be less than $0.01; provided, that any adjustments which by reason of this Section
7(d) are not required to be made shall be carried forward and taken into account in any subsequent adjustment; provided, further
that on any Conversion Date adjustments to the Conversion Price will be made with respect to any such adjustment carried forward and which
has not been taken into account before such date.
(e) Statement Regarding Adjustments; Notices.
Whenever the Conversion Price is to be adjusted in accordance with one or more of Section 7(a) or Section 7(b), the Corporation
shall: (i) compute the Conversion Price in accordance with Section 7(a) or Section 7(b), taking into account the
one cent threshold set forth in Section 7(d); (ii) (x) in the event that the Corporation shall give notice or make
a public announcement to the holders of Common Stock of any action of the type described in Section 7(a) (but only if the action
of the type described in Section 7(a) would result in an adjustment to the Conversion Price), or Section 7(g) (but only
if the action of the type described in Section 7(g) would result in a change in the type of securities or property to be delivered
upon conversion of the Preferred Stock), the Corporation shall, at the time of such notice or announcement, and in the case of any action
which would require the fixing of a record date, at least ten (10) days prior to such record date, give notice to each Holder by mail,
first class postage prepaid, at the address appearing in the Register, which notice shall specify the record date, if any, with respect
to any such action, the approximate date on which such action is to take place and the facts with respect to such action as shall be reasonably
necessary to indicate the effect on the Conversion Price and the number, kind or class of shares or other securities or property which
shall be deliverable upon conversion of the Preferred Stock or (y) in the event that the Corporation does not give notice or make
a public announcement as set forth in subclause (x) of this clause (ii), the Corporation shall, as soon as practicable following the occurrence
of an event that requires an adjustment to the Conversion Price pursuant to one or more of Section 7(a) or Section 7(b),
taking into account the one cent threshold set forth in Section 7(d) (or if the Corporation is not aware of such occurrence, as
soon as practicable after becoming so aware), provide, or cause to be provided, a written notice to the Holders of the occurrence of such
event, in the same manner and with the same detail as the notice set forth in subclause (x) of this clause (ii); and (iii) whenever
the Conversion Price shall be adjusted pursuant to one or more of Section 7(a) or Section 7(b), the Corporation shall, as
soon as practicable following the determination of the revised Conversion Price, (x) file at the principal office of the Corporation,
a statement showing in reasonable detail the facts requiring such adjustment, the Conversion Price that shall be in effect after such
adjustment and the method by which the adjustment to the Conversion Price was determined and (y) cause a copy of such statement
to be sent in the manner set forth in subclause (x) of clause (ii) to each Holder.
(f) Certain Adjustment Rules. If an adjustment
in the Conversion Price made pursuant to Section 7(a)(iv) would reduce the Conversion Price to an amount below the Floor Price,
then such adjustment in Conversion Price shall only reduce the Conversion Price to the Floor Price. As a condition precedent to the taking
of any action which would require an adjustment pursuant to this Section 7, the Corporation shall use its reasonable best efforts
to take any and all actions which may be necessary, including obtaining regulatory, NASDAQ (or such exchange or automated quotation system
on which the Common Stock is then listed) or stockholder approvals or exemptions, in order that the Corporation may thereafter validly
and legally issue as fully paid and nonassessable all shares of Common Stock issuable upon conversion of the Preferred Stock in compliance
with the applicable listing standards of NASDAQ (or such exchange or automated quotation system on which the Common Stock is then listed).
(g) Fundamental Transactions.
(i)
Subject to applicable law and the last sentence of this Section 7(g)(i), upon the occurrence of any Fundamental Transaction (the
date of such occurrence, a “Fundamental Transaction Date”), then, upon any subsequent conversion of the Preferred
Stock, the Holder shall have the right to receive, for each share of Common Stock that would have been issuable upon such conversion
immediately prior to the occurrence of such Fundamental Transaction, (i) the number of shares of Common Stock of the Corporation (if
it is the surviving entity), or (ii) common stock of the successor or acquiring corporation (if it is the surviving entity), as well
as any additional consideration (the “Alternate Consideration”) receivable as a result of such Fundamental
Transaction by a holder of the number of shares of Common Stock (including, for avoidance of doubt, the number of shares of Common
Stock in respect of any Accrued Dividends to the extent unpaid as of the Fundamental Transaction Date, calculated as the quotient of
(A) such Accrued Dividends divided by (B) the Conversion Price in effect immediately prior to such Fundamental Transaction, the
“Accrued Dividend Fundamental Transaction Shares”) for which the Preferred Stock is convertible immediately prior
to such Fundamental Transaction. For purposes of any such conversion, if holders of Common Stock are given any choice as to the
securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the
securities, cash or property it receives upon any conversion of the Preferred Stock following such Fundamental Transaction.
Notwithstanding the foregoing and for the avoidance of doubt, for any transaction that constitutes a Fundamental Transaction under
clauses (iii) or (v) of the definition of Fundamental Transaction where the Corporation is the surviving entity, upon any conversion
of the Preferred Stock subsequent to such Fundamental Transaction, the Holder shall be entitled to receive only (y) the number of
shares of Common Stock of the Corporation for which the Preferred Stock is convertible immediately prior to such Fundamental
Transaction, plus (z) the Accrued Dividend Fundamental Transaction Shares.
(ii) if the Corporation
is not the surviving company in any Fundamental Transaction or will be dissolved in connection with a Fundamental Transaction, the Corporation
shall cause, as a condition to the closing of such transaction, any successor entity in a Fundamental Transaction in which the Corporation
is not the survivor (the “Successor Entity”) to assume in writing all of the obligations of the Corporation under this
Certificate of Designations in accordance with the provisions of this Section 7(g) prior to the consummation of such Fundamental
Transaction and shall deliver to the Holders in exchange for the Preferred Stock a security of the Successor Entity evidenced by a written
instrument substantially similar in form and substance to the Preferred Stock which is convertible for a corresponding number of shares
of capital stock of such Successor Entity (or its parent entity) and any Alternate Consideration equivalent to the shares of Common Stock
(including any Accrued Dividend Fundamental Transaction Shares) receivable upon conversion of the Preferred Stock (without regard to any
limitations on the conversion of the Preferred Stock) prior to the consummation of such Fundamental Transaction, and with a conversion
price which applies the Conversion Price hereunder to such shares of capital stock and any Alternate Consideration (but taking into account
the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock
and any Alternate Consideration, such conversion price being for the purpose of protecting the economic value of the Preferred Stock immediately
prior to the consummation of such Fundamental Transaction). Upon the occurrence of any such Fundamental Transaction, to the extent necessary
to effectuate the foregoing provisions, the Successor Entity shall file a new Certificate of Designations with the same terms and conditions
or, if applicable, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental
Transaction, the provisions of this Certificate of Designations referring to the “Corporation” shall refer instead to the
Successor Entity), and may exercise every right and power of the Corporation and shall assume all of the obligations of the Corporation
under this Certificate of Designations with the same effect as if such Successor Entity had been named as the Corporation herein.
Section 8. Voting Rights.
(a) General. The Holders of shares of Preferred Stock shall
be entitled to vote with the holders of the Common Stock on all matters submitted to a vote of stockholders of the Corporation, except
as otherwise provided herein or as required by applicable law, voting together with the holders of Common Stock as a single class. For
such purposes, each Holder, for each share of Preferred Stock held by such Holder as of the record date for the determination of stockholders
entitled to vote on such matters, shall be entitled to 1.07 votes (as adjusted for any stock dividend,
stock split, reverse stock split, combination or similar event affecting the Preferred Stock), or, if no such record date is established,
each Holder, for each share of Preferred Stock held by such Holder as of the date such vote is taken or any written consent of stockholders
is solicited, shall be entitled to 1.07 votes (as adjusted for any stock dividend, stock split,
reverse stock split, combination or similar event affecting the Preferred Stock). The Holders of shares of Preferred Stock shall
be entitled to notice of any stockholders’ meeting in accordance with the Certificate of Incorporation and the By-laws as if they
were holders of record of Common Stock for such meeting.
(b) Class Voting Rights. So long as any
shares of Preferred Stock are outstanding, in addition to any other vote required by applicable law, the Corporation may not take any
of the following actions (including by means of merger, consolidation, reorganization, recapitalization or otherwise) without the prior
affirmative vote or written consent of the Holders representing at least a majority of the then-issued and outstanding shares of Preferred
Stock, voting as a separate class:
(i) amend, alter, repeal or
otherwise modify any provision of the Certificate of Incorporation or this Certificate of Designations in a manner that would alter or
change the terms or the powers, preferences, rights or privileges of the Preferred Stock as to affect them adversely;
(ii) authorize, create, increase
the authorized amount of, or issue any class or series of Senior Securities;
(iii) increase the authorized
number of shares of Preferred Stock; or
(iv) enter into any agreement
with respect to the foregoing.
(c) The consent or votes required in Section
8(b) shall be in addition to any approval of stockholders of the Corporation which may be required by law or pursuant to any provision
of the Certificate of Incorporation or the By-laws. Each Holder of shares of Preferred Stock will have one vote per share on any matter
on which Holders of shares of Preferred Stock are entitled to vote separately as a class, whether at a meeting or by written consent.
Section 9. Transfer Agent.
The Corporation shall appoint a Transfer Agent
and remove its Transfer Agent in accordance with the agreement between the Corporation and such Transfer Agent; provided that the
Corporation shall appoint a successor transfer agent of recognized standing who shall accept such appointment prior to the effectiveness
of such removal. Upon any such removal or appointment, the Corporation shall send notice thereof by first-class mail, postage prepaid,
to the Holders. When a Holder requests to register the transfer of shares of Preferred Stock, the Corporation or the Transfer Agent, as
applicable, shall register the transfer as requested if its reasonable requirements for such transaction are met.
Section 10. Miscellaneous.
(a) Taxes. The issuance or delivery of
shares of Preferred Stock, shares of Common Stock or other securities issued on account of Preferred Stock pursuant hereto, or certificates
representing such shares or securities, shall be made without charge to the Holder for such shares or certificates or for any tax in respect
of the issuance or delivery of such certificates or the securities represented thereby, including any share transfer, documentary, stamp
or similar tax; provided, however, that the Corporation shall not be required to pay any tax that may be payable in respect
of any transfer involved in the issuance or delivery of shares of Preferred Stock, shares of Common Stock or other securities in a name
other than that in which the shares of Preferred Stock with respect to which such shares or other securities were issued or delivered
are registered, or in respect of any payment to any Person other than a payment to the Holder thereof, and the transferee or payee, as
the case may be, shall pay or bear the cost of any such tax, and the Corporation shall not be required to make any such issuance, delivery
or payment unless and until the Person otherwise entitled to such issuance, delivery or payment has paid to the Corporation the amount
of any such tax or has established, to the satisfaction of the Corporation, that such tax has been paid or is not payable.
(b) Good Faith. The Corporation shall not,
by amendment of the Certificate of Incorporation or through reorganization, consolidation, merger, dissolution, sale of assets, or otherwise,
avoid or seek to avoid the observance or performance of any of the terms of this Certificate of Designations, but will at all times in
good faith assist in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order
to protect the rights of the Holders of Preferred Stock against impairment as set forth in this Certificate of Designations.
(c) Status of Shares. Shares of Preferred
Stock which have been converted, redeemed, repurchased or otherwise cancelled shall be retired and, following the filing of any certificate
required by the DGCL, have the status of authorized and unissued shares of Preferred Stock, without designation as to series until such
shares are once more, subject to and in accordance with the provisions of Section 8, designated as part of a particular series
of Preferred Stock by the Board of Directors.
(d) Notices. All notices referred to herein
shall be in writing, and, unless otherwise specified herein, all notices hereunder shall be deemed to have been given upon the earlier
of receipt thereof or three (3) Business Days after the mailing thereof if sent by registered or certified mail (or by first class mail
if the same shall be specifically permitted for such notice under the terms of this Certificate of Designations) with postage prepaid,
addressed: (i) if to the Corporation, to its office at 6272 W. 91st Avenue, Westminster, CO 80031, Attention: Chief Financial Officer,
or to any transfer or other agent of the Corporation designated to receive such notice as permitted by this Certificate of Designations,
or (ii) if to any Holder, to such Holder at the address of such Holder as listed in the Register or (iii) to such other
address as the Corporation or any such Holder, as the case may be, shall have designated by written notice similarly given.
(e) Severability. If any right, preference
or limitation of the Preferred Stock set forth in this Certificate of Designations (as amended from time to time) is invalid, unlawful
or incapable of being enforced by reason of any rule of law or public policy, all other rights, preferences and limitations set forth
in this Certificate of Designations (as so amended) which can be given effect without the invalid, unlawful or unenforceable right, preference
or limitation shall, nevertheless, remain in full force and effect, and no right, preference or limitation herein set forth shall be deemed
dependent upon any other such right, preference or limitation unless so expressed herein.
(f) Other Rights. Except as expressly provided
in any agreement between a Holder and the Corporation, the shares of Preferred Stock shall not have any voting powers, preferences or
relative, participating, optional or other special rights, or qualifications, limitations or restrictions thereof, other than as set forth
herein or in the Certificate of Incorporation or as provided by applicable law.
(g) Headings. The headings of the various
subdivisions hereof are for convenience of reference only and shall not affect the interpretation of any of the provisions hereof.
(h) Effectiveness. This Certificate of
Designations shall become effective upon the filing thereof with the Secretary of State of the State of Delaware.
[Remainder of this page intentionally left blank]
IN WITNESS WHEREOF, the Corporation has caused this Certificate of
Designations to be duly executed and acknowledged by its undersigned duly authorized officer this 10th day of August, 2023.
|
TRISALUS LIFE SCIENCES, INC. |
|
|
|
|
By: |
/s/ Christopher C. Dewey |
|
Name: |
Christopher C. Dewey |
|
Title: |
Chief Executive Officer |
[Signature Page to the Certificate of Designations]
ANNEX A
CONVERSION NOTICE
(TO BE EXECUTED BY THE REGISTERED HOLDER IN ORDER
TO
CONVERT SHARES OF SERIES A PREFERRED STOCK)
The undersigned hereby elects to convert the number
of shares of Series A Preferred Stock indicated below into shares of common stock, $0.0001 par value per share (the “Common Stock”),
of TRISALUS LIFE SCIENCES, INC., a Delaware corporation, according to the conditions hereof, as of the date written below.
Conversion calculations:
Date to Effect Conversion: ________________________________________________________________________
Number of shares of Series A Preferred Stock owned
prior to Conversion: ____________________________________
Number of shares of Series A Preferred Stock to
be Converted: ____________________________________________
Number of shares of Common Stock to be Issued:
______________________________________________________
Applicable Conversion Price: _____________________________________________________________________
Number of shares of Series A Preferred Stock subsequent
to Conversion: ____________________________________
|
[Holder] |
|
|
|
|
By: |
|
|
Name: |
|
|
Title: |
|
Exhibit 4.1
NUMBER |
|
NUMBER |
|
|
C- |
|
|
SHARES |
|
|
SEE REVERSE FOR CERTAIN DEFINITIONS |
|
|
CUSIP 89680M 101
|
TRISALUS LIFE SCIENCES, INC.
INCORPORATED UNDER THE LAWS OF THE STATE OF
DELAWARE
COMMON STOCK
This Certifies that
is the owner of
FULLY PAID AND NON-ASSESSABLE SHARES OF THE PAR VALUE OF $0.0001 EACH
OF THE COMMON STOCK OF
TRISALUS LIFE SCIENCES, INC.
(THE “CORPORATION”)
transferable on the books of the Corporation in person or by duly authorized
attorney upon surrender of this certificate properly endorsed.
This certificate is not valid unless countersigned by the Transfer
Agent and registered by the Registrar.
Witness the seal of the Corporation and the facsimile signatures of
its duly authorized officers.
Authorized Signatory |
|
[Corporate Seal]
Delaware |
|
Authorized Signatory |
TRISALUS LIFE SCIENCES, INC.
The Corporation will furnish without charge to each stockholder who
so requests the powers, designations, preferences and relative, participating, optional or other special rights of each class of stock
or series thereof of the Corporation and the qualifications, limitations, or restrictions of such preferences and/or rights. This certificate
and the shares represented thereby are issued and shall be held subject to all the provisions of the Company’s second amended and
restated certificate of incorporation and all amendments thereto and resolutions of the Board of Directors providing for the issue of
securities (copies of which may be obtained from the secretary of the Corporation), to all of which the holder of this certificate by
acceptance hereof assents. The following abbreviations, when used in the inscription on the face of this certificate, shall be construed
as though they were written out in full according to applicable laws or regulations:
TEN COM |
— |
as tenants in common |
UNIF GIFT MIN ACT |
— |
|
Custodian |
|
|
|
|
|
|
|
|
|
TEN ENT |
— |
as tenants by the entireties |
|
|
(Cust) |
|
(Minor) |
JT TEN |
— |
as joint tenants with right of survivorship and not as tenants in common |
|
|
|
under Uniform Gifts to Minors Act |
|
|
|
|
|
|
(State) |
Additional abbreviations may also be used though not in the above list.
For value received, hereby sells, assigns and transfers unto
(PLEASE INSERT SOCIAL SECURITY OR OTHER IDENTIFYING
NUMBER(S) OF ASSIGNEE(S))
(PLEASE PRINT OR TYPEWRITE NAME(S) AND ADDRESS(ES),
INCLUDING ZIP CODE, OF ASSIGNEE(S))
Shares of the capital stock represented by the within Certificate,
and hereby irrevocably constitutes and appoints
Attorney to transfer the said stock on the books of the within named
Corporation with full power of substitution in the premises.
|
NOTICE: THE SIGNATURE(S) TO THIS ASSIGNMENT MUST CORRESPOND WITH THE
NAME AS WRITTEN UPON THE FACE OF THE CERTIFICATE IN EVERY PARTICULAR, WITHOUT ALTERATION OR ENLARGEMENT OR ANY CHANGE WHATEVER.
|
Signature(s) Guaranteed: |
By |
|
|
THE SIGNATURE(S) MUST BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION
(BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM,
PURSUANT TO S.E.C. RULE 17Ad-15 (OR ANY SUCCESSOR RULE).
|
Exhibit 4.2
[Form of Warrant Certificate]
[FACE]
Number
Warrants
THIS WARRANT SHALL BE
VOID IF NOT EXERCISED PRIOR TO
THE EXPIRATION OF THE EXERCISE PERIOD PROVIDED FOR
IN THE WARRANT AGREEMENT DESCRIBED BELOW
TRISALUS
LIFE SCIENCES, INC.
Incorporated Under the Laws of the State of Delaware
CUSIP 89680M 119
Warrant Certificate
This
Warrant Certificate certifies that , or registered assigns, is the registered holder of warrant(s) evidenced hereby
(the “Warrants” and each, a “Warrant”) to purchase shares of common stock, $0.0001
par value per share (“Common Stock”), of TriSalus Life Sciences, Inc., a Delaware corporation (the “Company”).
Each whole Warrant entitles the holder, upon exercise during the period set forth in the Warrant Agreement referred to below, to receive
from the Company that number of fully paid and non-assessable shares of Common Stock as set forth below, at the exercise price (the “Exercise
Price”) as determined pursuant to the Warrant Agreement, payable in lawful money (or through “cashless exercise”
as provided for in the Warrant Agreement) of the United States of America upon surrender of this Warrant Certificate and payment of the
Exercise Price at the office or agency of the Warrant Agent referred to below, subject to the conditions set forth herein and in the Warrant
Agreement. Defined terms used in this Warrant Certificate but not defined herein shall have the meanings given to them in the Warrant
Agreement.
Each whole Warrant is initially exercisable for
one fully paid and non-assessable share of Common Stock. No fractional shares will be issued upon exercise of any Warrant. If, upon the
exercise of a Warrant, a holder would be entitled to receive a fractional interest in a share, the Company will, upon exercise, round
down to the nearest whole number of the number of shares of Common Stock to be issued to the holder. The number of shares of Common Stock
issuable upon exercise of the Warrants is subject to adjustment upon the occurrence of certain events set forth in the Warrant Agreement.
The initial Exercise Price per share of Common
Stock for any Warrant is equal to $11.50 per share. The Exercise Price is subject to adjustment upon the occurrence of certain events
set forth in the Warrant Agreement.
Subject to the conditions set forth in the Warrant
Agreement, the Warrants may be exercised only during the Exercise Period and to the extent not exercised by the end of such Exercise Period,
such Warrants shall become void.
The Warrants may be redeemed, subject to certain
conditions, as set forth in the Warrant Agreement.
Reference is hereby made to the further provisions
of this Warrant Certificate set forth on the reverse hereof and such further provisions shall for all purposes have the same effect as
though fully set forth at this place.
This Warrant Certificate shall not be valid unless
countersigned by the Warrant Agent, as such term is used in the Warrant Agreement.
This Warrant Certificate shall be governed by and
construed in accordance with the internal laws of the State of New York, without regard to conflicts of laws principles thereof.
TRISALUS LIFE SCIENCES, INC.
|
|
By: |
|
|
Name: |
|
|
Title: |
|
|
CONTINENTAL STOCK TRANSFER |
|
& TRUST COMPANY, as Warrant Agent |
|
|
|
By: |
|
|
Name: |
|
|
Title: |
|
|
[Form of Warrant Certificate]
[Reverse]
The Warrants evidenced by this Warrant Certificate
are part of a duly authorized issue of Warrants entitling the holder on exercise to receive shares of Common Stock and are issued or to
be issued pursuant to a Warrant Agreement dated as of December 17, 2020 (the “Warrant Agreement”), duly
executed and delivered by the Company to Continental Stock Transfer& Trust Company, a New York corporation, as warrant agent (the
“Warrant Agent”), which Warrant Agreement is hereby incorporated by reference in and made a part of this instrument
and is hereby referred to for a description of the rights, limitation of rights, obligations, duties and immunities thereunder of the
Warrant Agent, the Company and the holders (the words “holders” or “holder” meaning
the Registered Holders or Registered Holder) of the Warrants. A copy of the Warrant Agreement may be obtained by the holder hereof upon
written request to the Company. Defined terms used in this Warrant Certificate but not defined herein shall have the meanings given to
them in the Warrant Agreement.
Warrants may be exercised at any time during the
Exercise Period set forth in the Warrant Agreement. The holder of Warrants evidenced by this Warrant Certificate may exercise them by
surrendering this Warrant Certificate, with the form of election to purchase set forth hereon properly completed and executed, together
with payment of the Exercise Price as specified in the Warrant Agreement (or through “cashless exercise” as provided for in
the Warrant Agreement) at the principal corporate trust office of the Warrant agent. In the event that upon any exercise of Warrants evidenced
hereby the number of Warrants exercised shall be less than the total number of Warrants evidenced hereby, there shall be issued to the
holder hereof or his, her or its assignee, a new Warrant Certificate evidencing the number of Warrants not exercised.
Notwithstanding anything else in this Warrant Certificate
or the Warrant Agreement, no Warrant may be exercised unless at the time of exercise (i) a registration statement covering the shares
of Common Stock to be issued upon exercise is effective under the Securities Act and (ii) a prospectus thereunder relating to the
shares of Common Stock is current, except through “cashless exercise” as provided for in the Warrant Agreement.
The Warrant Agreement provides that upon the occurrence
of certain events the number of shares of Common Stock issuable upon exercise of the Warrants set forth on the face hereof may, subject
to certain conditions, be adjusted. If, upon exercise of a Warrant, the holder thereof would be entitled to receive a fractional interest
in a share of Common Stock, the Company shall, upon exercise, round down to the nearest whole number of shares of Common Stock to be issued
to the holder of the Warrant.
Warrant Certificates, when surrendered at the principal
corporate trust office of the Warrant Agent by the Registered Holder thereof in person or by legal representative or attorney duly authorized
in writing, may be exchanged, in the manner and subject to the limitations provided in the Warrant Agreement, but without payment of any
service charge, for another Warrant Certificate or Warrant Certificates of like tenor evidencing in the aggregate a like number of Warrants.
Upon due presentation for registration of transfer
of this Warrant Certificate at the office of the Warrant Agent a new Warrant Certificate or Warrant Certificates of like tenor and evidencing
in the aggregate a like number of Warrants shall be issued to the transferee(s) in exchange for this Warrant Certificate, subject
to the limitations provided in the Warrant Agreement, without charge except for any tax or other governmental charge imposed in connection
therewith.
The Company and the Warrant Agent may deem and
treat the Registered Holder(s) hereof as the absolute owner(s) of this Warrant Certificate (notwithstanding any notation of
ownership or other writing hereon made by anyone), for the purpose of any exercise hereof, of any distribution to the holder(s) hereof,
and for all other purposes, and neither the Company nor the Warrant Agent shall be affected by any notice to the contrary. Neither the
Warrants nor this Warrant Certificate entitles any holder hereof to any rights of a stockholder of the Company.
Election to Purchase
(To Be Executed Upon Exercise of Warrant)
The undersigned hereby irrevocably elects to exercise
the right, represented by this Warrant Certificate, to receive shares of Common Stock and herewith tenders payment for such shares of
Common Stock to the order of TriSalus Life Sciences, Inc. (the “Company”) in the amount of $_____ in accordance
with the terms hereof. The undersigned requests that a certificate for such shares of Common Stock be registered in the name of __________,
whose address is and that such shares of Common Stock be delivered to __________ whose address is __________. If said number of shares
of Common Stock is less than all of the shares of Common Stock purchasable hereunder, the undersigned requests that a new Warrant Certificate
representing the remaining balance of such shares of Common Stock be registered in the name of , whose address is and that such Warrant
Certificate be delivered to __________, whose address is __________.
In the event that the Warrant has been called for
redemption by the Company pursuant to Section 6.1 of the Warrant Agreement and the Company has required cashless exercise
pursuant to Section 6.4 of the Warrant Agreement, the number of shares of Common Stock that this Warrant is exercisable for
shall be determined in accordance with subsection 3.3.1(b) and Section 6.4 of the Warrant Agreement.
In the event that the Warrant is a Private Placement
Warrant or a Working Capital Warrant that is to be exercised on a “cashless” basis pursuant to subsection 3.3.1(c) of
the Warrant Agreement, the number of shares of Common Stock that this Warrant is exercisable for shall be determined in accordance with
subsection 3.3.1(c) of the Warrant Agreement.
In the event that the Warrant is to be exercised
on a “cashless” basis pursuant to Section 7.4 of the Warrant Agreement, the number of shares of Common Stock that
this Warrant is exercisable for shall be determined in accordance with Section 7.4 of the Warrant Agreement.
In the event that the Warrant may be exercised,
to the extent allowed by the Warrant Agreement, through cashless exercise (i) the number of shares of Common Stock that this Warrant
is exercisable for would be determined in accordance with the relevant section of the Warrant Agreement which allows for such cashless
exercise and (ii) the holder hereof shall complete the following: The undersigned hereby irrevocably elects to exercise the right,
represented by this Warrant Certificate, through the cashless exercise provisions of the Warrant Agreement, to receive shares of Common
Stock. If said number of shares is less than all of the shares of Common Stock purchasable hereunder (after giving effect to the cashless
exercise), the undersigned requests that a new Warrant Certificate representing the remaining balance of such shares of Common Stock be
registered in the name of , whose address is and that such Warrant Certificate be delivered to __________, whose address is __________.
[Signature Page Follows]
Date: , 20__ |
|
|
(Signature) |
|
|
|
|
|
|
|
|
|
|
|
(Address) |
|
|
|
|
|
(Tax Identification Number) |
|
|
Signature Guaranteed:
|
|
|
|
THE SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR
INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION
PROGRAM, PURSUANT TO S.E.C. RULE 17Ad-15 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED (OR ANY SUCCESSOR RULE)).
Exhibit 4.4
Description of Common
Stock
The following description summarizes selected
information regarding the common stock, $0.0001 par value per share (the “Common Stock”), of TriSalus Life Sciences, Inc.,
a Delaware corporation (“TriSalus,” the “Company,” “we,” “us” or “our”), as
well as relevant provisions of: (i) our Second Amended and Restated Certificate of Incorporation (“Certificate of Incorporation”);
(ii) our amended and restated bylaws (“Bylaws”); and (iii) the General Corporation Law of the State of Delaware
(the “DGCL”). The following summary is qualified in its entirety by, and should be read in conjunction with, the Certificate
of Incorporation and the Bylaws, copies of which have been filed as exhibits to the Current Report on Form 8-K (the “Form 8-K”)
to which this exhibit is attached, and the applicable provisions of the DGCL.
Authorized and Outstanding Stock
The Certificate of Incorporation authorizes
the issuance of 410,000,000 shares of capital stock, consisting of (a) 400,000,000 shares of Common Stock, having a par value per
share of $0.0001, and (b) 10,000,000 shares of preferred stock, having a par value per share of $0.0001 (the “preferred stock”).
An aggregate of 4,015,002 shares of preferred
stock, par value $0.0001 per share, designated as Series A Convertible Preferred Stock (the “Series A Convertible Preferred
Stock”) is issued and outstanding. See the Form 8-K to which this description is attached for a description of the Series A
Convertible Preferred Stock and the Certificate of Designations for the Series A Convertible Preferred Stock.
Common Stock
Voting Rights
Each holder of Common Stock will be entitled
to one (1) vote for each share of Common Stock held of record by such holder on all matters submitted to a vote of our stockholders;
provided, however, that, except as otherwise required in the Certificate of Incorporation or by applicable law, the holders of Common
Stock shall not be entitled to vote on any amendment to the Certificate of Incorporation or any certificate of designation filed with
respect to any series of our preferred stock that alters or changes the powers, preferences, rights or other terms of one or more outstanding
series of our preferred stock (including the Series A Convertible Preferred Stock) if the holders of such affected series are entitled,
either separately or together with the holders of one or more other such series, to vote thereon pursuant to the Certificate of Incorporation
(including any certificate of designation relating to any series of preferred stock) or pursuant to the DGCL.
Dividend Rights
Subject to applicable law and the rights of
the holders of any outstanding class of our preferred stock, including the Series A Convertible Preferred Stock, and the provisions
of the Certificate of Incorporation, holders of Common Stock will be entitled to receive such dividends and other distributions in cash,
stock or property of the Company when, as and if declared thereon by our board of directors (the “Board”), in its sole discretion,
from time to time out of assets or funds of the Company legally available therefor.
Rights upon Liquidation
Subject to applicable law and the rights and
preferences of the holders of any holders of any shares of any outstanding class of preferred stock, including the Series A Convertible
Preferred Stock, in the event of any liquidation, dissolution or winding up of our affairs, whether voluntary or involuntary, after payment
or provision for payment of our debts and any other payments required by law and amounts payable upon shares of preferred stock ranking
senior to the shares of Common Stock upon such dissolution, liquidation or winding up, if any, our remaining net assets will be distributed
to the holders of Common Stock and the holders of any other class or series of capital stock ranking equally with the Common Stock upon
such dissolution, liquidation or winding up, equally on a per share basis.
Preemptive or Other Rights
The holders of Common Stock will not have
preemptive or other subscription rights and there are no redemption or sinking fund provisions applicable to the Common Stock. The rights,
preferences and privileges of holders of the Common Stock will be subject to those of the holders of the Series A Convertible Preferred
Stock and any other series of preferred stock of that we may issue in the future.
Election of Directors
The Board is divided into three classes, Class I,
Class II and Class III, with members of each class serving staggered three-year terms with only one class of directors being
elected in each year. There is no cumulative voting with respect to the election of directors. Under the Bylaws, the election of directors
is determined by plurality vote.
Dividends
We have not paid any cash dividends on our
Common Stock to date. The payment of cash dividends in the future will be dependent upon our revenues and earnings, if any, capital requirements,
general financial condition, contractual restrictions and other factors that the Board may deem relevant and will be within the discretion
of the Board at such time. In addition, our ability to pay dividends may be limited by covenants of any existing and future outstanding
indebtedness that we or our subsidiaries incur.
Certain Anti-Takeover Provisions of Delaware
Law and our Certificate of Incorporation and Bylaws
We are subject to the provisions of Section 203
of the DGCL regulating corporate takeovers. This statute prevents certain Delaware corporations, under certain circumstances, from engaging
in a “business combination” with:
| • | a stockholder who owns 15% or more of our outstanding voting stock (otherwise known as an “interested stockholder”); |
| • | an affiliate of an interested stockholder; or |
| • | an associate of an interested stockholder, for three years following the date that the stockholder became an interested stockholder. |
A “business combination” includes
a merger or sale of more than 10% of our assets. However, the above provisions of Section 203 do not apply if:
| • | our Board approves the transaction that made the stockholder an “interested stockholder,” prior to the date of the transaction; |
| • | after the completion of the transaction that resulted in the stockholder becoming an interested stockholder, that stockholder owned
at least 85% of our voting stock outstanding at the time the transaction commenced, other than statutorily excluded shares of Common Stock;
or |
| • | on or subsequent to the date of the transaction, the initial business combination is approved by our Board and authorized at a meeting
of our stockholders, and not by written consent, by an affirmative vote of at least two-thirds of the outstanding voting stock not owned
by the interested stockholder. |
Our Certificate of Incorporation provides
that the Board is classified into three classes of directors, each of which will generally serve for a term of three years with only one
class of directors being elected in each year. As a result, in most circumstances, a person can gain control of our Board only by successfully
engaging in a proxy contest at two or more annual meetings.
The authorized but unissued Common Stock and
preferred stock are available for future issuances without stockholder approval and could be utilized for a variety of corporate purposes,
including future offerings to raise additional capital, acquisitions and employee benefit plans. The existence of authorized but unissued
and unreserved shares of Common Stock and preferred stock could render more difficult or discourage an attempt to obtain control of us
by means of a proxy contest, tender offer, merger or otherwise.
Exclusive Forum for Certain Lawsuits
Our Certificate of Incorporation requires,
to the fullest extent permitted by law, that derivative actions brought in our name, actions against directors, officers and employees
for breach of fiduciary duty and other similar actions may be brought only in the Court of Chancery in the State of Delaware. Although
we believe this provision benefits us by providing increased consistency in the application of Delaware law in the types of lawsuits to
which it applies, a court may determine that this provision is unenforceable, and to the extent it is enforceable, the provision may have
the effect of discouraging lawsuits against our directors and officers. Despite the fact that our Certificate of Incorporation provides
that the exclusive forum provision will be applicable to the fullest extent permitted by applicable law, Section 27 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations thereunder, creates exclusive federal
jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder.
As a result, the exclusive forum provision does not apply to suits brought to enforce any duty or liability created by the Exchange Act
or any other claim for which the federal courts have exclusive jurisdiction. In addition, our Certificate of Incorporation provides that,
unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall,
to the fullest extent permitted by law, be the exclusive forum for the resolution of any complaint asserting a cause of action arising
under the Securities Act of 1933, as amended (the “Securities Act”), or the rules and regulations promulgated thereunder.
We note, however, that there is uncertainty as to whether a court would enforce this provision and that investors cannot waive compliance
with the federal securities laws and the rules and regulations thereunder. Section 22 of the Securities Act creates concurrent
jurisdiction for state and federal courts over all suits brought to enforce any duty or liability created by the Securities Act or the
rules and regulations thereunder.
Special Meeting of Stockholders
Our Bylaws provide that special meetings of
our stockholders may be called only by a majority vote of our Board, by our Chief Executive Officer or by our Chairman.
Advance Notice Requirements for Stockholder
Proposals and Director Nominations
Our Bylaws provide that stockholders seeking
to bring business before our annual meeting of stockholders, or to nominate candidates for election as directors at our annual meeting
of stockholders, must provide timely notice of their intent in writing. To be timely, a stockholder’s notice will need to be received
by the Company’s secretary at our principal executive offices not later than the close of business on the 90th day nor earlier than
the opening of business on the 120th day prior to the anniversary date of the immediately preceding annual meeting of stockholders. Pursuant
to Rule 14a-8 of the Exchange Act, proposals seeking inclusion in our annual proxy statement must comply with the notice periods
contained therein. Our Bylaws also specify certain requirements as to the form and content of a stockholders’ meeting. These provisions
may preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors
at our annual meeting of stockholders.
Action by Written Consent
Any action required or permitted to be taken
by holders of our Common Stock must be effected by a duly called annual or special meeting of such stockholders and may not be effected
by written consent of the stockholders.
Transfer Agent
The transfer agent for our securities is Continental
Stock Transfer & Trust Company. The transfer agent’s address is One State Street Plaza, 30 Floor New York, New York 10004.
Listing of Common Stock
Our Common Stock is currently traded on the
Nasdaq Global Market under the symbol ”TLSI”.
Exhibit 10.1
AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT
THIS AMENDED AND RESTATED REGISTRATION RIGHTS
AGREEMENT (this “Agreement”), dated as of August 10, 2023, is made and entered into by and among (i) TriSalus
Life Sciences, Inc., a Delaware corporation (the “Company”) (formerly known as MedTech Acquisition Corp. (“MedTech”),
a Delaware corporation), (ii) MedTech Acquisition Sponsor LLC, a Delaware limited liability company (the “Sponsor”),
(iii) certain former stockholders of TriSalus Operating Life Sciences, Inc., a Delaware corporation (formerly known as TriSalus Life Sciences,
Inc. (“Legacy TriSalus”)) set forth on Schedule I hereto (the “TriSalus Holders”),
and (iv) all members of the Sponsor (the “Sponsor Holders” and, together with the Sponsor, the TriSalus Holders,
and any person or entity who hereafter becomes a party to this Agreement pursuant to Section 5.2 or Section 5.10
of this Agreement, a “Holder” and collectively the “Holders”).
RECITALS
WHEREAS, the Company and Legacy TriSalus
were party to that certain Agreement and Plan of Merger, dated as of November 11, 2022 (as amended, the “Merger Agreement”),
by and among the Company, MTAC Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of the Company (“Merger
Sub”), and Legacy TriSalus;
WHEREAS, pursuant to the Merger Agreement,
at the Closing (as defined in the Merger Agreement), Merger Sub will merge with and into Legacy TriSalus, with Legacy TriSalus continuing
as the surviving company and, after giving effect to the merger, the separate existence of Merger Sub will cease to exist and Legacy TriSalus
shall become a wholly owned subsidiary of the Company, which shall survive as the surviving corporation (the “Business Combination”);
WHEREAS, MedTech and the Sponsor entered
into that certain Registration Rights Agreement, dated as of December 17, 2020 (as it may be amended, supplemented, restated or otherwise
modified from time to time until the consummation of the Business Combination, the “Existing Agreement”);
WHEREAS, upon the consummation of the Business
Combination, the parties to the Existing Agreement desire to amend and restate the Existing Agreement in its entirety as set forth herein
and the Company, the Sponsor and the Holders desire to enter into this Agreement, pursuant to which the Company shall grant the Holders
certain registration rights with respect to the Registrable Securities (as defined below) on the terms and conditions set forth in this
Agreement.
NOW, THEREFORE, in consideration
of the representations, covenants and agreements contained herein, and certain other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows:
ARTICLE
I
DEFINITIONS
1.1 Definitions. The terms defined in this
Article I shall, for all purposes of this Agreement, have the respective meanings set forth below:
“Adverse Disclosure”
shall mean any public disclosure of material non-public information, which disclosure, in the good faith judgment of the chief executive
officer or chief financial officer of the Company, after consultation with counsel to the Company, (i) would be required to be made
in any Registration Statement or Prospectus in order for the applicable Registration Statement or Prospectus not to contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements contained therein (in the case of any prospectus
and any preliminary prospectus, in the light of the circumstances under which they were made) not misleading, (ii) would not be required
to be made at such time if the Registration Statement were not being filed or was effective, and (iii) the Company has a bona
fide business purpose for not making such information public.
“Agreement” shall have
the meaning given in the Preamble.
“Action” means any claim,
charge, action, suit, complaint, grievance, audit, investigation, inquiry, assessment, arbitration or legal, judicial or administrative
proceeding (whether at law or in equity).
“Block Trade” has the
meaning given in subsection 2.6.1.
“Board” shall mean the
board of directors of the Company.
“Business Combination”
shall have the meaning given in the Recitals hereto.
“Business Day” shall
mean any day other than a Saturday, a Sunday or other day on which commercial banks in New York, New York are authorized or required by
applicable law to close.
“Closing” shall have
the meaning given in the Merger Agreement.
“Commission” shall mean
the U.S. Securities and Exchange Commission.
“Common Stock” shall
mean the Company’s Common Stock, with a par value of $0.0001 per share.
“Company” shall have
the meaning given in the Recitals hereto.
“Demand Registration”
shall have the meaning given in subsection 2.1.1.
“Demanding Holder” shall
mean either (i) one or more Sponsor Holders holding at least a majority-in-interest of Registrable Securities held by Sponsor Holders
or (ii) one or more TriSalus Holders holding at least a majority-in-interest of Registrable Securities held by TriSalus Holders.
“Exchange Act” shall
mean the Securities Exchange Act of 1934, as it may be amended from time to time.
“Existing Agreement” shall have
the meaning given in the Recitals hereto.
“Form S-1” shall have the meaning
given in subsection 2.1.1.
“Form S-3” shall have
the meaning given in subsection 2.3.2.
“Form S-1 Shelf” shall
have the meaning given in subsection 2.3.1.
“Form S-3 Shelf” shall
have the meaning given in subsection 2.3.1.
“Founder Shares” shall
mean the 4,062,500 shares of MedTech’s Class B common stock, par value $0.0001 per share, issued to the Sponsor in a private
placement pursuant to the Subscription Agreement that are not forfeited at Closing and not subsequently forfeited by the Sponsor as described
in the Sponsor Support Agreement.
“Holder Information”
shall have the meaning given in subsection 4.1.2.
“Holders” shall have
the meaning given in the Preamble.
“Lock-up” shall have
the meaning given in Section 2.5.
“Lock-up Period” shall
mean any lock-up period with respect to the Registrable Securities included in the Company’s governing documents or any agreements
between a Holder and the Company or any of the Company’s subsidiaries.
“Maximum Number of Securities”
shall have the meaning given in subsection 2.1.4.
“Merger Agreement”
shall have the meaning given in the Recitals hereto.
“Minimum Takedown Threshold”
has the meaning set forth in subsection 2.3.4.
“Misstatement” shall
mean an untrue statement of a material fact or an omission to state a material fact required to be stated in a Registration Statement
or Prospectus, or necessary to make the statements in a Registration Statement or Prospectus (in the light of the circumstances under
which they were made) not misleading.
“Opt-Out Requests” has
the meaning set forth in Section 5.12.
“Other Coordinated Offering”
has the meaning set forth in subsection 2.6.1.
“Other Holders” has
the meaning set forth in subsection 2.2.1.
“Permitted Transferees”
means, in the case of any Holder, a person to whom, or entity to which, a Holder may transfer Registrable Securities; provided
that (a) such transfer does not violate the Company’s governing documents, or any agreements between such Holder and the Company
or any of the Company’s subsidiaries, or this Agreement, and (b) such transferee shall only be a Permitted Transferee if and
to the extent the transferor designates the transferee as a Permitted Transferee entitled to rights hereunder pursuant to subsection
5.2.3.
“Piggyback Registration”
shall have the meaning given in subsection 2.2.1.
“Prospectus” shall mean
the prospectus included in any Registration Statement, as supplemented by any and all prospectus supplements and as amended by any and
all post-effective amendments and including all material incorporated by reference in such prospectus.
“Qualified Additional Holder”
shall mean any stockholder of the Company that is a director or officer of the Company or any other stockholder of the Company that is
approved to become a “Holder” under this Agreement by the Holders holding a majority of Registrable Securities then outstanding
(such approval not to be unreasonably withheld, conditioned or delayed).
“Registrable Security”
shall mean (i) any outstanding shares of Common Stock or any warrants to purchase shares of Common Stock and (ii) shares of Common
Stock issued or issuable upon the exercise or conversion of any warrants or equity awards of the Company, in each case held by a Holder
immediately following the Closing (including any warrants or equity awards distributable pursuant to the Merger Agreement, any Founder
Shares, any warrants issued or issuable in connection with MedTech’s initial public offering or concurrent private placement and
any Working Capital Warrants) and (iii) any other equity security of the Company issued or issuable with respect to any such securities
by way of a stock dividend, share capitalization or share sub-division or in connection with a reclassification, recapitalization, merger,
consolidation, spin-off, reorganization or similar transaction; provided, however, that, as to any particular Registrable
Security, such securities shall cease to be Registrable Securities when: (a) a Registration Statement with respect to the sale of
such securities shall have become effective under the Securities Act and such securities shall have been sold, transferred, disposed of
or exchanged in accordance with such Registration Statement; (b) such securities shall have been otherwise transferred, new certificates
or book entry provisions for such securities not bearing a legend restricting further transfer shall have been delivered by the Company
and subsequent public distribution of such securities shall not require registration under the Securities Act; (c) such securities
shall have ceased to be outstanding; (d) such securities may be sold without registration pursuant to Rule 144 promulgated under
the Securities Act (or any successor rule promulgated thereafter by the Commission) without limitation as to volume and manner of sale
or public information requirements; or (e) such securities have been sold to, or through, a broker, dealer or underwriter in a public
distribution or other public securities transaction.
“Registration” shall
mean a registration, including an Underwritten Shelf Takedown, effected by preparing and filing a Registration Statement or similar document
in compliance with the requirements of the Securities Act, and the applicable rules and regulations promulgated thereunder, and such Registration
Statement becoming effective.
“Registration Expenses”
shall mean the out-of-pocket expenses of a Registration, including the following:
(A) all registration and filing fees (including
fees with respect to filings required to be made with the Financial Industry Regulatory Authority, Inc.) and any securities exchange on
which the Common Stock is then listed;
(B) fees and expenses of compliance with securities
or blue sky laws (including reasonable fees and disbursements of counsel for the Underwriters in connection with blue sky qualifications
of Registrable Securities);
(C) reasonable printing, messenger, telephone
and delivery expenses;
(D) reasonable fees and disbursements of counsel
for the Company;
(E) reasonable fees and disbursements of all
independent registered public accountants of the Company incurred specifically in connection with such Registration;
(F) the costs and expenses of the Company relating
to analyst and investor presentations or any “road show” undertaken in connection with the Registration and/or marketing of
the Registrable Securities; and
(G) reasonable fees and expenses up to $35,000
of one (1) legal counsel selected by the majority-in-interest of the Demanding Holders initiating a Demand Registration to be registered
for offer and sale in the applicable Registration or majority-in-interest of the Takedown Demanding Holders initiating an Underwritten
Shelf Takedown.
“Registration Statement”
shall mean any registration statement that covers the Registrable Securities pursuant to the provisions of this Agreement, including the
Prospectus included in such registration statement, amendments (including post-effective amendments) and supplements to such registration
statement, and all exhibits to and all material incorporated by reference in such registration statement.
“Requesting Holder”
shall have the meaning given in subsection 2.1.1.
“Securities Act” shall
mean the Securities Act of 1933, as amended from time to time.
“Shelf” shall mean the
Form S-1 Shelf, the Form S-3 Shelf or any Subsequent Shelf Registration Statement, as the case may be.
“Shelf Registration”
shall mean a Registration of Registrable Securities pursuant to a registration statement filed with the Commission in accordance with
and pursuant to Rule 415 promulgated under the Securities Act (or any successor rule then in effect).
“Sponsor” shall have
the meaning given in the Preamble hereto.
“Sponsor Support Agreement”
shall mean that certain Sponsor Support Agreement, dated as of November 11, 2022, by and among the Sponsor, MedTech and the Company.
“Subscription Agreement”
shall mean that certain Securities Subscription Agreement, dated as of September 11, 2020, between the Sponsor and MedTech.
“Subsequent Shelf Registration Statement”
shall have the meaning given in subsection 2.3.3.
“Takedown Demanding Holder”
shall have the meaning given in subsection 2.3.4.
“Takedown Requesting Holder”
shall have the meaning given in subsection 2.3.4.
“Underwriter” shall
mean a securities dealer who purchases any Registrable Securities as principal in an Underwritten Offering and not as part of such dealer’s
market-making activities.
“Underwritten Registration”
or “Underwritten Offering” shall mean a Registration in which securities of the Company are sold to an Underwriter
in a firm commitment underwriting for distribution to the public.
“Underwritten Shelf Takedown”
shall have the meaning given in subsection 2.3.4.
“Working Capital Warrants”
shall mean warrants to purchase Common Stock issuable upon the conversion of loans made to the Company by the Sponsor, an affiliate of
the Sponsor, or an officer or director of the Company.
1.2 Interpretive Provisions. For all purposes
of this Agreement, except as otherwise provided in this Agreement or unless the context otherwise requires:
1.2.1 the singular shall include the plural, and
the plural shall include the singular, unless the context clearly prohibits that construction.
1.2.2 the words “hereof,” “herein,”
“hereunder” and words of similar import, when used in this Agreement, refer to this Agreement as a whole and not to any particular
provision of this Agreement.
1.2.3 references in this Agreement to any law
shall be deemed also to refer to such law, and all rules and regulations promulgated thereunder.
1.2.4 whenever the words “include,”
“includes” or “including” are used in this Agreement, they shall mean “without limitation.”
1.2.5 the captions and headings of this Agreement
are for convenience of reference only and shall not affect the interpretation of this Agreement.
1.2.6 pronouns of any gender or neuter shall include,
as appropriate, the other pronoun forms.
1.2.7 the word “or” shall be construed
to mean “and/or” and the words “neither,” “nor,” “any,” “either” and “or”
shall not be exclusive, unless the context clearly prohibits that construction.
ARTICLE II
REGISTRATIONS
2.1 Demand Registration.
2.1.1 Request for Registration.
Subject to the provisions of subsections 2.1.4 and 2.3.1 and Section 2.4 hereof, at any time and from time
to time on or after the date the Company consummates the Business Combination, any Demanding Holder may make a written demand for
Registration of all or part of their Registrable Securities, which written demand shall describe the amount and type of securities
to be included in such Registration and the intended method(s) of distribution thereof separate from a Shelf Registration or
Underwritten Shelf Takedown (such written demand a “Demand Registration”). The Company shall, within five
(5) Business Days of the Company’s receipt of the Demand Registration, notify, in writing, all other Holders of
Registrable Securities of such demand, and each Holder of Registrable Securities who thereafter wishes to include all or a portion
of such Holder’s Registrable Securities in a Registration pursuant to a Demand Registration (each such Holder that includes
all or a portion of such Holder’s Registrable Securities in such Registration, a “Requesting
Holder”) shall so notify the Company, in writing, within five (5) days after the receipt by the Holder of the
notice from the Company. Upon receipt by the Company of any such written notification from a Requesting Holder(s) to the Company,
such Requesting Holder(s) shall be entitled to have their Registrable Securities included in a Registration pursuant to a Demand
Registration and the Company shall use commercially reasonable efforts to file, as soon thereafter as reasonably practicable, but
not more than forty-five (45) days after the Company’s receipt of the Demand Registration, a Registration Statement on
Form S-1 or any similar long-form registration statement that may be available at such time (“Form S-1”)
for the Registration of all Registrable Securities requested by the Demanding Holders and Requesting Holders pursuant to such Demand
Registration, and use commercially reasonable efforts to cause such Form S-1 to be declared effective as soon as reasonably
practicable after its initial filing. Under no circumstances shall the Company be obligated to effect more than an aggregate of one
(1) Registration per Demanding Holder pursuant to a Demand Registration under this subsection 2.1.1 with respect to any
or all Registrable Securities. Notwithstanding anything to the contrary herein, to the extent there is an active Form S-3 Shelf
covering a Holder’s or Holders’ Registrable Securities, this subsection 2.1.1 shall be inapplicable and any
request by such Holder or Holders to conduct an Underwritten Offering shall follow the procedures of subsection 2.3.4 herein
and shall be counted as an Underwritten Shelf Takedown.
2.1.2 Effective Registration. Notwithstanding
the provisions of subsection 2.1.1 above or any other part of this Agreement, a Registration pursuant to a Demand Registration
shall not count as a Registration unless and until (i) the Registration Statement filed with the Commission with respect to a Registration
pursuant to a Demand Registration has been declared effective by the Commission and (ii) the Company has complied with all of its
obligations under this Agreement with respect thereto; provided, further, that if, after such Registration Statement has
been declared effective, an offering of Registrable Securities in a Registration pursuant to a Demand Registration is subsequently interfered
with by any stop order or injunction of the Commission, federal or state court or any other governmental agency, then the Registration
Statement with respect to such Registration shall be deemed not to have been declared effective, unless and until, (i) such stop
order or injunction is removed, rescinded or otherwise terminated, and (ii) a majority-in-interest of the Demanding Holders initiating
such Demand Registration thereafter affirmatively elect to continue with such Registration and accordingly notify the Company in writing,
but in no event later than five (5) days after the removal, recission or other termination of such stop order or injunction, of such
election; and provided, further, that the Company shall not be obligated or required to file another Registration Statement
until the Registration Statement that has been previously filed with respect to a Registration pursuant to a Demand Registration becomes
effective or is subsequently terminated.
2.1.3 Underwritten Offering. Subject to
the provisions of subsections 2.1.4 and 2.3.1 and Section 2.4 hereof, at any time and from time to time on or
after the date the Company consummates the Business Combination, if a majority in interest of the Demanding Holders so advise the Company
as part of their Demand Registration that the offering of the Registrable Securities pursuant to such Demand Registration shall be in
the form of an Underwritten Offering, then the right of such Demanding Holders and Requesting Holder (if any) to include its Registrable
Securities in such Registration shall be conditioned upon such Holder’s participation in such Underwritten Offering and the inclusion
of such Holder’s Registrable Securities in such Underwritten Offering to the extent provided herein. All such Holders proposing
to distribute their Registrable Securities through an Underwritten Offering under this subsection 2.1.3 shall enter into an underwriting
agreement in customary form with the Underwriter(s) selected for such Underwritten Offering by the majority in interest of the Demanding
Holders initiating the Demand Registration and shall execute a customary lock-up agreement in favor of the Underwriters (in each case
on substantially the same terms and conditions as all such Holders participating in such Underwritten Offering).
2.1.4 Reduction of Underwritten
Offering. If the managing Underwriter or Underwriters in an Underwritten Registration pursuant to a Demand Registration, in good
faith, advises the Company, the Demanding Holders and the Requesting Holders (if any) in writing that the dollar amount or number of
Registrable Securities that the Demanding Holders and the Requesting Holders (if any) desire to sell, taken together with all other
Common Stock or other equity securities that the Company desires to sell and the Common Stock, if any, as to which a Registration
has been requested pursuant to separate written contractual piggy-back registration rights held by any other stockholders who desire
to sell, exceeds the maximum dollar amount or maximum number of equity securities that can be sold in the Underwritten Offering
without adversely affecting the proposed offering price, the timing, the distribution method, or the probability of success of such
offering (such maximum dollar amount or maximum number of such securities, as applicable, the “Maximum Number of
Securities”), then the Company shall include in such Underwritten Offering, as follows: (i) first, the
Registrable Securities of the Demanding Holders and the Requesting Holders (if any) (pro rata based on the respective number of
Registrable Securities that each Demanding Holder and Requesting Holder (if any) has requested be included in such Underwritten
Registration and the aggregate number of Registrable Securities that the Demanding Holders and Requesting Holders have requested be
included in such Underwritten Registration) that can be sold without exceeding the Maximum Number of Securities; (ii) second,
to the extent that the Maximum Number of Securities has not been reached under the foregoing clause (i), the Common Stock or other
equity securities that the Company desires to sell, which can be sold without exceeding the Maximum Number of Securities; and
(iii) third, to the extent that the Maximum Number of Securities has not been reached under the foregoing clauses (i) and
(ii), the Registrable Securities of Holders (pro rata, based on the respective number of Registrable Securities that each Holder has
requested be included in such Underwritten Registration) exercising their rights to register their Registrable Securities pursuant
to subsection 2.2.1 hereof; and (iv) fourth, to the extent that the Maximum Number of Securities has not been reached
under the foregoing clauses (i), (ii) and (iii), the Common Stock or other equity securities of other persons or entities that the
Company is obligated to register in a Registration pursuant to separate written contractual arrangements with such persons and that
can be sold without exceeding the Maximum Number of Securities.
2.1.5 Demand Registration Withdrawal. A
Demanding Holder shall have the right to withdraw all or any portion of its Registrable Securities included in a Demand Registration pursuant
to subsection 2.1.1 for any or no reason whatsoever upon written notification to the Company and the Underwriter or Underwriters
(if any) of their intention to withdraw from such Registration prior to the effectiveness of the Registration Statement filed with the
Commission pursuant to such Demand Registration; provided, however, that such withdrawn amount shall still be considered
a Demand Registration pursuant to subsection 2.1.1. Notwithstanding anything to the contrary in this Agreement, the Company shall
be responsible for the Registration Expenses incurred in connection with a Registration pursuant to a Demand Registration prior to its
withdrawal under this subsection 2.1.5.
2.2 Piggyback Registration.
2.2.1 Piggyback Rights. If, at any
time on or after the date the Company consummates the Business Combination, the Company proposes to file a Registration Statement on
Form S-3 under the Securities Act with respect to an offering of equity securities of the Company, or securities or other
obligations exercisable or exchangeable for, or convertible into equity securities of the Company, for its own account or for the
account of stockholders of the Company (or by the Company and by the stockholders of the Company including pursuant to Section 2.1
or subsection 2.3.4 hereof), other than a Registration Statement (or any registered offering with respect thereto) (i)
filed in connection with any employee share option or other benefit plan on Form S-8 (or other successor registration statement form
thereof), (ii) pursuant to a Registration Statement on Form S-4 (or other successor registration statement form thereof or
similar form that relates to a transaction subject to Rule 145 under the Securities Act or any successor rule thereto), (iii) for an
offering of debt that is convertible into equity securities of the Company, (iv) for an exchange offer or offering of
securities solely to the Company’s existing stockholders, (v) for a dividend reinvestment plan, (vi) for a rights
offering, (vii) for the exercise of any warrants, (viii) for a Block Trade, (ix) for an equity line of credit, or (x) for
an at-the-market offering of securities, then the Company shall give written notice of such proposed filing to all of the Holders of
Registrable Securities and the holders of other equity securities that the Company is obligated to register in a Registration
(collectively, the “Other Holders”) pursuant to separate written contractual piggy-back registration
rights, as soon as reasonably practicable but not less than five (5) Business Days before the anticipated filing date of such
Registration Statement, or, in the case of an Underwritten Offering pursuant to a Shelf Registration, the anticipated filing of the
applicable “red herring” prospectus or prospectus supplement, which notice shall (A) describe the amount and type
of securities to be included in such offering, the intended method(s) of distribution, and the name of the proposed managing
Underwriter or Underwriters, if any and if known, in such offering, and (B) offer to all of the Holders of Registrable
Securities the opportunity to include in such registered offering such number of Registrable Securities as such Holders may request
in writing within five (5) days after receipt of such written notice (such Registration a “Piggyback
Registration”); provided, that each such Holder agrees that the fact that such a notice has been delivered
shall constitute material non-public confidential information. Subject to subsection 2.2.2, the Company shall, in good faith,
cause such Registrable Securities and the securities of any Other Holders, to be included in such Piggyback Registration and shall
use commercially reasonable efforts to cause the managing Underwriter or Underwriters of a proposed Underwritten Offering to permit
the Registrable Securities requested by the Holders or Other Holders, as applicable, pursuant to this subsection 2.2.1 to be
included in a Piggyback Registration on the same terms and conditions as any similar securities of the Company included in such
Registration and to permit the sale or other disposition of such Registrable Securities in accordance with the intended method(s) of
distribution thereof. All such Holders proposing to distribute their Registrable Securities through an Underwritten Offering under
this subsection 2.2.1 shall enter into an underwriting agreement in customary form with the Underwriter or Underwriters
selected for such Underwritten Offering by the Company and shall execute a customary lock-up agreement in favor of the Underwriter
or Underwriters (in each case on substantially the same terms and conditions as all such Holders participating in such Underwritten
Offering).
2.2.2 Reduction of Piggyback Registration.
If the managing Underwriter or Underwriters in an Underwritten Registration that is to be a Piggyback Registration, in good faith, advises
the Company and the Holders of Registrable Securities participating in the Piggyback Registration in writing that the dollar amount or
number of the shares of Common Stock or other equity securities that the Company desires to sell, taken together with (i) the shares
of Common Stock, if any, as to which Registration has been demanded pursuant to separate written contractual arrangements with any Other
Holders, (ii) the Registrable Securities as to which Registration has been requested pursuant to Section 2.2 hereof,
and (iii) the shares of Common Stock, if any, as to which Registration has been requested pursuant to separate written contractual
piggy-back registration rights of Other Holders, exceeds the Maximum Number of Securities, then:
(a) If the Registration is initiated and undertaken
for the Company’s account, the Company shall include in any such Registration (i) first, the Common Stock or other equity securities
that the Company desires to sell, which can be sold without exceeding the Maximum Number of Securities and; (ii) second, to the extent
that the Maximum Number of Securities has not been reached under the foregoing clause (i), the Registrable Securities of Holders exercising
their rights to register their Registrable Securities pursuant to subsection 2.2.1 hereof and the Common Stock, if any, as to which
Registration has been requested by any Other Holders pursuant to separate written contractual piggy-back registration rights (pro rata
based on the respective number of Registrable Securities or shares of Common Stock that such Holder or Other Holder, as applicable, has
requested be included in such Piggyback Registration relative to the total number of Registrable Securities and shares of Common Stock
that all Holders and Other Holders have requested be included in such Piggyback Registration), which can be sold without exceeding the
Maximum Number of Securities;
(b) If the Registration is not initiated and
undertaken for the Company’s account and is pursuant to a request by persons or entities other than the Holders of Registrable
Securities, then the Company shall include in any such Registration (i) first, the Common Stock or other equity securities, if
any, of such requesting persons or entities, other than the Holders of Registrable Securities, which can be sold without exceeding
the Maximum Number of Securities; (ii) second, to the extent that the Maximum Number of Securities has not been reached under
the foregoing clause (a), the Registrable Securities of Holders exercising their rights to register their Registrable Securities
pursuant to subsection 2.2.1 hereof (pro rata based on the respective number of Registrable Securities that such Holder has
requested be included in such Piggyback Registration relative to the total number of Registrable Securities that all Holders have
requested be included in such Piggyback Registration), which can be sold without exceeding the Maximum Number of Securities;
(iii) third, to the extent that the Maximum Number of Securities has not been reached under the foregoing clauses (i) and
(ii), the Common Stock or other equity securities that the Company desires to sell, which can be sold without exceeding the Maximum
Number of Securities; and (iv) fourth, to the extent that the Maximum Number of Securities has not been reached under the
foregoing clauses (i), (ii) and (iii), the Common Stock or other equity securities for the account of any other persons or entities
that the Company is obligated to register pursuant to separate written contractual arrangements with such other person or entity
(pro rata based on the shares of Common Stock that such other person or entity, as applicable, has requested be included in such
Piggyback Registration relative to the total number of shares of Common Stock that such other persons or entities have requested be
included in such Piggyback Registration), which can be sold without exceeding the Maximum Number of Securities.
2.2.3 Piggyback Registration Withdrawal.
Any Holder of Registrable Securities shall have the right to withdraw from a Piggyback Registration for any or no reason whatsoever upon
written notification to the Company and the Underwriter or Underwriters (if any) of his, her or its intention to withdraw from such Piggyback
Registration prior to the effectiveness of the Registration Statement filed with the Commission with respect to such Piggyback Registration
or, in the case of a Piggyback Registration pursuant to a Shelf Registration, the filing of the applicable “red herring” prospectus
or prospectus supplement with respect to such Piggyback Registration used for marketing such transaction. The Company (whether on its
own good faith determination or as the result of a request for withdrawal by persons pursuant to separate written contractual obligations)
may withdraw a Registration Statement filed with the Commission in connection with a Piggyback Registration at any time prior to the effectiveness
of such Registration Statement. Notwithstanding anything to the contrary in this Agreement, the Company shall be responsible for the Registration
Expenses incurred in connection with the Piggyback Registration prior to its withdrawal under this subsection 2.2.3.
2.2.4 Unlimited Piggyback Registration Rights.
For purposes of clarity, any Registration effected pursuant to Section 2.2 hereof shall not be counted as a Registration pursuant
to a Demand Registration effected under Section 2.1 hereof or Underwritten Shelf Takedown effected under subsection 2.3.4
hereof.
2.3 Shelf Registrations.
2.3.1 Initial Shelf Registration. The
Company shall file with the Commission within forty-five (45) days of the Closing, and use commercially reasonable efforts to cause
to be declared effective as soon as reasonably practicable thereafter, a Registration Statement for a Shelf Registration on Form S-1
(the “Form S-1 Shelf”) or, if the Company is eligible to use a Registration Statement on Form S-3, a Shelf
Registration on Form S-3 (the “Form S-3 Shelf”), in each case, covering the resale of all the Registrable
Securities (determined as of two (2) Business Days prior to such filing) on a delayed or continuous basis. Such Shelf shall provide
for the resale of the Registrable Securities included therein pursuant to any method or combination of methods legally available to,
and requested by, any Holder named therein. The Company shall use its commercially reasonable efforts to maintain a Shelf in
accordance with the terms of this Agreement, and shall use its commercially reasonable efforts to prepare and file with the
Commission such amendments, including post-effective amendments, and supplements as may be necessary to keep a Shelf continuously
effective, available for use and in compliance with the provisions of the Securities Act until such time as there are no longer any
Registrable Securities, subject to Section 3.4 hereof. In the event the Company files a Form S-1 Shelf, the Company shall use its
commercially reasonable efforts to convert the Form S-1 Shelf (and any Subsequent Shelf Registration) to a Form S-3 Shelf as soon as
practicable after the Company is eligible to use Form S-3, or any similar short form registration. Notwithstanding anything to the
contrary herein, to the extent there is an active Form S-3 Shelf under this subsection 2.3.1, covering a Holder’s or
Holders’ Registrable Securities, and such Holder or Holders qualify as Demanding Holders pursuant to subsection 2.1.1
and wish to request an Underwritten Offering, such Underwritten Offering shall follow the procedures of subsection 2.3.4. The
Company shall have the right to remove any persons no longer holding Registrable Securities from the Shelf or any other shelf
registration statement by means of a post-effective amendment.
2.3.2 Registrations on Form S-3. The Holders
of Registrable Securities may, at any time and from time to time on or after the expiration of the Lock-up Period applicable to the Registrable
Securities of a Holder, to the extent that its Registrable Securities are not covered by an effective Shelf, request in writing that the
Company, pursuant to Rule 415 under the Securities Act (or any successor rule promulgated thereafter by the Commission), register the
resale of any or all of their Registrable Securities on Form S-3 or any similar short form registration statement that may be available
at such time (“Form S-3”), or if the Company is a well-known seasoned issuer (as defined in Rule 405 under the
Securities Act) on an automatic shelf registration statement; provided, however, that the Company shall not be obligated
to effect such request through an Underwritten Offering. Within five (5) days of the Company’s receipt of a written request
from a Holder or Holders of Registrable Securities for a Registration on Form S-3, the Company shall promptly give written notice of the
proposed Registration on Form S-3 to all other Holders of Registrable Securities, and each Holder of Registrable Securities who thereafter
wishes to include all or a portion of such Holder’s Registrable Securities in such Registration on Form S-3 shall so notify the
Company, in writing, within five (5) days after the receipt by the Holder of the notice from the Company. As soon as reasonably practicable
thereafter, but not more than fifteen (15) days after the Company’s initial receipt of such written request for a Registration
on Form S-3, the Company shall use commercially reasonable efforts to file a Form S-3 to register all or such portion of such Holder’s
Registrable Securities as are specified in such written request, together with all or such portion of Registrable Securities of any other
Holder or Holders joining in such request as are specified in the written notification given by such Holder or Holders, and shall use
commercially reasonable efforts to cause such Form S-3 to be declared effective as soon as reasonably practicable after its initial filing;
provided, that, the Company shall be obligated to effect a Registration pursuant to this subsection 2.3.2 hereof only if
(i) Form S-3 is available for such Registration; and (ii) the Holders of Registrable Securities, together with the Holders of
any other equity securities of the Company entitled to inclusion in such Registration, propose to sell Registrable Securities and such
other equity securities (if any) with a total offering price to the public reasonably expected to exceed, in the aggregate, $20 million.
2.3.3 Subsequent Shelf Registration.
If any Shelf ceases to be effective under the Securities Act for any reason at any time while Registrable Securities included
thereon are still outstanding, the Company shall, subject to Section 3.4, use its commercially reasonable efforts to as
promptly as is reasonably practicable cause such Shelf to again become effective under the Securities Act (including obtaining the
prompt withdrawal of any order suspending the effectiveness of such Shelf), and shall use its commercially reasonable efforts to as
promptly as is reasonably practicable amend such Shelf in a manner reasonably expected to result in the withdrawal of any order
suspending the effectiveness of such Shelf or file an additional registration statement (a “Subsequent Shelf
Registration”) registering the resale of all Registrable Securities from time to time, and pursuant to any method or
combination of methods legally available to, and reasonably requested by, any Holder named therein. If a Subsequent Shelf
Registration is filed, the Company shall use its commercially reasonable efforts to (i) cause such Subsequent Shelf
Registration to become effective under the Securities Act as promptly as is reasonably practicable after the filing thereof and
(ii) keep such Subsequent Shelf Registration continuously effective, available for use to permit Holders named therein to sell
their Registrable Securities included therein and in compliance with the provisions of the Securities Act until such time as there
are no longer any Registrable Securities included thereon. Any such Subsequent Shelf Registration shall be on Form S-3, or any
similar short form registration, to the extent that the Company is eligible to use such form. Without limiting the foregoing
provisions of this Section 2.3.3, in the event that any Holder holds Registrable Securities that are not registered for resale on a
delayed or continuous basis, the Company, upon request of a Holder shall promptly use its commercially reasonable efforts to cause
the resale of such Registrable Securities to be covered by either, at the Company’s option, a Shelf (including by means of a
post-effective amendment) or a Subsequent Shelf Registration and cause the same to be declared effective as soon as practicable
after such filing and such Shelf or Subsequent Shelf Registration shall be subject to the terms hereof; provided, however,
the Company shall only be required to cause such Registrable Securities to be so covered twice annually after inquiry of the
Holders.
2.3.4 Underwritten Shelf Takedown. At any
time and from time to time after a Form S-3 Shelf has been declared effective by the Commission, any Demanding Holder (the “Takedown
Demanding Holders”) may request to sell all or any portion of its Registrable Securities in an underwritten offering that
is registered pursuant to the Form S-3 Shelf (each, an “Underwritten Shelf Takedown”); provided that
the Company shall only be obligated to effect an Underwritten Shelf Takedown if such offering shall include Registrable Securities with
a total offering price (including piggyback securities and before deduction of underwriting discounts) reasonably expected to exceed,
in the aggregate, $20 million (the “Minimum Takedown Threshold”). All requests for Underwritten Shelf Takedowns
shall be made by giving written notice to the Company at least five (5) Business Days prior to the public announcement of such Underwritten
Shelf Takedown, which shall specify the approximate number of Registrable Securities proposed to be sold in the Underwritten Shelf Takedown
and the expected price range (net of underwriting discounts and commissions) of such Underwritten Shelf Takedown. The Company shall include
in any Underwritten Shelf Takedown the securities requested to be included by any Holder (each a “Takedown Requesting Holder”)
at least two (2) Business Days prior to the public announcement of such Underwritten Shelf Takedown pursuant to the piggyback registration
rights of such Holder set forth in Section 2.2 herein. The Takedown Demanding Holders holding a majority-in-interest of the
Registrable Securities proposed to be sold in the underwritten offering shall have the right to select the underwriter(s) for such offering,
subject to the Company’s prior approval which shall not be unreasonably withheld, conditioned or delayed. The Demanding Holders
may demand an aggregate of not more than four (4) Underwritten Shelf Takedowns pursuant to this Agreement (of which the Sponsor Holders
may demand not more than two (2)), and the Company is not obligated to effect (x) more than two (2) Underwritten Shelf Takedowns per year
(provided, that, the Sponsor Holders may demand not more than one (1) Underwritten Shelf Takedowns per year) or (y) an Underwritten Shelf
Takedown within sixty (60) days after the closing of a prior Underwritten Shelf Takedown. The Company shall use its commercially reasonable
efforts to effect such Underwritten Shelf Takedowns, including the filing of any prospectus supplement or any post-effective amendments
and otherwise taking any action necessary to include therein all disclosure and language deemed necessary or advisable by the Demanding
Holder to effect such Underwritten Shelf Takedown. For purposes of clarity, any Registration effected pursuant to this subsection 2.3.4
shall not be counted as a Registration pursuant to a Demand Registration effected under Section 2.1 hereof or Block Trade
or Other Coordinated Offering effected under Section 2.6 hereof.
2.3.5 Reduction of Underwritten Shelf Takedown.
If the managing Underwriters in an Underwritten Shelf Takedown, in good faith, advises the Company, the Takedown Demanding Holders and
the Takedown Requesting Holders (if any) in writing that the dollar amount or number of Registrable Securities that the Takedown Demanding
Holders and the Takedown Requesting Holders (if any) desire to sell, taken together with all other Common Stock or other equity securities
that the Company desires to sell, exceeds the Maximum Number of Securities, then the Company shall include in such Underwritten Shelf
Takedown, as follows: (i) first, the Registrable Securities of the Takedown Demanding Holders that can be sold without exceeding
the Maximum Number of Securities; (ii) second, to the extent that the Maximum Number of Securities has not been reached under the
foregoing clause (i), the Common Stock or other equity securities of the Takedown Requesting Holders, if any, that can be sold without
exceeding the Maximum Number of Securities determined pro rata based on the respective number of shares of Common Stock or other equity
securities that each Takedown Requesting Holder has so requested to be included in such Underwritten Shelf Takedown; (iii) third,
to the extent that the Maximum Number of Securities has not been reached under the foregoing clauses (i) and (ii), the Common Stock
or other equity securities that the Company desires to sell and that can be sold without exceeding the Maximum Number of Securities, and
(iv) fourth, to the extent that the Maximum Number of Securities has not been reached under the foregoing clauses (i), (ii) and (iii),
the Common Stock or other equity securities of other persons or entities that the Company is obligated to register in a Registration pursuant
to separate written contractual arrangements with such persons and that can be sold without exceeding the Maximum Number of Securities.
2.3.6 Underwritten Shelf Takedown Withdrawal.
A Takedown Demanding Holder shall have the right to withdraw from an Underwritten Shelf Takedown for any or no reason whatsoever upon
written notification to the Company and the Underwriters (if any) of its intention to withdraw from such Underwritten Shelf Takedown prior
to the public announcement of such Underwritten Shelf Takedown; provided that if any Takedown Demanding Holder delivers a written
notification to the Company and the Underwriters (if any) of its intention to withdraw from such Underwritten Shelf Takedown, the Company
shall not be required to continue such Underwritten Shelf Takedown unless the Minimum Takedown Threshold would still be satisfied by the
Registrable Securities proposed to be sold. Notwithstanding anything to the contrary in this Agreement, the Company shall be responsible
for the Registration Expenses incurred in connection with an Underwritten Shelf Takedown prior to a withdrawal under this subsection
2.3.6.
2.4 Restrictions on Registration Rights.
If (i) during the period starting with the date sixty (60) days prior to the Company’s good faith estimate of the date
of the filing of, and ending on a date one hundred and twenty (120) days after the effective date of, a Company initiated Registration
and provided that the Company has delivered written notice to the Holders prior to receipt of a Demand Registration pursuant to subsection
2.1.1 and it continues to actively employ, in good faith, all commercially reasonable efforts to cause the applicable Registration
Statement to be declared effective; (ii) the Holders have requested an Underwritten Registration and the Company and the Holders
are unable to obtain the commitment of underwriters to firmly underwrite the offer; or (iii) in the good faith judgment of the Board
such Registration would be seriously detrimental to the Company and the Board concludes as a result that it is essential to defer the
filing of such Registration Statement at such time, then in each case the Company shall furnish to such Holders a certificate signed by
the Chairman of the Board stating that in the good faith judgment of the Board it would be seriously detrimental to the Company for such
Registration Statement to be filed in the near future and that it is therefore essential to defer the filing of such Registration Statement.
In such event, the Company shall have the right to defer such filing for a period of not more than thirty (30) days; provided,
however, that the Company shall not defer its obligation in this manner more than two (2) times in any 12-month period.
2.5 Market Stand-off. In connection with
any Underwritten Offering of equity securities of the Company in which a Holder participates, if requested by the managing Underwriters,
such Holder agrees that it shall not Transfer any shares of Common Stock or other equity securities of the Company (other than those included
in such offering pursuant to this Agreement), without the prior written consent of the Company, during the ninety (90)-day period (or
such shorter time agreed to by the managing Underwriters) beginning on the date of pricing of such offering, except as expressly permitted
by such lock-up agreement or in the event the managing Underwriters otherwise agree by written consent and further agrees to execute a
customary lock-up agreement in favor of the Underwriters to such effect (in each case on substantially the same terms and conditions as
all such Holders) (a “Lock-Up”). Notwithstanding the foregoing, any release of a Lock-Up by Underwriters shall
only be effective if made on a pro rata basis, including with respect to management and employees, and any Lock-Up with Underwriters shall
contain a clause to this effect. Each of the Holders that is a director or officer of the Company shall execute and deliver any “lock-up”
agreement reasonably requested by the managing underwriter of such Underwritten Offering, but only to the extent as is required generally
of any executive officers or directors by such managing underwriter.
2.6 Block Trades; Other Coordinated Offerings.
2.6.1 Notwithstanding any other provision of
Article II, but subject to Sections 2.4 and 3.4, at any time and from time to time when an effective S-3 Shelf is on
file with the Commission, if a Demanding Holder wishes to engage in (a) an underwritten registered offering not involving a
“roadshow,” an offer commonly known as a “block trade” (a “Block Trade”) or (b) an
“at the market” or similar registered offering through a broker, sales agent or distribution agent, whether as agent or
principal, (an “Other Coordinated Offering”), in each case, with an anticipated aggregate offering price
of, either (x) at least $20 million or (y) all remaining Registrable Securities held by the Demanding Holder, then such Demanding
Holder only needs to notify the Company of the Block Trade or Other Coordinated Offering at least five (5) Business Days prior to
the day such offering is to commence and the Company shall as expeditiously as possible use its commercially reasonable efforts to
facilitate such Block Trade or Other Coordinated Offering; provided that the Demanding Holders representing a
majority-in-interest of the Registrable Securities wishing to engage in the Block Trade or Other Coordinated Offering shall use
commercially reasonable efforts to work with the Company and any Underwriters, brokers, sales agents or placement agents prior to
making such request in order to facilitate preparation of the registration statement, prospectus and other offering documentation
related to the Block Trade or Other Coordinated Offering.
2.6.2 Prior to the filing of the applicable “red
herring” prospectus or prospectus supplement used in connection with a Block Trade or Other Coordinated Offering, a majority-in-interest
of the Demanding Holders initiating such Block Trade or Other Coordinated Offering shall have the right to submit a Withdrawal Notice
to the Company, the Underwriter or Underwriters (if any) and any brokers, sales agents or placement agents (if any) of their intention
to withdraw from such Block Trade or Other Coordinated Offering. Notwithstanding anything to the contrary in this Agreement, the Company
shall be responsible for the Registration Expenses incurred in connection with a Block Trade or Other Coordinated Offering prior to its
withdrawal under this Section 2.6.2.
2.6.3 Notwithstanding anything to the contrary
in this Agreement, Section 2.2 shall not apply to a Block Trade or Other Coordinated Offering initiated by a Demanding Holder pursuant
to this Agreement.
2.6.4 The Demanding Holders in a Block Trade or
Other Coordinated Offering shall have the right to select the Underwriters and any brokers, sales agents or placement agents (if any)
for such Block Trade or Other Coordinated Offering.
2.6.5 A Demanding Holder may demand no more than
two (2) Block Trades or Other Coordinated Offerings pursuant to this Section 2.6 in any twelve (12) month period. For the avoidance of
doubt, any Block Trade or Other Coordinated Offering effected pursuant to this Section 2.6 shall not be counted as a demand for a Demand
Registration pursuant to Section 2.1 hereof or an Underwritten Shelf Takedown pursuant to subsection 2.3.4 hereof.
ARTICLE III
COMPANY PROCEDURES
3.1 General Procedures. If at any
time on or after the date of this Agreement the Company is required to effect the Registration of Registrable Securities, subject to
applicable law and any regulations promulgated by any securities exchange on which the Company’s equity securities are then
listed, each as interpreted by the Company with the advice of its counsel, the Company shall use its commercially reasonable efforts
to effect such Registration to permit the sale of such Registrable Securities in accordance with the intended plan of distribution
thereof, and pursuant thereto the Company shall, as expeditiously as possible:
3.1.1 prepare and file with the Commission as
soon as reasonably practicable a Registration Statement with respect to such Registrable Securities and use its commercially reasonable
efforts to cause such Registration Statement to be declared effective and remain effective until all Registrable Securities covered by
such Registration Statement have been sold;
3.1.2 prepare and file with the Commission such
amendments and post-effective amendments to the Registration Statement, and such supplements to the Prospectus, as may be (i) requested
by a Holder if additional selling securityholders that are such Holder’s pledgee, donees, transferees, assignees, successors, designees,
successors-in-interest and others who later come to hold any of Holder’s interest in the Registrable Securities other than through
a public sale are required to be included in a supplement to the Prospectus or (ii) any Underwriter of Registrable Securities or as may
be required by the rules, regulations or instructions applicable to the registration form used by the Company or by the Securities Act
or rules and regulations thereunder to keep the Registration Statement effective until all Registrable Securities covered by such Registration
Statement are sold in accordance with the intended plan of distribution set forth in such Registration Statement or supplement to the
Prospectus;
3.1.3 prior to any public offering of Registrable
Securities, use commercially reasonable efforts to (i) register or qualify the Registrable Securities covered by the Registration
Statement under such securities or “blue sky” laws of such jurisdictions in the United States as the Holders of Registrable
Securities included in such Registration Statement (in light of their intended plan of distribution) may request (or provide evidence
satisfactory to such Holders that the Registrable Securities are exempt from such registration or qualification) and (ii) take such
action necessary to cause such Registrable Securities covered by the Registration Statement to be registered with or approved by such
other governmental authorities as may be necessary by virtue of the business and operations of the Company and do any and all other acts
and things that may be necessary or advisable to enable the Holders of Registrable Securities included in such Registration Statement
to consummate the disposition of such Registrable Securities in such jurisdictions; provided, however, that the Company
shall not be required to qualify generally to do business in any jurisdiction where it would not otherwise be required to qualify or take
any action to which it would be subject to general service of process or taxation in any such jurisdiction where it is not then otherwise
so subject;
3.1.4 cause all such Registrable Securities to
be listed on each securities exchange or automated quotation system on which similar securities issued by the Company are then listed;
3.1.5 provide a transfer agent or warrant agent,
as applicable, and registrar for all such Registrable Securities no later than the effective date of such Registration Statement;
3.1.6 advise each seller of such Registrable Securities,
promptly after it shall receive notice or obtain knowledge thereof, of the issuance of any stop order by the Commission suspending the
effectiveness of such Registration Statement or the initiation or threatening of any proceeding for such purpose and promptly use its
commercially reasonable efforts to prevent the issuance of any stop order or to obtain its withdrawal if such stop order should be issued;
3.1.7 notify the Holders at any time when a Prospectus
relating to such Registration Statement is required to be delivered under the Securities Act, of the happening of any event as a result
of which the Prospectus included in such Registration Statement, as then in effect, includes a Misstatement, and then to correct such
Misstatement as set forth in Section 3.4 hereof;
3.1.8 permit a representative of the Holders (such
representative to be selected by a majority of the participating Holders), the Underwriters, if any, and any attorney or accountant retained
by such Holders or Underwriter to participate, other than as set forth in the definition of “Registration Expenses,” at each
such person’s own expense, in the preparation of the Registration Statement, and cause the Company’s officers, directors and
employees to supply all information reasonably requested by any such representative, Underwriter, attorney or accountant in connection
with the Registration; provided, however, that such representatives or Underwriters enter into a confidentiality agreement,
in form and substance reasonably satisfactory to the Company, prior to the release or disclosure of any such information; and, provided
further that such Holders, Underwriters, and their legal counsel must provide any comments promptly (and in any event with five (5)
Business Days) after receipt of such Registration Statement;
3.1.9 obtain a “cold comfort” letter
from the Company’s independent registered public accountants in the event of an Underwritten Registration, in customary form and
covering such matters of the type customarily covered by “cold comfort” letters as the managing Underwriter may reasonably
request, and reasonably satisfactory to the managing Underwriter;
3.1.10 on the date the Registrable Securities
are delivered for sale pursuant to such Registration, obtain an opinion, dated such date, of counsel representing the Company for the
purposes of such Registration, addressed to the placement agent or sales agent, if any, and the Underwriters, if any, covering such legal
matters with respect to the Registration in respect of which such opinion is being given as the placement agent, sales agent, or Underwriter
may reasonably request and as are customarily included in such opinions and negative assurance letters, and reasonably satisfactory to
the Company;
3.1.11 in the event of any Underwritten Offering,
enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the managing Underwriter of
such offering;
3.1.12 make available to its security holders,
as soon as reasonably practicable, an earnings statement covering the period of at least twelve (12) months beginning with the first
day of the Company’s first full calendar quarter after the effective date of the Registration Statement which satisfies the provisions
of Section 11(a) of the Securities Act and Rule 158 thereunder (or any successor rule promulgated thereafter by the Commission);
3.1.13 if the Registration involves the Registration
of Registrable Securities involving gross proceeds reasonably expected to be in excess of $25 million, use its reasonable efforts
to make available senior executives of the Company to participate in customary “road show” presentations that may be reasonably
requested by the Underwriter in any Underwritten Offering; and
3.1.14 otherwise, in good faith, cooperate reasonably
with, and take such customary actions as may reasonably be requested by the Holders, in connection with such Registration.
3.2 Registration Expenses. The Registration
Expenses of all Registrations shall be borne by the Company. It is acknowledged by the Holders that the Holders shall bear all incremental
selling expenses relating to the sale of Registrable Securities, such as Underwriters’ commissions and discounts, brokerage fees,
Underwriter marketing costs and, other than as set forth in the definition of “Registration Expenses,” all reasonable fees
and expenses of any legal counsel representing the Holders.
3.3 Requirements for Participation in Underwritten
Offerings. Notwithstanding anything in this Agreement to the contrary, if any Holder does not provide the Company with its requested
Holder Information, the Company may exclude such Holder’s Registrable Securities from the applicable Registration Statement or Prospectus
if the Company determines in good faith that such information is necessary to effect the Registration and such Holder continues thereafter
to withhold such information. No person may participate in any Underwritten Offering for equity securities of the Company pursuant to
a Registration initiated by the Company hereunder unless such person (i) agrees to sell such person’s securities on the basis
provided in any underwriting arrangements approved by the Company and (ii) completes and executes all customary questionnaires, powers
of attorney, indemnities, lock-up agreements, underwriting agreements and other customary documents as may be reasonably required under
the terms of such underwriting arrangements. The exclusion of a Holder’s Registrable Securities as a result of this Section 3.3
shall not affect the Registration of the other Registrable Securities to be included in such Registration. The representations, warranties
and covenants of the Company in any underwriting agreement which are made to or for the benefit of any Underwriters, to the extent applicable,
shall also be made to and for the benefit of Holders holding Registrable Securities included in such Registration Statement. No Holder
holding Registrable Securities included in such Registration Statement shall be required to make any representations or warranties in
the underwriting agreement except, if applicable, with respect to such Holder’s organization, good standing, authority, title to
Registrable Securities, lack of conflict of such sale with such Holder’s material agreements and organizational documents, and with
respect to written information relating to such Holder that such Holder has furnished in writing expressly for inclusion in such Registration
Statement.
3.4 Suspension of Sales; Adverse Disclosure.
Upon receipt of written notice from the Company that a Registration Statement or Prospectus contains a Misstatement, each of the Holders
shall forthwith discontinue disposition of Registrable Securities until he, she or it has received copies of a supplemented or amended
Prospectus correcting the Misstatement (it being understood that the Company hereby covenants to prepare and file such supplement or amendment
as soon as practicable after the time of such notice), or until he, she or it is advised in writing by the Company that the use of the
Prospectus may be resumed. If the filing, initial effectiveness or continued use of a Registration Statement in respect of any Registration
at any time would require the Company to make an Adverse Disclosure or would require the inclusion in such Registration Statement of financial
statements that are unavailable to the Company for reasons beyond the Company’s control, the Company may, upon giving prompt written
notice of such action to the Holders, delay the filing or initial effectiveness of, or suspend use of, such Registration Statement for
the shortest period of time, but in no event more than thirty (30) consecutive days or ninety (90) days in any rolling 12-month
period, determined in good faith by the Company to be necessary for such purpose. In the event the Company exercises its rights under
the preceding sentence, the Holders agree to suspend, immediately upon their receipt of the notice referred to above, their use of the
Prospectus relating to any Registration in connection with any sale or offer to sell Registrable Securities. The Company shall immediately
notify the Holders of the expiration of any period during which it exercised its rights under this Section 3.4.
3.5 Reporting Obligations. As long as any
Holder shall own Registrable Securities, the Company, at all times while it shall be a reporting company under the Exchange Act, covenants
to use commercially reasonable efforts to: (i) make and keep public information available, as those terms are understood and defined
in Rule 144 and (ii) file timely (or obtain extensions in respect thereof and file within the applicable grace period) all reports
required to be filed by the Company after the date hereof pursuant to Sections 13(a) or 15(d) of the Exchange Act. The Company further
covenants that it shall take such further action as any Holder may reasonably request, all to the extent required from time to time to
enable such Holder to sell shares of Common Stock held by such Holder without registration under the Securities Act within the limitation
of the exemptions provided by Rule 144 promulgated under the Securities Act (or any successor rule promulgated thereafter by the Commission),
including providing any reasonably requested legal opinions. Upon the request of any Holder, the Company shall deliver to such Holder
a written certification of a duly authorized officer as to whether it has complied with such requirements.
ARTICLE
IV
INDEMNIFICATION
AND CONTRIBUTION
4.1 Indemnification.
4.1.1 The Company agrees to indemnify, to the
extent permitted by law, each Holder of Registrable Securities, its officers and directors and each person who controls such Holder (within
the meaning of the Securities Act) against all losses, claims, damages, liabilities and expenses (including attorneys’ fees) caused
by any untrue or alleged untrue statement of material fact contained in any Registration Statement, Prospectus or preliminary Prospectus
or any amendment thereof or supplement thereto or any omission or alleged omission of a material fact required to be stated therein or
necessary to make the statements therein not misleading, except insofar as the same are caused by or contained in any information furnished
in writing to the Company by or on behalf of such Holder expressly for use therein. The Company shall indemnify the Underwriters, their
officers and directors and each person who controls such Underwriters (within the meaning of the Securities Act) to the same extent as
provided in the foregoing sentence with respect to the indemnification of the Holder.
4.1.2 In connection with any Registration Statement
in which a Holder of Registrable Securities is participating, such Holder shall furnish to the Company in writing such information and
affidavits as the Company reasonably requests for use in connection with any such Registration Statement or Prospectus (the “Holder
Information”) and, to the extent permitted by law, shall indemnify the Company, its directors and officers and agents and
each person who controls the Company (within the meaning of the Securities Act) against any losses, claims, damages, liabilities and expenses
(including reasonable attorneys’ fees) resulting from any untrue statement of material fact contained in the Registration Statement,
Prospectus or preliminary Prospectus or any amendment thereof or supplement thereto or any omission of a material fact required to be
stated therein or necessary to make the statements therein not misleading, but only to the extent that such untrue statement or omission
is contained in any information or affidavit so furnished in writing by such Holder expressly for use therein; provided, however,
that the obligation to indemnify shall be several, not joint and several, among such Holders of Registrable Securities, and the liability
of each such Holder of Registrable Securities shall be limited to the net proceeds received by such Holder from the sale of Registrable
Securities pursuant to such Registration Statement. The Holders of Registrable Securities shall indemnify the Underwriters, their officers,
directors and each person who controls such Underwriters (within the meaning of the Securities Act) to the same extent as provided in
the foregoing with respect to indemnification of the Company.
4.1.3 Any person entitled to indemnification herein
shall (i) give prompt written notice to the indemnifying party of any claim with respect to which it seeks indemnification (provided
that the failure to give prompt notice shall not impair any person’s right to indemnification hereunder to the extent such failure
has not materially prejudiced the indemnifying party in the defense of any such claim or any such litigation) and (ii) unless in
such indemnified party’s reasonable judgment a conflict of interest between such indemnified and indemnifying parties may exist
with respect to such claim, permit such indemnifying party to assume the defense of such claim with counsel reasonably satisfactory to
the indemnified party. If such defense is assumed, the indemnifying party shall not be subject to any liability for any settlement made
by the indemnified party without its consent (but such consent shall not be unreasonably withheld). An indemnifying party who is not entitled
to, or elects not to, assume the defense of a claim shall not be obligated to pay the fees and expenses of more than one counsel for all
parties indemnified by such indemnifying party with respect to such claim, unless in the reasonable judgment of any indemnified party
a conflict of interest may exist between such indemnified party and any other of such indemnified parties with respect to such claim.
No indemnifying party shall, without the consent of the indemnified party, consent to the entry of any judgment or enter into any settlement
which cannot be settled in all respects by the payment of money (and such money is so paid by the indemnifying party pursuant to the terms
of such settlement) or which settlement does not include as an unconditional term thereof the giving by the claimant or plaintiff to such
indemnified party of a release from all liability in respect to such claim or litigation.
4.1.4 The indemnification provided for under this
Agreement shall remain in full force and effect regardless of any investigation made by or on behalf of the indemnified party or any officer,
director or controlling person of such indemnified party and shall survive the transfer of securities. If the indemnification provided
under Section 4.1 hereof from the indemnifying party is unavailable or insufficient to hold harmless an indemnified party
in respect of any losses, claims, damages, liabilities and expenses referred to herein, then the indemnifying party, in lieu of indemnifying
the indemnified party, shall contribute to the amount paid or payable by the indemnified party as a result of such losses, claims, damages,
liabilities and expenses in such proportion as is appropriate to reflect the relative fault of the indemnifying party and the indemnified
party, as well as any other relevant equitable considerations. The relative fault of the indemnifying party and indemnified party shall
be determined by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of
a material fact or omission or alleged omission to state a material fact, was made by, or relates to information supplied by, such indemnifying
party or indemnified party, and the indemnifying party’s and indemnified party’s relative intent, knowledge, access to information
and opportunity to correct or prevent such action; provided, however, that the liability of any Holder under this subsection
4.1.4 shall be limited to the amount of the net proceeds received by such Holder in such offering giving rise to such liability. The
amount paid or payable by a party as a result of the losses or other liabilities referred to above shall be deemed to include, subject
to the limitations set forth in subsections 4.1.1 and 4.1.2 and 4.1.3 above, any legal or other fees, charges or
expenses reasonably incurred by such party in connection with any investigation or proceeding. The parties hereto agree that it would
not be just and equitable if contribution pursuant to this subsection 4.1.4 were determined by pro rata allocation or by any other
method of allocation, which does not take account of the equitable considerations referred to in this subsection 4.1.4. No person
guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution
pursuant to this subsection 4.1.4 from any person who was not guilty of such fraudulent misrepresentation.
ARTICLE
V
MISCELLANEOUS
5.1 Notices. Any notice or communication
under this Agreement must be in writing and given by (i) deposit in the United States mail, addressed to the party to be notified,
postage prepaid and registered or certified with return receipt requested, (ii) delivery in person or by courier service providing
evidence of delivery, or (iii) transmission by hand delivery, email or facsimile. Each notice or communication that is mailed, delivered,
or transmitted in the manner described above shall be deemed sufficiently given, served, sent, and received, in the case of mailed notices,
on the third (3rd) Business Day following the date on which it is mailed and, in the case of notices delivered by courier service,
hand delivery, email, or facsimile, at such time as it is delivered to the addressee (with the delivery receipt or the affidavit of messenger)
or at such time as delivery is refused by the addressee upon presentation. Any notice or communication under this Agreement must be addressed,
if to the Company, to: TriSalus Life Sciences, Inc. c/o Chief Financial Officer, 6272 W 91st Ave, Westminster, Colorado, with a copy to
Cooley LLP, c/o Matthew Browne, 10265 Science Center Drive, San Diego, California 92121-1117, and, if to any Holder, at such Holder’s
address or contact information as set forth in the Company’s books and records. Any party may change its address for notice at any
time and from time to time by written notice to the other parties hereto, and such change of address shall become effective thirty (30) days
after delivery of such notice as provided in this Section 5.1.
5.2 Assignment; No Third Party Beneficiaries.
5.2.1 This Agreement and the rights, duties and
obligations of the Company hereunder may not be assigned or delegated by the Company in whole or in part.
5.2.2 No Holder may assign or delegate such Holder’s
rights, duties or obligations under this Agreement, in whole or in part, except in connection with a transfer of Registrable Securities
by such Holder to a Permitted Transferee upon receipt by the Company of (a) written notice from such Holder stating the name and address
of the transferee and identifying the number of Registrable Securities with respect to which rights under this Agreement are being transferred
and the nature of the rights so transferred, and (b) a written agreement from such Permitted Transferee agreeing to become bound by the
transfer restrictions set forth in this Agreement. A Permitted Transferee of Registrable Securities who satisfies the conditions set forth
in this subsection 5.2.2. shall henceforth be a “Holder” for purposes of this Agreement.
5.2.3 This Agreement and the provisions hereof
shall be binding upon and shall inure to the benefit of each of the parties and its successors and the permitted assigns of the Holders,
which shall include Permitted Transferees.
5.2.4 This Agreement shall not confer any rights
or benefits on any persons that are not parties hereto, other than as expressly set forth in this Agreement and Section 5.2
hereof.
5.2.5 No assignment by any party hereto of such
party’s rights, duties and obligations hereunder shall be binding upon or obligate the Company unless and until the Company shall
have received (i) written notice of such assignment as provided in Section 5.1 hereof and (ii) the written agreement
of the assignee, in a form reasonably satisfactory to the Company, to be bound by the terms and provisions of this Agreement (which may
be accomplished by an addendum or certificate of joinder to this Agreement). Any transfer or assignment made other than as provided in
this Section 5.2 shall be null and void.
5.3 Counterparts. This Agreement may be
executed in multiple counterparts (including facsimile, PDF, DocuSign or similarly executed counterparts), each of which shall be deemed
an original, and all of which together shall constitute the same instrument, but only one of which need be produced.
5.4 Governing Law. The law of the State
of Delaware shall govern (a) all claims or matters related to or arising from this Agreement (including any tort or non-contractual claims)
and (b) any questions concerning the construction, interpretation, validity and enforceability of this Agreement, and the performance
of the obligations imposed by this Agreement, in each case without giving effect to any choice of law or conflict of law rules or provisions
(whether of the State of Delaware or any other jurisdiction) that would cause the application of the law of any jurisdiction other than
the State of Delaware.
5.5 Venue. Each party hereto submits to
the exclusive jurisdiction of first, the Court of Chancery of the State of Delaware or if such court declines jurisdiction, then to any
court of the State of Delaware or the Federal District Court for the District of Delaware, in any Action arising out of or relating to
this Agreement, agrees that all claims in respect of the Action shall be heard and determined in any such court and agrees not to bring
any Action arising out of or relating to this Agreement in any other courts. Nothing in this Section 5.5, however, shall affect
the right of any party to serve legal process in any other manner permitted by law or at equity. Each party hereto agrees that a final
judgment in any Action so brought shall be conclusive and may be enforced by suit on the judgment or in any other manner provided by law
or at equity. EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES ALL RIGHTS TO TRIAL BY JURY IN ANY ACTION BROUGHT TO RESOLVE ANY DISPUTE BETWEEN
OR AMONG ANY OF THE PARTIES (WHETHER ARISING IN CONTRACT, TORT OR OTHERWISE) ARISING OUT OF, CONNECTED WITH, RELATED OR INCIDENTAL TO
THIS AGREEMENT, THE TRANSACTIONS OR THE RELATIONSHIPS ESTABLISHED AMONG THE PARTIES UNDER THIS AGREEMENT. EACH PARTY FURTHER WARRANTS
AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS
JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL.
5.6 Amendments and Modifications.
Upon the written consent of the Company and the Holders of at least a majority in interest of the Registrable Securities at the time
in question, compliance with any of the provisions, covenants and conditions set forth in this Agreement may be waived, or any of
such provisions, covenants or conditions may be amended or modified; provided, however, that notwithstanding the
foregoing, any amendment hereto or waiver hereof that adversely affects one Holder, solely in his, her or its capacity as a holder
of the Registrable Securities, in a manner that is materially different from the other Holders (in such capacity) shall require the
consent of the Holder so affected; provided further, that a provision that has terminated with respect to a party shall not
require any consent of such party (and such party’s Registrable Securities shall not be considered in computing any
percentages) with respect to amending or modifying such provision. Each Holder agrees that any waiver, amendment or modification
effected in accordance with this Section 5.6 shall be binding on all Holders and their successors and assigns. No course of
dealing between any Holder or the Company and any other party hereto or any failure or delay on the part of a Holder or the Company
in exercising any rights or remedies under this Agreement shall operate as a waiver of any rights or remedies of any Holder or the
Company. No single or partial exercise of any rights or remedies under this Agreement by a party shall operate as a waiver or
preclude the exercise of any other rights or remedies hereunder or thereunder by such party.
5.7 Term. This Agreement shall terminate
upon the earlier of (a) with respect to any Holder on the date that such Holder no longer holds any Registrable Securities; (b) with respect
to any Holder (other than any Sponsor Holder who at the Closing was issued Registrable Securities subject to price-based vesting, a “Vesting
Sponsor Holder”) on the date that is three (3) years after the Closing; and (c) with respect to a Vesting Sponsor Holder
that at the time of vesting continues to hold at least 1% of the aggregate amount of shares of Common Stock that constitute Registrable
Securities (including shares underlying equity awards, warrants or other equity instruments convertible or exercisable into shares of
Common Stock) immediately following the Closing, the earlier of (A) one (1) year after the price-based vesting condition is
met (but in no event less than three (3) years after the Closing) and (B) six (6) years after the Closing; provided that, in all respects,
the provisions of Article IV shall survive any termination with respect to any such Holder.
5.8 Entire Agreement. This Agreement (including
all agreements entered into pursuant hereto and all certificates and instruments delivered pursuant hereto and thereto) constitute the
entire agreement of the parties with respect to the subject matter hereof and supersede all prior and contemporaneous agreements, representations,
understandings, negotiations and discussions between the parties, whether oral or written.
5.9 Titles and Headings. Titles and headings
of sections of this Agreement are for convenience only and shall not affect the construction of any provision of this Agreement.
5.10 Qualified Additional Holders. In the
event that after the date of this Agreement, the Company wishes to provide any Qualified Additional Holders registration rights as contemplated
by this Agreement, then the Company shall cause such Qualified Additional Holder to become a party to this Agreement by executing a joinder
agreement in the form attached hereto as Exhibit A, agreeing to be bound by and subject to the terms of this Agreement as a Holder and
thereafter such Qualified Additional Holder shall be deemed a Holder for all purposes under this Agreement.
5.11 Holder Information. Each Holder agrees,
if requested in writing, to represent to the Company the total number of Registrable Securities held by such Holder in order for the Company
to make determinations hereunder.
5.12 Opt-Out Requests. Each
Holder shall have the right, at any time and from time to time (including after receiving information regarding any potential public
offering), to elect to not receive any notice that the Company or any other Holders otherwise are required to deliver pursuant to
this Agreement by delivering to the Company a written statement signed by such Holder that it does not want to receive any notices
hereunder (an “Opt-Out Request”); in which case and notwithstanding anything to the contrary in this
Agreement the Company and other Holders shall not be required to, and shall not, deliver any notice or other information required to
be provided to Holders hereunder to the extent that the Company or such other Holders reasonably expect would result in a Holder
acquiring material non-public information within the meaning of Regulation FD promulgated under the Exchange Act. An
Opt-Out Request may state a date on which it expires or, if no such date is specified, shall remain in effect indefinitely. A
Holder who previously has given the Company an Opt-Out Request may revoke such request at any time, and there shall be no limit on
the ability of a Holder to issue and revoke subsequent Opt-Out Requests; provided that each Holder shall use commercially
reasonable efforts to minimize the administrative burden on the Company arising in connection with any such Opt-Out Requests.
[Signature Page Follows]
IN WITNESS WHEREOF, the undersigned have
caused this Agreement to be executed as of the date first written above.
|
COMPANY: |
|
|
|
TRISALUS LIFE SCIENCES, INC., |
|
|
a Delaware corporation |
|
|
|
By: |
/s/ Christopher Dewey |
|
|
Name: |
Christopher Dewey |
|
|
Title: |
Chief Executive Officer |
|
|
|
HOLDERS: |
|
|
|
MedTech Acquisition Sponsor LLC, |
|
|
a Delaware limited liability company |
|
|
|
By: |
/s/ Christopher Dewey |
|
|
Name: |
Christopher Dewey |
|
|
Title: |
Managing Member |
[Signature Page to Amended and Restated Registration
Rights Agreement]
IN WITNESS WHEREOF, the undersigned have
caused this Agreement to be executed as of the date first written above.
[Signature Page to Amended and Restated Registration
Rights Agreement]
Exhibit A
Form of Joinder
FORM OF JOINDER TO AMENDED AND RESTATED
REGISTRATION RIGHTS AGREEMENT
[
], 20[●]
Reference is made to that certain Amended and
Restated Registration Rights Agreement (as may be amended and/or restated from time to time, the “Registration Rights Agreement”),
dated as of August 10, 2023, by and among TriSalus Life Sciences, Inc., a Delaware corporation (the “Company”),
MedTech Acquisition Sponsor LLC, a Delaware limited liability company (the “Sponsor”), certain former stockholders
of TriSalus Operating Life Sciences, Inc., a Delaware corporation (formerly known as TriSalus Life Sciences, Inc. (“Legacy
TriSalus”)), and all members of the Sponsor listed under Holder on the signature page thereto. Capitalized terms used but
not otherwise defined herein shall have the meanings ascribed to such terms in the Registration Rights Agreement.
The undersigned hereby agrees to and does become
party to the Registration Rights Agreement as a Holder thereunder. This Joinder shall serve as a counterpart signature page to the Registration
Rights Agreement and by executing below the undersigned is deemed to have executed the Registration Rights Agreement with the same force
and effect as if originally named a party thereto.
This Joinder may be executed in multiple counterparts,
including by means of facsimile or electronic signature, each of which shall be deemed an original, but all of which together shall constitute
the same instrument.
[Remainder of Page Intentionally Left Blank.]
Exhibit 10.14
CERTAIN INFORMATION CONTAINED IN THIS
EXHIBIT, MARKED BY [**], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND
IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
TRISALUS LIFE SCIENCES
AT-WILL
EMPLOYMENT, CONFIDENTIAL INFORMATION,
INVENTION ASSIGNMENT AND ARBITRATION AGREEMENT
As a condition of my employment
with TriSalus Life Sciences, Inc. (the “Company”), and in consideration of my employment with the Company, my
receipt of the compensation now and hereafter paid to me by Company, and the Company’s agreement to provide me with access to Company
Confidential Information (as defined below). I agree to the following provisions of this At-Will Employment, Confidential Information, Invention
Assignment, and Arbitration Agreement (this “Agreement”):
WHEREAS, during the course
of my employment, I will have access to and knowledge of Company’s trade secrets and Company Confidential Information in accordance
with Colo. Rev. Stat. §8-2-113 and/or proprietary technology relating to Company’s products, services, and business, and to
have contact with, learn about, provide services to, and establish relationships with customers and business partners of Company.
WHEREAS, Company maintains
a technically skilled workforce by conducting specialized in-house training and development of employees which is vital to maintain a
competitive operation; and
WHEREAS, it is of material
benefit to me to participate in on the job training and receive additional training and knowledge provided by Company and it is of material
benefit to reasonably restrict the use of said training in a competitive marketplace and to restrict the disclosure of Company’s
trade secrets and Confidential Information with a nondisclosure and non-competition agreement both of which are reasonable in terms of
scope, geography and duration.
I UNDERSTAND AND ACKNOWLEDGE
THAT MY EMPLOYMENT WITH THE COMPANY IS FOR NO SPECIFIED TERM AND CONSTITUTES “AT-WILL” EMPLOYMENT. I ALSO UNDERSTAND THAT
ANY REPRESENTATION TO THE CONTRARY IS UNAUTHORIZED AND NOT VALID UNLESS IN WRITING AND SIGNED BY THE PRESIDENT OR CEO OF THE COMPANY.
ACCORDINGLY, I ACKNOWLEDGE THAT MY EMPLOYMENT RELATIONSHIP MAY BE TERMINATED AT ANY TIME, WITH OR WITHOUT GOOD CAUSE OR FOR
ANY OR NO CAUSE, AT MY OPTION OR AT THE OPTION OF THE COMPANY, WITH OR WITHOUT NOTICE. I FURTHER ACKNOWLEDGE THAT THE COMPANY MAY MODIFY
JOB TITLES, SALARIES, AND BENEFITS FROM TIME TO TIME AS IT DEEMS NECESSARY.
A. Definition
of Company Confidential Information. I understand that “Company Confidential Information” means information (including
any and all combinations of individual items of information) that the Company has or will develop, acquire, create, compile, discover
or own, that has value in or to the Company’s business which is not generally known and which the Company wishes to maintain as
confidential. Company Confidential Information includes both information disclosed by the Company to me, and information developed or
learned by me during the course of my employment with the Company. Company Confidential Information also includes all information of which
the unauthorized disclosure could be detrimental to the interests of the Company, whether or not such information is identified as Company
Confidential Information. By example, and without limitation, Company Confidential Information includes any and all non-public information
that relates to the actual or anticipated business and/or products, research or development of the Company, or to the Company’s
technical data, trade secrets, or know-how, including, but not limited to, research, product plans, or other information regarding the
Company’s products or services and markets therefor, customer lists and customers (including, but not limited to, customers of the
Company on which I called or with which I may become acquainted during the term of my employment), software, developments, inventions,
discoveries, ideas, processes, formulas, technology, designs, drawings, engineering, hardware configuration information, marketing, finances,
and other business information disclosed by the Company either directly or indirectly in writing, orally or by drawings or inspection
of premises, parts, equipment, or other Company property. Notwithstanding the foregoing, Company Confidential Information shall not include
any such information which I can establish (i) was publicly known or made generally available prior to the time of disclosure by
the Company to me; (ii) becomes publicly known or made generally available after disclosure by the Company to me through no wrongful
action or omission by me; or (iii) is in my rightful possession, without confidentiality obligations, at the time of disclosure by
the Company as shown by my then-contemporaneous written records; provided that any combination of individual items of information shall
not be deemed to be within any of the foregoing exceptions merely because one or more of the individual items are within such exception,
unless the combination as a whole is within such exception. I understand that nothing in this Agreement is intended to limit employees’
rights to discuss the terms, wages, and working conditions of their employment, as protected by applicable law.
B. Nonuse
and Nondisclosure. I agree that during and after my employment with the Company, I will hold in the strictest confidence and
take all reasonable precautions to prevent any unauthorized use or disclosure of Company Confidential Information. I will not (i) use
Company Confidential Information for any purpose whatsoever other than for the benefit of the Company in the course of my employment,
or (ii) disclose Company Confidential Information to any third party without the prior written authorization of the President, CEO,
or the Board of Directors of the Company. Prior to disclosure, when compelled by applicable law, I shall provide prior written notice
to the President, CEO, and General Counsel of the Company (as applicable). I agree that I obtain no title to any Company Confidential
Information, and that the Company retains all Confidential Information as the sole property of the Company. I understand that my unauthorized
use, threat of use or disclosure of Company Confidential Information during my employment may lead to disciplinary action, up to and including,
immediate termination and legal action by the Company. I understand that my obligations under this Section 2.B shall continue
after termination of my employment and also that nothing in this Agreement prevents me from engaging in protected activity, as described
in Section 14 below.
C. Former
Employer Confidential Information. I agree that during my employment with the Company, I will not improperly use, disclose, or
induce the Company to use any proprietary information or trade secrets of any former employer or other person or entity with which I have
an obligation to keep such proprietary information or trade secrets in confidence. I further agree that I will not bring onto the Company’s
premises or transfer onto the Company’s technology systems any unpublished document, proprietary information, or trade secrets belonging
to any such third party unless disclosure to, and use by, the Company has been consented to, in writing, by such third party and the Company.
D. Third
Party Information. I recognize that the Company has received, and in the future may receive, from third parties (for example, customers,
suppliers, licensors, licensees, partners, and collaborators) as well as its subsidiaries and affiliates (“Associated Third Parties”),
information which the Company is required to maintain and treat as confidential or proprietary information of such Associated Third Parties
(“Associated Third Party Confidential Information”), and I agree to use such Associated Third Party Confidential Information
only as directed by the Company and to not use or disclose such Associated Third Party Confidential Information in a manner that would
violate the Company’s obligations to such Associated Third Parties. By way of example, Associated Third Party Confidential Information
may include the habits or practices of Associated Third Parties, the technology of Associated Third Parties, requirements of Associated
Third Parties, and information related to the business conducted between the Company and such Associated Third Parties. I agree at all
times during my employment with the Company and thereafter, that I owe the Company and its Associated Third Parties a duty to hold all
such Associated Third Party Confidential Information in the strictest confidence, and not to use it or to disclose it to any person, firm,
corporation, or other third party except as necessary in carrying out my work for the Company consistent with the Company’s agreement
with such Associated Third Parties. I further agree to comply with any and all Company policies and guidelines that may be adopted from
time to time regarding Associated Third Parties and Associated Third Party Confidential Information. I understand that my unauthorized
use or disclosure of Associated Third Party Confidential Information or violation of any Company policies during my employment may lead
to disciplinary action, up to and including, immediate termination and legal action by the Company.
A. Assignment
of Inventions. As between the Company and myself, I agree that all right, title, and interest in and to any and all copyrightable
material, notes, records, drawings, designs, logos, inventions, improvements, developments, discoveries, ideas and trade secrets conceived,
discovered, authored, invented, developed or reduced to practice by me, solely or in collaboration with others, during the period of time
I am in the employ of the Company (including during my off-duty hours), or with the use of Company’s equipment, supplies, facilities,
or Company Confidential Information, and any copyrights, patents, trade secrets, mask work rights or other intellectual property rights
relating to the foregoing, except as provided in Section 3.G below (collectively, “Inventions”), are the
sole property of the Company. I also agree to promptly make full written disclosure to the Company of any Inventions, and to deliver and
assign and hereby irrevocably assign fully to the Company all of my right, title and interest in and to Inventions. I agree that this
assignment includes a present conveyance to the Company of ownership of Inventions that are not yet in existence. I further acknowledge
that all original works of authorship that are made by me (solely or jointly with others) within the scope of and during the period of
my employment with the Company and that are protectable by copyright are “works made for hire,” as that term is defined in
the United States Copyright Act. I understand and agree that the decision whether or not to commercialize or market any Inventions is
within the Company’s sole discretion and for the Company’s sole benefit, and that no royalty or other consideration will be
due to me as a result of the Company’s efforts to commercialize or market any such Inventions. I agree that I will abide by the
Company Protocols as provided to me to document and track all projects I am working on while employed at the Company.
B. Pre-Existing
Materials. I will inform the Company in writing before incorporating any inventions, discoveries, ideas, original works of authorship,
developments, improvements, trade secrets and other proprietary information or intellectual property rights owned by me or in which I
have an interest prior to, or separate from, my employment with the Company (attached hereto as Exhibit A) (“Prior
Inventions”) into any Invention or otherwise utilizing any Prior Invention in the course of my employment with the Company;
and the Company is hereby granted a nonexclusive, royalty-free, perpetual, irrevocable, transferable worldwide license (with the right
to grant and authorize sublicenses) to make, have made, use, import, offer for sale, sell, reproduce, distribute, modify, adapt, prepare
derivative works of, display, perform, and otherwise exploit such incorporated or utilized Prior Inventions, without restriction, including,
without limitation, as part of, or in connection with, such Invention, and to practice any method related thereto. I will not incorporate
any inventions, discoveries, ideas, original works of authorship, developments, improvements, trade secrets and other proprietary information
or intellectual property rights owned by any third party into any Invention without the Company’s prior written permission. I have
attached hereto as Exhibit A a list describing all Prior Inventions that relate to the Company’s current or anticipated
business, products, or research and development or, if no such list is attached, I represent and warrant that there are no such Prior
Inventions. Furthermore, I represent and warrant that if any Prior Inventions are included on Exhibit A, they
will not materially affect my ability to perform all obligations under this Agreement.
C. Moral
Rights. Any assignment to the Company of Inventions includes all rights of attribution, paternity, integrity, modification, disclosure
and withdrawal, and any other rights throughout the world that may be known as or referred to as “moral rights,” “artist’s
rights,” “droit moral,” or the like (collectively, “Moral Rights”). To the extent that Moral Rights
cannot be assigned under applicable law, I hereby waive and agree not to enforce any and all Moral Rights, including, without limitation,
any limitation on subsequent modification, to the extent permitted under applicable law.
D. Maintenance
of Records. I agree to keep and maintain adequate, current, accurate, and authentic written records of all Inventions made by me (solely
or jointly with others) during the term of my employment with the Company. The records will be in the form of notes, sketches, drawings,
electronic files, reports, or any other format that may be specified by the Company. As between the Company and myself, the records are
and will be available to and remain the sole property of the Company at all times.
E. Further
Assurances. I agree to assist the Company, or its designee, at the Company’s expense, in every proper way to secure the Company’s
rights in the Inventions in any and all countries, including the disclosure to the Company of all pertinent information and data with
respect thereto, the execution of all applications, specifications, oaths, assignments, and all other instruments that the Company shall
deem proper or necessary in order to apply for, register, obtain, maintain, defend, and enforce such rights, and in order to deliver,
assign and convey to the Company, its successors, assigns, and nominees the sole and exclusive rights, title, and interest in and to all
Inventions, and testifying in a suit or other proceeding relating to such Inventions. I agree to reasonably cooperate in any matter brought
by or against the Company that I have personal knowledge, if needed. I further agree that my obligations under this Section 3.E
shall continue after the termination of this Agreement.
F. Attorney-in-Fact.
I agree that, if the Company is unable because of my unavailability, mental or physical incapacity, or for any other reason to secure
my signature with respect to any Inventions, including, without limitation, for the purpose of applying for or pursuing any application
for any United States or foreign patents or mask work or copyright registrations covering the Inventions assigned to the Company in Section 3.A,
then I hereby irrevocably designate and appoint the Company and its duly authorized officers and agents as my agent and attorney-in-fact,
to act for and on my behalf to execute and file any papers and oaths, and to do all other lawfully permitted acts with respect to such
Inventions to further the prosecution and issuance of patents, copyright and mask work registrations with the same legal force and effect
as if executed by me. This power of attorney shall be deemed coupled with an interest, and shall be irrevocable.
G. Exception
to Assignments. I UNDERSTAND THAT THE PROVISIONS OF THIS AGREEMENT REQUIRING ASSIGNMENT OF INVENTIONS (AS DEFINED ABOVE) TO THE COMPANY
DO NOT APPLY TO ANY INVENTION THAT I HAVE DEVELOPED ENTIRELY ON MY OWN TIME WITHOUT USING THE COMPANY’S EQUIPMENT, SUPPLIES, FACILITIES,
TRADE SECRET INFORMATION OR COMPANY CONFIDENTIAL INFORMATION, EXCEPT FOR THOSE OTHER INVENTIONS THAT EITHER (I) RELATE AT THE TIME
OF CONCEPTION OR REDUCTION TO PRACTICE OF SUCH OTHER INVENTION TO THE COMPANY’S BUSINESS, OR ACTUAL OR DEMONSTRABLY ANTICIPATED
RESEARCH OR DEVELOPMENT OF THE COMPANY OR (II) RESULT FROM ANY WORK THAT I PERFORMED FOR THE COMPANY. I WILL ADVISE THE COMPANY PROMPTLY
IN WRITING OF ANY INVENTIONS THAT I BELIEVE CONSTITUTES AN OTHER INVENTION AND IS NOT OTHERWISE DISCLOSED ON EXHIBIT A
TO PERMIT A DETERMINATION OF OWNERSHIP BY THE COMPANY. ANY SUCH DISCLOSURE WILL BE RECEIVED IN CONFIDENCE.
| 4. | CONFLICTING OBLIGATIONS |
A. Current
Obligations. I agree that during the term of my employment with the Company, I will not engage in or undertake any other employment,
occupation, consulting relationship, or commitment that is directly related to the business in which the Company is now involved or becomes
involved or has plans to become involved, nor will I engage in any other activities that conflict with my obligations to the Company.
B. Prior
Relationships. Without limiting Section 4.A, I represent and warrant that I have no other agreements, relationships,
or commitments to any other person or entity that conflict with the provisions of this Agreement, my obligations to the Company under
this Agreement, or my ability to become employed and perform the services for which I am being hired by the Company. I further agree that
if I have signed a confidentiality agreement or similar type of agreement with any former employer or other entity, I will comply
with the terms of any such agreement to the extent that its terms are lawful under applicable law. I represent and warrant that after
undertaking a careful search (including searches of my computers, cell phones, electronic devices, and documents), I have returned
all property and confidential information belonging to all prior employers (and/or other third parties I have performed services for in
accordance with the terms of my applicable agreement). Moreover, I agree to fully indemnify the Company, its directors, officers,
agents, employees, investors, shareholders, administrators, affiliates, divisions, subsidiaries, predecessor and successor corporations,
and assigns for all verdicts, judgments, settlements, and other losses incurred by any of them resulting from my breach of my obligations
under any agreement with a third party to which I am a party or obligation to which I am bound, as well as any reasonable attorneys’
fees and costs if the plaintiff is the prevailing party in such an action, except as prohibited by law.
| 5. | RETURN OF COMPANY MATERIALS |
A. Definition
of Electronic Media Equipment and Electronic Media Systems. I understand that “Electronic Media Equipment” includes,
but is not limited to, computers, external storage devices, thumb drives, mobile devices (including, but not limited to, smart phones,
tablets, and e-readers), telephone equipment, and other electronic media devices. I understand that “Electronic Media Systems”
includes, but is not limited to, computer servers, messaging and email systems or accounts, applications for computers or mobile devices,
and web-based services (including cloud-based information storage accounts).
B. Return
of Company Property. I understand that anything that I created or worked on for the Company while working for the Company belongs
solely to the Company and that I cannot remove, retain, or use such information without the Company’s express written permission.
Accordingly, upon separation from employment with the Company or upon the Company’s request at any other time, I will immediately
deliver to the Company, and will not keep in my possession, recreate, or deliver to anyone else, any and all Company property, including,
but not limited to, Company Confidential Information, Associated Third Party Confidential Information, all Company equipment including
all Company Electronic Media Equipment, all tangible embodiments of the Inventions, all electronically stored information and passwords
to access such information, Company credit cards, records, data, notes, notebooks, reports, files, proposals, lists, correspondence, specifications,
drawings, blueprints, sketches, materials, photographs, charts, any other documents and property, and reproductions of any of the foregoing
items including, without limitation, those records maintained pursuant to Section 3.D. Notwithstanding the foregoing, I
understand that I am allowed to keep a copy of the Company’s employee handbook and personnel records relating to my employment.
C. Return
of Company Information on Company Electronic Media Equipment. In connection with my obligation to return information to the Company, I
agree that I will not copy, delete, or alter any information, including personal information voluntarily created or stored, contained
in Company Electronic Media Equipment before I return the information to the Company.
D. Return
of Company Information on Personal Electronic Media Equipment. In addition, if I have used any personal Electronic Media Equipment
or personal Electronic Media Systems to create, receive, store, review, prepare or transmit any Company information, including, but not
limited to, Company Confidential Information, I agree to make a prompt and reasonable search for such information in good faith,
including reviewing any personal Electronic Media Equipment or personal Electronic Media Systems to locate such information and, if I
locate such information, I agree to notify the Company of that fact and then provide the Company with a computer-useable copy of
all such Company information from those equipment and systems. I agree to cooperate reasonably with the Company to verify that the necessary
copying is completed (including upon request providing a sworn declaration confirming the return of property and deletion of information),
and, upon confirmation of compliance by the Company, I agree to delete and expunge all Company information.
E. No
Expectation of Privacy in Company Property. I understand that I have no expectation of privacy in Company property, and I agree that
any Company property is subject to inspection by Company personnel at any time with or without further notice. As to any personal Electronic
Media Equipment or personal Electronic Media Systems that I have used for Company purposes, I agree that the Company, at its sole
discretion, may have reasonable access, as determined by the Company in good faith, to such personal Electronic Media Equipment or personal
Electronic Media Systems to review, retrieve, destroy, or ensure the permanent deletion of Company information from such equipment or
systems or to take such other actions necessary to protect the Company or Company property, as determined by the Company reasonably and
in good faith. I also consent to an exit interview and an audit to confirm my compliance with this Section 5, and I will certify
in writing that I have complied with the requirements of this Section 5.
| 6. | TERMINATION CERTIFICATION |
Upon separation from employment
with the Company, I agree to immediately sign and deliver to the Company the “Termination Certification” attached hereto
as Exhibit C.
| 7. | NOTIFICATION OF NEW EMPLOYER |
In the event that I leave
the employ of the Company, I hereby grant consent to notification by the Company to my new employer about my obligations under this
Agreement. I also agree to keep the Company advised of my home and business address for a period of three (3) years after termination
of my employment with the Company, so that the Company can contact me regarding my continuing obligations provided by this Agreement.
| 8. | COVENANT NOT TO COMPETE AND NO SOLICITATION |
A. Covenant
Not to Compete. I agree that during the course of my employment and for a period of twelve (12) months immediately following the termination
of my relationship with the Company for any reason, whether with or without cause, at the option either of the Company or myself, with
or without notice, I will not, without the prior written consent of the Company: (i) serve as a partner, principal, licensor,
licensee, employee, consultant, officer, director, manager, agent, affiliate, representative, advisor, promoter, associate, investor,
or otherwise for (except for passive ownership of one percent (1%) or less of any entity whose securities have been registered under the
Securities Act of 1933, as amended, or Section 12 of the Securities Exchange Act of 1934, as amended); (ii) directly or indirectly,
own, purchase, organize or take preparatory steps for the organization of; or (iii) build, design, finance, acquire, lease, operate,
manage, control, invest in, work or consult for or otherwise join, participate in or affiliate myself with, any business whose business,
products or operations are in any respect involved in the Covered Business. For purposes of this Agreement, “Covered Business”
shall mean any business in which the Company is engaged or in which the Company has plans to be engaged, or any service that the Company
provides or has plans to provide at the time of my departure, including without limitation, any business that is engaged in researching,
designing, developing, manufacturing, marketing and/or sales of medical devices for regional delivery and therapeutics used in that delivery
to treat solid tumors. The foregoing covenant shall cover my activities in every part of the Territory. For purposes of this Agreement,
“Territory” shall mean: all counties in the state in which I primarily perform services for Company; (ii) all
other states of the United States of America in which Company, with my involvement in some capacity, including, without limitation, my
having knowledge of Company Confidential Information related thereto, provided goods or services, had customers, or otherwise conducted
business at any time during the two-year period prior to the date of the termination of my relationship with Company; and (iii) any
other countries (including China) from which Company provided goods or services, had customers, or otherwise conducted business, with
my involvement in some capacity, including, without limitation, my having knowledge of Company Confidential Information related thereto,
at any time during the two-year period prior to the date of the termination of my relationship with Company.
Should I obtain other employment during my employment
with the Company or within six (6) months immediately following the termination of my relationship with the Company, I agree
to provide written notification to the Company as to the name and address of my new employer, the position that I expect to hold, and
a general description of my duties and responsibilities, at least three (3) business days prior to starting such employment.
I understand that the foregoing non-compete restriction
is applicable to me only if my total annualized cash compensation meets or exceeds the greater of (i) $101,250.00; or (ii) the
compensation threshold established by the Colorado State Department of Labor and Employment (the “Colorado Non-Compete Compensation
Threshold”). For avoidance of doubt, if my annualized cash compensation does not meet or exceed the Colorado Non-Compete Compensation
Threshold as specified in Colo. Rev. Stat. Ann. §8-2-113(2)(b), I will not be subject to the restrictions contained in this
Section 8(A).
(1) Non-Solicitation
of Customers or Prospective Customers. I agree that for a period of twelve (12) months immediately following the termination of my
relationship with the Company for any reason, whether with or without cause, at the option either of the Company or myself, with or without
notice, I will not (i) contact, or cause to be contacted, directly or indirectly, or engage in any form of oral, verbal, written,
recorded, transcribed, or electronic communication with any Customer or Prospective Customer for the purposes of conducting business that
is competitive or similar to that of the Company or for the purpose of disadvantaging the Company’s business in any way, (ii) solicit
or accept business from any Customer or Prospective Customer, in each case, for the purpose of providing goods or services in a Covered
Business, or (iii) solicit or induce any Customer or Prospective Customer to terminate, reduce or alter, in a manner adverse to the
Company, any existing business arrangement or agreement with the Company. For purposes of this Agreement, “Customer”
shall mean all persons or entities that have used the Company’s services at any time during the two-year period preceding the termination
of my employment with the Company, and “Prospective Customer” means any person or entity with whom the Company or any
of its subsidiaries or affiliates has communicated or whom the Company or any of its subsidiaries or affiliates has solicited for the
purposes of obtaining such person or entity as a Customer and/or whom the Company or any of its subsidiaries or affiliates has analyzed
concerning the potential of such person or entity to become a Customer, at any time during the two-year period preceding the termination
of my employment with the Company. I acknowledge and agree that the Customers and Prospective Customers did not use or inquire of the
Company’s services solely as a result of my efforts, and that the efforts of other Company personnel and resources are responsible
for the Company’s relationship with the Customers and/or the Prospective Customers. I further acknowledge and agree that the identity
of the Customers and/or the Prospective Customers is not readily ascertainable or discoverable through public sources, and that the Company’s
list of Customers and Prospective Customers was cultivated with great effort and secured through the expenditure of considerable time
and money by the Company. I understand that the provisions of this Section 8(B)(1) (the “Customer Non-Solicitation
Restrictions”) are applicable to me only if my total annualized cash compensation meets or exceeds the greater of: (i) $60,750.00;
or (ii) the compensation threshold established by the Colorado State Department of Labor and Employment (the “Colorado Customer
Non-Solicitation Compensation Threshold”). For avoidance of doubt, if my annualized cash compensation does not meet or exceed
the Colorado Customer Non-Solicitation Compensation Threshold as specified in Colo. Rev. Stat. Ann. §8-2-113(2)(d), I will not
be subject to the Customer Non-Solicitation Restrictions.
(2) Non-Solicitation
of Employees, Consultants and Independent Contractors. I agree that for a period of twelve (12) months immediately following the termination
of my relationship with the Company for any reason, whether with or without cause, at the option either of the Company or myself, with
or without notice, I will not directly or indirectly solicit or recruit, or attempt to solicit or recruit, any person who is or was
an employee, third party consultant or independent contractor of the Company or any of its subsidiaries or affiliates at any time during
the two-year period prior to such solicitation or recruitment to leave their employment or consultant or contractor relationship with
the Company, nor will I contact any employee, third party consultant or independent contractor of the Company, or cause them to be contacted,
for the purpose of terminating their employment or service relationship with the Company.
(3) Non-Solicitation
of Others. I agree that for a period of twelve (12) months immediately following the termination of my relationship with the Company
for any reason, whether with or without cause, at the option either of the Company or myself, with or without notice, I will not
solicit, encourage, or induce, or cause to be solicited, encouraged or induced, directly or indirectly, any franchisee, joint venture,
supplier, vendor or contractor who conducted business with the Company at any time during the two-year period preceding the termination
of my employment with the Company, to terminate or adversely modify any business relationship with the Company or not to proceed with,
or enter into, any business relationship with the Company, nor shall I otherwise interfere with any business relationship between the
Company and any such franchisee, joint venture, supplier, vendor or contractor.
C. Acknowledgements.
I acknowledge that I will derive significant value from the Company’s agreement to provide me with Company Confidential Information
to enable me to optimize the performance of my duties to the Company. I further acknowledge that my fulfillment of the obligations contained
in this Agreement, including, but not limited to, my obligation neither to disclose nor to use Company Confidential Information other
than for the Company’s exclusive benefit and my obligations not to compete and not to solicit contained in subsections (A) and
(B) above, is necessary to protect Company Confidential Information and, consequently, to preserve the value and goodwill of the
Company. I also acknowledge the time, geographic and scope limitations of my obligations under subsections (A) and (B) above
are fair and reasonable in all respects, especially in light of the Company’s need to protect Company Confidential Information and
the scope and nature of the Company’s business, and that I will not be precluded from gainful employment if I am obligated not to
compete with the Company or solicit its customers, employees, or others during the period and within the Territory as described above.
In the event of my breach or violation of this Section 8, or good faith allegation by the Company of my breach or violation
of this Section 8, the restricted periods set forth in this Section 8 shall be tolled until such breach or violation,
or dispute related to an allegation by the Company that I have breached or violated this Section 8, has been duly cured or
resolved, as applicable. I agree that nothing in this Section 8 shall affect my continuing obligations under this Agreement
during and after this twelve (12) month period, including, without limitation, my obligations under Section 2.
D. Separate
Covenants. The covenants contained in subsections (A) and (B) above shall be construed
as a series of separate covenants, one for each city, county and state of any geographic area in the Territory. Except for geographic
coverage, each such separate covenant shall be deemed identical in terms to the covenant contained in subsections (A) and (B) above.
If, in any judicial or arbitral proceeding, a court or arbitrator refuses to enforce any of such separate covenants (or any part thereof),
then such unenforceable covenant (or such part) shall be revised, or if revision is not permitted it shall be eliminated from this Agreement,
to the extent necessary to permit the remaining separate covenants (or portions thereof) to be enforced. In the event that the provisions
of subsections (A) and (B) above are deemed to exceed the time, geographic or scope limitations permitted by applicable law,
then such provisions shall be reformed to the maximum time, geographic or scope limitations, as the case may be, then permitted by such
law. In the event that the applicable court or arbitrator does not exercise the power granted to it in the prior sentence, I and
the Company agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will
achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term.
| 9. | CONFLICT OF INTEREST GUIDELINES |
I agree to diligently adhere
to all policies of the Company, including the Company’s insider trading policies and the Company’s Conflict of Interest Guidelines.
A copy of the Company’s current Conflict of Interest Guidelines is attached as Exhibit D hereto, but I understand that
these Conflict of Interest Guidelines may be revised from time to time during my employment.
Without
limiting my obligations under Section 3.E above, I agree to execute any proper oath or verify any proper
document required to carry out the terms of this Agreement. I represent and warrant that my performance of all the terms of this Agreement
will not breach any agreement to keep in confidence information acquired by me in confidence or in trust prior to my employment by the
Company. I hereby represent and warrant that I have not entered into, and I will not enter into, any oral or written agreement in conflict
herewith.
I acknowledge that I have
no reasonable expectation of privacy in any Company Electronic Media Equipment or Company Electronic Media System. All information, data,
and messages created, received, sent, or stored in Company Electronic Media Equipment or Company Electronic Media Systems are, at all
times, the property of the Company. As such, the Company has the right to audit and search all such items and systems, without further
notice to me, to ensure that the Company is licensed to use the software on the Company’s devices in compliance with the Company’s
software licensing policies, to ensure compliance with the Company’s policies, and for any other business-related purposes in the
Company’s sole discretion. I understand that I am not permitted to add any unlicensed, unauthorized, or non-compliant applications
to the Company’s technology systems, including, without limitation, open source or free software not authorized by the Company,
and that I shall refrain from copying unlicensed software onto the Company’s technology systems or using non-licensed software or
websites. I understand that it is my responsibility to comply with the Company’s policies governing use of the Company’s documents
and the internet, email, telephone, and technology systems to which I will have access in connection with my employment. In addition,
as to any personal Electronic Media Equipment or personal Electronic Media Systems or other personal property that I have used for Company
purposes, I agree that the Company may have reasonable access, to such personal Electronic Media Equipment or personal Electronic
Media Systems or other personal property to review, retrieve, destroy, or ensure the permanent deletion of Company information from such
equipment or systems or property or take such other actions that are needed to protect the Company or Company property, as determined
by the Company reasonably and in good faith.
I am aware that the Company
has or may acquire software and systems that are capable of monitoring and recording all Company network traffic to and from any Company
Electronic Media Equipment or Company Electronic Media Systems. The Company reserves the right to access, review, copy, and delete any
of the information, data, or messages accessed through Company Electronic Media Equipment or Electronic Media Systems, with or without
notice to me and/or in my absence. This includes, but is not limited to, all e-mail messages sent or received, all website visits, all
chat sessions, all news group activity (including groups visited, messages read, and postings by me), and all file transfers into and
out of the Company’s internal networks. The Company further reserves the right to retrieve previously deleted messages from e-mail
or voicemail and monitor usage of the Internet, including websites visited and any information I have downloaded. In addition, the Company
may review Internet and technology systems activity and analyze usage patterns, and may choose to publicize this data to assure that technology
systems are devoted to legitimate business purposes.
| 12. | ARBITRATION AND EQUITABLE RELIEF |
A. Arbitration.
IN CONSIDERATION OF MY EMPLOYMENT WITH THE COMPANY, ITS PROMISE TO ARBITRATE ALL EMPLOYMENT-RELATED DISPUTES WITH ME, AND MY RECEIPT
OF COMPENSATION AND OTHER COMPANY BENEFITS, AT PRESENT AND IN THE FUTURE, I AGREE THAT ANY AND ALL CONTROVERSIES, CLAIMS, OR DISPUTES
THAT I MAY HAVE WITH THE COMPANY (INCLUDING ANY COMPANY EMPLOYEE, OFFICER, DIRECTOR, TRUSTEE, OR BENEFIT PLAN OF THE COMPANY, IN
THEIR CAPACITY AS SUCH OR OTHERWISE), ARISING OUT OF, RELATING TO, OR RESULTING FROM MY EMPLOYMENT OR RELATIONSHIP WITH THE COMPANY OR
THE TERMINATION OF MY EMPLOYMENT OR RELATIONSHIP WITH THE COMPANY, INCLUDING ANY BREACH OF THIS AGREEMENT, SHALL BE SUBJECT TO BINDING
ARBITRATION UNDER THE FEDERAL ARBITRATION ACT (THE “FAA”) AND THAT THE FAA, INCLUDING ITS PROCEDURAL PROVISIONS FOR COMPELLING
ARBITRATION, SHALL GOVERN AND APPLY TO THIS ARBITRATION AGREEMENT (INCLUDING COMPELLING ARBITRATION IN STATE OR FEDERAL COURT) WITH FULL
FORCE AND EFFECT. I FURTHER AGREE TO THE FULLEST EXTENT PERMITTED BY LAW THAT I MAY BRING ANY ARBITRATION PROCEEDING ONLY IN MY INDIVIDUAL
CAPACITY, AND NOT AS A PLAINTIFF, REPRESENTATIVE, OR CLASS MEMBER IN ANY PURPORTED CLASS, COLLECTIVE OR REPRESENTATIVE LAWSUIT, OR
PROCEEDING. TO THE FULLEST EXTENT PERMITTED BY LAW, I AGREE TO ARBITRATE ANY AND ALL COMMON LAW AND/OR STATUTORY CLAIMS UNDER
LOCAL, STATE, OR FEDERAL LAW, INCLUDING, BUT NOT LIMITED TO, CLAIMS UNDER TITLE VII OF THE CIVIL RIGHTS ACT OF 1964, THE AMERICANS
WITH DISABILITIES ACT OF 1990, THE AGE DISCRIMINATION IN EMPLOYMENT ACT OF 1967, THE OLDER WORKERS BENEFIT PROTECTION ACT, THE WORKER
ADJUSTMENT AND RETRAINING NOTIFICATION ACT, THE FAIR LABOR STANDARDS ACT, THE FAMILY AND MEDICAL LEAVE ACT, THE COLORADO CIVIL RIGHTS
LAWS, THE COLORADO WAGE LAW, THE COLORADO WAGE CLAIM ACT, CLAIMS RELATING TO EMPLOYMENT STATUS, CLAIMS RELATING TO COMPENSATION (CASH,
EQUITY, BONUS, OR OTHERWISE), CLAIMS RELATING TO CLASSIFICATION, AND CLAIMS OF HARASSMENT, DISCRIMINATION, WRONGFUL TERMINATION, AND BREACH
OF CONTRACT. TO THE FULLEST EXTENT PERMITTED BY LAW, I ALSO AGREE TO ARBITRATE ANY AND ALL DISPUTES ARISING OUT OF OR RELATING TO
THE INTERPRETATION OR APPLICATION OF THIS AGREEMENT TO ARBITRATE, BUT NOT DISPUTES ABOUT THE ENFORCEABILITY, REVOCABILITY, OR VALIDITY
OF THIS AGREEMENT TO ARBITRATE OR THE CLASS, COLLECTIVE, AND REPRESENTATIVE PROCEEDING WAIVER HEREIN. WITH RESPECT TO ALL SUCH CLAIMS
AND DISPUTES THAT I AGREE TO ARBITRATE, I HEREBY EXPRESSLY AGREE TO WAIVE, AND DO WAIVE, ANY RIGHT TO A TRIAL BY JURY. I FURTHER
UNDERSTAND THAT THIS AGREEMENT TO ARBITRATE ALSO APPLIES TO ANY DISPUTES THAT THE COMPANY MAY HAVE WITH ME. I UNDERSTAND THAT NOTHING
IN THIS AGREEMENT REQUIRES ME TO ARBITRATE CLAIMS THAT CANNOT BE ARBITRATED UNDER APPLICABLE LAW, SUCH AS SEXUAL ASSAULT DISPUTES AND
SEXUAL HARASSMENT DISPUTES AS DEFINED IN THE FAA OR CLAIMS UNDER THE SARBANES-OXLEY ACT.
B. Procedure.
I AGREE THAT ANY ARBITRATION WILL BE ADMINISTERED BY JAMS, PURSUANT TO ITS EMPLOYMENT ARBITRATION RULES & PROCEDURES (THE
“JAMS RULES”), WHICH ARE AVAILABLE AT http://www.jamsadr.com/rules-employment-arbitration/.
IF THE JAMS RULES CANNOT BE ENFORCED AS TO THE ARBITRATION, THEN THE PARTIES AGREE THAT THEY WILL ARBITRATE THIS DISPUTE UNDER THE
COL. REV. STAT. SECTION 13-22-201 ET SEQ. (THE “RULES”). I AGREE THAT THE ARBITRATOR SHALL HAVE THE POWER TO
DECIDE ANY MOTIONS BROUGHT BY ANY PARTY TO THE ARBITRATION, INCLUDING MOTIONS FOR SUMMARY JUDGMENT AND/OR ADJUDICATION, AND
MOTIONS TO DISMISS, APPLYING THE STANDARDS SET FORTH UNDER THE COLORADO RULES OF CIVIL PROCEDURE. I AGREE THAT THE ARBITRATOR SHALL
ISSUE A WRITTEN DECISION ON THE MERITS. I ALSO AGREE THAT THE ARBITRATOR SHALL HAVE THE POWER TO AWARD ANY REMEDIES AVAILABLE UNDER
APPLICABLE LAW, AND THAT THE ARBITRATOR MAY AWARD ATTORNEYS’ FEES AND COSTS TO THE PREVAILING PARTY, WHERE PERMITTED BY
APPLICABLE LAW. I AGREE THAT THE DECREE OR AWARD RENDERED BY THE ARBITRATOR MAY BE ENTERED AS A FINAL AND BINDING JUDGMENT IN
ANY COURT HAVING JURISDICTION THEREOF. I UNDERSTAND THAT THE COMPANY WILL PAY FOR ANY ADMINISTRATIVE OR HEARING FEES CHARGED BY THE
ARBITRATOR OR JAMS EXCEPT THAT I SHALL PAY ANY FILING FEES ASSOCIATED WITH ANY ARBITRATION THAT I INITIATE, BUT ONLY SO MUCH OF THE
FILING FEES AS I WOULD HAVE INSTEAD PAID HAD I FILED A COMPLAINT IN A COURT OF LAW THAT WOULD HAVE HAD JURISDICTION OVER SUCH
COMPLAINT. I AGREE THAT THE ARBITRATOR SHALL ADMINISTER AND CONDUCT ANY ARBITRATION IN ACCORDANCE WITH COLORADO LAW, INCLUDING
THE COLORADO RULES OF CIVIL PROCEDURE AND THE COLORADO RULES OF EVIDENCE, AND THAT THE ARBITRATOR SHALL APPLY SUBSTANTIVE AND
PROCEDURAL COLORADO LAW TO ANY DISPUTE OR CLAIM, WITHOUT REFERENCE TO RULES OF CONFLICT-OF-LAW. I AGREE THAT ANY ARBITRATION UNDER
THIS AGREEMENT SHALL BE CONDUCTED DENVER, COLORADO.
C. Remedy.
EXCEPT FOR THE PURSUIT OF ANY PROVISIONAL REMEDY, IF ANY, PERMITTED BY THE RULES OR OTHERWISE PROVIDED BY THIS AGREEMENT, I
AGREE THAT ARBITRATION SHALL BE THE SOLE, EXCLUSIVE, AND FINAL REMEDY FOR ANY DISPUTE BETWEEN THE COMPANY AND ME.
D. Administrative
Relief. I UNDERSTAND THAT THIS AGREEMENT DOES NOT PROHIBIT ME FROM PURSUING AN ADMINISTRATIVE CLAIM WITH A LOCAL, STATE, OR FEDERAL
ADMINISTRATIVE BODY OR GOVERNMENT AGENCY THAT IS AUTHORIZED TO ENFORCE OR ADMINISTER LAWS RELATED TO EMPLOYMENT, INCLUDING, BUT NOT
LIMITED TO, THE COLORADO CIVIL RIGHTS COMMISSION, THE EQUAL EMPLOYMENT OPPORTUNITY COMMISSION, THE NATIONAL LABOR RELATIONS BOARD, OR
THE WORKERS’ COMPENSATION BOARD. THIS AGREEMENT DOES, HOWEVER, PRECLUDE ME FROM PURSUING A COURT ACTION REGARDING ANY SUCH CLAIM,
EXCEPT AS PERMITTED BY LAW.
E. Voluntary
Nature of Agreement. I ACKNOWLEDGE AND AGREE THAT I AM EXECUTING THIS AGREEMENT VOLUNTARILY AND WITHOUT ANY DURESS OR UNDUE INFLUENCE
BY THE COMPANY OR ANYONE ELSE. I FURTHER ACKNOWLEDGE AND AGREE THAT I HAVE CAREFULLY READ THIS AGREEMENT AND THAT I HAVE ASKED ANY QUESTIONS
NEEDED FOR ME TO UNDERSTAND THE TERMS, CONSEQUENCES, AND BINDING EFFECT OF THIS AGREEMENT AND FULLY UNDERSTAND IT, INCLUDING THAT
I AM WAIVING MY RIGHT TO A JURY TRIAL. FINALLY, I AGREE THAT I HAVE BEEN PROVIDED AN OPPORTUNITY TO SEEK THE ADVICE
OF AN ATTORNEY OF MY CHOICE BEFORE SIGNING THIS AGREEMENT.
A. Governing
Law; Consent to Personal Jurisdiction. With the exception of the arbitration requirements set forth in Section 12 herein,
this Agreement will be governed by the laws of the State of Colorado without regard to Colorado’s conflicts-of-law rules that
may result in the application of the laws of any jurisdiction other than Colorado. To the extent that any lawsuit is permitted under this
Agreement, I hereby expressly consent to the personal and exclusive jurisdiction and venue of the state and federal courts located
in Colorado for any lawsuit filed against me by the Company.
B. Assignability.
This Agreement will be binding upon my heirs, executors, assigns, administrators, and other legal representatives, and will be for the
benefit of the Company, its successors, and its assigns. The Associated Third Parties are intended third-party beneficiaries to this Agreement
with respect to my obligations in Section 2.D. Notwithstanding anything to the contrary herein, the Company may assign this
Agreement and its rights and obligations under this Agreement to any successor to all, or substantially all, of the Company’s relevant
assets, whether by merger, consolidation, reorganization, reincorporation, sale of assets or stock, or otherwise. For the avoidance of
doubt, the Company’s successors and assigns are authorized to enforce the Company’s rights under this Agreement.
C. Entire
Agreement. This Agreement, together with the Exhibits herein and any executed written offer letter or employment agreement between
me and the Company, to the extent such materials are not in conflict with this Agreement, sets forth the entire agreement and understanding
between the Company and me with respect to the subject matter herein and supersedes all prior written and oral agreements, discussions,
or representations between us, including, but not limited to, any representations made during my interview(s) or relocation negotiations.
I represent and warrant that I am not relying on any statement or representation not contained in this Agreement. Any subsequent change
or changes in my duties, salary, compensation, conditions or any other terms of my employment will not affect the validity or scope of
this Agreement.
D. Headings.
Headings are used in this Agreement for reference only and shall not be considered when interpreting this Agreement.
E. Severability.
If a court or other body of competent jurisdiction finds, or the Parties mutually believe, any provision of this Agreement, or portion
thereof, to be invalid or unenforceable, such provision will be enforced to the maximum extent permissible so as to effect the intent
of the Parties, and the remainder of this Agreement will continue in full force and effect.
F. Modification,
Waiver. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, will be effective unless
in a writing signed by the President or CEO of the Company and me. Waiver by the Company of a breach of any provision of this Agreement
will not operate as a waiver of any other or subsequent breach.
G. Survivorship.
The rights and obligations of the Parties to this Agreement will survive termination of my employment with the Company.
| 14. | Protected Activity Not Prohibited |
I understand that nothing
in this Agreement limits or prohibits me from filing a charge or complaint with, or otherwise communicating or cooperating with or participating
in any investigation or proceeding that may be conducted by, any federal, state or local government agency or commission, including the
Securities and Exchange Commission, the Equal Employment Opportunity Commission, the Occupational Safety and Health Administration, and
the National Labor Relations Board (“Government Agencies”), including disclosing documents or other information as
permitted by law, without giving notice to, or receiving authorization from, the Company. Notwithstanding, in making any such disclosures
or communications, I agree to take all reasonable precautions to prevent any unauthorized use or disclosure of any information that
may constitute Company Confidential Information to any parties other than the Government Agencies. I further understand that I am not
permitted to disclose the Company’s attorney-client privileged communications or attorney work product. In addition, I hereby
acknowledge that the Company has provided me with notice in compliance with the Defend Trade Secrets Act of 2016 regarding immunity from
liability for limited disclosures of trade secrets. The full text of the notice is attached in Exhibit B.
SIGNATURE PAGE OF TRISALUS LIFE SCIENCES, INC.’S
AT-WILL EMPLOYMENT, CONFIDENTIAL INFORMATION, INVENTION ASSIGNMENT, AND ARBITRATION AGREEMENT
Date: |
2/9/23 |
|
/s/James Alecxih |
|
|
|
Signature |
|
|
|
|
|
|
|
James Alecxih |
|
|
|
Name of Employee (typed or printed) |
|
|
|
|
Date: |
|
|
|
|
|
|
Signature |
|
|
|
|
|
|
|
|
|
|
|
Name of Witness (typed or printed) |
EXHIBIT A
LIST OF PRIOR INVENTIONS
AND ORIGINAL WORKS OF AUTHORSHIP
[**]
EXHIBIT B
SECTION 7 OF THE DEFEND TRADE SECRETS ACT
OF 2016
“ . . . An individual shall not be held
criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that—(A) is made—(i) in
confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for
the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in
a lawsuit or other proceeding, if such filing is made under seal An individual who files a lawsuit for retaliation by an employer for
reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information
in the court proceeding, if the individual—(A) files any document containing the trade secret under seal; and (B) does
not disclose the trade secret, except pursuant to court order.”
EXHIBIT C
TRISALUS LIFE SCIENCES TERMINATION CERTIFICATION
This is to certify that I
do not have in my possession, nor have I failed to return, any devices, records, data, notes, reports, proposals, lists, correspondence,
specifications, drawings, blueprints, sketches, materials, equipment, any other documents or property, or reproductions of any and all
aforementioned items belonging to TriSalus Life Sciences, Inc. (the “Company”). Notwithstanding the foregoing, I
understand that I may keep a copy of the Company’s employee handbook.
I further certify that I have
complied with all the terms of the Company’s At-Will Employment, Confidential Information, Invention Assignment, and Arbitration
Agreement (the “Agreement”) signed by me, including the reporting of any inventions and original works of authorship
(as defined therein) conceived or made by me (solely or jointly with others), as covered by that Agreement.
I understand that pursuant
to the Agreement, and subject to its protected activity exclusion, I am obligated to preserve, as confidential, all Company
Confidential Information and Associated Third Party Confidential Information, including trade secrets, confidential knowledge, data, or
other proprietary information relating to products, processes, know-how, designs, formulas, developmental or experimental work, computer
programs, databases, other original works of authorship, customer lists, business plans, financial information, or other subject matter
pertaining to any business of the Company or any of its employees, clients, consultants, or licensees. I understand that I am obligated
to comply, and confirm that I agree to comply, with any and all other continuing obligations to the Company as set forth in the Agreement.
After leaving the Company’s
employment, I will be employed by _________________________________________ in the position of _______________________.
Date: |
|
|
/s/ James Alecxih |
|
|
|
Signature |
|
|
|
|
|
|
|
|
|
|
|
Name of Employee (typed or printed) |
EXHIBIT D
TRISALUS LIFE SCIENCES, INC. CONFLICT OF
INTEREST GUIDELINES
It is the policy of TriSalus
Life Sciences, Inc. (the “Company”), to conduct its affairs in strict compliance with the letter and spirit of
the law and to adhere to the highest principles of business ethics. Accordingly, all officers, employees, and independent contractors
must avoid activities that are in conflict, or give the appearance of being in conflict, with these principles and with the interests
of the Company. The following are potentially compromising situations that must be avoided:
1. Revealing
confidential information to outsiders or misusing confidential information. Unauthorized divulging of information is a violation of this
policy whether or not for personal gain and whether or not harm to the Company is intended. (The At-Will Employment, Confidential Information, Invention
Assignment, and Arbitration Agreement elaborates on this principle and is a binding agreement.)
2. Accepting
or offering substantial gifts, excessive entertainment, favors, or payments that may be deemed to constitute undue influence or otherwise
be improper or embarrassing to the Company.
3. Participating
in civic or professional organizations that might involve divulging confidential information of the Company.
4. Initiating
or approving personnel actions affecting reward or punishment of employees or applicants where there is a family relationship or is, or
appears to be, a personal or social involvement.
5. Initiating or approving any form of personal or social harassment of employees.
6. Investing
or holding outside directorship in suppliers, customers, or competing companies, including financial speculations, where such investment
or directorship might influence in any manner a decision or course of action of the Company.
7. Borrowing from or lending to employees, customers, or suppliers.
8. Acquiring real estate of interest to the Company.
9. Improperly
using or disclosing to the Company any proprietary information or trade secrets of any other employer or other person or entity with whom
obligations of confidentiality exist.
10. Unlawfully
discussing prices, costs, customers, sales, or markets with competing companies or their employees.
11. Making any unlawful agreement with distributors with respect to prices.
12. Improperly
using or authorizing the use of any inventions that are the subject of patent claims of any other person or entity.
13. Engaging in any conduct that is not in the best interest of the Company.
Each officer, employee, and
independent contractor must take every necessary action to ensure compliance with these guidelines and to bring problem areas to the attention
of higher management for review. Violations of this conflict of interest policy may result in immediate termination of employment.
Nothing in these guidelines
is intended to limit employees’ rights to discuss the terms, wages, and working conditions of their employment, as protected by
applicable law, including any rights an employee may have under Section 7 of the National Labor Relations Act. Also, nothing in these
guidelines limits or prohibits employees from filing a charge or complaint with, or otherwise communicating or cooperating with or participating
in any investigation or proceeding that may be conducted by, any federal, state or local government agency or commission, including the
Securities and Exchange Commission, the Equal Employment Opportunity Commission, the Occupational Safety and Health Administration, and
the National Labor Relations Board (“Government Agencies”), including disclosing documents or other information as
permitted by law, without giving notice to, or receiving authorization from, the Company. Notwithstanding, in making any such disclosures
or communications, employees must take all reasonable precautions to prevent any unauthorized use or disclosure of any information that
may constitute Company Confidential Information to any parties other than the Government Agencies. Employees may not disclose the Company’s
attorney-client privileged communications or attorney work product.
Exhibit 10.15
SUREFIRE MEDICAL, INC.
2009 EQUITY INCENTIVE PLAN
AS AMENDED
| 1. | Purposes of the Plan. The purposes of this Plan are: |
| ● | to attract and retain the best available personnel for positions of substantial responsibility, |
| ● | to provide additional incentive to Employees, Directors and Consultants, and |
| ● | to promote the success of the Company’s business. |
The Plan permits the grant of Incentive Stock Options,
Nonstatutory Stock Options, Stock Appreciation Rights, Restricted Stock and Restricted Stock Units.
| 2. | Definitions. As used herein, the following definitions will apply: |
(a) “Administrator”
means the Board or any of its Committees as will be administering the Plan, in accordance with Section 4 of the Plan.
(b) “Applicable
Laws” means the requirements relating to the administration of equity-based awards under U.S. state corporate laws, U.S. federal
and state securities laws, the Code, any stock exchange or quotation system on which the Common Stock is listed or quoted and the applicable
laws of any foreign country or jurisdiction where Awards are, or will be, granted under the Plan.
(c) “Award”
means, individually or collectively, a grant under the Plan of Options, Stock Appreciation Rights, Restricted Stock, or Restricted Stock
Units.
(d) “Award
Agreement” means the written or electronic agreement setting forth the terms and provisions applicable to each Award granted
under the Plan. The Award Agreement is subject to the terms and conditions of the Plan.
| (e) | “Board” means the Board of Directors of the Company. |
| (f) | “Change in Control” means the occurrence of any of the following events: |
(i) Change
in Ownership of the Company. A change in the ownership of the Company which occurs on the date that any one person, or more than one
person acting as a group (“Person”), acquires ownership of the stock of the Company that, together with the stock held by
such Person, constitutes more than 50% of the total voting power of the stock of the Company, except that any change in the ownership
of the stock of the Company as a result of a private financing of the Company that is approved by the Board will not be considered a Change
in Control; or
(ii) Change
in Effective Control of the Company. If the Company has a class of securities registered pursuant to Section 12 of the Exchange
Act, a change in the effective control of the Company which occurs on the date that a majority of members of the Board is replaced during
any twelve (12) month period by Directors whose appointment or election is not endorsed by a majority of the members of the Board prior
to the date of the appointment or election. For purposes of this clause (ii), if any Person is considered to be in effective control of
the Company, the acquisition of additional control of the Company by the same Person will not be considered a Change in Control; or
(iii) Change
in Ownership of a Substantial Portion of the Company’s Assets. A change in the ownership of a substantial portion of the Company’s
assets which occurs on the date that any Person acquires (or has acquired during the twelve (12) month period ending on the date of the
most recent acquisition by such person or persons) assets from the Company that have a total gross fair market value equal to or more
than 50% of the total gross fair market value of all of the assets of the Company immediately prior to such acquisition or acquisitions.
For purposes of this subsection (iii), gross fair market value means the value of the assets of the Company, or the value of the assets
being disposed of, determined without regard to any liabilities associated with such assets.
For purposes of this Section 2(f),
persons will be considered to be acting as a group if they are owners of a corporation that enters into a merger, consolidation, purchase
or acquisition of stock, or similar business transaction with the Company.
Notwithstanding the foregoing,
a transaction will not be deemed a Change in Control unless the transaction qualifies as a change in control event within the meaning
of Code Section 409A, as it has been and may be amended from time to time, and any proposed or final Treasury Regulations and Internal
Revenue Service guidance that has been promulgated or may be promulgated thereunder from time to time.
Further and for the
avoidance of doubt, a transaction will not constitute a Change in Control if: (i) its sole purpose is to change the state of
the Company’s incorporation, or (ii) its sole purpose is to create a holding company that will be owned in substantially
the same proportions by the persons who held the Company’s securities immediately before such transaction.
(g) “Code”
means the Internal Revenue Code of 1986, as amended. Any reference to a section of the Code herein will be a reference to any successor
or amended section of the Code.
(h) “Committee”
means a committee of Directors or of other individuals satisfying Applicable Laws appointed by the Board, or by the compensation committee
of the Board, in accordance with Section 4 hereof.
| (i) | “Common Stock” means the common stock of the Company. |
| (j) | “Company” means Surefire Medical, Inc., a Delaware corporation, or any successor thereto. |
(k) “Consultant”
means any person, including an advisor, engaged by the Company or a Parent or Subsidiary to render services to such entity.
| (l) | “Director” means a member of the Board. |
(m) “Disability”
means total and permanent disability as defined in Code Section 22(e)(3), provided that in the case of Awards other than Incentive
Stock Options, the Administrator in its discretion may determine whether a permanent and total disability exists in accordance with uniform
and non-discriminatory standards adopted by the Administrator from time to time.
(n) “Employee”
means any person, including officers and Directors, employed by the Company or any Parent or Subsidiary of the Company. Neither service
as a Director nor payment of a director’s fee by the Company will be sufficient to constitute “employment” by the Company.
| (o) | “Exchange Act” means the Securities Exchange Act of 1934, as amended. |
(p) “Exchange
Program” means a program under which (i) outstanding Awards are surrendered or cancelled in exchange for Awards of the
same type (which may have higher or lower exercise prices and different terms), Awards of a different type, and/or cash, (ii) Participants
would have the opportunity to transfer any outstanding Awards to a financial institution or other person or entity selected by the Administrator,
and/or (iii) the exercise price of an outstanding Award is reduced or increased. The Administrator will determine the terms and conditions
of any Exchange Program in its sole discretion.
(q) “Fair
Market Value” means, as of any date, the value of Common Stock determined as follows:
(i) If
the Common Stock is listed on any established stock exchange or a national market system, including without limitation the Nasdaq Global
Select Market, the Nasdaq Global Market or the Nasdaq Capital Market of The Nasdaq Stock Market, its Fair Market Value will be the closing
sales price for such stock (or the closing bid, if no sales were reported) as quoted on such exchange or system on the day of determination,
as reported in The Wall Street Journal or such other source as the Administrator deems reliable;
(ii) If
the Common Stock is regularly quoted by a recognized securities dealer but selling prices are not reported, the Fair Market Value of a
Share will be the mean between the high bid and low asked prices for the Common Stock on the day of determination (or, if no bids and
asks were reported on that date, as applicable, on the last trading date such bids and asks were reported), as reported in The Wall
Street Journal or such other source as the Administrator deems reliable; or
(iii) In
the absence of an established market for the Common Stock, the Fair Market Value will be determined in good faith by the Administrator.
(r) “Incentive
Stock Option” means an Option that by its terms qualifies and is otherwise intended to qualify as an incentive stock option
within the meaning of Code Section 422 and the regulations promulgated thereunder.
(s) “Nonstatutory
Stock Option” means an Option that by its terms does not qualify or is not intended to qualify as an Incentive Stock Option.
| (t) | “Option” means a stock option granted pursuant to the Plan. |
(u) “Parent”
means a “parent corporation,” whether now or hereafter existing, as defined in Code Section 424(e).
| (v) | “Participant” means the holder of an outstanding Award. |
(w) “Period
of Restriction” means the period during which the transfer of Shares of Restricted Stock are subject to restrictions and therefore,
the Shares are subject to a substantial risk of forfeiture. Such restrictions may be based on the passage of time, the achievement of
target levels of performance, or the occurrence of other events as determined by the Administrator.
| (x) | “Plan” means this 2009 Equity Incentive Plan. |
(y) “Restricted
Stock” means Shares issued pursuant to an Award of Restricted Stock under Section 8 of the Plan, or issued pursuant to
the early exercise of an Option.
(z) “Restricted
Stock Unit” means a bookkeeping entry representing an amount equal to the Fair Market Value of one Share, granted pursuant to
Section 9. Each Restricted Stock Unit represents an unfunded and unsecured obligation of the Company.
(aa) “Service
Provider” means an Employee, Director or Consultant.
(bb) “Share”
means a share of the Common Stock, as adjusted in accordance with Section 13 of the Plan.
(cc) “Stock Appreciation Right”
means an Award, granted alone or in connection with an Option, that pursuant to Section 7 is designated as a Stock Appreciation Right.
(dd) “Subsidiary” means a “subsidiary
corporation,” whether now or hereafter existing, as defined in Code Section 424(f).
| 3. | Stock Subject to the Plan. |
(a) Stock
Subject to the Plan. Subject to the provisions of Section 13 of the Plan, the maximum aggregate number of Shares that may be
subject to Awards and sold under the Plan is 28,101,979 Shares. The Shares may be authorized but unissued, or reacquired Common
Stock.
(b) Lapsed
Awards. If an Award expires or becomes unexercisable without having been exercised in full, is surrendered pursuant to an
Exchange Program, or, with respect to Restricted Stock or Restricted Stock Units, is forfeited to or repurchased by the Company due
to the failure to vest, the unpurchased Shares (or for Awards other than Options or Stock Appreciation Rights the forfeited or
repurchased Shares) which were subject thereto will become available for future grant or sale under the Plan (unless the Plan has
terminated). With respect to Stock Appreciation Rights, only Shares actually issued pursuant to a Stock Appreciation Right will
cease to be available under the Plan; all remaining Shares under Stock Appreciation Rights will remain available for future grant or
sale under the Plan (unless the Plan has terminated). Shares that have actually been issued under the Plan under any Award will not
be returned to the Plan and will not become available for future distribution under the Plan; provided, however, that if Shares
issued pursuant to Awards of Restricted Stock or Restricted Stock Units are repurchased by the Company or are forfeited to the
Company due to the failure to vest, such Shares will become available for future grant under the Plan. Shares used to pay the
exercise price of an Award or to satisfy the tax withholding obligations related to an Award will become available for future grant
or sale under the Plan. To the extent an Award under the Plan is paid out in cash rather than Shares, such cash payment will not
result in reducing the number of Shares available for issuance under the Plan. Notwithstanding the foregoing and, subject to
adjustment as provided in Section 13, the maximum number of Shares that may be issued upon the exercise of Incentive Stock
Options will equal the aggregate Share number stated in Section 3(a), plus, to the extent allowable under Code Section 422
and the Treasury Regulations promulgated thereunder, any Shares that become available for issuance under the Plan pursuant to
Section 3(b).
(c) Share
Reserve. The Company, during the term of this Plan, will at all times reserve and keep available such number of Shares as will be
sufficient to satisfy the requirements of the Plan.
| 4. | Administration of the Plan. |
(i) Multiple
Administrative Bodies. Different Committees with respect to different groups of Service Providers may administer the Plan.
(ii) Other
Administration. Other than as provided above, the Plan will be administered by (A) the Board or (B) a Committee, which Committee
will be constituted to satisfy Applicable Laws.
(b) Powers
of the Administrator. Subject to the provisions of the Plan, and in the case of a Committee, subject to the specific duties delegated
by the Board to such Committee, the Administrator will have the authority, in its discretion:
| (i) | to determine the Fair Market Value; |
| (ii) | to select the Service Providers to whom Awards may be granted hereunder; |
| (iii) | to determine the number of Shares to be covered by each Award |
| (iv) | to approve forms of Award Agreements for use under the Plan; |
(v) to
determine the terms and conditions, not inconsistent with the terms of the Plan, of any Award granted hereunder. Such terms and conditions
include, but are not limited to, the exercise price, the time or times when Awards may be exercised (which may be based on performance
criteria), any vesting acceleration or waiver of forfeiture restrictions, and any restriction or limitation regarding any Award or the
Shares relating thereto, based in each case on such factors as the Administrator will determine;
(vi) to
institute and determine the terms and conditions of an Exchange Program;
(vii) to
construe and interpret the terms of the Plan and Awards granted pursuant to the Plan;
(viii) to
prescribe, amend and rescind rules and regulations relating to the Plan, including rules and regulations relating to sub-plans
established for the purpose of satisfying applicable foreign laws or for qualifying for favorable tax treatment under applicable foreign
laws;
(ix) to
modify or amend each Award (subject to Section 18(c) of the Plan), including but not limited to the discretionary authority
to extend the post-termination exercisability period of Awards and to extend the maximum term of an Option (subject to Section 6(d));
(x)
to allow Participants to satisfy withholding tax obligations in a manner prescribed in Section 14;
(xi) to
authorize any person to execute on behalf of the Company any instrument required to effect the grant of an Award previously granted by
the Administrator;
(xii) to
allow a Participant to defer the receipt of the payment of cash or the delivery of Shares that otherwise would be due to such Participant
under an Award; and
(xiii) to
make all other determinations deemed necessary or advisable for administering the Plan.
(c) Effect
of Administrator’s Decision. The Administrator’s decisions, determinations and interpretations will be final and binding
on all Participants and any other holders of Awards.
5. Eligibility.
Nonstatutory Stock Options, Stock Appreciation Rights, Restricted Stock, and Restricted Stock Units may be granted to Service Providers.
Incentive Stock Options may be granted only to Employees.
(a) Grant
of Options. Subject to the terms and provisions of the Plan, the Administrator, at any time and from time to time, may grant Options
in such amounts as the Administrator, in its sole discretion, will determine.
(b) Option
Agreement. Each Award of an Option will be evidenced by an Award Agreement that will specify the exercise price, the term of the Option,
the number of Shares subject to the Option, the exercise restrictions, if any, applicable to the Option, and such other terms and conditions
as the Administrator, in its sole discretion, will determine.
(c) Limitations.
Each Option will be designated in the Award Agreement as either an Incentive Stock Option or a Nonstatutory Stock Option. Notwithstanding
such designation, however, to the extent that the aggregate Fair Market Value of the Shares with respect to which Incentive Stock Options
are exercisable for the first time by the Participant during any calendar year (under all plans of the Company and any Parent or Subsidiary)
exceeds one hundred thousand dollars ($100,000), such Options will be treated as Nonstatutory Stock Options. For purposes of this Section 6(c), Incentive
Stock Options will be taken into account in the order in which they were granted, the Fair Market Value of the Shares will be determined
as of the time the Option with respect to such Shares is granted, and calculation will be performed in accordance with Code Section 422
and Treasury Regulations promulgated thereunder.
(d) Term
of Option. The term of each Option will be stated in the Award Agreement; provided, however, that the term will be no more than ten
(10) years from the date of grant thereof. In the case of an Incentive Stock Option granted to a Participant who, at the time the
Incentive Stock Option is granted, owns stock representing more than ten percent (10%) of the total combined voting power of all classes
of stock of the Company or any Parent or Subsidiary, the term of the Incentive Stock Option will be five (5) years from the date
of grant or such shorter term as may be provided in the Award Agreement.
| (e) | Option Exercise Price and Consideration. |
(i) Exercise
Price. The per Share exercise price for the Shares to be issued pursuant to the exercise of an Option will be determined by the Administrator,
but will be no less than one hundred percent (100%) of the Fair Market Value per Share on the date of grant. In addition, in the case
of an Incentive Stock Option granted to an Employee who owns stock representing more than ten percent (10%) of the voting power of all
classes of stock of the Company or any Parent or Subsidiary, the per Share exercise price will be no less than one hundred ten percent
(110%) of the Fair Market Value per Share on the date of grant. Notwithstanding the foregoing provisions of this Section 6(e)(i),
Options may be granted with a per Share exercise price of less than one hundred percent (100%) of the Fair Market Value per Share on the
date of grant pursuant to a transaction described in, and in a manner consistent with, Code Section 424(a).
(ii) Waiting
Period and Exercise Dates. At the time an Option is granted, the Administrator will fix the period within which the Option may be
exercised and will determine any conditions that must be satisfied before the Option may be exercised.
(iii) Form of
Consideration. The Administrator will determine the acceptable form of consideration for exercising an Option, including the
method of payment. In the case of an Incentive Stock Option, the Administrator will determine the acceptable form of consideration
at the time of grant. Such consideration may consist entirely of: (1) cash; (2) check; (3) promissory note, to the
extent permitted by Applicable Laws, (4) other Shares, provided that such Shares have a Fair Market Value on the date of
surrender equal to the aggregate exercise price of the Shares as to which such Option will be exercised and provided further that
accepting such Shares will not result in any adverse accounting consequences to the Company, as the Administrator determines in its
sole discretion; (5) consideration received by the Company under cashless exercise program (whether through a broker or
otherwise) implemented by the Company in connection with the Plan; (6) by net exercise, (7) such other consideration and
method of payment for the issuance of Shares to the extent permitted by Applicable Laws, or (8) any combination of the
foregoing methods of payment. In making its determination as to the type of consideration to accept, the Administrator will consider
if acceptance of such consideration may be reasonably expected to benefit the Company.
(i) Procedure
for Exercise; Rights as a Stockholder. Any Option granted hereunder will be exercisable according to the terms of the Plan and at
such times and under such conditions as determined by the Administrator and set forth in the Award Agreement. An Option may not be exercised
for a fraction of a Share.
An Option will be deemed exercised
when the Company receives: (i) notice of exercise (in such form as the Administrator may specify from time to time) from the
person entitled to exercise the Option, and (ii) full payment for the Shares with respect to which the Option is exercised
(together with applicable tax withholding). Full payment may consist of any consideration and method of payment authorized by the
Administrator and permitted by the Award Agreement and the Plan. Shares issued upon exercise of an Option will be issued in the name
of the Participant or, if requested by the Participant, in the name of the Participant and his or her spouse. Until the Shares are
issued (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), no
right to vote or receive dividends or any other rights as a stockholder will exist with respect to the Shares subject to an Option,
notwithstanding the exercise of the Option. The Company will issue (or cause to be issued) such Shares promptly after the Option is
exercised. No adjustment will be made for a dividend or other right for which the record date is prior to the date the Shares are
issued, except as provided in Section 13 of the Plan.
Exercising an Option in any
manner will decrease the number of Shares thereafter available, both for purposes of the Plan and for sale under the Option, by the number
of Shares as to which the Option is exercised.
(ii) Termination
of Relationship as a Service Provider. If a Participant ceases to be a Service Provider, other than upon the Participant’s termination
as the result of the Participant’s death or Disability, the Participant may exercise his or her Option within thirty (30) days of
termination, or such alternative period of time as is specified in the Award Agreement (but in no event later than the expiration of the
term of such Option as set forth in the Award Agreement) to the extent that the Option is vested on the date of termination. Unless otherwise
provided by the Administrator, if on the date of termination the Participant is not vested as to his or her entire Option, the Shares
covered by the unvested portion of the Option will revert to the Plan as of the date such Option expires (but in no event will such unvested
portion of the Option vest after such termination unless otherwise provided by the Administrator). If after termination the Participant
does not exercise his or her Option within the time specified by the Administrator, the Option will terminate, and the Shares covered
by such Option will revert to the Plan.
(iii) Disability
of Participant. If a Participant ceases to be a Service Provider as a result of the Participant’s Disability, the
Participant may exercise his or her Option within six (6) months of termination, or such alternative period of time as
is specified in the Award Agreement (but in no event later than the expiration of the term of such Option as set forth in the Award
Agreement) to the extent the Option is vested on the date of termination. Unless otherwise provided by the Administrator, if on the
date of termination the Participant is not vested as to his or her entire Option, the Shares covered by the unvested portion of the
Option will revert to the Plan as of the date such Option expires (but in no event will such unvested portion of the Option vest
after such termination unless otherwise provided by the Administrator). If after termination the Participant does not exercise his
or her Option within the time specified herein, the Option will terminate, and the Shares covered by such Option will revert to the
Plan.
(iv) Death
of Participant. If a Participant dies while a Service Provider, the Option may be exercised within six (6) months following the
Participant’s death, or within such longer period of time as is specified in the Award Agreement (but in no event later than the
expiration of the term of such Option as set forth in the Award Agreement) to the extent that the Option is vested on the date of death,
by the Participant’s designated beneficiary, provided such beneficiary has been designated prior to the Participant’s death
in a form acceptable to the Administrator. If no such beneficiary has been designated by the Participant, then such Option may be exercised
by the personal representative of the Participant’s estate or by the person(s) to whom the Option is transferred pursuant to
the Participant’s will or in accordance with the laws of descent and distribution. Unless otherwise provided by the Administrator,
if at the time of death Participant is not vested as to his or her entire Option, the Shares covered by the unvested portion of the Option
will immediately revert to the Plan as of the date such Option expires (but in no event will such unvested portion of the Option vest
after such termination unless otherwise provided by the Administrator). If the Option is not so exercised within the time specified herein,
the Option will terminate, and the Shares covered by such Option will revert to the Plan.
| 7. | Stock Appreciation Rights. |
(a) Grant
of Stock Appreciation Rights. Subject to the terms and conditions of the Plan, a Stock Appreciation Right may be granted to Service
Providers at any time and from time to time as will be determined by the Administrator, in its sole discretion.
(b) Number
of Shares. The Administrator will have complete discretion to determine the number of Shares subject to any Award of Stock Appreciation
Rights.
(c) Exercise
Price and Other Terms. The per Share exercise price for the Shares that will determine the amount of the payment to be received upon
exercise of a Stock Appreciation Right as set forth in Section 7(f) will be determined by the Administrator and will be no less
than one hundred percent (100%) of the Fair Market Value per Share on the date of grant. Otherwise, the Administrator, subject to the
provisions of the Plan, will have complete discretion to determine the terms and conditions of Stock Appreciation Rights granted under
the Plan.
(d) Stock
Appreciation Right Agreement. Each Stock Appreciation Right grant will be evidenced by an Award Agreement that will specify the exercise
price, the term of the Stock Appreciation Right, the conditions of exercise, and such other terms and conditions as the Administrator,
in its sole discretion, will determine.
(e) Expiration
of Stock Appreciation Rights. A Stock Appreciation Right granted under the Plan will expire upon the date determined by the Administrator,
in its sole discretion, and set forth in the Award Agreement. Notwithstanding the foregoing, the rules of Section 6(d) relating
to the maximum term and Section 6(f) relating to exercise also will apply to Stock Appreciation Rights.
(f) Payment
of Stock Appreciation Right Amount. Upon exercise of a Stock Appreciation Right, a Participant will be entitled to receive payment
from the Company in an amount determined by multiplying:
(i) The
difference between the Fair Market Value of a Share on the date of exercise over the exercise price; times
| (ii) | The number of Shares with respect to which the Stock Appreciation Right is exercised. |
At the discretion of the Administrator, the payment
upon Stock Appreciation Right exercise may be in cash, in Shares of equivalent value, or in some combination thereof.
(a) Grant
of Restricted Stock. Subject to the terms and provisions of the Plan, the Administrator, at any time and from time to time, may grant
Shares of Restricted Stock to Service Providers in such amounts as the Administrator, in its sole discretion, will determine.
(b) Restricted
Stock Agreement. Each Award of Restricted Stock will be evidenced by an Award Agreement that will specify the Period of Restriction,
the number of Shares granted, and such other terms and conditions as the Administrator, in its sole discretion, will determine. Unless
the Administrator determines otherwise, the Company as escrow agent will hold Shares of Restricted Stock until the restrictions on such
Shares have lapsed.
(c) Transferability.
Except as provided in this Section 8 or as the Administrator determines, Shares of Restricted Stock may not be sold, transferred,
pledged, assigned, or otherwise alienated or hypothecated until the end of the applicable Period of Restriction.
(d) Other
Restrictions. The Administrator, in its sole discretion, may impose such other restrictions on Shares of Restricted Stock as it may
deem advisable or appropriate.
(e) Removal
of Restrictions. Except as otherwise provided in this Section 8, Shares of Restricted Stock covered by each Restricted Stock
grant made under the Plan will be released from escrow as soon as practicable after the last day of the Period of Restriction or at such
other time as the Administrator may determine. The Administrator, in its discretion, may accelerate the time at which any restrictions
will lapse or be removed.
(f) Voting
Rights. During the Period of Restriction, Service Providers holding Shares of Restricted Stock granted hereunder may exercise full
voting rights with respect to those Shares, unless the Administrator determines otherwise.
(g) Dividends
and Other Distributions. During the Period of Restriction, Service Providers holding Shares of Restricted Stock will be entitled to
receive all dividends and other distributions paid with respect to such Shares, unless the Administrator provides otherwise. If any such
dividends or distributions are paid in Shares, the Shares will be subject to the same restrictions on transferability and forfeitability
as the Shares of Restricted Stock with respect to which they were paid.
(h) Return
of Restricted Stock to Company. On the date set forth in the Award Agreement, the Restricted Stock for which restrictions have not
lapsed will revert to the Company and again will become available for grant under the Plan.
| 9. | Restricted Stock Units. |
(a) Grant.
Restricted Stock Units may be granted at any time and from time to time as determined by the Administrator. After the Administrator determines
that it will grant Restricted Stock Units, it will advise the Participant in an Award Agreement of the terms, conditions, and restrictions
related to the grant, including the number of Restricted Stock Units.
(b) Vesting
Criteria and Other Terms. The Administrator will set vesting criteria in its discretion, which, depending on the extent to which the
criteria are met, will determine the number of Restricted Stock Units that will be paid out to the Participant. The Administrator may
set vesting criteria based upon the achievement of Company-wide, business unit, or individual goals (including, but not limited to, continued
employment or service), or any other basis determined by the Administrator in its discretion.
(c) Earning
Restricted Stock Units. Upon meeting the applicable vesting criteria, the Participant will be entitled to receive a payout as determined
by the Administrator. Notwithstanding the foregoing, at any time after the grant of Restricted Stock Units, the Administrator, in its
sole discretion, may reduce or waive any vesting criteria that must be met to receive a payout.
(d) Form and
Timing of Payment. Payment of earned Restricted Stock Units will be made as soon as practicable after the date(s) determined
by the Administrator and set forth in the Award Agreement. The Administrator, in its sole discretion, may settle earned Restricted Stock
Units in cash, Shares, or a combination of both.
(e) Cancellation.
On the date set forth in the Award Agreement, all unearned Restricted Stock Units will be forfeited to the Company.
10. Compliance
With Code Section 409A. Awards will be designed and operated in such a manner that they are either exempt from the application
of, or comply with, the requirements of Code Section 409A, except as otherwise determined in the sole discretion of the Administrator.
The Plan and each Award Agreement under the Plan is intended to meet the requirements of Code Section 409A and will be construed
and interpreted in accordance with such intent, except as otherwise determined in the sole discretion of the Administrator. To the extent
that an Award or payment, or the settlement or deferral thereof, is subject to Code Section 409A the Award will be granted, paid,
settled or deferred in a manner that will meet the requirements of Code Section 409A, such that the grant, payment, settlement or
deferral will not be subject to the additional tax or interest applicable under Code Section 409A.
11. Leaves
of Absence/Transfer Between Locations. Unless the Administrator provides otherwise, vesting of Awards granted hereunder will be suspended
during any unpaid leave of absence. A Participant will not cease to be an Employee in the case of (i) any leave of absence approved
by the Company or (ii) transfers between locations of the Company or between the Company, its Parent, or any Subsidiary. For purposes
of Incentive Stock Options, no such leave may exceed three (3) months, unless reemployment upon expiration of such leave is guaranteed
by statute or contract. If reemployment upon expiration of a leave of absence approved by the Company is not so guaranteed, then six (6) months
following the first (1st) day of such leave, any Incentive Stock Option held by the Participant will cease to be treated as an Incentive
Stock Option and will be treated for tax purposes as a Nonstatutory Stock Option.
| 12. | Limited Transferability of Awards. |
(a) Unless
determined otherwise by the Administrator, Awards may not be sold, pledged, assigned, hypothecated, or otherwise transferred in any manner
other than by will or by the laws of descent and distribution, and may be exercised, during the lifetime of the Participant, only by the
Participant. If the Administrator makes an Award transferable, such Award may only be transferred (i) by will, (ii) by the laws
of descent and distribution, or (iii) as permitted by Rule 701 of the Securities Act of 1933, as amended (the “Securities
Act”).
(b) Further,
until the Company becomes subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act, or after the Administrator
determines that it is, will, or may no longer be relying upon the exemption from registration under the Exchange Act as set forth in Rule 12h-1(f) promulgated
under the Exchange Act, an Option, or prior to exercise, the Shares subject to the Option, may not be pledged, hypothecated or otherwise
transferred or disposed of, in any manner, including by entering into any short position, any “put equivalent position” or
any “call equivalent position” (as defined in Rule 16a-1(h) and Rule 16a-1(b) of the Exchange Act, respectively),
other than to (i) persons who are “family members” (as defined in Rule 701(c)(3) of the Securities Act) through
gifts or domestic relations orders, or (ii) to an executor or guardian of the Participant upon the death or disability of the Participant.
Notwithstanding the foregoing sentence, the Administrator, in its sole discretion, may determine to permit transfers to the Company or
in connection with a Change in Control or other acquisition transactions involving the Company to the extent permitted by Rule 12h-1(f).
| 13. | Adjustments; Dissolution or Liquidation; Merger or Change in Control. |
(a) Adjustments.
In the event that any dividend or other distribution (whether in the form of cash, Shares, other securities, or other property), recapitalization,
stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase, or exchange of Shares
or other securities of the Company, or other change in the corporate structure of the Company affecting the Shares occurs, the Administrator,
in order to prevent diminution or enlargement of the benefits or potential benefits intended to be made available under the Plan, will
adjust the number and class of Shares that may be delivered under the Plan and/or the number, class, and price of Shares covered by each
outstanding Award; provided, however, that the Administrator will make such adjustments to an Award required by Section 25102(o) of
the California Corporations Code to the extent the Company is relying upon the exemption afforded thereby with respect to the Award.
(b) Dissolution
or Liquidation. In the event of the proposed dissolution or liquidation of the Company, the Administrator will notify each Participant
as soon as practicable prior to the effective date of such proposed transaction. To the extent it has not been previously exercised, an
Award will terminate immediately prior to the consummation of such proposed action.
(c) Merger
or Change in Control. In the event of a merger or Change in Control, each outstanding Award will be treated as the Administrator determines
without a Participant’s consent, including, without limitation, that (i) Awards will be assumed, or substantially equivalent
Awards will be substituted, by the acquiring or succeeding corporation (or an affiliate thereof) with appropriate adjustments as to the
number and kind of shares and prices; (ii) upon written notice to a Participant, that the Participant’s Awards will terminate
upon or immediately prior to the consummation of such merger or Change in Control (subject to the provisions of the preceding paragraph);
(iii) outstanding Awards will vest and become exercisable, realizable, or payable, or restrictions applicable to an Award will lapse,
in whole or in part prior to or upon consummation of such merger or Change in Control, and, to the extent the Administrator determines,
terminate upon or immediately prior to the effectiveness of such merger of Change in Control; (iv) (A) the termination of an
Award in exchange for an amount of cash and/or property, if any, equal to the amount that would have been attained upon the exercise of
such Award or realization of the Participant’s rights as of the date of the occurrence of the transaction (and, for the avoidance
of doubt, if as of the date of the occurrence of the transaction the Administrator determines in good faith that no amount would have
been attained upon the exercise of such Award or realization of the Participant’s rights, then such Award may be terminated by the
Company without payment), or (B) the replacement of such Award with other rights or property selected by the Administrator in its
sole discretion; or (v) any combination of the foregoing. In taking any of the actions permitted under this subsection 13(c), the
Administrator will not be obligated to treat all Awards, all Awards held by a Participant, or all Awards of the same type, similarly.
In the event that the successor
corporation does not assume or substitute for the Award (or portion thereof), the Participant will fully vest in and have the right to
exercise all of his or her outstanding Options and Stock Appreciation Rights, including Shares as to which such Awards would not otherwise
be vested or exercisable, all restrictions on Restricted Stock and Restricted Stock Units will lapse, and, with respect to Awards with
performance-based vesting, all performance goals or other vesting criteria will be deemed achieved at one hundred percent (100%) of target
levels and all other terms and conditions met. In addition, if an Option or Stock Appreciation Right is not assumed or substituted in
the event of a merger or Change in Control, the Administrator will notify the Participant in writing or electronically that the Option
or Stock Appreciation Right will be exercisable for a period of time determined by the Administrator in its sole discretion, and the Option
or Stock Appreciation Right will terminate upon the expiration of such period.
For the purposes of this subsection
13(c), an Award will be considered assumed if, following the merger or Change in Control, the Award confers the right to purchase or receive,
for each Share subject to the Award immediately prior to the merger or Change in Control, the consideration (whether stock, cash, or other
securities or property) received in the merger or Change in Control by holders of Common Stock for each Share held on the effective date
of the transaction (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority
of the outstanding Shares); provided, however, that if such consideration received in the merger or Change in Control is not solely common
stock of the successor corporation or its Parent, the Administrator may, with the consent of the successor corporation, provide for the
consideration to be received upon the exercise of an Option or Stock Appreciation Right or upon the payout of a Restricted Stock Unit,
for each Share subject to such Award, to be solely common stock of the successor corporation or its Parent equal in fair market value
to the per share consideration received by holders of Common Stock in the merger or Change in Control.
Notwithstanding anything in
this Section 13(c) to the contrary, an Award that vests, is earned or paid-out upon the satisfaction of one or more performance
goals will not be considered assumed if the Company or its successor modifies any of such performance goals without the Participant’s
consent; provided, however, a modification to such performance goals only to reflect the successor corporation’s post-Change in
Control corporate structure will not be deemed to invalidate an otherwise valid Award assumption.
Notwithstanding anything in
this Section 13(c) to the contrary, if a payment under an Award Agreement is subject to Code Section 409A and if the change
in control definition contained in the Award Agreement does not comply with the definition of “change of control” for purposes
of a distribution under Code Section 409A, then any payment of an amount that is otherwise accelerated under this Section will
be delayed until the earliest time that such payment would be permissible under Code Section 409A without triggering any penalties
applicable under Code Section 409A.
(a) Withholding
Requirements. Prior to the delivery of any Shares or cash pursuant to an Award (or exercise thereof), the Company will have the power
and the right to deduct or withhold, or require a Participant to remit to the Company, an amount sufficient to satisfy federal, state,
local, foreign or other taxes (including the Participant’s FICA obligation) required to be withheld with respect to such Award (or
exercise thereof).
(b) Withholding
Arrangements. The Administrator, in its sole discretion and pursuant to such procedures as it may specify from time to time, may
permit a Participant to satisfy such tax withholding obligation, in whole or in part by (without limitation) (i) paying cash, (ii) electing
to have the Company withhold otherwise deliverable Shares having a Fair Market Value equal to the minimum statutory amount required
to be withheld, (iii) delivering to the Company already-owned Shares having a Fair Market Value equal to the statutory amount
required to be withheld, provided the delivery of such Shares will not result in any adverse accounting consequences, as the
Administrator determines in its sole discretion, or (iv) selling a sufficient number of Shares otherwise deliverable to the
Participant through such means as the Administrator may determine in its sole discretion (whether through a broker or otherwise)
equal to the amount required to be withheld. The amount of the withholding requirement will be deemed to include any amount which
the Administrator agrees may be withheld at the time the election is made, not to exceed the amount determined by using the maximum
federal, state or local marginal income tax rates applicable to the Participant with respect to the Award on the date that the
amount of tax to be withheld is to be determined. The Fair Market Value of the Shares to be withheld or delivered will be determined
as of the date that the taxes are required to be withheld.
15. No
Effect on Employment or Service. Neither the Plan nor any Award will confer upon a Participant any right with respect to continuing
the Participant’s relationship as a Service Provider with the Company, nor will they interfere in any way with the Participant’s
right or the Company’s right to terminate such relationship at any time, with or without cause, to the extent permitted by Applicable
Laws.
16. Date
of Grant. The date of grant of an Award will be, for all purposes, the date on which the Administrator makes the determination granting
such Award, or such other later date as is determined by the Administrator. Notice of the determination will be provided to each Participant
within a reasonable time after the date of such grant.
17. Term
of Plan. Subject to Section 21 of the Plan, the Plan will become effective upon its adoption by the Board. Unless sooner terminated
under Section 18, it will continue in effect for a term of ten (10) years from the later of (a) the effective date of the
Plan, or (b) the earlier of the most recent Board or stockholder approval of an increase in the number of Shares reserved for issuance
under the Plan.
| 18. | Amendment and Termination of the Plan. |
(a) Amendment
and Termination. The Board may at any time amend, alter, suspend or terminate the Plan.
(b) Stockholder
Approval. The Company will obtain stockholder approval of any Plan amendment to the extent necessary and desirable to comply with
Applicable Laws.
(c) Effect
of Amendment or Termination. No amendment, alteration, suspension or termination of the Plan will impair the rights of any Participant,
unless mutually agreed otherwise between the Participant and the Administrator, which agreement must be in writing and signed by the Participant
and the Company. Termination of the Plan will not affect the Administrator’s ability to exercise the powers granted to it hereunder
with respect to Awards granted under the Plan prior to the date of such termination.
| 19. | Conditions Upon Issuance of Shares. |
(a) Legal
Compliance. Shares will not be issued pursuant to the exercise of an Award unless the exercise of such Award and the issuance and
delivery of such Shares will comply with Applicable Laws and will be further subject to the approval of counsel for the Company with respect
to such compliance.
(b) Investment
Representations. As a condition to the exercise of an Award, the Company may require the person exercising such Award to represent
and warrant at the time of any such exercise that the Shares are being purchased only for investment and without any present intention
to sell or distribute such Shares if, in the opinion of counsel for the Company, such a representation is required.
20. Inability
to Obtain Authority. The inability of the Company to obtain authority from any regulatory body having jurisdiction, which authority
is deemed by the Company’s counsel to be necessary to the lawful issuance and sale of any Shares hereunder, will relieve the Company
of any liability in respect of the failure to issue or sell such Shares as to which such requisite authority will not have been obtained.
21. Stockholder
Approval. The Plan will be subject to approval by the stockholders of the Company within twelve (12) months after the date the Plan
is adopted by the Board. Such stockholder approval will be obtained in the manner and to the degree required under Applicable Laws.
22. Information
to Participants. Beginning on the earlier of (i) the date that the aggregate number of Participants under this Plan is five hundred
(500) or more and the Company is relying on the exemption provided by Rule 12h-1(f)(1) under the Exchange Act and (ii) the
date that the Company is required to deliver information to Participants pursuant to Rule 701 under the Securities Act, and until
such time as the Company becomes subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act, is no longer
relying on the exemption provided by Rule 12h-1(f)(1) under the Exchange Act or is no longer required to deliver information
to Participants pursuant to Rule 701 under the Securities Act, the Company shall provide to each Participant the information described
in paragraphs (e)(3), (4), and (5) of Rule 701 under the Securities Act not less frequently than every six (6) months with
the financial statements being not more than 180 days old and with such information provided either by physical or electronic delivery
to the Participants or by written notice to the Participants of the availability of the information on an Internet site that may be password-protected
and of any password needed to access the information. The Company may request that Participants agree to keep the information to be provided
pursuant to this section confidential. If a Participant does not agree to keep the information to be provided pursuant to this section
confidential, then the Company will not be required to provide the information unless otherwise required pursuant to Rule 12h-1(f)(1) under
the Exchange Act or Rule 701 of the Securities Act.
AMENDMENT
TO TRISALUS LIFE SCIENCES, INC.
AMENDED AND RESTATED 2009 EQUITY INCENTIVE PLAN,
AS AMENDED
Pursuant to the authority
reserved to the Board of Directors (the “Board”) of TriSalus Life Sciences, Inc., a corporation organized under
the laws of the State of Delaware (the “Company”), under Section 18(a) of the Company’s 2009 Amended
and Restated Equity Incentive Plan, as amended (the “Plan”), the Board hereby amends the Plan as follows.
Section 13(c) of the Plan is hereby amended by adding the
following sentence at the end of Section 13(c):
“Pursuant to that certain Agreement
and Plan of Merger, dated as of November 11, 2022, by and among the Company, MedTech Acquisition Corporation, a Delaware corporation
and MTAC Merger Sub, Inc., a Delaware corporation (as amended, the “Merger Agreement”), subject to and contingent
upon the Effective Time (as defined in the Merger Agreement, the “Effective Time”), no new Awards (including, but not
limited to, any Options) shall be granted under the Plan following the Effective Time.”
Except as set forth in this amendment, the Plan
shall be unaffected hereby and shall remain in full force and effect.
* * * *
[Signature
Page Follows]
Exhibit 10.16
SUREFIRE MEDICAL, INC. DBA TRISALUS™
LIFE SCIENCES
AMENDED AND RESTATED 2009 STOCK OPTION PLAN
STOCK OPTION AGREEMENT
Unless otherwise defined
herein, the terms defined in the 2009 Stock Option Plan, as amended from time to time (the “Plan”), shall have
the same defined meanings in this Stock Option Agreement (the “Option Agreement”).
| I. | NOTICE
OF STOCK OPTION GRANT |
Name:
Address:
The undersigned Participant
has been granted an Option to purchase Common Stock of the Company, subject to the terms and conditions of the Plan and this Option Agreement,
as follows:
|
Date
of Grant: |
|
|
|
Vesting Commencement Date: |
|
|
|
|
Exercise Price per Share: |
$ |
|
|
|
Total Number of Shares Granted: |
|
|
|
|
Total Exercise Price: |
$ |
|
|
|
Type of Option: |
X |
Incentive
Stock Option
|
|
|
|
|
|
|
|
|
|
Nonstatutory
Stock Option |
|
|
Term/Expiration Date: |
|
|
|
Vesting
Schedule:
This Option shall be exercisable, in
whole or in part, according to the following vesting schedule:
[25% of the total number
of Shares subject to such Option (rounded down to the nearest whole number) shall vest and become exercisable on the one year anniversary
of the Vesting Commencement Date, and 1/48th of the total number of Shares subject to such Option (rounded down to the nearest whole
number) shall vest and become exercisable on each monthly anniversary of the Vesting Commencement Date thereafter, for so long as the
Participant continues to act as a Service Provider through each applicable vesting event, so that the 100% of the Shares subject to the
Option are vested and exercisable on the four year anniversary of the Vesting Commencement Date.]
Termination
Period:
This Option shall be exercisable
for three (3) months after Participant ceases to be a Service Provider, unless such termination is as a result of (i) Participant’s
death or Disability, in which case this Option shall be exercisable for twelve (12) months after Participant ceases to be a Service Provider
or (ii) Participant’s termination by the Company for Cause (as defined below), in which case this Option shall cease to be
exercisable as of the date that Participant ceases to be a Service Provider, provided, however, that the Option shall not
terminate (and shall remain outstanding) until the three (3)-month anniversary of the date that Participant ceases to be a Service Provider
(but shall not vest or be exercisable following the date that Participant ceases to be a Service Provider unless otherwise provided by
the Company). Notwithstanding the foregoing sentence, in no event may this Option be exercised after the Term/Expiration Date as provided
above and this Option may be subject to earlier termination as provided in Section 8 of the Plan.
For purposes hereof, “Cause”
means, with respect to the Participant, the occurrence of any of the following events (unless another definition is provided in an employment
agreement or other applicable written agreement with the Participant and the Company): (i) the Participant’s willful failure
to perform his or her duties and responsibilities to the Company or the Participant’s violation of any written Company policy;
(ii) the Participant’s commission of any act of fraud, embezzlement, dishonesty or any other willful misconduct that has caused
or is reasonably expected to result in injury to the Company; (iii) the Participant’s unauthorized use or disclosure of any
proprietary information or trade secrets of the Company or any other party to whom the Participant owes an obligation of nondisclosure
as a result of his or her relationship with the Company; or (iv) the Participant’s material breach of any of his or her obligations
under any written agreement or covenant with the Company. The determination as to whether the Participant’s termination as a Service
Provider has occurred for Cause shall be made in good faith by the Company and shall be final and binding on the Participant. The foregoing
definition does not in any way limit the Company’s ability to terminate the Participant’s employment or consulting relationship
at any time, subject to Applicable Laws.
1. Grant
of Option. The Administrator of the Company hereby grants to the Participant named in the Notice of Stock Option Grant in Part I
of this Agreement (“Participant”), an option (the “Option”) to purchase the number
of Shares set forth in the Notice of Stock Option Grant, at the exercise price per Share set forth in the Notice of Stock Option Grant
(the “Exercise Price”), and subject to the terms and conditions of the Plan, which is incorporated herein by
reference. Subject to Section 14 of the Plan, in the event of a conflict between the terms and conditions of the Plan and this Option
Agreement, the terms and conditions of the Plan shall prevail.
If designated in the Notice
of Stock Option Grant as an Incentive Stock Option (“ISO”), this Option is intended to qualify as an Incentive
Stock Option as defined in Section 422 of the Code. Nevertheless, to the extent that it exceeds the $100,000 rule of Code Section 422(d),
this Option shall be treated as a Nonstatutory Stock Option (“NSO”). Further, if for any reason this Option
(or portion thereof) shall not qualify as an ISO, then, to the extent of such nonqualification, such Option (or portion thereof) shall
be regarded as a NSO granted under the Plan. In no event shall the Administrator, the Company or any Parent or Subsidiary or any of their
respective employees or directors have any liability to Participant (or any other person) due to the failure of the Option to qualify
for any reason as an ISO.
(a) Right
to Exercise. This Option shall be exercisable during its term in accordance with the Vesting Schedule set out in the Notice of Stock
Option Grant and with the applicable provisions of the Plan and this Option Agreement.
(b) Method
of Exercise. This Option shall be exercisable by delivery of an exercise notice in the form attached as Exhibit A (the
“Exercise Notice”) or in a manner and pursuant to such procedures as the Administrator may determine, which
shall state the election to exercise the Option, the number of Shares with respect to which the Option is being exercised (the “Exercised
Shares”), and such other representations and agreements as may be required by the Company. The Exercise Notice shall be
accompanied by payment of the aggregate Exercise Price as to all Exercised Shares, together with any applicable tax withholding. This
Option shall be deemed to be exercised upon receipt by the Company of such fully executed Exercise Notice accompanied by the aggregate
Exercise Price, together with any applicable tax withholding.
No Shares shall be issued pursuant
to the exercise of an Option unless such issuance and such exercise comply with Applicable Laws. Assuming such compliance, for income
tax purposes the Shares shall be considered transferred to Participant on the date on which the Option is exercised with respect to such
Shares.
3. Participant’s
Representations. In the event the Shares have not been registered under the Securities Act of 1933, as amended (the “Securities
Act”), at the time this Option is exercised, Participant shall, if required by the Company, concurrently with the exercise
of all or any portion of this Option, deliver to the Company his or her Investment Representation Statement in the form attached hereto
as Exhibit B.
4. Lock-Up
Period. Participant hereby agrees that Participant shall not offer, pledge, sell, contract to sell, sell any option or contract to
purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose
of, directly or indirectly, any Common Stock (or other securities) of the Company or enter into any swap, hedging or other arrangement
that transfers to another, in whole or in part, any of the economic consequences of ownership of any Common Stock (or other securities)
of the Company held by Participant (other than those included in the registration) for a period specified by the representative of the
underwriters of Common Stock (or other securities) of the Company not to exceed one hundred and eighty (180) days following the effective
date of any registration statement of the Company filed under the Securities Act (or such other period as may be requested by the Company
or the underwriters to accommodate regulatory restrictions on (i) the publication or other distribution of research reports and
(ii) analyst recommendations and opinions, including, but not limited to, the restrictions contained in NASD Rule 2711(f)(4) or
NYSE Rule 472(f)(4), or any successor provisions or amendments thereto).
Participant agrees to execute
and deliver such other agreements as may be reasonably requested by the Company or the underwriter which are consistent with the foregoing
or which are necessary to give further effect thereto. In addition, if requested by the Company or the representative of the underwriters
of Common Stock (or other securities) of the Company, Participant shall provide, within ten (10) days of such request, such information
as may be required by the Company or such representative in connection with the completion of any public offering of the Company’s
securities pursuant to a registration statement filed under the Securities Act. The obligations described in this Section 4 shall
not apply to a registration relating solely to employee benefit plans on Form S-1 or Form S-8 or similar forms that may be
promulgated in the future, or a registration relating solely to a Commission Rule 145 transaction on Form S-4 or similar forms
that may be promulgated in the future. The Company may impose stop-transfer instructions with respect to the shares of Common Stock (or
other securities) subject to the foregoing restriction until the end of said one hundred and eighty (180) day (or other) period. Participant
agrees that any transferee of the Option or shares acquired pursuant to the Option shall be bound by this Section 4.
5. Method
of Payment. Payment of the aggregate Exercise Price shall be by any of the following, or a combination thereof, at the election of
the Participant:
(c) consideration
received by the Company under a formal cashless exercise program adopted by the Company in connection with the Plan; or
(d) surrender
of other Shares which (i) shall be valued at its Fair Market Value on the date of exercise, and (ii) must be owned free and
clear of any liens, claims, encumbrances or security interests, if accepting such Shares, in the sole discretion of the Administrator,
shall not result in any adverse accounting consequences to the Company.
6. Restrictions
on Exercise. This Option may not be exercised until such time as the Plan has been approved by the stockholders of the Company, or
if the issuance of such Shares upon such exercise or the method of payment of consideration for such shares would constitute a violation
of any Applicable Law.
| 7. | Non-Transferability of Option. |
(a) This
Option may not be transferred in any manner otherwise than by will or by the laws of descent or distribution and may be exercised during
the lifetime of Participant only by Participant. The terms of the Plan and this Option Agreement shall be binding upon the executors,
administrators, heirs, successors and assigns of Participant.
(b) Further,
until the Company becomes subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act, or after the Administrator
determines that it is, will, or may no longer be relying upon the exemption from registration of Options under the Exchange Act as set
forth in Rule 12h-1(f) promulgated under the Exchange Act (the “Reliance End Date”), Participant
shall not transfer this Option or, prior to exercise, the Shares subject to this Option, in any manner other than (i) to persons
who are “family members” (as defined in Rule 701(c)(3) of the Securities Act) through gifts or domestic relations
orders, or
(ii) to an executor or guardian of Participant
upon the death or disability of Participant. Until the Reliance End Date, the Options and, prior to exercise, the Shares subject to this
Option, may not be pledged, hypothecated or otherwise transferred or disposed of, including by entering into any short position, any
“put equivalent position” or any “call equivalent position” (as defined in Rule 16a-1(h) and Rule 16a-1(b) of
the Exchange Act, respectively), other than as permitted in clauses (i) and (ii) of this paragraph.
8. Term
of Option. This Option may be exercised only within the term set out in the Notice of Stock Option Grant, and may be exercised during
such term only in accordance with the Plan and the terms of this Option Agreement.
(a) Tax
Withholding. Participant agrees to make appropriate arrangements with the Company (or the Parent or Subsidiary employing or retaining
Participant) for the satisfaction of all Federal, state, local and foreign income and employment tax withholding requirements applicable
to the Option exercise. Participant acknowledges and agrees that the Company may refuse to honor the exercise and refuse to deliver the
Shares if such withholding amounts are not delivered at the time of exercise.
(b) Notice
of Disqualifying Disposition of ISO Shares. If the Option granted to Participant herein is an ISO, and if Participant sells or otherwise
disposes of any of the Shares acquired pursuant to the ISO on or before the later of (i) the date two (2) years after the Date
of Grant, or (ii) the date one (1) year after the date of exercise, Participant shall immediately notify the Company in writing
of such disposition. Participant agrees that Participant may be subject to income tax withholding by the Company on the compensation
income recognized by Participant.
(c) Code
Section 409A. Under Code Section 409A, an Option that vests after December 31, 2004 (or that vested on or prior
to such date but which was materially modified after October 3, 2004) that was granted with a per Share exercise price that is
determined by the Internal Revenue Service (the “IRS”) to be less than the Fair Market Value of a Share on
the date of grant (a “discount option”) may be considered “deferred compensation.” An Option
that is a “discount option” may result in (i) income recognition by Participant prior to the exercise of the
Option, (ii) an additional twenty percent (20%) federal income tax, and (iii) potential penalty and interest charges. The
“discount option” may also result in additional state income, penalty and interest tax to the Participant. Participant
acknowledges that the Company cannot and has not guaranteed that the IRS will agree that the per Share exercise price of this Option
equals or exceeds the Fair Market Value of a Share on the date of grant in a later examination. Participant agrees that if the IRS
determines that the Option was granted with a per Share exercise price that was less than the Fair Market Value of a Share on the
date of grant, Participant shall be solely responsible for Participant’s costs related to such a determination.
10. Entire
Agreement; Governing Law. The Plan is incorporated herein by reference. The Plan and this Option Agreement constitute the entire
agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements
of the Company and Participant with respect to the subject matter hereof, and may not be modified adversely to the Participant’s
interest except by means of a writing signed by the Company and Participant. This Option Agreement is governed by the internal substantive
laws but not the choice of law rules of Delaware.
11. No
Guarantee of Continued Service. PARTICIPANT ACKNOWLEDGES AND AGREES THAT THE VESTING OF SHARES PURSUANT TO THE VESTING SCHEDULE HEREOF
IS EARNED ONLY BY CONTINUING AS A SERVICE PROVIDER AT THE WILL OF THE COMPANY (OR THE PARENT OR SUBSIDIARY EMPLOYING OR RETAINING PARTICIPANT)
AND NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS OPTION OR ACQUIRING SHARES HEREUNDER. PARTICIPANT FURTHER ACKNOWLEDGES AND
AGREES THAT THIS AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO NOT CONSTITUTE AN EXPRESS
OR IMPLIED PROMISE OF CONTINUED ENGAGEMENT AS A SERVICE PROVIDER FOR THE VESTING PERIOD, FOR ANY PERIOD, OR AT ALL, AND SHALL NOT INTERFERE
IN ANY WAY WITH PARTICIPANT’S RIGHT OR THE RIGHT OF THE COMPANY (OR THE PARENT OR SUBSIDIARY EMPLOYING OR RETAINING PARTICIPANT)
TO TERMINATE PARTICIPANT’S RELATIONSHIP AS A SERVICE PROVIDER AT ANY TIME, WITH OR WITHOUT CAUSE.
Participant acknowledges
receipt of a copy of the Plan and represents that he or she is familiar with the terms and provisions thereof, and hereby accepts this
Option subject to all of the terms and provisions thereof. Participant has reviewed the Plan and this Option in their entirety, has had
an opportunity to obtain the advice of counsel prior to executing this Option and fully understands all provisions of the Option. Participant
hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising
under the Plan or this Option. Participant further agrees to notify the Company upon any change in the residence address indicated below.
PARTICIPANT |
SUREFIRE MEDICAL, INC. DBA TRISALUS™ LIFE SCIENCES |
|
|
Signature |
By |
|
|
Print Name |
Print Name |
|
|
|
Title |
Residence Address |
|
EXHIBIT A
2009 STOCK OPTION PLAN
EXERCISE NOTICE
SUREFIRE MEDICAL, INC.
DBA TRISALUS™ LIFE SCIENCES
6272 W. 91st Avenue Westminster, CO 80031
Attention: President
Exercise
of Option. Effective as of today,______________, __, the undersigned (“Participant”) hereby elects
to exercise Participant’s option (the “Option”) to purchase,______________shares of the Common Stock
(the “Shares”) of SUREFIRE MEDICAL, INC. DBA TRISALUS™ LIFE SCIENCES (the “Company”)
under and pursuant to the 2009 Stock Option Plan (the “Plan”) and the Stock Option Agreement dated November 12,
2019 (the “Option Agreement”).
Delivery
of Payment. Participant herewith delivers to the Company the full purchase price of the Shares, as set forth in the Option
Agreement, and any and all withholding taxes due in connection with the exercise of the Option.
Representations
of Participant. Participant acknowledges that Participant has received, read and understood the Plan and the Option Agreement
and agrees to abide by and be bound by their terms and conditions.
Rights
as Stockholder. Until the issuance of the Shares (as evidenced by the appropriate entry on the books of the Company or of
a duly authorized transfer agent of the Company), no right to vote or receive dividends or any other rights as a stockholder shall exist
with respect to the Common Stock subject to an Award, notwithstanding the exercise of the Option. The Shares shall be issued to Participant
as soon as practicable after the Option is exercised in accordance with the Option Agreement. No adjustment shall be made for a dividend
or other right for which the record date is prior to the date of issuance except as provided in Section 8 of the Plan.
Company’s
Right of First Refusal. Before any Shares held by Participant or any transferee (either being sometimes referred to herein
as the “Holder”) may be sold or otherwise transferred (including transfer by gift or operation of law), the
Company or its assignee(s) shall have a right of first refusal to purchase the Shares on the terms and conditions set forth in this
Section 5 (the “Right of First Refusal”).
Notice
of Proposed Transfer. The Holder of the Shares shall deliver to the Company a written notice (the
“Notice”) stating: (i) the Holder’s bona fide intention to sell or otherwise transfer such
Shares; (ii) the name of each proposed purchaser or other transferee (“Proposed Transferee”);
(iii) the number of Shares to be transferred to each Proposed Transferee; and (iv) the bona fide cash price or other
consideration for which the Holder proposes to transfer the Shares (the “Offered Price”), and the Holder
shall offer the Shares at the Offered Price to the Company or its assignee(s).
Exercise
of Right of First Refusal. At any time within thirty (30) days after receipt of the Notice, the Company and/or its assignee(s) may,
by giving written notice to the Holder, elect to purchase all, but not less than all, of the Shares proposed to be transferred to any
one or more of the Proposed Transferees, at the purchase price determined in accordance with subsection (c) below.
Purchase
Price. The purchase price (“Purchase Price”) for the Shares purchased by the Company or its assignee(s) under
this Section 5 shall be the Offered Price. If the Offered Price includes consideration other than cash, the cash equivalent value
of the non-cash consideration shall be determined by the Board of Directors of the Company in good faith.
Payment.
Payment of the Purchase Price shall be made, at the option of the Company or its assignee(s), in cash (by check), by cancellation of
all or a portion of any outstanding indebtedness of the Holder to the Company (or, in the case of repurchase by an assignee, to the assignee),
or by any combination thereof within thirty (30) days after receipt of the Notice or in the manner and at the times set forth in the
Notice.
Holder’s
Right to Transfer. If all of the Shares proposed in the Notice to be transferred to a given Proposed Transferee are not purchased
by the Company and/or its assignee(s) as provided in this Section 5, then the Holder may sell or otherwise transfer such Shares
to that Proposed Transferee at the Offered Price or at a higher price, provided that such sale or other transfer is consummated
within one hundred and twenty (120) days after the date of the Notice, that any such sale or other transfer is effected in accordance
with any applicable securities laws and that the Proposed Transferee agrees in writing that the provisions of this Section 5 shall
continue to apply to the Shares in the hands of such Proposed Transferee. If the Shares described in the Notice are not transferred to
the Proposed Transferee within such period, a new Notice shall be given to the Company, and the Company and/or its assignees shall again
be offered the Right of First Refusal before any Shares held by the Holder may be sold or otherwise transferred.
Exception
for Certain Family Transfers. Anything to the contrary contained in this Section 5 notwithstanding, the transfer of any
or all of the Shares during the Participant’s lifetime or on the Participant’s death by will or intestacy to the Participant’s
immediate family or a trust for the benefit of the Participant’s immediate family shall be exempt from the provisions of this Section 5.
“Immediate Family” as used herein shall mean spouse, lineal descendant or antecedent, father, mother, brother
or sister. In such case, the transferee or other recipient shall receive and hold the Shares so transferred subject to the provisions
of this Section 5, and there shall be no further transfer of such Shares except in accordance with the terms of this Section 5.
Termination
of Right of First Refusal. The Right of First Refusal shall terminate as to any Shares upon the earlier of (i) the first
sale of Common Stock of the Company to the general public, or (ii) a Change in Control in which the successor corporation has equity
securities that are publicly traded.
Tax
Consultation. Participant understands that Participant may suffer adverse tax consequences as a result of Participant’s
purchase or disposition of the Shares. Participant represents that Participant has consulted with any tax consultants Participant deems
advisable in connection with the purchase or disposition of the Shares and that Participant is not relying on the Company for any tax
advice.
Restrictive
Legends and Stop-Transfer Orders.
Legends.
Participant understands and agrees that the Company shall cause the legends set forth below or legends substantially equivalent thereto,
to be placed upon any certificate(s) evidencing ownership of the Shares together with any other legends that may be required by
the Company or by state or federal securities laws:
THE SECURITIES REPRESENTED HEREBY
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE “ACT”) AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED,
PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR, IN THE OPINION OF COUNSEL SATISFACTORY TO THE ISSUER OF THESE
SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS IN COMPLIANCE THEREWITH.
THE SHARES REPRESENTED BY THIS CERTIFICATE
ARE SUBJECT TO CERTAIN RESTRICTIONS ON TRANSFER AND A RIGHT OF FIRST REFUSAL HELD BY THE ISSUER OR ITS ASSIGNEE(S) AS SET FORTH
IN THE EXERCISE NOTICE BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL
OFFICE OF THE ISSUER. SUCH TRANSFER RESTRICTIONS AND RIGHT OF FIRST REFUSAL ARE BINDING ON TRANSFEREES OF THESE SHARES.
THE SHARES REPRESENTED BY THIS CERTIFICATE
ARE SUBJECT TO RESTRICTIONS ON TRANSFER FOR A PERIOD OF TIME FOLLOWING THE EFFECTIVE DATE OF THE UNDERWRITTEN PUBLIC OFFERING OF THE
COMPANY’S SECURITIES SET FORTH IN AN AGREEMENT BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES AND MAY NOT BE SOLD
OR OTHERWISE DISPOSED OF BY THE HOLDER PRIOR TO THE EXPIRATION OF SUCH PERIOD WITHOUT THE CONSENT OF THE COMPANY OR THE MANAGING UNDERWRITER.
Stop-Transfer
Notices. Participant agrees that, in order to ensure compliance with the restrictions referred to herein, the Company may
issue appropriate “stop transfer” instructions to its transfer agent, if any, and that, if the Company transfers its own
securities, it may make appropriate notations to the same effect in its own records.
Refusal
to Transfer. The Company shall not be required (i) to transfer on its books any Shares that have been sold or
otherwise transferred in violation of any of the provisions of this Exercise Notice or (ii) to treat as owner of such Shares or
to accord the right to vote or pay dividends to any purchaser or other transferee to whom such Shares shall have been so
transferred.
Successors
and Assigns. The Company may assign any of its rights under this Exercise Notice to single or multiple assignees, and this
Exercise Notice shall inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer herein
set forth, this Exercise Notice shall be binding upon Participant and his or her heirs, executors, administrators, successors and assigns.
Interpretation.
Any dispute regarding the interpretation of this Exercise Notice shall be submitted by Participant or by the Company forthwith to the
Administrator, which shall review such dispute at its next regular meeting. The resolution of such a dispute by the Administrator shall
be final and binding on all parties.
Governing
Law; Severability. This Exercise Notice is governed by the internal substantive laws, but not the choice of law rules, of
Delaware. In the event that any provision hereof becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable
or void, this Exercise Notice shall continue in full force and effect.
Entire
Agreement. The Plan and Option Agreement are incorporated herein by reference. This Exercise Notice, the Plan, the Option
Agreement and the Investment Representation Statement constitute the entire agreement of the parties with respect to the subject matter
hereof and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject
matter hereof, and may not be modified adversely to the Participant’s interest except by means of a writing signed by the Company
and Participant.
|
SUBMITTED BY: |
ACCEPTED BY: |
|
|
|
|
PARTICIPANT |
SUREFIRE MEDICAL, INC. |
|
|
|
|
|
DBA TRISALUS™ LIFE SCIENCES |
|
|
|
Signature |
|
|
By |
Print Name |
|
|
Print Name |
|
Address: |
|
Title |
|
|
Address: |
|
|
Date Received |
EXHIBIT B
INVESTMENT REPRESENTATION STATEMENT
|
PARTICIPANT |
: |
|
|
COMPANY |
: |
SUREFIRE MEDICAL, INC. DBA TRISALUS™
LIFE SCIENCES |
|
SECURITY |
: |
COMMON STOCK |
|
AMOUNT |
: |
|
|
DATE |
: |
|
In connection with the purchase
of the above-listed Securities, the undersigned Participant represents to the Company the following:
Participant is aware of the
Company’s business affairs and financial condition and has acquired sufficient information about the Company to reach an informed
and knowledgeable decision to acquire the Securities. Participant is acquiring these Securities for investment for Participant’s
own account only and not with a view to, or for resale in connection with, any “distribution” thereof within the meaning
of the Securities Act of 1933, as amended (the “Securities Act”).
Participant acknowledges
and understands that the Securities constitute “restricted securities” under the Securities Act and have not been registered
under the Securities Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona
fide nature of Participant’s investment intent as expressed herein. In this connection, Participant understands that, in the view
of the Securities and Exchange Commission, the statutory basis for such exemption may be unavailable if Participant’s representation
was predicated solely upon a present intention to hold these Securities for the minimum capital gains period specified under tax statutes,
for a deferred sale, for or until an increase or decrease in the market price of the Securities, or for a period of one (1) year
or any other fixed period in the future. Participant further understands that the Securities must be held indefinitely unless they are
subsequently registered under the Securities Act or an exemption from such registration is available. Participant further acknowledges
and understands that the Company is under no obligation to register the Securities. Participant understands that the certificate evidencing
the Securities shall be imprinted with any legend required under applicable state securities laws.
Participant is familiar
with the provisions of Rule 701 and Rule 144, each promulgated under the Securities Act, which, in substance, permit
limited public resale of “restricted securities” acquired, directly or indirectly from the issuer thereof, in a
non-public offering subject to the satisfaction of certain conditions. Rule 701 provides that if the issuer qualifies under
Rule 701 at the time of the grant of the Option to Participant, the exercise shall be exempt from registration under the
Securities Act. In the event the Company becomes subject to the reporting requirements of Section 13 or 15(d) of the
Securities Exchange Act of 1934, ninety (90) days thereafter (or such longer period as any market stand-off agreement may require)
the Securities exempt under Rule 701 may be resold, subject to the satisfaction of the applicable conditions specified by
Rule 144, including in the case of affiliates (1) the availability of certain public information about the Company,
(2) the amount of Securities being sold during any three (3) month period not exceeding specified limitations,
(3) the resale being made in an unsolicited “broker’s transaction”, transactions directly with a “market maker” or “riskless
principal transactions” (as those terms are defined under the Securities Exchange Act of 1934) and (4) the timely filing of
a Form 144, if applicable.
In the event that the Company
does not qualify under Rule 701 at the time of grant of the Option, then the Securities may be resold in certain limited circumstances
subject to the provisions of Rule 144, which may require (i) the availability of current public information about the Company;
(ii) the resale to occur more than a specified period after the purchase and full payment (within the meaning of Rule 144)
for the Securities; and (iii) in the case of the sale of Securities by an affiliate, the satisfaction of the conditions set forth
in sections (2), (3) and (4) of the paragraph immediately above.
Participant further understands
that in the event all of the applicable requirements of Rule 701 or 144 are not satisfied, registration under the Securities Act,
compliance with Regulation A, or some other registration exemption shall be required; and that, notwithstanding the fact that Rules 144
and 701 are not exclusive, the Staff of the Securities and Exchange Commission has expressed its opinion that persons proposing to sell
private placement securities other than in a registered offering and otherwise than pursuant to Rules 144 or 701 shall have a substantial
burden of proof in establishing that an exemption from registration is available for such offers or sales, and that such persons and
their respective brokers who participate in such transactions do so at their own risk. Participant understands that no assurances can
be given that any such other registration exemption shall be available in such event.
|
PARTICIPANT |
|
|
|
Signature |
|
|
|
Print Name |
|
|
|
Date |
Exhibit 10.17
SUREFIRE MEDICAL, INC. DBA TRISALUS™
LIFE SCIENCES
AMENDED AND RESTATED 2009 STOCK OPTION PLAN
EARLY EXERCISE STOCK OPTION AGREEMENT
Unless otherwise defined herein,
the terms defined in the 2009 Stock Option Plan, as amended from time to time (the “Plan”), shall have the same
defined meanings in this Early Exercise Stock Option Agreement (the “Option Agreement”).
| I. | NOTICE OF STOCK OPTION GRANT |
Name:
Address:
The undersigned Participant
has been granted an Option to purchase Common Stock of the Company, subject to the terms and conditions of the Plan and this Option Agreement,
as follows:
|
Date of Grant: |
|
|
|
|
|
|
|
|
|
Vesting Commencement Date: |
|
|
|
|
|
|
|
|
|
Exercise Price per Share: |
|
|
|
|
|
|
|
|
|
Total Number of Shares Granted: |
|
|
|
|
|
|
|
|
|
Total Exercise Price: |
|
|
|
|
|
|
|
|
|
Type of Option: |
|
Nonstatutory Stock Option |
|
|
|
|
|
|
|
Term/Expiration Date: |
|
|
|
Vesting
Schedule:
This Option shall vest, in whole or in part, according to
the following vesting schedule:
[25% of the total number of
Shares subject to such Option (rounded down to the nearest whole number) shall vest on the one year anniversary of the Vesting Commencement
Date, and 1/48th of the total number of Shares subject to such Option (rounded down to the nearest whole number) shall vest on each monthly
anniversary of the Vesting Commencement Date thereafter, for so long as the Participant continues to act as a Service Provider through
each applicable vesting event, so that the 100% of the Shares subject to the Option are vested on the four year anniversary of the Vesting
Commencement Date.]
Termination
Period:
This Option shall be
exercisable with respect to any vested portion of the Option for three (3) months after Participant ceases to be a Service
Provider, unless such termination is as a result of (i) Participant’s death or Disability, in which case this Option
shall be exercisable with respect to any vested portion of the Option for twelve (12) months after Participant ceases to be a
Service Provider or (ii) Participant’s termination by the Company for Cause (as defined below), in which case this Option
shall cease to be exercisable as of the date that Participant ceases to be a Service Provider, provided, however, that
the Option shall not terminate (and shall remain outstanding) until the three (3)-month anniversary of the date that Participant
ceases to be a Service Provider (but shall not vest or be exercisable following the date that Participant ceases to be a Service
Provider unless otherwise provided by the Company). Notwithstanding the foregoing sentence, in no event may this Option be exercised
after the Term/Expiration Date as provided above and this Option may be subject to earlier termination as provided in Section 8
of the Plan. No unvested portion of this Option shall be exercisable after Participant ceases to be a Service Provider, unless
otherwise provided by the Company.
For purposes hereof,
“Cause” means, with respect to the Participant, the occurrence of any of the following events (unless another
definition is provided in an employment agreement or other applicable written agreement with the Participant and the Company):
(i) the Participant’s willful failure to perform his or her duties and responsibilities to the Company or the
Participant’s violation of any written Company policy; (ii) the Participant’s commission of any act of fraud,
embezzlement, dishonesty or any other willful misconduct that has caused or is reasonably expected to result in injury to the
Company; (iii) the Participant’s unauthorized use or disclosure of any proprietary information or trade secrets of the
Company or any other party to whom the Participant owes an obligation of nondisclosure as a result of his or her relationship with
the Company; or (iv) the Participant’s material breach of any of his or her obligations under any written agreement or
covenant with the Company. The determination as to whether the Participant’s termination as a Service Provider has occurred
for Cause shall be made in good faith by the Company and shall be final and binding on the Participant. The foregoing definition
does not in any way limit the Company’s ability to terminate the Participant’s employment or consulting relationship at
any time, subject to Applicable Laws.
1. Grant
of Option. The Administrator of the Company hereby grants to the Participant named in the Notice of Stock Option Grant in Part I
of this Option Agreement (“Participant”), an option (the “Option”) to purchase the
number of Shares set forth in the Notice of Stock Option Grant, at the exercise price per Share set forth in the Notice of Stock Option
Grant (the “Exercise Price”), and subject to the terms and conditions of the Plan, which is incorporated herein
by reference. Subject to Section 14 of the Plan, in the event of a conflict between the terms and conditions of the Plan and this
Option Agreement, the terms and conditions of the Plan shall prevail.
(a) Vesting.
This Option shall become vested in such amounts and at such times as are set forth in the Vesting Schedule set out in the Notice of Stock
Option Grant. The installments provided for in the Vesting Schedule are cumulative.
(b) Right
to Exercise. Any portion of this Option or the entire Option may be exercised in whole or in part at any time prior to the time when
the Option or portion thereof becomes unexercisable under Section 9, provided that each unvested Share with
respect to which the Option is exercised (a “Restricted Share”) shall be subject to the Company Repurchase
Right (as defined below) for so long as the Option shall remain unvested with respect to such Share under the terms of this Option Agreement.
The Restricted Shares shall be released from the Company Repurchase Right as set forth in Section 3(a)(iv).
(c) Method
of Exercise. This Option shall be exercisable by delivery of an exercise notice in the form attached as Exhibit A (the
“Exercise Notice”) or in a manner and pursuant to such procedures as the Administrator may determine, which
shall state the election to exercise the Option, the number of Shares with respect to which the Option is being exercised (the “Exercised
Shares”), and such other representations and agreements as may be required by the Company. The Exercise Notice shall be
accompanied by payment of the aggregate Exercise Price as to all Exercised Shares, together with any applicable tax withholding, and if
the Option is exercised as to any Restricted Shares, each of the following (the “Additional Documents”): (i) any
share certificate(s) representing such Restricted Shares; (ii) the stock assignment duly endorsed in blank, attached as Exhibit C
(the “Stock Assignment”), executed by Participant; and (iii) the Joint Escrow Instructions of the Company
and Participant, attached as Exhibit D (the “Joint Escrow Instructions”), executed by Participant.
This Option shall be deemed to be exercised upon receipt by the Company of such fully executed Exercise Notice accompanied by the aggregate
Exercise Price, together with any applicable tax withholding and any required Additional Documents.
No Shares shall be issued pursuant to the exercise
of an Option unless such issuance and such exercise comply with Applicable Laws.
Company
Repurchase Right.
Upon Participant’s
ceasing to be a Service Provider for any reason, the Company shall have the right and option to repurchase all of the Restricted Shares
from Participant, or Participant’s transferee or legal representative, as the case may be, for a purchase price equal to the price
per Share paid for such Restricted Shares (the “Company Repurchase Right”).
The Company may exercise
the Company Repurchase Right by delivering, personally or by registered mail, to Participant (or his or her transferee or legal representative,
as the case may be), within ninety (90) days of the date Participant ceases to be a Service Provider, a notice in writing indicating the
Company’s intention to exercise the Company Repurchase Right and setting forth a date for closing not later than thirty (30) days
from the mailing of such notice. The closing shall take place at the Company’s office. At the closing, the holder of any certificates
for the Restricted Shares shall deliver the stock certificate or certificates evidencing the Restricted Shares, and the Company shall
deliver the purchase price therefore. At its option, the Company may elect to make payment for the Restricted Shares to a bank selected
by the Company. The Company shall avail itself of this option by a notice in writing to Participant stating the name and address of the
bank, date of closing, and waiving the closing at the Company’s office.
If the Company does not elect
to exercise the Company Repurchase Right by giving the requisite notice within ninety (90) days following the date Participant ceases
to be a Service Provider, the Company Repurchase Right shall terminate.
The Restricted Shares shall
be released from the Company Repurchase Right upon vesting of the Option with respect to such Shares in accordance with the terms of this
Option Agreement. For the avoidance of doubt, all Restricted Shares shall at all times be assumed to be unvested Shares to the fullest
extent possible under the terms of this Option Agreement, unless otherwise provided by the Administrator. Fractional Shares shall be rounded
down to the nearest whole Share.
Escrow.
Participant hereby authorizes
and directs the Secretary of the Company, or such other person designated by the Administrator from time to time, to transfer the Restricted
Shares as to which the Company Repurchase Right has been exercised from Participant (or his or her transferee or legal representative,
as the case may be) to the Company.
To ensure the availability
for delivery of the Restricted Shares upon repurchase by the Company pursuant to the Company Repurchase Right, Participant appoints the
Secretary of the Company, or such other person designated by the Administrator from time to time as escrow agent, as its attorney-in-fact
to sell, assign and transfer unto the Company, such Restricted Shares, if any, repurchased by the Company pursuant to the Company Repurchase
Right and shall, upon execution of the applicable Exercise Notice, deliver and deposit with the Secretary of the Company, or such other
person designated by the Administrator from time to time, any share certificate(s) representing the Restricted Shares, together with
the Stock Assignment. The Restricted Shares and Stock Assignment shall be held by the Secretary, or such other person designated by the
Administrator from time to time, in escrow, pursuant to the Joint Escrow Instructions, until the Company exercises the Company Repurchase
Right, until such Restricted Shares are released from the Company Repurchase Right as set forth in Section 3(a)(iv) or until
such time as this Option Agreement no longer is in effect. Upon release of the Restricted Shares from the Company’s Repurchase Right,
the escrow agent shall as soon as reasonably practicable deliver to Participant any certificate or certificates representing such Shares
in the escrow agent’s possession belonging to Participant, and the escrow agent shall be discharged of all further obligations hereunder.
The Company, or its designee,
shall not be liable for any act it may do or omit to do with respect to holding the Restricted Shares in escrow and while acting in good
faith and in the exercise of its judgment.
Transferability
of Restricted Shares. The Restricted Shares may not be sold, assigned, transferred, pledged or otherwise encumbered, either
voluntarily or by operation of law, except by will or the laws of descent and distribution. Any transferee of the Restricted Shares shall
hold such Shares subject to all of the provisions hereof and the Exercise Notice and Additional Documents executed by Participant with
respect to such Shares. Any transfer or attempted transfer of any of the Restricted Shares not in accordance with the terms of this Option
Agreement shall be void and the Company may enforce the terms of this Option Agreement by stop transfer instructions or similar actions
by the Company and its agents or designees.
Rights
as a Stockholder. Except as otherwise provided herein, upon exercise of the Option, Participant shall have all the rights
of a stockholder with respect to the Restricted Shares, including the right to receive any cash or stock dividends or other
distributions paid to or made with respect to the Restricted Shares, subject to the restrictions described in the following
sentence, which restrictions shall lapse when the Restricted Shares are released from the Company Repurchase Right as set forth in
Section 3(a)(iv). Unless otherwise provided by the Administrator, if any dividends or distributions are paid in shares, or
consist of a dividend or distribution to holders of Common Stock of property other than an ordinary cash dividend, the shares or
other property will be subject to the same restrictions on transferability as the Restricted Shares with respect to which they were
paid and shall automatically be forfeited to the Company for no consideration in the event the Company exercises the Company
Repurchase Right for the Restricted Shares with respect to which they were paid. In no event shall a dividend or distribution be
paid with respect to Restricted Shares later than the end of the calendar year in which the dividends are paid to holders of Common
Stock or, if later, the 15th day of the third month following the later of (i) the date the dividends are paid to holders of
Common Stock and (ii) the date the Restricted Shares with respect to which the dividends are paid vest.
Section 83(b) Election
for Restricted Shares. Participant acknowledges that, with respect to the exercise of the Option for Restricted Shares, unless
an election is filed by Participant with the Internal Revenue Service and, if necessary, the proper state taxing authorities, within 30
days of the purchase of the Shares, electing pursuant to Section 83(b) of the Code (and similar state tax provisions if applicable)
to be taxed currently on any difference between the purchase price of the Shares and their fair market value on the date of purchase,
there will be a recognition of taxable income to Participant, measured by the excess, if any, of the fair market value of the Shares,
at the time the Company Repurchase Right lapses over the purchase price for the Shares. Participant represents that Participant has consulted
any tax consultant(s) Participant deems advisable in connection with the purchase of the Shares or the filing of the election under
Section 83(b) of the Code and similar tax provisions.
PARTICIPANT ACKNOWLEDGES THAT
IT IS PARTICIPANT’S SOLE RESPONSIBILITY AND NOT THE COMPANY’S TO TIMELY FILE THE ELECTION UNDER SECTION 83(b) OF
THE CODE, EVEN IF PARTICIPANT REQUESTS THE COMPANY OR ITS REPRESENTATIVE TO MAKE THIS FILING ON PARTICIPANT’S BEHALF.
4. Participant’s
Representations. In the event the Shares have not been registered under the Securities Act of 1933, as amended (the “Securities
Act”), at the time this Option is exercised, Participant shall, if required by the Company, concurrently with the exercise
of all or any portion of this Option, deliver to the Company his or her Investment Representation Statement in the form attached hereto
as Exhibit B.
5. Lock-Up
Period. Participant hereby agrees that Participant shall not offer, pledge, sell, contract to sell, sell any option or contract to
purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose
of, directly or indirectly, any Common Stock (or other securities) of the Company or enter into any swap, hedging or other arrangement
that transfers to another, in whole or in part, any of the economic consequences of ownership of any Common Stock (or other securities)
of the Company held by Participant (other than those included in the registration) for a period specified by the representative of the
underwriters of Common Stock (or other securities) of the Company not to exceed one hundred and eighty (180) days following the effective
date of any registration statement of the Company filed under the Securities Act (or such other period as may be requested by the Company
or the underwriters to accommodate regulatory restrictions on (i) the publication or other distribution of research reports and (ii) analyst
recommendations and opinions, including, but not limited to, the restrictions contained in NASD Rule 2711(f)(4) or NYSE Rule 472(f)(4),
or any successor provisions or amendments thereto).
Participant agrees to
execute and deliver such other agreements as may be reasonably requested by the Company or the underwriter which are consistent with
the foregoing or which are necessary to give further effect thereto. In addition, if requested by the Company or the representative
of the underwriters of Common Stock (or other securities) of the Company, Participant shall provide, within ten (10) days of
such request, such information as may be required by the Company or such representative in connection with the completion of any
public offering of the Company’s securities pursuant to a registration statement filed under the Securities Act. The
obligations described in this Section 5 shall not apply to a registration relating solely to employee benefit plans on
Form S-1 or Form S-8 or similar forms that may be promulgated in the future, or a registration relating solely to a
Commission Rule 145 transaction on Form S-4 or similar forms that may be promulgated in the future. The Company may impose
stop-transfer instructions with respect to the shares of Common Stock (or other securities) subject to the foregoing restriction
until the end of said one hundred and eighty (180) day (or other) period. Participant agrees that any transferee of the Option or
shares acquired pursuant to the Option shall be bound by this Section 5.
6. Method
of Payment. Payment of the aggregate Exercise Price shall be by any of the following, or a combination thereof, at the election of
the Participant:
(c) consideration
received by the Company under a formal cashless exercise program adopted by the Company in connection with the Plan; or
(d) surrender
of other Shares which (i) shall be valued at its Fair Market Value on the date of exercise, and (ii) must be owned free and
clear of any liens, claims, encumbrances or security interests, if accepting such Shares, in the sole discretion of the Administrator,
shall not result in any adverse accounting consequences to the Company.
7. Restrictions
on Exercise. This Option may not be exercised until such time as the Plan has been approved by the stockholders of the Company, or
if the issuance of such Shares upon such exercise or the method of payment of consideration for such shares would constitute a violation
of any Applicable Law.
| 8. | Non-Transferability of Option. |
(a) This
Option may not be transferred in any manner otherwise than by will or by the laws of descent or distribution and may be exercised during
the lifetime of Participant only by Participant. The terms of the Plan and this Option Agreement shall be binding upon the executors,
administrators, heirs, successors and assigns of Participant.
(b) Further,
until the Company becomes subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act, or after the
Administrator determines that it is, will, or may no longer be relying upon the exemption from registration of Options under the
Exchange Act as set forth in Rule 12h-1(f) promulgated under the Exchange Act (the “Reliance End
Date”), Participant shall not transfer this Option or, prior to exercise, the Shares subject to this Option, in any
manner other than (i) to persons who are “family members” (as defined in Rule 701(c)(3) of the Securities
Act) through gifts or domestic relations orders, or (ii) to an executor or guardian of Participant upon the death or disability
of Participant. Until the Reliance End Date, the Options and, prior to exercise, the Shares subject to this Option, may not be
pledged, hypothecated or otherwise transferred or disposed of, including by entering into any short position, any “put
equivalent position” or any “call equivalent position” (as defined in Rule 16a-1(h) and
Rule 16a-1(b) of the Exchange Act, respectively), other than as permitted in clauses (i) and (ii) of this
paragraph.
9. Term
of Option. This Option may be exercised only within the term set out in the Notice of Stock Option Grant, and may be exercised during
such term only in accordance with the Plan and the terms of this Option Agreement.
(a) Tax
Withholding. Participant agrees to make appropriate arrangements with the Company (or the Parent or Subsidiary employing or retaining
Participant) for the satisfaction of all Federal, state, local and foreign income and employment tax withholding requirements applicable
to the Option exercise. Participant acknowledges and agrees that the Company may refuse to honor the exercise and refuse to deliver the
Shares if such withholding amounts are not delivered at the time of exercise.
(b) Code
Section 409A. Under Code Section 409A, an Option that was granted with a per Share exercise price that is determined by
the Internal Revenue Service (the “IRS”) to be less than the Fair Market Value of a Share on the date of grant
(a “discount option”) may be considered “deferred compensation.” An Option that is a “discount
option” may result in (i) income recognition by Participant prior to the exercise of the Option, (ii) an additional twenty
percent (20%) federal income tax, and (iii) potential penalty and interest charges. The “discount option” may also result
in additional state income, penalty and interest tax to the Participant. Participant acknowledges that the Company cannot and has not
guaranteed that the IRS will agree that the per Share exercise price of this Option equals or exceeds the Fair Market Value of a Share
on the date of grant in a later examination. Participant agrees that if the IRS determines that the Option was granted with a per Share
exercise price that was less than the Fair Market Value of a Share on the date of grant, Participant shall be solely responsible for Participant’s
costs related to such a determination.
11. Entire
Agreement; Governing Law. The Plan is incorporated herein by reference. The Plan and this Option Agreement constitute the entire agreement
of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the
Company and Participant with respect to the subject matter hereof, and may not be modified adversely to the Participant’s interest
except by means of a writing signed by the Company and Participant. This Option Agreement is governed by the internal substantive laws
but not the choice of law rules of Delaware.
12. No
Guarantee of Continued Service. PARTICIPANT ACKNOWLEDGES AND AGREES THAT THE VESTING OF SHARES PURSUANT TO THE VESTING SCHEDULE HEREOF
IS EARNED ONLY BY CONTINUING AS A SERVICE PROVIDER AT THE WILL OF THE COMPANY (OR THE PARENT OR SUBSIDIARY EMPLOYING OR RETAINING PARTICIPANT)
AND NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS OPTION OR ACQUIRING SHARES HEREUNDER. PARTICIPANT FURTHER ACKNOWLEDGES AND
AGREES THAT THIS OPTION AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO NOT CONSTITUTE
AN EXPRESS OR IMPLIED PROMISE OF CONTINUED ENGAGEMENT AS A SERVICE PROVIDER FOR THE VESTING PERIOD, FOR ANY PERIOD, OR AT ALL, AND SHALL
NOT INTERFERE IN ANY WAY WITH PARTICIPANT’S RIGHT OR THE RIGHT OF THE COMPANY (OR THE PARENT OR SUBSIDIARY EMPLOYING OR RETAINING
PARTICIPANT) TO TERMINATE PARTICIPANT’S RELATIONSHIP AS A SERVICE PROVIDER AT ANY TIME, WITH OR WITHOUT CAUSE.
Participant acknowledges receipt
of a copy of the Plan and represents that he or she is familiar with the terms and provisions thereof, and hereby accepts this Option
subject to all of the terms and provisions thereof. Participant has reviewed the Plan and this Option in their entirety, has had an opportunity
to obtain the advice of counsel prior to executing this Option and fully understands all provisions of the Option. Participant hereby
agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under
the Plan or this Option. Participant further agrees to notify the Company upon any change in the residence address indicated below.
PARTICIPANT |
|
SUREFIRE MEDICAL, INC. DBA
|
|
|
TRISALUS™ LIFE SCIENCES |
|
|
|
Signature |
|
By |
|
|
|
Print Name |
|
Print Name |
|
|
|
Residence Address |
|
Title |
EXHIBIT A
2009 STOCK OPTION PLAN
EXERCISE NOTICE
SUREFIRE MEDICAL, INC.
DBA TRISALUS™ LIFE SCIENCES
6272 W. 91st Avenue
Westminster, CO 80031
Attention: President
Exercise
of Option. Effective as of today, ,
, the undersigned (“Participant”) hereby elects to exercise Participant’s
option (the “Option”) to purchase shares
of the Common Stock (the “Shares”) of SUREFIRE MEDICAL, INC. DBA TRISALUS™ LIFE SCIENCES (the “Company”)
under and pursuant to the 2009 Stock Option Plan (the “Plan”) and the Early Exercise Stock Option Agreement
dated , (the “Option Agreement”).
Delivery
of Payment. Participant herewith delivers to the Company the full purchase price of the Shares, as set forth in the Option
Agreement, and any and all withholding taxes due in connection with the exercise of the Option.
Representations
of Participant. Participant acknowledges that Participant has received, read and understood the Plan and the Option Agreement
and agrees to abide by and be bound by their terms and conditions.
Rights
as Stockholder. Until the issuance of the Shares (as evidenced by the appropriate entry on the books of the Company or of a
duly authorized transfer agent of the Company), no right to vote or receive dividends or any other rights as a stockholder shall exist
with respect to the Common Stock subject to an Award, notwithstanding the exercise of the Option. The Shares shall be issued to Participant
as soon as practicable after the Option is exercised in accordance with the Option Agreement. No adjustment shall be made for a dividend
or other right for which the record date is prior to the date of issuance except as provided in Section 8 of the Plan.
Company’s
Right of First Refusal. Before any Shares held by Participant or any transferee (either being sometimes referred to herein
as the “Holder”) may be sold or otherwise transferred (including transfer by gift or operation of law), the
Company or its assignee(s) shall have a right of first refusal to purchase the Shares on the terms and conditions set forth in this
Section 5 (the “Right of First Refusal”).
Notice
of Proposed Transfer. The Holder of the Shares shall deliver to the Company a written notice (the
“Notice”) stating: (i) the Holder’s bona fide intention to sell or otherwise transfer such
Shares; (ii) the name of each proposed purchaser or other transferee (“Proposed Transferee”);
(iii) the number of Shares to be transferred to each Proposed Transferee; and (iv) the bona fide cash price or other
consideration for which the Holder proposes to transfer the Shares (the “Offered Price”), and the Holder
shall offer the Shares at the Offered Price to the Company or its assignee(s).
Exercise
of Right of First Refusal. At any time within thirty (30) days after receipt of the Notice, the Company and/or its assignee(s) may,
by giving written notice to the Holder, elect to purchase all, but not less than all, of the Shares proposed to be transferred to any
one or more of the Proposed Transferees, at the purchase price determined in accordance with subsection (c) below.
Purchase
Price. The purchase price (“Purchase Price”) for the Shares purchased by the Company or its assignee(s) under
this Section 5 shall be the Offered Price. If the Offered Price includes consideration other than cash, the cash equivalent value
of the non-cash consideration shall be determined by the Board of Directors of the Company in good faith.
Payment.
Payment of the Purchase Price shall be made, at the option of the Company or its assignee(s), in cash (by check), by cancellation of all
or a portion of any outstanding indebtedness of the Holder to the Company (or, in the case of repurchase by an assignee, to the assignee),
or by any combination thereof within thirty (30) days after receipt of the Notice or in the manner and at the times set forth in the Notice.
Holder’s
Right to Transfer. If all of the Shares proposed in the Notice to be transferred to a given Proposed Transferee are not purchased
by the Company and/or its assignee(s) as provided in this Section 5, then the Holder may sell or otherwise transfer such Shares
to that Proposed Transferee at the Offered Price or at a higher price, provided that such sale or other transfer is consummated
within one hundred and twenty (120) days after the date of the Notice, that any such sale or other transfer is effected in accordance
with any applicable securities laws and that the Proposed Transferee agrees in writing that the provisions of this Section 5 shall
continue to apply to the Shares in the hands of such Proposed Transferee. If the Shares described in the Notice are not transferred to
the Proposed Transferee within such period, a new Notice shall be given to the Company, and the Company and/or its assignees shall again
be offered the Right of First Refusal before any Shares held by the Holder may be sold or otherwise transferred.
Exception
for Certain Family Transfers. Anything to the contrary contained in this Section 5 notwithstanding, the transfer of any
or all of the Shares during the Participant’s lifetime or on the Participant’s death by will or intestacy to the Participant’s
immediate family or a trust for the benefit of the Participant’s immediate family shall be exempt from the provisions of this Section 5.
“Immediate Family” as used herein shall mean spouse, lineal descendant or antecedent, father, mother, brother
or sister. In such case, the transferee or other recipient shall receive and hold the Shares so transferred subject to the provisions
of this Section 5, and there shall be no further transfer of such Shares except in accordance with the terms of this Section 5.
Termination
of Right of First Refusal. The Right of First Refusal shall terminate as to any Shares upon the earlier of (i) the first
sale of Common Stock of the Company to the general public, or (ii) a Change in Control in which the successor corporation has equity
securities that are publicly traded.
Tax
Consultation. Participant understands that Participant may suffer adverse tax consequences as a result of Participant’s
purchase or disposition of the Shares. Participant represents that Participant has consulted with any tax consultants Participant deems
advisable in connection with the purchase or disposition of the Shares and that Participant is not relying on the Company for any tax
advice.
Restrictive
Legends and Stop-Transfer Orders.
Legends.
Participant understands and agrees that the Company shall cause the legends set forth below or legends substantially equivalent thereto,
to be placed upon any certificate(s) evidencing ownership of the Shares together with any other legends that may be required by the
Company or by state or federal securities laws:
THE SECURITIES
REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE “ACT”) AND MAY NOT BE OFFERED, SOLD
OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR, IN THE OPINION OF COUNSEL SATISFACTORY
TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS IN COMPLIANCE THEREWITH.
THE SHARES REPRESENTED
BY THIS CERTIFICATE MAY BE SUBJECT TO REPURCHASE PURSUANT TO, AND MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH, THE TERMS OF AN
AGREEMENT BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF THE ISSUER.
SUCH REPURCHASE AND/OR TRANSFER RESTRICTIONS ARE BINDING ON TRANSFEREES OF THESE SHARES.
THE SHARES REPRESENTED
BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON TRANSFER FOR A PERIOD OF TIME FOLLOWING THE EFFECTIVE DATE OF THE UNDERWRITTEN PUBLIC
OFFERING OF THE COMPANY’S SECURITIES SET FORTH IN AN AGREEMENT BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES AND MAY NOT
BE SOLD OR OTHERWISE DISPOSED OF BY THE HOLDER PRIOR TO THE EXPIRATION OF SUCH PERIOD WITHOUT THE CONSENT OF THE COMPANY OR THE MANAGING
UNDERWRITER.
Stop-Transfer
Notices. Participant agrees that, in order to ensure compliance with the restrictions referred to herein, the Company may issue
appropriate “stop transfer” instructions to its transfer agent, if any, and that, if the Company transfers its own securities,
it may make appropriate notations to the same effect in its own records.
Refusal
to Transfer. The Company shall not be required (i) to transfer on its books any Shares that have been sold or
otherwise transferred in violation of any of the provisions of this Exercise Notice or (ii) to treat as owner of such Shares or
to accord the right to vote or pay dividends to any purchaser or other transferee to whom such Shares shall have been so
transferred.
Successors
and Assigns. The Company may assign any of its rights under this Exercise Notice to single or multiple assignees, and this
Exercise Notice shall inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer herein
set forth, this Exercise Notice shall be binding upon Participant and his or her heirs, executors, administrators, successors and assigns.
Interpretation.
Any dispute regarding the interpretation of this Exercise Notice shall be submitted by Participant or by the Company forthwith to
the Administrator, which shall review such dispute at its next regular meeting. The resolution of such a dispute by the
Administrator shall be final and binding on all parties.
Governing
Law; Severability. This Exercise Notice is governed by the internal substantive laws, but not the choice of law rules, of Delaware.
In the event that any provision hereof becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void,
this Exercise Notice shall continue in full force and effect.
Entire
Agreement. The Plan and Option Agreement are incorporated herein by reference. This Exercise Notice, the Plan, the Option Agreement
and the Investment Representation Statement constitute the entire agreement of the parties with respect to the subject matter hereof and
supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof,
and may not be modified adversely to the Participant’s interest except by means of a writing signed by the Company and Participant.
SUBMITTED BY: |
|
ACCEPTED BY: |
|
|
|
PARTICIPANT |
|
SUREFIRE MEDICAL,INC. |
|
|
DBA TRISALUS™ LIFE SCIENCES |
|
|
|
Signature |
|
By |
|
|
|
|
Print Name |
|
Print Name |
|
|
|
Address: |
|
Title |
|
|
|
|
|
Address: |
|
|
|
|
|
Date Received |
EXHIBIT B
INVESTMENT REPRESENTATION STATEMENT
PARTICIPANT |
: |
|
|
|
|
COMPANY |
: |
SUREFIRE MEDICAL, INC. DBA TRISALUS™ LIFE SCIENCES |
|
|
|
SECURITY |
: |
COMMON STOCK |
|
|
|
AMOUNT |
: |
|
|
|
|
DATE |
: |
|
In connection with the purchase
of the above-listed Securities, the undersigned Participant represents to the Company the following:
Participant is aware of the
Company’s business affairs and financial condition and has acquired sufficient information about the Company to reach an informed
and knowledgeable decision to acquire the Securities. Participant is acquiring these Securities for investment for Participant’s
own account only and not with a view to, or for resale in connection with, any “distribution” thereof within the meaning of
the Securities Act of 1933, as amended (the “Securities Act”).
Participant acknowledges and
understands that the Securities constitute “restricted securities” under the Securities Act and have not been registered under
the Securities Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature
of Participant’s investment intent as expressed herein. In this connection, Participant understands that, in the view of the Securities
and Exchange Commission, the statutory basis for such exemption may be unavailable if Participant’s representation was predicated
solely upon a present intention to hold these Securities for the minimum capital gains period specified under tax statutes, for a deferred
sale, for or until an increase or decrease in the market price of the Securities, or for a period of one (1) year or any other fixed
period in the future. Participant further understands that the Securities must be held indefinitely unless they are subsequently registered
under the Securities Act or an exemption from such registration is available. Participant further acknowledges and understands that the
Company is under no obligation to register the Securities. Participant understands that the certificate evidencing the Securities shall
be imprinted with any legend required under applicable state securities laws.
Participant is familiar with the provisions
of Rule 701 and Rule 144, each promulgated under the Securities Act, which, in substance, permit limited public resale of
“restricted securities” acquired, directly or indirectly from the issuer thereof, in a non-public offering subject to
the satisfaction of certain conditions. Rule 701 provides that if the issuer qualifies under Rule 701 at the time of the
grant of the Option to Participant, the exercise shall be exempt from registration under the Securities Act. In the event the
Company becomes subject to the reporting requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934,
ninety (90) days thereafter (or such longer period as any market stand-off agreement may require) the Securities exempt under
Rule 701 may be resold, subject to the satisfaction of the applicable conditions specified by Rule 144, including in the
case of affiliates (1) the availability of certain public information about the Company, (2) the amount of Securities
being sold during any three (3) month period not exceeding specified limitations, (3) the resale being made in an
unsolicited “broker’s transaction”, transactions directly with a “market maker” or “riskless
principal transactions” (as those terms are defined under the Securities Exchange Act of 1934) and (4) the timely filing
of a Form 144, if applicable.
In the event that the Company
does not qualify under Rule 701 at the time of grant of the Option, then the Securities may be resold in certain limited circumstances
subject to the provisions of Rule 144, which may require (i) the availability of current public information about the Company;
(ii) the resale to occur more than a specified period after the purchase and full payment (within the meaning of Rule 144) for
the Securities; and (iii) in the case of the sale of Securities by an affiliate, the satisfaction of the conditions set forth in
sections (2), (3) and (4) of the paragraph immediately above.
Participant further understands
that in the event all of the applicable requirements of Rule 701 or 144 are not satisfied, registration under the Securities Act,
compliance with Regulation A, or some other registration exemption shall be required; and that, notwithstanding the fact that Rules 144
and 701 are not exclusive, the Staff of the Securities and Exchange Commission has expressed its opinion that persons proposing to sell
private placement securities other than in a registered offering and otherwise than pursuant to Rules 144 or 701 shall have a substantial
burden of proof in establishing that an exemption from registration is available for such offers or sales, and that such persons and their
respective brokers who participate in such transactions do so at their own risk. Participant understands that no assurances can be given
that any such other registration exemption shall be available in such event.
|
PARTICIPANT |
|
|
|
Signature |
|
|
|
Print Name |
|
|
|
Date |
EXHIBIT C
STOCK ASSIGNMENT
(see instructions below)
FOR VALUE RECEIVED I,
___, hereby sell, assign and transfer
unto the
shares of the Common Stock of SUREFIRE MEDICAL, INC. DBA TRISALUS™ LIFE SCIENCES registered in my name on the books of
said corporation [represented by Certificate No. ______ ] and do hereby irrevocably constitute and appoint Latham &
Watkins LLP to transfer the said stock on the books of the within named corporation with full power of substitution in the
premises.
This Stock Assignment may
be used only in accordance with the Early Exercise Stock Option Agreement between SUREFIRE MEDICAL, INC. DBA TRISALUS™ LIFE
SCIENCES and the undersigned dated , .
Dated: ,
INSTRUCTIONS:
Please do not fill in any blanks other than the signature line. The purpose of this assignment is to enable the Company
to exercise the Company Repurchase Right, as set forth in the Early Exercise Stock Option Agreement, without requiring additional signatures
on the part of Participant.
EXHIBIT D
JOINT ESCROW INSTRUCTIONS
, _______
Secretary
SUREFIRE MEDICAL, INC. DBA TRISALUS™ LIFE SCIENCES
As Escrow Agent for both SUREFIRE
MEDICAL, INC. DBA TRISALUS™ LIFE SCIENCES (the “Company”) and the undersigned purchaser of
stock of the Company (the “Participant”), you are hereby authorized and directed to hold the documents
delivered to you pursuant to the terms of that certain Early Exercise Stock Option Agreement (the
“Agreement”) between the Company and the undersigned, in accordance with the following instructions:
1. In
the event the Company or any entitled parties (referred to collectively for convenience herein as the “Company”)
exercises the Company Repurchase Right set forth in the Agreement, the Company shall give to Participant and you a written notice specifying
the number of shares of stock to be purchased, the purchase price, and the time for a closing hereunder at the principal office of the
Company. Participant and the Company hereby irrevocably authorize and direct you to close the transaction contemplated by such notice
in accordance with the terms of said notice.
2. At
the closing, you are directed (a) to date the stock assignments necessary for the transfer in question, (b) to fill in the number
of shares being transferred, and (c) to deliver the same, together with any certificate evidencing the shares of stock to be transferred,
to the Company or its assignee, against the simultaneous delivery to you of the purchase price (by cash, a check, or a combination thereof)
for the number of shares of stock being purchased pursuant to the exercise of the Company Repurchase Right.
3. Participant
irrevocably authorizes the Company to deposit with you any certificates evidencing shares of stock to be held by you hereunder and any
additions and substitutions to said shares as defined in the Agreement. Participant hereby irrevocably constitutes and appoints you as
Participant’s attorney-in-fact and agent for the term of this escrow to execute, with respect to such securities, all documents
necessary or appropriate to make such securities negotiable and to complete any transaction herein contemplated, including but not limited
to the filing with any applicable state blue sky authority of any required applications for consent to, or notice of transfer of, the
securities. Subject to the provisions of this Section 3 and to the terms of the Agreement, Participant shall exercise all rights
and privileges of a stockholder of the Company while the stock is held by you.
4. Upon
written request of Participant, but no more than once per calendar year, unless the Company Repurchase Right has been exercised, you
will deliver to Participant a certificate or certificates representing the number of shares of stock as are not then subject to the
Company Repurchase Right or will provide Participant evidence that such shares have been duly entered into the records of the
Company. Within 120 days after the date Participant ceases to be a Service Provider (within the meaning of the Agreement), you will
deliver to Participant a certificate or certificates representing the aggregate number of shares held or issued pursuant to the
Agreement and not purchased by the Company or any other entitled parties pursuant to exercise of the Company Repurchase Right or
will provide Participant evidence that such shares have been duly entered into the records of the Company.
5. If
at the time of termination of this escrow you should have in your possession any documents, securities, or other property belonging to
Participant, you shall deliver all of the same to Participant and shall be discharged of all further obligations hereunder.
6. Your
duties hereunder may be altered, amended, modified or revoked only by a writing signed by all of the parties hereto.
7. You
shall be obligated only for the performance of such duties as are specifically set forth herein and may rely and shall be protected in
relying or refraining from acting on any instrument reasonably believed by you to be genuine and to have been signed or presented by the
proper party or parties. You shall not be personally liable for any act you may do or omit to do hereunder as escrow agent or as attorney-in-fact
for Participant while acting in good faith, and any act done or omitted by you pursuant to the advice of your own attorneys shall be conclusive
evidence of such good faith.
8. You
are hereby expressly authorized to disregard any and all warnings given by any of the parties hereto or by any other person or corporation,
excepting only orders or process of courts of law and are hereby expressly authorized to comply with and obey orders, judgments or decrees
of any court. In case you obey or comply with any such order, judgment or decree, you shall not be liable to any of the parties hereto
or to any other person, firm or corporation by reason of such compliance, notwithstanding any such order, judgment or decree being subsequently
reversed, modified, annulled, set aside, vacated or found to have been entered without jurisdiction.
9. You
shall not be liable in any respect on account of the identity, authorities or rights of the parties executing or delivering or purporting
to execute or deliver the Agreement or any documents or papers deposited or called for hereunder.
10. You
shall not be liable for the expiration of any rights under any applicable state, federal or local statute of limitations or similar statute
or regulation with respect to these Joint Escrow Instructions or any documents deposited with you.
11. You
shall be entitled to employ such legal counsel and other experts as you may deem necessary properly to advise you in connection with your
obligations hereunder, may rely upon the advice of such counsel, and may pay such counsel reasonable compensation therefor.
12. Your
responsibilities as escrow agent hereunder shall terminate if you shall cease to be an officer or agent of the Company or if you shall
resign by written notice to each party. In the event of any such termination, the Company shall appoint a successor escrow agent.
13. If
you reasonably require other or further instruments in connection with these Joint Escrow Instructions or obligations in respect hereto,
the necessary parties hereto shall join in furnishing such instruments.
14. It
is understood and agreed that should any dispute arise with respect to the delivery and/or ownership or right of possession of the
securities held by you hereunder, you are authorized and directed to retain in your possession without liability to anyone all or
any part of said securities until such disputes shall have been settled either by mutual written agreement of the parties concerned
or by a final order, decree or judgment of a court of competent jurisdiction after the time for appeal has expired and no appeal has
been perfected, but you shall be under no duty whatsoever to institute or defend any such proceedings.
15. Any
notice required or permitted hereunder shall be given in writing and shall be deemed effectively given upon personal delivery or upon
deposit in the United States Post Office, by registered or certified mail with postage and fees prepaid, addressed to each of the other
parties thereunto entitled at such addresses as a party may designate by written notice to each of the other parties hereto.
16. By
signing these Joint Escrow Instructions, you become a party hereto only for the purpose of the Joint Escrow Instructions; you do not become
a party to the Agreement.
17. This
instrument shall be binding upon and inure to the benefit of the parties hereto, and their respective successors and permitted assigns.
18. These
Joint Escrow Instructions shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, excluding
that body of law pertaining to conflicts of law.
(signature page follows)
These Joint Escrow Instructions shall be effective as of the date first
set forth above.
|
SUREFIRE MEDICAL, INC. DBA |
|
TRISALUS™ LIFE SCIENCES. |
|
|
|
By: |
|
Name: |
|
Title: |
|
|
|
PARTICIPANT |
|
|
|
By: |
|
Name: |
|
Address: |
|
|
|
ESCROW AGENT |
|
|
|
By: |
|
Name: |
|
Title: |
Form of 83(b) Election and Instructions
These instructions are provided to assist you
if you choose to make an election under Section 83(b) of the Internal Revenue Code of 1986, as amended, with respect to the
shares of common stock of SUREFIRE MEDICAL, INC. DBA TRISALUS™ LIFE SCIENCES transferred to you. Please consult with your
personal tax advisor as to whether an election of this nature will be in your best interests in light of your personal tax situation.
The executed original of the Section 83(b) election
must be filed with the Internal Revenue Service not later than 30 days after the date the shares were transferred to you. PLEASE NOTE:
There is no remedy for failure to file on time. The steps outlined below should be followed to ensure the election is mailed and filed
correctly and in a timely manner. ALSO, PLEASE NOTE: If you make the Section 83(b) election, the election is irrevocable.
Complete the Section 83(b) election
form (attached as Attachment 1) and make three copies of the signed election form. (If you live in a community property state,
your spouse or registered domestic partner should sign the Section 83(b) election form as well.)
Prepare the cover letter to the Internal Revenue
Service (sample letter attached as Attachment 2).
Send the cover letter with the originally executed
Section 83(b) election form and one copy via certified mail, return receipt requested to the Internal Revenue Service at the
address of the Internal Revenue Service where you file your personal tax returns. We suggest that you have the package date-stamped at
the post office. The post office will provide you with a certified receipt that includes a dated postmark. Enclose a self-addressed, stamped
envelope so that the Internal Revenue Service may return a date-stamped copy to you. However, your postmarked receipt is your proof of
having timely filed the Section 83(b) election if you do not receive confirmation from the Internal Revenue Service.
One copy must be sent to SUREFIRE MEDICAL, INC.
DBA TRISALUS™ LIFE SCIENCES for its records. Note that you do not need to attach a copy of your election with your federal
income tax return for the applicable calendar year.
Retain the Internal Revenue Service file stamped
copy (when returned) for your records.
Please consult your personal tax advisor for the
address of the office of the Internal Revenue Service to which you should mail your election form.
ATTACHMENT 1
Election Under Internal Revenue Code Section 83(b)
The undersigned taxpayer hereby elects, pursuant
to Section 83(b) of the Internal Revenue Code of 1986, as amended, to include in taxpayer’s gross income for the current
taxable year the amount of any compensation taxable to taxpayer in connection with taxpayer’s receipt of shares (the “Shares”)
of Common Stock of SUREFIRE MEDICAL, INC. DBA TRISALUS™ LIFE SCIENCES, a Delaware corporation (the “Company”).
The name, address and taxpayer identification
number of the undersigned taxpayer are:
SSN:
The name, address and taxpayer identification number of the
Taxpayer’s spouse/registered domestic partner are (complete if applicable):
SSN:
Description of the property with respect to which the election is being
made:
_____________________(______) Shares of the
Company.
The date on which the property was transferred
was .
The taxable year to which this election relates is calendar year .
Nature of restrictions to which the property is subject:
The Shares are subject to repurchase
by the Company or its assignee upon the occurrence of certain events. This repurchase right lapses based upon the continued performance
of services by the taxpayer over time.
The fair market value at the time of transfer
(determined without regard to any lapse restrictions, as defined in Treasury Regulation Section 1.83-3(i)) of the Shares was $ per
Share x Shares = $ .
The amount paid by the taxpayer for Shares was
$ per Share x Shares
= $ .
The amount to include in gross income is
$ .
The undersigned taxpayer will file this election with the
Internal Revenue Service office with which taxpayer files his or her annual income tax return not later than 30 days after the date
of transfer of the property. A copy of this statement has been furnished to the Company. The undersigned is the person performing
the services in connection with which the property was transferred.
The undersigned understands that the foregoing election may not be
revoked except with the consent of the Commissioner.
Dated: |
_________________,______ |
Taxpayer
Signature: |
|
The undersigned spouse or registered domestic partner of Taxpayer joins
in this election. (Complete if applicable.)
Dated: |
_________________,______ |
Spouse’s or Domestic Partner’s Signature: |
|
ATTACHMENT 2
Sample Cover Letter to Internal Revenue Service
_________________________,______
VIA CERTIFIED MAIL
RETURN RECEIPT REQUESTED
Internal Revenue Service
[Address where taxpayer files returns]
| Re: | Election under Section 83(b) of the Internal Revenue Code of 1986 Taxpayer: |
Taxpayer’s Social Security Number:
Taxpayer’s Spouse/Domestic Partner:
Taxpayer’s Spouse’s/Domestic
Partner’s Social Security Number:
Ladies and Gentlemen:
Enclosed please find an original and one copy
of an Election under Section 83(b) of the Internal Revenue Code of 1986, as amended, being made by the taxpayer referenced above.
Please acknowledge receipt of the enclosed materials by stamping the enclosed copy of the Election and returning it to me in the self-addressed
stamped envelope provided herewith.
Enclosures
cc: SUREFIRE MEDICAL, INC. DBA TRISALUS™
LIFE SCIENCES
Exhibit 10.18
SUREFIRE MEDICAL, INC. DBA TRISALUS™
LIFE SCIENCES
AMENDED AND RESTATED 2009 STOCK OPTION PLAN
STOCK OPTION AGREEMENT
Unless otherwise defined
herein, the terms defined in the 2009 Stock Option Plan, as amended from time to time (the “Plan”), shall have
the same defined meanings in this Stock Option Agreement (the “Option Agreement”).
| I. | NOTICE OF STOCK OPTION GRANT |
Grant of Option:
Pursuant to the option grant
summary tab (the “Grant Notice”) on the website to which this Option Agreement is associated, SUREFIRE MEDICAL, INC.
DBA TRISALUS™ LIFE SCIENCES (the “Company”) has granted to the option holder set forth in the Grant Notice
(“Participant”) an option (“Option”) under the Plan to purchase the number of Shares
indicated in the Grant Notice. By Participant’s electronic acceptance of this Option on the Grant Notice, Participant acknowledges
receipt of a copy of the Plan and represents that Participant is familiar with the terms and provisions thereof, and hereby accepts this
Option subject to all of the terms and provisions of the Plan, this Option Agreement and the Grant Notice. Participant has reviewed the
Plan, this Option Agreement and the Grant Notice in their entirety, has had an opportunity to obtain the advice of counsel prior to accepting
this Option and fully understands all provisions of this Option Agreement, the Plan and the Grant Notice. Participant hereby agrees to
accept as binding, conclusive and final all decisions or interpretations of the Administrator of the Plan upon any questions arising
under the Plan or the Option.
Vesting Schedule:
This Option shall vest and
become exercisable in accordance with the vesting schedule set forth in the Grant Notice, subject to Participant remaining a Service
Provider of the Company through each applicable vesting date (the “Vesting Schedule”).
Termination Period:
This Option shall be exercisable
for three (3) months after Participant ceases to be a Service Provider, unless such termination is as a result of (i) Participant’s
death or Disability, in which case this Option shall be exercisable for twelve (12) months after Participant ceases to be a Service Provider
or (ii) Participant’s termination by the Company for Cause (as defined below), in which case this Option shall cease to be
exercisable as of the date that Participant ceases to be a Service Provider, provided, however, that the Option shall not
terminate (and shall remain outstanding) until the three (3)-month anniversary of the date that Participant ceases to be a Service Provider
(but shall not vest or be exercisable following the date that Participant ceases to be a Service Provider unless otherwise provided by
the Company). Notwithstanding the foregoing sentence, in no event may this Option be exercised after the Term/Expiration Date as provided
above and this Option may be subject to earlier termination as provided in Section 8 of the Plan.
For purposes hereof,
“Cause” means, with respect to the Participant, the occurrence of any of the following events (unless another
definition is provided in an employment agreement or other applicable written agreement with the Participant and the Company):
(i) the Participant’s willful failure to perform his or her duties and responsibilities to the Company or the
Participant’s violation of any written Company policy; (ii) the Participant’s commission of any act of fraud,
embezzlement, dishonesty or any other willful misconduct that has caused or is reasonably expected to result in injury to the
Company; (iii) the Participant’s unauthorized use or disclosure of any proprietary information or trade secrets of the
Company or any other party to whom the Participant owes an obligation of nondisclosure as a result of his or her relationship with
the Company; or (iv) the Participant’s material breach of any of his or her obligations under any written agreement or
covenant with the Company. The determination as to whether the Participant’s termination as a Service Provider has occurred
for Cause shall be made in good faith by the Company and shall be final and binding on the Participant. The foregoing definition
does not in any way limit the Company’s ability to terminate the Participant’s employment or consulting relationship at
any time, subject to Applicable Laws.
1. Grant
of Option. The Administrator of the Company hereby grants to the Participant the Option to purchase the number of Shares set forth
in the Grant Notice, at the exercise price per Share set forth in the Grant Notice (the “Exercise Price”),
and subject to the terms and conditions of the Plan, which is incorporated herein by reference. Subject to Section 14 of the Plan,
in the event of a conflict between the terms and conditions of the Plan and this Option Agreement, the terms and conditions of the Plan
shall prevail.
If designated in the Grant
Notice as an Incentive Stock Option (“ISO”), this Option is intended to qualify as an Incentive Stock Option
as defined in Section 422 of the Code. Nevertheless, to the extent that this Option exceeds the $100,000 limit imposed by Code Section 422(d),
this Option shall be treated as a Nonstatutory Stock Option (“NSO”). Further, if for any reason this Option
(or portion thereof) shall not qualify as an ISO, then, to the extent of such nonqualification, such Option (or portion thereof) shall
be regarded as a NSO granted under the Plan. In no event shall the Administrator, the Company or any Parent or Subsidiary or any of their
respective employees or directors have any liability to Participant (or any other person) due to the failure of the Option to qualify
for any reason as an ISO.
(a) Right
to Exercise. This Option shall be exercisable during its term in accordance with the Vesting Schedule set out in the Grant Notice
and with the applicable provisions of the Plan and this Option Agreement.
(b) Method
of Exercise. This Option shall be exercisable by delivery of an exercise notice in the form attached as Exhibit A (the
“Exercise Notice”) or in a manner and pursuant to such procedures as the Administrator may determine, which
shall state the election to exercise the Option, the number of Shares with respect to which the Option is being exercised (the “Exercised
Shares”), and such other representations and agreements as may be required by the Company. The Exercise Notice shall be
accompanied by payment of the aggregate Exercise Price as to all Exercised Shares, together with any applicable tax withholding. This
Option shall be deemed to be exercised upon receipt by the Company of such fully executed Exercise Notice accompanied by the aggregate
Exercise Price, together with any applicable tax withholding.
No Shares shall be issued
pursuant to the exercise of an Option unless such issuance and such exercise comply with Applicable Laws. Assuming such compliance,
for income tax purposes the Shares shall be considered transferred to Participant on the date on which the Option is exercised with
respect to such Shares.
3. Participant’s
Representations. In the event the Shares have not been registered under the Securities Act of 1933, as amended (the “Securities
Act”), at the time this Option is exercised, Participant shall, if required by the Company, concurrently with the exercise
of all or any portion of this Option, deliver to the Company his or her Investment Representation Statement in the form attached hereto
as Exhibit B.
4. Lock-Up
Period. Participant hereby agrees that Participant shall not offer, pledge, sell, contract to sell, sell any option or contract to
purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose
of, directly or indirectly, any Common Stock (or other securities) of the Company or enter into any swap, hedging or other arrangement
that transfers to another, in whole or in part, any of the economic consequences of ownership of any Common Stock (or other securities)
of the Company held by Participant (other than those included in the registration) for a period specified by the representative of the
underwriters of Common Stock (or other securities) of the Company not to exceed one hundred and eighty (180) days following the effective
date of any registration statement of the Company filed under the Securities Act (or such other period as may be requested by the Company
or the underwriters to accommodate regulatory restrictions on (i) the publication or other distribution of research reports and
(ii) analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule 2241, or
any successor provisions or amendments thereto).
Participant agrees to execute
and deliver such other agreements as may be reasonably requested by the Company or the underwriter which are consistent with the foregoing
or which are necessary to give further effect thereto. In addition, if requested by the Company or the representative of the underwriters
of Common Stock (or other securities) of the Company, Participant shall provide, within ten (10) days of such request, such information
as may be required by the Company or such representative in connection with the completion of any public offering of the Company’s
securities pursuant to a registration statement filed under the Securities Act. The obligations described in this Section 4 shall
not apply to a registration relating solely to employee benefit plans on Form S-1 or Form S-8 or similar forms that may be
promulgated in the future, or a registration relating solely to a Commission Rule 145 transaction on Form S-4 or similar forms
that may be promulgated in the future. The Company may impose stop-transfer instructions with respect to the shares of Common Stock (or
other securities) subject to the foregoing restriction until the end of said one hundred and eighty (180) day (or other) period. Participant
agrees that any transferee of the Option or shares acquired pursuant to the Option shall be bound by this Section 4.
5. Method
of Payment. Payment of the aggregate Exercise Price shall be by any of the following, or a combination thereof, at the election of
the Participant:
(c) consideration
received by the Company under a formal cashless exercise program adopted by the Company in connection with the Plan; or
(d) surrender
of other Shares which (i) shall be valued at its Fair Market Value on the date of exercise, and (ii) must be owned free
and clear of any liens, claims, encumbrances or security interests, if accepting such Shares, in the sole discretion of the
Administrator, shall not result in any adverse accounting consequences to the Company.
6. Restrictions
on Exercise. This Option may not be exercised until such time as the Plan has been approved by the stockholders of the Company, or
if the issuance of such Shares upon such exercise or the method of payment of consideration for such shares would constitute a violation
of any Applicable Law.
| 7. | Non-Transferability of Option. |
(a) This
Option may not be transferred in any manner otherwise than by will or by the laws of descent or distribution and may be exercised during
the lifetime of Participant only by Participant. The terms of the Plan and this Option Agreement shall be binding upon the executors,
administrators, heirs, successors and assigns of Participant.
(b) Without
limiting Section 7(a), until the Company becomes subject to the reporting requirements of Section 13 or 15(d) of the Exchange
Act, or after the Administrator determines that it is, will, or may no longer be relying upon the exemption from registration of Options
under the Exchange Act as set forth in Rule 12h-1(f) promulgated under the Exchange Act (the “Reliance End Date”),
Participant shall not transfer this Option or, prior to exercise, the Shares subject to this Option, in any manner other than (i) to
persons who are “family members” (as defined in Rule 701(c)(3) of the Securities Act) through gifts or domestic
relations orders, or (ii) to an executor or guardian of Participant upon the death or disability of Participant. Until the Reliance
End Date, the Options and, prior to exercise, the Shares subject to this Option, may not be pledged, hypothecated or otherwise transferred
or disposed of, including by entering into any short position, any “put equivalent position” or any “call equivalent
position” (as defined in Rule 16a-1(h) and Rule 16a-1(b) of the Exchange Act, respectively), other than as
permitted in clauses (i) and (ii) of this paragraph.
8. Term
of Option. This Option may be exercised only within the term set out in the Grant Notice, and may be exercised during such term only
in accordance with the Plan and the terms of this Option Agreement.
(a) Tax
Withholding. Participant agrees to make appropriate arrangements with the Company (or the Parent or Subsidiary employing or retaining
Participant) for the satisfaction of all Federal, state, local and foreign income and employment tax withholding requirements applicable
to any exercise of the Option. Participant acknowledges and agrees that no exercise of the Option shall be deemed complete until such
withholding amounts are delivered to the Company.
(b) Notice
of Disqualifying Disposition of ISO Shares. If the Option granted to Participant herein is an ISO, and if Participant sells or otherwise
disposes of any of the Shares acquired pursuant to the ISO on or before the later of (i) the date two (2) years after the date
of grant, or (ii) the date one (1) year after the date of exercise, Participant shall immediately notify the Company in writing
of such disposition. Participant agrees that Participant may be subject to income tax withholding by the Company on the compensation
income recognized by Participant.
(c) Code
Section 409A. Under Code Section 409A, an Option that was granted with a per Share exercise price that is determined by
the Internal Revenue Service (the “IRS”) to be less than the Fair Market Value of a Share on the date of grant
(a “discount option”) may be considered “deferred compensation.” An Option that is a “discount
option” may result in (i) income recognition by Participant prior to the exercise of the Option, (ii) an additional twenty
percent (20%) federal income tax, and (iii) potential penalty and interest charges. The “discount option” may also result
in additional state income, penalty and interest tax to the Participant. Participant acknowledges that the Company cannot and has not
guaranteed that the IRS will agree that the per Share exercise price of this Option equals or exceeds the Fair Market Value of a Share
on the date of grant in a later examination. Participant agrees that if the IRS determines that the Option was granted with a per Share
exercise price that was less than the Fair Market Value of a Share on the date of grant, Participant shall be solely responsible for
Participant’s costs related to such a determination.
10. Entire
Agreement; Governing Law. The Plan is incorporated herein by reference. The Plan and this Option Agreement constitute the entire
agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements
of the Company and Participant with respect to the subject matter hereof, and may not be modified adversely to the Participant’s
interest except by means of a writing signed by the Company and Participant. This Option Agreement is governed by the internal substantive
laws but not the choice of law rules of Delaware.
11. No
Guarantee of Continued Service. PARTICIPANT ACKNOWLEDGES AND AGREES THAT THE VESTING OF SHARES PURSUANT TO THE VESTING SCHEDULE HEREOF
IS EARNED ONLY BY CONTINUING AS A SERVICE PROVIDER AT THE WILL OF THE COMPANY (OR THE PARENT OR SUBSIDIARY EMPLOYING OR RETAINING PARTICIPANT)
AND NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS OPTION OR ACQUIRING SHARES HEREUNDER. PARTICIPANT FURTHER ACKNOWLEDGES AND
AGREES THAT THIS OPTION AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE DO NOT CONSTITUTE AN EXPRESS OR IMPLIED
PROMISE OF CONTINUED ENGAGEMENT AS A SERVICE PROVIDER FOR THE VESTING PERIOD, FOR ANY PERIOD, OR AT ALL, AND SHALL NOT INTERFERE IN ANY
WAY WITH PARTICIPANT’S RIGHT OR THE RIGHT OF THE COMPANY (OR THE PARENT OR SUBSIDIARY EMPLOYING OR RETAINING PARTICIPANT) TO TERMINATE
PARTICIPANT’S RELATIONSHIP AS A SERVICE PROVIDER AT ANY TIME, WITH OR WITHOUT CAUSE.
* * * * *
EXHIBIT A
2009 STOCK OPTION PLAN
EXERCISE NOTICE
SUREFIRE MEDICAL, INC.
DBA TRISALUS™ LIFE SCIENCES
6272 W. 91st Avenue
Westminster, CO 80031
Attention: President
1. Exercise
of Option. Effective as of today, ,
, the undersigned (“Participant”) hereby elects to exercise Participant’s
option (the “Option”) to purchase shares of the Common Stock (the “Shares”) of SUREFIRE
MEDICAL, INC. DBA TRISALUS™ LIFE SCIENCES (the “Company”) under and pursuant to the 2009 Stock Option
Plan (the “Plan”) and the Stock Option Agreement dated ,
(the “Option Agreement”).
2. Delivery
of Payment. Participant herewith delivers to the Company the full purchase price of the Shares, as set forth in the Option Agreement,
and any and all withholding taxes due in connection with the exercise of the Option.
3. Representations
of Participant. Participant acknowledges that Participant has received, read and understood the Plan and the Option Agreement and
agrees to abide by and be bound by their terms and conditions.
4. Rights
as Stockholder. Until the issuance of the Shares (as evidenced by the appropriate entry on the books of the Company or of a duly
authorized transfer agent of the Company), no right to vote or receive dividends or any other rights as a stockholder shall exist with
respect to the Common Stock subject to an Award, notwithstanding the exercise of the Option. The Shares shall be issued to Participant
as soon as practicable after the Option is exercised in accordance with the Option Agreement. No adjustment shall be made for a dividend
or other right for which the record date is prior to the date of issuance except as provided in Section 8 of the Plan.
5. Company’s
Right of First Refusal. Before any Shares held by Participant or any transferee (either being sometimes referred to herein as the
“Holder”) may be sold or otherwise transferred (including transfer by gift or operation of law), the Company
or its assignee(s) shall have a right of first refusal to purchase the Shares on the terms and conditions set forth in this Section 5
(the “Right of First Refusal”).
(a) Notice
of Proposed Transfer. The Holder of the Shares shall deliver to the Company a written notice (the “Notice”)
stating: (i) the Holder’s bona fide intention to sell or otherwise transfer such Shares; (ii) the name of each proposed
purchaser or other transferee (“Proposed Transferee”); (iii) the number of Shares to be transferred to
each Proposed Transferee; and (iv) the bona fide cash price or other consideration for which the Holder proposes to transfer the
Shares (the “Offered Price”), and the Holder shall offer the Shares at the Offered Price to the Company or
its assignee(s).
(b) Exercise
of Right of First Refusal. At any time within thirty (30) days after receipt of the Notice, the Company and/or its
assignee(s) may, by giving written notice to the Holder, elect to purchase all, but not less than all, of the Shares proposed
to be transferred to any one or more of the Proposed Transferees, at the purchase price determined in accordance with subsection
(c) below.
(c) Purchase
Price. The purchase price (“Purchase Price”) for the Shares purchased by the Company or its assignee(s) under
this Section 5 shall be the Offered Price. If the Offered Price includes consideration other than cash, the cash equivalent value
of the non-cash consideration shall be determined by the Board of Directors of the Company in good faith.
(d) Payment.
Payment of the Purchase Price shall be made, at the option of the Company or its assignee(s), in cash (by check), by cancellation of
all or a portion of any outstanding indebtedness of the Holder to the Company (or, in the case of repurchase by an assignee, to the assignee),
or by any combination thereof within thirty (30) days after receipt of the Notice or in the manner and at the times set forth in the
Notice.
(e) Holder’s
Right to Transfer. If all of the Shares proposed in the Notice to be transferred to a given Proposed Transferee are not purchased
by the Company and/or its assignee(s) as provided in this Section 5, then the Holder may sell or otherwise transfer such Shares
to that Proposed Transferee at the Offered Price or at a higher price, provided that such sale or other transfer is consummated
within one hundred and twenty (120) days after the date of the Notice, that any such sale or other transfer is effected in accordance
with any applicable securities laws and that the Proposed Transferee agrees in writing that the provisions of this Section 5 shall
continue to apply to the Shares in the hands of such Proposed Transferee. If the Shares described in the Notice are not transferred to
the Proposed Transferee within such period, a new Notice shall be given to the Company, and the Company and/or its assignees shall again
be offered the Right of First Refusal before any Shares held by the Holder may be sold or otherwise transferred.
(f) Exception
for Certain Family Transfers. Anything to the contrary contained in this Section 5 notwithstanding, the transfer of any or all
of the Shares during the Participant’s lifetime or on the Participant’s death by will or intestacy to the Participant’s
immediate family or a trust for the benefit of the Participant’s immediate family shall be exempt from the provisions of this Section 5.
“Immediate Family” as used herein shall mean spouse, lineal descendant or antecedent, father, mother, brother
or sister. In such case, the transferee or other recipient shall receive and hold the Shares so transferred subject to the provisions
of this Section 5, and there shall be no further transfer of such Shares except in accordance with the terms of this Section 5.
(g) Termination
of Right of First Refusal. The Right of First Refusal shall terminate as to any Shares upon the earlier of (i) the first
sale of Common Stock of the Company to the general public, or (ii) a Change in Control in which the successor corporation has
equity securities that are publicly traded.
6. Tax
Consultation. Participant understands that Participant may suffer adverse tax consequences as a result of Participant’s purchase
or disposition of the Shares. Participant represents that Participant has consulted with any tax consultants Participant deems advisable
in connection with the purchase or disposition of the Shares and that Participant is not relying on the Company for any tax advice.
| 7. | Restrictive Legends and Stop-Transfer Orders. |
(a) Legends.
Participant understands and agrees that the Company shall cause any certificates issued evidencing the Shares to have the legends set
forth below or legends substantially equivalent thereto, together with any other legends that may be required by state or federal securities
laws:
THE SECURITIES
REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE “ACT”) AND MAY NOT BE OFFERED, SOLD
OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR, IN THE OPINION OF COUNSEL SATISFACTORY
TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS IN COMPLIANCE THEREWITH.
THE SHARES REPRESENTED
BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN RESTRICTIONS ON TRANSFER AND A RIGHT OF FIRST REFUSAL HELD BY THE ISSUER OR ITS ASSIGNEE(S) AS
SET FORTH IN THE EXERCISE NOTICE BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES, A COPY OF WHICH MAY BE OBTAINED AT
THE PRINCIPAL OFFICE OF THE ISSUER. SUCH TRANSFER RESTRICTIONS AND RIGHT OF FIRST REFUSAL ARE BINDING ON TRANSFEREES OF THESE SHARES.
THE SHARES REPRESENTED
BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON TRANSFER FOR A PERIOD OF TIME FOLLOWING THE EFFECTIVE DATE OF THE UNDERWRITTEN PUBLIC
OFFERING OF THE COMPANY’S SECURITIES SET FORTH IN AN AGREEMENT BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES AND MAY NOT
BE SOLD OR OTHERWISE DISPOSED OF BY THE HOLDER PRIOR TO THE EXPIRATION OF SUCH PERIOD WITHOUT THE CONSENT OF THE COMPANY OR THE MANAGING
UNDERWRITER.
(b) Stop-Transfer
Notices. Participant agrees that, in order to ensure compliance with the restrictions referred to herein, the Company may issue appropriate
“stop transfer” instructions to its transfer agent, if any, and that, if the Company transfers its own securities, it may
make appropriate notations to the same effect in its own records.
(c) Refusal
to Transfer. The Company shall not be required (i) to transfer on its books any Shares that have been sold or otherwise transferred
in violation of any of the provisions of this Exercise Notice or (ii) to treat as owner of such Shares or to accord the right to
vote or pay dividends to any purchaser or other transferee to whom such Shares shall have been so transferred.
(d) Uncertificated
Form. To the extent the Shares are issued in uncertificated form, this Section 7 provides the Participant with notice that the
Shares are subject to the aforementioned restrictions in satisfaction of the notice requirement set forth in Section 151(f) of
the Delaware General Corporation Law.
8. Successors
and Assigns. The Company may assign any of its rights under this Exercise Notice to single or multiple assignees, and this Exercise
Notice shall inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer herein set forth,
this Exercise Notice shall be binding upon Participant and his or her heirs, executors, administrators, successors and assigns.
9. Interpretation.
Any dispute regarding the interpretation of this Exercise Notice shall be submitted by Participant or by the Company forthwith to the
Administrator, which shall review such dispute at its next regular meeting. The resolution of such a dispute by the Administrator shall
be final and binding on all parties.
10. Governing
Law; Severability. This Exercise Notice is governed by the internal substantive laws, but not the choice of law rules, of Delaware.
In the event that any provision hereof becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void,
this Exercise Notice shall continue in full force and effect.
11. Entire
Agreement. The Plan and Option Agreement are incorporated herein by reference. This Exercise Notice, the Plan, the Option Agreement
and the Investment Representation Statement constitute the entire agreement of the parties with respect to the subject matter hereof
and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter
hereof, and may not be modified adversely to the Participant’s interest except by means of a writing signed by the Company and
Participant.
SUBMITTED BY: |
ACCEPTED BY: |
|
|
PARTICIPANT |
SUREFIRE MEDICAL, INC. |
|
|
|
DBA TRISALUS™ LIFE SCIENCES |
|
|
Signature |
By |
|
|
Print Name |
Print Name |
|
|
Address: |
Title |
|
|
|
Address: |
|
|
|
Date Received |
EXHIBIT B
INVESTMENT REPRESENTATION STATEMENT
PARTICIPANT |
: |
|
|
|
|
COMPANY |
: |
SUREFIRE MEDICAL, INC. DBA TRISALUS™ LIFE SCIENCES |
|
|
|
SECURITY |
: |
COMMON STOCK |
|
|
|
AMOUNT |
: |
|
|
|
|
DATE |
: |
|
In connection with the purchase
of the above-listed Securities, the undersigned Participant represents to the Company the following:
Participant is aware of the
Company’s business affairs and financial condition and has acquired sufficient information about the Company to reach an informed
and knowledgeable decision to acquire the Securities. Participant is acquiring these Securities for investment for Participant’s
own account only and not with a view to, or for resale in connection with, any “distribution” thereof within the meaning
of the Securities Act of 1933, as amended (the “Securities Act”).
(a) Participant
acknowledges and understands that the Securities constitute “restricted securities” under the Securities Act and have not
been registered under the Securities Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things,
the bona fide nature of Participant’s investment intent as expressed herein. In this connection, Participant understands that,
in the view of the Securities and Exchange Commission, the statutory basis for such exemption may be unavailable if Participant’s
representation was predicated solely upon a present intention to hold these Securities for the minimum capital gains period specified
under tax statutes, for a deferred sale, for or until an increase or decrease in the market price of the Securities, or for a period
of one (1) year or any other fixed period in the future. Participant further understands that the Securities must be held indefinitely
unless they are subsequently registered under the Securities Act or an exemption from such registration is available. Participant further
acknowledges and understands that the Company is under no obligation to register the Securities. Participant understands that the certificate
evidencing the Securities shall be imprinted with any legend required under applicable state securities laws.
(b) Participant
is familiar with the provisions of Rule 701 and Rule 144, each promulgated under the Securities Act, which, in substance,
permit limited public resale of “restricted securities” acquired, directly or indirectly from the issuer thereof, in a
non-public offering subject to the satisfaction of certain conditions. Rule 701 provides that if the issuer qualifies under
Rule 701 at the time of the grant of the Option to Participant, the exercise shall be exempt from registration under the
Securities Act. In the event the Company becomes subject to the reporting requirements of Section 13 or 15(d) of the
Securities Exchange Act of 1934, ninety (90) days thereafter (or such longer period as any market stand-off agreement may require)
the Securities exempt under Rule 701 may be resold, subject to the satisfaction of the applicable conditions specified by
Rule 144, including in the case of affiliates (1) the availability of certain public information about the Company,
(2) the amount of Securities being sold during any three (3) month period not exceeding specified limitations,
(3) the resale being made in an unsolicited “broker’s transaction”, transactions directly with a
“market maker” or “riskless principal transactions” (as those terms are defined under the Securities
Exchange Act of 1934) and (4) the timely filing of a Form 144, if applicable.
In the event that the Company
does not qualify under Rule 701 at the time of grant of the Option, then the Securities may be resold in certain limited circumstances
subject to the provisions of Rule 144, which may require (i) the availability of current public information about the Company;
(ii) the resale to occur more than a specified period after the purchase and full payment (within the meaning of Rule 144)
for the Securities; and (iii) in the case of the sale of Securities by an affiliate, the satisfaction of the conditions set forth
in sections (2), (3) and (4) of the paragraph immediately above.
(c) Participant
further understands that in the event all of the applicable requirements of Rule 701 or 144 are not satisfied, registration under
the Securities Act, compliance with Regulation A, or some other registration exemption shall be required; and that, notwithstanding the
fact that Rules 144 and 701 are not exclusive, the Staff of the Securities and Exchange Commission has expressed its opinion that
persons proposing to sell private placement securities other than in a registered offering and otherwise than pursuant to Rules 144
or 701 shall have a substantial burden of proof in establishing that an exemption from registration is available for such offers or sales,
and that such persons and their respective brokers who participate in such transactions do so at their own risk. Participant understands
that no assurances can be given that any such other registration exemption shall be available in such event.
|
PARTICIPANT |
|
|
|
Signature |
|
|
|
Print Name |
|
|
|
Date |
Exhibit 10.19
SUREFIRE MEDICAL, INC. DBA TRISALUS™
LIFE SCIENCES
AMENDED AND RESTATED 2009 STOCK OPTION PLAN
EARLY EXERCISE STOCK OPTION AGREEMENT
Unless otherwise defined
herein, the terms defined in the 2009 Stock Option Plan, as amended from time to time (the “Plan”), shall have
the same defined meanings in this Early Exercise Stock Option Agreement (the “Option Agreement”).
| I. | NOTICE
OF STOCK OPTION GRANT |
Grant of Option:
Pursuant to the option grant
summary tab (the “Grant Notice”) on the website to which this Option Agreement is associated, SUREFIRE MEDICAL, INC.
DBA TRISALUS™ LIFE SCIENCES (the “Company”) has granted to the option holder set forth in the Grant Notice
(“Participant”) an option (“Option”) under the Plan to purchase the number of Shares
indicated in the Grant Notice. By Participant’s electronic acceptance of this Option on the Grant Notice, Participant acknowledges
receipt of a copy of the Plan and represents that Participant is familiar with the terms and provisions thereof, and hereby accepts this
Option subject to all of the terms and provisions of the Plan, this Option Agreement and the Grant Notice. Participant has reviewed the
Plan, this Option Agreement and the Grant Notice in their entirety, has had an opportunity to obtain the advice of counsel prior to accepting
this Option and fully understands all provisions of this Option Agreement, the Plan and the Grant Notice. Participant hereby agrees to
accept as binding, conclusive and final all decisions or interpretations of the Administrator of the Plan upon any questions arising
under the Plan or the Option.
Vesting
Schedule:
This Option shall vest in
accordance with the vesting schedule set forth in the Grant Notice, subject to Participant remaining a Service Provider of the Company
through each applicable vesting date (the “Vesting Schedule”).
Termination
Period:
This Option shall be exercisable
with respect to any vested portion of the Option for three (3) months after Participant ceases to be a Service Provider, unless
such termination is as a result of (i) Participant’s death or Disability, in which case this Option shall be exercisable with
respect to any vested portion of the Option for twelve (12) months after Participant ceases to be a Service Provider or (ii) Participant’s
termination by the Company for Cause (as defined below), in which case this Option shall cease to be exercisable as of the date that
Participant ceases to be a Service Provider, provided, however, that the Option shall not terminate (and shall remain outstanding)
until the three (3)-month anniversary of the date that Participant ceases to be a Service Provider (but shall not vest or be exercisable
following the date that Participant ceases to be a Service Provider unless otherwise provided by the Company). Notwithstanding the foregoing
sentence, in no event may this Option be exercised after the Term/Expiration Date as provided above and this Option may be subject to
earlier termination as provided in Section 8 of the Plan. No unvested portion of this Option shall be exercisable after Participant
ceases to be a Service Provider, unless otherwise provided by the Company.
For purposes hereof, “Cause”
means, with respect to the Participant, the occurrence of any of the following events (unless another definition is provided in an employment
agreement or other applicable written agreement with the Participant and the Company): (i) the Participant’s willful failure
to perform his or her duties and responsibilities to the Company or the Participant’s violation of any written Company policy;
(ii) the Participant’s commission of any act of fraud, embezzlement, dishonesty or any other willful misconduct that has caused
or is reasonably expected to result in injury to the Company; (iii) the Participant’s unauthorized use or disclosure of any
proprietary information or trade secrets of the Company or any other party to whom the Participant owes an obligation of nondisclosure
as a result of his or her relationship with the Company; or (iv) the Participant’s material breach of any of his or her obligations
under any written agreement or covenant with the Company. The determination as to whether the Participant’s termination as a Service
Provider has occurred for Cause shall be made in good faith by the Company and shall be final and binding on the Participant. The foregoing
definition does not in any way limit the Company’s ability to terminate the Participant’s employment or consulting relationship
at any time, subject to Applicable Laws.
1. Grant
of Option. The Administrator of the Company hereby grants to the Participant the Option to purchase the number of Shares set forth
in the Grant Notice, at the exercise price per Share set forth in the Grant Notice (the “Exercise Price”),
and subject to the terms and conditions of the Plan, which is incorporated herein by reference. As set forth in the Grant Notice, the
Option constitutes a Nonstatutory Stock Option. Subject to Section 14 of the Plan, in the event of a conflict between the terms
and conditions of the Plan and this Option Agreement, the terms and conditions of the Plan shall prevail.
(a) Vesting.
This Option shall become vested in such amounts and at such times as are set forth in the Vesting Schedule set out in the Grant Notice.
The installments provided for in the Vesting Schedule are cumulative.
(b) Right
to Exercise. Any portion of this Option or the entire Option may be exercised in whole or in part at any time prior to the time when
the Option or portion thereof becomes unexercisable under Section 9, provided that each unvested Share with respect to which
the Option is exercised (a “Restricted Share”) shall be subject to the Company Repurchase Right (as defined
below) for so long as the Option shall remain unvested with respect to such Share under the terms of this Option Agreement. The Restricted
Shares shall be released from the Company Repurchase Right as set forth in Section 3(a)(iv).
(c) Method
of Exercise. This Option shall be exercisable by delivery of an exercise notice in the form attached as Exhibit A (the
“Exercise Notice”) or in a manner and pursuant to such procedures as the Administrator may determine, which
shall state the election to exercise the Option, the number of Shares with respect to which the Option is being exercised (the “Exercised
Shares”), and such other representations and agreements as may be required by the Company. The Exercise Notice shall be
accompanied by payment of the aggregate Exercise Price as to all Exercised Shares, together with any applicable tax withholding, and
if the Option is exercised as to any Restricted Shares, each of the following (the “Additional Documents”):
(i) any share certificate(s) representing such Restricted Shares; (ii) the stock assignment duly endorsed in blank, attached
as Exhibit C (the “Stock Assignment”), executed by Participant; and (iii) the Joint Escrow
Instructions of the Company and Participant, attached as Exhibit D (the “Joint Escrow Instructions”),
executed by Participant. This Option shall be deemed to be exercised upon receipt by the Company of such fully executed Exercise Notice
accompanied by the aggregate Exercise Price, together with any applicable tax withholding and any required Additional Documents.
No Shares shall be issued pursuant
to the exercise of an Option unless such issuance and such exercise comply with Applicable Laws.
| (a) | Company Repurchase Right. |
(i) Upon
Participant’s ceasing to be a Service Provider for any reason, the Company shall have the right and option to repurchase all of
the Restricted Shares from Participant, or Participant’s transferee or legal representative, as the case may be, for a purchase
price equal to the price per Share paid for such Restricted Shares (the “Company Repurchase Right”).
(ii) The
Company may exercise the Company Repurchase Right by delivering, personally or by registered mail, to Participant (or his or her transferee
or legal representative, as the case may be), within ninety (90) days of the date Participant ceases to be a Service Provider, a notice
in writing indicating the Company’s intention to exercise the Company Repurchase Right and setting forth a date for closing not
later than thirty (30) days from the mailing of such notice. The closing shall take place at the Company’s office. At the closing,
the holder of any certificates for the Restricted Shares shall deliver the stock certificate or certificates evidencing the Restricted
Shares, and the Company shall deliver the purchase price therefore. At its option, the Company may elect to make payment for the Restricted
Shares to a bank selected by the Company. The Company shall avail itself of this option by a notice in writing to Participant stating
the name and address of the bank, date of closing, and waiving the closing at the Company’s office.
(iii) If
the Company does not elect to exercise the Company Repurchase Right by giving the requisite notice within ninety (90) days following
the date Participant ceases to be a Service Provider, the Company Repurchase Right shall terminate.
(iv) The
Restricted Shares shall be released from the Company Repurchase Right upon vesting of the Option with respect to such Shares in accordance
with the terms of this Option Agreement. For the avoidance of doubt, all Restricted Shares shall at all times be assumed to be unvested
Shares to the fullest extent possible under the terms of this Option Agreement, unless otherwise provided by the Administrator. Fractional
Shares shall be rounded down to the nearest whole Share.
(i) Participant
hereby authorizes and directs the Secretary of the Company, or such other person designated by the Administrator from time to time, to
transfer the Restricted Shares as to which the Company Repurchase Right has been exercised from Participant (or his or her transferee
or legal representative, as the case may be) to the Company.
(ii) To
ensure the availability for delivery of the Restricted Shares upon repurchase by the Company pursuant to the Company Repurchase Right,
Participant appoints the Secretary of the Company, or such other person designated by the Administrator from time to time as escrow agent,
as its attorney-in-fact to sell, assign and transfer unto the Company, such Restricted Shares, if any, repurchased by the Company pursuant
to the Company Repurchase Right and shall, upon execution of the applicable Exercise Notice, deliver and deposit with the Secretary of
the Company, or such other person designated by the Administrator from time to time, any share certificate(s) representing the Restricted
Shares, together with the Stock Assignment. The Restricted Shares and Stock Assignment shall be held by the Secretary, or such other
person designated by the Administrator from time to time, in escrow, pursuant to the Joint Escrow Instructions, until the Company exercises
the Company Repurchase Right, until such Restricted Shares are released from the Company Repurchase Right as set forth in Section 3(a)(iv) or
until such time as this Option Agreement no longer is in effect. Upon release of the Restricted Shares from the Company’s Repurchase
Right, the escrow agent shall as soon as reasonably practicable deliver to Participant any certificate or certificates representing such
Shares in the escrow agent’s possession belonging to Participant, and the escrow agent shall be discharged of all further obligations
hereunder.
(iii) The
Company, or its designee, shall not be liable for any act it may do or omit to do with respect to holding the Restricted Shares in escrow
and while acting in good faith and in the exercise of its judgment.
(c) Transferability
of Restricted Shares. The Restricted Shares may not be sold, assigned, transferred, pledged or otherwise encumbered, either voluntarily
or by operation of law, except by will or the laws of descent and distribution. Any transferee of the Restricted Shares shall hold such
Shares subject to all of the provisions hereof and the Exercise Notice and Additional Documents executed by Participant with respect
to such Shares. Any transfer or attempted transfer of any of the Restricted Shares not in accordance with the terms of this Option Agreement
shall be void and the Company may enforce the terms of this Option Agreement by stop transfer instructions or similar actions by the
Company and its agents or designees.
(d) Rights
as a Stockholder. Except as otherwise provided herein, upon exercise of the Option, Participant shall have all the rights of a stockholder
with respect to the Restricted Shares, including the right to receive any cash or stock dividends or other distributions paid to or made
with respect to the Restricted Shares, subject to the restrictions described in the following sentence, which restrictions shall lapse
when the Restricted Shares are released from the Company Repurchase Right as set forth in Section 3(a)(iv). Unless otherwise provided
by the Administrator, if any dividends or distributions are paid in shares, or consist of a dividend or distribution to holders of Common
Stock of property other than an ordinary cash dividend, the shares or other property will be subject to the same restrictions on transferability
as the Restricted Shares with respect to which they were paid and shall automatically be forfeited to the Company for no consideration
in the event the Company exercises the Company Repurchase Right for the Restricted Shares with respect to which they were paid. In no
event shall a dividend or distribution be paid with respect to Restricted Shares later than the end of the calendar year in which the
dividends are paid to holders of Common Stock or, if later, the 15th day of the third month following the later of (i) the date
the dividends are paid to holders of Common Stock and (ii) the date the Restricted Shares with respect to which the dividends are
paid vest.
(e) Section 83(b) Election
for Restricted Shares. Participant acknowledges that, with respect to the exercise of the Option for Restricted Shares, unless an
election is filed by Participant with the Internal Revenue Service and, if necessary, the proper state taxing authorities, within 30
days of the purchase of the Shares, electing pursuant to Section 83(b) of the Code (and similar state tax provisions if applicable)
to be taxed currently on any difference between the purchase price of the Shares and their fair market value on the date of purchase,
there will be a recognition of taxable income to Participant, measured by the excess, if any, of the fair market value of the Shares,
at the time the Company Repurchase Right lapses over the purchase price for the Shares. Participant represents that Participant has consulted
any tax consultant(s) Participant deems advisable in connection with the purchase of the Shares or the filing of the election under
Section 83(b) of the Code and similar tax provisions.
PARTICIPANT ACKNOWLEDGES
THAT IT IS PARTICIPANT’S SOLE RESPONSIBILITY AND NOT THE COMPANY’S TO TIMELY FILE THE ELECTION UNDER SECTION 83(b) OF
THE CODE, EVEN IF PARTICIPANT REQUESTS THE COMPANY OR ITS REPRESENTATIVE TO MAKE THIS FILING ON PARTICIPANT’S BEHALF.
4. Participant’s
Representations. In the event the Shares have not been registered under the Securities Act of 1933, as amended (the “Securities
Act”), at the time this Option is exercised, Participant shall, if required by the Company, concurrently with the exercise
of all or any portion of this Option, deliver to the Company his or her Investment Representation Statement in the form attached hereto
as Exhibit B.
5. Lock-Up
Period. Participant hereby agrees that Participant shall not offer, pledge, sell, contract to sell, sell any option or contract to
purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose
of, directly or indirectly, any Common Stock (or other securities) of the Company or enter into any swap, hedging or other arrangement
that transfers to another, in whole or in part, any of the economic consequences of ownership of any Common Stock (or other securities)
of the Company held by Participant (other than those included in the registration) for a period specified by the representative of the
underwriters of Common Stock (or other securities) of the Company not to exceed one hundred and eighty (180) days following the effective
date of any registration statement of the Company filed under the Securities Act (or such other period as may be requested by the Company
or the underwriters to accommodate regulatory restrictions on (i) the publication or other distribution of research reports and
(ii) analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule 2241, or
any successor provisions or amendments thereto).
Participant agrees to execute
and deliver such other agreements as may be reasonably requested by the Company or the underwriter which are consistent with the foregoing
or which are necessary to give further effect thereto. In addition, if requested by the Company or the representative of the underwriters
of Common Stock (or other securities) of the Company, Participant shall provide, within ten (10) days of such request, such information
as may be required by the Company or such representative in connection with the completion of any public offering of the Company’s
securities pursuant to a registration statement filed under the Securities Act. The obligations described in this Section 5 shall
not apply to a registration relating solely to employee benefit plans on Form S-1 or Form S-8 or similar forms that may be
promulgated in the future, or a registration relating solely to a Commission Rule 145 transaction on Form S-4 or similar forms
that may be promulgated in the future. The Company may impose stop-transfer instructions with respect to the shares of Common Stock (or
other securities) subject to the foregoing restriction until the end of said one hundred and eighty (180) day (or other) period. Participant
agrees that any transferee of the Option or shares acquired pursuant to the Option shall be bound by this Section 5.
6. Method
of Payment. Payment of the aggregate Exercise Price shall be by any of the following, or a combination thereof, at the election of
the Participant:
(c) consideration
received by the Company under a formal cashless exercise program adopted by the Company in connection with the Plan; or
(d) surrender
of other Shares which (i) shall be valued at its Fair Market Value on the date of exercise, and (ii) must be owned free and
clear of any liens, claims, encumbrances or security interests, if accepting such Shares, in the sole discretion of the Administrator,
shall not result in any adverse accounting consequences to the Company.
7. Restrictions
on Exercise. This Option may not be exercised until such time as the Plan has been approved by the stockholders of the Company, or
if the issuance of such Shares upon such exercise or the method of payment of consideration for such shares would constitute a violation
of any Applicable Law.
| 8. | Non-Transferability of Option. |
(a) This
Option may not be transferred in any manner otherwise than by will or by the laws of descent or distribution and may be exercised during
the lifetime of Participant only by Participant. The terms of the Plan and this Option Agreement shall be binding upon the executors,
administrators, heirs, successors and assigns of Participant.
(b) Without
limiting Section 8(a), until the Company becomes subject to the reporting requirements of Section 13 or 15(d) of the Exchange
Act, or after the Administrator determines that it is, will, or may no longer be relying upon the exemption from registration of Options
under the Exchange Act as set forth in Rule 12h-1(f) promulgated under the Exchange Act (the “Reliance End Date”),
Participant shall not transfer this Option or, prior to exercise, the Shares subject to this Option, in any manner other than (i) to
persons who are “family members” (as defined in Rule 701(c)(3) of the Securities Act) through gifts or domestic
relations orders, or (ii) to an executor or guardian of Participant upon the death or disability of Participant. Until the Reliance
End Date, the Options and, prior to exercise, the Shares subject to this Option, may not be pledged, hypothecated or otherwise transferred
or disposed of, including by entering into any short position, any “put equivalent position” or any “call equivalent
position” (as defined in Rule 16a-1(h) and Rule 16a-1(b) of the Exchange Act, respectively), other than as
permitted in clauses (i) and (ii) of this paragraph.
9. Term
of Option. This Option may be exercised only within the term set out in the Grant Notice, and may be exercised during such term only
in accordance with the Plan and the terms of this Option Agreement.
(a) Tax
Withholding. Participant agrees to make appropriate arrangements with the Company (or the Parent or Subsidiary employing or retaining
Participant) for the satisfaction of all Federal, state, local and foreign income and employment tax withholding requirements applicable
to any exercise of the Option. Participant acknowledges and agrees that no exercise of the Option shall be deemed complete until such
withholding amounts are delivered to the Company.
(b) Code
Section 409A. Under Code Section 409A, an Option that was granted with a per Share exercise price that is determined by
the Internal Revenue Service (the “IRS”) to be less than the Fair Market Value of a Share on the date of grant
(a “discount option”) may be considered “deferred compensation.” An Option that is a “discount
option” may result in (i) income recognition by Participant prior to the exercise of the Option, (ii) an additional twenty
percent (20%) federal income tax, and (iii) potential penalty and interest charges. The “discount option” may also result
in additional state income, penalty and interest tax to the Participant. Participant acknowledges that the Company cannot and has not
guaranteed that the IRS will agree that the per Share exercise price of this Option equals or exceeds the Fair Market Value of a Share
on the date of grant in a later examination. Participant agrees that if the IRS determines that the Option was granted with a per Share
exercise price that was less than the Fair Market Value of a Share on the date of grant, Participant shall be solely responsible for
Participant’s costs related to such a determination.
11. Entire
Agreement; Governing Law. The Plan is incorporated herein by reference. The Plan and this Option Agreement constitute the entire
agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements
of the Company and Participant with respect to the subject matter hereof, and may not be modified adversely to the Participant’s
interest except by means of a writing signed by the Company and Participant. This Option Agreement is governed by the internal substantive
laws but not the choice of law rules of Delaware.
12. No
Guarantee of Continued Service. PARTICIPANT ACKNOWLEDGES AND AGREES THAT THE VESTING OF SHARES PURSUANT TO THE VESTING SCHEDULE HEREOF
IS EARNED ONLY BY CONTINUING AS A SERVICE PROVIDER AT THE WILL OF THE COMPANY (OR THE PARENT OR SUBSIDIARY EMPLOYING OR RETAINING PARTICIPANT)
AND NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS OPTION OR ACQUIRING SHARES HEREUNDER. PARTICIPANT FURTHER ACKNOWLEDGES AND
AGREES THAT THIS OPTION AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE DO NOT CONSTITUTE AN EXPRESS OR IMPLIED
PROMISE OF CONTINUED ENGAGEMENT AS A SERVICE PROVIDER FOR THE VESTING PERIOD, FOR ANY PERIOD, OR AT ALL, AND SHALL NOT INTERFERE IN ANY
WAY WITH PARTICIPANT’S RIGHT OR THE RIGHT OF THE COMPANY (OR THE PARENT OR SUBSIDIARY EMPLOYING OR RETAINING PARTICIPANT) TO TERMINATE
PARTICIPANT’S RELATIONSHIP AS A SERVICE PROVIDER AT ANY TIME, WITH OR WITHOUT CAUSE.
* * * * *
EXHIBIT A
2009 STOCK OPTION PLAN
EXERCISE NOTICE
SUREFIRE MEDICAL, INC.
DBA TRISALUS™ LIFE SCIENCES
6272 W. 91st Avenue
Westminster, CO 80031
Attention: President
1. Exercise
of Option. Effective as of today, _____________, ____, the undersigned (“Participant”) hereby elects to
exercise Participant’s option (the “Option”) to purchase shares of the Common Stock (the “Shares”)
of SUREFIRE MEDICAL, INC. DBA TRISALUS™ LIFE SCIENCES (the “Company”) under and pursuant to the
2009 Stock Option Plan (the “Plan”) and the Early Exercise Stock Option Agreement dated ____________, ___(the
“Option Agreement”).
2. Delivery
of Payment. Participant herewith delivers to the Company the full purchase price of the Shares, as set forth in the Option Agreement,
and any and all withholding taxes due in connection with the exercise of the Option.
3. Representations
of Participant. Participant acknowledges that Participant has received, read and understood the Plan and the Option Agreement and
agrees to abide by and be bound by their terms and conditions.
4. Rights
as Stockholder. Until the issuance of the Shares (as evidenced by the appropriate entry on the books of the Company or of a duly
authorized transfer agent of the Company), no right to vote or receive dividends or any other rights as a stockholder shall exist with
respect to the Common Stock subject to an Award, notwithstanding the exercise of the Option. The Shares shall be issued to Participant
as soon as practicable after the Option is exercised in accordance with the Option Agreement. No adjustment shall be made for a dividend
or other right for which the record date is prior to the date of issuance except as provided in Section 8 of the Plan.
5. Company’s
Right of First Refusal. Before any Shares held by Participant or any transferee (either being sometimes referred to herein as the
“Holder”) may be sold or otherwise transferred (including transfer by gift or operation of law), the Company
or its assignee(s) shall have a right of first refusal to purchase the Shares on the terms and conditions set forth in this Section 5
(the “Right of First Refusal”).
(a) Notice
of Proposed Transfer. The Holder of the Shares shall deliver to the Company a written notice (the “Notice”)
stating: (i) the Holder’s bona fide intention to sell or otherwise transfer such Shares; (ii) the name of each proposed
purchaser or other transferee (“Proposed Transferee”); (iii) the number of Shares to be transferred to
each Proposed Transferee; and (iv) the bona fide cash price or other consideration for which the Holder proposes to transfer the
Shares (the “Offered Price”), and the Holder shall offer the Shares at the Offered Price to the Company or
its assignee(s).
(b) Exercise
of Right of First Refusal. At any time within thirty (30) days after receipt of the Notice, the Company and/or its assignee(s) may,
by giving written notice to the Holder, elect to purchase all, but not less than all, of the Shares proposed to be transferred to any
one or more of the Proposed Transferees, at the purchase price determined in accordance with subsection (c) below.
(c) Purchase
Price. The purchase price (“Purchase Price”) for the Shares purchased by the Company or its assignee(s) under
this Section 5 shall be the Offered Price. If the Offered Price includes consideration other than cash, the cash equivalent value
of the non-cash consideration shall be determined by the Board of Directors of the Company in good faith.
(d) Payment.
Payment of the Purchase Price shall be made, at the option of the Company or its assignee(s), in cash (by check), by cancellation of
all or a portion of any outstanding indebtedness of the Holder to the Company (or, in the case of repurchase by an assignee, to the assignee),
or by any combination thereof within thirty (30) days after receipt of the Notice or in the manner and at the times set forth in the
Notice.
(e) Holder’s
Right to Transfer. If all of the Shares proposed in the Notice to be transferred to a given Proposed Transferee are not purchased
by the Company and/or its assignee(s) as provided in this Section 5, then the Holder may sell or otherwise transfer such Shares
to that Proposed Transferee at the Offered Price or at a higher price, provided that such sale or other transfer is consummated
within one hundred and twenty (120) days after the date of the Notice, that any such sale or other transfer is effected in accordance
with any applicable securities laws and that the Proposed Transferee agrees in writing that the provisions of this Section 5 shall
continue to apply to the Shares in the hands of such Proposed Transferee. If the Shares described in the Notice are not transferred to
the Proposed Transferee within such period, a new Notice shall be given to the Company, and the Company and/or its assignees shall again
be offered the Right of First Refusal before any Shares held by the Holder may be sold or otherwise transferred.
(f) Exception
for Certain Family Transfers. Anything to the contrary contained in this Section 5 notwithstanding, the transfer of any or all
of the Shares during the Participant’s lifetime or on the Participant’s death by will or intestacy to the Participant’s
immediate family or a trust for the benefit of the Participant’s immediate family shall be exempt from the provisions of this Section 5.
“Immediate Family” as used herein shall mean spouse, lineal descendant or antecedent, father, mother, brother
or sister. In such case, the transferee or other recipient shall receive and hold the Shares so transferred subject to the provisions
of this Section 5, and there shall be no further transfer of such Shares except in accordance with the terms of this Section 5.
(g) Termination
of Right of First Refusal. The Right of First Refusal shall terminate as to any Shares upon the earlier of (i) the first sale
of Common Stock of the Company to the general public, or (ii) a Change in Control in which the successor corporation has equity
securities that are publicly traded.
6. Tax
Consultation. Participant understands that Participant may suffer adverse tax consequences as a result of Participant’s purchase
or disposition of the Shares. Participant represents that Participant has consulted with any tax consultants Participant deems advisable
in connection with the purchase or disposition of the Shares and that Participant is not relying on the Company for any tax advice.
| 7. | Restrictive Legends and Stop-Transfer Orders. |
(a) Legends.
Participant understands and agrees that the Company shall cause any certificates issued evidencing the Shares to have the legends set
forth below or legends substantially equivalent thereto, together with any other legends that may be required by state or federal securities
laws:
THE SECURITIES REPRESENTED HEREBY HAVE
NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE “ACT”) AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED,
PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR, IN THE OPINION OF COUNSEL SATISFACTORY TO THE ISSUER OF THESE
SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS IN COMPLIANCE THEREWITH.
THE SHARES REPRESENTED BY THIS CERTIFICATE
MAY BE SUBJECT TO REPURCHASE PURSUANT TO, AND MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH, THE TERMS OF AN AGREEMENT BETWEEN
THE ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF THE ISSUER. SUCH REPURCHASE
AND/OR TRANSFER RESTRICTIONS ARE BINDING ON TRANSFEREES OF THESE SHARES.
THE SHARES REPRESENTED BY THIS CERTIFICATE
ARE SUBJECT TO RESTRICTIONS ON TRANSFER FOR A PERIOD OF TIME FOLLOWING THE EFFECTIVE DATE OF THE UNDERWRITTEN PUBLIC OFFERING OF THE
COMPANY’S SECURITIES SET FORTH IN AN AGREEMENT BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES AND MAY NOT BE SOLD
OR OTHERWISE DISPOSED OF BY THE HOLDER PRIOR TO THE EXPIRATION OF SUCH PERIOD WITHOUT THE CONSENT OF THE COMPANY OR THE MANAGING UNDERWRITER.
(b) Stop-Transfer
Notices. Participant agrees that, in order to ensure compliance with the restrictions referred to herein, the Company may issue appropriate
“stop transfer” instructions to its transfer agent, if any, and that, if the Company transfers its own securities, it may
make appropriate notations to the same effect in its own records.
(c) Refusal
to Transfer. The Company shall not be required (i) to transfer on its books any Shares that have been sold or otherwise transferred
in violation of any of the provisions of this Exercise Notice or (ii) to treat as owner of such Shares or to accord the right to
vote or pay dividends to any purchaser or other transferee to whom such Shares shall have been so transferred.
(d) Uncertificated
Form. To the extent the Shares are issued in uncertificated form, this Section 7 provides the Participant with notice that the
Shares are subject to the aforementioned restrictions in satisfaction of the notice requirement set forth in Section 151(f) of
the Delaware General Corporation Law.
8. Successors
and Assigns. The Company may assign any of its rights under this Exercise Notice to single or multiple assignees, and this Exercise
Notice shall inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer herein set forth,
this Exercise Notice shall be binding upon Participant and his or her heirs, executors, administrators, successors and assigns.
9. Interpretation.
Any dispute regarding the interpretation of this Exercise Notice shall be submitted by Participant or by the Company forthwith to the
Administrator, which shall review such dispute at its next regular meeting. The resolution of such a dispute by the Administrator shall
be final and binding on all parties.
10. Governing
Law; Severability. This Exercise Notice is governed by the internal substantive laws, but not the choice of law rules, of Delaware.
In the event that any provision hereof becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void,
this Exercise Notice shall continue in full force and effect.
11. Entire
Agreement. The Plan and Option Agreement are incorporated herein by reference. This Exercise Notice, the Plan, the Option Agreement
and the Investment Representation Statement constitute the entire agreement of the parties with respect to the subject matter hereof
and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter
hereof, and may not be modified adversely to the Participant’s interest except by means of a writing signed by the Company and
Participant.
SUBMITTED BY: |
|
ACCEPTED BY: |
|
|
SUREFIRE MEDICAL, INC. |
PARTICIPANT |
|
DBA TRISALUS™ LIFE SCIENCES |
|
|
|
Signature |
|
By |
|
|
|
|
|
|
Print Name |
|
Print Name |
|
|
|
|
|
Title |
Address: |
|
|
|
|
Address: |
|
|
|
|
|
Date Received |
EXHIBIT B
INVESTMENT REPRESENTATION STATEMENT
PARTICIPANT |
: |
|
|
|
|
COMPANY |
: |
SUREFIRE MEDICAL, INC. DBA TRISALUS™ LIFE
SCIENCES |
|
|
|
SECURITY |
: |
COMMON STOCK |
|
|
|
AMOUNT |
: |
|
|
|
|
DATE |
: |
|
In connection with the purchase
of the above-listed Securities, the undersigned Participant represents to the Company the following:
(a) Participant
is aware of the Company’s business affairs and financial condition and has acquired sufficient information about the Company to
reach an informed and knowledgeable decision to acquire the Securities. Participant is acquiring these Securities for investment for
Participant’s own account only and not with a view to, or for resale in connection with, any “distribution” thereof
within the meaning of the Securities Act of 1933, as amended (the “Securities Act”).
(b) Participant
acknowledges and understands that the Securities constitute “restricted securities” under the Securities Act and have not
been registered under the Securities Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things,
the bona fide nature of Participant’s investment intent as expressed herein. In this connection, Participant understands that,
in the view of the Securities and Exchange Commission, the statutory basis for such exemption may be unavailable if Participant’s
representation was predicated solely upon a present intention to hold these Securities for the minimum capital gains period specified
under tax statutes, for a deferred sale, for or until an increase or decrease in the market price of the Securities, or for a period
of one (1) year or any other fixed period in the future. Participant further understands that the Securities must be held indefinitely
unless they are subsequently registered under the Securities Act or an exemption from such registration is available. Participant further
acknowledges and understands that the Company is under no obligation to register the Securities. Participant understands that the certificate
evidencing the Securities shall be imprinted with any legend required under applicable state securities laws.
Participant is familiar with
the provisions of Rule 701 and Rule 144, each promulgated under the Securities Act, which, in substance, permit limited public
resale of “restricted securities” acquired, directly or indirectly from the issuer thereof, in a non-public offering subject
to the satisfaction of certain conditions. Rule 701 provides that if the issuer qualifies under Rule 701 at the time of the
grant of the Option to Participant, the exercise shall be exempt from registration under the Securities Act. In the event the Company
becomes subject to the reporting requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, ninety (90) days
thereafter (or such longer period as any market stand-off agreement may require) the Securities exempt under Rule 701 may be resold,
subject to the satisfaction of the applicable conditions specified by Rule 144, including in the case of affiliates (1) the
availability of certain public information about the Company, (2) the amount of Securities being sold during any three (3) month
period not exceeding specified limitations, (3) the resale being made in an unsolicited “broker’s transaction”,
transactions directly with a “market maker” or “riskless principal transactions” (as those terms are defined
under the Securities Exchange Act of 1934) and (4) the timely filing of a Form 144, if applicable.
In the event that the Company
does not qualify under Rule 701 at the time of grant of the Option, then the Securities may be resold in certain limited circumstances
subject to the provisions of Rule 144, which may require (i) the availability of current public information about the Company;
(ii) the resale to occur more than a specified period after the purchase and full payment (within the meaning of Rule 144)
for the Securities; and (iii) in the case of the sale of Securities by an affiliate, the satisfaction of the conditions set forth
in sections (2), (3) and (4) of the paragraph immediately above.
(c) Participant
further understands that in the event all of the applicable requirements of Rule 701 or 144 are not satisfied, registration under
the Securities Act, compliance with Regulation A, or some other registration exemption shall be required; and that, notwithstanding the
fact that Rules 144 and 701 are not exclusive, the Staff of the Securities and Exchange Commission has expressed its opinion that
persons proposing to sell private placement securities other than in a registered offering and otherwise than pursuant to Rules 144
or 701 shall have a substantial burden of proof in establishing that an exemption from registration is available for such offers or sales,
and that such persons and their respective brokers who participate in such transactions do so at their own risk. Participant understands
that no assurances can be given that any such other registration exemption shall be available in such event.
|
PARTICIPANT |
|
|
|
Signature |
|
|
|
Print Name |
|
|
|
Date |
EXHIBIT C
STOCK ASSIGNMENT
(see instructions below)
FOR VALUE RECEIVED I, ,
hereby sell, assign and transfer unto _____________ the shares of the Common Stock of SUREFIRE MEDICAL, INC. DBA TRISALUS™
LIFE SCIENCES registered in my name on the books of said corporation [represented by Certificate No. _____ ] and do hereby irrevocably
constitute and appoint Latham & Watkins LLP to transfer the said stock on the books of the within named corporation with
full power of substitution in the premises.
This Stock Assignment may
be used only in accordance with the Early Exercise Stock Option Agreement between SUREFIRE MEDICAL, INC. DBA TRISALUS™ LIFE
SCIENCES and the undersigned dated , .
Dated: ,
Signature:
INSTRUCTIONS:
Please do not fill in any blanks other than the signature line. The purpose of this assignment is to enable the Company
to exercise the Company Repurchase Right, as set forth in the Early Exercise Stock Option Agreement, without requiring additional signatures
on the part of Participant.
EXHIBIT D
JOINT ESCROW INSTRUCTIONS
, ________
Secretary
SUREFIRE MEDICAL, INC. DBA TRISALUS™ LIFE SCIENCES
As Escrow Agent for
both SUREFIRE MEDICAL, INC. DBA TRISALUS™ LIFE SCIENCES (the “Company”) and the undersigned purchaser
of stock of the Company (the “Participant”), you are hereby authorized and directed to hold the documents delivered
to you pursuant to the terms of that certain Early Exercise Stock Option Agreement (the “Agreement”) between
the Company and the undersigned, in accordance with the following instructions:
1. In
the event the Company or any entitled parties (referred to collectively for convenience herein as the “Company”)
exercises the Company Repurchase Right set forth in the Agreement, the Company shall give to Participant and you a written notice specifying
the number of shares of stock to be purchased, the purchase price, and the time for a closing hereunder at the principal office of the
Company. Participant and the Company hereby irrevocably authorize and direct you to close the transaction contemplated by such notice
in accordance with the terms of said notice.
2. At
the closing, you are directed (a) to date the stock assignments necessary for the transfer in question, (b) to fill in the
number of shares being transferred, and (c) to deliver the same, together with any certificate evidencing the shares of stock to
be transferred, to the Company or its assignee, against the simultaneous delivery to you of the purchase price (by cash, a check, or
a combination thereof) for the number of shares of stock being purchased pursuant to the exercise of the Company Repurchase Right.
3. Participant
irrevocably authorizes the Company to deposit with you any certificates evidencing shares of stock to be held by you hereunder and any
additions and substitutions to said shares as defined in the Agreement. Participant hereby irrevocably constitutes and appoints you as
Participant’s attorney-in-fact and agent for the term of this escrow to execute, with respect to such securities, all documents
necessary or appropriate to make such securities negotiable and to complete any transaction herein contemplated, including but not limited
to the filing with any applicable state blue sky authority of any required applications for consent to, or notice of transfer of, the
securities. Subject to the provisions of this Section 3 and to the terms of the Agreement, Participant shall exercise all rights
and privileges of a stockholder of the Company while the stock is held by you.
4. Upon
written request of Participant, but no more than once per calendar year, unless the Company Repurchase Right has been exercised, you
will deliver to Participant a certificate or certificates representing the number of shares of stock as are not then subject to the Company
Repurchase Right or will provide Participant evidence that such shares have been duly entered into the records of the Company. Within
120 days after the date Participant ceases to be a Service Provider (within the meaning of the Agreement), you will deliver to Participant
a certificate or certificates representing the aggregate number of shares held or issued pursuant to the Agreement and not purchased
by the Company or any other entitled parties pursuant to exercise of the Company Repurchase Right or will provide Participant evidence
that such shares have been duly entered into the records of the Company.
5. If
at the time of termination of this escrow you should have in your possession any documents, securities, or other property belonging to
Participant, you shall deliver all of the same to Participant and shall be discharged of all further obligations hereunder.
6. Your
duties hereunder may be altered, amended, modified or revoked only by a writing signed by all of the parties hereto.
7. You
shall be obligated only for the performance of such duties as are specifically set forth herein and may rely and shall be protected in
relying or refraining from acting on any instrument reasonably believed by you to be genuine and to have been signed or presented by
the proper party or parties. You shall not be personally liable for any act you may do or omit to do hereunder as escrow agent or as
attorney-in-fact for Participant while acting in good faith, and any act done or omitted by you pursuant to the advice of your own attorneys
shall be conclusive evidence of such good faith.
8. You
are hereby expressly authorized to disregard any and all warnings given by any of the parties hereto or by any other person or corporation,
excepting only orders or process of courts of law and are hereby expressly authorized to comply with and obey orders, judgments or decrees
of any court. In case you obey or comply with any such order, judgment or decree, you shall not be liable to any of the parties hereto
or to any other person, firm or corporation by reason of such compliance, notwithstanding any such order, judgment or decree being subsequently
reversed, modified, annulled, set aside, vacated or found to have been entered without jurisdiction.
9. You
shall not be liable in any respect on account of the identity, authorities or rights of the parties executing or delivering or purporting
to execute or deliver the Agreement or any documents or papers deposited or called for hereunder.
10. You
shall not be liable for the expiration of any rights under any applicable state, federal or local statute of limitations or similar statute
or regulation with respect to these Joint Escrow Instructions or any documents deposited with you.
11. You
shall be entitled to employ such legal counsel and other experts as you may deem necessary properly to advise you in connection with
your obligations hereunder, may rely upon the advice of such counsel, and may pay such counsel reasonable compensation therefor.
12. Your
responsibilities as escrow agent hereunder shall terminate if you shall cease to be an officer or agent of the Company or if you shall
resign by written notice to each party. In the event of any such termination, the Company shall appoint a successor escrow agent.
13. If
you reasonably require other or further instruments in connection with these Joint Escrow Instructions or obligations in respect hereto,
the necessary parties hereto shall join in furnishing such instruments.
14. It
is understood and agreed that should any dispute arise with respect to the delivery and/or ownership or right of possession of the securities
held by you hereunder, you are authorized and directed to retain in your possession without liability to anyone all or any part of said
securities until such disputes shall have been settled either by mutual written agreement of the parties concerned or by a final order,
decree or judgment of a court of competent jurisdiction after the time for appeal has expired and no appeal has been perfected, but you
shall be under no duty whatsoever to institute or defend any such proceedings.
15. Any
notice required or permitted hereunder shall be given in writing and shall be deemed effectively given upon personal delivery or upon
deposit in the United States Post Office, by registered or certified mail with postage and fees prepaid, addressed to each of the other
parties thereunto entitled at such addresses as a party may designate by written notice to each of the other parties hereto.
16. By
signing these Joint Escrow Instructions, you become a party hereto only for the purpose of the Joint Escrow Instructions; you do not
become a party to the Agreement.
17. This
instrument shall be binding upon and inure to the benefit of the parties hereto, and their respective successors and permitted assigns.
18. These
Joint Escrow Instructions shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, excluding
that body of law pertaining to conflicts of law.
(signature page follows)
These Joint Escrow Instructions shall be effective
as of the date first set forth above.
|
SUREFIRE MEDICAL, INC. DBA
TRISALUS™ LIFE SCIENCES. |
|
|
|
By: |
|
Name: |
|
Title: |
|
|
|
PARTICIPANT |
|
|
|
By: |
|
Name: |
|
Address: |
|
|
|
|
|
ESCROW AGENT |
|
|
|
By: |
|
Name: |
|
Title: |
Form of 83(b) Election and Instructions
These instructions are provided to assist you
if you choose to make an election under Section 83(b) of the Internal Revenue Code of 1986, as amended, with respect to the
shares of common stock of SUREFIRE MEDICAL, INC. DBA TRISALUS™ LIFE SCIENCES transferred to you. Please consult with your
personal tax advisor as to whether an election of this nature will be in your best interests in light of your personal tax situation.
The executed original of the Section 83(b) election
must be filed with the Internal Revenue Service not later than 30 days after the date the shares were transferred to you. PLEASE NOTE:
There is no remedy for failure to file on time. The steps outlined below should be followed to ensure the election is mailed and filed
correctly and in a timely manner. ALSO, PLEASE NOTE: If you make the Section 83(b) election, the election is irrevocable.
Complete the Section 83(b) election
form (attached as Attachment 1) and make three copies of the signed election form. (If you live in a community property state,
your spouse or registered domestic partner should sign the Section 83(b) election form as well.)
Prepare the cover letter to the Internal Revenue
Service (sample letter attached as Attachment 2).
Send the cover letter with the originally executed
Section 83(b) election form and one copy via certified mail, return receipt requested to the Internal Revenue Service at the
address of the Internal Revenue Service where you file your personal tax returns. We suggest that you have the package date-stamped at
the post office. The post office will provide you with a certified receipt that includes a dated postmark. Enclose a self-addressed,
stamped envelope so that the Internal Revenue Service may return a date-stamped copy to you. However, your postmarked receipt is your
proof of having timely filed the Section 83(b) election if you do not receive confirmation from the Internal Revenue Service.
One copy must be sent to SUREFIRE MEDICAL, INC.
DBA TRISALUS™ LIFE SCIENCES for its records. Note that you do not need to attach a copy of your election with your federal
income tax return for the applicable calendar year.
Retain the Internal Revenue Service file stamped
copy (when returned) for your records.
Please consult your personal tax advisor for
the address of the office of the Internal Revenue Service to which you should mail your election form.
ATTACHMENT 1
Election Under Internal Revenue Code Section 83(b)
The undersigned taxpayer hereby elects, pursuant
to Section 83(b) of the Internal Revenue Code of 1986, as amended, to include in taxpayer’s gross income for the current
taxable year the amount of any compensation taxable to taxpayer in connection with taxpayer’s receipt of shares (the “Shares”)
of Common Stock of SUREFIRE MEDICAL, INC. DBA TRISALUS™ LIFE SCIENCES, a Delaware corporation (the “Company”).
The name, address and taxpayer identification
number of the undersigned taxpayer are:
______________________
______________________
______________________
SSN:
The name, address and taxpayer identification
number of the Taxpayer’s spouse/registered domestic partner are (complete if applicable):
______________________
______________________
______________________
SSN:
Description of the property with respect to which the election is
being made:
_______________________
(______________) Shares of the Company.
The date on which the property was transferred
was _____________________. The taxable year to which this election relates is calendar year _______.
Nature of restrictions to which the property is subject:
The Shares are subject to repurchase
by the Company or its assignee upon the occurrence of certain events. This repurchase right lapses based upon the continued performance
of services by the taxpayer over time.
The fair market value at the time of transfer
(determined without regard to any lapse restrictions, as defined in Treasury Regulation Section 1.83-3(i)) of the Shares was $__________
per Share x _________ Shares = $ __________.
The amount paid by the taxpayer for Shares was $ per
Share x ____________ Shares = $ __________.
The amount to include in gross income is $____________.
The undersigned taxpayer will file this election
with the Internal Revenue Service office with which taxpayer files his or her annual income tax return not later than 30 days after the
date of transfer of the property. A copy of this statement has been furnished to the Company. The undersigned is the person performing
the services in connection with which the property was transferred.
The undersigned understands that the foregoing
election may not be revoked except with the consent of the Commissioner.
Dated: |
____________, _______ |
|
Taxpayer Signature: |
___________________________________ |
The undersigned spouse or registered domestic partner of Taxpayer
joins in this election. (Complete if applicable.)
Dated: |
____________, _______ |
|
Spouse’s or Domestic Partner’s Signature: |
______________________________ |
ATTACHMENT 2
Sample Cover Letter to Internal Revenue Service
____________________, _______
VIA CERTIFIED MAIL
RETURN RECEIPT REQUESTED
Internal Revenue
Service
[Address where taxpayer files returns]
| Re: | Election under Section 83(b) of the Internal Revenue Code of
1986 Taxpayer: |
| | Taxpayer’s Social Security Number: |
| | Taxpayer’s Spouse/Domestic Partner: |
| | Taxpayer’s Spouse’s/Domestic Partner’s Social Security Number: |
Ladies and Gentlemen:
Enclosed please find an original and one copy
of an Election under Section 83(b) of the Internal Revenue Code of 1986, as amended, being made by the taxpayer referenced
above. Please acknowledge receipt of the enclosed materials by stamping the enclosed copy of the Election and returning it to me in the
self-addressed stamped envelope provided herewith.
Enclosures
cc: SUREFIRE
MEDICAL, INC. DBA TRISALUS™ LIFE SCIENCES
Exhibit 10.20
TriSalus
Life Sciences, Inc.
2009 Equity Incentive Plan
Notice
of Restricted Stock Unit Award
1. You
(“Participant”) have been granted Restricted Stock Units (“RSUs”) representing shares of the Common
Stock of TriSalus Life Sciences, Inc. (the “Company”) on the following terms:
Name of Participant: |
[ ] |
|
|
Total Number of RSUs Granted: |
[ ] |
|
|
Date of Grant: |
[ ] |
|
|
Vesting Start Date: |
[ ] |
|
|
Expiration Date: |
The earlier of (i) seven (7) years from the Date of Grant and (ii) the termination of the Merger Agreement (as defined below) prior to Closing (as defined in the Merger Agreement). |
|
|
Vesting: |
[To vest, the Service-Based Requirement and the Liquidity Event Requirement must be satisfied prior to the Expiration Date, in each case, subject to the Participant’s Continuous Service as of the date each such requirement is satisfied, as set forth below.] |
|
|
[Service-Based Requirement: |
The Service-Based Requirement will be satisfied in four equal annual installments (rounded down to the nearest whole RSU, except for the last installment where the previous fractions shall vest), commencing on the first anniversary of the Vesting Start Date and continuing on each of the next three anniversaries thereafter, provided that the Participant remains in Continuous Service through each such date.] |
Liquidity Event Requirement: |
The Liquidity Event Requirement will be satisfied (as to any then outstanding RSUs that have not previously been terminated pursuant to Section 2 of the Restricted Stock Unit Agreement) upon the consummation of the Merger as defined in the Merger Agreement (the “Closing”); provided that if the Merger Agreement is terminated prior to the Closing (such date of termination, the “Merger Termination Date”), the Liquidity Event Requirement shall not be satisfied and the RSUs shall immediately expire. “Merger Agreement” shall mean that certain Agreement and Plan of Merger (the “Merger Agreement”) by and among the Company, MedTech Acquisition Corporation, a Delaware corporation (“MTAC”), and MTAC Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of MTAC (“Merger Sub”), pursuant to which, subject to the satisfaction or waiver of certain conditions set forth therein, Merger Sub will merge with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of MTAC (the “Liquidity Event”). [In order to satisfy the Liquidity Event Requirement, the Participant must remain in Continuous Service through the Closing.] |
|
|
Settlement: |
Settlement of RSUs refers to the issuance of shares of Common Stock once the RSU is vested. If an RSU vests as a result of satisfaction of both applicable vesting requirements as described above, the Company will deliver one share of Common Stock for each vested RSU subject to this award at the time of settlement specified in Section 4 of the Restricted Stock Unit Agreement. |
By signing below or otherwise accepting this Award
in a manner acceptable to the Company, you and the Company agree that these RSUs are granted under and governed by the terms and conditions
of this Notice of Restricted Stock Unit Award, the TriSalus Life Sciences, Inc. 2009 Equity Incentive Plan (as amended, the “Plan”)
and the Restricted Stock Unit Agreement. These latter two documents are attached to, and made a part of, this Notice of Restricted Stock
Unit Award. Capitalized terms not otherwise defined herein or in the Restricted Stock Unit Agreement shall have the meaning set forth
in the Plan. You hereby acknowledge that the vesting of the RSUs pursuant to this Notice of Restricted Stock Unit Award is conditioned
on the satisfaction [of the Service-Based Requirement and the occurrence], on or before the Expiration Date, of the Liquidity Event. You
shall have no right with respect to the RSUs to the extent the Liquidity Event does not occur on or before the Expiration Date [(regardless
of the extent to which the Service-Based Requirement was satisfied)]. Section 9 of the Restricted Stock Unit Agreement also includes
important acknowledgements.
Participant: |
|
TriSalus Life Sciences, Inc. |
|
|
|
|
|
|
|
|
By: |
|
Email Address: |
|
Title: |
|
|
|
|
|
Address for Mailing Stock Certificate (only applicable if the Company
has certificated shares):
THE RSUS GRANTED PURSUANT TO THE NOTICE OF
RESTRICTED STOCK UNIT AWARD AND THIS AGREEMENT AND THE SHARES OF COMMON STOCK ISSUABLE THEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, PLEDGED, OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH
ACT OR AN OPINION OF COUNSEL, SATISFACTORY TO THE COMPANY AND ITS COUNSEL, THAT SUCH REGISTRATION IS NOT REQUIRED.
TriSalus
Life Sciences, Inc.
2009 Equity Incentive Plan
Restricted
Stock Unit Agreement
Grant of Restricted Stock
Units.
Grant.
On the terms and conditions set forth in the Notice of Restricted Stock Unit Award and this Agreement, the Company grants to you on the
Date of Grant the number of RSUs set forth in the Notice of Restricted Stock Unit Award. Each RSU represents the right to receive one
share of Common Stock on the terms and conditions set forth in this Agreement.
Consideration.
No payment is required for the RSUs that have been granted to you.
Nature
of Units; No Rights As a Stockholder. Your RSUs are mere bookkeeping entries and represent only the Company’s unfunded
and unsecured promise to issue shares of Common Stock on a future date under specified conditions. As a holder of RSUs, you have no rights
other than the rights of a general creditor of the Company. Your RSUs carry neither voting rights nor rights to cash dividends. You have
no rights as a stockholder of the Company unless and until your RSUs are settled pursuant to Section 4.
Stock
Plan and Defined Terms. Your RSUs are granted pursuant to the Plan, a copy of which you acknowledge having received. The provisions
of the Plan are incorporated into this Agreement by this reference. Certain capitalized terms are defined in Section 10 of this Agreement.
Capitalized terms not otherwise defined herein or in the Notice of Restricted Stock Unit Award shall have the meanings set forth in the
Plan.
Vesting.
Generally.
The RSUs vest in accordance with the vesting schedule set forth in the Notice of Restricted Stock Unit Award. You will receive a benefit
with respect to an RSU only if [both the Service-Based Requirement and] the Liquidity Event Requirement are satisfied on or before the
Expiration Date. [Your RSUs will not vest (in whole or in part) if only one (or if neither) of such requirements is satisfied on or before
the Expiration Date.]
Termination
of Continuous Service. If your Continuous Service terminates for any reason, all RSUs which have not vested (i.e., which have
not met [both the Service-Based Requirement and] the Liquidity Event Requirement) as of the date your Continuous Service terminates shall
automatically terminate and be cancelled on the date that is 30 days after your termination date (such 30-day period, the “Post-Termination
Period”).
Expiration
of RSUs. If a Liquidity Event does not occur on or before the Expiration Date set forth in the Notice of Restricted Stock Unit
Award, all RSUs [(regardless of whether or not, or the extent to which, the Service-Based Requirement had been satisfied as to such RSUs)]
shall automatically terminate and be cancelled upon such date. Upon a termination of one or more RSUs pursuant to this Section 2,
you will have no further right with respect to such RSUs or the shares of Common Stock previously allocated thereto.
Part-Time
Employment and Leaves of Absence. [If you commence working on a part-time basis, then the Company may adjust the Service-Based
Requirement set forth in the Notice of Restricted Stock Unit Award. If you go on a leave of absence, then, to the extent permitted by
applicable law, the Company may adjust or suspend the Service-Based Requirement set forth in the Notice of Restricted Stock Unit Award.]
Except as provided in the preceding sentence, Continuous Service shall be deemed to continue for any purpose under this Agreement while
you are on a bona fide leave of absence approved by the Company in writing. Continuous Service shall be deemed to terminate when
such leave ends, unless you immediately return to active work when such leave ends.
RESTRICTIONS APPLICABLE
TO RSUS.
Except as otherwise provided
in or pursuant to this Agreement or the Plan, these RSUs and the rights and privileges conferred hereby shall not be sold, assigned, transferred,
pledged, hypothecated, or otherwise disposed of by you prior to the settlement of the RSUs. However, you may designate a third party who,
in the event of your death, shall thereafter be entitled to receive any distribution of shares of Common Stock to which you were entitled
at the time of your death pursuant to this Agreement by delivering a written beneficiary designation to the Company’s headquarters
on the prescribed form before your death. If you deliver no such beneficiary designation or if your designated beneficiaries do not survive
you, your estate will receive payments in respect of any vested RSUs.
SETTLEMENT of RSUs.
Settlement
Date. Upon or following a Vesting Date with respect to a particular RSU, the Company will settle the RSU by one share of Common
Stock for that RSU. In connection with the satisfaction of the Liquidity Event Requirement, settlement of any then service-vested RSUs
will, subject to Section 2(b) below, occur 210 days after the Liquidity Event with respect to all RSUs vested on or before such
settlement date (such date, the “Initial Settlement Date”). Any RSUs that vest after the Initial Settlement Date will
be settled on or as soon as practicable after the Vesting Date applicable to the RSUs.
Change
in Initial Settlement Date. To the extent permitted by Code Section 409A, settlement of any RSUs described in the second
sentence of Section 4(a) may occur up to 30 days earlier than the Initial Settlement Date, on a later date in the same calendar
year as the Initial Settlement Date or, if later, by the 15th day of the third calendar month following the Initial Settlement
Date. In addition, settlement of any RSUs described in such second sentence may be accelerated to the extent permitted by Treasury Regulation
Sections 1.409A-3(j)(4)(vi) and (xi). Any decision made pursuant to this Subsection (b) will be made by the Company’s
Board in its sole discretion, and no Participant will be permitted, directly or indirectly, to select the calendar year of settlement.
Form of
Delivery. The form of any delivery of shares of Common Stock (e.g., a stock certificate or electronic entry evidencing such
shares) shall be determined by the Company.
Legality
of Issuance. No shares of Common Stock shall be issued to you upon settlement of these RSUs unless and until the Company has
determined that (i) you and the Company have taken any actions required to register the shares of Common Stock under the Securities
Act or to perfect an exemption from the registration requirements thereof; (ii) any applicable listing requirement of any stock exchange
or other securities market on which stock is listed has been satisfied; and (iii) any other applicable provision of federal, State
or foreign law has been satisfied. The Company shall have no liability to issue shares of Common Stock in respect of the RSUs unless it
is able to do so in compliance with applicable law.
Taxes.
Withholding
Taxes. No consideration will be paid to you in respect of this Award unless you have made arrangements satisfactory to the
Company and your Employer for the payment of all applicable federal, State, local and foreign income and employment withholding taxes
which arise in connection with the vesting and/or settlement of these RSUs (the “Withholding Taxes”). To the extent
that you fail to make such arrangements with respect to these RSUs, then you will permanently forfeit such RSUs. At the discretion of
the Company, these arrangements may include (i) withholding from other compensation or amounts that are owed to you by your Employer,
(ii) payment in cash, (iii) if the Common Stock is publicly traded, payment from the proceeds of the sale of shares through
a Company-approved broker, or (iv) withholding a number of shares of Common Stock that otherwise would be issued to you when the
RSUs are settled. If the Withholding Taxes are satisfied pursuant to clause (iv), you will be deemed to have been issued the full number
of shares subject to the RSUs and the Fair Market Value of the withheld shares, determined as of the date when taxes otherwise would have
been withheld in cash, will be applied to the Withholding Taxes and such amount will be remitted to appropriate tax authorities by the
Company or your Employer. You acknowledge that the responsibility for all Withholding Taxes is yours and may exceed the amount actually
withheld by the Company or your Employer.
Section 409A.
The settlement of these RSUs is intended to comply with the requirements of Code Section 409A and shall be administered and interpreted
in a manner that complies with such requirements so that this award is not subject to additional tax or interest under Code Section 409A.
To the extent that any provision of this Agreement is ambiguous as to its compliance with Code Section 409A, the provision shall
be read in such a manner so that all payments hereunder comply with Code Section 409A. In this regard, to the extent necessary to
comply with Code Section 409A, any reference to your “termination of employment” or similar terms will mean your “separation
from service” within the meaning of Code Section 409A(a)(2)(A)(i) (a “Separation”). In addition, if
this Award is payable upon your Separation and you are a “specified employee” of the Company or any affiliate thereof within
the meaning of Code Section 409A(a)(2)(B)(i) on the day of your Separation, then no such payment shall be made prior to the
date that is the earlier of (i) six months and one day after your Separation, or (ii) your death, but only to the extent such
delay is necessary so that this award is not subject to additional tax or interest under Code Section 409A. Each installment of your
RSUs that vests is intended to constitute a separate payment for purposes of Code Section 409A.
Restrictions
APPLICABLE TO SHARES.
Securities
Law Restrictions. Regardless of whether the offering and sale of shares of Common Stock under the Plan have been registered
under the Securities Act or have been registered or qualified under the securities laws of any State or other relevant jurisdiction, the
Company at its discretion may impose restrictions upon the sale, pledge or other transfer of such shares (including the placement of appropriate
legends on the stock certificates (or electronic equivalent) or the imposition of stop-transfer instructions) and may refuse (or may be
required to refuse) to transfer shares of Common Stock acquired hereunder (or shares proposed to be transferred in a subsequent transfer)
if, in the judgment of the Company, such restrictions, legends or refusal are necessary or appropriate to achieve compliance with the
Securities Act or other relevant securities or other laws, including without limitation under Regulation S of the Securities Act or pursuant
to another available exemption from registration. You (or the beneficiary or your personal representative in the event of your death or
incapacity, as the case may be) shall deliver to the Company any representations or other documents or assurances as the Company may deem
necessary or reasonably desirable to ensure compliance with all applicable legal and regulatory requirements.
Market
Stand-Off. In connection with any underwritten public offering by the Company of its equity securities pursuant to an effective
registration statement filed under the Securities Act, including the Company’s initial public offering, you or a transferee shall
not directly or indirectly sell, make any short sale of, loan, hypothecate, pledge, offer, grant or sell any option or other contract
for the purchase of, purchase any option or other contract for the sale of, or otherwise dispose of or transfer, or agree to engage in
any of the foregoing transactions with respect to, any shares acquired under this Agreement without the prior written consent of the Company
or its managing underwriter. Such restriction (the “Market Stand-Off”) shall be in effect for such period of time following
the date of the final prospectus for the offering as may be requested by the Company or such underwriter. In no event, however, shall
such period exceed 180 days plus such additional period as may reasonably be requested by the Company or such underwriter to accommodate
regulatory restrictions on (i) the publication or other distribution of research reports or (ii) analyst recommendations and
opinions, including (without limitation) the restrictions set forth in Rule 2711(f)(4) of the National Association of Securities
Dealers and Rule 472(f)(4) of the New York Stock Exchange, as amended, or any similar successor rules. The Market Stand-Off
shall in any event terminate two years after the date of the Company’s initial public offering. In the event of the declaration
of a stock dividend, a spin-off, a stock split, an adjustment in conversion ratio, a recapitalization or a similar transaction affecting
the Company’s outstanding securities without receipt of consideration, any new, substituted or additional securities which are by
reason of such transaction distributed with respect to any shares subject to the Market Stand-Off, or into which such shares of Common
Stock thereby become convertible, shall immediately be subject to the Market Stand-Off. In order to enforce the Market Stand-Off, the
Company may impose stop-transfer instructions with respect to the shares of Common Stock acquired under this Agreement until the end of
the applicable stand-off period. The Company’s underwriters shall be beneficiaries of the agreement set forth in this Section 6(b).
This Section 6(b) shall not apply to shares of Common Stock registered in the public offering under the Securities Act.
Investment
Intent at Grant. You represent and agree that the shares of Common Stock to be acquired upon settlement of these RSUs will
be acquired for investment, and not with a view to the sale or distribution thereof.
Investment
Intent at Settlement. In the event that the sale of shares of Common Stock under the Plan is not registered under the Securities
Act but an exemption is available that requires an investment representation or other representation, you shall represent and agree at
the time of issuance that the shares of Common Stock being acquired upon settlement of these RSUs are being acquired for investment, and
not with a view to the sale or distribution thereof, and shall make such other representations as are deemed necessary or appropriate
by the Company and its counsel, including, at the time of settlement, such representations as required by Regulation S of the Securities
Act (if the Company is relying on such exemption).
Rights
of the Company. The Company shall not be required to (i) transfer on its books any shares of Common Stock that have been
sold or transferred in contravention of this Agreement or (ii) treat as the owner of shares of Common Stock, or otherwise to accord
voting, dividend or liquidation rights to, any transferee to whom the shares of Common Stock have been transferred in contravention of
this Agreement.
Legends.
All certificates evidencing the shares of Common Stock issued under this Agreement shall bear the following legend:
“THE SHARES REPRESENTED HEREBY
(AND ANY INTEREST THEREIN) MAY NOT BE SOLD, ASSIGNED, TRANSFERRED, ENCUMBERED OR IN ANY MANNER DISPOSED OF, EXCEPT IN COMPLIANCE
WITH THE TERMS OF THE RESTRICTED STOCK UNIT AGREEMENT PURSUANT TO WHICH SUCH SHARES WERE ACQUIRED. THE SHARES ARE SUBJECT TO RESTRICTIONS
ON TRANSFER AS SET FORTH IN SUCH RESTRICTED STOCK UNIT AGREEMENT. THE SECRETARY OF THE COMPANY WILL UPON WRITTEN REQUEST FURNISH A COPY
OF SUCH RESTRICTED STOCK UNIT AGREEMENT TO THE HOLDER HEREOF WITHOUT CHARGE.”
All certificates evidencing shares of Common Stock
issued under this Agreement in an unregistered transaction shall bear the following legend (and such other restrictive legends as are
required or deemed advisable under the provisions of any applicable law):
“THE SHARES REPRESENTED HEREBY
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) OR ANY SECURITIES LAWS OF ANY U.S. STATE,
AND MAY NOT BE SOLD, REOFFERED, PLEDGED, ASSIGNED, ENCUMBERED OR OTHERWISE TRANSFERRED OR DISPOSED OF WITHOUT AN EFFECTIVE REGISTRATION
THEREOF UNDER SUCH ACT OR AN OPINION OF COUNSEL, SATISFACTORY TO THE COMPANY AND ITS COUNSEL, THAT SUCH REGISTRATION IS NOT REQUIRED.
IN THE ABSENCE OF REGISTRATION OR THE AVAILABILITY (CONFIRMED BY OPINION OF COUNSEL) OF AN ALTERNATIVE EXEMPTION FROM REGISTRATION UNDER
THE ACT (INCLUDING WITHOUT LIMITATION IN ACCORDANCE WITH REGULATION S UNDER THE ACT), THESE SHARES MAY NOT BE SOLD, REOFFERED, PLEDGED,
ASSIGNED, ENCUMBERED OR OTHERWISE TRANSFERRED OR DISPOSED OF. HEDGING TRANSACTIONS INVOLVING THESE SHARES MAY NOT BE CONDUCTED UNLESS
IN COMPLIANCE WITH THE ACT.”
Removal
of Legends. If, in the opinion of the Company and its counsel, any legend placed on a stock certificate representing shares
of Common Stock issued under this Agreement is no longer required, the holder of such certificate shall be entitled to exchange such certificate
for a certificate representing the same number of shares but without such legend.
Administration.
Any determination by the Company and its counsel in connection with any of the matters set forth in this Section 6 shall be conclusive
and binding on you and all other persons.
Adjustment
Of Shares of Common stock.
2. In
the event of any transaction described in Section 13(a) of the Plan, the terms of these RSUs (including, without limitation,
the number and kind of shares subject to these RSUs) shall be adjusted as set forth in Section 13(a) of the Plan. In the event
that the Company is a party to a merger or consolidation or in the event of a sale of all or substantially all of the Company’s
stock or assets, these RSUs shall be subject to the treatment provided by the Board in its sole discretion, as provided in Section 13
of the Plan; provided, however, that any action taken must either preserve the exemption of your RSUs from Code Section 409A or comply
with Code Section 409A. Any additional RSUs and any new, substituted or additional shares, cash or other property that become subject
to this award as a result of any such transaction shall be subject to the same conditions and restrictions as applicable to the RSUs to
which they relate.
Miscellaneous
provisions.
No
Retention Rights. Nothing in this Agreement or in the Plan shall confer upon you the right to remain in Continuous Service
in any capacity for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Company (or any
Subsidiary employing or retaining you) or you, which rights are hereby expressly reserved by each, to terminate your Continuous Service
at any time and for any reason, with or without cause.
Notice.
Any notice required by the terms of this Agreement shall be given in writing. It shall be deemed effective upon (i) personal delivery,
(ii) deposit with the United States Postal Service, by registered or certified mail, with postage and fees prepaid, (iii) deposit
with Federal Express Corporation, with shipping charges prepaid or (iv) deposit with any internationally recognized express mail
courier service, with shipping charges prepaid. Notice shall be addressed to the Company at its principal executive office and to you
at the address that you most recently provided to the Company in accordance with this Section 8(b). In addition, to the extent required
or permitted pursuant to rules established by the Company from time to time, notices may be delivered electronically.
Modifications
and Waivers. No provision of this Agreement shall be modified, waived or discharged unless the modification, waiver or discharge
is agreed to in writing and signed by you and by an authorized officer of the Company (other than you). No waiver by either party of any
breach of, or of compliance with, any condition or provision of this Agreement by the other party shall be considered a waiver of any
other condition or provision or of the same condition or provision at another time.
Entire
Agreement. The Notice of Restricted Stock Unit Award, this Agreement and the Plan constitute the entire understanding between
you and the Company regarding the subject matter hereof. They supersede any other agreements, representations or understandings (whether
oral or written and whether express or implied) that relate to the subject matter hereof.
Choice
of Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, as such laws
are applied to contracts entered into and performed in such State.
Severability.
Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Agreement shall be held to be prohibited by or invalid under applicable law, such provision shall be
ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining
provisions of this Agreement.
Successors
and Assigns. Except as otherwise expressly provided to the contrary, the provisions of this Agreement shall inure to the benefit
of, and be binding upon, the Company and its successors and assigns and be binding upon you and your legal representatives, heirs, legatees,
distributees, assigns and transferees by operation of law, whether or not any such person has become a party to this Agreement or has
agreed in writing to join herein and to be bound by the terms, conditions and restrictions hereof.
Acknowledgements.
In addition to the other terms,
conditions and restrictions imposed on your RSUs and the shares issuable upon settlement of your RSUs pursuant to this Agreement and the
Plan, you expressly acknowledge being subject to Section 6 (Restrictions Applicable to Shares, including without limitation the Market
Stand-Off), as well as the following provisions:
Tax
Consequences. You acknowledge that there will be tax consequences upon vesting and/or settlement of the RSUs and/or
disposition of the shares of Common Stock, if any, received hereunder, and you should consult a tax adviser regarding your tax obligations
prior to such event. You acknowledge that the Company is not providing any tax, legal, or financial advice, nor is the Company making
any recommendations regarding your participation in the Plan or acquisition or sale of shares subject to this Award. You are hereby advised
to consult with your own personal tax, legal, and financial advisors regarding your participation in the Plan. You further acknowledge
that the Company (i) makes no representations or undertakings regarding the tax treatment of the award of RSUs, including, but not
limited to the grant, vesting, or settlement of the RSUs, the subsequent sale of shares acquired pursuant to such RSUs, and the receipt
of any dividends; and (ii) does not commit to and is under no obligation to structure the terms of the grant of the RSUs to reduce
or eliminate your tax liability or achieve any particular tax result. You agree that the Company does not have a duty to design or administer
the RSUs, the Plan or its other compensation programs in a manner that minimizes your tax liability. You shall not make any claim against
the Company or its Board, officers, or employees related to tax matters arising from this award or your other compensation.
Electronic
Delivery of Documents. You acknowledge and agree that the Company may, in its sole discretion, deliver all documents relating
the Company, the Plan or these RSUs and all other documents that the Company is required to deliver to its security holders (including,
without limitation, disclosures that may be required by the Securities and Exchange Commission) by email or other means of electronic
transmission (including by posting them on a website maintained by the Company or a third party under contract with the Company). You
acknowledge that you may incur costs in connection with any such delivery by means of electronic transmission, including the cost of accessing
the internet and printing fees, and that an interruption of internet access may interfere with his or her ability to access the documents.
Plan
Discretionary. You understand and acknowledge that (i) the Plan is entirely discretionary, (ii) the Company and your
employer have reserved the right to amend, suspend or terminate the Plan at any time, (iii) the grant of the RSUs does not in any
way create any contractual or other right to receive additional grants of RSUs (or benefits in lieu of RSUs) at any time or in any amount
and (iv) all determinations with respect to any additional grants, including (without limitation) the times when RSUs will be granted,
the number of shares offered, and the vesting schedule, will be at the sole discretion of the Company.
Termination
of Continuous Service. You understand and acknowledge that participation in the Plan ceases upon termination of your Continuous
Service for any reason, except as may explicitly be provided otherwise in the Plan or this Agreement.
Extraordinary
Compensation. The value of your RSUs and the shares issuable thereunder shall be an extraordinary item of compensation outside
the scope of your employment contract, if any, and shall not be considered a part of your normal or expected compensation for purposes
of calculating severance, resignation, redundancy or end-of-service payments, bonuses, long-service awards, pension or retirement benefits
or similar payments.
Authorization
to Disclose. You hereby authorize and direct your employer to disclose to the Company or any Subsidiary any information regarding
your employment, the nature and amount of your compensation and the fact and conditions of your participation in the Plan, as your employer
deems necessary or appropriate to facilitate the administration of the Plan.
Personal
Data Authorization. You consent to the collection, use and transfer of personal data as described in this Subsection (g).
You understand and acknowledge that the Company, your Employer and the Company’s other Subsidiaries hold certain personal information
regarding you for the purpose of managing and administering the Plan, including (without limitation) your name, home address, telephone
number, date of birth, social insurance number, salary, nationality, job title, any shares or directorships held in the Company and details
of all RSUs or any other entitlements to shares awarded, canceled, exercised, vested, unvested or outstanding in your favor (the “Data”).
You further understand and acknowledge that the Company and/or its Subsidiaries will transfer Data among themselves as necessary for the
purpose of implementation, administration and management of your participation in the Plan and that the Company and/or any Subsidiary
may each further transfer Data to any third party assisting the Company in the implementation, administration and management of the Plan.
You understand and acknowledge that the recipients of Data may be located in the United States or elsewhere. You authorize such recipients
to receive, possess, use, retain and transfer Data, in electronic or other form, for the purpose of administering your participation in
the Plan, including a transfer to any broker or other third party with whom you elect to deposit shares acquired under the Plan of such
Data as may be required for the administration of the Plan and/or the subsequent holding of shares on your behalf. You may, at any time,
view the Data, require any necessary modifications of Data or withdraw the consents set forth in this Subsection (g) by contacting
the Company in writing.
Definitions.
“Agreement”
means this Restricted Stock Unit Agreement.
“Continuous Service”
means that the Participant’s service with the Company as a Service Provider is not interrupted or terminated. A change in the capacity
in which the Participant renders service to the Company or one of its Subsidiaries will not terminate a Participant’s Continuous
Service, provided that there is no interruption or termination of the Participant’s Continuous Service. To the extent permitted
by law, the Board or the chief executive officer of the Company, in that party’s sole discretion, may determine whether Continuous
Service will be considered interrupted in the case of (i) any leave of absence approved by the Company, including sick leave, military
leave or an other personal leave, or (ii) transfers between the Company, one of its Subsidiaries, or their successors. Notwithstanding
the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in an Award only to such extent as may
be provided in the Company’s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable
to the Participant, or as otherwise required by law. In addition, to the extent required for exemption form or compliance with Section 409A
of the Code, the determination of whether there has been a termination of Continuous Service will be made, and such term will be construed,
in a manner that is consistent with the definition of “separation from service” as defined under Treasury Regulation Section 1.409A-1(h).
“Date of Grant”
means the date specified in the Notice of Restricted Stock Unit Award, which date shall be the later of (i) the date on which the
Board resolved to grant these RSUs or (ii) your first date of Continuous Service.
“Expiration Date”
means the expiration date of the RSUs as set forth in the Notice of Restricted Stock Unit Award.
“Liquidity Event Requirement”
means the requirements as described in the Notice of Restricted Stock Unit Award.
“Plan” means
the TriSalus Life Sciences, Inc. 2009 Equity Incentive Plan, as in effect on the Date of Grant.
[“Service-Based Requirement”
means the requirement to provide Service over the period of time set forth in the Notice of Restricted Stock Unit Award.]
“Vesting Date”
means the date that the [Service-Based Requirement and the] Liquidity Event Requirement set forth in the Notice of Restricted Stock Unit
Award have been satisfied.
Exhibit 10.21
TriSalus
Life Sciences, Inc.
2023
Equity Incentive Plan
Adopted
by the Board of Directors: August 10, 2023
Approved by the Stockholders: August 8, 2023
1. General.
(a) Plan
Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees,
Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate
and to provide a means by which such persons may be given an opportunity to benefit from increases in value of the Common Stock through
the granting of Awards.
(b)
Available Awards. The Plan provides for the grant of the following
Awards: (i) Incentive Stock Options; (ii) Nonstatutory Stock Options; (iii) SARs; (iv) Restricted Stock Awards;
(v) RSU Awards; (vi) Performance Awards; and (vii) Other Awards.
(c)
Adoption Date; Effective Date. The Plan will come into existence on
the Adoption Date, but no Award may be granted prior to the Effective Date.
2. Shares
Subject to the Plan.
(a) Share
Reserve. Subject to adjustment in accordance with Section 2(c) and any
adjustments as necessary to implement any Capitalization Adjustments, the aggregate number of shares of Common Stock that may be
issued pursuant to Awards will not exceed 5,585,008 shares of Common Stock (equal to twelve percent (12%) of the Fully Diluted
Common Stock determined as of immediately after the Effective Time). In addition, subject to any adjustments as necessary to
implement any Capitalization Adjustments, such aggregate number of shares of Common Stock will automatically increase on
January 1 of each year for a period of ten years commencing on January 1, 2024 and ending on (and including)
January 1, 2033, in an amount equal to five percent (5%) of the total number of shares of the Fully Diluted Common Stock
determined as of the day prior to such increase; provided, however that the Board may act prior to January 1st of a
given year to provide that the increase for such year will be a lesser number of shares of Common Stock.
(b) Aggregate
Incentive Stock Option Limit. Subject to any adjustments as necessary to implement any Capitalization
Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options
is 16,755,023 shares (equal to three hundred percent (300%) of the total number of shares of Common Stock initially reserved for issuance
under Section 2(a)), or if lesser, the aggregate number of shares of Common Stock reserved under Section 2(a).
(c) Share
Reserve Operation.
(i) Limit
Applies to Common Stock Issued Pursuant to Awards. For clarity, the Share Reserve is a limit
on the number of shares of Common Stock that may be issued pursuant to Awards and does not limit the granting of Awards, except that
the Company will keep available at all times the number of shares of Common Stock reasonably required to satisfy its obligations to issue
shares pursuant to such Awards. Shares may be issued in connection with a merger or acquisition as permitted by, as applicable, Nasdaq
Listing Rule 5635(c), NYSE Listed Company Manual Section 303A.08, NYSE American Company Guide Section 711 or other applicable
rule, and such issuance will not reduce the number of shares available for issuance under the Plan.
(ii) Actions
that Do Not Constitute Issuance of Common Stock and Do Not Reduce Share Reserve. The following
actions do not result in an issuance of shares under the Plan and accordingly do not reduce the number of shares subject to the Share
Reserve and available for issuance under the Plan: (1) the expiration or termination of any portion of an Award without the shares
covered by such portion of the Award having been issued; (2) the settlement of any portion of an Award in cash (i.e., the
Participant receives cash rather than Common Stock); (3) the withholding of shares that would otherwise be issued by the Company
to satisfy the exercise, strike or purchase price of an Award; or (4) the withholding of shares that would otherwise be issued by
the Company to satisfy a tax withholding obligation in connection with an Award.
(iii) Reversion
of Previously Issued Shares of Common Stock to Share Reserve. The following shares of Common
Stock previously issued pursuant to an Award and accordingly initially deducted from the Share Reserve will be added back to the Share
Reserve and again become available for issuance under the Plan: (1) any shares that are forfeited back to or repurchased by the
Company because of a failure to meet a contingency or condition required for the vesting of such shares, (2) any shares that are
reacquired by the Company to satisfy the exercise, strike or purchase price of an Award, and (3) any shares that are reacquired
by the Company to satisfy a tax withholding obligation in connection with an Award.
3. Eligibility
and Limitations.
(a) Eligible
Award Recipients. Subject to the terms of the Plan, Employees, Directors and Consultants are
eligible to receive Awards.
(b) Specific
Award Limitations.
(i) Limitations
on Incentive Stock Option Recipients. Incentive Stock Options may be granted only to Employees
of the Company or a “parent corporation” or “subsidiary corporation” thereof (as such terms are defined in Sections
424(e) and (f) of the Code).
(ii) Incentive
Stock Option $100,000 Limitation. To the extent that the aggregate Fair Market Value (determined
at the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder
during any calendar year (under all plans of the Company and any Affiliates) exceeds $100,000 (or such other limit established in the
Code) or otherwise does not comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed
such limit (according to the order in which they were granted) or otherwise do not comply with such rules will be treated as Nonstatutory
Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s).
(iii) Limitations
on Incentive Stock Options Granted to Ten Percent Stockholders. A Ten Percent Stockholder may
not be granted an Incentive Stock Option unless (1) the exercise price of such Option is at least 110% of the Fair Market Value
of a share of Common Stock on the date of grant of such Option and (2) the Option is not exercisable after the expiration of five
years from the date of grant of such Option.
(iv) Limitations
on Nonstatutory Stock Options and SARs. Nonstatutory Stock Options and SARs may not be granted
to Employees, Directors and Consultants unless the stock underlying such Awards qualifies as “service recipient stock” under
Section 409A or unless such Awards otherwise comply with the requirements of Section 409A.
(c) Aggregate
Incentive Stock Option Limit. The aggregate maximum number of shares of Common Stock that may
be issued pursuant to the exercise of Incentive Stock Options is the number of shares specified in Section 2(b).
(d) Non-Employee
Director Compensation Limit. The aggregate value of all compensation granted or paid, as applicable,
to any individual for service as a Non-Employee Director with respect to any period commencing on the date of the Company’s Annual
Meeting of Stockholders for a particular year and ending on the day immediately prior to the date of the Company’s Annual Meeting
of Stockholders for the next subsequent year (the “Annual Period”), including Awards granted and cash fees
paid by the Company to such Non-Employee Director, will not exceed (1) $750,000 in total value or (2) in the event such Non-Employee
Director is first appointed or elected to the Board during such Annual Period, $1,000,000 in total value, in each case, calculating the
value of any equity awards based on the grant date fair value of such equity awards for financial reporting purposes. The limitations
in this Section 3(d) shall apply commencing with the Annual Period that begins on the Company’s first Annual Meeting
of Stockholders following the Effective Date.
4. Options
and Stock Appreciation Rights.
Each
Option and SAR will have such terms and conditions as determined by the Board. Each Option will be designated in writing as an Incentive
Stock Option or Nonstatutory Stock Option at the time of grant; provided, however, that if an Option is not so designated or if an Option
designated as an Incentive Stock Option fails to qualify as an Incentive Stock Option, then such Option will be a Nonstatutory Stock
Option, and the shares purchased upon exercise of each type of Option will be separately accounted for. Each SAR will be denominated
in shares of Common Stock equivalents. The terms and conditions of separate Options and SARs need not be identical; provided, however,
that each Option Agreement and SAR Agreement will conform (through incorporation of provisions hereof by reference in the Award Agreement
or otherwise) to the substance of each of the following provisions:
(a) Term.
Subject to Section 3(b) regarding Ten Percent Stockholders, no Option or SAR will
be exercisable after the expiration of ten years from the date of grant of such Award or such shorter period specified in the Award Agreement.
(b) Exercise
or Strike Price. Subject to Section 3(b) regarding Ten Percent Stockholders, the exercise
or strike price of each Option or SAR will not be less than 100% of the Fair Market Value on the date of grant of such Award. Notwithstanding
the foregoing, an Option or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value on the date
of grant of such Award if such Award is granted pursuant to an assumption of or substitution for another option or stock appreciation
right pursuant to a Corporate Transaction and in a manner consistent with the provisions of Sections 409A and, if applicable, 424(a) of
the Code.
(c) Exercise
Procedure and Payment of Exercise Price for Options. In order to exercise an Option, the Participant
must provide notice of exercise to the Plan Administrator in accordance with the procedures specified in the Option Agreement or otherwise
provided by the Company. The Board has the authority to grant Options that do not permit all of the following methods of payment (or
otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to utilize a particular
method of payment. The exercise price of an Option may be paid, to the extent permitted by Applicable Law and as determined by the Board,
by one or more of the following methods of payment to the extent set forth in the Option Agreement:
(i) by
cash or check, bank draft or money order payable to the Company;
(ii) pursuant
to a “cashless exercise” program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to
the issuance of the Common Stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt
of irrevocable instructions to pay the exercise price to the Company from the sales proceeds;
(iii) by
delivery to the Company (either by actual delivery or attestation) of shares of Common Stock that are already owned by the Participant
free and clear of any liens, claims, encumbrances or security interests, with a Fair Market Value on the date of exercise that does not
exceed the exercise price, provided that (1) at the time of exercise the Common Stock is publicly traded, (2) any remaining
balance of the exercise price not satisfied by such delivery is paid by the Participant in cash or other permitted form of payment, (3) such
delivery would not violate any Applicable Law or agreement restricting the redemption of the Common Stock, (4) any certificated
shares are endorsed or accompanied by an executed assignment separate from certificate, and (5) such shares have been held by the
Participant for any minimum period necessary to avoid adverse accounting treatment as a result of such delivery;
(iv) if
the Option is a Nonstatutory Stock Option, by a “net exercise” arrangement pursuant to which the Company will reduce the
number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value on the date of
exercise that does not exceed the exercise price, provided that (1) such shares used to pay the exercise price will not be exercisable
thereafter and (2) any remaining balance of the exercise price not satisfied by such net exercise is paid by the Participant in
cash or other permitted form of payment; or
(v) in
any other form of consideration that may be acceptable to the Board and permissible under Applicable Law.
(d) Exercise
Procedure and Payment of Appreciation Distribution for SARs. In order to exercise any SAR, the
Participant must provide notice of exercise to the Plan Administrator in accordance with the SAR Agreement. The appreciation distribution
payable to a Participant upon the exercise of a SAR will not be greater than an amount equal to the excess of (i) the aggregate
Fair Market Value on the date of exercise of a number of shares of Common Stock equal to the number of Common Stock equivalents that
are vested and being exercised under such SAR, over (ii) the strike price of such SAR. Such appreciation distribution may be paid
to the Participant in the form of Common Stock or cash (or any combination of Common Stock and cash) or in any other form of payment,
as determined by the Board and specified in the SAR Agreement.
(e) Transferability.
Options and SARs may not be transferred to third party financial institutions for value. The
Board may impose such additional limitations on the transferability of an Option or SAR as it determines. In the absence of any such
determination by the Board, the following restrictions on the transferability of Options and SARs will apply, provided that except as
explicitly provided herein, neither an Option nor a SAR may be transferred for consideration and provided, further, that if an
Option is an Incentive Stock Option, such Option may be deemed to be a Nonstatutory Stock Option as a result of such transfer:
(i) Restrictions
on Transfer. An Option or SAR will not be transferable, except by will or by the laws of descent
and distribution, and will be exercisable during the lifetime of the Participant only by the Participant; provided, however, that the
Board may permit transfer of an Option or SAR in a manner that is not prohibited by applicable tax and securities laws upon the Participant’s
request, including to a trust if the Participant is considered to be the sole beneficial owner of such trust (as determined under Section 671
of the Code and applicable state law) while such Option or SAR is held in such trust, provided that the Participant and the trustee enter
into a transfer and other agreements required by the Company.
(ii) Domestic
Relations Orders. Notwithstanding the foregoing, subject to the execution of transfer documentation
in a format acceptable to the Company and subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be
transferred pursuant to a domestic relations order.
(f) Vesting.
The Board may impose such restrictions on or conditions to the vesting and/or exercisability
of an Option or SAR as determined by the Board. Except as otherwise provided in the Award Agreement or other written agreement between
a Participant and the Company or an Affiliate, vesting of Options and SARs will cease upon termination of the Participant’s Continuous
Service.
(g) Termination
of Continuous Service for Cause. Except as explicitly otherwise provided in the Award Agreement
or other written agreement between a Participant and the Company or an Affiliate, if a Participant’s Continuous Service is terminated
for Cause, the Participant’s Options and SARs will terminate and be forfeited immediately upon such termination of Continuous Service,
and the Participant will be prohibited from exercising any portion (including any vested portion) of such Awards on and after the date
of such termination of Continuous Service and the Participant will have no further right, title or interest in such forfeited Award,
the shares of Common Stock subject to the forfeited Award, or any consideration in respect of the forfeited Award.
(h) Post-Termination
Exercise Period Following Termination of Continuous Service for Reasons Other than Cause. Subject
to Section 4(i), if a Participant’s Continuous Service terminates for any reason other than for Cause, the Participant may
exercise his or her Option or SAR to the extent vested, but only within the following period of time or, if applicable, such other period
of time provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate; provided, however,
that in no event may such Award be exercised after the expiration of its maximum term (as set forth in Section 4(a)):
(i) three
months following the date of such termination if such termination is a termination without Cause (other than any termination due to the
Participant’s Disability or death);
(ii) 12
months following the date of such termination if such termination is due to the Participant’s Disability;
(iii) 18
months following the date of such termination if such termination is due to the Participant’s death; or
(iv) 18
months following the date of the Participant’s death if such death occurs following the date of such termination but during the
period such Award is otherwise exercisable (as provided in (i) or (ii) above).
Following the date
of such termination, to the extent the Participant does not exercise such Award within the applicable Post-Termination Exercise Period
(or, if earlier, prior to the expiration of the maximum term of such Award), such unexercised portion of the Award will terminate, and
the Participant will have no further right, title or interest in the terminated Award, the shares of Common Stock subject to the terminated
Award, or any consideration in respect of the terminated Award.
(i) Restrictions
on Exercise; Extension of Exercisability. A Participant may not exercise an Option or SAR at
any time that the issuance of shares of Common Stock upon such exercise would violate Applicable Law. Except as otherwise provided in
the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, if a Participant’s Continuous
Service terminates for any reason other than for Cause and, at any time during the last thirty (30) days of the applicable Post-Termination
Exercise Period: (i) the exercise of the Participant’s Option or SAR would be prohibited solely because the issuance of shares
of Common Stock upon such exercise would violate Applicable Law, or (ii) the immediate sale of any shares of Common Stock issued
upon such exercise would violate the Company’s Trading Policy, then the applicable Post-Termination Exercise Period will be extended
to the last day of the calendar month that commences following the date the Award would otherwise expire, with an additional extension
of the exercise period to the last day of the next calendar month to apply if any of the foregoing restrictions apply at any time during
such extended exercise period, generally without limitation as to the maximum permitted number of extensions); provided, however, that
in no event may such Award be exercised after the expiration of its maximum term (as set forth in Section 4(a)).
(j) Non-Exempt
Employees. No Option or SAR, whether or not vested, granted to an Employee who is a non-exempt
employee for purposes of the Fair Labor Standards Act of 1938, as amended, will be first exercisable for any shares of Common Stock until
at least six months following the date of grant of such Award. Notwithstanding the foregoing, in accordance with the provisions of the
Worker Economic Opportunity Act, any vested portion of such Award may be exercised earlier than six months following the date of grant
of such Award in the event of (i) such Participant’s death or Disability, (ii) a Corporate Transaction in which such
Award is not assumed, continued or substituted, (iii) a Change in Control, or (iv) such Participant’s retirement (as
such term may be defined in the Award Agreement or another applicable agreement or, in the absence of any such definition, in accordance
with the Company’s then current employment policies and guidelines). This Section 4(j) is intended to operate so that
any income derived by a non-exempt employee in connection with the exercise or vesting of an Option or SAR will be exempt from his or
her regular rate of pay.
(k) Whole
Shares. Options and SARs may be exercised only with respect to whole shares of Common Stock
or their equivalents.
5. Awards
Other Than Options and Stock Appreciation Rights.
(a) Restricted
Stock Awards and RSU Awards. Each Restricted Stock Award and RSU Award will have such terms
and conditions as determined by the Board; provided, however, that each Restricted Stock Award Agreement and RSU Award Agreement will
conform (through incorporation of the provisions hereof by reference in the Award Agreement or otherwise) to the substance of each of
the following provisions:
(i) Form of
Award.
(1) Restricted
Stock Awards: To the extent consistent with the Company’s Bylaws, at the Board’s election, shares of Common Stock subject
to a Restricted Stock Award may be (A) held in book entry form subject to the Company’s instructions until such shares become
vested or any other restrictions lapse, or (B) evidenced by a certificate, which certificate will be held in such form and manner
as determined by the Board. Unless otherwise determined by the Board, a Participant will have voting and other rights as a stockholder
of the Company with respect to any shares subject to a Restricted Stock Award.
(2) RSU
Awards: An RSU Award represents a Participant’s right to be issued on a future date the number of shares of Common Stock that is
equal to the number of restricted stock units subject to the RSU Award. As a holder of an RSU Award, a Participant is an unsecured creditor
of the Company with respect to the Company's unfunded obligation, if any, to issue shares of Common Stock in settlement of such Award
and nothing contained in the Plan or any RSU Agreement, and no action taken pursuant to its provisions, will create or be construed to
create a trust of any kind or a fiduciary relationship between a Participant and the Company or an Affiliate or any other person. A Participant
will not have voting or any other rights as a stockholder of the Company with respect to any RSU Award (unless and until shares are actually
issued in settlement of a vested RSU Award).
(ii) Consideration.
(1) Restricted
Stock Awards: A Restricted Stock Award may be granted in consideration for (A) cash or check, bank draft or money order payable
to the Company, (B) past services to the Company or an Affiliate, or (C) any other form of consideration (including future
services) as the Board may determine and as is permissible under Applicable Law.
(2) RSU
Awards: Unless otherwise determined by the Board at the time of grant, an RSU Award will be granted in consideration for the Participant’s
services to the Company or an Affiliate, such that the Participant will not be required to make any payment to the Company (other than
such services) with respect to the grant or vesting of the RSU Award, or the issuance of any shares of Common Stock pursuant to the RSU
Award. If, at the time of grant, the Board determines that any consideration must be paid by the Participant (in a form other than the
Participant’s services to the Company or an Affiliate) upon the issuance of any shares of Common Stock in settlement of the RSU
Award, such consideration may be paid in any form of consideration as the Board may determine and permissible under Applicable Law.
(iii) Vesting.
The Board may impose such restrictions on or conditions to the vesting of a Restricted Stock
Award or RSU Award as determined by the Board. Except as otherwise provided in the Award Agreement or other written agreement between
a Participant and the Company or an Affiliate, vesting of Restricted Stock Awards and RSU Awards will cease upon termination of the Participant’s
Continuous Service.
(iv) Termination
of Continuous Service. Except as otherwise provided in the Award Agreement or other written
agreement between a Participant and the Company or an Affiliate, if a Participant’s Continuous Service terminates for any reason,
(1) the Company may receive through a forfeiture condition or a repurchase right any or all of the shares of Common Stock held by
the Participant under his or her Restricted Stock Award that have not vested as of the date of such termination and the Participant will
have no further right, title or interest in the Restricted Stock Award, the shares of Common Stock subject to the Restricted Stock Award,
or any consideration in respect of the Restricted Stock Award and (2) any portion of his or her RSU Award that has not vested will
be forfeited upon such termination and the Participant will have no further right, title or interest in the RSU Award, the shares of
Common Stock issuable pursuant to the RSU Award, or any consideration in respect of the RSU Award.
(v) Dividends
and Dividend Equivalents. Dividends or dividend equivalents may be paid or credited, as applicable,
with respect to any shares of Common Stock subject to a Restricted Stock Award or RSU Award, as determined by the Board and specified
in the Award Agreement. Except as provided in an Award Agreement, any dividends or dividend equivalents will only be paid to the Participant
at the same time and pursuant to the same conditions as the underlying shares of Restricted Stock or RSUs vest or settle, as applicable.
(vi) Settlement
of RSU Awards. An RSU Award may be settled by the issuance of shares of Common Stock or cash
(or any combination thereof) or in any other form of payment, as determined by the Board and specified in the RSU Award Agreement. At
the time of grant, the Board may determine to impose such restrictions or conditions that delay such delivery to a date following the
vesting of the RSU Award.
(b) Performance
Awards. With respect to any Performance Award, the length of any Performance Period, the Performance
Goals to be achieved during the Performance Period, the amount, timing and form of payment of amounts earned under the Award, the other
terms and conditions of such Award, and the measure of whether and to what degree such Performance Goals have been attained will be determined
by the Board.
(c) Other
Awards. Other forms of Awards valued in whole or in part by reference to, or otherwise based
on, Common Stock, including the appreciation in value thereof may be granted either alone or in addition to Awards provided for under
Section 4 and the preceding provisions of this Section 5. Subject to the provisions of the Plan, the Board will have sole and
complete discretion to determine the persons to whom and the time or times at which such Other Awards will be granted, the number of
shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Awards and all other terms and conditions
of such Other Awards.
6. Adjustments
upon Changes in Common Stock; Other Corporate Events.
(a) Capitalization
Adjustments. In the event of a Capitalization Adjustment, the Board shall appropriately and
proportionately adjust: (i) the class(es) and maximum number of shares of Common Stock subject to the Plan, and the maximum number
of shares by which the Share Reserve may annually increase pursuant to Section 2(a); (ii) the class(es) and maximum number
of shares that may be issued pursuant to the exercise of Incentive Stock Options pursuant to Section 2(a); (iii) the class(es)
and number of securities and exercise price, strike price or purchase price of Common Stock subject to outstanding Awards; and (iv) any
Performance Goals affected by the Capitalization Adjustment. The Board shall make such adjustments, and its determination shall be final,
binding and conclusive. Notwithstanding the foregoing, no fractional shares or rights for fractional shares of Common Stock shall be
created in order to implement any Capitalization Adjustment. The Board shall determine an appropriate equivalent benefit, if any, for
any fractional shares or rights to fractional shares that might be created by the adjustments referred to in the preceding provisions
of this Section.
(b) Dissolution
or Liquidation. Except as otherwise provided in the Award Agreement, in the event of a dissolution
or liquidation of the Company, all outstanding Awards (other than Awards consisting of vested and outstanding shares of Common Stock
not subject to a forfeiture condition or the Company’s right of repurchase) will terminate immediately prior to the completion
of such dissolution or liquidation, and the shares of Common Stock subject to the Company’s repurchase rights or subject to a forfeiture
condition may be repurchased or reacquired by the Company notwithstanding the fact that the holder of such Award is providing Continuous
Service, provided, however, that the Board may determine to cause some or all Awards to become fully vested, exercisable and/or no longer
subject to repurchase or forfeiture (to the extent such Awards have not previously expired or terminated) before the dissolution or liquidation
is completed but contingent on its completion.
(c) Corporate
Transaction. The following provisions will apply to Awards in the event of a Corporate Transaction
except as set forth in Section 11 unless otherwise provided in the instrument evidencing the Award or any other written agreement
between the Company or any Affiliate and the Participant.
(i) Awards
May Be Assumed. In the event of a Corporate Transaction, any surviving corporation or acquiring
corporation (or the surviving or acquiring corporation’s parent company) may assume or continue any or all Awards outstanding under
the Plan or may substitute similar awards for Awards outstanding under the Plan (including but not limited to, awards to acquire the
same consideration paid to the stockholders of the Company pursuant to the Corporate Transaction), and any reacquisition or repurchase
rights held by the Company in respect of Common Stock issued pursuant to Awards may be assigned by the Company to the successor of the
Company (or the successor’s parent company, if any), in connection with such Corporate Transaction. A surviving corporation or
acquiring corporation (or its parent) may choose to assume or continue only a portion of an Award or substitute a similar award for only
a portion of an Award, or may choose to assume or continue the Awards held by some, but not all Participants. The terms of any assumption,
continuation or substitution will be set by the Board.
(ii) Awards
Held by Current Participants. In the event of a Corporate Transaction in which the surviving
corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Awards or substitute similar
awards for such outstanding Awards, then with respect to Awards that have not been assumed, continued or substituted and that are held
by Participants whose Continuous Service has not terminated prior to the effective time of the Corporate Transaction (referred to as
the “Current Participants”), the vesting of such Awards (and, with respect to Options and Stock Appreciation
Rights, the time when such Awards may be exercised) will be accelerated in full to a date prior to the effective time of such Corporate
Transaction (contingent upon the effectiveness of the Corporate Transaction) as the Board determines (or, if the Board does not determine
such a date, to the date that is five days prior to the effective time of the Corporate Transaction), and such Awards will terminate
if not exercised (if applicable) at or prior to the effective time of the Corporate Transaction, and any reacquisition or repurchase
rights held by the Company with respect to such Awards will lapse (contingent upon the effectiveness of the Corporate Transaction). With
respect to the vesting of Performance Awards that will accelerate upon the occurrence of a Corporate Transaction pursuant to this subsection
(ii) and that have multiple vesting levels depending on the level of performance, unless otherwise provided in the Award Agreement,
the vesting of such Performance Awards will accelerate at 100% of the target level upon the occurrence of the Corporate Transaction in
which the Awards are not assumed in accordance with Section 6(c)(i). With respect to the vesting of Awards that will accelerate
upon the occurrence of a Corporate Transaction pursuant to this subsection (ii) and are settled in the form of a cash payment, such
cash payment will be made no later than 30 days following the occurrence of the Corporate Transaction or such later date as required
to comply with Section 409A of the Code.
(iii) Awards
Held by Persons other than Current Participants. In the event of a Corporate Transaction in
which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Awards
or substitute similar awards for such outstanding Awards, then with respect to Awards that have not been assumed, continued or substituted
and that are held by persons other than Current Participants, such Awards will terminate if not exercised (if applicable) prior to the
occurrence of the Corporate Transaction; provided, however, that any reacquisition or repurchase rights held by the Company with respect
to such Awards will not terminate and may continue to be exercised notwithstanding the Corporate Transaction.
(iv) Payment
for Awards in Lieu of Exercise. Notwithstanding the foregoing, in the event an Award will terminate
if not exercised prior to the effective time of a Corporate Transaction, the Board may provide, in its sole discretion, that the holder
of such Award may not exercise such Award but will receive a payment, in such form as may be determined by the Board, equal in value,
at the effective time, to the excess, if any, of (1) the value of the property the Participant would have received upon the exercise
of the Award (including, at the discretion of the Board, any unvested portion of such Award), over (2) any exercise price payable
by such holder in connection with such exercise; provided that the Board may also determine that the payment to be made to the Participant
with respect to such Award shall be made in the same form, at the same time and subject to the same conditions as the payments to be
made to the Company shareholders in connection with the Corporate Transaction to the exempt permitted by Code Section 409A. If the
amount so determined for any Award is $0, then such Award automatically shall be cancelled at the effective time for no consideration.
(d) Appointment
of Stockholder Representative. As a condition to the receipt of an Award under this Plan, a
Participant will be deemed to have agreed that the Award will be subject to the terms of any agreement governing a Corporate Transaction
involving the Company, including, without limitation, a provision for the appointment of a stockholder representative that is authorized
to act on the Participant’s behalf with respect to any escrow, indemnities and any contingent consideration.
(e) No
Restriction on Right to Undertake Transactions. The grant of any Award under the Plan and the
issuance of shares pursuant to any Award does not affect or restrict in any way the right or power of the Company or the stockholders
of the Company to make or authorize any adjustment, recapitalization, reorganization or other change in the Company’s capital structure
or its business, any merger or consolidation of the Company, any issue of stock or of options, rights or options to purchase stock or
of bonds, debentures, preferred or prior preference stocks whose rights are superior to or affect the Common Stock or the rights thereof
or which are convertible into or exchangeable for Common Stock, or the dissolution or liquidation of the Company, or any sale or transfer
of all or any part of its assets or business, or any other corporate act or proceeding, whether of a similar character or otherwise.
7. Administration.
(a) Administration
by Board. The Board will administer the Plan unless and until the Board delegates administration
of the Plan to a Committee or Committees, as provided in subsection (c) below.
(b) Powers
of Board. The Board will have the power, subject to, and within the limitations of, the express
provisions of the Plan:
(i) To
determine from time to time (1) which of the persons eligible under the Plan will be granted Awards; (2) when and how each
Award will be granted; (3) what type or combination of types of Award will be granted; (4) the provisions of each Award granted
(which need not be identical), including the time or times when a person will be permitted to receive an issuance of Common Stock or
other payment pursuant to an Award; (5) the number of shares of Common Stock or cash equivalent with respect to which an Award will
be granted to each such person; (6) the Fair Market Value applicable to an Award; and (7) the terms of any Performance Award
that is not valued in whole or in part by reference to, or otherwise based on, the Common Stock, including the amount of cash payment
or other property that may be earned and the timing of payment.
(ii) To
construe and interpret the Plan and Awards granted under it, and to establish, amend and revoke rules and regulations for its administration.
The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan or in any Award Agreement, in
a manner and to the extent it deems necessary or expedient to make the Plan or Award fully effective.
(iii) To
settle all controversies regarding the Plan and Awards granted under it.
(iv) To
accelerate the time at which an Award may first be exercised or the time during which an Award or any part thereof will vest, notwithstanding
the provisions in the Award Agreement stating the time at which it may first be exercised or the time during which it will vest.
(v) To
prohibit the exercise of any Option, SAR or other exercisable Award during a period of up to thirty (30) days prior to the consummation
of any pending stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution (other than
normal cash dividends) of Company assets to stockholders, or any other change affecting the shares of Common Stock or the share price
of the Common Stock including any Corporate Transaction, for reasons of administrative convenience.
(vi) To
suspend or terminate the Plan at any time. Suspension or termination of the Plan will not Materially Impair rights and obligations under
any Award granted while the Plan is in effect except with the written consent of the affected Participant.
(vii) To
amend the Plan in any respect the Board deems necessary or advisable; provided, however, that stockholder approval will be required
for any amendment to the extent required by Applicable Law. Except as provided above, rights under any Award granted before amendment
of the Plan will not be Materially Impaired by any amendment of the Plan unless (1) the Company requests the consent of the affected
Participant, and (2) such Participant consents in writing.
(viii) To
submit any amendment to the Plan for stockholder approval.
(ix) To
approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more Awards, including, but not limited
to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any specified
limits in the Plan that are not subject to Board discretion; provided however, that, a Participant’s rights under any Award
will not be Materially Impaired by any such amendment unless (1) the Company requests the consent of the affected Participant, and
(2) such Participant consents in writing.
(x) Generally,
to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company
and that are not in conflict with the provisions of the Plan or Awards.
(xi) To
adopt such procedures and sub-plans as are necessary or appropriate to permit and facilitate participation in the Plan by, or take advantage
of specific tax treatment for Awards granted to, Employees, Directors or Consultants who are foreign nationals or employed outside the
United States (provided that Board approval will not be necessary for immaterial modifications to the Plan or any Award Agreement to
ensure or facilitate compliance with the laws of the relevant foreign jurisdiction).
(xii) To
effect, at any time and from time to time, subject to the consent of any Participant whose Award is Materially Impaired by such action,
(1) the reduction of the exercise price (or strike price) of any outstanding Option or SAR; (2) the cancellation of any outstanding
Option or SAR and the grant in substitution therefor of (A) a new Option, SAR, Restricted Stock Award, RSU Award or Other Award,
under the Plan or another equity plan of the Company, covering the same or a different number of shares of Common Stock, (B) cash
and/or (C) other valuable consideration (as determined by the Board); or (3) any other action that is treated as a repricing
under generally accepted accounting principles.
(c) Delegation
to Committee.
(i) General.
The Board may delegate some or all of the administration of the Plan to a Committee or Committees.
If administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan,
the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to another Committee
or a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan
to the Board will thereafter be to the Committee or subcommittee), subject, however, to such resolutions, not inconsistent with the provisions
of the Plan, as may be adopted from time to time by the Board. Each Committee may retain the authority to concurrently administer the
Plan with Committee or subcommittee to which it has delegated its authority hereunder and may, at any time, revest in such Committee
some or all of the powers previously delegated. The Board may retain the authority to concurrently administer the Plan with any Committee
and may, at any time, revest in the Board some or all of the powers previously delegated.
(ii) Rule 16b-3
Compliance. To the extent an Award is intended to qualify for the exemption from Section 16(b) of
the Exchange Act that is available under Rule 16b-3 of the Exchange Act, the Award will be granted by the Board or a Committee that
consists solely of two or more Non-Employee Directors, as determined under Rule 16b-3(b)(3) of the Exchange Act and thereafter
any action establishing or modifying the terms of the Award will be approved by the Board or a Committee meeting such requirements to
the extent necessary for such exemption to remain available.
(d) Effect
of Board’s Decision. All determinations, interpretations and constructions made by the
Board or any Committee in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons.
(e) Delegation
to an Officer. The Board or any Committee may delegate to one or more Officers the authority
to take any action hereunder that could be taken by the Board or Committee with respect to Employees who are not Officers to the extent
permitted by Applicable Law; provided, however, that the resolutions or charter adopted by the Board or any Committee evidencing such
delegation will specify the total number of shares of Common Stock that may be subject to the Awards granted by such Officer and that
such Officer may not grant an Award to himself or herself. Any such Awards will be granted on the applicable form of Award Agreement
most recently approved for use by the Board or the Committee, unless otherwise provided in the resolutions approving the delegation authority.
Notwithstanding anything to the contrary herein, neither the Board nor any Committee may delegate to an Officer who is acting solely
in the capacity of an Officer (and not also as a Director) the authority to determine the Fair Market Value.
8. Tax
Withholding
(a) Withholding
Authorization. As a condition to acceptance of any Award under the Plan, a Participant authorizes
withholding from payroll and any other amounts payable to such Participant, and otherwise agrees to make adequate provision for (including),
any sums required to satisfy any U.S. federal, state, local and/or foreign tax or social insurance contribution withholding obligations
of the Company or an Affiliate, if any, which arise in connection with the grant, exercise, vesting or settlement of such Award, as applicable.
Accordingly, a Participant may not be able to exercise an Award even though the Award is vested, and the Company shall have no obligation
to issue shares of Common Stock subject to an Award, unless and until such obligations are satisfied.
(b) Satisfaction
of Withholding Obligation. To the extent permitted by the terms of an Award Agreement, the Company
may, in its sole discretion, satisfy any U.S. federal, state, local and/or foreign tax or social insurance withholding obligation relating
to an Award by any of the following means or by a combination of such means: (i) causing the Participant to tender a cash payment;
(ii) withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection
with the Award; (iii) withholding cash from an Award settled in cash; (iv) withholding payment from any amounts otherwise payable
to the Participant; (v) allowing a Participant to effectuate a “cashless exercise” pursuant to a program developed under
Regulation T as promulgated by the Federal Reserve Board; or (vi) by such other method as may be set forth in the Award Agreement.
(c) No
Obligation to Notify or Minimize Taxes; No Liability to Claims. Except as required by Applicable
Law the Company has no duty or obligation to any Participant to advise such holder as to the time or manner of exercising such Award.
Furthermore, the Company has no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of
an Award or a possible period in which the Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences
of an Award to the holder of such Award and will not be liable to any holder of an Award for any adverse tax consequences to such holder
in connection with an Award. As a condition to accepting an Award under the Plan, each Participant (i) agrees to not make any claim
against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from such Award or
other Company compensation and (ii) acknowledges that such Participant was advised to consult with his or her own personal tax,
financial and other legal advisors regarding the tax consequences of the Award and has either done so or knowingly and voluntarily declined
to do so. Additionally, each Participant acknowledges any Option or SAR granted under the Plan is exempt from Section 409A only
if the exercise or strike price is at least equal to the “fair market value” of the Common Stock on the date of grant as
determined by the Internal Revenue Service and there is no other impermissible deferral of compensation associated with the Award. Additionally,
as a condition to accepting an Option or SAR granted under the Plan, each Participant agrees not make any claim against the Company,
or any of its Officers, Directors, Employees or Affiliates in the event that the Internal Revenue Service asserts that such exercise
price or strike price is less than the “fair market value” of the Common Stock on the date of grant as subsequently determined
by the Internal Revenue Service.
(d) Withholding
Indemnification. As a condition to accepting an Award under the Plan, in the event that the
amount of the Company’s and/or its Affiliate’s withholding obligation in connection with such Award was greater than the
amount actually withheld by the Company and/or its Affiliates, each Participant agrees to indemnify and hold the Company and/or its Affiliates
harmless from any failure by the Company and/or its Affiliates to withhold the proper amount.
9. Miscellaneous.
(a) Source
of Shares. The stock issuable under the Plan will be shares of authorized but unissued or reacquired
Common Stock, including shares repurchased by the Company on the open market or otherwise.
(b) Use
of Proceeds from Sales of Common Stock. Proceeds from the sale of shares of Common Stock pursuant
to Awards will constitute general funds of the Company.
(c) Corporate
Action Constituting Grant of Awards. Corporate action constituting a grant by the Company of
an Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board,
regardless of when the instrument, certificate, or letter evidencing the Award is communicated to, or actually received or accepted by,
the Participant. In the event that the corporate records (e.g., Board consents, resolutions or minutes) documenting the corporate action
approving the grant contain terms (e.g., exercise price, vesting schedule or number of shares) that are inconsistent with those in the
Award Agreement or related grant documents as a result of a clerical error in the Award Agreement or related grant documents, the corporate
records will control and the Participant will have no legally binding right to the incorrect term in the Award Agreement or related grant
documents.
(d) Stockholder
Rights. No Participant will be deemed to be the holder of, or to have any of the rights of a
holder with respect to, any shares of Common Stock subject to such Award unless and until (i) such Participant has satisfied all
requirements for exercise of the Award pursuant to its terms, if applicable, and (ii) the issuance of the Common Stock subject to
such Award is reflected in the records of the Company.
(e) No
Employment or Other Service Rights. Nothing in the Plan, any Award Agreement or any other instrument
executed thereunder or in connection with any Award granted pursuant thereto will confer upon any Participant any right to continue to
serve the Company or an Affiliate in the capacity in effect at the time the Award was granted or affect the right of the Company or an
Affiliate to terminate at will and without regard to any future vesting opportunity that a Participant may have with respect to any Award
(i) the employment of an Employee with or without notice and with or without cause, (ii) the service of a Consultant pursuant
to the terms of such Consultant’s agreement with the Company or an Affiliate, or (iii) the service of a Director pursuant
to the Bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state or foreign jurisdiction
in which the Company or the Affiliate is incorporated, as the case may be. Further, nothing in the Plan, any Award Agreement or any other
instrument executed thereunder or in connection with any Award will constitute any promise or commitment by the Company or an Affiliate
regarding the fact or nature of future positions, future work assignments, future compensation or any other term or condition of employment
or service or confer any right or benefit under the Award or the Plan unless such right or benefit has specifically accrued under the
terms of the Award Agreement and/or Plan.
(f) Change
in Time Commitment. In the event a Participant’s regular level of time commitment in the
performance of his or her services for the Company and any Affiliates is reduced (for example, and without limitation, if the Participant
is an Employee of the Company and the Employee has a change in status from a full-time Employee to a part-time Employee or takes an extended
leave of absence) after the date of grant of any Award to the Participant, the Board may determine, to the extent permitted by Applicable
Law, to (i) make a corresponding reduction in the number of shares or cash amount subject to any portion of such Award that is scheduled
to vest or become payable after the date of such change in time commitment, and (ii) in lieu of or in combination with such a reduction,
extend the vesting or payment schedule applicable to such Award. In the event of any such reduction, the Participant will have no right
with respect to any portion of the Award that is so reduced or extended.
(g) Execution
of Additional Documents. As a condition to accepting an Award under the Plan, the Participant
agrees to execute any additional documents or instruments necessary or desirable, as determined in the Plan Administrator’s sole
discretion, to carry out the purposes or intent of the Award, or facilitate compliance with securities and/or other regulatory requirements,
in each case at the Plan Administrator’s request.
(h) Electronic
Delivery and Participation. Any reference herein or in an Award Agreement to a “written”
agreement or document will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor
website thereto) or posted on the Company’s intranet (or other shared electronic medium controlled by the Company to which the
Participant has access). By accepting any Award the Participant consents to receive documents by electronic delivery and to participate
in the Plan through any on-line electronic system established and maintained by the Plan Administrator or another third party selected
by the Plan Administrator. The form of delivery of any Common Stock (e.g., a stock certificate or electronic entry evidencing such shares)
shall be determined by the Company.
(i) Clawback/Recovery.
All Awards granted under the Plan will be subject to recoupment in accordance with any clawback
policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on
which the Company’s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection
Act or other Applicable Law and any clawback policy that the Company otherwise adopts, to the extent applicable and permissible under
Applicable Law. In addition, the Board may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the
Board determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares
of Common Stock or other cash or property upon the occurrence of Cause. No recovery of compensation under such a clawback policy will
be an event giving rise to a Participant’s right to voluntarily terminate employment upon a “resignation for good reason,”
or for a “constructive termination” or any similar term under any plan of or agreement with the Company.
(j) Securities
Law Compliance. A Participant will not be issued any shares in respect of an Award unless either
(i) the shares are registered under the Securities Act; or (ii) the Company has determined that such issuance would be exempt
from the registration requirements of the Securities Act. Each Award also must comply with other Applicable Law governing the Award,
and a Participant will not receive such shares if the Company determines that such receipt would not be in material compliance with Applicable
Law.
(k) Transfer
or Assignment of Awards; Issued Shares. Except as expressly provided in the Plan or the form
of Award Agreement, Awards granted under the Plan may not be transferred or assigned by the Participant. After the vested shares subject
to an Award have been issued, or in the case of Restricted Stock and similar awards, after the issued shares have vested, the holder
of such shares is free to assign, hypothecate, donate, encumber or otherwise dispose of any interest in such shares provided that any
such actions are in compliance with the provisions herein, the terms of the Trading Policy and Applicable Law.
(l) Effect
on Other Employee Benefit Plans. The value of any Award granted under the Plan, as determined
upon grant, vesting or settlement, shall not be included as compensation, earnings, salaries, or other similar terms used when calculating
any Participant’s benefits under any employee benefit plan sponsored by the Company or any Affiliate, except as such plan otherwise
expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any of the Company's or any Affiliate's
employee benefit plans.
(m) Deferrals.
To the extent permitted by Applicable Law, the Board, in its sole discretion, may determine
that the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may
be deferred and may also establish programs and procedures for deferral elections to be made by Participants. Deferrals will be made
in accordance with the requirements of Section 409A.
(n) Section 409A.
Unless otherwise expressly provided for in an Award Agreement, the Plan and Award Agreements
will be interpreted to the greatest extent possible in a manner that makes the Plan and the Awards granted hereunder exempt from Section 409A,
and, to the extent not so exempt, in compliance with the requirements of Section 409A. If the Board determines that any Award granted
hereunder is not exempt from and is therefore subject to Section 409A, the Award Agreement evidencing such Award will incorporate
the terms and conditions necessary to avoid the consequences specified in Section 409A(a)(1) of the Code, and to the extent
an Award Agreement is silent on terms necessary for compliance, such terms are hereby incorporated by reference into the Award Agreement.
Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise), if the shares
of Common Stock are publicly traded, and if a Participant holding an Award that constitutes “deferred compensation” under
Section 409A is a “specified employee” for purposes of Section 409A, no distribution or payment of any amount that
is due because of a “separation from service” (as defined in Section 409A without regard to alternative definitions
thereunder) will be issued or paid before the date that is six (6) months and one day following the date of such Participant’s
“separation from service” or, if earlier, the date of the Participant’s death, unless such distribution or payment
can be made in a manner that complies with Section 409A, and any amounts so deferred will be paid in a lump sum on the day after
such six month period elapses, with the balance paid thereafter on the original schedule.
(o) Choice
of Law. This Plan and any controversy arising out of or relating to this Plan shall be
governed by, and construed in accordance with, the internal laws of the State of Delaware, without regard to conflict of law principles
that would result in any application of any law other than the law of the State of Delaware.
10. Covenants
of the Company.
(a) Compliance
with Law. The Company will seek to obtain from each regulatory commission or agency, as may
be deemed to be necessary, having jurisdiction over the Plan such authority as may be required to grant Awards and to issue and sell
shares of Common Stock upon exercise or vesting of the Awards; provided, however, that this undertaking will not require the Company
to register under the Securities Act the Plan, any Award or any Common Stock issued or issuable pursuant to any such Award. If, after
reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such regulatory commission or agency the authority
that counsel for the Company deems necessary or advisable for the lawful issuance and sale of Common Stock under the Plan, the Company
will be relieved from any liability for failure to issue and sell Common Stock upon exercise or vesting of such Awards unless and until
such authority is obtained. A Participant is not eligible for the grant of an Award or the subsequent issuance of Common Stock pursuant
to the Award if such grant or issuance would be in violation of any Applicable Law.
11. Additional
Rules for Awards Subject to Section 409A.
(a) Application.
Unless the provisions of this Section of the Plan are expressly superseded by the provisions
in the form of Award Agreement, the provisions of this Section shall apply and shall supersede anything to the contrary set forth
in the Award Agreement for a Non-Exempt Award.
(b) Non-Exempt
Awards Subject to Non-Exempt Severance Arrangements. To the extent a Non-Exempt Award is subject
to Section 409A due to application of a Non-Exempt Severance Arrangement, the following provisions of this subsection (b) apply.
(i) If
the Non-Exempt Award vests in the ordinary course during the Participant’s Continuous Service in accordance with the vesting schedule
set forth in the Award Agreement, and does not accelerate vesting under the terms of a Non-Exempt Severance Arrangement, in no event
will the shares be issued in respect of such Non-Exempt Award any later than the later of: (i) December 31st of
the calendar year that includes the applicable vesting date, or (ii) the 60th day that follows the applicable vesting
date.
(ii) If
vesting of the Non-Exempt Award accelerates under the terms of a Non-Exempt Severance Arrangement in connection with the Participant’s
Separation from Service, and such vesting acceleration provisions were in effect as of the date of grant of the Non-Exempt Award and,
therefore, are part of the terms of such Non-Exempt Award as of the date of grant, then the shares will be earlier issued in settlement
of such Non-Exempt Award upon the Participant’s Separation from Service in accordance with the terms of the Non-Exempt Severance
Arrangement, but in no event later than the 60th day that follows the date of the Participant’s Separation from Service.
However, if at the time the shares would otherwise be issued the Participant is subject to the distribution limitations contained in
Section 409A applicable to “specified employees,” as defined in Section 409A(a)(2)(B)(i) of the Code, such
shares shall not be issued before the date that is six months following the date of such Participant’s Separation from Service,
or, if earlier, the date of the Participant’s death that occurs within such six month period.
(iii) If
vesting of a Non-Exempt Award accelerates under the terms of a Non-Exempt Severance Arrangement in connection with a Participant’s
Separation from Service, and such vesting acceleration provisions were not in effect as of the date of grant of the Non-Exempt Award
and, therefore, are not a part of the terms of such Non-Exempt Award on the date of grant, then such acceleration of vesting of the Non-Exempt
Award shall not accelerate the issuance date of the shares, but the shares shall instead be issued on the same schedule as set forth
in the Grant Notice as if they had vested in the ordinary course during the Participant’s Continuous Service, notwithstanding the
vesting acceleration of the Non-Exempt Award. Such issuance schedule is intended to satisfy the requirements of payment on a specified
date or pursuant to a fixed schedule, as provided under Treasury Regulations Section 1.409A-3(a)(4).
(c) Treatment
of Non-Exempt Awards Upon a Corporate Transaction for Employees and Consultants. The provisions
of this subsection (c) shall apply and shall supersede anything to the contrary set forth in the Plan with respect to the permitted
treatment of any Non-Exempt Award in connection with a Corporate Transaction if the Participant was either an Employee or Consultant
upon the applicable date of grant of the Non-Exempt Award.
(i) Vested
Non-Exempt Awards. The following provisions shall apply to any Vested Non-Exempt Award in connection
with a Corporate Transaction:
(1) If
the Corporate Transaction is also a Section 409A Change in Control then the Acquiring Entity may not assume, continue or substitute
the Vested Non-Exempt Award. Upon the Section 409A Change in Control the settlement of the Vested Non-Exempt Award will automatically
be accelerated and the shares will be immediately issued in respect of the Vested Non-Exempt Award. Alternatively, the Company may instead
provide that the Participant will receive a cash settlement equal to the Fair Market Value of the shares that would otherwise be issued
to the Participant upon the Section 409A Change in Control.
(2) If
the Corporate Transaction is not also a Section 409A Change in Control, then the Acquiring Entity must either assume, continue or
substitute each Vested Non-Exempt Award. The shares to be issued in respect of the Vested Non-Exempt Award shall be issued to the Participant
by the Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Corporate Transaction had
not occurred. In the Acquiring Entity’s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute
a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant
on such issuance dates, with the determination of the Fair Market Value of the shares made on the date of the Corporate Transaction.
(ii) Unvested
Non-Exempt Awards. The following provisions shall apply to any Unvested Non-Exempt Award unless
otherwise determined by the Board pursuant to subsection (e) of this Section.
(1) In
the event of a Corporate Transaction, the Acquiring Entity shall assume, continue or substitute any Unvested Non-Exempt Award. Unless
otherwise determined by the Board, any Unvested Non-Exempt Award will remain subject to the same vesting and forfeiture restrictions
that were applicable to the Award prior to the Corporate Transaction. The shares to be issued in respect of any Unvested Non-Exempt Award
shall be issued to the Participant by the Acquiring Entity on the same schedule that the shares would have been issued to the Participant
if the Corporate Transaction had not occurred. In the Acquiring Entity’s discretion, in lieu of an issuance of shares, the Acquiring
Entity may instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would
otherwise be issued to the Participant on such issuance dates, with the determination of Fair Market Value of the shares made on the
date of the Corporate Transaction.
(2) If
the Acquiring Entity will not assume, substitute or continue any Unvested Non-Exempt Award in connection with a Corporate Transaction,
then such Award shall automatically terminate and be forfeited upon the Corporate Transaction with no consideration payable to any Participant
in respect of such forfeited Unvested Non-Exempt Award. Notwithstanding the foregoing, to the extent permitted and in compliance with
the requirements of Section 409A, the Board may in its discretion determine to elect to accelerate the vesting and settlement of
the Unvested Non-Exempt Award upon the Corporate Transaction, or instead substitute a cash payment equal to the Fair Market Value of
such shares that would otherwise be issued to the Participant, as further provided in subsection (e)(ii) below. In the absence of
such discretionary election by the Board, any Unvested Non-Exempt Award shall be forfeited without payment of any consideration to the
affected Participants if the Acquiring Entity will not assume, substitute or continue the Unvested Non-Exempt Awards in connection with
the Corporate Transaction.
(3) The
foregoing treatment shall apply with respect to all Unvested Non-Exempt Awards upon any Corporate Transaction, and regardless of whether
or not such Corporate Transaction is also a Section 409A Change in Control.
(d) Treatment
of Non-Exempt Awards Upon a Corporate Transaction for Non-Employee Directors. The following
provisions of this subsection (d) shall apply and shall supersede anything to the contrary that may be set forth in the Plan with
respect to the permitted treatment of a Non-Exempt Director Award in connection with a Corporate Transaction.
(i) If
the Corporate Transaction is also a Section 409A Change in Control then the Acquiring Entity may not assume, continue or substitute
the Non-Exempt Director Award. Upon the Section 409A Change in Control the vesting and settlement of any Non-Exempt Director Award
will automatically be accelerated and the shares will be immediately issued to the Participant in respect of the Non-Exempt Director
Award. Alternatively, the Company may provide that the Participant will instead receive a cash settlement equal to the Fair Market Value
of the shares that would otherwise be issued to the Participant upon the Section 409A Change in Control pursuant to the preceding
provision.
(ii) If
the Corporate Transaction is not also a Section 409A Change in Control, then the Acquiring Entity must either assume, continue or
substitute the Non-Exempt Director Award. Unless otherwise determined by the Board, the Non-Exempt Director Award will remain subject
to the same vesting and forfeiture restrictions that were applicable to the Award prior to the Corporate Transaction. The shares to be
issued in respect of the Non-Exempt Director Award shall be issued to the Participant by the Acquiring Entity on the same schedule that
the shares would have been issued to the Participant if the Corporate Transaction had not occurred. In the Acquiring Entity’s discretion,
in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each applicable issuance date, equal
to the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination
of Fair Market Value made on the date of the Corporate Transaction.
(e) If
the RSU Award is a Non-Exempt Award, then the provisions in this Section 11(e) shall apply and supersede anything to the contrary
that may be set forth in the Plan or the Award Agreement with respect to the permitted treatment of such Non-Exempt Award:
(i) Any
exercise by the Board of discretion to accelerate the vesting of a Non-Exempt Award shall not result in any acceleration of the scheduled
issuance dates for the shares in respect of the Non-Exempt Award unless earlier issuance of the shares upon the applicable vesting dates
would be in compliance with the requirements of Section 409A.
(ii) The
Company explicitly reserves the right to earlier settle any Non-Exempt Award to the extent permitted and in compliance with the requirements
of Section 409A, including pursuant to any of the exemptions available in Treasury Regulations Section 1.409A-3(j)(4)(ix).
(iii) To
the extent the terms of any Non-Exempt Award provide that it will be settled upon a Change in Control or Corporate Transaction, to the
extent it is required for compliance with the requirements of Section 409A, the Change in Control or Corporate Transaction event
triggering settlement must also constitute a Section 409A Change in Control. To the extent the terms of a Non-Exempt Award provides
that it will be settled upon a termination of employment or termination of Continuous Service, to the extent it is required for compliance
with the requirements of Section 409A, the termination event triggering settlement must also constitute a Separation From Service.
However, if at the time the shares would otherwise be issued to a Participant in connection with a “separation from service”
such Participant is subject to the distribution limitations contained in Section 409A applicable to “specified employees,”
as defined in Section 409A(a)(2)(B)(i) of the Code, such shares shall not be issued before the date that is six months following
the date of the Participant’s Separation From Service, or, if earlier, the date of the Participant’s death that occurs within
such six month period.
(iv) The
provisions in this subsection (e) for delivery of the shares in respect of the settlement of an RSU Award that is a Non-Exempt Award
are intended to comply with the requirements of Section 409A so that the delivery of the shares to the Participant in respect of
such Non-Exempt Award will not trigger the additional tax imposed under Section 409A, and any ambiguities herein will be so interpreted.
12. Severability.
If
all or any part of the Plan or any Award Agreement is declared by any court or governmental authority to be unlawful or invalid, such
unlawfulness or invalidity shall not invalidate any portion of the Plan or such Award Agreement not declared to be unlawful or invalid.
Any Section of the Plan or any Award Agreement (or part of such a Section) so declared to be unlawful or invalid shall, if possible,
be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible
while remaining lawful and valid.
13. Termination
of the Plan.
The
Board may suspend or terminate the Plan at any time. No Incentive Stock Options may be granted after the tenth anniversary of the earlier
of: (i) the Adoption Date, or (ii) the date the Plan is approved by the Company’s stockholders. No Awards may be granted
under the Plan while the Plan is suspended or after it is terminated.
14. Definitions.
As
used in the Plan, the following definitions apply to the capitalized terms indicated below:
(a) “Acquiring
Entity” means the surviving or acquiring corporation (or its parent company) in connection with a Corporate Transaction.
(b) “Adoption
Date” means the date the Plan is first approved by the Board or Compensation Committee.
(c) “Affiliate”
means, at the time of determination, any “parent” or “subsidiary” of the Company as such terms are defined in
Rule 405 promulgated under the Securities Act. The Board may determine the time or times at which “parent” or “subsidiary”
status is determined within the foregoing definition.
(d) “Applicable
Law” means any applicable securities, federal, state, foreign, material local or municipal or other law, statute, constitution,
principle of common law, resolution, ordinance, code, edict, decree, rule, listing rule, regulation, judicial decision, ruling or requirement
issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Body (including
under the authority of any applicable self-regulating organization such as the Nasdaq Stock Market, New York Stock Exchange, or the Financial
Industry Regulatory Authority).
(e) “Award”
means any right to receive Common Stock, cash or other property granted under the Plan (including an Incentive Stock Option, a Nonstatutory
Stock Option, a Restricted Stock Award, an RSU Award, a SAR, a Performance Award or any Other Award).
(f) “Award
Agreement” means a written or electronic agreement between the Company and a Participant evidencing the terms and conditions
of an Award. The Award Agreement generally consists of the Grant Notice and the agreement containing the written summary of the general
terms and conditions applicable to the Award and which is provided, including through electronic means, to a Participant along with the
Grant Notice.
(g) “Board”
means the Board of Directors of the Company (or its designee). Any decision or determination made by the Board shall be a decision or
determination that is made in the sole discretion of the Board (or its designee), and such decision or determination shall be final and
binding on all Participants.
(h) “Capitalization
Adjustment” means any change that is made in, or other events that occur with respect to, the Common Stock subject to the
Plan or subject to any Award after the date the Plan is adopted by the Board without the receipt of consideration by the Company through
merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large
nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change
in corporate structure or any similar equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards
Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible
securities of the Company will not be treated as a Capitalization Adjustment.
(i) “Cause”
has the meaning ascribed to such term in any written agreement between a Participant and the Company defining such term and, in the absence
of such agreement, such term means, with respect to a Participant, the occurrence of any of the following events: (i) the Participant’s
dishonest statements or acts with respect to the Company or any Affiliate of the Company, or any current or prospective customers, suppliers,
vendors or other third parties with which such entity does business; (ii) the Participant’s commission of (A) a felony
or (B) any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii) the Participant’s failure to perform
the Participant’s assigned duties and responsibilities to the reasonable satisfaction of the Company which failure continues, in
the reasonable judgment of the Company, after written notice given to the Participant by the Company; (iv) the Participant’s
gross negligence, willful misconduct or insubordination with respect to the Company or any Affiliate of the Company; or (v) the
Participant’s material violation of any provision of any agreement(s) between the Participant and the Company relating to
noncompetition, nonsolicitation, nondisclosure and/or assignment of inventions or material violation of any provision of Company policy.
The determination that a termination of the Participant’s Continuous Service is either for Cause or without Cause will be made
by the Board with respect to Participants who are executive officers of the Company and by the Company’s Chief Executive Officer
with respect to Participants who are not executive officers of the Company. Any determination by the Company that the Continuous Service
of a Participant was terminated with or without Cause for the purposes of outstanding Awards held by such Participant will have no effect
upon any determination of the rights or obligations of the Company or such Participant for any other purpose.
(j) “Change
in Control” or “Change of Control” means the occurrence, in a single transaction or in a series
of related transactions, of any one or more of the following events:
(i) any
Exchange Act Person becomes the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined
voting power of the Company’s then outstanding securities other than by virtue of a merger, consolidation or similar transaction.
Notwithstanding the foregoing, a Change in Control shall not be deemed to occur (A) on account of the acquisition of securities
of the Company directly from the Company, (B) on account of the acquisition of securities of the Company by an investor, any affiliate
thereof or any other Exchange Act Person that acquires the Company’s securities in a transaction or series of related transactions
the primary purpose of which is to obtain financing for the Company through the issuance of equity securities, or (C) solely because
the level of Ownership held by any Exchange Act Person (the “Subject Person”) exceeds the designated percentage
threshold of the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing
the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result
of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the Owner of any
additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then
outstanding voting securities Owned by the Subject Person over the designated percentage threshold, then a Change in Control shall be
deemed to occur;
(ii) there
is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the Company and, immediately after the
consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own,
directly or indirectly, either (A) outstanding voting securities representing more than 50% of the combined outstanding voting power
of the Acquiring Entity in such merger, consolidation or similar transaction or (B) more than 50% of the combined outstanding voting
power of the parent of the Acquiring Entity in such merger, consolidation or similar transaction, in each case in substantially the same
proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such transaction;
(iii) there
is consummated a sale, lease, exclusive license or other disposition of all or substantially all of the consolidated assets of the Company
and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of
the Company and its Subsidiaries to an Entity, more than 50% of the combined voting power of the voting securities of which are Owned
by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of the Company
immediately prior to such sale, lease, license or other disposition; or
(iv) individuals
who, on the date the Plan is adopted by the Board, are members of the Board (the “Incumbent Board”) cease for
any reason to constitute at least a majority of the members of the Board; provided, however, that if the appointment or election (or
nomination for election) of any new Board member was approved or recommended by a majority vote of the members of the Incumbent Board
then still in office, such new member shall, for purposes of this Plan, be considered as a member of the Incumbent Board.
Notwithstanding
the foregoing or any other provision of this Plan, (A) the term Change in Control shall not include a sale of assets, merger or
other transaction effected exclusively for the purpose of changing the domicile of the Company, (B) the definition of Change in
Control (or any analogous term) in an individual written agreement between the Company or any Affiliate and the Participant shall supersede
the foregoing definition with respect to Awards subject to such agreement; provided, however, that if no definition of Change in Control
or any analogous term is set forth in such an individual written agreement, the foregoing definition shall apply, and (C) with respect
to any nonqualified deferred compensation that becomes payable on account of the Change in Control, the transaction or event described
in clause (i), (ii), (iii), or (iv) also constitutes a Section 409A Change in Control if required in order for the payment
not to violate Section 409A of the Code.
(k) “Code”
means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.
(l) “Committee”
means the Compensation Committee and any other committee of one or more Directors to whom authority has been delegated by the Board or
Compensation Committee in accordance with the Plan.
(m) “Common
Stock” means the common stock, par value $0.0001 per share, of the Company.
(n) “Company”
means TriSalus Life Sciences, Inc., a Delaware corporation.
(o) “Compensation
Committee” means the Compensation Committee of the Board.
(p) “Consultant”
means any person, including an advisor, who is (i) engaged by the Company or an Affiliate to render consulting or advisory services
and is compensated for such services, or (ii) serving as a member of the board of directors of an Affiliate and is compensated for
such services. However, service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered
a “Consultant” for purposes of the Plan. Notwithstanding the foregoing, a person is treated as a Consultant under this Plan
only if a Form S-8 Registration Statement under the Securities Act is available to register either the offer or the sale of the
Company’s securities to such person.
(q) “Continuous
Service” means that the Participant’s service with the Company or an Affiliate, whether as an Employee, Director
or Consultant, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Company or
an Affiliate as an Employee, Director or Consultant or a change in the Entity for which the Participant renders such service, provided
that there is no interruption or termination of the Participant’s service with the Company or an Affiliate, will not terminate
a Participant’s Continuous Service; provided, however, that if the Entity for which a Participant is rendering services
ceases to qualify as an Affiliate, as determined by the Board, such Participant’s Continuous Service will be considered to have
terminated on the date such Entity ceases to qualify as an Affiliate. For example, a change in status from an Employee of the Company
to a Consultant of an Affiliate or to a Director will not constitute an interruption of Continuous Service. To the extent permitted by
law, the Board or the chief executive officer of the Company, in that party’s sole discretion, may determine whether Continuous
Service will be considered interrupted in the case of (i) any leave of absence approved by the Company, including sick leave, military
leave or any other personal leave, or (ii) transfers between the Company, an Affiliate, or their successors. Notwithstanding the
foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in an Award only to such extent as may be
provided in the Company’s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable
to the Participant, or as otherwise required by law. In addition, to the extent required for exemption from or compliance with Section 409A,
the determination of whether there has been a termination of Continuous Service will be made, and such term will be construed, in a manner
that is consistent with the definition of “separation from service” as defined under Treasury Regulation Section 1.409A-1(h) (without
regard to any alternative definition thereunder).
(r) “Corporate
Transaction” means the consummation, in a single transaction or in a series of related transactions, of any one or more
of the following events:
(i) a
sale or other disposition of all or substantially all, as determined by the Board, of the consolidated assets of the Company and its
Subsidiaries;
(ii) a
sale or other disposition of at least 50% of the outstanding securities of the Company;
(iii) a
merger, consolidation or similar transaction following which the Company is not the surviving corporation; or
(iv) a
merger, consolidation or similar transaction following which the Company is the surviving corporation but the shares of Common Stock
outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger,
consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.
Notwithstanding
the foregoing or any other provision of this Plan, (A) the term Corporate Transaction shall not include a sale of assets, merger
or other transaction effected exclusively for the purpose of changing the domicile of the Company, (B) the definition of Corporate
Transaction (or any analogous term) in an individual written agreement between the Company or any Affiliate and the Participant shall
supersede the foregoing definition with respect to Awards subject to such agreement; provided, however, that if no definition of Corporate
Transaction or any analogous term is set forth in such an individual written agreement, the foregoing definition shall apply, and (C) with
respect to any nonqualified deferred compensation that becomes payable on account of the Corporate Transaction, the transaction or event
described in clause (i), (ii), (iii), or (iv) also constitutes a Section 409A Change in Control if required in order for the
payment not to violate Section 409A of the Code.
(s) “Director”
means a member of the Board.
(t) “determine”
or “determined” means as determined by the Board or the Committee (or its designee) in its sole
discretion.
(u) “Disability”
means, with respect to a Participant, such Participant is unable to engage in any substantial gainful activity by reason of any medically
determinable physical or mental impairment which can be expected to result in death or which has lasted or can be expected to last for
a continuous period of not less than 12 months, as provided in Section 22(e)(3) of the Code, and will be determined by the
Board on the basis of such medical evidence as the Board deems warranted under the circumstances.
(v) “Effective
Date” means the effective date of this Plan, which is the date of the closing of the transactions contemplated by the Merger
Agreement, provided that this Plan is approved by the Company’s stockholders prior to such date.
(w) “Effective
Time” has the meaning set forth in the Merger Agreement.
(x) “Employee”
means any person employed by the Company or an Affiliate. However, service solely as a Director, or payment of a fee for such services,
will not cause a Director to be considered an “Employee” for purposes of the Plan.
(y) “Employer”
means the Company or the Affiliate of the Company that employs the Participant.
(z) “Entity”
means a corporation, partnership, limited liability company or other entity.
(aa) “Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.
(bb) “Exchange
Act Person” means any natural person, Entity or “group” (within the meaning of Section 13(d) or 14(d) of
the Exchange Act), except that “Exchange Act Person” will not include (i) the Company or any Subsidiary of the Company,
(ii) any employee benefit plan of the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities
under an employee benefit plan of the Company or any Subsidiary of the Company, (iii) an underwriter temporarily holding securities
pursuant to a registered public offering of such securities, (iv) an Entity Owned, directly or indirectly, by the stockholders of
the Company in substantially the same proportions as their Ownership of stock of the Company, or (v) any natural person, Entity
or “group” (within the meaning of Section 13(d) or 14(d) of the Exchange Act) that, as of the Effective Date,
is the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company’s
then outstanding securities.
(cc) “Fair
Market Value” means, as of any date, unless otherwise determined by the Board, the value of the Common Stock (as determined
on a per share or aggregate basis, as applicable) determined as follows:
(i) If
the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value will be the closing
sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the
Common Stock) on the date of determination, as reported in a source the Board deems reliable.
(ii) If
there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the closing selling
price on the last preceding date for which such quotation exists.
(iii) In
the absence of such markets for the Common Stock, or if otherwise determined by the Board, the Fair Market Value will be determined by
the Board in good faith and in a manner that complies with Sections 409A and 422 of the Code.
(dd) “Fully
Diluted Common Stock” means the number of shares of Common Stock, determined as of the applicable time of measurement,
equal to the sum of (i) the total number of shares of Common Stock issued and outstanding and (ii) the total number of shares
of Common Stock subject to securities that are convertible into or exercisable for shares of Common Stock (whether vested or unvested).
(ee) “Governmental
Body” means any: (i) nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction
of any nature; (ii) federal, state, local, municipal, foreign or other government; (iii) governmental or regulatory body, or
quasi-governmental body of any nature (including any governmental division, department, administrative agency or bureau, commission,
authority, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or Entity and any court or other tribunal,
and for the avoidance of doubt, any Tax authority) or other body exercising similar powers or authority; or (iv) self-regulatory
organization (including the Nasdaq Stock Market, New York Stock Exchange, and the Financial Industry Regulatory Authority).
(ff) “Grant
Notice” means the notice provided to a Participant that he or she has been granted an Award under the Plan and which includes
the name of the Participant, the type of Award, the date of grant of the Award, number of shares of Common Stock subject to the Award
or potential cash payment right, (if any), the vesting schedule for the Award (if any) and other key terms applicable to the Award.
(gg) “Incentive
Stock Option” means an option granted pursuant to Section 4 of the Plan that is intended to be, and qualifies as,
an “incentive stock option” within the meaning of Section 422 of the Code.
(hh) “Materially
Impair” means any amendment to the terms of the Award that materially adversely affects the Participant’s rights
under the Award. A Participant's rights under an Award will not be deemed to have been Materially Impaired by any such amendment if the
Board, in its sole discretion, determines that the amendment, taken as a whole, does not materially impair the Participant's rights.
For example, the following types of amendments to the terms of an Award do not Materially Impair the Participant’s rights under
the Award: (i) imposition of reasonable restrictions on the minimum number of shares subject to an Option or SAR that may be exercised,
(ii) to maintain the qualified status of the Award as an Incentive Stock Option under Section 422 of the Code, (iii) to
change the terms of an Incentive Stock Option in a manner that disqualifies, impairs or otherwise affects the qualified status of the
Award as an Incentive Stock Option under Section 422 of the Code, (iv) to clarify the manner of exemption from, or to bring
the Award into compliance with or qualify it for an exemption from, Section 409A,or (v) to comply with other Applicable Laws.
(ii) “Merger
Agreement” means that certain Agreement and Plan of Merger, dated as of November 11, 2022, as amended April 4,
2023, May 13, 2023, and July 5, 2023, by and among MedTech Acquisition Corporation, a Delaware corporation (“MTAC”),
MTAC Merger Sub, Inc., a Delaware corporation and direct, wholly owned subsidiary of MTAC, and TriSalus Life Sciences, Inc.,
a Delaware corporation.
(jj) “Non-Employee
Director” means a Director who either (i) is not a current employee or officer of the Company or an Affiliate, does
not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in
any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation
S-K promulgated pursuant to the Securities Act (“Regulation S-K”)), does not possess an interest in any other
transaction for which disclosure would be required under Item 404(a) of Regulation S-K, and is not engaged in a business relationship
for which disclosure would be required pursuant to Item 404(b) of Regulation S-K; or (ii) is otherwise considered a “non-employee
director” for purposes of Rule 16b-3.
(kk) “Non-Exempt
Award” means any Award that is subject to, and not exempt from, Section 409A, including as the result of (i) a
deferral of the issuance of the shares subject to the Award which is elected by the Participant or imposed by the Company, or (ii) the
terms of any Non-Exempt Severance Agreement.
(ll) “Non-Exempt
Director Award” means a Non-Exempt Award granted to a Participant who was a Director but not an Employee on the applicable
grant date.
(mm) “Non-Exempt
Severance Arrangement” means a severance arrangement or other agreement between the Participant and the Company that provides
for acceleration of vesting of an Award and issuance of the shares in respect of such Award upon the Participant’s termination
of employment or separation from service (as such term is defined in Section 409A(a)(2)(A)(i) of the Code (and without regard
to any alternative definition thereunder) (“Separation from Service”) and such severance benefit does not satisfy
the requirements for an exemption from application of Section 409A provided under Treasury Regulations Section 1.409A-1(b)(4),
1.409A-1(b)(9) or otherwise.
(nn)
“Nonstatutory Stock Option”
means any option granted pursuant to Section 4 of the Plan that does not qualify as an Incentive Stock Option.
(oo) “Officer”
means a person who is an officer of the Company within the meaning of Section 16 of the Exchange Act.
(pp) “Option”
means an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan.
(qq) “Option
Agreement” means a written or electronic agreement between the Company and the Optionholder evidencing the terms and conditions
of the Option grant. The Option Agreement includes the Grant Notice for the Option and the agreement containing the written summary of
the general terms and conditions applicable to the Option and which is provided, including through electronic means, to a Participant
along with the Grant Notice. Each Option Agreement will be subject to the terms and conditions of the Plan.
(rr) “Optionholder”
means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option.
(ss) “Other
Award” means an award valued in whole or in part by reference to, or otherwise based on, Common Stock, including the appreciation
in value thereof (e.g., options or stock rights with an exercise price or strike price less than 100% of the Fair Market Value at the
time of grant) that is not an Incentive Stock Option, Nonstatutory Stock Option, SAR, Restricted Stock Award, RSU Award or Performance
Award.
(tt) “Other
Award Agreement” means a written or electronic agreement between the Company and a holder of an Other Award evidencing
the terms and conditions of an Other Award grant. Each Other Award Agreement will be subject to the terms and conditions of the Plan.
(uu) “Own,”
“Owned,” “Owner,” “Ownership” means that a person or Entity
will be deemed to “Own,” to have “Owned,” to be the “Owner” of, or to have acquired “Ownership”
of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise,
has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities.
(vv) “Participant”
means an Employee, Director or Consultant to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds
an outstanding Award.
(ww) “Performance
Award” means an Award that may vest or may be exercised or a cash award that may vest or become earned and paid contingent
upon the attainment during a Performance Period of certain Performance Goals and which is granted under the terms and conditions of Section 5(b) pursuant
to such terms as are approved by the Board. In addition, to the extent permitted by Applicable Law and set forth in the applicable Award
Agreement, the Board may determine that cash or other property may be used in payment of Performance Awards. Performance Awards that
are settled in cash or other property are not required to be valued in whole or in part by reference to, or otherwise based on, the Common
Stock.
(xx) “Performance
Criteria” means the one or more criteria that the Board will select for purposes of establishing the Performance Goals
for a Performance Period. The Performance Criteria that will be used to establish such Performance Goals may be based on any one of,
or combination of, the following as determined by the Board: earnings (including earnings per share and net earnings); earnings before
interest, taxes and depreciation; earnings before interest, taxes, depreciation and amortization; total stockholder return; return on
equity or average stockholder’s equity; return on assets, investment, or capital employed; stock price; margin (including gross
margin); income (before or after taxes); operating income; operating income after taxes; pre-tax profit; operating cash flow; sales or
revenue targets; increases in revenue or product revenue; expenses and cost reduction goals; improvement in or attainment of working
capital levels; economic value added (or an equivalent metric); market share; cash flow; cash flow per share; share price performance;
debt reduction; customer satisfaction; stockholders’ equity; capital expenditures; debt levels; operating profit or net operating
profit; workforce diversity; growth of net income or operating income; billings; financing; regulatory milestones; stockholder liquidity;
corporate governance and compliance; intellectual property; personnel matters; progress of internal research; progress of partnered programs;
partner satisfaction; budget management; partner or collaborator achievements; internal controls, including those related to the Sarbanes-Oxley
Act of 2002; investor relations, analysts and communication; implementation or completion of projects or processes; employee retention;
number of users, including unique users; strategic partnerships or transactions (including in-licensing and out-licensing of intellectual
property); establishing relationships with respect to the marketing, distribution and sale of the Company’s products; supply chain
achievements; co-development, co-marketing, profit sharing, joint venture or other similar arrangements; individual performance goals;
corporate development and planning goals; and other measures of performance selected by the Board or Committee whether or not listed
herein.
(yy) “Performance
Goals” means, for a Performance Period, the one or more goals established by the Board for the Performance Period based
upon the Performance Criteria. Performance Goals may be based on a Company-wide basis, with respect to one or more business units, divisions,
Affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or
the performance of one or more relevant indices. Unless specified otherwise by the Board (i) in the Award Agreement at the time
the Award is granted or (ii) in such other document setting forth the Performance Goals at the time the Performance Goals are established,
the Board will appropriately make adjustments in the method of calculating the attainment of Performance Goals for a Performance Period
as follows: (1) to exclude restructuring and/or other nonrecurring charges; (2) to exclude exchange rate effects; (3) to
exclude the effects of changes to generally accepted accounting principles; (4) to exclude the effects of any statutory adjustments
to corporate tax rates; (5) to exclude the effects of items that are “unusual” in nature or occur “infrequently”
as determined under generally accepted accounting principles; (6) to exclude the dilutive effects of acquisitions or joint ventures;
(7) to assume that any business divested by the Company achieved performance objectives at targeted levels during the balance of
a Performance Period following such divestiture; (8) to exclude the effect of any change in the outstanding shares of common stock
of the Company by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, spin-off,
combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash
dividends; (9) to exclude the effects of stock based compensation and the award of bonuses under the Company’s bonus plans;
(10) to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed under
generally accepted accounting principles; and (11) to exclude the goodwill and intangible asset impairment charges that are required
to be recorded under generally accepted accounting principles. In addition, the Board may establish or provide for other adjustment items
in the Award Agreement at the time the Award is granted or in such other document setting forth the Performance Goals at the time the
Performance Goals are established. In addition, the Board retains the discretion to reduce or eliminate the compensation or economic
benefit due upon attainment of Performance Goals and to define the manner of calculating the Performance Criteria it selects to use for
such Performance Period for any reason. Partial achievement of the specified criteria may result in the payment or vesting corresponding
to the degree of achievement as specified in the Award Agreement or the written terms of a Performance Cash Award.
(zz) “Performance
Period” means the period of time selected by the Board over which the attainment of one or more Performance Goals will
be measured for the purpose of determining a Participant’s right to vesting or exercise of an Award. Performance Periods may be
of varying and overlapping duration, at the sole discretion of the Board.
(aaa) “Plan”
means this TriSalus Life Sciences, Inc. 2023 Equity Incentive Plan, as amended from time to time.
(bbb) “Plan
Administrator” means the person, persons, and/or third-party administrator designated by the Company to administer the
day to day operations of the Plan and the Company’s other equity incentive programs.
(ccc) “Post-Termination
Exercise Period” means the period following termination of a Participant’s Continuous Service within which an Option
or SAR is exercisable, as specified in Section 4(h).
(ddd)
“Restricted Stock Award” or
“RSA” means an Award of shares of Common Stock which is granted pursuant to the terms and conditions of
Section 5(a).
(eee) “Restricted
Stock Award Agreement” means a written or electronic agreement between the Company and a holder of a Restricted Stock Award
evidencing the terms and conditions of a Restricted Stock Award grant. The Restricted Stock Award Agreement includes the Grant Notice
for the Restricted Stock Award and the agreement containing the written summary of the general terms and conditions applicable to the
Restricted Stock Award and which is provided, including by electronic means, to a Participant along with the Grant Notice. Each Restricted
Stock Award Agreement will be subject to the terms and conditions of the Plan.
(fff) “RSU
Award” or “RSU” means an Award of restricted stock units representing the right to receive an
issuance of shares of Common Stock which is granted pursuant to the terms and conditions of Section 5(a).
(ggg) “RSU
Award Agreement” means a written or electronic agreement between the Company and a holder of an RSU Award evidencing the
terms and conditions of an RSU Award. The RSU Award Agreement includes the Grant Notice for the RSU Award and the agreement containing
the written summary of the general terms and conditions applicable to the RSU Award and which is provided, including by electronic means,
to a Participant along with the Grant Notice. Each RSU Award Agreement will be subject to the terms and conditions of the Plan.
(hhh) “Rule 16b-3”
means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time.
(iii) “Rule 405”
means Rule 405 promulgated under the Securities Act.
(jjj) “Section 409A”
means Section 409A of the Code and the regulations and other guidance thereunder.
(kkk) “Section 409A
Change in Control” means a change in the ownership or effective control of the Company, or in the ownership of a substantial
portion of the Company’s assets, as provided in Section 409A(a)(2)(A)(v) of the Code and Treasury Regulations Section 1.409A-3(i)(5) (without
regard to any alternative definition thereunder).
(lll) “Securities
Act” means the Securities Act of 1933, as amended.
(mmm) “Share
Reserve” means the number of shares available for issuance under the Plan as set forth in Section 2(a).
(nnn) “Stock
Appreciation Right” or “SAR” means a right to receive the appreciation on Common Stock that is
granted pursuant to the terms and conditions of Section 4.
(ooo) “SAR
Agreement” means a written or electronic agreement between the Company and a holder of a SAR evidencing the terms and conditions
of a SAR grant. The SAR Agreement includes the Grant Notice for the SAR and the agreement containing the written summary of the general
terms and conditions applicable to the SAR and which is provided, including by electronic means, to a Participant along with the Grant
Notice. Each SAR Agreement will be subject to the terms and conditions of the Plan.
(ppp) “Subsidiary”
means, with respect to the Company, (i) any corporation of which more than 50% of the outstanding capital stock having ordinary
voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other
class or classes of such corporation will have or might have voting power by reason of the happening of any contingency) is at the time,
directly or indirectly, Owned by the Company, and (ii) any partnership, limited liability company or other entity in which the Company
has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than 50%.
(qqq) “Ten
Percent Stockholder” means a person who Owns (or is deemed to Own pursuant to Section 424(d) of the Code) stock
possessing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate.
(rrr) “Trading
Policy” means the Company’s policy permitting certain individuals to sell Company shares only during certain "window"
periods and/or otherwise restricts the ability of certain individuals to transfer or encumber Company shares, as in effect from time
to time.
(sss) “Unvested
Non-Exempt Award” means the portion of any Non-Exempt Award that had not vested in accordance with its terms upon or prior
to the date of any Corporate Transaction.
(ttt) “Vested
Non-Exempt Award” means the portion of any Non-Exempt Award that had vested in accordance with its terms upon or prior
to the date of a Corporate Transaction.
Exhibit 10.22
TriSalus
Life Sciences, Inc.
Stock
Option Grant Notice
(2023
Equity Incentive Plan)
TriSalus
Life Sciences, Inc. (the “Company”), pursuant to its 2023 Equity Incentive Plan (the “Plan”),
has granted to you (“Optionholder”) an option to purchase the number of shares of the Common Stock set forth
below (“Option”). Your Option is subject to all of the terms and conditions as set forth herein and in the
Plan, and the Stock Option Agreement and the Notice of Exercise, all of which are attached hereto and incorporated herein in their entirety.
Capitalized terms not explicitly defined herein but defined in the Plan or the Stock Option Agreement shall have the meanings set forth
in the Plan or the Stock Option Agreement, as applicable.
Optionholder: |
|
|
Date of
Grant: |
|
|
Vesting
Commencement Date: |
|
|
Number
of Shares of Common Stock Subject to Option: |
|
|
Exercise
Price (Per Share): |
|
|
Total
Exercise Price: |
|
|
Expiration
Date: |
|
|
Type
of Grant: |
|
[Incentive
Stock Option]1 OR [Nonstatutory Stock Option] |
Exercise
and |
|
|
Vesting
Schedule: |
|
Subject
to the Optionholder’s Continuous Service through each applicable vesting date, the Option will vest as follows: |
|
|
[ ] |
Optionholder
acknowledgements: By your signature below or by
electronic acceptance or authentication in a form authorized by the Company, you understand and agree that:
| • | The
Option is governed by this Stock Option Grant Notice, and the provisions of the Plan and
the Stock Option Agreement and the Notice of Exercise, all of which are made a part of this
document. Unless otherwise provided in the Plan, this Grant Notice and the Stock Option Agreement
(together, the “Option Agreement”) may not be modified, amended
or revised except in a writing signed by you and a duly authorized officer of the Company. |
| • | [If
the Option is an Incentive Stock Option, it (plus other outstanding Incentive Stock Options
granted to you) cannot be first exercisable for more than $100,000 in value (measured by
exercise price) in any calendar year. Any excess over $100,000 is a Nonstatutory Stock Option.]1 |
| • | You
consent to receive this Grant Notice, the Stock Option Agreement, the Plan, the Prospectus
and any other Plan-related documents by electronic delivery and to participate in the Plan
through an on-line or electronic system established and maintained by the Company or another
third party designated by the Company. |
1
If this is an Incentive Stock Option, it (plus other outstanding Incentive Stock Options)
cannot be first exercisable for more than $100,000 in value (measured by exercise price) in any calendar year. Any excess over $100,000
is a Nonstatutory Stock Option.
| • | You
have read and are familiar with the provisions of the Plan, the Stock Option Agreement, the
Notice of Exercise and the Prospectus. In the event of any conflict between the provisions
in this Grant Notice, the Option Agreement, the Notice of Exercise, or the Prospectus and
the terms of the Plan, the terms of the Plan shall control. |
| • | The
Option Agreement sets forth the entire understanding between you and the Company regarding
the acquisition of Common Stock and supersedes all prior oral and written agreements, promises
and/or representations on that subject with the exception of other equity awards previously
granted to you and any written employment agreement, offer letter, severance agreement, written
severance plan or policy, or other written agreement between the Company and you in each
case that specifies the terms that should govern this Option. |
| • | Counterparts
may be delivered via facsimile, electronic mail (including pdf or any electronic signature
complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or
other applicable law) or other transmission method and any counterpart so delivered will
be deemed to have been duly and validly delivered and be valid and effective for all purposes. |
TriSalus
Life Sciences, Inc. |
|
Optionholder: |
|
|
|
|
|
By: |
|
|
|
|
|
Signature |
|
|
Signature |
|
|
|
|
|
Title: |
|
|
Date: |
|
|
|
|
|
|
Date: |
|
|
|
|
Attachments:
Stock Option Agreement, 2023 Equity Incentive Plan, Notice of Exercise
TriSalus
Life Sciences, Inc.
2023
EQUITY INCENTIVE PLAN
STOCK
OPTION AGREEMENT
As
reflected by your Stock Option Grant Notice (“Grant Notice”), TriSalus Life Sciences, Inc. (the “Company”)
has granted you an option under its 2023 Equity Incentive Plan (the “Plan”) to purchase a number of shares
of Common Stock at the exercise price indicated in your Grant Notice (the “Option”). Capitalized terms not
explicitly defined in this Agreement but defined in the Grant Notice or the Plan shall have the meanings set forth in the Grant Notice
or Plan, as applicable. The terms of your Option as specified in the Grant Notice and this Stock Option Agreement constitute your Option
Agreement.
The
general terms and conditions applicable to your Option are as follows:
1. Governing
plan document. Your Option is subject to all the
provisions of the Plan, including but not limited to the provisions in:
(a) Section 6
regarding the impact of a Capitalization Adjustment, dissolution, liquidation, or Transaction on your Option;
(b) Section 9(e) regarding
the Company’s retained rights to terminate your Continuous Service notwithstanding the grant of the Option; and
(c) Section 8(c) regarding
the tax consequences of your Option.
Your
Option is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated
and adopted pursuant to the Plan. In the event of any conflict between the Option Agreement and the provisions of the Plan, the provisions
of the Plan shall control.
2. Vesting.
Your Option will vest as provided in your Grant Notice, subject to the provisions contained
herein and the terms of the Plan. Vesting will cease upon the termination of your Continuous Service.
3. Exercise.
(a) You
may generally exercise the vested portion of your Option for whole shares of Common Stock at any time during its term by delivery of
payment of the exercise price and applicable withholding taxes and other required documentation to the Plan Administrator in accordance
with the exercise procedures established by the Plan Administrator, which may include an electronic submission. Please review Sections
4(i), 4(j) and 7(b)(v) of the Plan, which may restrict or prohibit your ability to exercise your Option during certain periods.
(b) To
the extent permitted by Applicable Law, you may pay your Option exercise price as follows:
(i) cash,
check, bank draft or money order;
(ii) pursuant
to a “cashless exercise” program as further described in Section 4(c)(ii) of the Plan if at the time of exercise
the Common Stock is publicly traded;
(iii) subject
to Company and/or Committee consent at the time of exercise, by delivery of previously owned shares of Common Stock as further described
in Section 4(c)(iii) of the Plan; or
(iv) subject
to Company and/or Committee consent at the time of exercise, if the Option is a Nonstatutory Stock Option, by a “net exercise”
arrangement as further described in Section 4(c)(iv) of the Plan.
(c) By
accepting your Option, you agree that you will not sell, dispose of, transfer, make any short sale of, grant any option for the purchase
of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to any shares of Common Stock
or other securities of the Company held by you, for a period of one hundred eighty (180) days following the effective date of a registration
statement of the Company filed under the Securities Act or such longer period as the underwriters or the Company will request to facilitate
compliance with FINRA Rule 2241 or any successor or similar rules or regulation (the “Lock-Up Period”);
provided, however, that nothing contained in this Section 3(c) will prevent the exercise of a repurchase option, if
any, in favor of the Company during the Lock-Up Period. You further agree to execute and deliver such other agreements as may be reasonably
requested by the Company or the underwriters that are consistent with the foregoing or that are necessary to give further effect thereto.
In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to your shares of Common Stock
until the end of such period. You also agree that any transferee of any shares of Common Stock (or other securities) of the Company held
by you will be bound by this Section 3(c). The underwriters of the Company’s stock are intended third party beneficiaries
of this Section 3(c) and will have the right, power and authority to enforce the provisions hereof as though they were a party
hereto.
4. Term.
You may not exercise your Option before the commencement of its term or after its term expires.
The term of your Option commences on the Date of Grant and expires, subject to the provisions of Section 4(h) of the Plan,
upon the earliest of the following:
(a) immediately
upon the termination of your Continuous Service for Cause;
(b) three
(3) months after the termination of your Continuous Service for any reason other than Cause, your Disability or your death (except
as otherwise provided in Section 4(d) below); provided, however, that if during any part of such three (3) month
period your Option is not exercisable solely because of the condition set forth in the section below regarding “Securities Law
Compliance,” your Option will not expire until the earlier of the Expiration Date or until it has been exercisable for an aggregate
period of three (3) months after the termination of your Continuous Service; provided further, if during any part of such
three (3) month period, the sale of any shares of Common Stock received upon exercise of your Option would violate the Company’s
insider trading policy, then your Option will not expire until the earlier of the Expiration Date or until it has been exercisable for
an aggregate period of three (3) months after the termination of your Continuous Service during which the sale of the shares of
Common Stock received upon exercise of your Option would not be in violation of the Company’s insider trading policy. Notwithstanding
the foregoing, if (i) you are a Non-Exempt Employee, (ii) your Continuous Service terminates within six (6) months after
the Date of Grant, and (iii) you have vested in a portion of your Option at the time of your termination of Continuous Service,
your Option will not expire until the earlier of (x) the later of (A) the date that is seven (7) months after the Date
of Grant, and (B) the date that is three (3) months after the termination of your Continuous Service, and (y) the Expiration
Date;
(c) twelve
(12) months after the termination of your Continuous Service due to your Disability (except as otherwise provided in Section 4(d) below);
(d) eighteen
(18) months after your death if you die either during your Continuous Service or within three (3) months after your Continuous Service
terminates for any reason other than Cause;
(e) immediately
upon a Corporate Transaction if the Board has determined that the Option will terminate in connection with a Corporate Transaction;
(f) the
Expiration Date indicated in your Grant Notice; or
(g) the
day before the tenth (10th) anniversary of the Date of Grant.
If
your Option is an Incentive Stock Option, note that to obtain the federal income tax advantages associated with an Incentive Stock Option,
the Code requires that at all times beginning on the Date of Grant and ending on the day three (3) months before the date of your
Option’s exercise, you must be an employee of the Company or an Affiliate, except in the event of your death or Disability. The
Company has provided for extended exercisability of your Option under certain circumstances for your benefit but cannot guarantee that
your Option will necessarily be treated as an Incentive Stock Option if you continue to provide services to the Company or an Affiliate
as a Consultant or Director after your employment terminates or if you otherwise exercise your Option more than three (3) months
after the date your employment with the Company or an Affiliate terminates.
5. Withholding
obligations. As further provided in Section 8
of the Plan: (a) you may not exercise your Option unless the applicable tax withholding obligations are satisfied, and (b) at
the time you exercise your Option, in whole or in part, or at any time thereafter as requested by the Company, you hereby authorize withholding
from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for (including by means of a “cashless
exercise” pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board to the extent permitted
by the Company), any sums required to satisfy the federal, state, local and foreign tax withholding obligations, if any, which arise
in connection with the exercise of your Option in accordance with the withholding procedures established by the Company. Accordingly,
you may not be able to exercise your Option even though the Option is vested, and the Company shall have no obligation to issue shares
of Common Stock subject to your Option, unless and until such obligations are satisfied. In the event that the amount of the Company’s
withholding obligation in connection with your Option was greater than the amount actually withheld by the Company, you agree to indemnify
and hold the Company harmless from any failure by the Company to withhold the proper amount.
6. Incentive
stock option disposition requirement. If your Option
is an Incentive Stock Option, you must notify the Company in writing within 15 days after the date of any disposition of any of the shares
of the Common Stock issued upon exercise of your Option that occurs within two years after the date of your Option grant or within one
year after such shares of Common Stock are transferred upon exercise of your Option.
7. Transferability.
Except as otherwise provided in Section 4(e) of the Plan, your Option is not transferable,
except by will or by the applicable laws of descent and distribution, and is exercisable during your life only by you.
8. Corporate
transaction. Your Option is subject to the terms
of any agreement governing a Corporate Transaction involving the Company, including, without limitation, a provision for the appointment
of a stockholder representative that is authorized to act on your behalf with respect to any escrow, indemnities and any contingent consideration.
9. Securities
law compliance. In no event may you exercise your Option unless the Common Stock issuable upon
exercise are then registered under the Securities Act or, if not registered, the Company has determined that your exercise and the issuance
of the shares would be exempt from the registration requirements of the Securities Act. The exercise of your Option also must comply
with all other applicable laws and regulations governing your Option, and you may not exercise your Option if the Company determines
that such exercise would not be in material compliance with such laws and regulations.
10. No
liability for taxes. As a condition to accepting the Option, you hereby (a) agree to not
make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from
the Option or other Company compensation and (b) acknowledge that you were advised to consult with your own personal tax, financial
and other legal advisors regarding the tax consequences of the Option and have either done so or knowingly and voluntarily declined to
do so. Additionally, you acknowledge that the Option is exempt from Section 409A only if the exercise price is at least equal to
the “fair market value” of the Common Stock on the date of grant as determined by the Internal Revenue Service and there
is no other impermissible deferral of compensation associated with the Option. Additionally, as a condition to accepting the Option,
you agree not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates in the event that the Internal
Revenue Service asserts that such exercise is less than the “fair market value” of the Common Stock on the date of grant
as subsequently determined by the Internal Revenue Service.
11. Severability.
If any part of this Option Agreement or the Plan is declared by any court or Governmental Body to be unlawful or invalid, such unlawfulness
or invalidity will not invalidate any portion of this Option Agreement or the Plan not declared to be unlawful or invalid. Any Section of
this Option Agreement (or part of such a Section) so declared to be unlawful or invalid will, if possible, be construed in a manner which
will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and
valid.
12. Option
not a service contract. Your Option is not an employment or service contract, and nothing in
your Option will be deemed to create in any way whatsoever any obligation on your part to continue in the employ or service of the Company
or an Affiliate, or of the Company or an Affiliate to continue your employment or service. In addition, nothing in your Option will obligate
the Company or an Affiliate, their respective shareholders, boards of directors, officers or employees to continue any relationship that
you might have as a Director or Consultant for the Company or an Affiliate.
13. Governing
plan document. Your Option is subject to all the provisions of the Plan, the provisions
of which are hereby made a part of your Option, and is further subject to all interpretations, amendments, rules and regulations,
which may from time to time be promulgated and adopted pursuant to the Plan. If there is any conflict between the provisions of your
Option and those of the Plan, the provisions of the Plan will control. In addition, your Option (and any compensation paid or shares
issued under your Option) is subject to recoupment in accordance with The Dodd–Frank Wall Street Reform and Consumer Protection
Act and any implementing regulations thereunder, any clawback policy adopted by the Company and any compensation recovery policy otherwise
required by applicable law.
14. Other
documents. You hereby acknowledge receipt of or
the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act,
which includes the document containing Plan information specified in Section 10(a) of the Securities Act (the “Prospectus”).
In addition, you acknowledge receipt of the Company’s Trading Policy.
15. Questions.
If you have questions regarding these or any other terms and conditions applicable to your Option,
including a summary of the applicable federal income tax consequences please see the Prospectus.
* * * *
2023
Equity Incentive
Plan
Notice
of Exercise
TriSalus
Life Sciences, Inc.
TriSalus
Life Sciences, Inc. |
|
|
[Street
Address] |
|
|
[City,
State, Zip] |
Date of Exercise: |
|
This
constitutes notice to TriSalus Life Sciences, Inc. (the “Company”) that I elect to purchase the below
number of shares of Common Stock of the Company (the “Shares”) by exercising my Option for the price set forth
below. Capitalized terms not explicitly defined in this Notice of Exercise but defined in the Grant Notice, Option Agreement or 2023
Equity Incentive Plan (the “Plan”) shall have the meanings set forth in the Grant Notice, Option Agreement
or Plan, as applicable. Use of certain payment methods is subject to Company and/or Committee consent and certain additional requirements
set forth in the Option Agreement and the Plan.
Type of option (check one): |
Incentive ¨ |
|
Nonstatutory ¨ |
|
|
|
|
Stock option dated: |
|
|
|
|
|
|
|
Number of Shares as to which option is exercised: |
|
|
|
|
|
|
|
Certificates to be issued in name of: |
|
|
|
|
|
|
|
Total exercise price: |
$ |
|
|
$ |
|
|
|
|
|
Cash payment delivered herewith: |
$ |
|
|
$ |
|
|
|
|
|
[Value of ________ Shares delivered herewith: |
$ |
|
|
$ |
|
|
|
|
|
[Value of ________ Shares pursuant to net exercise]: |
$ |
|
|
$ |
|
|
|
|
|
[Regulation T Program (cashless exercise): |
$ |
|
|
$ |
|
By
this exercise, I agree (i) to provide such additional documents as you may require pursuant to the terms of the Plan, (ii) to
satisfy the tax withholding obligations, if any, relating to the exercise of this Option as set forth in the Option Agreement, and (iii) if
this exercise relates to an incentive stock option, to notify you in writing within 15 days after the date of any disposition of any
of the Shares issued upon exercise of this Option that occurs within two years after the Date of Grant or within one year after such
Shares are issued upon exercise of this Option.
I
further agree that I will not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into
any hedging or similar transaction with the same economic effect as a sale with respect to any shares of Common Stock or other securities
of the Company that I hold, for a period of one hundred eighty (180) days following the effective date of a registration statement of
the Company filed under the Securities Act or such longer period as the underwriters or the Company will request to facilitate compliance
with FINRA Rule 2241 or any successor or similar rules or regulation (the “Lock-Up Period”); provided,
however, that nothing contained in this paragraph will prevent the exercise of a repurchase option, if any, in favor of the Company
during the Lock-Up Period. I further agree to execute and deliver such other agreements as may be reasonably requested by the Company
or the underwriters that are consistent with the foregoing or that are necessary to give further effect thereto. I further agree that
in order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to shares of Common Stock
that I hold until the end of such period. I also agree that any transferee of any shares of Common Stock (or other securities) of the
Company that I hold will be bound by this paragraph. The underwriters of the Company’s stock are intended third party beneficiaries
of this paragraph and will have the right, power and authority to enforce the provisions hereof as though they were a party hereto.
Exhibit 10.23
TriSalus
Life Sciences, Inc.
RSU
Award Grant Notice
(2023
Equity Incentive Plan)
TriSalus
Life Sciences, Inc. (the “Company”) has awarded to you (the “Participant”) the
number of restricted stock units specified and on the terms set forth below in consideration of your services (the “RSU Award”).
Your RSU Award is subject to all of the terms and conditions as set forth herein and in the Company’s 2023 Equity Incentive Plan
(the “Plan”) and the Award Agreement (the “Agreement”), which are attached hereto
and incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the Plan or the Agreement shall
have the meanings set forth in the Plan or the Agreement.
|
Participant: |
|
|
|
Date of
Grant: |
|
|
|
Vesting
Commencement Date: |
|
|
|
Number
of Restricted Stock Units: |
|
|
Vesting
Schedule: |
|
Subject
to the Participant’s Continuous Service through each applicable vesting date, the RSU Award will vest as follows: |
|
|
|
|
[ ]. |
|
|
Issuance
Schedule: |
|
One share
of Common Stock will be issued for each restricted stock unit which vests at the time set forth in Section 6 of the Agreement. |
Participant
Acknowledgements: By your signature below or by electronic acceptance or authentication in a
form authorized by the Company, you understand and agree that:
| • | The
RSU Award is governed by this RSU Award Grant Notice (this “Grant Notice”),
and the provisions of the Plan and the Agreement, all of which are made a part of this document.
Unless otherwise provided in the Plan, this Grant Notice and the Agreement (together, the
“RSU Award Agreement”) may not be modified, amended or revised
except in a writing signed by you and a duly authorized officer of the Company. |
| • | You
have read and are familiar with the provisions of the Plan, the RSU Award Agreement and the
document containing the Plan information specified in Section 10(a) of the Securities
Act (the “Prospectus”). In the event of any conflict between the
provisions in the RSU Award Agreement, or the Prospectus and the terms of the Plan, the terms
of the Plan shall control. |
| • | You
consent to receive this Grant Notice, the RSU Award Agreement, the Plan, the Prospectus and
any other Plan-related documents by electronic delivery and to participate in the Plan through
an on-line or electronic system established and maintained by the Company or another third
party designated by the Company. |
| • | The
RSU Award Agreement sets forth the entire understanding between you and the Company regarding
the acquisition of Common Stock and supersedes all prior oral and written agreements, promises
and/or representations on that subject with the exception of: (i) other equity awards
previously granted to you, and (ii) any written employment agreement, offer letter,
severance agreement, written severance plan or policy, or other written agreement between
the Company and you in each case that specifies the terms that should govern this RSU Award. |
| • | Counterparts
may be delivered via facsimile, electronic mail (including pdf or any electronic signature
complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or
other applicable law) or other transmission method and any counterpart so delivered will
be deemed to have been duly and validly delivered and be valid and effective for all purposes. |
TriSalus
Life Sciences, Inc. |
|
Participant: |
|
|
|
|
|
By: |
|
|
|
|
|
Signature |
|
|
Signature |
|
|
|
|
|
Title: |
|
|
Date: |
|
|
|
|
|
|
Date: |
|
|
|
|
Attachments:
RSU Award Agreement, 2023 Equity Incentive Plan
TriSalus
Life Sciences, Inc.
2023
Equity Incentive Plan
Award
Agreement (RSU Award)
As
reflected by your Restricted Stock Unit Grant Notice (“Grant Notice”) TriSalus Life Sciences, Inc. (the
“Company”) has granted you a RSU Award under its 2023 Equity Incentive Plan (the “Plan”)
for the number of restricted stock units as indicated in your Grant Notice (the “RSU Award”). The terms of
your RSU Award as specified in this Award Agreement for your RSU Award (this “Agreement”) and the Grant Notice
constitute your “RSU Award Agreement”. Defined terms not explicitly defined in this Agreement but defined in
the Grant Notice or the Plan shall have the same definitions as in the Grant Notice or Plan, as applicable.
The
general terms applicable to your RSU Award are as follows:
1. GOVERNING
PLAN DOCUMENT. Your RSU Award is subject to all the provisions of the Plan, including but not
limited to the provisions in:
(a) Section 6
of the Plan regarding the impact of a Capitalization Adjustment, dissolution, liquidation, or Corporate Transaction on your RSU Award;
(b) Section 9(e) of
the Plan regarding the Company’s retained rights to terminate your Continuous Service notwithstanding the grant of the RSU Award;
and
(c) Section 8(c) of
the Plan regarding the tax consequences of your RSU Award.
Your
RSU Award is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated
and adopted pursuant to the Plan. In the event of any conflict between the RSU Award Agreement and the provisions of the Plan, the provisions
of the Plan shall control. Your RSU Award (and any compensation paid or shares issued under your RSU Award) is subject to recoupment
in accordance with The Dodd–Frank Wall Street Reform and Consumer Protection Act and any implementing regulations thereunder, any
clawback policy adopted by the Company and any compensation recovery policy otherwise required by applicable law. No recovery of compensation
under such a clawback policy will be an event giving rise to a right to voluntarily terminate employment upon a resignation for “good
reason,” or for a “constructive termination” or any similar term under any plan of or agreement with the Company.
2. Grant
Of The RSU Award. This RSU Award represents your
right to be issued on a future date the number of shares of the Company’s Common Stock that is equal to the number of restricted
stock units indicated in the Grant Notice as modified to reflect any Capitalization Adjustment and subject to your satisfaction of the
vesting conditions set forth therein (the “Restricted Stock Units”). Any additional Restricted Stock Units
that become subject to the RSU Award pursuant to Capitalization Adjustments as set forth in the Plan and the provisions of Section 4
below, if any, shall be subject, in a manner determined by the Board, to the same forfeiture restrictions, restrictions on transferability,
and time and manner of delivery as applicable to the other Restricted Stock Units covered by your RSU Award.
3. Vesting.
Your Restricted Stock Units will vest, if at all, in accordance with the vesting schedule
provided in the Grant Notice, subject to the provisions contained herein and the terms of the Plan. Vesting will cease upon the termination
of your Continuous Service and the Restricted Stock Units that were not vested on the date of such termination will be forfeited at no
cost to the Company and you will have no further right, title or interest in or to such RSU Award or the Common Stock to be issued in
respect of such portion of the RSU Award.
4. Dividends.
You may become entitled to receive payments equal to any cash dividends and other distributions
paid with respect to a corresponding number of shares of Common Stock to be issued in respect of the Restricted Stock Units covered by
your RSU Award. Any such dividends or distributions shall be subject to the same forfeiture restrictions as apply to the Restricted Stock
Units and shall be paid at the same time that the corresponding shares are issued in respect of your vested Restricted Stock Units, provided,
however that to the extent any such dividends or distributions are paid in shares of Common Stock, then you will automatically be granted
a corresponding number of additional Restricted Stock Units subject to the RSU Award (the “Dividend Units”),
and further provided that such Dividend Units shall be subject to the same forfeiture restrictions and restrictions on transferability,
and same timing requirements for issuance of shares, as apply to the Restricted Stock Units subject to the RSU Award with respect to
which the Dividend Units relate.
5. Withholding
Obligations. As further provided in Section 8
of the Plan, you hereby authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate
provision for, any sums required to satisfy the federal, state, local and foreign tax withholding obligations, if any, which arise in
connection with your RSU Award (the “Withholding Obligation”) in accordance with the withholding procedures
established by the Company. Unless the Withholding Obligation is satisfied, the Company shall have no obligation to deliver to you any
Common Stock in respect of the RSU Award. In the event the Withholding Obligation of the Company arises prior to the delivery to you
of Common Stock or it is determined after the delivery of Common Stock to you that the amount of the Withholding Obligation was greater
than the amount withheld by the Company, you agree to indemnify and hold the Company harmless from any failure by the Company to withhold
the proper amount.
6. Date
Of Issuance.
(a) The
issuance of shares in respect of the Restricted Stock Units is intended to comply with Treasury Regulations Section 1.409A-1(b)(4) and
will be construed and administered in such a manner. Subject to the satisfaction of the Withholding Obligation, if any, in the event
one or more Restricted Stock Units vests, the Company shall issue to you one (1) share of Common Stock for each Restricted Stock
Unit that vests on the applicable vesting date(s) (subject to any adjustment under Section 4 above, and subject to any different
provisions in the Grant Notice). Each issuance date determined by this paragraph is referred to as an “Original Issuance
Date.”
(b) If
the Original Issuance Date falls on a date that is not a business day, delivery shall instead occur on the next following business day.
In addition, if:
(i) the
Original Issuance Date does not occur (1) during an “open window period” applicable to you, as determined by the Company
in accordance with the Company’s then-effective policy on trading in Company securities, or (2) on a date when you are otherwise
permitted to sell shares of Common Stock on an established stock exchange or stock market (including but not limited to under a previously
established written trading plan that meets the requirements of Rule 10b5-1 under the Exchange Act and was entered into in compliance
with the Company’s policies (a “10b5-1 Arrangement) or under such other policy expressly approved by the Company),
and
(ii) either
(1) a Withholding Obligation does not apply, or (2) the Company decides, prior to the Original Issuance Date, (A) not
to satisfy the Withholding Obligation by withholding shares of Common Stock from the shares otherwise due, on the Original Issuance Date,
to you under this Award, and (B) not to permit you to enter into a “same day sale” commitment with a broker-dealer (including
but not limited to a commitment under a 10b5-1 Arrangement) and (C) not to permit you to pay your Withholding Obligation in cash,
(iii) then
the shares that would otherwise be issued to you on the Original Issuance Date will not be delivered on such Original Issuance Date
and will instead be delivered on the first business day when you are not prohibited from selling shares of the Company’s Common
Stock in the open public market or on such other date determined by the Company, but in no event later than December 31 of the calendar
year in which the Original Issuance Date occurs (that is, the last day of your taxable year in which the Original Issuance Date occurs),
or, if and only if permitted in a manner that complies with Treasury Regulations Section 1.409A-1(b)(4), no later than the
date that is the 15th day of the third calendar month of the applicable year following the year in which the shares of Common Stock under
this RSU Award are no longer subject to a “substantial risk of forfeiture” within the meaning of Treasury Regulations Section 1.409A-1(d).
(c) To
the extent the RSU Award is a Non-Exempt Award, the provisions of Section 11 of the Plan shall apply.
7. Lock-Up
Period. By accepting your RSU Award, you agree that you will not sell, dispose of, transfer,
make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic
effect as a sale with respect to any shares of Common Stock or other securities of the Company held by you, for a period of one hundred
eighty (180) days following the effective date of a registration statement of the Company filed under the Securities Act or such longer
period as the underwriters or the Company will request to facilitate compliance with FINRA Rule 2241 or any successor or similar
rules or regulation (the “Lock-Up Period”); provided, however, that nothing contained in this Section 7
will prevent the exercise of a repurchase option, if any, in favor of the Company during the Lock-Up Period. You further agree to execute
and deliver such other agreements as may be reasonably requested by the Company or the underwriters that are consistent with the foregoing
or that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer
instructions with respect to your shares of Common Stock until the end of such period. You also agree that any transferee of any shares
of Common Stock (or other securities) of the Company held by you will be bound by this Section 7. The underwriters of the Company’s
stock are intended third party beneficiaries of this Section 7 and will have the right, power and authority to enforce the provisions
hereof as though they were a party hereto.
8. Transferability.
Except as otherwise provided in the Plan, your RSU Award is not transferable, except by will
or by the applicable laws of descent and distribution.
9. Corporate
Transaction. Your RSU Award is subject to the terms
of any agreement governing a Corporate Transaction involving the Company, including, without limitation, a provision for the appointment
of a stockholder representative that is authorized to act on your behalf with respect to any escrow, indemnities and any contingent consideration.
10. RSU
Award not a Service Contract.
(a) Nothing
in this Agreement (including, but not limited to, the vesting of your RSU Award or the issuance of the shares in respect of your RSU
Award), the Plan or any covenant of good faith and fair dealing that may be found implicit in this Agreement or the Plan shall: (i) confer
upon you any right to continue in the employ or service of, or affiliation with, the Company or an Affiliate; (ii) constitute any
promise or commitment by the Company or an Affiliate regarding the fact or nature of future positions, future work assignments, future
compensation or any other term or condition of employment or affiliation; (iii) confer any right or benefit under this Agreement
or the Plan unless such right or benefit has specifically accrued under the terms of this Agreement or Plan; or (iv) deprive the
Company of the right to terminate you at will and without regard to any future vesting opportunity that you may have.
(b) By
accepting this RSU Award, you acknowledge and agree that the right to continue vesting in the RSU Award pursuant to the vesting schedule
provided in the Grant Notice may not be earned unless (in addition to any other conditions described in the Grant Notice and this Agreement)
you continue as an employee, director or consultant at the will of the Company and affiliate, as applicable (not through the act of being
hired, being granted this RSU Award or any other award or benefit) and that the Company has the right to reorganize, sell, spin-out or
otherwise restructure one or more of its businesses or Affiliates at any time or from time to time, as it deems appropriate (a “reorganization”).
You acknowledge and agree that such a reorganization could result in the termination of your Continuous Service, or the termination of
Affiliate status of your employer and the loss of benefits available to you under this Agreement, including but not limited to, the termination
of the right to continue vesting in the RSU Award. You further acknowledge and agree that this Agreement, the Plan, the transactions
contemplated hereunder and the vesting schedule set forth herein or any covenant of good faith and fair dealing that may be found implicit
in any of them do not constitute an express or implied promise of continued engagement as an employee or consultant for the term of this
Agreement, for any period, or at all, and shall not interfere in any way with the Company’s right to terminate your Continuous
Service at any time, with or without your cause or notice, or to conduct a reorganization.
11. Securities
Law Compliance. You may not be issued any Common Stock under your RSU Award unless the
Common Stock underlying the Restricted Stock Units are either (i) then registered under the Securities Act, or (ii) the Company
has determined that such issuance would be exempt from the registration requirements of the Securities Act. Your RSU Award must also
comply with other applicable laws and regulations governing the RSU Award, and you shall not receive such Common Stock if the Company
determines that such receipt would not be in material compliance with such laws and regulations.
12. No
Liability For Taxes. As a condition to accepting the RSU Award, you hereby (a) agree to
not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising
from the RSU Award or other Company compensation and (b) acknowledge that you were advised to consult with your own personal tax,
financial and other legal advisors regarding the tax consequences of the RSU Award and have either done so or knowingly and voluntarily
declined to do so.
13. Severability.
If any part of this RSU Award Agreement or the Plan is declared by any court or Governmental Body to be unlawful or invalid, such unlawfulness
or invalidity will not invalidate any portion of this RSU Award Agreement or the Plan not declared to be unlawful or invalid. Any Section of
this RSU Award Agreement (or part of such a Section) so declared to be unlawful or invalid will, if possible, be construed in a manner
which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful
and valid.
14. Other
Documents. You hereby acknowledge receipt of or
the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act,
which includes the Prospectus. In addition, you acknowledge receipt of the Company’s Trading Policy.
15. Headings.
The headings of the Sections in this RSU Award Agreement are inserted for convenience only and shall not be deemed to constitute a part
of this RSU Award Agreement or to affect the meaning of this RSU Award Agreement.
16. Compliance
With Section 409A Of The Code. This RSU Award is intended to be exempt from
the application of Section 409A of the Code, including but not limited to by reason of complying with the “short-term deferral”
rule set forth in Treasury Regulation Section 1.409A-1(b)(4) and any ambiguities herein shall be interpreted accordingly.
Notwithstanding the foregoing, if it is determined that the RSU Award fails to satisfy the requirements of the short-term deferral rule and
is otherwise not exempt from, and determined to be deferred compensation subject to Section 409A of the Code, this RSU Award shall
comply with Section 409A to the extent necessary to avoid adverse personal tax consequences and any ambiguities herein shall be
interpreted accordingly. If it is determined that the RSU Award is deferred compensation subject to Section 409A and you are a “Specified
Employee” (within the meaning set forth in Section 409A(a)(2)(B)(i) of the Code) as of the date of your “Separation
from Service” (as defined in Section 409A), then the issuance of any shares that would otherwise be made upon the date of
your Separation from Service or within the first six (6) months thereafter will not be made on the originally scheduled date(s) and
will instead be issued in a lump sum on the date that is six (6) months and one day after the date of the Separation from Service,
with the balance of the shares issued thereafter in accordance with the original vesting and issuance schedule set forth above, but if
and only if such delay in the issuance of the shares is necessary to avoid the imposition of adverse taxation on you in respect of the
shares under Section 409A of the Code. Each installment of shares that vests is intended to constitute a “separate payment”
for purposes of Treasury Regulation Section 1.409A-2(b)(2).
17. Questions.
If you have questions regarding these or any other terms and conditions applicable to your RSU
Award, including a summary of the applicable federal income tax consequences please see the Prospectus.
Exhibit 10.24
TriSalus
Life Sciences, Inc.
2023 Employee Stock Purchase Plan
Adopted
by the Board of Directors: August 10, 2023
Approved by the Stockholders: August 8, 2023
1. General;
Purpose.
(a) The
Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to purchase
shares of Common Stock. The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees under an Employee Stock
Purchase Plan. In addition, the Plan permits the Company to grant a series of Purchase Rights to Eligible Employees that do not meet
the requirements of an Employee Stock Purchase Plan.
(b) The
Plan includes two components: a 423 Component and a Non-423 Component. The Company intends (but makes no undertaking or representation
to maintain) the 423 Component to qualify as a Qualified Employee Stock Purchase Plan. The provisions of the 423 Component, accordingly,
will be construed in a manner that is consistent with the requirements of Section 423 of the Code. In addition, this Plan authorizes
grants of Purchase Rights under the Non-423 Component that do not meet the requirements of a Qualified Employee Stock Purchase Plan.
Except as otherwise provided in the Plan or determined by the Board, the Non-423 Component will operate and be administered in the same
manner as the 423 Component. In addition, the Company may make separate Offerings which vary in terms (provided that such terms are not
inconsistent with the provisions of the Plan or the requirements of a Qualified Employee Stock Purchase Plan to the extent the Offering
is made under the 423 Component), and the Company will designate which Designated Company is participating in each separate Offering.
(c) The
Company, by means of the Plan, seeks to retain the services of Eligible Employees, to secure and retain the services of new Employees
and to provide incentives for such persons to exert maximum efforts for the success of the Company and its Related Corporations.
2. Administration.
(a) The
Board will administer the Plan unless and until the Board delegates administration of the Plan to a Committee or Committees, as provided
in Section 2(c).
(b) The
Board will have the power, subject to, and within the limitations of, the express provisions of the Plan:
(i) To
determine how and when Purchase Rights will be granted and the provisions of each Offering (which need not be identical).
(ii) To
designate from time to time (A) which Related Corporations of the Company will be eligible to participate in the Plan as Designated
423 Companies, (B) which Related Corporations or Affiliates will be eligible to participate in the Plan as Designated Non-423 Companies,
(C) which Affiliates or Related Corporations may be excluded from participation in the Plan, and (D) which Designated Companies
will participate in each separate Offering (to the extent that the Company makes separate Offerings).
(iii) To
construe and interpret the Plan and Purchase Rights, and to establish, amend and revoke rules and regulations for its administration.
The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan, in a manner and to the extent
it deems necessary or expedient to make the Plan fully effective.
(iv) To
settle all controversies regarding the Plan and Purchase Rights granted under the Plan.
(v) To
suspend or terminate the Plan at any time as provided in Section 11.
(vi) To
amend the Plan at any time as provided in Section 11.
(vii) Generally,
to exercise such powers and to perform such acts as it deems necessary or expedient to promote the best interests of the Company and
its Related Corporations and to carry out the intent that the Plan be treated as a Qualified Employee Stock Purchase Plan with respect
to the 423 Component.
(viii) To
adopt such rules, procedures and sub-plans as are necessary or appropriate to permit or facilitate participation in the Plan by Employees
who are foreign nationals or employed or located outside the United States. Without limiting the generality of, and consistent with,
the foregoing, the Board specifically is authorized to adopt rules, procedures, and sub-plans regarding, without limitation, eligibility
to participate in the Plan, the definition of eligible “earnings,” handling and making of Contributions, establishment of
bank or trust accounts to hold Contributions, payment of interest, conversion of local currency, obligations to pay payroll tax, determination
of beneficiary designation requirements, withholding procedures and handling of share issuances, any of which may vary according to applicable
requirements, and which, if applicable to a Designated Non-423 Company, do not have to comply with the requirements of Section 423
of the Code.
(c) The
Board may delegate some or all of the administration of the Plan to a Committee or Committees. If administration is delegated to a Committee,
the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been
delegated to the Committee, including the power to delegate to a subcommittee any of the administrative powers the Committee is authorized
to exercise (and references in this Plan and any applicable Offering Document to the Board will thereafter be to the Committee or subcommittee),
subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board.
Further, to the extent not prohibited by Applicable Law, the Board or Committee may, from time to time, delegate some or all of its authority
under the Plan to one or more officers of the Company or other persons or groups of persons as it deems necessary, appropriate or advisable
under conditions or limitations that it may set at or after the time of the delegation. The Board may retain the authority to concurrently
administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated. Whether
or not the Board has delegated administration of the Plan to a Committee, the Board will have the final power to determine all questions
of policy and expediency that may arise in the administration of the Plan.
(d) All
determinations, interpretations and constructions made by the Board in good faith will not be subject to review by any person and will
be final, binding and conclusive on all persons.
3. Shares
of Common Stock Subject to the Plan.
(a) Subject
to the provisions of Section 10(a) relating to Capitalization Adjustments, the maximum number of shares of Common Stock that
may be issued under the Plan will not exceed 1,396,252 shares of Common Stock (equal to three percent (3%) of the Fully Diluted Common
Stock determined as of immediately after the Effective Time) (the “Initial Share Reserve”), plus the number
of shares of Common Stock that are automatically added on January 1st of each year for a period of up to ten years, commencing on
January 1, 2024 and ending on (and including) January 1, 2033, in an amount equal to the lesser of (x) two percent
(2%) of the total number of shares of the Fully Diluted Common Stock determined as of the day prior to such increase, and (y) 2,792,503
shares of Common Stock (equal to two hundred percent (200%) of the Initial Share Reserve). Notwithstanding the foregoing, the Board may
act prior to the first day of any calendar year to provide that there will be no January 1st increase in the share reserve
for such calendar year or that the increase in the share reserve for such calendar year will be a lesser number of shares of Common Stock
than would otherwise occur pursuant to the preceding sentence. For the avoidance of doubt, up to the maximum number of shares of Common
Stock reserved under this Section 3(a) may be used to satisfy purchases of Common Stock under the 423 Component and any remaining
portion of such maximum number of shares may be used to satisfy purchases of Common Stock under the Non-423 Component.
(b) If
any Purchase Right granted under the Plan terminates without having been exercised in full, the shares of Common Stock not purchased
under such Purchase Right will again become available for issuance under the Plan.
(c) The
stock purchasable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by
the Company on the open market.
4. Grant
of Purchase Rights; Offering.
(a) The
Board may from time to time grant or provide for the grant of Purchase Rights to Eligible Employees under an Offering (consisting of
one or more Purchase Periods) on an Offering Date or Offering Dates selected by the Board. Each Offering will be in such form and will
contain such terms and conditions as the Board will deem appropriate, and with respect to the 423 Component, will comply with the requirement
of Section 423(b)(5) of the Code that all Employees granted Purchase Rights will have the same rights and privileges (except
as permitted by any regulations issued thereunder). The terms and conditions of an Offering shall be incorporated by reference into the
Plan and treated as part of the Plan. The provisions of separate Offerings need not be identical, but each Offering will include (through
incorporation of the provisions of this Plan by reference in the document comprising the Offering or otherwise) the period during which
the Offering will be effective, which period will not exceed 27 months beginning with the Offering Date, and the substance of the provisions
contained in Sections 5 through 8, inclusive.
(b) If
a Participant has more than one Purchase Right outstanding under the Plan, unless he or she otherwise indicates in forms delivered to
the Company or a third party designated by the Company (each, a “Company Designee”): (i) each form will
apply to all of his or her Purchase Rights under the Plan, and (ii) a Purchase Right with a lower exercise price (or an earlier-granted
Purchase Right, if different Purchase Rights have identical exercise prices) will be exercised to the fullest possible extent before
a Purchase Right with a higher exercise price (or a later-granted Purchase Right if different Purchase Rights have identical exercise
prices) will be exercised.
(c) The
Board will have the discretion to structure an Offering so that if the Fair Market Value of a share of Common Stock on the first Trading
Day of a new Purchase Period within that Offering is less than or equal to the Fair Market Value of a share of Common Stock on the Offering
Date for that Offering, then (i) that Offering will terminate immediately as of that first Trading Day, and (ii) the Participants
in such terminated Offering will be automatically enrolled in a new Offering beginning on the first Trading Day of such new Purchase
Period.
5. Eligibility.
(a) Purchase
Rights may be granted only to Employees of the Company or, as the Board may designate in accordance with Section 2(b), to Employees
of a Related Corporation or an Affiliate. Except as provided in Section 5(b) or as required by Applicable Law, an Employee
will not be eligible to be granted Purchase Rights unless, on the Offering Date, the Employee has been in the employ of the Company,
the Related Corporation or the Affiliate, as the case may be, for such continuous period preceding such Offering Date as the Board may
(unless prohibited by Applicable Law) require, but in no event will the required period of continuous employment be equal to or greater
than two years. In addition, the Board may provide that no Employee will be eligible to be granted Purchase Rights under the Plan unless,
on the Offering Date, such Employee’s customary employment with the Company, the Related Corporation, or the Affiliate is more
than 20 hours per week and more than five months per calendar year or such other criteria as the Board may determine consistent with
Section 423 of the Code with respect to the 423 Component. The Board may also exclude from participation in the Plan or any Offering
Employees who are "highly compensated employees" (within the meaning of Section 423(b)(4)(D) of the Code) of the
Company or a Related Corporation or a subset of such highly compensated employees.
(b) The
Board may provide that each person who, during the course of an Offering, first becomes an Eligible Employee will, on a date or dates
specified in the Offering which coincides with the day on which such person becomes an Eligible Employee or which occurs thereafter,
receive a Purchase Right under that Offering, which Purchase Right will thereafter be deemed to be a part of that Offering. Such Purchase
Right will have the same characteristics as any Purchase Rights originally granted under that Offering, as described herein, except that:
(i) the
date on which such Purchase Right is granted will be the “Offering Date” of such Purchase Right for all purposes, including
determination of the exercise price of such Purchase Right;
(ii) the
period of the Offering with respect to such Purchase Right will begin on its Offering Date and end coincident with the end of such Offering;
and
(iii) the
Board may provide that if such person first becomes an Eligible Employee within a specified period of time before the end of the Offering,
he or she will not receive any Purchase Right under that Offering.
(c) No
Employee will be eligible for the grant of any Purchase Rights under the 423 Component if, immediately after any such Purchase Rights
are granted, such Employee owns stock possessing five percent (5%) or more of the total combined voting power or value of all classes
of stock of the Company or of any Related Corporation. For purposes of this Section 5(c), the rules of Section 424(d) of
the Code will apply in determining the stock ownership of any Employee, and stock which such Employee may purchase under all outstanding
Purchase Rights and options will be treated as stock owned by such Employee.
(d) As
specified by Section 423(b)(8) of the Code, an Eligible Employee may be granted Purchase Rights under the 423 Component only
if such Purchase Rights, together with any other rights granted under all Qualified Employee Stock Purchase Plans of the Company and
any Related Corporations, do not permit such Eligible Employee’s rights to purchase stock of the Company or any Related Corporation
to accrue at a rate which, when aggregated, exceeds $25,000 of Fair Market Value of such stock (determined at the time such rights are
granted, and which, with respect to the Plan, will be determined as of their respective Offering Dates) for each calendar year in which
such rights are outstanding at any time.
(e) Officers
of the Company and any Designated Company, if they are otherwise Eligible Employees, will be eligible to participate in Offerings under
the Plan. Notwithstanding the foregoing, the Board may (unless prohibited by Applicable Law) provide in an Offering that Employees who
are highly compensated Employees (or a subset thereof) within the meaning of Section 423(b)(4)(D) of the Code will not be eligible
to participate.
(f) Notwithstanding
anything in this Section 5 to the contrary, in the case of an Offering under the Non-423 Component, an Eligible Employee (or group
of Eligible Employees) may be excluded from participation in the Plan or an Offering if the Board has determined, in its sole discretion,
that such individuals shall be excluded.
6.
Purchase Rights; Purchase Price.
(a) On
each Offering Date, each Eligible Employee, pursuant to an Offering made under the Plan, will be granted a Purchase Right to purchase
up to that number of shares of Common Stock purchasable either with a maximum percentage of eligible compensation or with a maximum dollar
amount, as designated by the Board, during the period that begins on the Offering Date (or such later date as the Board determines for
a particular Offering) and ends on the date stated in the Offering, which date will be no later than the end of the Offering.
(b) The
Board will establish one or more Purchase Dates during an Offering on which Purchase Rights granted for that Offering will be exercised
and shares of Common Stock will be purchased in accordance with such Offering.
(c) In
connection with each Offering made under the Plan, the Board may specify (i) a maximum number of shares of Common Stock that may
be purchased by any Participant on any Purchase Date during such Offering, (ii) a maximum aggregate number of shares of Common Stock
that may be purchased by all Participants pursuant to such Offering and/or (iii) a maximum aggregate number of shares of Common
Stock that may be purchased by all Participants on any Purchase Date under the Offering. If the aggregate purchase of shares of Common
Stock issuable upon exercise of Purchase Rights granted under the Offering would exceed any such maximum aggregate number, then, in the
absence of any Board action otherwise, a pro rata (based on each Participant’s accumulated Contributions) allocation of the shares
of Common Stock (rounded down to the nearest whole share) available will be made in as nearly a uniform manner as will be practicable
and equitable.
(d) The
purchase price of shares of Common Stock acquired pursuant to Purchase Rights will be specified by the Board prior to commencement of
an Offering and will not be less than the lesser of:
(i) an
amount equal to 85% of the Fair Market Value of the shares of Common Stock on the Offering Date; or
(ii) an
amount equal to 85% of the Fair Market Value of the shares of Common Stock on the applicable Purchase Date.
7. Participation;
Withdrawal; Termination.
(a) An
Eligible Employee may elect to participate in an Offering and authorize payroll deductions as the means of making Contributions by completing
and delivering to the Company or a Company Designee, within the time specified in the Offering, an enrollment form provided by the Company
or Company Designee. The enrollment form will specify the amount of Contributions not to exceed the maximum amount specified by the Board.
Each Participant’s Contributions will be credited to a bookkeeping account for such Participant under the Plan and will be deposited
with the general funds of the Company except where Applicable Law requires that Contributions be deposited with a third party. If permitted
in the Offering, a Participant may begin such Contributions with the first payroll occurring on or after the Offering Date (or, in the
case of a payroll date that occurs after the end of the prior Offering but before the Offering Date of the next new Offering, Contributions
from such payroll will be included in the new Offering). If permitted in the Offering, a Participant may thereafter reduce (including
to zero) or increase his or her Contributions. If required under Applicable Law or if specifically provided in the Offering and to the
extent permitted by Section 423 of the Code with respect to the 423 Component, in addition to or instead of making Contributions
by payroll deductions, a Participant may make Contributions through payment by cash, check or wire transfer prior to a Purchase Date.
(b) During
an Offering, a Participant may cease making Contributions and withdraw from the Offering by delivering to the Company or a Company Designee
a withdrawal form provided by the Company. The Company may impose a deadline before a Purchase Date for withdrawing. Upon such withdrawal,
such Participant’s Purchase Right in that Offering will immediately terminate and the Company will distribute as soon as practicable
to such Participant all of his or her accumulated but unused Contributions and such Participant’s Purchase Right in that Offering
shall thereupon terminate. A Participant’s withdrawal from that Offering will have no effect upon his or her eligibility to participate
in any other Offerings under the Plan, but such Participant will be required to deliver a new enrollment form to participate in subsequent
Offerings.
(c) Unless
otherwise required by Applicable Law, Purchase Rights granted pursuant to any Offering under the Plan will terminate immediately if the
Participant either (i) is no longer an Employee for any reason or for no reason (subject to any post-employment participation period
required by Applicable Law) or (ii) is otherwise no longer eligible to participate. The Company will distribute as soon as practicable
to such individual all of his or her accumulated but unused Contributions (and if applicable, accumulated interest).
(d) Unless
otherwise determined by the Board, a Participant whose employment transfers or whose employment terminates with an immediate rehire (with
no break in service) by or between the Company and a Designated Company or between Designated Companies will not be treated as having
terminated employment for purposes of participating in the Plan or an Offering; however, if a Participant transfers from an Offering
under the 423 Component to an Offering under the Non-423 Component, the exercise of the Participant’s Purchase Right will be qualified
under the 423 Component only to the extent such exercise complies with Section 423 of the Code. If a Participant transfers from
an Offering under the Non-423 Component to an Offering under the 423 Component, the exercise of the Purchase Right will remain non-qualified
under the Non-423 Component. The Board may establish different and additional rules governing transfers between separate Offerings
within the 423 Component and between Offerings under the 423 Component and Offerings under the Non-423 Component.
(e) During
a Participant’s lifetime, Purchase Rights will be exercisable only by such Participant. Purchase Rights are not transferable by
a Participant, except by will, by the laws of descent and distribution, or, if permitted by the Company, by a beneficiary designation
as described in Section 9.
(f) Unless
otherwise specified in the Offering or as required by Applicable Law, the Company will have no obligation to pay interest on Contributions.
8. Exercise
of Purchase Rights.
(a) On
each Purchase Date, each Participant’s accumulated Contributions will be applied to the purchase of shares of Common Stock, up
to the maximum number of shares of Common Stock permitted by the Plan and the applicable Offering, at the purchase price specified in
the Offering. No fractional shares will be issued unless specifically provided for in the Offering.
(b) Unless
otherwise provided in the Offering, if any amount of accumulated Contributions remains in a Participant’s account after the purchase
of shares of Common Stock and such remaining amount is less than the amount required to purchase one share of Common Stock on the final
Purchase Date of an Offering, then such remaining amount will be held in such Participant’s account for the purchase of shares
of Common Stock under the next Offering under the Plan, unless such Participant withdraws from or is not eligible to participate in such
next Offering, in which case such amount will be distributed to such Participant after the final Purchase Date without interest (unless
the payment of interest is otherwise required by Applicable Law). If the amount of Contributions remaining in a Participant’s account
after the purchase of shares of Common Stock is at least equal to the amount required to purchase one (1) whole share of Common
Stock on the final Purchase Date of an Offering, then such remaining amount will be distributed in full to such Participant after the
final Purchase Date of such Offering without interest (unless otherwise required by Applicable Law).
(c) No
Purchase Rights may be exercised to any extent unless the shares of Common Stock to be issued upon such exercise under the Plan are covered
by an effective registration statement pursuant to the Securities Act and the Plan is in material compliance with all applicable U.S.
federal and state, foreign and other securities, exchange control and other laws applicable to the Plan. If on a Purchase Date the shares
of Common Stock are not so registered or the Plan is not in such compliance, no Purchase Rights will be exercised on such Purchase Date,
and, subject to Section 423 of the Code with respect to the 423 Component, the Purchase Date will be delayed until the shares of
Common Stock are subject to such an effective registration statement and the Plan is in material compliance, except that the Purchase
Date will in no event be more than 27 months from the Offering Date. If, on the Purchase Date, as delayed to the maximum extent permissible,
the shares of Common Stock are not registered and the Plan is not in material compliance with all Applicable Laws, as determined by the
Company in its sole discretion, no Purchase Rights will be exercised and all accumulated but unused Contributions will be distributed
to the Participants without interest (unless the payment of interest is otherwise required by Applicable Law).
9. Designation
of Beneficiary.
(a) The
Company may, but is not obligated to, permit a Participant to submit a form designating a beneficiary who will receive any shares of
Common Stock and/or Contributions from the Participant’s account under the Plan if the Participant dies before such shares and/or
Contributions are delivered to the Participant. The Company may, but is not obligated to, permit the Participant to change such designation
of beneficiary. Any such designation and/or change must be on a form approved by the Company.
(b) If
a Participant dies, and in the absence of a valid beneficiary designation, the Company will deliver any shares of Common Stock and/or
Contributions to the executor or administrator of the estate of the Participant. If no executor or administrator has been appointed (to
the knowledge of the Company), the Company, in its sole discretion, may deliver such shares of Common Stock and/or Contributions, without
interest (unless the payment of interest is otherwise required by Applicable Law) to the Participant’s spouse, dependents or relatives,
or if no spouse, dependent or relative is known to the Company, then to such other person as the Company may designate.
10. Adjustments
upon Changes in Common Stock; Corporate Transactions.
(a) In
the event of a Capitalization Adjustment, the Board will appropriately and proportionately adjust: (i) the class(es) and maximum
number of securities subject to the Plan pursuant to Section 3(a), (ii) the class(es) and maximum number of securities by which
the share reserve is to increase automatically each year pursuant to Section 3(a), (iii) the class(es) and number of securities
subject to, and the purchase price applicable to outstanding Offerings and Purchase Rights, and (iv) the class(es) and number of
securities that are the subject of the purchase limits under each ongoing Offering. The Board will make these adjustments, and its determination
will be final, binding and conclusive.
(b) In
the event of a Corporate Transaction, then: (i) any surviving corporation or acquiring corporation (or the surviving or acquiring
corporation’s parent company) may assume or continue outstanding Purchase Rights or may substitute similar rights (including a
right to acquire the same consideration paid to the stockholders in the Corporate Transaction) for outstanding Purchase Rights, or (ii) if
any surviving or acquiring corporation (or its parent company) does not assume or continue such Purchase Rights or does not substitute
similar rights for such Purchase Rights, then the Participants’ accumulated Contributions will be used to purchase shares of Common
Stock (rounded down to the nearest whole share) within ten business days (or such other period specified by the Board) prior to the Corporate
Transaction under the outstanding Purchase Rights, and the Purchase Rights will terminate immediately after such purchase.
11. Amendment,
Termination or Suspension of the Plan.
(a) The
Board may amend the Plan at any time in any respect the Board deems necessary or advisable. However, except as provided in Section 10(a) relating
to Capitalization Adjustments, stockholder approval will be required for any amendment of the Plan for which stockholder approval is
required by Applicable Law.
(b) The
Board may suspend or terminate the Plan at any time. No Purchase Rights may be granted under the Plan while the Plan is suspended or
after it is terminated.
(c) Any
benefits, privileges, entitlements and obligations under any outstanding Purchase Rights granted before an amendment, suspension or termination
of the Plan will not be materially impaired by any such amendment, suspension or termination except (i) with the consent of the
person to whom such Purchase Rights were granted, (ii) as necessary to facilitate compliance with any laws, listing requirements,
or governmental regulations (including, without limitation, the provisions of Section 423 of the Code and the regulations and other
interpretive guidance issued thereunder relating to Qualified Employee Stock Purchase Plans) including without limitation any such regulations
or other guidance that may be issued or amended after the date the Plan is adopted by the Board, or (iii) as necessary to obtain
or maintain favorable tax, listing, or regulatory treatment. To be clear, the Board may amend outstanding Purchase Rights without a Participant’s
consent if such amendment is necessary to ensure that the Purchase Right and/or the Plan complies with the requirements of Section 423
of the Code with respect to the 423 Component or with respect to other Applicable Laws. Notwithstanding anything in the Plan or any Offering
Document to the contrary, the Board will be entitled to: (i) establish the exchange ratio applicable to amounts withheld in a currency
other than U.S. dollars; (ii) permit Contributions in excess of the amount designated by a Participant in order to adjust for mistakes
in the Company’s processing of properly completed Contribution elections; (iii) establish reasonable waiting and adjustment
periods and/or accounting and crediting procedures to ensure that amounts applied toward the purchase of Common Stock for each Participant
properly correspond with amounts withheld from the Participant’s Contributions; (iv) amend any outstanding Purchase Rights
or clarify any ambiguities regarding the terms of any Offering to enable the Purchase Rights to qualify under and/or comply with Section 423
of the Code with respect to the 423 Component; and (v) establish other limitations or procedures as the Board determines in its
sole discretion advisable that are consistent with the Plan. The actions of the Board pursuant to this paragraph will not be considered
to alter or impair any Purchase Rights granted under an Offering as they are part of the initial terms of each Offering and the Purchase
Rights granted under each Offering.
12. Tax
Qualification; Tax Withholding.
(a) Although
the Company may endeavor to (i) qualify a Purchase Right for special tax treatment under the laws of the United States or jurisdictions
outside of the United States or (ii) avoid adverse tax treatment, the Company makes no representation to that effect and expressly
disavows any covenant to maintain special or to avoid unfavorable tax treatment, notwithstanding anything to the contrary in this Plan.
The Company will be unconstrained in its corporate activities without regard to the potential negative tax impact on Participants.
(b) Each
Participant will make arrangements, satisfactory to the Company and any applicable Related Corporation, to enable the Company or the
Related Corporation to fulfill any withholding obligation for Tax-Related Items. Without limitation to the foregoing, in the Company’s
sole discretion and subject to Applicable Law, such withholding obligation may be satisfied in whole or in part by (i) withholding
from the Participant’s salary or any other cash payment due to the Participant from the Company or a Related Corporation; (ii) withholding
from the proceeds of the sale of shares of Common Stock acquired under the Plan, either through a voluntary sale or a mandatory sale
arranged by the Company; or (iii) any other method deemed acceptable by the Board. The Company shall not be required to issue any
shares of Common Stock under the Plan until such obligations are satisfied.
(c) The
423 Component is exempt from the application of Section 409A of the Code, and any ambiguities herein shall be interpreted to so
be exempt from Section 409A of the Code. The Non-423 Component is intended to be exempt from the application of Section 409A
of the Code under the short-term deferral exception and any ambiguities shall be construed and interpreted in accordance with such intent.
In furtherance of the foregoing and notwithstanding any provision in the Plan to the contrary, if the Committee determines that an option
granted under the Plan may be subject to Section 409A of the Code or that any provision in the Plan would cause an option under
the Plan to be subject to Section 409A, the Committee may amend the terms of the Plan and/or of an outstanding option granted under
the Plan, or take such other action the Committee determines is necessary or appropriate, in each case, without the participant’s
consent, to exempt any outstanding option or future option that may be granted under the Plan from or to allow any such options to comply
with Section 409A of the Code, but only to the extent any such amendments or action by the Committee would not violate Section 409A
of the Code. Notwithstanding the foregoing, the Company shall have no liability to a participant or any other party if the option under
the Plan that is intended to be exempt from or compliant with Section 409A of the Code is not so exempt or compliant or for any
action taken by the Committee with respect thereto.
13. Effective
Date of Plan.
The
Plan will become effective immediately prior to and contingent upon the Effective Date. No Purchase Rights will be exercised unless and
until the Plan has been approved by the stockholders of the Company, which approval must be within 12 months before or after the date
the Plan is adopted (or if required under Section 11(a) above, materially amended) by the Board.
14. Miscellaneous
Provisions.
(a) Proceeds
from the sale of shares of Common Stock pursuant to Purchase Rights will constitute general funds of the Company.
(b) A
Participant will not be deemed to be the holder of, or to have any of the rights of a holder with respect to, shares of Common Stock
subject to Purchase Rights unless and until the Participant’s shares of Common Stock acquired upon exercise of Purchase Rights
are recorded in the books of the Company (or its transfer agent).
(c) The
Plan and Offering do not constitute an employment contract. Nothing in the Plan or in the Offering will in any way alter the at will
nature of a Participant’s employment or amend a Participant’s employment contract, if applicable, or be deemed to create
in any way whatsoever any obligation on the part of any Participant to continue in the employ of the Company or a Related Corporation
or an Affiliate, or on the part of the Company, a Related Corporation or an Affiliate to continue the employment of a Participant.
(d) The
provisions of the Plan will be governed by the laws of the State of Delaware without resort to that state’s conflicts of laws rules.
(e) If
any particular provision of the Plan is found to be invalid or otherwise unenforceable, such provision will not affect the other provisions
of the Plan, but the Plan will be construed in all respects as if such invalid provision were omitted.
(f) If
any provision of the Plan does not comply with Applicable Law, such provision shall be construed in such a manner as to comply with Applicable
Law.
15. Definitions.
As
used in the Plan, the following definitions will apply to the capitalized terms indicated below:
(a) “423
Component” means the part of the Plan, which excludes the Non-423 Component, pursuant to which Purchase Rights that satisfy
the requirements for a Qualified Employee Stock Purchase Plan may be granted to Eligible Employees.
(b) “Affiliate”
means any entity, other than a Related Corporation, whether now or subsequently established, which is at the time of determination, a
“parent” or “subsidiary” of the Company as such terms are defined in Rule 405 promulgated under the Securities
Act. The Board may determine the time or times at which “parent” or “subsidiary” status is determined within
the foregoing definition.
(c) “Applicable
Law” means shall mean the Code and any applicable securities, federal, state, foreign, material local or municipal or other
law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, listing rule, regulation, judicial
decision, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority
of any Governmental Body (or under the authority of the New York Stock Exchange, NASDAQ Stock Market or the Financial Industry Regulatory
Authority).
(d) “Board”
means the Board of Directors of the Company.
(e) “Capitalization
Adjustment” means any change that is made in, or other events that occur with respect to, the Common Stock subject to the
Plan or subject to any Purchase Right after the date the Plan is adopted by the Board without the receipt of consideration by the Company
through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash,
large nonrecurring cash dividend, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure
or other similar equity restructuring transaction, as that term is used in Financial Accounting Standards Board Accounting Standards
Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible securities of the
Company will not be treated as a Capitalization Adjustment.
(f) “Code”
means the U.S. Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.
(g) “Committee”
means a committee of one or more members of the Board to whom authority has been delegated by the Board in accordance with Section 2(c).
(h) “Common
Stock” means the common stock, par value $0.0001 per share, of the Company.
(i) “Company”
means TriSalus Life Sciences, Inc., a Delaware corporation.
(j) “Contributions”
means the payroll deductions and other additional payments specifically provided for in the Offering that a Participant contributes to
fund the exercise of a Purchase Right. A Participant may make additional payments into his or her account if specifically provided for
in the Offering, and then only if the Participant has not already had the maximum permitted amount withheld during the Offering through
payroll deductions and, with respect to the 423 Component, to the extent permitted by Section 423.
(k) “Corporate
Transaction” means the consummation, in a single transaction or in a series of related transactions, of any one or more
of the following events:
(i) a
sale or other disposition of all or substantially all, as determined by the Board in its sole discretion, of the consolidated assets
of the Company and its subsidiaries;
(ii) a
sale or other disposition of more than 50% of the outstanding securities of the Company;
(iii) a
merger, consolidation or similar transaction following which the Company is not the surviving corporation; or
(iv) a
merger, consolidation or similar transaction following which the Company is the surviving corporation but the shares of Common Stock
outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger,
consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.
(l) “Designated
423 Company” means any Related Corporation selected by the Board as participating in the 423 Component.
(m) “Designated
Company” means any Designated Non-423 Corporation or Designated 423 Company, provided, however, that at any given time,
a Related Corporation participating in the 423 Component shall not be a Related Corporation participating in the Non-423 Component.
(n) “Designated
Non-423 Company” means any Related Corporation or Affiliate selected by the Board as participating in the Non-423 Component.
(o) “Director”
means a member of the Board.
(p) “Effective
Date” means the effective date of this Plan, which is the date of the closing of the transactions contemplated by the Merger
Agreement.
(q) “Effective
Time” shall have the meaning set forth in the Merger Agreement.
(r) “Eligible
Employee” means an Employee who meets the requirements set forth in the document(s) governing the Offering for eligibility
to participate in the Offering, provided that such Employee also meets the requirements for eligibility to participate set forth in the
Plan.
(s) “Employee”
means any person, including an Officer or Director, who is “employed” for purposes of Section 423(b)(4) of the
Code by the Company or a Related Corporation or solely with respect to the Non-423 Component, an Affiliate. However, service solely as
a Director, or payment of a fee for such services, will not cause a Director to be considered an “Employee” for purposes
of the Plan.
(t) “Exchange
Act” means the U.S. Securities Exchange Act of 1934, as amended and the rules and regulations promulgated thereunder.
(u) “Fair
Market Value” means, as of any date, the value of the Common Stock determined as follows:
(i) If
the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value of a share of
Common Stock will be, unless otherwise determined by the Board, the closing sales price for such stock as quoted on such exchange or
market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported
in such source as the Board deems reliable. Unless otherwise provided by the Board, if there is no closing sales price for the Common
Stock on the date of determination, then the Fair Market Value will be the closing sales price on the last preceding date for which such
quotation exists.
(ii) In
the absence of such markets for the Common Stock, the Fair Market Value will be determined by the Board in good faith in compliance with
Applicable Laws and regulations and, to the extent applicable as determined in the sole discretion of the Board, in a manner that complies
with Sections 409A of the Code.
(v) “Fully
Diluted Common Stock” means the number of shares of Common Stock, determined as of the applicable time of measurement,
equal to the sum of (i) the total number of shares of Common Stock issued and outstanding and (ii) the total number of shares
of Common Stock subject to securities that are convertible into or exercisable for shares of Common Stock (whether vested or unvested).
(w) “Governmental
Body” means any: (a) nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction
of any nature; (b) federal, state, local, municipal, foreign or other government; (c) governmental or regulatory body, or quasi-governmental
body of any nature (including any governmental division, department, administrative agency or bureau, commission, authority, instrumentality,
official, ministry, fund, foundation, center, organization, unit, body or entity and any court or other tribunal, and for the avoidance
of doubt, any tax authority) or other body exercising similar powers or authority; or (d) self-regulatory organization (including
the New York Stock Exchange, the NASDAQ Stock Market and the Financial Industry Regulatory Authority).
(x) “Merger
Agreement” means that certain Agreement and Plan of Merger, dated as of November 11, 2022, as amended April 4,
2023, May 13, 2023, and July 5, 2023, by and among MedTech Acquisition Corporation, a Delaware corporation (“MTAC”),
MTAC Merger Sub, Inc., a Delaware corporation and direct, wholly owned subsidiary of MTAC, and TriSalus Life Sciences, Inc.,
a Delaware corporation.
(y) “Non-423
Component” means the part of the Plan, which excludes the 423 Component, pursuant to which Purchase Rights that are not
intended to satisfy the requirements for a Qualified Employee Stock Purchase Plan may be granted to Eligible Employees.
(z) “Offering”
means the grant to Eligible Employees of Purchase Rights, with the exercise of those Purchase Rights automatically occurring at the end
of one or more Purchase Periods. The terms and conditions of an Offering will generally be set forth in the “Offering Document”
approved by the Board for that Offering.
(aa) “Offering
Date” means a date selected by the Board for an Offering to commence.
(bb) “Officer”
means a person who is an officer of the Company or a Related Corporation within the meaning of Section 16 of the Exchange Act.
(cc) “Participant”
means an Eligible Employee who holds an outstanding Purchase Right.
(dd) “Plan”
means this TriSalus Life Sciences, Inc. 2023 Employee Stock Purchase Plan, as amended from time to time, including both the 423
Component and the Non-423 Component.
(ee) “Purchase
Date” means one or more dates during an Offering selected by the Board on which Purchase Rights will be exercised and on
which purchases of shares of Common Stock will be carried out in accordance with such Offering.
(ff) “Purchase
Period” means a period of time specified within an Offering, generally beginning on the Offering Date or on the first Trading
Day following a Purchase Date, and ending on a Purchase Date. An Offering may consist of one or more Purchase Periods.
(gg) “Purchase
Right” means an option to purchase shares of Common Stock granted pursuant to the Plan.
(hh) “Qualified
Employee Stock Purchase Plan” means a plan that grants Purchase Rights intended to be options issued under an “employee
stock purchase plan,” as that term is defined in Section 423(b) of the Code.
(ii) “Related
Corporation” means any “parent corporation” or “subsidiary corporation” of the Company whether
now or subsequently established, as those terms are defined in Sections 424(e) and (f), respectively, of the Code.
(jj) “Securities
Act” means the U.S. Securities Act of 1933, as amended.
(kk) “Tax-Related
Items” means any income tax, social insurance, payroll tax, fringe benefit tax, payment on account or other tax-related
items arising out of or in relation to a Participant’s participation in the Plan, including, but not limited to, the exercise of
a Purchase Right and the receipt of shares of Common Stock or the sale or other disposition of shares of Common Stock acquired under
the Plan.
(ll) “Trading
Day” means any day on which the exchange(s) or market(s) on which shares of Common Stock are listed, including
but not limited to the New York Stock Exchange, Nasdaq Global Select Market, the Nasdaq Global Market, the Nasdaq Capital Market or any
successors thereto, is open for trading.
Exhibit 10.25
TRISALUS LIFE SCIENCES, INC.
INDEMNIFICATION AGREEMENT
This INDEMNIFICATION AGREEMENT
(this “Agreement”) is dated as of , 20 and is between
TriSalus Life Sciences, Inc., a Delaware corporation (the “Company”), and
(“Indemnitee”).
RECITALS
A. Indemnitee’s service to the
Company substantially benefits the Company.
B. Individuals
are reluctant to serve as directors or officers of corporations or in certain other capacities unless they are provided with adequate
protection through insurance or indemnification against the risks of claims and actions against them arising out of such service.
C. Indemnitee
does not regard the protection currently provided by applicable law, the Company’s governing documents and any insurance as adequate
under the present circumstances, and Indemnitee may not be willing to serve as a director or officer without additional protection.
D. In order to
induce Indemnitee to continue to provide services to the Company, it is reasonable, prudent and necessary for the Company to contractually
obligate itself to indemnify, and to advance expenses on behalf of, Indemnitee as permitted by applicable law.
E. This Agreement
is a supplement to and in furtherance of the indemnification provided in the Company’s certificate of incorporation and bylaws,
and any resolutions adopted pursuant thereto, and this Agreement shall not be deemed a substitute therefor, nor shall this Agreement be
deemed to limit, diminish or abrogate any rights of Indemnitee thereunder.
AGREEMENT
The parties agree as follows:
1. Definitions.
(a) “Affiliate”
shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by, or is under common control
with, such Person.
(b) “Beneficial
Owner” shall have the meaning given to such term in Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the
“Exchange Act”); provided, however, that “Beneficial Owner” shall exclude any Person otherwise becoming
a Beneficial Owner solely by reason of (i) the stockholders of the Company approving a merger of the Company with another Person,
or entering into tender or support agreements relating thereto, provided such merger was approved by the Company’s board of directors,
or (ii) the Company’s board of directors approving a sale of securities by the Company to such Person.
(c) A
“Change in Control” shall be deemed to occur upon the earliest to occur after the date of this Agreement of
any of the following events:
(i) Acquisition
of Stock by Third Party. Any Person (as defined below) becomes the Beneficial Owner, directly or indirectly, of securities of the
Company representing 50% or more of the combined voting power of the Company’s then outstanding securities;
(ii) Change
in Board Composition. During any period of two consecutive years (not including any period prior to the execution of this Agreement),
individuals who at the beginning of such period constituted the Company’s board of directors and any Approved Directors cease for
any reason to constitute at least a majority of the members of the Company’s board of directors. “Approved Directors”
means new directors (other than a director designated by a person who has entered into an agreement with the Company to effect a transaction
described in Sections 1(c)(i), 1(c)(iii) or 1(c)(iv)) whose election or nomination by the Company’s board of directors (or,
if applicable, by the Company’s stockholders) was approved by a vote of at least two thirds of the directors then still in office
who either were directors at the beginning of such two-year period or whose election or nomination for election was previously so approved;
(iii) Corporate
Transactions. The effective date of a merger or consolidation of the Company with any other entity, other than a merger or consolidation
that would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to
represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) more than 50% of
the combined voting power of the voting securities of the surviving entity outstanding immediately after such merger or consolidation
and with the power to elect a majority of the board of directors or other governing body of such surviving entity; or
(iv) Liquidation.
The approval by the Company’s board of directors of a complete liquidation or the dissolution of the Company or an agreement
for the sale, lease or disposition by the Company of all or substantially all of the Company’s assets; or
(v) Other
Events. Any other event of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A
(or in response to any similar item on any similar schedule or form) promulgated under the Exchange Act, whether or not the Company is
then subject to such reporting requirement, except the completion of the transactions contemplated by the Agreement and Plan of Merger,
dated as of November 11, 2022 and as amended, among the Company (formerly known as MedTech Acquisition Corporation), MTAC Merger Sub,
Inc. and TriSalus Operating Life Sciences, Inc. (formerly known as TriSalus Life Sciences, Inc.), shall not be considered a Change in
Control.
(d) “Corporate
Status” describes the status of a person who is or was a director, trustee, general partner, managing member, officer, employee,
agent or fiduciary of the Company or any other Enterprise.
(e) “DGCL”
means the General Corporation Law of the State of Delaware.
(f) “Disinterested
Director” means a director of the Company who is not and was not a party to the Proceeding in respect of which indemnification
is sought by Indemnitee.
(g) “Enterprise”
means the Company and any other corporation, partnership, limited liability company, joint venture, trust, employee benefit plan or other
enterprise of which Indemnitee is or was serving at the request of the Company as a director, trustee, general partner, managing member,
officer, employee, agent or fiduciary.
(h) “Expenses”
include all reasonable and actually incurred attorneys’ fees, retainers, court costs, transcript costs, fees and costs of experts,
witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all
other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or
defend, investigating, being or preparing to be a witness in, or otherwise participating in, a Proceeding. Expenses also include (i) Expenses
incurred in connection with any appeal resulting from any Proceeding, including without limitation the premium, security for, and other
costs relating to any cost bond, supersede as bond or other appeal bond or their equivalent, and (ii) for purposes of Section 11(d), Expenses
incurred by Indemnitee in connection with the interpretation, enforcement or defense of Indemnitee’s rights under this Agreement
or under any directors’ and officers’ liability insurance policies maintained by the Company. Expenses, however, shall not
include amounts paid in settlement by Indemnitee or the amount of judgments or fines against Indemnitee.
(i) “Independent
Counsel” means a law firm, or a partner or member of a law firm, that is experienced in matters of corporation law and neither
presently is, nor in the past five years has been, retained to represent (i) the Company, any Enterprise or Indemnitee in any matter
material to any such party (other than as Independent Counsel with respect to matters concerning Indemnitee under this Agreement, or other
indemnitees under similar indemnification agreements), or (ii) any other party to the Proceeding giving rise to a claim for indemnification
hereunder. Notwithstanding the foregoing, the term Independent Counsel shall not include any person who, under the applicable standards
of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action
to determine Indemnitee’s rights under this Agreement.
(j) “Person”
shall have the meaning set forth in Sections 13(d) and 14(d) of the Exchange Act; provided, however, that Person shall exclude
(i) the Company, (ii) any trustee or other fiduciary holding securities under an employee benefit plan of the Company, and (iii) any
corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership
of stock of the Company.
(k) “Proceeding”
means any threatened, pending or completed action, suit, arbitration, mediation, alternate dispute resolution mechanism,
investigation, inquiry, administrative hearing or proceeding, whether brought in the right of the Company or otherwise and whether
of a civil, criminal, administrative or investigative nature, whether formal or informal, including any appeal therefrom and
including without limitation any such Proceeding pending as of the date of this Agreement, in which Indemnitee was, is or will be
involved as a party, a potential party, a non-party witness or otherwise by reason of (i) the fact that Indemnitee is or was a
director or officer of the Company, (ii) any action taken by Indemnitee or any action or inaction on Indemnitee’s part
while acting as a director or officer of the Company, or (iii) the fact that they are or were serving at the request of the
Company as a director, trustee, general partner, managing member, officer, employee, agent or fiduciary of the Company or any other
Enterprise, in each case whether or not serving in such capacity at the time any liability or Expense is incurred for which
indemnification or advancement of Expenses can be provided under this Agreement.
(l) “to
the fullest extent permitted by applicable law” means to the fullest extent permitted by all applicable laws, including
without limitation: (i) the fullest extent permitted by DGCL as of the date of this Agreement and (ii) the fullest extent authorized
or permitted by any amendments to or replacements of the DGCL adopted after the date of this Agreement that increase the extent to which
a corporation may indemnify its officers and directors.
(m) In
connection with any Proceeding relating to an employee benefit plan: references to “fines” shall include any
excise taxes assessed on a person with respect to any employee benefit plan; references to “serving at the request of the
Company” shall include any service as a director, officer, employee or agent of the Company which imposes duties on, or
involves services by, such director, officer, employee or agent with respect to an employee benefit plan, its participants or beneficiaries;
and a person who acted in good faith and in a manner they reasonably believed to be in the best interests of the participants and beneficiaries
of an employee benefit plan shall be deemed to have acted in a manner “not opposed to the best interests of the Company”
as referred to in this Agreement.
2. Indemnity in Third-Party
Proceedings. The Company shall indemnify Indemnitee in accordance with the provisions of this Section 2 if Indemnitee is, or is threatened
to be made, a party to or witness or other participant in any Proceeding, other than a Proceeding by or in the right of the Company to
procure a judgment in its favor. Pursuant to this Section 2, Indemnitee shall be indemnified to the fullest extent permitted by applicable
law against all Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by Indemnitee or on their behalf
in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner Indemnitee
reasonably believed to be in or not opposed to the best interests of the Company and, in the case of a criminal Proceeding had no reasonable
cause to believe that Indemnitee’s conduct was unlawful. The parties hereto intend that this Agreement shall provide to the fullest
extent permitted by law for indemnification in excess of that expressly permitted by statute, including, without limitation, any indemnification
provided by the Company’s certificate of incorporation or bylaws, vote of the Company’s stockholders or disinterested directors
or applicable law.
3. Indemnity in Proceedings
by or in the Right of the Company. The Company shall indemnify Indemnitee in accordance with the provisions of this Section 3 if Indemnitee
is, or is threatened to be made, a party to or a witness or other participant in any Proceeding by or in the right of the Company to procure
a judgment in its favor. Pursuant to this Section 3, Indemnitee shall be indemnified to the fullest extent permitted by applicable law
against all Expenses incurred by Indemnitee or on their behalf in connection with such Proceeding or any claim, issue or matter therein
if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the
Company. No indemnification for Expenses shall be made under this Section 3 in respect of any claim, issue or matter as to which Indemnitee
shall have been finally adjudged by a court of competent jurisdiction to be liable to the Company, unless and only to the extent that
the Delaware Court of Chancery or any court in which the Proceeding was brought shall determine upon application that, despite the adjudication
of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification for such
Expenses as the Delaware Court of Chancery or such other court shall deem proper.
4. Indemnification
for Expenses of a Party Who is Wholly or Partly Successful. Notwithstanding any other provision of this Agreement, in circumstances
where indemnification is not available under Section 2 or 3, as the case may be, to the fullest extent permitted by law and to the extent
that Indemnitee is a party to, or participant in, and is successful (on the merits or otherwise) in defense of, any Proceeding or any
claim, issue or matter therein, the Company shall indemnify Indemnitee against all Expenses incurred by Indemnitee or on Indemnitee’s
behalf in connection therewith. For purposes of this Section 4, the termination of any claim, issue or matter in such a Proceeding by
dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.
5. Partial Indemnification.
If Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for some or a portion of Expenses, but
not, however, for the total amount thereof, the Company shall nevertheless indemnify Indemnitee for the portion thereof to which Indemnitee
is entitled.
6. Exclusions.
Notwithstanding any provision in this Agreement, the Company shall not be obligated under this Agreement to make any indemnity in connection
with any Proceeding (or any part of any Proceeding):
(a) for
which payment has actually been made to or on behalf of Indemnitee under any statute, insurance policy, indemnity provision, vote or otherwise,
except with respect to any excess beyond the amount paid;
(b) for
an accounting or disgorgement of profits pursuant to Section 16(b) of the Exchange Act, or similar provisions of federal, state or local
statutory law or common law, if Indemnitee is held liable therefor (including pursuant to any settlement arrangements);
(c) for
any reimbursement of the Company by Indemnitee of (i) any bonus or other incentive-based or equity-based compensation or of any profits
realized by Indemnitee from the sale of securities of the Company, as required in each case under the Exchange Act (including any such
reimbursements that arise from an accounting restatement of the Company pursuant to Section 304 of the Sarbanes-Oxley Act of 2002 (the
“Sarbanes-Oxley Act”), or the payment to the Company of profits arising from the purchase and sale by Indemnitee of securities
in violation of Section 306 of the Sarbanes-Oxley Act), if Indemnitee is held liable therefor (including pursuant to any settlement arrangements)
or (ii) any compensation pursuant to any compensation recoupment or clawback policy adopted by the Company’s board of directors
or the compensation committee of the Company’s board of directors, including but not limited to any such policy adopted to comply
with stock exchange listing requirements implementing Section 10D of the Exchange Act;
(d) initiated
by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its directors,
officers, employees, agents or other indemnitees, unless (i) the Company’s board of directors authorized the Proceeding (or
the relevant part of the Proceeding) prior to its initiation, (ii) the Company provides the indemnification, in its sole discretion,
pursuant to the powers vested in the Company under applicable law, (iii) otherwise authorized in Section 11(d) or (iv) otherwise
required by applicable law; provided, for the avoidance of doubt, Indemnitee shall not be deemed for purposes of this paragraph, to have
initiated any Proceeding (or any part of a Proceeding) by reason of (i) having asserted any affirmative defenses in connection with
a claim not initiated by Indemnitee or (ii) having made any counterclaim (whether permissive or mandatory) in connection with any
claim not initiated by Indemnitee; or
(e) if prohibited by the DGCL
or other applicable law.
7. Advances of Expenses.
The Company shall advance the Expenses incurred by Indemnitee in connection with any Proceeding prior to its final disposition, and such
advancement shall be made as soon as reasonably practicable, but in any event no later than 30 days, after the receipt by the Company
of a written statement or statements requesting such advances from time to time (which shall include invoices received by Indemnitee in
connection with such Expenses but, in the case of invoices in connection with legal services, any references to legal work performed or
to expenditure made that would cause Indemnitee to waive any privilege accorded by applicable law shall not be included with the invoice).
Advances shall be unsecured and interest free and made without regard to Indemnitee’s ability to repay such advances. Indemnitee
hereby undertakes to repay any advance to the extent that it is ultimately determined that Indemnitee is not entitled to be indemnified
by the Company, except, with respect to advances of expenses made pursuant to Section 11(d), in which case Indemnitee makes the
undertaking provided in Section 11(d). This Section 7 shall not apply to the extent advancement is prohibited by law and shall not apply
to any Proceeding (or any part of any Proceeding) for which indemnity is not permitted under this Agreement, but shall apply to any Proceeding
(or any part of any Proceeding) referenced in Section 6(b) or 6(c) prior to a determination that Indemnitee is not entitled to be indemnified
by the Company.
8. Procedures for Notification and Defense
of Claim.
(a)
Indemnitee shall notify the Company in writing of any matter with respect to which Indemnitee intends to seek indemnification or
advancement of Expenses as soon as reasonably practicable following the receipt by Indemnitee of notice thereof. The written
notification to the Company shall include, in reasonable detail, a description of the nature of the Proceeding and the facts
underlying the Proceeding. The failure by Indemnitee to notify the Company will not relieve the Company from any liability that it
may have to Indemnitee hereunder or otherwise than under this Agreement, and any delay in so notifying the Company shall not
constitute a waiver by Indemnitee of any rights, except to the extent that such failure or delay materially prejudices the
Company.
(b) If,
at the time of the receipt of a notice of a Proceeding pursuant to the terms hereof, the Company has directors’ and officers’
liability insurance in effect that may be applicable to the Proceeding, the Company shall give prompt notice of the commencement of the
Proceeding to the insurers in accordance with the procedures set forth in the applicable policies. The Company shall thereafter take all
commercially reasonable action to cause such insurers to pay, on behalf of Indemnitee, all amounts payable as a result of such Proceeding
in accordance with the terms of such policies.
(c) In
the event the Company may be obligated to make any indemnity in connection with a Proceeding, the Company shall be entitled to assume
the defense of such Proceeding with counsel approved by Indemnitee, which approval shall not be unreasonably withheld, conditioned or
delayed, upon the delivery to Indemnitee of written notice of its election to do so. After delivery of such notice, approval of such counsel
by Indemnitee and the retention of such counsel by the Company, the Company will not be liable to Indemnitee for any fees or expenses
of counsel subsequently incurred by Indemnitee with respect to the same Proceeding. Notwithstanding the Company’s assumption of
the defense of any such Proceeding, the Company shall be obligated to pay the fees and expenses of Indemnitee’s separate counsel
to the extent (i) the employment of separate counsel by Indemnitee is authorized by the Company, (ii) counsel for the Company
or Indemnitee shall have reasonably concluded that there is a conflict of interest between the Company and Indemnitee in the conduct of
any such defense such that Indemnitee needs to be separately represented, (iii) the Company is not financially or legally able to
perform its indemnification obligations, or (iv) the Company shall not have retained, or shall not continue to retain, counsel to
defend such Proceeding. Regardless of any provision in this Agreement, Indemnitee shall have the right to employ counsel in any Proceeding
at Indemnitee’s personal expense. The Company shall not be entitled, without the consent of Indemnitee, to assume the defense of
any claim brought by or in the right of the Company.
(d)
Indemnitee shall give the Company such information and cooperation in connection with the Proceeding as may be reasonably appropriate.
(e) The
Company shall not be liable to indemnify Indemnitee for any settlement of any Proceeding (or any part thereof) effected without the Company’s
prior written consent, which shall not be unreasonably withheld, conditioned or delayed. The Company acknowledges that a settlement or
other disposition short of final judgment may be successful if it permits a party to avoid expense, delay, distraction, disruption and
uncertainty. In the event that any action, claim or proceeding to which Indemnitee is a party is resolved in a settlement to which the
Company has given its prior written consent, such settlement shall be treated as a success on the merits in the settled action, suit or
proceeding.
(f) The
Company shall not settle any Proceeding (or any part thereof) in a manner that imposes any penalty or liability on Indemnitee not paid
by the Company without Indemnitee’s prior written consent, which shall not be unreasonably withheld, conditioned or delayed.
9. Procedures upon Application for Indemnification.
(a) To
obtain indemnification under this Agreement, Indemnitee shall submit to the Company a written request, including therein or therewith
such documentation and information as is reasonably available to Indemnitee and as is reasonably necessary to determine whether and to
what extent Indemnitee is entitled to indemnification following the final disposition of the Proceeding. Any delay in providing the request
will not relieve the Company from its obligations under this Agreement, except to the extent such failure is prejudicial.
(b) Upon
written request by Indemnitee for indemnification pursuant to Section 9(a), a determination with respect to Indemnitee’s
entitlement thereto shall be made as follows, provided that a Change in Control shall not have occurred: (i) by a majority vote
of the Disinterested Directors, even though less than a quorum of the Company’s board of directors; (ii) by a committee
of Disinterested Directors designated by a majority vote of the Disinterested Directors, even though less than a quorum of the
Company’s board of directors; (iii) if there are no such Disinterested Directors or, if a majority of Disinterested
Directors so direct, by Independent Counsel in a written opinion to the Company’s board of directors, a copy of which shall be
delivered to Indemnitee; or (iv) if so directed by the Company’s board of directors, by the stockholders of the Company.
If a Change in Control shall have occurred, a determination with respect to Indemnitee’s entitlement to indemnification shall
be made by Independent Counsel in a written opinion to the Company’s board of directors, a copy of which shall be delivered to
Indemnitee. If it is determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within ten days
after such determination. Indemnitee shall cooperate with the person, persons or entity making the determination with respect to
Indemnitee’s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance
request any documentation or information that is not privileged or otherwise protected from disclosure and that is reasonably
available to Indemnitee and reasonably necessary to such determination. Any costs or expenses (including attorneys’ fees and
disbursements) actually and reasonably incurred by Indemnitee in so cooperating with the person, persons or entity making such
determination shall be borne by the Company, to the extent permitted by applicable law.
(c) In
the event the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 9(b), the Independent
Counsel shall be selected as provided in this Section 9(c). If a Change in Control shall not have occurred, the Independent Counsel shall
be selected by the Company’s board of directors, and the Company shall give written notice to Indemnitee advising them of the identity
of the Independent Counsel so selected. If a Change in Control shall have occurred, the Independent Counsel shall be selected by Indemnitee
(unless Indemnitee shall request that such selection be made by the Company’s board of directors, in which event the preceding sentence
shall apply), and Indemnitee shall give written notice to the Company advising it of the identity of the Independent Counsel so selected.
In either event, Indemnitee or the Company, as the case may be, may, within ten days after such written notice of selection shall have
been given, deliver to the Company or to Indemnitee, as the case may be, a written objection to such selection; provided, however, that
such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of “Independent
Counsel” as defined in Section 1, and the objection shall set forth with particularity the factual basis of such assertion. Absent
a proper and timely objection, the person so selected shall act as Independent Counsel. If such written objection is so made and substantiated,
the Independent Counsel so selected may not serve as Independent Counsel unless and until such objection is withdrawn or a court has determined
that such objection is without merit. If, within 20 days after the later of (i) submission by Indemnitee of a written request for
indemnification pursuant to Section 9(a) and (ii) the final disposition of the Proceeding, the parties have not agreed upon an Independent
Counsel, either the Company or Indemnitee may petition a court of competent jurisdiction for resolution of any objection that shall have
been made by the Company or Indemnitee to the other’s selection of Independent Counsel and for the appointment as Independent Counsel
of a person selected by the court or by such other person as the court shall designate, and the person with respect to whom all objections
are so resolved or the person so appointed shall act as Independent Counsel under Section 9(b). Upon the due commencement of any judicial
proceeding or arbitration pursuant to Section 11(a), the Independent Counsel shall be discharged and relieved of any further responsibility
in such capacity (subject to the applicable standards of professional conduct then prevailing).
(d) The
Company shall pay the reasonable fees and expenses of any Independent Counsel and shall fully indemnify such counsel against any and all
Expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto. Notwithstanding
any other provision of this Agreement, the Company shall not be required to pay Expenses of more than one Independent Counsel in connection
with all matters concerning a single Indemnitee, and such Independent Counsel shall be the Independent Counsel for any or all other indemnitees
under agreements similar to this Agreement unless (a) the Company otherwise determines or (B) any Indemnitee shall provide a written statement
setting forth in detail a reasonable objection to such Independent Counsel representing other indemnitees under agreements similar to
this Agreement.
10. Presumptions
and Effect of Certain Proceedings.
(a) In
making a determination with respect to entitlement to indemnification hereunder, the person, persons or entity making such determination
shall, to the fullest extent not prohibited by law, presume that Indemnitee is entitled to indemnification under this Agreement, and the
Company shall, to the fullest extent not prohibited by law, have the burden of proof to overcome that presumption by clear and convincing
evidence.
(b) The
termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of
nolo contendere or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the
right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner that they reasonably
believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had
reasonable cause to believe that their conduct was unlawful.
(c) For
purposes of any determination of good faith, Indemnitee shall be deemed to have acted in good faith to the extent Indemnitee relied in
good faith on (i) the records or books of account of the Enterprise, including financial statements, (ii) information supplied
to Indemnitee by the officers of the Enterprise in the course of their duties, (iii) the advice of legal counsel for the Enterprise
or its board of directors or counsel selected by any committee of the board of directors or (iv) information or records given or
reports made to the Enterprise by an independent certified public accountant, an appraiser, investment banker or other expert selected
with reasonable care by the Enterprise or its board of directors or any committee of the board of directors. The provisions of this Section
10(c) shall not be deemed to be exclusive or to limit in any way the other circumstances in which Indemnitee may be deemed to have met
the applicable standard of conduct set forth in this Agreement.
(d) Neither
the knowledge, actions nor failure to act of any other director, officer, agent or employee of the Enterprise shall be imputed to Indemnitee
for purposes of determining the right to indemnification under this Agreement.
(e) The
Company acknowledges that a settlement or other disposition short of final judgment may be successful if it permits a party to avoid expense,
delay, distraction, disruption and uncertainty. In the event that any Proceeding to which Indemnitee is a party is resolved in any manner
other than by adverse judgment against Indemnitee (including, without limitation, settlement of such action, claim or proceeding with
or without payment of money or other consideration) it shall be presumed that Indemnitee has been successful on the merits or otherwise
in such Proceeding. Anyone seeking to overcome this presumption shall have the burden of proof and the burden of persuasion by clear and
convincing evidence.
11. Remedies of Indemnitee.
(a) Subject
to Section 11(e), in the event that (i) a determination is made pursuant to Section 9(b) that Indemnitee is not entitled to indemnification
under this Agreement, (ii) advancement of Expenses is not timely made pursuant to Section 7 or 11(d), (iii) no determination
of entitlement to indemnification shall have been made pursuant to Section 9 within 90 days after the later of the receipt by the Company
of the request for indemnification or the final disposition of the Proceeding, (iv) payment of indemnification pursuant to this Agreement
is not made (A) within 10 days after a determination has been made that Indemnitee is entitled to indemnification or (B) with respect
to indemnification pursuant to Sections 4 and 11(d), within 30 days after receipt by the Company of a written request therefor, or (v) the
Company or any other person or entity takes or threatens to take any action to declare this Agreement void or unenforceable, or institutes
any litigation or other action or proceeding designed to deny, or to recover from, Indemnitee the benefits provided or intended to be
provided to Indemnitee hereunder, Indemnitee shall be entitled to an adjudication by a court of competent jurisdiction of their entitlement
to such indemnification or advancement of Expenses. Alternatively, Indemnitee, at their option, may seek an award in arbitration with
respect to their entitlement to such indemnification or advancement of Expenses, to be conducted by a single arbitrator pursuant to the
Commercial Arbitration Rules of the American Arbitration Association. Indemnitee shall commence such proceeding seeking an adjudication
or an award in arbitration within 12 months following the date on which Indemnitee first has the right to commence such proceeding pursuant
to this Section 11(a); provided, however, that the foregoing clause shall not apply in respect of a proceeding brought by Indemnitee
to enforce their rights under Section 4. The Company shall not oppose Indemnitee’s right to seek any such adjudication or award
in arbitration in accordance with this Agreement.
(b) Neither
(i) the failure of the Company, its board of directors, any committee or subgroup of the board of directors, Independent Counsel
or stockholders to have made a determination that indemnification of Indemnitee is proper in the circumstances because Indemnitee has
met the applicable standard of conduct, nor (ii) an actual determination by the Company, its board of directors, any committee or
subgroup of the board of directors, Independent Counsel or stockholders that Indemnitee has not met the applicable standard of conduct,
shall create a presumption that Indemnitee has or has not met the applicable standard of conduct. In the event that a determination shall
have been made pursuant to Section 9 that Indemnitee is not entitled to indemnification, any judicial proceeding or arbitration commenced
pursuant to this Section 11 shall be conducted in all respects as a de novo trial, or arbitration, on the merits, and Indemnitee
shall not be prejudiced by reason of that adverse determination. In any judicial proceeding or arbitration commenced pursuant to this
Section 11, the Company shall, to the fullest extent not prohibited by law, have the burden of proving Indemnitee is not entitled to indemnification
or advancement of Expenses, as the case may be, and the burden of proof shall be by clear and convincing evidence.
(c) To
the fullest extent not prohibited by law, the Company shall be precluded from asserting in any judicial proceeding or arbitration commenced
pursuant to this Section 11 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate
in any such court or before any such arbitrator that the Company is bound by all the provisions of this Agreement. If a determination
shall have been made pursuant to Section 9 that Indemnitee is entitled to indemnification, the Company shall be bound by such determination
in any judicial proceeding or arbitration commenced pursuant to this Section 11, absent (i) a misstatement by Indemnitee of a material
fact, or an omission of a material fact necessary to make Indemnitee’s statements not materially misleading, in connection with
the request for indemnification, or (ii) a prohibition of such indemnification under applicable law.
(d) To
the extent not prohibited by law, the Company shall indemnify Indemnitee against all Expenses incurred by Indemnitee in connection with
any action for indemnification or advancement of Expenses from the Company under this Agreement, any other agreement, the Company’s
certificate of incorporation or bylaws or under any directors’ and officers’ liability insurance policies maintained by the
Company to the extent Indemnitee is successful in such action, and, if requested by Indemnitee, shall (as soon as reasonably practicable,
but in any event no later than 30 days, after receipt by the Company of a written request therefor) advance such Expenses to Indemnitee,
subject to the provisions of Section 7. Indemnitee hereby undertakes to repay such advances to the extent the Indemnitee is ultimately
unsuccessful in such action or arbitration.
(e)
Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement of Indemnitee to indemnification under
this Agreement shall be required to be made prior to the final disposition of the Proceeding.
12. Contribution.
To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee,
the Company, in lieu of indemnifying Indemnitee, shall contribute to the amounts incurred by Indemnitee, whether for Expenses, judgments,
fines or amounts paid or to be paid in settlement, in connection with any claim relating to an indemnifiable event under this Agreement,
in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to reflect (i) the
relative benefits received by the Company and Indemnitee as a result of the events and transactions giving rise to such Proceeding; and
(ii) the relative fault of Indemnitee and the Company (and its other directors, officers, employees and agents) in connection with
such events and transactions.
13. Non-exclusivity.
The rights of indemnification and to receive advancement of Expenses as provided by this Agreement shall not be deemed exclusive of any
other rights to which Indemnitee may at any time be entitled under applicable law, the Company’s certificate of incorporation or
bylaws, any agreement, a vote of stockholders or a resolution of directors, or otherwise. To the extent that a change in Delaware law,
whether by statute or judicial decision, permits greater indemnification or advancement of Expenses than would be afforded currently under
the Company’s certificate of incorporation and bylaws and this Agreement, it is the intent of the parties hereto that Indemnitee
shall enjoy by this Agreement the greater benefits so afforded by such change, subject to the restrictions expressly set forth herein
or therein. Except as expressly set forth herein, no right or remedy herein conferred is intended to be exclusive of any other right or
remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or
hereafter existing at law or in equity or otherwise. Except as expressly set forth herein, the assertion or employment of any right or
remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy.
14. Primary
Responsibility. The Company acknowledges that to the extent Indemnitee is serving as a director on the Company’s board of
directors at the request or direction of a private equity or venture capital fund or other entity and/or certain of its Affiliates
(collectively, the “Secondary Indemnitors”), Indemnitee may have certain rights to indemnification and
advancement of expenses provided by such Secondary Indemnitors. The Company agrees that, as between the Company and the Secondary
Indemnitors, the Company is primarily responsible for amounts required to be indemnified or advanced under the Company’s
certificate of incorporation or bylaws or this Agreement and any obligation of the Secondary Indemnitors to provide indemnification
or advancement for the same amounts is secondary to those Company obligations. To the extent not in contravention of any insurance
policy or policies providing liability or other insurance for the Company or any director, trustee, general partner, managing
member, officer, employee, agent or fiduciary of the Company or any other Enterprise, the Company waives any right of contribution
or subrogation against the Secondary Indemnitors with respect to the liabilities for which the Company is primarily responsible
under this Section 14. In the event of any payment by the Secondary Indemnitors of amounts otherwise required to be indemnified or
advanced by the Company under the Company’s certificate of incorporation or bylaws or this Agreement, the Secondary
Indemnitors shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee for indemnification or
advancement of expenses under the Company’s certificate of incorporation or bylaws or this Agreement or, to the extent such
subrogation is unavailable and contribution is found to be the applicable remedy, shall have a right of contribution with respect to
the amounts paid. The Secondary Indemnitors are express third-party beneficiaries of the terms of this Section 14.
15. No Duplication
of Payments. Subject to Section 14, the Company shall not be liable under this Agreement to make any payment of amounts otherwise
indemnifiable hereunder (or for which advancement is provided hereunder) if and to the extent that Indemnitee has otherwise actually received
payment for such amounts under any insurance policy, contract, agreement or otherwise.
16. Insurance.
To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, trustees, general
partners, managing members, officers, employees, agents or fiduciaries of the Company or any other Enterprise, Indemnitee shall be covered
by such policy or policies to the same extent as the most favorably-insured persons under such policy or policies in a comparable position.
17. Subrogation.
Subject to Section 14, in the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment
to all of the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights,
including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.
18. Services to the
Company. Indemnitee agrees to serve as a director or officer of the Company or, at the request of the Company, as a director, trustee,
general partner, managing member, officer, employee, agent or fiduciary of another Enterprise, for so long as Indemnitee is duly elected
or appointed or until Indemnitee tenders their resignation or is removed from such position. Indemnitee may at any time and for any reason
resign from such position (subject to any other contractual obligation or any obligation imposed by operation of law), in which event
the Company shall have no obligation under this Agreement to continue Indemnitee in such position. This Agreement shall not be deemed
an employment contract between the Company (or any of its subsidiaries or any Enterprise) and Indemnitee. Indemnitee specifically acknowledges
that any employment with the Company (or any of its subsidiaries or any Enterprise) is at will, and Indemnitee may be discharged at any
time for any reason, with or without cause, with or without notice, except as may be otherwise expressly provided in any executed, written
employment contract between Indemnitee and the Company (or any of its subsidiaries or any Enterprise), any existing formal severance policies
adopted by the Company’s board of directors or, with respect to service as a director or officer of the Company, the Company’s
certificate of incorporation or bylaws or the DGCL. No such document shall be subject to any oral modification thereof.
19. Duration.
This Agreement shall continue until and terminate upon the later of (a) six years after the date that Indemnitee shall have ceased to
serve as a director or officer of the Company or as a director, trustee, general partner, managing member, officer, employee, agent or
fiduciary of any other Enterprise, as applicable; or (b) one year after the final termination of any Proceeding, including any appeal,
then pending in respect of which Indemnitee is granted rights of indemnification or advancement of Expenses hereunder and of any Proceeding
commenced by Indemnitee pursuant to Section 11 relating thereto.
20. Successors.
This Agreement shall be binding upon the Company and its successors and assigns, including any direct or indirect successor, by purchase,
merger, consolidation or otherwise, to all or substantially all of the business or assets of the Company, and shall inure to the benefit
of Indemnitee and Indemnitee’s heirs, executors and administrators. Further, the Company shall require and cause any successor (whether
direct or indirect by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company,
by written agreement, expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Company
would be required to perform if no such succession had taken place.
21. Severability.
Nothing in this Agreement is intended to require or shall be construed as requiring the Company to do or fail to do any act in
violation of applicable law. The Company’s inability, pursuant to court order or other applicable law, to perform its
obligations under this Agreement shall not constitute a breach of this Agreement. If any provision or provisions of this Agreement
shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (i) the validity, legality and enforceability
of the remaining provisions of this Agreement (including without limitation, each portion of any section of this Agreement
containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable)
shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted by law;
(ii) such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the
maximum effect to the intent of the parties hereto; and (iii) to the fullest extent possible, the provisions of this Agreement
(including, without limitation, each portion of any section of this Agreement containing any such provision held to be invalid,
illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the
intent manifested thereby.
22. Enforcement.
The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in
order to induce Indemnitee to serve as a director or officer of the Company, and the Company acknowledges that Indemnitee is relying upon
this Agreement in serving as a director or officer of the Company.
23. Entire Agreement.
This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all
prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof;
provided, however, that this Agreement is a supplement to and in furtherance of the Company’s certificate of incorporation
and bylaws and applicable law.
24. Modification and
Waiver. No supplement, modification or amendment to this Agreement shall be binding unless executed in writing by the parties hereto.
No amendment, alteration or repeal of this Agreement shall adversely affect any right of Indemnitee under this Agreement in respect of
any action taken or omitted by such Indemnitee in their Corporate Status prior to such amendment, alteration or repeal. No waiver of any
of the provisions of this Agreement shall constitute or be deemed a waiver of any other provision of this Agreement nor shall any waiver
constitute a continuing waiver.
25. Notices. All
notices and other communications required or permitted hereunder shall be in writing and shall be mailed by registered or certified mail,
postage prepaid, sent by facsimile or electronic mail or otherwise delivered by hand, messenger or courier service addressed:
(a) if
to Indemnitee, to Indemnitee’s address, facsimile number or electronic mail address as shown on the signature page of this Agreement
or in the Company’s records, as may be updated in accordance with the provisions hereof; or
(b) if
to the Company, to 6272 W. 91st Avenue, Westminster, CO 80031, Attention: Chief Financial Officer or at such other current address as
the Company shall have furnished to Indemnitee.
Each such notice or other communication
shall for all purposes of this Agreement be treated as effective or having been given (i) if delivered by hand, messenger or courier
service, when delivered (or if sent via a nationally-recognized overnight courier service, freight prepaid, specifying next-business-day
delivery, one business day after deposit with the courier), or (ii) if sent via mail, at the earlier of its receipt or five days
after the same has been deposited in a regularly-maintained receptacle for the deposit of the United States mail, addressed and mailed
as aforesaid, or (iii) if sent via facsimile, upon confirmation of facsimile transfer or, if sent via electronic mail, upon confirmation
of delivery when directed to the relevant electronic mail address, if sent during normal business hours of the recipient, or if not sent
during normal business hours of the recipient, then on the recipient’s next business day.
26. Applicable Law
and Consent to Jurisdiction. This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State
of Delaware, without regard to its conflict of laws rules. Except with respect to any arbitration commenced by Indemnitee pursuant to
Section 11(a), the Company and Indemnitee hereby irrevocably and unconditionally (i) agree that any action or proceeding arising
out of or in connection with this Agreement shall be brought only in the Delaware Court of Chancery, and not in any other state or federal
court in the United States of America or any court in any other country, (ii) consent to submit to the exclusive jurisdiction of
the Delaware Court of Chancery for purposes of any action or proceeding arising out of or in connection with this Agreement, (iii) appoint,
to the extent such party is not otherwise subject to service of process in the State of Delaware, Corporation Service Company, at 251
Little Falls Dr., Wilmington, DE 19808, as its agent in the State of Delaware as such party’s agent for acceptance of legal process
in connection with any such action or proceeding against such party with the same legal force and validity as if served upon such party
personally within the State of Delaware, (iv) waive any objection to the laying of venue of any such action or proceeding in the
Delaware Court of Chancery, and (v) waive, and agree not to plead or to make, any claim that any such action or proceeding brought
in the Delaware Court of Chancery has been brought in an improper or inconvenient forum.
27. Counterparts.
This Agreement may be executed in two or more counterparts, each of which shall for all purposes be deemed to be an original but all
of which together shall constitute one and the same Agreement. This Agreement may also be executed and delivered by facsimile
signature and in counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall
constitute one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to
be produced to evidence the existence of this Agreement.
28. Captions.
The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this
Agreement or to affect the construction thereof.
(signature page follows)
The parties are signing this Indemnification Agreement as of the date
stated in the introductory sentence.
|
TRISALUS LIFE SCIENCES, INC. |
|
|
|
|
By: |
|
|
|
|
|
Name: |
|
|
|
|
|
Title: |
|
|
INDEMNITEE |
|
|
|
|
By: |
|
|
|
|
|
Name: |
|
|
|
|
|
Title: |
|
Exhibit 10.26
TriSalus
Life Sciences, Inc.
Non-Employee
Director Compensation Policy
Each member of
the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to TriSalus Life
Sciences, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible
Director”) will receive the compensation described in this Non-Employee Director Compensation Policy (this “Policy”)
for his or her Board service on and following the Effective Date (as defined below). An Eligible Director may decline all or any portion
of his or her compensation by giving notice to the Company prior to the date cash may be paid or equity awards are to be granted, as
the case may be. This Policy is effective as of the Effective Date and may be amended at any time in the sole discretion of the Board
or the Compensation Committee of the Board (the “Compensation Committee”). For purposes of this Policy, the
“Effective Date” shall mean the date on which the closing of the transactions contemplated by the Agreement
and Plan of Merger, dated as of November 11, 2022 and as amended, among the Company (formerly known as MedTech Acquisition Corporation),
MTAC Merger Sub, Inc. and TriSalus Operating Life Sciences, Inc. (formerly known as TriSalus Life Sciences, Inc.) (the
“SPAC Merger”) occurs.
Annual Cash Compensation
The annual cash
compensation amount set forth below is payable to Eligible Directors in equal quarterly installments, payable in arrears on the last
day of each fiscal quarter in which the service occurred. If an Eligible Director joins the Board or a committee of the Board at a time
other than effective as of the first day of a fiscal quarter, each annual retainer set forth below will be pro-rated based on days served
in the applicable fiscal year, with the pro-rated amount paid for the first fiscal quarter in which the Eligible Director provides the
service, and regular full quarterly payments thereafter. All annual cash fees are vested upon payment.
| 1. | Annual Board
Service Retainer: |
| a. | All Eligible Directors: $50,000 |
| b. | Chairman
of the Board Service Retainer (in addition to Eligible Director Service Retainer): $30,000 |
| 2. | Annual Committee Member Service
Retainer: |
| a. | Member of the Sciences &
Technology Committee: $7,500 |
| b. | Member of the Audit Committee:
$7,500 |
| c. | Member of the Compensation Committee:
$7,500 |
| d. | Member of the Nominating &
Governance Committee: $7,500 |
| 3. | Annual Committee
Chair Service Retainer (in lieu of Committee Member Service Retainer): |
| a. | Chairman of the Sciences &
Technology Committee: $25,000 |
| b. | Chairman of the Audit Committee:
$20,000 |
| c. | Chairman of the Compensation Committee:
$15,000 |
| d. | Chairman of the Nominating &
Governance Committee: $15,000 |
Equity Compensation
The equity compensation
set forth below will be granted under the TriSalus Life Sciences, Inc. 2023 Equity Incentive Plan as may be amended from time to
time, or any successor plan thereto (the “Plan”), subject to the stockholders’ approval of the Plan.
All stock options granted under this Policy will be nonstatutory stock options, with an exercise price per share equal to 100% of the
Fair Market Value (as defined in the Plan) of the underlying Common Stock (as defined in the Plan) on the date of grant, and a term of
ten years from the date of grant (subject to earlier termination in connection with a termination of service as provided in the Plan).
1. SPAC
Merger Grant: On the Effective Date (or if such date is not a market trading day, the first market trading day thereafter), each
Eligible Director serving on the Board as of immediately following the closing of the SPAC Merger, will be automatically, and without
further action by the Board or Compensation Committee, granted a stock option for 35,000 shares (“SPAC Merger Grant”).
The shares subject to each SPAC Merger Grant will vest in equal annual installments over a three-year period such that the option is
fully vested on the third anniversary of the date of grant, subject to the Eligible Director’s Continuous Service (as defined in
the Plan) through each such vesting date and will vest in full upon a Change in Control (as defined in the Plan)
2. Initial
Grant: On the date of the Eligible Director’s initial election or appointment to the Board (or, if such date is not a market
trading day, the first market trading day thereafter), for each Eligible Director who is first elected or appointed to the Board after
the Effective Date, the Eligible Director will be automatically, and without further action by the Board or Compensation Committee, granted
a stock option for 35,000 shares (“Initial Grant”). The shares subject to each Initial Grant will vest in equal
annual installments over a three-year period such that the option is fully vested on the third anniversary of the date of grant, subject
to the Eligible Director’s Continuous Service (as defined in the Plan) through each such vesting date and will vest in full upon
a Change in Control (as defined in the Plan).
3. Annual
Grant: On the date of each annual stockholder meeting held after the Effective Date, for each Eligible Director who continues to
serve as a non-employee member of the Board (or who is first elected or appointed to the Board at such annual stockholder meeting), the
Eligible Director will be automatically, and without further action by the Board or Compensation Committee, granted a stock option for
15,000 shares (the “Annual Grant”). In addition, each Eligible Director who is first elected or appointed to
the Board following the first annual stockholder meeting held after the Effective Date and other than at an annual stockholder meeting
will be automatically, and without further action by the Board or Compensation Committee, granted an Annual Grant, pro-rated for the
number of months remaining until the next annual stockholder meeting. The shares subject to the Annual Grant will vest on the one-year
anniversary of the date of grant, provided that the Annual Grant will in any case be fully vested on the date of the Company’s
next annual stockholder meeting, subject to the Eligible Director’s Continuous Service (as defined in the Plan) through such vesting
date and will vest in full upon a Change in Control (as defined in the Plan).
Non-Employee
Director Compensation Limit
Notwithstanding
the foregoing, the aggregate value of all compensation granted or paid, as applicable, to an Eligible
Director shall in no event exceed the limits set forth in Section 3(d) of the Plan.
Ability to Decline
Compensation
An Eligible Director
may decline all or any portion of his or her compensation by giving notice to the Company prior to the date cash may be paid or equity
awards are to be granted, as the case may be.
Expenses
The Company will
reimburse Eligible Directors for ordinary, necessary and reasonable out-of-pocket travel expenses to cover in-person attendance at and
participation in Board and committee meetings; provided, that the Eligible Director timely submit to the Company appropriate documentation
substantiating such expenses in accordance with the Company’s travel and expense policy, as in effect from time to time.
Approved by
the Board of Directors: August 10, 2023
Effective: August 10,
2023
Exhibit 16.1
August 16, 2023
Office of the Chief Accountant
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Ladies and Gentlemen:
We have read the statements made by TriSalus Life
Sciences, Inc. (“TriSalus”) included under Item 4.01 of its Form 8-K dated August 16, 2023. We agree with the statements concerning
our Firm under Item 4.01, in which we were informed of our dismissal on August 10, 2023. We are not in a position to agree or disagree
with other statements contained therein.
Very truly yours,
/s/ WithumSmith+Brown, PC
New York, New York
Exhibit 21.1
LIST OF SUBSIDIARIES OF TRISALUS LIFE SCIENCES,
INC.
| 1. | TriSalus Operating Life Sciences, Inc. |
Exhibit 99.1
TRISALUS LIFE SCIENCES, INC.
Condensed Consolidated Balance Sheets
(unaudited, in thousands except share and per
share data)
| |
June 30,
2023 | | |
December 31,
2022 | |
Assets | |
| | | |
| | |
Assets | |
| | | |
| | |
Cash and cash equivalents | |
$ | 3,904 | | |
$ | 9,414 | |
Accounts receivable | |
| 2,094 | | |
| 1,557 | |
Inventory, net | |
| 1,522 | | |
| 1,471 | |
Prepaid expenses | |
| 4,859 | | |
| 4,772 | |
Total current assets | |
| 12,379 | | |
| 17,214 | |
Property and equipment, net | |
| 1,885 | | |
| 2,231 | |
Right-of-use assets | |
| 1,322 | | |
| 1,381 | |
Intangible assets, net | |
| 858 | | |
| 802 | |
Other assets | |
| 367 | | |
| 367 | |
Total assets | |
$ | 16,811 | | |
$ | 21,995 | |
Liabilities, Convertible Preferred Stock and Stockholders’ Deficit | |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Trade payables | |
$ | 4,297 | | |
$ | 4,947 | |
Accrued liabilities | |
| 9,106 | | |
| 6,377 | |
Series B-2 tranche liabilities | |
| 959 | | |
| 4,702 | |
Series B-3 warrant liabilities | |
| 17,190 | | |
| 15,819 | |
Short-term lease liabilities | |
| 384 | | |
| 370 | |
Other current liabilities | |
| 253 | | |
| 141 | |
Total current liabilities | |
| 32,189 | | |
| 32,356 | |
Long-term lease liabilities | |
| 1,410 | | |
| 1,593 | |
Warrant liabilities | |
| 262 | | |
| 369 | |
Total liabilities | |
| 33,861 | | |
| 34,318 | |
Commitments and contingencies | |
| | | |
| | |
Convertible preferred stock | |
| 181,313 | | |
| 164,006 | |
Stockholders’ deficit: | |
| | | |
| | |
Common stock, $0.001 par value per share. Authorized 1,250,000,000 shares at June 30, 2023, and December 31, 2022, respectively; issued and outstanding, 18,138,685 and 14,075,524 shares at June 30, 2023, and December 31, 2022, respectively | |
| 18 | | |
| 14 | |
Additional paid-in capital | |
| 13,200 | | |
| 10,015 | |
Accumulated deficit | |
| (211,581 | ) | |
| (186,358 | ) |
Total stockholders’ deficit | |
| (198,363 | ) | |
| (176,329 | ) |
Total liabilities, convertible preferred stock and stockholders’ deficit | |
$ | 16,811 | | |
$ | 21,995 | |
See accompanying notes to condensed consolidated
financial statements.
TRISALUS LIFE SCIENCES, INC.
Condensed Consolidated Statements of Operations
(unaudited, in thousands except share and per
share data)
| |
Three Months Ended June 30, | | |
Six Months Ended June 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Revenue | |
$ | 4,612 | | |
$ | 2,878 | | |
$ | 7,596 | | |
$ | 5,248 | |
Cost of goods sold | |
| 772 | | |
| 364 | | |
| 1,434 | | |
| 741 | |
Gross profit | |
| 3,840 | | |
| 2,514 | | |
| 6,162 | | |
| 4,507 | |
Operating expenses: | |
| | | |
| | | |
| | | |
| | |
Research and development | |
| 6,862 | | |
| 5,516 | | |
| 12,504 | | |
| 10,283 | |
Sales and marketing | |
| 3,492 | | |
| 3,146 | | |
| 6,741 | | |
| 5,851 | |
General and administrative | |
| 4,920 | | |
| 2,517 | | |
| 8,472 | | |
| 4,929 | |
Loss from operations | |
| (11,434 | ) | |
| (8,665 | ) | |
| (21,555 | ) | |
| (16,556 | ) |
Interest income | |
| 36 | | |
| 25 | | |
| 71 | | |
| 26 | |
Interest expense | |
| (4 | ) | |
| — | | |
| (9 | ) | |
| — | |
Loss on equity issuance | |
| (3,604 | ) | |
| — | | |
| (4,189 | ) | |
| — | |
Change in fair value of tranche and warrant liabilities | |
| 1,070 | | |
| — | | |
| 3,491 | | |
| — | |
Other income and expense, net | |
| (25 | ) | |
| (36 | ) | |
| (43 | ) | |
| (19 | ) |
Loss before income taxes | |
| (13,961 | ) | |
| (8,676 | ) | |
| (22,234 | ) | |
| (16,549 | ) |
Income tax benefit | |
| (13 | ) | |
| (3 | ) | |
| (8 | ) | |
| (3 | ) |
Net loss available to common stockholders | |
$ | (13,974 | ) | |
$ | (8,679 | ) | |
$ | (22,242 | ) | |
$ | (16,552 | ) |
Deemed dividend related to Series B-2 preferred stock down round provision | |
$ | (2,022 | ) | |
$ | — | | |
$ | (2,981 | ) | |
$ | — | |
Net loss attributable to common stockholders | |
$ | (15,996 | ) | |
$ | (8,679 | ) | |
$ | (25,223 | ) | |
$ | (16,552 | ) |
Net loss per share, basic and diluted | |
$ | (0.89 | ) | |
$ | (0.75 | ) | |
$ | (1.48 | ) | |
$ | (1.39 | ) |
Weighted average common shares outstanding, basic and diluted | |
| 18,056,822 | | |
| 12,272,254 | | |
| 17,068,505 | | |
| 11,890,802 | |
See accompanying notes to condensed consolidated
financial statements.
TRISALUS LIFE SCIENCES, INC.
Condensed Consolidated Statements of Stockholders’
Deficit
(unaudited, in thousands except share data)
| |
Six months ended June 30, 2022 | |
| |
Common stock | | |
Additional | | |
Accumulated | | |
| |
| |
Shares | | |
Amount | | |
paid-in capital | | |
deficit | | |
Total | |
At December 31, 2021 | |
| 10,719,806 | | |
$ | 11 | | |
$ | 6,727 | | |
$ | (136,342 | ) | |
$ | (129,604 | ) |
Exercise of options | |
| 1,401,250 | | |
| 1 | | |
| 60 | | |
| — | | |
| 61 | |
Stock-based compensation | |
| 0 | | |
| — | | |
| 62 | | |
| — | | |
| 62 | |
Net loss | |
| 0 | | |
| — | | |
| — | | |
| (7,873 | ) | |
| (7,873 | ) |
At March 31, 2022 | |
| 12,121,056 | | |
$ | 12 | | |
$ | 6,849 | | |
$ | (144,215 | ) | |
$ | (137,354 | ) |
Exercise of options | |
| 379,989 | | |
| — | | |
| 4 | | |
| — | | |
| 4 | |
Stock-based compensation | |
| — | | |
| — | | |
| 70 | | |
| — | | |
| 70 | |
Net loss | |
| — | | |
| — | | |
| — | | |
| (8,679 | ) | |
| (8,679 | ) |
At June 30, 2022 | |
| 12,501,045 | | |
$ | 12 | | |
$ | 6,923 | | |
$ | (152,894 | ) | |
$ | (145,959 | ) |
| |
Six months ended June 30, 2023 | |
| |
Common stock | | |
Additional | | |
Accumulated | | |
| |
| |
Shares | | |
Amount | | |
paid-in capital | | |
deficit | | |
Total | |
At December 31, 2022 | |
| 14,075,524 | | |
$ | 14 | | |
$ | 10,015 | | |
$ | (186,358 | ) | |
$ | (176,329 | ) |
Exercise of options | |
| 3,877,352 | | |
| 4 | | |
| 46 | | |
| — | | |
| 50 | |
Stock-based compensation | |
| — | | |
| — | | |
| 73 | | |
| — | | |
| 73 | |
Deemed dividend | |
| — | | |
| — | | |
| 959 | | |
| (959 | ) | |
| — | |
Net loss | |
| — | | |
| — | | |
| — | | |
| (8,268 | ) | |
| (8,268 | ) |
At March 31, 2023 | |
| 17,952,876 | | |
| 18 | | |
| 11,093 | | |
| (195,585 | ) | |
| (184,474 | ) |
Exercise of options | |
| 185,809 | | |
| — | | |
| 16 | | |
| — | | |
| 16 | |
Stock-based compensation | |
| — | | |
| — | | |
| 69 | | |
| — | | |
| 69 | |
Deemed dividend | |
| — | | |
| — | | |
| 2,022 | | |
| (2,022 | ) | |
| — | |
Net loss | |
| — | | |
| — | | |
| — | | |
| (13,974 | ) | |
| (13,974 | ) |
At June 30, 2023 | |
| 18,138,685 | | |
$ | 18 | | |
$ | 13,200 | | |
$ | (211,581 | ) | |
$ | (198,363 | ) |
See accompanying notes to condensed consolidated
financial statements.
TRISALUS LIFE SCIENCES, INC.
Condensed Consolidated Statements of Cash Flows
(unaudited, in thousands)
|
|
Six Months Ended June 30, |
|
|
|
2023 |
|
|
2022 |
|
Cash flows from operating activities: |
|
|
|
|
|
|
|
|
Net loss available to common stockholders |
|
$ |
(22,242 |
) |
|
$ |
(16,552 |
) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
334 |
|
|
|
281 |
|
Gain on fair value adjustment of warrants |
|
|
(3,491 |
) |
|
|
(19 |
) |
Non-cash interest expense |
|
|
— |
|
|
|
197 |
|
Loss on equity issuance |
|
|
4,189 |
|
|
|
— |
|
Stock-based compensation expense |
|
|
142 |
|
|
|
132 |
|
Gain (loss) on disposal of fixed assets |
|
|
60 |
|
|
|
49 |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
(537 |
) |
|
|
(132 |
) |
Inventory |
|
|
(51 |
) |
|
|
(55 |
) |
Prepaid expenses |
|
|
(266 |
) |
|
|
(1,471 |
) |
ROU assets |
|
|
59 |
|
|
|
— |
|
Trade payables, accrued expenses and other liabilities |
|
|
2,064 |
|
|
|
(1,116 |
) |
Net cash used in operating activities |
|
|
(19,739 |
) |
|
|
(18,686 |
) |
Cash flows from investing activities: |
|
|
|
|
|
|
|
|
Purchases of property and equipment |
|
|
(38 |
) |
|
|
(400 |
) |
Cash paid for intellectual property and licenses |
|
|
(66 |
) |
|
|
(21 |
) |
Net cash used in investing activities |
|
|
(104 |
) |
|
|
(421 |
) |
Cash flows from financing activities: |
|
|
|
|
|
|
|
|
Proceeds from the issuance of preferred stock |
|
|
9,184 |
|
|
|
3,499 |
|
Proceeds from exercise of preferred stock warrants |
|
|
5,126 |
|
|
|
— |
|
Payments on finance lease liabilities |
|
|
(43 |
) |
|
|
(3 |
) |
Cash proceeds from the exercise of stock options and warrants for common stock |
|
|
66 |
|
|
|
66 |
|
Net cash provided by financing activities |
|
|
14,333 |
|
|
|
3,562 |
|
Decrease in cash, cash equivalents and restricted cash |
|
|
(5,510 |
) |
|
|
(15,545 |
) |
Cash, cash equivalents and restricted cash, beginning of period |
|
|
9,664 |
|
|
|
30,301 |
|
Cash, cash equivalents and restricted cash, end of period |
|
$ |
4,154 |
|
|
$ |
14,756 |
|
See accompanying notes to condensed consolidated
financial statements.
TriSalus Life Sciences, Inc.
Notes to Consolidated Financial Statements
(in thousands, except share and per share data)
(Unaudited)
TriSalus Life Sciences, Inc. (the “Company,”
“we,” “us”), a Delaware corporation, was incorporated in 2009 as Surefire Medical, Inc. We began doing business
as TriSalus Life Sciences (“TriSalus”) in 2018, and changed our name to TriSalus Life Sciences, Inc. in August 2021.
We are engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve
outcomes in difficult to treat liver and pancreatic cancer. Our technology is utilized in the delivery of our therapeutics and administered
by interventional radiologists. We are developing and marketing two product lines — Pressure Enabled Drug Delivery
(“PEDD™) infusion systems, in use today, and an investigational agent, SD-101, which shows potential to enhance immune system
response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. Our PEDD with SmartValve™ is
the only technology designed to work in synchrony with the cardiac cycle to open collapsed vessels in the tumor to enable deeper perfusion
and improve therapeutic drug delivery in tumors with high intratumoral pressure. PEDD with SmartValve has been shown in prospective and
retrospective clinical studies and in multiple pre-clinical models to improve therapy uptake and tumor response.
TriNav™ is the newest therapy delivery device
with SmartValve technology for the proprietary PEDD approach. Current sales consist of the TriNav Infusion System, introduced in 2020,
and a family of related guiding catheters. In 2020, we gained transitional pass-through payments (“TPT”) approval from the
Centers for Medicare & Medicaid Services (“CMS”), which allows hospitals to cover the cost of using TriNav. The approval
is scheduled to expire at the end of 2023. On June 1, 2023, TriSalus applied for a new technology Ambulatory Payment Classifications
("APC") code with CMS and met with them on June 26, 2023, to review the application. If granted, the new technology APC
code would allow for continuing reimbursement for the TriNav device at similar reimbursement rates for the period beginning January 1,
2024, but there can be no assurance that such code will be granted or that continuing reimbursement will be available at similar reimbursement
rates, or at all.
We believe the full potential of our technology
can be realized through the combination of our drug delivery technology with immune-oncology drugs, so, in July 2020, we acquired
our first immune-oncology drug, SD-101, and began clinical development of SD-101 for treatment of liver and pancreatic cancers.
We have funded operations to date principally
with proceeds from the sale of preferred stock and from the issuance of debt and convertible debt. Since inception of the Company in 2009
through June 30, 2023, we have issued for cash $122,980 of preferred stock, which, along with $523 from common stock and $57,466
from convertible notes and warrants, has funded our accumulated deficit of $211,581. During the six months ended June 30, 2023,
we raised $9,183 in cash through the issuance of Series B-2 preferred stock, $5,127 in cash through the issuance of Series B-3
preferred stock, and $66 from the exercise of stock options.
As of June 30, 2023, we had cash and cash
equivalents of $3,904. The Company is still in its early stage, has yet to generate revenues sufficient to create positive cash flow and
has an accumulated deficit of $211,581 as of June 30, 2023. We are currently undergoing a strategic transformation from a company
focused solely on the sale of our infusion systems to a therapeutics company whereby our medical devices will be marketed alongside the
pharmaceutical drugs and other treatments that the devices deliver to patients. This transformation requires that we restructure our operating
infrastructure, resulting in an increase in operating expenses — including the development of a candidate pharmaceutical — that,
in the short term, will not be fully offset by increased revenues. We expect that, absent the plans described below, cash on hand will
last into the third quarter of 2023.
In accordance with ASC Topic 205-40, Presentation
of Financial Statements, Going Concern: Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern,
we are required to evaluate whether there is substantial doubt about our ability to continue as a going concern each reporting period.
In evaluating our ability to continue as a going concern, management projected our cash flow sources and needs and evaluated the conditions
and events have raised substantial doubt about our ability to continue as a going concern within one year after the date that these consolidated
financial statements were issued. Management’s plans to address the conditions and events have considered our current projections
of future cash flows, current financial condition, sources of liquidity and debt obligations for at least one year from the date of issuance
of these consolidated financial statements in considering whether we have the ability to fund future operations and meet our obligations
as they become due in the normal course of business.
Our ability to fund future operations and to continue
the execution of our long-term business plan and strategy, including our transformation into a therapeutics company, will require that
we raise additional capital through the issuance of additional equity and/or long-term debt. There can be no assurance that we will be
able to raise such additional financing or, if available, that such financing can be obtained on satisfactory terms. If adequate capital
resources are not available on a timely basis, we intend to consider limiting our operations substantially. This limitation of operations
could include a hiring freeze, reductions in our workforce, reduction in cash compensation, deferring clinical trials and capital expenditures,
and reducing other operating costs.
Our current operating plan, which is in part determined
based on our most recent results and trends, along with the items noted above, causes substantial doubt to exist about our ability to
continue as a going concern and management’s plans do not alleviate the existence of substantial doubt. Our financial statements
have been prepared assuming we will continue as a going concern, which contemplates the continuity of normal business activities and realization
of assets and settlement of liabilities in the normal course of business, and do not include any adjustments that might be necessary should
we be unable to continue as a going concern.
We are subject to various risks and uncertainties
frequently encountered by companies in the early stages of growth, particularly companies in the rapidly evolving market for medical technology-based
and pharmaceutical products and services. Such risks and uncertainties include, but are not limited to, a limited operating history, need
for additional capital, a volatile business and technological environment, the process to test and obtain approval to market the candidate
pharmaceutical, an evolving business model, and demand for our products. To address these risks, we must, among other things, gain access
to capital in amounts and on acceptable terms, maintain and increase our customer base, implement and successfully execute our business
strategy, develop the candidate pharmaceutical, continue to enhance our technology, provide superior customer service, and attract, retain,
and motivate qualified personnel. There can be no guarantee that we will be successful in addressing such risks.
On August 10, 2023, we completed the Business
Combination with MedTech Acquisition Corporation, in which we received $42,854, less expenses of the Business Combination of $6,050.
(2) | Summary of Significant Accounting Policies |
Basis of Presentation
The accompanying interim unaudited condensed consolidated
financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange
Commission (“SEC”). The interim unaudited condensed consolidated financial statements are comprised of the financial statements
of the Company. In management’s opinion, the interim financial data presented includes all adjustments necessary for a fair presentation.
All intercompany accounts and transactions have been eliminated. Certain information required by U.S. generally accepted accounting principles
(“GAAP”) has been condensed or omitted in accordance with rules and regulations of the SEC. Operating results for the
six months ended June 30, 2023, are not necessarily indicative of the results that may be expected for any future period or
for the year ending December 31, 2023. The accompanying Unaudited Condensed Financial Statements should be read in conjunction with
the audited Consolidated Financial Statements included elsewhere in this registration statement/prospectus.
(a) | Cash, Cash Equivalents and Restricted Cash |
We consider all highly liquid investments with
original maturities of three months or less at time of purchase to be cash equivalents. We invest excess cash primarily in money
market funds.
The preparation of the consolidated financial
statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue
and expenses during the reporting period. Actual results could differ significantly from those estimates. The most significant estimates
relate to the valuation of warrant and tranche liabilities, and the valuation allowance on deferred tax assets.
Our financial instruments consist of cash, accounts
receivable, accounts payable, and warrants to purchase preferred stock. The carrying values of these financial instruments (other than
warrants and tranche liabilities, which are held at fair value) approximate fair value at June 30, 2023, and December 31, 2022.
In general, asset and liability fair values are determined using the following categories:
Level 1 — Inputs utilize
quoted prices in active markets for identical assets or liabilities.
Level 2 — Inputs include
quoted prices for similar assets or liabilities in active markets, and inputs other than quoted prices that are observable for the asset
or liability, either directly or indirectly.
Level 3 — Inputs are
unobservable inputs and include situations where there is little, if any, market activity for the balance sheet items at period end. Pricing
inputs are unobservable for the terms and are based on the Company’s own assumptions about the assumptions that a market participant
would use.
Our warrants and tranche liabilities are measured
at fair value on a recurring basis. The carrying amount of outstanding warrant liabilities was $17,452 and $16,188 at June 30, 2023,
and December 31, 2022, respectively. The carrying amount of outstanding tranche liabilities was $959 and $4,702 at June 30,
2023, and December 31, 2022, respectively. These carrying values represent the remeasurement to fair value each reporting period
based on unobservable inputs, or Level 3 inputs, using assumptions made by us, including the probabilities assigned to the status
quo scenario and the potential closing of the Business Combination (see Note 11) scenario, the value of the Series B-3 warrants upon
closing of the Business Combination, the fair value of the Company, the fair value of the underlying preferred stock, the Company’s
volatility, discount rate, and expected term of the related instrument. See Note 8 for further discussion. These assumptions require significant
judgment on the part of management and actual outcomes may materially differ from those estimated by management.
In March 2023, we sold shares of Series B-2
preferred stock with accompanying warrants to purchase Series B-3 preferred stock as part of the Second Tranche Closings (see Note
8). At issuance, the warrants issued to purchase Series B-3 preferred stock had a fair value of $4,654 and have been classified as
a liability. The issuance of the Series B-2 preferred stock and accompanying warrants to purchase Series B-3 preferred stock
as part of the Second Tranche Closings resulted in a $584 loss on equity issuance.
In June 2023, we sold shares of Series B-2 preferred stock with
accompanying warrants to purchase Series B-3 preferred stock as part of the Second Tranche Closings (see Note 8). At issuance, the
warrants issued to purchase Series B-3 preferred stock had a fair value of $10,047 and have been classified as a liability. The issuance
of the Series B-2 preferred stock and accompanying warrants to purchase Series B-3 preferred stock as part of the Second Tranche
Closings resulted in a $3,605 loss on equity issuance.
The following tables summarize the changes in
fair value of our outstanding warrant and tranche liabilities in the six months ended June 30, 2023 and 2022:
Level 3 Liabilities | |
Fair Value at December 31, 2021 | | |
Change
in
Unrealized
(Gains) Losses | | |
Issuances
(Settlements) | | |
Net
Transfer
In (Out) of
Level 3 | | |
Fair Value at June 30, 2022 | |
Warrant liability | |
$ | 391 | | |
$ | (19 | ) | |
$ | — | | |
$ | — | | |
$ | 372 | |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Level
3
Liabilities | |
Fair Value at December 31, 2022 | | |
Change
in
Unrealized
(Gains) Losses | | |
Issuances
(Settlements) | | |
Net Transfer In (Out) of Level 3 | | |
Fair Value at June 30, 2023 | |
Warrant liability | |
$ | 369 | | |
$ | (1 | ) | |
$ | (106 | ) | |
$ | — | | |
$ | 262 | |
Series B-2 tranche liabilities | |
$ | 4,702 | | |
$ | (2,241 | ) | |
$ | (1,502 | )(1) | |
$ | — | | |
$ | 959 | |
Series B-3 warrant liabilities | |
$ | 15,819 | | |
$ | (1,248 | ) | |
$ | 2,619 | (2) | |
$ | — | | |
$ | 17,190 | |
(1) | This amount includes the gain on extinguishment of the tranche liabilities. |
(2) | This amount includes settlements of $12,082, transferred to convertible preferred stock, offset by issuances of $14,701 |
(4) | Cash, cash equivalents and restricted cash |
Cash, cash equivalents and restricted cash, as
presented in the Condensed Consolidated Statements of Cash Flows, consisted of the following:
| |
June 30,
2023 | | |
December 31,
2022 | |
Cash and cash equivalents | |
$ | 3,904 | | |
$ | 9,414 | |
Restricted cash (included in Other assets) | |
| 250 | | |
| 250 | |
Total cash, cash equivalents and restricted cash shown in the Consolidated Statements of Cash Flows | |
$ | 4,154 | | |
$ | 9,664 | |
Restricted cash is $250 held by our bank to support
our corporate credit card program.
The components of inventory are summarized as
follows:
| |
June 30, 2023 | | |
December 31, 2022 | |
Raw materials | |
$ | 620 | | |
$ | 753 | |
Finished goods | |
| 902 | | |
| 718 | |
Inventory, net | |
$ | 1,522 | | |
$ | 1,471 | |
Finished goods amounts include a reserve for excess
or obsolete inventory of $43 as of June 30, 2023 and December 31, 2022.
Accrued Liabilities consists of the following:
| |
June 30, 2023 | | |
December 31, 2022 | |
Accrued liabilities | |
$ | 4,240 | | |
$ | 2,905 | |
Accrued bonus | |
| 4,140 | | |
| 2,896 | |
Accrued vacation | |
| 391 | | |
| 329 | |
Accrued payroll | |
| 335 | | |
| 247 | |
| |
$ | 9,106 | | |
$ | 6,377 | |
At the end of each interim period, we make our
best estimate of the effective tax rate expected to be applicable for the full calendar year and use that rate to provide for income taxes
on a current year-to-date basis before discrete items. If a reliable estimate cannot be made, we may make a reasonable estimate of the
annual effective tax rate, including use of the actual effective rate for the year-to-date. The impact of the discrete items is recorded
in the quarter in which they occur.
We utilize the balance sheet method of accounting
for income taxes and deferred taxes which are determined based on the differences between the financial statements and tax basis of assets
and liabilities given the provisions of the enacted tax laws. In assessing the realizability of the deferred tax assets, we considered
whether it is more likely than not that some portion or all of the deferred tax assets will not be realized through the generation of
future taxable income. In making this determination, we assessed all of the evidence available at the time including recent earnings,
forecasted income projections, and historical financial performance. We have fully reserved deferred tax assets as a result of this assessment.
Based on our full valuation allowance against
the net deferred tax assets, our effective federal tax rate for the calendar year is zero, and we recorded an immaterial income tax expense
in the six months ended June 30, 2023 and 2022.
(8) | Convertible Preferred Stock |
Since inception, we have issued various series
of preferred stock as more fully described below. Prior to June 2021, the preferred stock was redeemable at any time after February 21,
2022, upon the affirmative vote of two thirds of the then outstanding shares of preferred stock. In June 2021, the redemption feature
was eliminated, however, the in-substance redemption feature described below is still in place. Upon an acquisition of the Company, the
proceeds will be used to first pay the liquidation preferences on the preferred stock, as defined below, prior to payment to common stockholders.
We have determined this is an in-substance redemption feature since holders of preferred stock represent a majority of our board of directors
and control a majority of the stockholder vote on an as-if-converted basis. Thus, a decision to pursue an acquisition or accept the terms
of an acquisition — and thereby redeem the convertible preferred stock — is deemed to be outside
of our control. As a result, our convertible preferred stock has been classified as temporary equity in the accompanying condensed consolidated
balance sheets. We have not adjusted the carrying values of the convertible preferred stock to the respective liquidation preferences
of such shares as the instruments are currently not redeemable and we believe it is not probable that the instruments will become redeemable
at this point in time. Adjustments to increase the carrying values of the respective liquidation preferences will be made if and when
it becomes probable that an event will occur obligating us to pay such amounts.
Convertible preferred stock at June 30, 2023,
and December 31, 2022, is as follows:
Series | |
June 30, 2023 | | |
December 31, 2022 | |
Series A-1 preferred stock, $0.001 par value per share. Authorized, issued, and outstanding 5,331,943 shares at June 30, 2023, and December 31, 2022 | |
$ | 6,065 | | |
$ | 6,065 | |
Series A-2 preferred stock, $0.001 par value per share. Authorized, issued, and outstanding 23,307,464 shares at June 30, 2023, and December 31, 2022 | |
| 8,976 | | |
| 8,976 | |
Series A-3 preferred stock, $0.001 par value per share. Authorized, issued, and outstanding 24,792,020 shares at June 30, 2023, and December 31, 2022 | |
| 10,611 | | |
| 10,611 | |
Series A-4 preferred stock, $0.001 par value per share. Authorized, issued, and outstanding 5,169,690 shares at June 30, 2023, and December 31, 2022 | |
| 1,993 | | |
| 1,993 | |
Series A-5 preferred stock, $0.001 par value per share. Authorized 29,715,910 shares; issued and outstanding 29,545,455 shares at June 30, 2023, and December 31, 2022 | |
| 12,858 | | |
| 12,858 | |
Series A-6 preferred stock, $0.001 par value per share. Authorized 32,601,000 shares; issued and outstanding 32,391,000 shares at June 30, 2023, and December 31, 2022 | |
| 15,476 | | |
| 15,476 | |
Series B preferred stock, $0.001 par value per share. Authorized 284,065,377 shares; issued and outstanding 283,030,377 and 282,580,377 shares at June 30, 2023, and December 31, 2022, respectively | |
| 84,637 | | |
| 84,528 | |
Series B-1 preferred stock, $0.001 par value per share. Authorized, issued, and outstanding 67,142,854 shares at June 30, 2023, and December 31, 2022 | |
| 23,500 | | |
| 23,499 | |
Series B-2 preferred stock, $0.001 par value per share. Authorized 71,428,570 shares; issued and outstanding 54,824,787 and 28,571,428 shares at June 30, 2023 and December 31, 2022, respectively | |
| — | | |
| — | |
Series B-3 preferred stock, $0.001 par value per share. Authorized 342,857,136 shares; issued and outstanding 102,446,428 and 0 shares at June 30, 2023, and December 31, 2022, respectively | |
| 17,197 | | |
| — | |
Total convertible preferred stock | |
$ | 181,313 | | |
$ | 164,006 | |
The following table summarizes activity in convertible
preferred stock in the six months ended June 30, 2023, and 2022.
Series | |
Balance at December 31, 2022 | | |
Issuances | | |
Balance at June 30, 2023 | |
Series A-1 | |
$ | 6,065 | | |
$ | — | | |
$ | 6,065 | |
Series A-2 | |
| 8,976 | | |
| — | | |
| 8,976 | |
Series A-3 | |
| 10,611 | | |
| — | | |
| 10,611 | |
Series A-4 | |
| 1,993 | | |
| — | | |
| 1,993 | |
Series A-5 | |
| 12,858 | | |
| — | | |
| 12,858 | |
Series A-6 | |
| 15,476 | | |
| — | | |
| 15,476 | |
Series B | |
| 84,528 | | |
| 109 | | |
| 84,637 | |
Series B-1 | |
| 23,499 | | |
| 1 | | |
| 23,500 | |
Series B-2 | |
| — | | |
| — | | |
| — | |
Series B-3 | |
| — | | |
| 17,197 | | |
| 17,197 | |
Total convertible preferred stock | |
$ | 164,006 | | |
$ | 17,307 | | |
$ | 181,313 | |
Series |
|
Balance at
December 31, 2021 |
|
|
Issuances |
|
|
Balance at
June 30, 2022 |
|
Series A-1 |
|
$ |
6,065 |
|
|
$ |
— |
|
|
$ |
6,065 |
|
Series A-2 |
|
|
8,976 |
|
|
|
— |
|
|
|
8,976 |
|
Series A-3 |
|
|
10,611 |
|
|
|
— |
|
|
|
10,611 |
|
Series A-4 |
|
|
1,993 |
|
|
|
— |
|
|
|
1,993 |
|
Series A-5 |
|
|
12,858 |
|
|
|
— |
|
|
|
12,858 |
|
Series A-6 |
|
|
15,476 |
|
|
|
— |
|
|
|
15,476 |
|
Series B |
|
|
84,528 |
|
|
|
— |
|
|
|
84,528 |
|
Series B-1 |
|
|
20,000 |
|
|
|
3,499 |
|
|
|
23,499 |
|
Total convertible preferred stock |
|
$ |
160,507 |
|
|
$ |
3,499 |
|
|
$ |
164,006 |
|
Warrants to purchase convertible preferred stock
at June 30, 2023, and December 31, 2022, are as follows:
Series | |
June 30, 2023 | | |
December 31, 2022 | |
Series A-5 preferred stock, $0.44 exercise price | |
| 170,455 | | |
| 170,455 | |
Series A-6 preferred stock, $0.50 exercise price | |
| 210,000 | | |
| 210,000 | |
Series B preferred stock, $0.01 exercise price | |
| 1,035,000 | | |
| 1,485,000 | |
Series B-3 preferred stock, $0.05 exercise price | |
| 116,852,720 | | |
| 114,285,712 | |
Total warrants | |
| 118,268,175 | | |
| 116,151,167 | |
The following table summarizes activity in warrants
to purchase preferred stock in the six months ended June 30, 2023. There was no activity in the six months ended June 30,
2022.
Series | |
Balance at December 31, 2022 | | |
Exercises | | |
Issuances | | |
Balance at June 30, 2023 | |
Series A-5 | |
| 170,455 | | |
| — | | |
| — | | |
| 170,455 | |
Series A-6 | |
| 210,000 | | |
| — | | |
| — | | |
| 210,000 | |
Series B | |
| 1,485,000 | | |
| (450,000 | ) | |
| — | | |
| 1,035,000 | |
Series B-3 | |
| 114,285,712 | | |
| (102,446,428 | ) | |
| 105,013,436 | | |
| 116,852,720 | |
As of June 30, 2023, the Company is authorized
to issue up to 886,411,964 shares of preferred stock, with 170,455 shares of Series A-5, 210,000 shares of Series A-6, 1,035,000
shares of Series B, 16,603,783 shares of Series B-2 and 240,410,708 shares of Series B-3 available for issuance. All other
authorized shares have been issued. The original issue prices for the Series A-1, A-2, A-3, A-4, A-5, A-6, B, B-1, B-2, and B-3 Preferred
Stock are $1.224, $0.387, $0.43, $0.396, $0.44, $0.50, $0.30, $0.35 $0.35, and $0.05, respectively. All shares of preferred stock had
the following rights as of June 30, 2023:
Each share of preferred stock is convertible into
common stock at any time at the option of the holder. The conversion rate is equal to the original issue price for each share of preferred
stock plus any declared but unpaid dividends divided by the conversion price. The conversion ratio may be adjusted from time to time based
upon the occurrence of certain events or circumstances, such as stock splits, dividends, recapitalizations, certain corporate transactions,
and certain dilutive issuances. Each share of preferred stock will be automatically convertible into shares of the common stock at the
then-prevailing conversion ratio if (i) approved by (a) the holders of a two-thirds of the outstanding shares of preferred stock
(voting together as a single class on an as-converted basis), and (b) the majority of either the Series A-5 or Series A-6
preferred stock voting each individually as a separate class, or (ii) upon the closing of an underwritten initial public offering
of the Company’s common stock pursuant to an effective registration statement under the Securities Act of 1933, as amended, in which
(a) the per share price of the Common Stock is not less than $1.00 (adjusted for any stock dividends, combinations, splits, or recapitalizations)
and (b) the aggregate net cash proceeds are at least $50,000.
Each holder of shares of preferred stock is entitled
to the number of votes on an as-if converted basis to shares of common stock. Certain corporate actions require the approval of a majority
of the holders of preferred stock, including but not limited to changes in the authorized shares of preferred stock, authorization of
any new class or series of preferred stock, effecting a recapitalization, increasing or decreasing the authorized size of the Board of
Directors, the payment of certain dividends and capital distributions, a sale, liquidation or dissolution of the Company, and certain
incurrences of debt.
Dividends are payable on preferred stock in preference
to common stock when and if declared by the board on a noncumulative, annual basis and are paid to the holders of preferred stock in proportion
of their individual dividend amounts to the total dividend amount of all preferred holders. The per annum preferred dividend rates for
each share of Series A-1, A-2, A-3, A-4, A-5, A-6, B, B-1, B-2, and B-3 preferred stock are $0.09792, $0.03096, $0.0344, $0.03168,
$0.0352, $0.04, $0.024, $0.028, $0.028, and $0.0004, respectively. To date, the board has not declared any dividends on the preferred
stock.
| (iv) | Liquidation Preferences |
The terms of the preferred stock provide for liquidation
preferences in the event of a change in control, liquidation, dissolution, or certain other fundamental transactions of the Company (a
“Liquidation Event”), none of which were deemed probable of occurring at June 30, 2023. Preferences are payable in the
following order of priority and in the following amounts as of June 30, 2023 (plus all declared but unpaid dividends);
Liquidation Preference | |
Series | |
Shares | | |
Price | | |
Aggregate
Liquidation
Preference | |
1 | |
Series B-3 preferred stock | |
| 102,446,428 | | |
$ | 0.050 | | |
$ | 5,122 | |
1 | |
Series B-2 preferred stock | |
| 54,824,787 | | |
| 0.350 | | |
| 19,189 | |
2 | |
Series B-1 preferred stock | |
| 67,142,854 | | |
| 0.350 | | |
| 23,500 | |
2 | |
Series B preferred stock | |
| 283,030,377 | | |
| 0.300 | | |
| 84,909 | |
3 | |
Series A-6 preferred stock | |
| 32,391,000 | | |
| 0.500 | | |
| 16,196 | |
4 | |
Series A-5 preferred stock | |
| 29,545,455 | | |
| 0.440 | | |
| 13,000 | |
4 | |
Series A-4 preferred stock | |
| 5,169,690 | | |
| 0.396 | | |
| 2,047 | |
5 | |
Series A-3 preferred stock | |
| 24,792,020 | | |
| 0.430 | | |
| 10,661 | |
6 | |
Series A-2 preferred stock | |
| 23,307,464 | | |
| 0.387 | | |
| 9,020 | |
7 | |
Series A-1 preferred stock | |
| 5,331,943 | | |
| 1.224 | | |
| 6,526 | |
| |
Total liquidation preference | |
| | | |
| | | |
$ | 190,170 | |
If the assets of the Company or the consideration
received in such Liquidation Event are insufficient to make payment in full to all holders of a particular series of preferred stock,
then such assets will be distributed ratably to the holders of such series of preferred stock in proportion to the full amounts to which
they would otherwise have been entitled. After payment of the aforementioned liquidation preferences, any remaining proceeds from a Liquidation
Event will be distributed to all preferred and common stockholders — except for stockholders holding Series A-1
or Series A-2 Preferred Stock — pro rata on an as-if converted basis.
October 2022 Financing
In early October 2022, we sold 28,571,428
shares of Series B-2 preferred stock in a private financing, primarily to existing stockholders, at a price of $0.35 per share, raising
approximately $9,755 in net proceeds (the “B-2 Preferred Stock Financing”). For each share sold, we also issued a warrant
to purchase four shares of Series B-3 preferred stock (with total warrants issued being for 114,285,712 shares of Series B-3
preferred stock) with a strike price of $0.05 per share. The B-2 Preferred Stock Financing included, at our audit committee’s option,
a second tranche for the sale of up to 20,990,498 shares of Series B-2 preferred stock for $7,347 (which could be increased up to
$10,000 through the sale of additional shares), with each such share of Series B-2 preferred stock accompanied by a warrant to purchase
four shares of Series B-3 preferred stock at a strike price of $0.05 per share, for a total of 83,961,992 shares of Series B-3
preferred stock, and a third tranche, at the election of investors who participated in the second tranche, for the sale of up to 12,381,544
shares of Series B-2 preferred stock for $4,334 (which could be increased up to an aggregate of 14,285,714 shares of Series B-2
preferred stock for approximately $5,000 through the sale of additional shares of Series B-2 preferred stock), with each such share
of Series B-2 preferred stock accompanied by a warrant to purchase eight shares of Series B-3 preferred stock at a strike price
of $0.05 per share, for a total of 99,052,352 shares of Series B-3 preferred stock. Investors can elect to not participate in the
second tranche, and thereby give up their rights to participate in the third tranche, but such election would cause all of their shares
of Series B-2 preferred stock and Series B-3 preferred stock to immediately convert to common stock and any warrants to purchase
Series B-3 preferred stock to convert to warrants to purchase common stock.
As a result of the issuance of the Series B-2
preferred stock, accompanying warrants to purchase Series B-3 preferred stock, and the second and third tranche rights and obligations,
the anti-dilution feature of all prior issued preferred stock series was triggered. In accordance with the anti-dilution rights in the
Company’s certificate of incorporation, and in connection with the initial closing of the B-2 Preferred Stock Financing, the conversion
prices of the Company’s preferred stock (i) were adjusted to $1.06 for Series A-1 preferred stock, $0.33 for Series A-2
preferred stock, $0.37 for Series A-3 preferred stock, $0.34 for Series A-4 preferred stock, $0.37 for Series A-5 preferred
stock, $0.42 for Series A-6 preferred stock, $0.26 for Series B preferred stock, and $0.30 for Series B-1 preferred stock
and (ii) set to $0.35 for Series B-2 preferred stock and $0.05 for Series B-3 preferred stock, which correlate to approximate
(in each case rounded to three decimals) exchange ratios of 1.155 to 1 for Series A-1 preferred stock, 1.173 to 1 for Series A-2
preferred stock, 1.162 to 1 for Series A-3 preferred stock, 1.165 to 1 for Series A-4 preferred stock, 1.189 to 1 for Series A-5
preferred stock, 1.190 to 1 for Series A-6 preferred stock, 1.154 to 1 for Series B preferred stock, 1.167 to 1 for Series B-1
preferred stock, 1 to 1 for Series B-2 preferred stock and 1 to 1 for Series B-3 preferred stock.
We offered the Series B-2 preferred stock
to all of our existing preferred stockholders (representing approximately 99.2% of our then-outstanding shares on an as-converted to common
stock basis) to continue to fund our operations through the expected period for completing the Business Combination (see Note 11), including
expenses expected to be incurred in connection with the Business Combination and readying ourselves to be a public company. Board members,
executives and other employees who participated in the B-2 Preferred Stock Financing did so under the same terms as other holders who
do not provide services. As such, the Company concluded the B-2 Preferred Stock Financing was not compensatory and is not within the scope
of ASC Topic 718, Compensation — Stock Compensation.
The warrants to purchase Series B-3 preferred
stock (“Series B-3 Warrants”) represent freestanding financial instruments that should be recognized as a liability as
we are required to deliver puttable shares upon exercise of the warrants, which may be ultimately settled for cash due to the in-substance
redemption feature, as described above. Similarly, the combined rights and obligations for the second and third tranches for Series B-2
preferred stock (“Series B-2 Tranche Liability”) represents a freestanding financial instrument that should be classified
as a liability under ASC 480 as, (i) the decision to exercise the tranche is outside of our control, as holders of Series B-2
preferred stock represent a majority of our Audit Committee (which, pursuant to the financing agreements for the B-2 Preferred Stock Financing
determines whether to call the second tranche), and (ii) the Company is required to deliver puttable shares upon execution of the
tranches rights and obligations, which may be ultimately settled in cash. Both the Series B-3 Warrants and the Series B-2 Tranche
Liability are classified as liabilities and are presented on the balance sheet at their estimated fair values at each reporting date and
immediately prior to settlement with the resulting change in fair value recognized in earnings.
2023 Financing
In January through June 2023, holders
of warrants to purchase 102,446,428 shares of Series B-3 preferred stock exercised their purchase rights, for proceeds of approximately
$5,122. In addition, $12,082 of warrant liabilities was transferred to Series B-3 preferred stock. Also, holders of warrants to purchase
450,000 shares of Series B preferred stock exercised their purchase rights, for proceeds of $4, plus the transfer of warrant liabilities
of $106 to Series B preferred stock.
In February 2023, we amended the Series B-2
preferred stock agreement and warrant agreement to purchase Series B-3 preferred stock to extend the expiration date for the second
tranche from February 28, 2023, to May 31, 2023.
In March 2023, we effectuated closings (“Second
Tranche Closings”) of a portion of the second tranche of the B-2 Preferred Stock Financing whereby (i) 8,396,207 shares of
Series B-2 preferred stock and accompanying warrants to purchase 33,584,828 shares of Series B-3 preferred stock, representing
40% of the shares committed in the second tranche, were sold for an aggregate purchase price of approximately $2,932, net of execution
costs, and (ii) 714,285 shares of Series B-2 preferred stock and accompanying warrants to purchase 2,857,140 shares of Series B-3
preferred stock, none of which were shares committed in the second tranche, were sold for an aggregate purchase price of $250. As a result
of the closings of a portion of the second tranche of the B-2 Preferred Stock Financing described above, in accordance with the anti-dilution
rights in the Company’s certificate of incorporation, the conversion prices of the Company’s preferred stock (i) were
adjusted to $1.02 for Series A-1 preferred stock, $0.32 for Series A-2 preferred stock, $0.35 for Series A-3 preferred
stock, $0.33 for Series A-4 preferred stock, $0.35 for Series A-5 preferred stock, $0.40 for Series A-6 preferred stock,
$0.25 for Series B preferred stock, and $0.29 for Series B-1 preferred stock and (ii) remained the same for Series B-2
preferred stock ($0.35) and Series B-3 preferred stock ($0.05), which correlate to approximate (in each case rounded to three decimals)
exchange ratios of 1.200 to 1 for Series A-1 preferred stock, 1.209 to 1 for Series A-2 preferred stock, 1.229 to 1 for Series A-3
preferred stock, 1.200 to 1 for Series A-4 preferred stock, 1.257 to 1 for Series A-5 preferred stock, 1.250 to 1 for Series A-6
preferred stock, 1.200 to 1 for Series B preferred stock, 1.207 to 1 for Series B-1 preferred stock, 1 to 1 for Series B-2
preferred stock and 1 to 1 for Series B-3 preferred stock.
On May 12, 2023, we amended the Series B-2
preferred stock agreement and warrant agreement to purchase Series B-3 preferred stock to extend the expiration date for the second
tranche from May 31, 2023 to July 31, 2023.
In June 2023, we effectuated closings of
a portion of the second tranche of the B-2 Preferred Stock Financing whereby (i) 10,428,583 shares of Series B-2 preferred stock and accompanying
warrants to purchase 41,714,332 shares of Series B-3 preferred stock, representing approximately 49.7% of the shares committed in the
second tranche, were sold for an aggregate purchase price of approximately $3,650, and (ii) 6,714,284 shares of Series B-2 preferred
stock and accompanying warrants to purchase 26,857,136 shares of Series B-3 preferred stock, none of which were shares committed in the
second tranche, were sold for an aggregate purchase price of $2,350. As a result of the closings of a portion of the second tranche of
the B-2 Preferred Stock Financing described above, in accordance with the anti-dilution rights in the Company’s certificate
of incorporation, the conversion prices of the Company’s preferred stock (i) were adjusted to $0.96 for Series A-1 preferred stock,
$0.30 for Series A-2 preferred stock, $0.33 for Series A-3 preferred stock, $0.31 for Series A-4 preferred stock, $0.33 for Series A-5
preferred stock, $0.37 for Series A-6 preferred stock, $0.24 for Series B preferred stock, and $0.27 for Series B-1 preferred stock and
(ii) remained the same for Series B-2 preferred stock ($0.35) and Series B-3 preferred stock ($0.05), which correlate to approximate (in
each case rounded to three decimals) exchange ratios of 1.275 to 1 for Series A-1 preferred stock, 1.290 to 1 for Series A-2 preferred
stock, 1.303 to 1 for Series A-3 preferred stock, 1.277 to 1 for Series A-4 preferred stock, 1.333 to 1 for Series A-5 preferred stock,
1.351 to 1 for Series A-6 preferred stock, 1.250 to 1 for Series B preferred stock, 1.296 to 1 for Series B-1 preferred stock, 1 to 1
for Series B-2 preferred stock and 1 to 1 for Series B-3 preferred stock. Any portion of the Series B-3 warrants that remain unexercised
at the time the Business Combination is consummated will automatically be net settled for shares of the Company’s common stock (“TriSalus
Common Stock”) immediately prior to the closing of the Business Combination (see Note 11) and exchanged into shares of common stock,
par value $0.0001 of the combined company (“Combined Company Common Stock”) at the Effective Time.
In July 2023, holders of warrants to purchase 90,619,356 shares
of Series B-3 preferred stock exercised their purchase rights for proceeds of approximately $4.5 million.
The fair value of the Series B-3 Warrants
as of June 30, 2023 and December 31, 2022 was determined using a probability-weighted expected outcome model whereby the following
two scenarios were probability-weighted based on the Company’s expectation of each occurring: (1) a status quo scenario whereby
the Company would continue as a private company and (2) a scenario where the Business Combination would close. Under the status quo
scenario, the Series B-3 Warrants, including warrants to be issued under the second and third tranches, were valued using the Black-Scholes
model. The fair value of the Series B-2 Tranche Liability was determined using a Binomial Tranche Model. Both models incorporated
the following significant assumptions for the respective valuation dates:
| |
June 30, 2023 | | |
December 31, 2022 | |
Series B-2 preferred stock fair value per share | |
$ | 0.36 | | |
$ | 0.37 | |
Series B-2 preferred stock exercise price per share | |
$ | 0.35 | | |
$ | 0.35 | |
Series B-3 preferred stock fair value per share | |
$ | 0.06 | | |
$ | 0.08 | |
Series B-3 Warrants exercise price per share | |
$ | 0.05 | | |
$ | 0.05 | |
Volatility | |
| 35.0% – 55.0% | | |
| 50.0% – 65.0% | |
Risk free rate | |
| 5.2% – 5.5% | | |
| 4.0% – 4.7% | |
Series B-2 Tranche Liability expected term | |
| 0.1 – 0.5 | | |
| 0.2 – 0.4 years | |
Series B-3 Warrants expected term | |
| 5.3 – 6.0 years | | |
| 5.8 – 6.0 years | |
Expected dividends | |
| — | | |
| — | |
The fair value of the underlying shares of Series B-2
preferred stock and warrants to purchase Series B-3 preferred stock used in these models were derived from estimates of the Company’s
equity fair value using the Guideline Public Company Method, specifically revenue multiples of comparable public companies were multiplied
by the Company’s forecasted 2023 and 2024 revenue. The valuation of Series B-3 Warrants under the Business Combination scenario
incorporates an estimate of the fair value of the underlying Series B-3 preferred stock upon the close of the Business Combination
of $0.23 and $0.27 per share, at June 30, 2023 and December 31, 2022, respectively, which is based upon the enterprise value
stated in the merger agreement of $220,000 allocated to all outstanding shares of preferred stock, warrants to purchase preferred stock,
and common stock on an as-if converted basis, discounted at 30% from the expected Business Combination closing date. The Business Combination
scenario as of June 30, 2023, and December 31, 2022, assumed there would be no additional exercises of the second and third
tranches, and thus no value was assigned to the outstanding tranche rights and obligations, as the Company would not exercise its right
to call the remaining second tranche.
The fair value of the Series B-3 Warrant Liabilities at issuance
resulting from the completion of the Second Tranche Closings was estimated at $14,701. The excess of the warrant liability’s fair
value compared to the proceeds received in the Second Tranche Closings resulted in a charge to loss on equity issuance in the condensed
consolidated statements of operations of $5,511 for the six months ended June 30, 2023.
Basic net loss attributable to common stockholders
per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding
for the period. During periods where we might earn net income, we would allocate to participating securities a proportional share of net
income determined by dividing total weighted-average participating securities by the sum of the total weighted-average common shares and
participating securities (the “two-class method”). Our preferred stock participates in any dividends declared by us and are
therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings
per share during periods of income. During periods where we incurred net losses, we allocate no loss to participating securities because
they have no contractual obligation to share in our losses. We computed diluted loss per common share after giving consideration to the
dilutive effect of stock options and warrants that are outstanding during the period, except where such nonparticipating securities would
be antidilutive. Because we have reported net losses for the six-month periods ended June 30, 2023 and 2022, diluted net loss per
common share is the same as basic net loss per common share for those periods.
The following potentially dilutive securities
(in common stock equivalent shares) have been excluded from the computation of diluted weighted-average shares outstanding because such
securities have an antidilutive impact due to losses reported:
| |
June 30, | |
| |
2023 | | |
2022 | |
Preferred stock | |
| 627,982,018 | | |
| 470,260,803 | |
Preferred stock warrants | |
| 118,268,175 | | |
| 1,865,455 | |
Common stock warrants | |
| — | | |
| — | |
Options to purchase common stock | |
| 69,389,688 | | |
| 60,859,556 | |
| |
| 815,639,881 | | |
| 532,985,814 | |
As described in Note 8, the triggering of the
anti-dilution feature resulting from the closing of the second tranche of the Initial Preferred Stock Financing decreased the conversion
prices applicable to all outstanding shares for previously issued preferred stock. As a result, a deemed dividend to the preferred stockholders
of $2,981 was recorded as an increase in the net loss attributable to common stockholders reflected in our unaudited consolidated statement
of operations for the six months ended June 30, 2023. The deemed dividend increased the net loss per common share by $0.17 for
the six months ended June 30, 2023.
(10) | Commitments and Contingencies |
From time to time, we may have certain contingent
liabilities, including litigation, which arise in the ordinary course of its business activities. We accrue contingent liabilities when
it is probable that future expenditures will be made and such expenditures can be reasonably estimated. In the opinion of management,
there are no pending claims for which the outcome is expected to result in a material adverse effect on our consolidated financial position,
results of operations, or cash flows.
Other than as described above, we are not a party
to any legal proceedings and we are not aware of any claims or actions pending or threatened against us. In the future, we might from
time to time become involved in litigation relating to claims arising from our ordinary course of business.
(11) | Merger Agreement with MedTech Acquisition Corporation |
On November 11, 2022, we entered into an
Agreement and Plan of Merger (as amended on April 4, 2023, May 13, 2023 and July 5, 2023, the “Merger Agreement”)
with MedTech Acquisition Corporation, a Delaware corporation (“MTAC”), and MTAC Merger Sub, Inc., a Delaware corporation
and wholly owned subsidiary of MTAC (“Merger Sub”). On May 13, 2023, MTAC, Merger Sub, and TriSalus entered into an amendment
to the Merger Agreement to: (i) extend the Final Outside Date to September 22, 2023 (based on a potential Extension of MTAC’s
last date to consummate an initial business combination under its Existing Charter), (ii) clarify that no greenshoe or other investor-held
options to purchase MTAC’s securities that are exercisable at the investor’s sole discretion will count towards the Available
Closing MTAC Cash, and (iii) reduce the minimum available cash condition from $60 million to $35 million. The aggregate consideration
payable to our stockholders was approximately $220,000, payable solely in shares of MTAC common stock.
On August 8, 2023, the stockholders of MTAC
approved the Business Combination..
Pursuant to the Merger Agreement, on August 10,
2023, Merger Sub merged with and into TriSalus, with TriSalus surviving as a wholly owned subsidiary of MTAC (the “Business Combination”)
and 890,020,482 shares of TriSalus Common Stock (after conversion of all outstanding shares of preferred stock and all in-the-money warrants)
were exchanged for approximately 22,000,000 shares of MTAC common stock, reflecting an exchange ratio of approximately 0.02471853. In
connection with the consummation of the Business Combination, MTAC was renamed “TriSalus Life Sciences, Inc.”
Immediately prior to the effective time of the
Business Combination, each issued and outstanding share of TriSalus’ Series A-1, Series A-2, Series A-3, Series A-4,
Series A-5, Series A-6, Series B, Series B-1, Series B-2, and Series B-3 preferred stock, par value $0.001
(collectively, the “TriSalus Preferred Stock”) was converted into shares of TriSalus Common Stock at the then-applicable conversion
rates. In addition, each outstanding warrant to purchase shares of TriSalus Common Stock or TriSalus Preferred Stock (each, a “TriSalus
Warrant”) that is in-the-money and would be exercised or otherwise exchanged in full in accordance with its terms by virtue of the
occurrence of the Business Combination, was automatically exercised for shares of TriSalus Common Stock. TriSalus Warrants that were out-of-the-money
were canceled for no consideration.
At the effective time, each outstanding option to purchase shares of
TriSalus Common Stock under TriSalus’ equity incentive plans, whether or not then vested and exercisable, and each restricted stock
unit award with respect to TriSalus Common Stock under TriSalus’ equity incentive plans, was assumed and converted into an option
to purchase shares of MTAC common stock and restricted stock unit with respect to MTAC common stock, respectively.
Exhibit 99.2
Management’s Discussion and Analysis of Financial
Condition and Results of Operations of TriSalus
The following discussion and analysis of
our financial condition and results of operations should be read in conjunction with our unaudited interim consolidated financial
statements and the related notes thereto as of June 30, 2023 and for the three and six months ended June 30, 2023 and 2022
included in Exhibit 99.1 to this Current Report on Form 8-K (the “Form 8-K”) and our audited consolidated
financial statements as of and for the fiscal year ended December 31, 2022 included in our definitive proxy statement and final
prospectus, dated July 18, 2023 (the “Proxy Statement/Prospectus”). This discussion and analysis contains
forward-looking statements, such as statements of our plans, objectives, expectations and intentions. Any statements that are not
statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,”
“intend,” “anticipate,” “target,” “estimate,” “expect,”
“will,” “continue,” “project,” and the like, and/or future tense or conditional constructions
(“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain
of these forward-looking statements. These forward-looking statements are subject to risks and uncertainties, including those we
describe under “Cautionary Note Regarding Forward-Looking Statements” and “Risk Factors” and elsewhere in
this Form 8-K and in the Proxy Statement/Prospectus, that could cause actual results or events to differ materially from those
expressed or implied by the forward-looking statements. The Company’s actual results and the timing of events could differ
materially from those anticipated in these forward-looking statements as a result of a variety of factors.
For purposes of this discussion, “TriSalus,”
“the Company,” “we,” “us” or “our” refer to TriSalus Life Sciences, Inc. (which changed
its name to TriSalus Operating Life Sciences, Inc. in connection with the Business Combination) and its subsidiaries prior to the
consummation of the Business Combination and TriSalus Life Sciences, Inc. (formerly known as MedTech Acquisition Corporation) after
the consummation of the Business Combination, unless the context otherwise requires.
Capitalized terms used but not defined in this
Exhibit 99.2 shall have the meanings ascribed to them in the Proxy Statement/Prospectus.
Overview
TriSalus is engaged in the research, development,
and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult to treat liver and
pancreatic cancer. Our technology is utilized in the delivery of our therapeutics and administered by interventional radiologists. We
are developing and marketing two product lines — Pressure Enabled Drug Delivery infusion systems, in use today, and
an investigational agent, SD-101, which shows potential to enhance response to checkpoint inhibitor therapy used to treat hepatocellular
cancer, pancreatic cancer and other liver solid tumors.
In 2020, we also launched TriNav™, which
is our newest liver therapy delivery device with SmartValve technology for our proprietary PEDD approach. In November 2019, we gained
TPT payments approval from CMS, which allows hospitals to cover the cost of using TriNav. The approval began in January 2020 and
is scheduled to expire at the end of 2023;. On June 1, 2023, TriSalus applied for a new technology Ambulatory Payment Classifications
("APC") code with CMS and met with them on June 26, 2023 to review the application. If granted, the new technology APC
code would allow for continuing reimbursement for the TriNav device at similar reimbursement rates for the period beginning January 1,
2024, but there can be no assurance that such code will be granted or that continuing reimbursement will be available at similar reimbursement
rates or at all.
We are currently in our early stage of development
and have yet to generate revenues sufficient to drive positive cash flows from operations. Beginning in 2020, we began a strategic transformation
from a company focused solely on the sale of our infusion systems to a therapeutic company whereby our medical devices are marketed alongside
the pharmaceutical drugs and other treatments that the devices deliver to patients. This transformation led us to acquire our first immune-oncology
drug, SD-101, in July 2020, and to begin clinical development of SD-101 for the treatment of liver and pancreatic cancers.
The Business Combination
On November 11, 2022, we entered into an
Agreement and Plan of Merger (the "Merger Agreement") with MedTech Acquisition Corporation ("MTAC") and MTAC Merger
Sub, Inc., a wholly owned subsidiary of MTAC ("Merger Sub"), pursuant to which, TriSalus will merge with and into Merger
Sub, with TriSalus surviving the merger and becoming a wholly owned subsidiary of MTAC (the "Business Combination"). The aggregate
consideration payable to the stockholders of TriSalus is $220.0 million, payable solely in shares of Combined Company Common Stock.
The closing of the Business Combination is subject to certain conditions including, among others, (i) the stockholders of TriSalus
and the stockholders of MTAC approving of the Business Combination, (ii) the Nasdaq Stock Market approving for listing the Combined
Company Common Stock to be issued in connection with the Business Combination, (iii) MTAC having at least $60.0 million in Available
Closing MTAC Cash at closing, and (iv) MTAC has $5.0 million or more in net tangible assets at closing. In May 2023, the
Merger Agreement was amended to change the Available Closing MTAC Cash at closing to $35.0 million.
On August 8, 2023, the stockholders of MTAC
approved the Business Combination, and the Business Combination closed on August 10, 2023. Pursuant to the Merger Agreement, 890,020,482
shares of TriSalus common stock (after conversion of all outstanding shares of preferred stock and all in-the-money warrants) were exchanged
for approximately 22,000,000 shares of MTAC common stock, reflecting an exchange ratio of approximately 0.02471853.
Following the consummation of the Business Combination,
TriSalus was deemed the accounting acquirer and is accounting for the Business Combination as a reverse recapitalization. See “Unaudited
Pro Forma Condensed Combined Financial Information” included in Exhibit 99.3 to this Report for additional information
on the Business Combination and related financial impact.
As a result of the Business Combination, we will
hire additional personnel and implement procedures and processes to address public company regulatory requirements and customary practices.
We expect to incur additional annual expenses as a public company for, among other things, directors’ and officers’ liability
insurance, director fees, and additional internal and external accounting, legal and administrative resources.
Factors Affecting Our Performance
We believe that our performance and future success
depend on several factors that present significant opportunities for us but also pose risks and challenges, including those discussed
below and in the section titled “Risk Factors” in the Proxy Statement/Prospectus In particular, our performance is
affected by:
| 1) | The continued acceptance and growth of TriNav in the marketplace. While we believe TriNav to be a superior
technology for the delivery of therapies to tumors, particularly high-density tumors, there are other technologies with which we compete.
Our ability to grow TriNav sales depends on the skills of our sales force and the willingness of the marketplace to use TriNav. |
| 2) | Our ability to maintain our current TriNav pricing and gross margins to help fund the rest of our
activities. Our current pricing allows us to generate a substantial gross margin, which provides funds to support our growth and our
research and development (“R&D”) for both TriNav and SD-101. TriNav sells at a significant premium to competitive products.
Our higher price is currently supported by the TPT payment program from CMS; however, the current TPT authorization expires on December 31,
2023. On June 1, 2023, TriSalus applied for a new technology APC with CMS and met with them on June 26, 2023 to review the application.
If granted, the new technology APC code would allow for continuing reimbursement for the TriNav device at similar reimbursement rates
for the period beginning January 1, 2024, but there can be no assurance that such code will be granted or that continuing reimbursement
will be available at similar reimbursement rates or at all. If we are unable to obtain such permanent reimbursement or continuing reimbursement
is not available at similar reimbursement rates, we may be forced to reduce our price to compete, which would impact our margins. |
| 3) | The success and cost of our clinical trials of SD-101. SD-101 is in Phase 1
human trials to determine if, when delivered via TriNav, it is safe and effective in treating certain cancers. As with all drug candidates,
the cost of operating clinical trials can be substantial, with no guarantee that the trials will result in favorable data. |
| 4) | Obtaining FDA approval of SD-101 for sale. Our clinical trials are still in
early stages, and there is no certainty that we will generate favorable data or that, upon review, the FDA will approve SD-101 for
sale. |
Recent Developments
In October 2022, we sold 28,571,428 shares
of Series B-2 preferred stock in a private financing, primarily to existing stockholders, at a price of $0.35 per share (raising
approximately $9.8 million, net of issuance costs) (the “Initial Preferred Stock Financing”). For each share sold, we
also issued a warrant to purchase four shares of Series B-3 preferred stock for no additional consideration (warrants to purchase
an aggregate of 114,285,712 shares of Series B-3 preferred stock were issued in the Initial Preferred Stock Financing). The strike
price of the warrants issued was $0.05 per share. The Initial Preferred Stock Financing included, at the unilateral option of the Company,
a second tranche for to the sale of up to 20,990,498 shares of Series B-2 preferred stock for approximately $7.3 million (which
could be increased up to an aggregate of 28,571,428 shares of Series B-2 preferred stock for approximately $10.0 million), with
each such share of Series B-2 preferred stock accompanied by a warrant to purchase four shares of Series B-3 preferred stock
at a strike price of $0.05 per share (warrants to purchase up to an aggregate of 114,285,712 shares of Series B-3 preferred stock
may be issued in closings of the second tranche of the Initial Preferred Stock Financing assuming the full $10.0 million is sold);
and a third tranche, at the unilateral election of investors who participated in the second tranche, for the sale of up to 12,381,544
shares of Series B-2 preferred stock, for approximately $4.3 million (which could be increased up to an aggregate of 14,285,714
shares of Series B-2 preferred stock for approximately $5.0 million), with each such share of Series B-2 preferred stock
accompanied by a warrant to purchase eight shares of Series B-3 preferred stock at a strike price of $0.05 per share (warrants to
purchase up to an aggregate of 114,285,712 shares of Series B-3 preferred stock may be issued in the third tranche closing assuming
the full $5.0 million is sold). We made offers to participate in the Series B-2 preferred stock financing to all of our existing
preferred stockholders (representing approximately 99.2% of our then outstanding shares on an as converted to common stock basis) to continue
to fund our operations through the expected period for completing the Business Combination, including our expenses in connection with
the Business Combination and readying ourselves to be a public company.
In March 2023, we effectuated closings of
a portion of the second tranche of the Initial Preferred Stock Financing whereby (i) 8,396,207 shares of Series B-2 preferred
stock and accompanying warrants to purchase 33,584,828 shares of Series B-3 preferred stock, representing 40% of the shares committed
in the second tranche, were sold for an aggregate purchase price of approximately $2.9 million, and (ii) 714,285 shares of Series B-2
preferred stock and accompanying warrants to purchase 2,857,140 shares of Series B-3 preferred stock, none of which were shares committed
in the second tranche, were sold for an aggregate purchase price of $0.25 million. As a result of the closings of a portion of the
second tranche of the Initial Preferred Stock Financing described above, in accordance with the anti-dilution rights in the Company’s
certificate of incorporation, the conversion prices of the Company’s preferred stock (i) were adjusted to $1.02 for Series A-1
preferred stock, $0.32 for Series A-2 preferred stock, $0.35 for Series A-3 preferred stock, $0.33 for Series A-4 preferred
stock, $0.35 for Series A-5 preferred stock, $0.40 for Series A-6 preferred stock, $0.25 for Series B preferred stock,
and $0.29 for Series B-1 preferred stock and (ii) remained the same for Series B-2 preferred stock ($0.35) and Series B-3
preferred stock ($0.05), which correlate to approximate (in each case rounded to three decimals) exchange ratios of 1.200 to 1 for Series A-1
preferred stock, 1.209 to 1 for Series A-2 preferred stock, 1.229 to 1 for Series A-3 preferred stock, 1.200 to 1 for Series A-4
preferred stock, 1.257 to 1 for Series A-5 preferred stock, 1.250 to 1 for Series A-6 preferred stock, 1.200 to 1 for Series B
preferred stock, 1.207 to 1 for Series B-1 preferred stock, 1 to 1 for Series B-2 preferred stock and 1 to 1 for Series B-3
preferred stock.
In June 2023, we effectuated closings of
a portion of the second tranche of the Initial Preferred Stock Financing whereby (i) 10,428,583 shares of Series B-2 preferred
stock and accompanying warrants to purchase 41,714,332 shares of Series B-3 preferred stock, representing approximately 49.7% of
the shares committed in the second tranche, were sold for an aggregate purchase price of approximately $3.7 million, and (ii) 6,714,284
shares of Series B-2 preferred stock and accompanying warrants to purchase 26,857,136 shares of Series B-3 preferred stock,
none of which were shares committed in the second tranche, were sold for an aggregate purchase price of approximately $2.3 million. As
a result of the closings of a portion of the second tranche of the Initial Preferred Stock Financing described above, in accordance with
the anti-dilution rights in the Company’s certificate of incorporation, the conversion prices of the Company’s preferred stock
(i) were adjusted to $0.96 for Series A-1 preferred stock, $0.30 for Series A-2 preferred stock, $0.33 for Series A-3
preferred stock, $0.31 for Series A-4 preferred stock, $0.33 for Series A-5 preferred stock, $0.37 for Series A-6 preferred
stock, $0.24 for Series B preferred stock, and $0.27 for Series B-1 preferred stock and (ii) remained the same for Series B-2
preferred stock ($0.35) and Series B-3 preferred stock ($0.05), which correlate to approximate (in each case rounded to three decimals)
exchange ratios of 1.275 to 1 for Series A-1 preferred stock, 1.290 to 1 for Series A-2 preferred stock, 1.303 to 1 for Series A-3
preferred stock, 1.277 to 1 for Series A-4 preferred stock, 1.333 to 1 for Series A-5 preferred stock, 1.351 to 1 for Series A-6
preferred stock, 1.250 to 1 for Series B preferred stock, 1.296 to 1 for Series B-1 preferred stock, 1 to 1 for Series B-2
preferred stock and 1 to 1 for Series B-3 preferred stock.
In July 2023, holders of warrants to purchase 90,619,356 shares
of Series B-3 preferred stock exercised their purchase rights for proceeds of approximately $4.5 million.
Components of Results of Operations
The following discussion sets forth certain components
of our consolidated statements of operations as well as factors that impact those items.
Revenue
We currently operate in one reportable segment
and revenue is generated primarily from sales of PEDD infusion systems to our customers, principally related to TriNav. Revenue is recognized
when control of the promised goods or services is transferred to the customer in an amount that reflects the consideration to which we
expect to be entitled in exchange for those products or services.
The primary end-user customers for our products
are hospitals, clinics and physicians. We had certain arrangements with our distributors under which they purchase our products and then
resell them in geographic markets where we do not have a sales presence. These arrangements provided for a discount on the invoice when
the distributor resold our units at our normal sales price. Such sales are recorded net of the discounts. All such arrangements were
terminated on or before December 31, 2022.
Cost of Goods Sold
Cost of goods sold primarily consists of raw materials,
direct labor and manufacturing overhead costs related to sales of TriNav.
Gross Profit and Gross Margin
Gross profit represents revenue less cost of goods
sold. Gross margin is gross profit expressed as a percentage of revenue. Our gross margin and overall profitability may in the future
fluctuate from period to period based on a number of factors, such as the innovation initiatives we undertake, manufacturing costs and
efficiencies, and obtaining a permanent reimbursement code for our product.
Operating Expenses
Our operating expenses consist of R&D, sales
and marketing and general and administrative expenses.
Research and Development
R&D expenses include engineering, regulatory,
pre-clinical and clinical activities. We expense R&D costs as incurred. We recognize expenses for certain development activities,
such as preclinical studies and manufacturing, based on an evaluation of the progress to completion of specific tasks using data or other
information provided to us by our vendors. Payments for these activities are based on the terms of the individual agreements, which may
differ from the pattern of expenses incurred. Non-refundable advance payments for goods or services to be received in the future for use
in R&D activities are recorded as prepaid expenses. These amounts are recognized as an expense as the goods are delivered or the related
services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered.
R&D activities account for a significant portion
of our operating expenses. We expect our R&D expenses to increase significantly in future periods as we continue to implement our
business strategy, which includes advancing our manufacturing technologies into and through clinical development of SD-101, expanding
our R&D efforts, including hiring additional personnel to support our R&D efforts, and seeking regulatory approvals for our drug
candidates that successfully complete clinical trials. In addition, drug candidates in later stages of clinical development generally
incur higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration
of later-stage clinical trials. Accordingly, although we expect our R&D expenses to increase as SD-101 advances into later stages
of clinical development, we do not believe that it is possible at this time to accurately project total program-specific expenses through
to commercialization.
Sales and Marketing
Sales and marketing expense consists primarily
of salaries, commissions, travel and related business expenses, attendance at medical society meetings, product promotions and marketing
activities.
General and Administrative
General and administrative expense includes executive
management, finance, information technology, human resources, business development, legal, and the administrative and professional costs
associated with those activities. General and administrative costs also include corporate facility costs, including rent, utilities, depreciation
and maintenance, not otherwise included in production or R&D expenses, as well as regulatory and professional fees for legal, patent,
accounting and other consulting services.
Interest Expense
Interest expense primarily consists of interest
incurred under the term loan, convertible notes and amortization of debt issuance costs.
Loss on Conversion of Convertible Notes
Loss on conversion of convertible notes primarily
consists of the remaining balance of unamortized debt discounts associated with the conversion of the convertible notes upon a qualified
financing.
Loss on Equity Issuance
Loss on equity issuance represents the excess
of the fair value of the warrants to purchase Series B-3 preferred stock and the Series B-2 tranche liabilities over the proceeds
received from the Initial Preferred Stock Financing and subsequent tranche closings.
Change in Fair Value of Tranche and Warrant Liabilities
Change in fair value of warrant and tranche liabilities
represents the change in fair value of the warrants to purchase Series B-3 preferred stock and the Series B-2 tranche liabilities
at each reporting period that were issued as part of the Initial Preferred Stock Financing.
Other Income and Expense, Net
Other income and expense primarily consists of
gain on forgiveness of our Paycheck Protection Program (“PPP”) loan.
Deemed dividend related to Series B-2 preferred stock down
round provision
The deemed dividend represents the value attributed
to the increase in shares of common stock that preferred stockholders received as a result of the Series B-2 preferred stock financing
rounds in October 2022 and March 2023, which was deemed to be a down round and triggered the anti-dilution provisions associated
with our preferred stock. The resulting increase in value of the preferred stock was deemed to be a dividend to the preferred stockholders
and was recognized as a non-cash adjustment to additional paid-in-capital.
Income Tax Benefit (Expense)
Our income tax provision consists primarily of
U.S. federal and state income taxes. We maintain a full valuation allowance for our federal and state deferred tax assets, including net
operating loss carryforwards, as we have concluded that it is not more likely than not that the deferred tax assets will be realized.
Results of Operations:
The following table sets forth our consolidated
statements of operations data for each of the periods indicated (in thousands):
| |
Three Months Ended June 30, | | |
Six Months Ended June 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Revenue | |
$ | 4,612 | | |
$ | 2,878 | | |
$ | 7,596 | | |
$ | 5,248 | |
Cost of goods sold | |
| 772 | | |
| 364 | | |
| 1,434 | | |
| 741 | |
Gross profit | |
| 3,840 | | |
| 2,514 | | |
| 6,162 | | |
| 4,507 | |
Operating expenses: | |
| | | |
| | | |
| | | |
| | |
Research and development | |
| 6,862 | | |
| 5,516 | | |
| 12,504 | | |
| 10,283 | |
Sales and marketing | |
| 3,492 | | |
| 3,146 | | |
| 6,741 | | |
| 5,851 | |
General and administrative | |
| 4,920 | | |
| 2,517 | | |
| 8,472 | | |
| 4,929 | |
Loss from operations | |
| (11,434 | ) | |
| (8,665 | ) | |
| (21,555 | ) | |
| (16,556 | ) |
Interest income | |
| 36 | | |
| 25 | | |
| 71 | | |
| 26 | |
Interest expense | |
| (4 | ) | |
| — | | |
| (9 | ) | |
| — | |
Loss on equity issuance | |
| (3,604 | ) | |
| — | | |
| (4,189 | ) | |
| — | |
Change in fair value of tranche and warrant liabilities | |
| 1,070 | | |
| — | | |
| 3,491 | | |
| — | |
Other income and expense, net | |
| (25 | ) | |
| (36 | ) | |
| (43 | ) | |
| (19 | ) |
Loss before income taxes | |
| (13,961 | ) | |
| (8,676 | ) | |
| (22,234 | ) | |
| (16,549 | ) |
Income tax benefit (expense) | |
| (13 | ) | |
| (3 | ) | |
| (8 | ) | |
| (3 | ) |
Net loss available to common stockholders | |
$ | (13,974 | ) | |
$ | (8,679 | ) | |
$ | (22,242 | ) | |
$ | (16,552 | ) |
Deemed dividend related to Series B-2 preferred stock down round provision | |
$ | (2,022 | ) | |
$ | — | | |
$ | (2,981 | ) | |
$ | — | |
Net loss attributable to common stockholders | |
$ | (15,996 | ) | |
$ | (8,679 | ) | |
$ | (25,223 | ) | |
$ | (16,552 | ) |
The following table sets forth our consolidated
statements of operations data expressed as a percentage of revenue:
| |
Three Months Ended June 30, | | |
Six Months Ended June 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Revenue | |
| 100.0 | % | |
| 100.0 | % | |
| 100.0 | % | |
| 100.0 | % |
Cost of goods sold | |
| 16.7 | | |
| 12.6 | | |
| 18.9 | | |
| 14.1 | |
Gross profit | |
| 83.3 | | |
| 87.4 | | |
| 81.1 | | |
| 85.9 | |
Operating expenses: | |
| | | |
| | | |
| | | |
| | |
Research and development | |
| 148.8 | | |
| 191.7 | | |
| 164.6 | | |
| 195.9 | |
Sales and marketing | |
| 75.7 | | |
| 109.3 | | |
| 88.7 | | |
| 111.5 | |
General and administrative | |
| 106.7 | | |
| 87.5 | | |
| 111.5 | | |
| 93.9 | |
Loss from operations | |
| (247.9 | ) | |
| (301.1 | ) | |
| (283.8 | ) | |
| (315.5 | ) |
Interest income | |
| 0.8 | | |
| 0.9 | | |
| 0.9 | | |
| 0.5 | |
Interest expense | |
| (0.1 | ) | |
| — | | |
| (0.1 | ) | |
| — | |
Loss on equity issuance | |
| (78.1 | ) | |
| — | | |
| (55.1 | ) | |
| — | |
Change in fair value of tranche and warrant liabilities | |
| 23.2 | | |
| — | | |
| 46.0 | | |
| 0.0 | |
Other income and expense, net | |
| (0.5 | ) | |
| (1.3 | ) | |
| (0.6 | ) | |
| (0.4 | ) |
Loss before income taxes | |
| (302.7 | ) | |
| (301.5 | ) | |
| (292.7 | ) | |
| (315.3 | ) |
Income tax benefit (expense) | |
| (0.3 | ) | |
| (0.1 | ) | |
| (0.1 | ) | |
| (0.1 | ) |
Net loss available to common stockholders | |
| (303.0 | )% | |
| (301.6 | )% | |
| (292.8 | )% | |
| (315.4 | )% |
Deemed dividend related to Series B-2 preferred stock down round provision | |
| (43.8 | )% | |
| —% | | |
| (39.2 | )% | |
| 0.0 | % |
Net loss attributable to common stockholders | |
| (346.8 | )% | |
| (301.6 | )% | |
| (332.1 | )% | |
| (315.4 | )% |
Comparison of the Three Months Ended June 30, 2023, and 2022
Revenue
| |
Three Months Ended June 30, | | |
$ | | |
% | |
| |
2023 | | |
2022 | | |
Change | | |
Change | |
| |
| | |
| | |
| | |
| |
| |
(dollars in thousands) | | |
| | |
| |
Revenue | |
$ | 4,612 | | |
$ | 2,878 | | |
$ | 1,734 | | |
| 60.3 | % |
Revenue increased by $1.7 million or 60.3% for
the three months ended June 30, 2023, as compared to the three months ended June 30, 2022. The increase in revenue was primarily
due to an increase of $1.5 million in sales of TriNav as our launch of the product, begun in 2020, recovered from the impact of the
Covid-19 pandemic. In addition, we recorded a reduction in sales discounts of $0.2 million as we terminated the distributor agreements
that required the discounts.
Cost of Goods Sold and Gross Profit
| |
Three Months Ended June 30, | | |
$ | | |
% | |
| |
2023 | | |
2022 | | |
Change | | |
Change | |
| |
| | |
| | |
| | |
| |
| |
(dollars in thousands) | | |
| | |
| |
Cost of goods sold | |
$ | 772 | | |
$ | 364 | | |
$ | 408 | | |
| 112.1 | % |
Gross profit | |
$ | 3,840 | | |
$ | 2,514 | | |
$ | 1,326 | | |
| 52.7 | % |
Cost of goods sold increased by $0.4 million,
or 112.1%, for the three months ended June 30, 2023, as compared to the three months ended June 30, 2022. The increase in cost
of goods sold was primarily due to additional production of TriNav to support our sales growth.
Gross profit increased by $1.3 million or 52.7%,
and gross margin decreased to 83.3% from 87.4% for the three months ended June 30, 2023, as compared to the three months ended June 30,
2022, respectively. The increase in gross profit was due primarily to the increase in revenue. The reduction in gross margin was driven
principally by higher labor costs, partially offset by lower material costs.
Operating Expenses
Research and Development
| |
Three Months Ended June 30, | | |
$ | | |
% | |
| |
2023 | | |
2022 | | |
Change | | |
Change | |
| |
| | |
| | |
| | |
| |
| |
(dollars in thousands) | | |
| | |
| |
Research and development | |
$ | 6,862 | | |
$ | 5,516 | | |
$ | 1,346 | | |
| 24.4 | % |
R&D expenses increased by $1.3 million, or
24.4%, for the three months ended June 30, 2023, as compared to the three months ended June 30, 2022. The increase was primarily
driven by increased activity in our three clinical trials of our drug candidate, SD-101, along with small increases in headcount related
expenses and travel.
Sales and Marketing
| |
Three Months Ended June 30, | | |
$ | | |
% | |
| |
2023 | | |
2022 | | |
Change | | |
Change | |
| |
| | |
| | |
| | |
| |
| |
(dollars in thousands) | | |
| | |
| |
Sales and marketing | |
$ | 3,492 | | |
$ | 3,146 | | |
$ | 346 | | |
| 11.0 | % |
Sales and marketing expenses increased by $0.3
million or 11.0%, for the three months ended June 30, 2023, as compared to the three months ended June 30, 2022. The increase
was primarily driven by a $0.8 million increase for payroll and travel expenses due to increased headcount of sales and marketing
personnel to support our sales of TriNav. The increase was partially offset by a reduction in professional services of $0.5 million, reflecting
lower expenditures after completing development of our web site and social media platforms.
General and Administrative
| |
Three Months Ended June 30, | | |
$ | | |
% | |
| |
2023 | | |
2022 | | |
Change | | |
Change | |
| |
| | |
| | |
| | |
| |
| |
(dollars in thousands) | | |
| | |
| |
General and administrative | |
$ | 4,920 | | |
$ | 2,517 | | |
$ | 2,403 | | |
| 95.5 | % |
General and administrative expenses increased
by $2.4 million, or 95.5%, for the three months ended June 30, 2023, as compared to the three months ended June 30, 2022. The
increase was primarily due to a $1.8 million increase for professional services, principally for consulting and auditing work in
connection with our issuance of Series B-2 preferred stock and the Business Combination, and a $0.6 increase in payroll and travel
expenses related to additional personnel.
Interest Income
| |
Three Months Ended June 30, | | |
$ | | |
% | |
| |
2023 | | |
2022 | | |
Change | | |
Change | |
| |
| | |
| | |
| | |
| |
| |
(dollars in thousands) | | |
| | |
| |
Interest income | |
$ | 36 | | |
$ | 25 | | |
$ | 11 | | |
| N/A | |
Interest income increased by $11 thousand for
the three months ended June 30, 2023, as compared to the three months ended June 30, 2022. The increase was due to higher interest
received from the investment of our excess cash in short-term money market funds in three months ended June 30, 2023.
Loss on Equity Issuance
| |
Three Months Ended June 30, | | |
$ | | |
% | |
| |
2023 | | |
2022 | | |
Change | | |
Change | |
| |
| | |
| | |
| | |
| |
| |
(dollars in thousands) | | |
| | |
| |
Loss on equity issuance | |
$ | (3,604 | ) | |
$ | — | | |
$ | (3,604 | ) | |
| N/A | |
A loss on equity issuance of $3.6 million was recorded in the
three months ended June 30, 2023, attributable to the issuance of Series B-2 preferred stock and the accompanying warrants to purchase
Series B-3 preferred stock, which were valued at $4.0 million in excess of the proceeds received as part of the partial closing
of the second tranche. The fair value exceeded proceeds primarily due to the issuance of warrants to purchase four shares of Series B-3
preferred stock for every one share of Series B-2 preferred stock purchased. This was partially offset by a gain on the extinguishment
of the tranche liabilities of $0.6 million due to the issuance of 17,142,867 shares of Series B-2 preferred stock, with accompanying warrants
to purchase four shares of Series B-3 preferred stock, in June 2023 for proceeds of $6,000.
Change in Fair Value of Tranche and Warrant Liabilities
| |
Three Months Ended June 30, | | |
$ | | |
% | |
| |
2023 | | |
2022 | | |
Change | | |
Change | |
| |
| | |
| | |
| | |
| |
| |
(dollars in thousands) | | |
| | |
| |
Change in fair value of tranche and warrant liabilities | |
$ | 1,070 | | |
$ | — | | |
$ | 1,070 | | |
| N/A% | |
The change in fair value of tranche and warrant
liabilities resulted in a gain of $1.1 million in the three months ended June 30, 2023.
Deemed dividend related to Series B-2 preferred stock down
round provision
| |
Three Months Ended June 30, | | |
$ | | |
% | |
| |
2023 | | |
2022 | | |
Change | | |
Change | |
| |
| | |
| | |
| | |
| |
| |
(dollars in thousands) | | |
| | |
| |
Deemed dividend related to Series B-2 preferred stock down round provision | |
$ | (2,022 | ) | |
$ | — | | |
$ | (2,022 | ) | |
| N/A | |
The deemed dividend is related to the closings
of a portion of the second tranche of the Initial Preferred Stock Financing in June 2023, which was deemed to be a down round and
triggered the anti-dilution provisions associated with our preferred stock. As a result, the conversion prices of all prior series of
preferred stock were adjusted such that the holders would receive more shares of common stock upon conversion than previously. The resulting
increase in value of the preferred stock was deemed to be a dividend to the preferred stockholders and we recognized a $2.0 million, non-cash
adjustment to additional paid-in-capital for the three months ended June 30, 2023. There was no such adjustment recorded in the three
months ended June 30, 2022.
Comparison of the Six Months Ended June 30, 2023, and 2022
Revenue
| |
Six Months Ended June 30, | | |
$ | | |
% | |
| |
2023 | | |
2022 | | |
Change | | |
Change | |
| |
| | |
| | |
| | |
| |
| |
(dollars in thousands) | | |
| | |
| |
Revenue | |
$ | 7,596 | | |
$ | 5,248 | | |
$ | 2,348 | | |
| 44.7 | % |
Revenue increased $2.3 million, or 44.7%, for
the six months ended June 30, 2023, as compared to the six months ended June 30, 2022. The increase was primarily due to higher
sales volume of TriNav, amounting to $2.0 million, and a reduction in discounts of $0.3 million as a result of the shift away
from sales to distributors.
Cost of Goods Sold and Gross Profit
| |
Six Months Ended June 30, | | |
$ | | |
% | |
| |
2023 | | |
2022 | | |
Change | | |
Change | |
| |
| | |
| | |
| | |
| |
| |
(dollars in thousands) | | |
| | |
| |
Cost of goods sold | |
$ | 1,434 | | |
$ | 741 | | |
$ | 693 | | |
| 93.5 | % |
Gross profit | |
$ | 6,162 | | |
$ | 4,507 | | |
$ | 1,655 | | |
| 36.7 | % |
Cost of goods sold increased by $0.7 million,
or 93.5%, for the six months ended June 30, 2023, as compared to the six months ended June 30, 2022. The increase in cost of
goods sold was primarily due to the higher volume of TriNav produced in the period to support the higher sales volume.
Gross profit increased by $1.7 million, or 36.7%,
for the six months ended June 30, 2023, as compared to the six months ended June 30, 2022, and gross margin decreased from 85.9%
to 81.1%. The increase in gross profit was driven primarily by higher sales volume. The decrease in gross margin was driven primarily
by higher material costs.
Operating Expenses
Research and Development
| |
Six Months Ended June 30, | | |
$ | | |
% | |
| |
2023 | | |
2022 | | |
Change | | |
Change | |
| |
| | |
| | |
| | |
| |
| |
(dollars in thousands) | | |
| | |
| |
Research and development | |
$ | 12,504 | | |
$ | 10,283 | | |
$ | 2,221 | | |
| 21.6 | % |
R&D expenses increased by $2.2 million, or
21.6%, for the six months ended June 30, 2023, as compared to the six months ended June 30, 2022. The increase was primarily
due to a $1.8 million increase in spend on our clinical trials, an increase of $0.5 million for development of manufacturing of SD-101,
and a decrease of $0.1 million in spend on professional services as we increased our headcount.
Sales and Marketing
| |
Six Months Ended June 30, | | |
$ | | |
% | |
| |
2023 | | |
2022 | | |
Change | | |
Change | |
| |
| | |
| | |
| | |
| |
| |
(dollars in thousands) | | |
| | |
| |
Sales and marketing | |
$ | 6,741 | | |
$ | 5,851 | | |
$ | 890 | | |
| 15.2 | % |
Sales and marketing expenses increased by $0.9
million, or 15.2%, for the six months ended June 30, 2023, as compared to the six months ended June 30, 2022. The increase was
primarily driven by a $1.2 million increase for additional payroll expenses due to an increase in headcount of sales and marketing
personnel, and $0.1 million of additional travel expense, partially offset by a $0.5 million decrease in marketing expense,
reflecting lower expenditures after completing development of our web site and social media platforms.
General and Administrative Expenses
| |
Six Months Ended June 30, | | |
$ | | |
% | |
| |
2023 | | |
2022 | | |
Change | | |
Change | |
| |
| | |
| | |
| | |
| |
| |
(dollars in thousands) | | |
| | |
| |
General and administrative expenses | |
$ | 8,472 | | |
$ | 4,929 | | |
$ | 3,543 | | |
| 71.9 | % |
General and administrative expenses increased
by $3.5 million, or 71.9%, for the six months ended June 30, 2023, as compared to the six months ended June 30, 2022. The increase
was primarily due to a $2.8 million increase in professional service fee due to additional legal and audit-related expenditures for the
Business Combination, and a $0.7 million increase for payroll and personnel expenses due to increased headcount of general and administrative
personnel.
Interest Income
| |
Six Months Ended June 30, | | |
$ | | |
% | |
| |
2023 | | |
2022 | | |
Change | | |
Change | |
| |
| | |
| | |
| | |
| |
| |
(dollars in thousands) | | |
| | |
| |
Interest income | |
$ | 71 | | |
$ | 26 | | |
$ | 45 | | |
| (173.1 | %) |
Interest income increased by $45.0 thousand, or
(173.1%), for the six months ended June 30, 2023, as compared to the six months ended June 30, 2022. The increase was primarily
due to a combination of higher surplus cash balances invested in money market funds and higher interest rates during the six months ended
June 30, 2023.
Loss on Equity Issuance
| |
Six Months Ended June 30, | | |
$ | | |
% | |
| |
2023 | | |
2022 | | |
Change | | |
Change | |
| |
| | |
| | |
| | |
| |
| |
(dollars in thousands) | | |
| | |
| |
Loss on equity issuance | |
$ | (4,189 | ) | |
$ | — | | |
$ | (4,189 | ) | |
| N/A | |
A loss on equity issuance of $4.2 million was
recorded in the six months ended June 30, 2023, attributable to the issuance of Series B-2 preferred stock and the accompanying
warrants to purchase Series B-3 preferred stock and related tranche obligations, which were valued in excess of the proceeds received
as part of the transaction. The fair value exceeded proceeds primarily due to the issuance of warrants to purchase four shares of Series B-3
preferred stock for every one share of Series B-2 preferred stock purchased in the Initial Preferred Stock Financing.
Change in Fair Value of Tranche and Warrant Liabilities
| |
Six Months Ended June 30, | | |
$ | | |
% | |
| |
2023 | | |
2022 | | |
Change | | |
Change | |
| |
| | |
| | |
| | |
| |
| |
(dollars in thousands) | | |
| | |
| |
Change in fair value of tranche and warrant liabilities | |
$ | 3,491 | | |
$ | — | | |
$ | 3,491 | | |
| N/A | |
The change in fair value of tranche and warrant
liabilities resulted in a loss of $3.5 million in the six months ended June 30, 2023. There were no tranche or warrant liabilities
in the six months ended June 30, 2022.
Deemed dividend related to Series B-2 preferred stock down
round provision
| |
Six Months Ended June 30, | | |
$ | | |
% | |
| |
2023 | | |
2022 | | |
Change | | |
Change | |
| |
| | |
| | |
| | |
| |
| |
(dollars in thousands) | | |
| | |
| |
Deemed dividend related to Series B-2 preferred stock down round provision | |
$ | (2,981 | ) | |
$ | — | | |
$ | (2,981 | ) | |
| N/A | |
The deemed dividend is related to the Initial
Preferred Stock Financing, which was deemed to be a down round and triggered the anti-dilution provisions associated with our preferred
stock. As a result, the conversion prices of all prior series of preferred stock were adjusted such that the holders would receive more
shares of common stock upon conversion than previously. The resulting increase in value of the preferred stock was deemed to be a dividend
to the preferred stockholders and we recognized a $3.0 million, non-cash adjustment to additional paid-in-capital for the six months ended
June 30, 2023. There was no such adjustment recorded in the six months ended June 30, 2022.
Liquidity and Capital Resources
Overview
Since inception, we have incurred significant
net losses and expect to continue to incur net losses for the foreseeable future due to the investments we will continue to make in R&D
and sales and marketing, and due to additional general and administrative costs we expect to incur as a public company. We incurred net
losses of $22.2 million for the six months ended June 30, 2023. We had cash and cash equivalents of approximately $3.9 million
at June 30, 2023. Since inception, we have financed operations primarily through the issuance of preferred stock, convertible notes,
and term loans. We are still in our early stages of development and have yet to generate revenues sufficient to fund cash flows from operations.
Our ability to fund future operations and execute our long-term business plan and strategy, including our transformation into a therapeutics
company, will require that we raise additional capital through the issuance of additional equity and/or debt. There can be no assurance
that we will be able to raise such additional financing on satisfactory terms. If additional capital is not secured when required, we
may need to delay or curtail our operations until such funding is received. If we cannot expand our operations or otherwise capitalize
on our business opportunities because we lack sufficient capital, our business, financial condition and results of operations could be
materially adversely affected. As a result, we have concluded that there is substantial doubt of our ability to continue as a going concern
for a reasonable period of time, which is considered to be one year from the issuance date of the financial statements.
Our ability to continue as a going concern is
dependent upon obtaining additional capital and financing including through the consummation of the Business Combination. Our financial
statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that
might be necessary should we be unable to continue as a going concern. In connection with the consummation of the Business Combination
on August 10, 2023, we raised an additional $36.8 million of cash (net of expenses related to closing the Business Combination).
In addition, as described below, we received $4.5 million in cash proceeds from the exercise of warrants to purchase Series B-3 preferred
stock in July 2023. We believe that the proceeds from the Business Combination and exercise of warrants should be sufficient to fund
our operations through key data read-outs expected in mid-2024. However, unless we are able to raise additional capital, we do not currently
expect that our existing cash and cash equivalents and additional cash received in connection with the Business Combination
will be sufficient to fund our projected liquidity requirements for the next 12 months, creating substantial doubt about our ability to
continue as a going concern. We have based these estimates on assumptions that may prove to be wrong and we could use our available capital
resources sooner than we currently expect, and future capital requirements and the adequacy of available funds will depend on many factors,
including those described in the section titled “Risk Factors” in this Report and the Proxy Statement/Prospectus. See also
“—Funding Requirements” below.
In October 2022, we raised $9.8 million,
net of issuance costs, through the issuance of Series B-2 preferred stock and warrants to purchase Series B-3 preferred stock.
This issuance also included, at our option, a second tranche of Series B-2 preferred stock and warrants to purchase Series B-3
preferred stock (“Series B-3 Warrants”) for up to approximately $7.4 million (which could be increased to $10 million)
and a third tranche, at the election of investors in the second tranche, of up to $4.3 million (which could be increased to $5 million)
of Series B-2 preferred stock and warrants to purchase Series B-3 preferred stock, subject, in all respects, to the covenants
in the Merger Agreement prohibiting us from issuing additional securities during the Interim Period without MTAC’s prior consent.
We offered the Series B-2 preferred stock to all of our preferred stockholders at the time of the Initial Preferred Stock Financing
(representing approximately 99.2% of our then outstanding shares on an as-converted to common stock basis).
In January through June 2023, holders
of warrants to purchase 102,446,428 shares of Series B-3 preferred stock exercised their purchase right, for proceeds of approximately
$5.1 million. In March 2023, we effectuated (i) a closing of a portion of the second tranche of the Initial Preferred Stock
Financing whereby 8,396,207 shares of Series B-2 preferred stock and accompanying warrants to purchase 33,584,828 shares of Series B-3
preferred stock, representing 40% of the shares committed in the second tranche, were sold for an aggregate purchase price of $2.9 million,
and (ii) an additional closing under the purchase agreement for the Initial Preferred Stock Financing whereby 714,285 shares of Series B-2
preferred stock and accompanying warrants to purchase 2,857,140 shares of Series B-3 preferred stock were sold for an aggregate purchase
price of $0.2 million.
In June 2023, we effectuated (i) a closing
of a portion of the second tranche of the Initial Preferred Stock Financing whereby 10,428,583 shares of Series B-2 preferred stock
and accompanying warrants to purchase 41,714,332 shares of Series B-3 preferred stock, representing approximately 49.7% of the shares
committed in the second tranche, were sold for an aggregate purchase price of $3.7 million, and (ii) an additional closing under
the purchase agreement for the Initial Preferred Stock Financing whereby 6,714,284 shares of Series B-2 preferred stock and accompanying
warrants to purchase 26,857,136 shares of Series B-3 preferred stock were sold for an aggregate purchase price of $2.3 million.
In July 2023, holders of warrants to purchase 90,619,356 shares
of Series B-3 preferred stock exercised their purchase rights for proceeds of approximately $4.5 million.
Any Series B-3 Warrants that were not exercised
for cash were automatically net settled for shares of TriSalus Common Stock immediately prior to the closing of the Business Combination
and exchanged into shares of Combined Company Common Stock at the Effective Time.
Cash Flows
Comparison of the Six Months Ended June 30, 2023, and June 30,
2022
The following table presents net cash from operating,
investing, and financing activities (in thousands):
| |
Six Months Ended June 30, | |
| |
2023 | | |
2022 | |
Net cash used in operating activities | |
$ | (19,739 | ) | |
$ | (18,686 | ) |
Net cash used in investing activities | |
| (104 | ) | |
| (421 | ) |
Net cash provided by financing activities | |
| 14,333 | | |
| 3,562 | |
Net increase / (decrease) in cash, cash equivalents and restricted cash | |
$ | (5,510 | ) | |
$ | (15,545 | ) |
Cash Used in Operating Activities
For the six months ended June 30, 2023, net
cash used in operating activities was $19.7 million. The net cash used in operating activities consisted of net loss of $22.2 million,
adjusted for non-cash charges totaling $1.2 million, primarily related to a gain on the adjustment of the fair value of warrants
to purchase preferred stock of $3.5 million, partially offset by a loss on equity issuance of $4.2 million. Net operating assets
and liabilities decreased $1.3 million, due primarily to an increase in accounts payable and accrued liabilities.
For the six months ended June 30, 2022, net
cash used in operating activities was $18.7 million. The net cash used in operating activities consisted of net loss of $16.6 million,
adjusted for non-cash charges totaling $0.6 million, primarily related to depreciation and amortization of $0.3 million, non-cash
interest expense of $0.2 million, and stock-based compensation expense of $0.1 million. In addition, there was a net increase of
$2.8 million in our net operating assets and liabilities. The increase in our net operating assets and liabilities was driven by
an increases in prepaid expenses of $1.5 million and accounts receivable of $0.1 million, and a decrease in trade payable, accrued
expenses and other current liabilities of $1.1 million.
Cash Used in Investing Activities
Net cash used in investing activities of $0.1 million
for the six months ended June 30, 2023, was primarily due to payments to acquire or maintain intellectual property.
Net cash used in investing activities of $0.4 million
for the six months ended June 30, 2022, was primarily due to purchases of property and equipment of $0.4 million.
Cash Used in Financing Activities
Net cash provided by financing activities of $14.3 million
for the six months ended June 30, 2023, consisted principally of proceeds from the issuance of Series B-2 preferred stock of
$9.2 million, and proceeds from the exercise of warrants to purchase Series B-3 preferred stock of $5.1 million.
Net cash provided by financing activities of $3.6 million
for the six months ended June 30, 2022, consisted of proceeds from the issuance of Series B-2 preferred stock.
Funding Requirements
Our primary use of cash is to fund operating expenses,
which consist of research, development and clinical expenses related to our lead product candidate SD-101, and preclinical programs, sales
and marketing expenses related to the growth of TriNav, as well as general and administrative expenses. We plan to advance the development
of SD-101, initiate new research and pre-clinical development efforts and seek marketing approval for product candidates that we successfully
develop. If we obtain approval for our product candidates, we expect to incur commercialization expenses, which may be significant, related
to establishing sales, marketing, manufacturing capabilities, distribution and other commercial infrastructure to commercialize such products.
Accordingly, we may need to obtain substantial additional funding in connection with our continuing operations. Inflation and rising interest
rates may result in an economic recession globally or in the U.S., which could lead to a reduction in product demand, a decrease in corporate
capital expenditures, prolonged unemployment, labor shortages, reduction in consumer confidence, adverse geopolitical and macroeconomic
events, or any similar negative economic condition. Economic conditions in some parts of the world have been worsening, with disruptions
to, and volatility and uncertainty in, the credit and financial markets in the U.S. and worldwide resulting from the effects of inflation
and rising interest rates. These conditions have been further exacerbated by recent and potential future disruptions in access to bank
deposits or lending commitments due to bank failures, the war in Ukraine and the lingering effects of the COVID-19 pandemic. It is not
possible at this time to estimate the long-term impact that these and related events could have on our business, as the impact will depend
on future developments, which are highly uncertain and cannot be predicted. If these conditions persist and deepen, we could experience
an inability to access additional capital, or our liquidity could otherwise be impacted. If we are unable to raise capital when needed
and on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs and/or other efforts.
A recession or additional market corrections resulting from the impact of difficult macroeconomic conditions, disruptions in the banking
system, and the lingering effects of the COVID-19 pandemic could materially affect our business and the value of our securities.
We also expect to continue to incur significant
expenses in connection with our ongoing activities related to TriNav, including sales and marketing expenses and expenditures to support
expansion of our production capacity to support our expected sales growth. Our future capital requirements, both near and long-term, will
depend on many factors, including but not limited to: the success of our commercialization of TriNav including, among other things, continued
patient and physician adoption of TriNav and our ability to maintain adequate reimbursement for TriNav; the cost of commercialization
activities for TriNav, including manufacturing, distribution, marketing and sales; net product revenues received from sales of TriNav;
the outcome, timing and cost of the regulatory approval process for SD-101 by the FDA, including the potential for the FDA to require
that we perform more studies and clinical trials than those that we currently expect; the costs involved in preparing, filing and prosecuting
patent applications and annuity fees relating to issued patents; the cost of maintaining and enforcing our intellectual property rights,
as well as the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against
us; the initiation, progress, timing, costs and results of clinical trials and other research and development related to our product candidates;
and the extent to which we in-license, acquire or otherwise partner in development or commercialization of other products, product candidates
or technologies; the achievement of milestones or occurrence of other developments that trigger payments under the Dynavax Agreement or
any other collaboration or other agreements; the number of future product candidates that we may pursue and their development requirements;
the costs of commercialization activities for any of our product candidates that may receive marketing approval to the extent such costs
are not the responsibility of any future collaborators, including the costs and timing of establishing product sales, marketing, distribution
and manufacturing capabilities; the amount and timing of future revenue, if any, received from commercial sales of our current and future
product candidates upon any marketing approvals; and the costs of operating as a public company.
Until such time, if ever, as we can generate substantial
product revenues, we expect to finance our cash needs through a combination of securities offerings, debt financings, collaborations,
strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible
debt securities, existing ownership interest in our company may be materially diluted, and the terms of these securities may include liquidation
or other preferences that adversely affect common stockholders’ rights. Debt financing, if available, may involve agreements that
include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures
or declaring dividends.
If we raise funds through additional collaborations,
strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future
revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable
to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product
development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer
to develop and market ourselves.
As of June 30, 2023, we had $3.9 million
in cash and cash equivalents. We also had $250 thousand in restricted cash to support our corporate credit card program. We will
likely require additional capital in the near term in order to continue to fund our operations through equity or debt financings, partnerships,
collaborations, or other sources which may not be available on a timely basis, on favorable terms, or at all, and such capital, if obtained,
may not be sufficient to enable us to continue to implement our long-term business strategy.
Additionally, we may never become profitable,
or if we do, may not be able to sustain profitability on a recurring basis. If we cannot capitalize on our business opportunities because
we lack sufficient capital, our business, financial condition and results of operations could be materially adversely affected and we
may need to delay or curtail our operations until such funding is received.
Our continuation as a going concern is dependent
on our ability to generate sufficient cash flows from operations and/or obtain additional capital through equity or debt financings, partnerships,
collaborations, or other sources to carry out our long-term business strategy. If we are unable to continue as a going concern, we may
have to liquidate our assets and may receive less than fair value for such assets and less than the value at which such assets are carried
on our financial statements, and it is likely that investors will lose all or a part of their investment. As discussed in Note 1 to our
unaudited consolidated financial statements included in Exhibit 99.1 to this Form 8-K, there is substantial doubt regarding
our ability to continue as a going concern as of June 30, 2023.
Contractual Obligations and Commitments
Our contractual obligations as of June 30,
2023, include lease obligations of $1.8 million, reflecting the minimum commitments for our principal administrative and production facility
and other office spaces. See Note 15 to our audited consolidated financial statements included in the Proxy Statement/Prospectus for more
information on our lease obligations, including the scheduled maturities and timing of cash payments related to these obligations.
Pursuant to the Asset Purchase Agreement, dated
July 31, 2020, between TriSalus and Dynavax, we have paid Dynavax $11 million as of June 30, 2023, and may be required
to pay Dynavax up to an additional $159 million upon the achievement of certain development and regulatory milestones with respect
to SD-101. We will also be required to pay up to $80 million upon achieving certain commercial milestones once sales of SD-101 have
begun. The Dynavax Agreement also obligates us to pay low double-digit royalties based on potential future net sales of product containing
SD-101 compound on a product-by-product and country-by-country basis during the applicable royalty term. Such royalties are subject to
reduction by up to 50% in certain circumstances.
Off-Balance Sheet Arrangements
We did not have during the periods presented,
and we do not currently have, any off-balance sheet financing arrangements or any relationships with unconsolidated entities or financial
partnerships, including entities sometimes referred to as structured finance or special purpose entities, which were established for the
purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.
Critical Accounting Policies and Estimates:
Our significant accounting policies are summarized
in Note 2 “Summary of Significant Accounting Policies” in the unaudited condensed consolidated
financial statements included in Exhibit 99.1. While all of these significant accounting policies affect the reporting of
our financial condition and results of operations, we view certain of these policies as critical. Policies determined to be critical are
those policies that have the most significant impact on our financial statements and require us to use a greater degree of judgment and/or
estimates. Actual results may differ from those estimates. Additionally, changes in accounting estimates could occur in the future from
period to period.
Revenue Recognition
Our revenue is derived from shipments of our TriNav
infusion devices to our customers which are generally comprised of hospitals, clinics and physicians, and is recognized in accordance
with the provisions of the Financial Accounting Standards Board (“ASB”) ASC 606, Revenue from Contracts with Customers,
and all related applicable guidance.
Under ASC 606, revenue is recognized when a customer
obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange
for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606,
we perform the following five steps: (i) identify the contract; (ii) identify the performance obligation; (iii) determine
the transaction price; (iv) allocate the transaction price; and (v) recognize revenue.
We contract with our customers based on customer
purchase orders. For each contract, we consider the promise to transfer products, each of which is distinct, to be the identified performance
obligation. As part of our performance obligation, products are delivered in accordance with the terms of the purchase order and we do
not have any on-going service obligation after delivery.
We maintain a single, discrete transaction price
for each of the products, with no adjustments since the price is approved by CMS. We do not have multiple performance obligations to complete
when a purchase order is fulfilled, hence the transaction price is always allocated fully to the units being sold.
Revenue is recognized when the units for
a purchase order have been shipped and control of the units has transferred to the customer. Ex-works shipment is followed, wherein
we recognize revenue when the shipment leaves our premises. In certain cases where purchase orders specify alternate shipping terms, usually
delivery at place, revenue recognition is deferred until we are assured the units are delivered.
Sales, value add, and other taxes collected on
behalf of third parties are excluded from revenue. Revenues from product sales are recorded at the net sales price (transaction price),
which includes estimates of variable consideration for which reserves are established for discounts, returns, rebates and allowances.
We do not have a history of any refunds, allowances or other concessions provided to our customers from the agreed-upon sales price after
delivery of the product. We do not offer discounts, except to distributors as discussed below. We had certain arrangements with distributors
under which the distributors purchased and then resold our products in geographic markets where we did not have sales presence. These
arrangements provided for a discount on the invoice. When the distributor resold our units at our normal sales price, the discount
served to compensate the distributor for their efforts. We recorded these sales net of the discounts.
One of our distributors, ACD, accounted for approximately 26% and 20% of our sales for six months ended June 30, 2023, and the year
ended December 31, 2022, respectively. We discontinued the distributor agreement with ACD in December 2022.
We provide certain customers with rebates that
are explicitly stated in our contracts and are recorded as a reduction of revenue in the period the conditions for the rebates are achieved.
The rebates result from performance-based offers that are primarily based on attaining contractually specified sales volumes.
Research and Development
R&D costs include our engineering, regulatory,
pre-clinical and clinical activities. R&D costs are expensed as incurred. Approximately 28% of our R&D costs are headcount-related;
the balance is external services we purchase, such as pre-clinical supplies and materials, clinical study management and supplies, and
consulting related to our R&D.
We are required to estimate our expenses resulting
from our obligations under agreements with vendors, consultants, and contract research organizations, in connection with conducting R&D
activities. The financial terms of these contracts are subject to negotiations, which vary from agreement to agreement and may result
in payment flows that do not match the periods over which goods or services are provided. We reflect R&D expenses in our consolidated
financial statements by matching those expenses with the period in which services and efforts are expended. We account for these expenses
according to the progress of the agreements, along with preparation of financial models, taking into account discussions with research
and other key personnel as to the progress of studies or other services being performed. To date, we have had no material differences
between our estimates of such expenses and the amounts actually incurred. Nonrefundable advance payments for goods and services are deferred
and recognized as expense in the period that the related goods are consumed or services are performed.
Warrant and Tranche Rights and Obligation Liabilities
We classified the Series B-2 tranche rights
and obligations and Series B-3 Warrants as liabilities on the consolidated balance sheets. We measured the Series B-2 Tranche
Rights and Series B-3 Warrants at fair value upon issuance in October 2022, March 2023, and June 2023, and remeasured
the liabilities to fair value at December 31, 2022, March 31, 2023, and June 30, 2023, with changes in the fair value at
each measurement date recognized in Change in fair value of tranche and warrant liabilities in the consolidated statements of operations.
The fair value of the Series B-2 tranche
liabilities was determined using a Binomial Tranche Model. The fair value of the Series B-3 Warrants was determined using a probability-weighted
expected outcome model whereby the following two scenarios were probability-weighted based on the Company’s expectation of each
occurring: (1) a status quo scenario whereby the Company would continue as a private company and (2) a scenario where the Business
Combination would close. Under the status quo scenario, the Series B-3 Warrants, including warrants to be issued under the second
and third tranches, were valued using the Black-Scholes model.
The fair value of the Series B-2 tranche
liabilities and Series B-3 Warrants used various inputs and assumptions that required management to apply judgment and make estimates,
including:
| · | the equity value under the status quo scenario, which was determined using the Guideline Public Company method within the market approach
to estimate the fair value of equity on a minority, marketable basis using selected publicly traded peer companies and valuation multiples
based on size, growth, profitability, and other relevant factors; |
| · | the fair value of underlying Series B-2 preferred stock, which was determined using the Option Pricing Model to allocate the
Company’s equity value among its various classes of equity securities under the status quo scenario; |
| · | issuance and exercise price, which was based on the terms of the purchase agreement; |
| · | expected term, which we based on the expiry periods as defined in the purchase agreement; |
| · | expected volatility, which was based on the historical equity volatility of publicly traded peer companies
for a term equal to the expected term of the warrants and tranche liabilities; |
| · | risk-free interest rate, which was determined by reference to the U.S. Treasury yield curve for time
periods commensurate with the expected terms of the warrants and tranche liabilities; and |
| · | expected dividend yield, which we estimate to be zero based on the fact that we have never paid or
declared dividends. |
These estimates
may be subjective in nature and involve uncertainties and matters of judgment and therefore cannot be determined with exact precision.
The scenario probability is the most sensitive estimated input into the calculation of the fair value of the Series B-3 Warrants.
The risk of exposure is estimated using a sensitivity analysis of potential changes in the significant unobservable inputs, primarily
the scenario probability input that is the most susceptible to valuation risk.
Emerging Growth Company Status
Section 102(b)(1) of the JOBS Act exempts
emerging growth companies from being required to comply with new or revised financial accounting standards. The JOBS Act provides that
a company can choose not to take advantage of the extended transition period and comply with the requirements that apply to non-emerging
growth companies, and any such election to not take advantage of the extended transition period is irrevocable. MTAC previously elected
to avail itself of the extended transition period, and following the consummation of the Business Combination, the Combined Company will
be an emerging growth company and will take advantage of the benefits of the extended transition period that the emerging growth company
status permits. During the extended transition period, it may be difficult or impossible to compare our financial results with the financial
results of another public company that complies with public company effective dates for accounting standard updates because of the potential
differences in accounting standards used.
The Combined Company will remain an emerging growth
company under the JOBS Act until the earlier of: (1) the last day of the fiscal year (a) following the fifth anniversary of
the closing of MTAC’s initial public offering (i.e., December 31, 2025), (b) in which the Combined Company has total annual
gross revenue of at least $1.235 billion, or (c) in which the Combined Company is deemed to be a “large accelerated filer”
under the rules of the SEC, which means the market value of the Combined Company’s common equity that is held by non-affiliates
exceeds $700.0 million as of the end of the prior fiscal year’s second fiscal quarter; and (2) the date on which the Combined
Company has issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.
Recent Accounting Pronouncements
Note 2(q) to
our audited consolidated financial statements included in the Proxy Statement/Prospectus includes more information about recent accounting
pronouncements, the timing of their adoption, and our assessment, to the extent we have made one, of their potential impact on our financial
condition and our results of operations.
Exhibit 99.3
UNAUDITED PRO FORMA
CONDENSED COMBINED FINANCIAL
INFORMATION
Capitalized terms
used but not defined in this Exhibit 99.3 shall have the meanings ascribed to them in this Current Report on Form 8-K (the
“Form 8-K”) and, if not defined in the Form 8-K, the final prospectus and definitive proxy statement, dated
July 18, 2023 (the “proxy statement/prospectus”), filed by MedTech Acquisition Corporation (“MTAC” who,
after the Business Combination, became TriSalus Life Sciences, Inc.) with the U.S. Securities and Exchange Commission (the
“SEC”).
Introduction
The following unaudited
pro forma condensed combined financial information presents the combination of the financial information of MTAC and New TriSalus adjusted
to give effect to the Business Combination and related transactions. The unaudited pro forma condensed combined financial information
has been prepared in accordance with Article 11 of Regulation S-X and should be read in conjunction with the accompanying notes.
Defined terms included below have the same meaning as terms defined and included in the proxy statement/prospectus.
The unaudited pro forma
condensed combined balance sheet as of June 30, 2023, gives pro forma effect to the Business Combination and Preferred Stock PIPE
Investment as if it was completed on June 30, 2023. The unaudited pro forma condensed combined statements of operations for the six
months ended June 30, 2023 and the year ended December 31, 2022, give pro forma effect to the Business Combination and Preferred
Stock PIPE Investment as if it had occurred on January 1, 2022, the beginning of the earliest period presented.
The unaudited pro forma
condensed combined financial information was derived from, and should be read in conjunction with, the following historical financial
statements and the accompanying notes, which are included or incorporated by reference into this Form 8-K:
| ● | The historical unaudited condensed consolidated financial statements of Legacy TriSalus as of and for the six months ended June 30,
2023, and the historical audited consolidated financial statements of Legacy TriSalus as of and for the year ended December 31, 2022;
and |
| ● | The historical unaudited financial statements of MTAC as of and for the six months ended June 30, 2023, and the historical audited
financial statements of MTAC as of and for the year ended December 31, 2022. |
The foregoing historical
financial statements have been prepared in accordance with GAAP. The unaudited pro forma condensed combined financial information has
been prepared based on the aforementioned historical financial statements and the assumptions and adjustments as described in the notes
to the unaudited pro forma condensed combined financial information. The pro forma adjustments reflect transaction accounting adjustments
related to the Business Combination and Preferred Stock PIPE Investment, which is discussed in further detail below. The unaudited pro
forma condensed combined financial statements are presented for illustrative purposes only and do not purport to represent the consolidated
results of operations or consolidated financial position that would actually have occurred had the Business Combination and Preferred
Stock PIPE Investment been consummated on the dates assumed or to project consolidated results of operations or consolidated financial
position for any future date or period. Actual results may differ materially from the assumptions within the accompanying unaudited pro
forma condensed combined financial information.
The unaudited pro forma
condensed combined financial information should also be read together with “Management’s Discussion and Analysis of Financial
Condition and Results of Operations of TriSalus,” “Management’s Discussion and Analysis of Financial Condition
and Results of Operations of MTAC,” and other financial information included or incorporated by reference into this Form 8-K.
Description of the Business Combination
On August 10,
2023 (the “Closing Date”), pursuant to the terms of the Merger Agreement, Merger Sub merged with and into Legacy TriSalus,
with Legacy TriSalus surviving the merger as a wholly-owned subsidiary of MTAC. Upon the close of the Business Combination, each share
of MTAC’s Class A Common Stock and each share of MTAC’s Class B Common Stock that was outstanding was reclassified
into a single class of common stock.
Immediately
prior to the effective time of the Merger (the “Effective Time”), shares of Legacy TriSalus Preferred Stock converted into
shares of Legacy TriSalus Common Stock based on the applicable Exchange Ratio. In addition, each outstanding warrant of Legacy TriSalus
(“Legacy TriSalus Warrant”) to purchase shares of Legacy TriSalus Preferred Stock or Legacy TriSalus Common Stock that was
in-the-money and would have been exercised or otherwise exchanged in full in accordance with its terms by virtue of the occurrence of
the Business Combination, was automatically exercised for shares of Legacy TriSalus Common Stock. Legacy TriSalus Warrants that were out-of-the-money
and automatically expired worthless in accordance with their terms were cancelled for no consideration. Following the Legacy TriSalus
Preferred Stock Conversion and the exercise of the Legacy TriSalus Warrants, the Legacy TriSalus Common Stock
was converted into the right to receive such number of shares of New TriSalus Common Stock as was equal to (i) the number of shares
of New TriSalus Common Stock multiplied by (ii) the Exchange Ratio (subject to rounding mechanisms as described in the Merger
Agreement). The total shares of New TriSalus Common Stock issued to holders of Legacy TriSalus Common Stock was 21,999,886, which includes
the issuance of Legacy TriSalus Common Stock resulting from the Legacy TriSalus Preferred
Stock Conversion and exercise of Legacy TriSalus Warrants. At the Effective Time, each outstanding
option to purchase shares of Legacy TriSalus Common Stock, , whether or not then vested and exercisable,
was assumed and converted into an option to purchase such number of shares of New TriSalus Common Stock as was equal to (i) the number
of shares of Legacy TriSalus Common Stock subject to such option prior to the Effective Time multiplied by (ii) the Exchange
Ratio (subject to rounding mechanisms described in the Merger Agreement), with a per share exercise price equal to the exercise price
prior to the Effective Time divided by the Exchange Ratio. The Exchange Ratio was 0.02471853.
In connection with
the Business Combination, the Preferred Stock PIPE Investment closed with the Preferred Stock PIPE Investors purchasing 4,015,002 shares
of Series A Convertible Preferred Stock at a purchase price of $10.00 per share, for an aggregate purchase price of approximately
$40.2 million.
Total Capitalization |
|
Shares |
|
|
% |
|
TriSalus Stockholders |
|
|
21,999,886 |
|
|
|
72.6 |
|
MTAC Public Stockholders |
|
|
254,295 |
|
|
|
0.8 |
|
Preferred Stock PIPE Investors(1) |
|
|
4,015,002 |
|
|
|
13.2 |
|
Holders of founder shares(2) |
|
|
4,062,500 |
|
|
|
13.4 |
|
Total Shares |
|
|
30,331,683 |
|
|
|
100.0 |
|
(1) | Assumes the 4,015,002 shares of Series A Convertible Preferred Stock issued at $10.00 per share in the Preferred Stock PIPE Investment
are converted into shares of New TriSalus Common Stock at the initial conversion price of $10.00 per share. |
(2) | Includes 3,125,000 Sponsor Earnout Shares that are subject to vesting and forfeiture if the New TriSalus Common Stock does not meet
certain price thresholds following the Closing Date. While unvested, holders of the Sponsor Earnout Shares will have full ownership rights
to the Sponsor Earnout Shares, including the right to vote such shares. For additional information, see “Business Combination
Proposal — Related Agreements — Sponsor Support Agreement” in the proxy statement/prospectus. The founder shares
(including Sponsor Earnout Shares) were distributed pro rata to the members of the Sponsor in connection with the consummation of the
Business Combination. |
Accounting for the Business Combination
The Business Combination
has been accounted for as a reverse recapitalization in accordance with GAAP. Under this method of accounting, MTAC has been treated as
the “acquired” company for financial reporting purposes. This determination was primarily based on the fact that subsequent
to the Business Combination, the Legacy TriSalus stockholders have a majority of the voting power of New TriSalus, Legacy TriSalus comprises
all of the ongoing operations of New TriSalus, Legacy TriSalus has appointed a majority of the governing body of New TriSalus, and Legacy
TriSalus’ senior management comprises all of the senior management of New TriSalus. Accordingly, for accounting purposes, the Business
Combination has been treated as the equivalent of Legacy TriSalus issuing shares for the net assets of MTAC, accompanied by a recapitalization.
The net assets of MTAC have been stated at historical cost, with no goodwill or other intangible assets recorded. The financial statements
of New TriSalus represent a continuation of the financial statements of Legacy TriSalus.
Accounting for the Sponsor Earnout Shares
New TriSalus has restructured
the 6,250,000 shares of common stock previously outstanding and held by the Sponsor (the “Sponsor Shares”), with such Sponsor
Shares reclassified into shares of New TriSalus Common Stock as of the Effective Time. Thirty-five percent (35%), or 2,187,500 shares,
of the Sponsor Shares have been forfeited and canceled as of the Effective Time; fifteen percent (15%), or 937,500 shares, of the Sponsor
Shares have fully vested and are free from forfeiture; and fifty percent (50%), or 3,125,000 shares, of the Sponsor Shares are subject
to vesting and forfeiture if the New TriSalus Common Stock does not meet certain price thresholds prior to the fifth anniversary of the
Closing Date. One-fourth of the Sponsor Earnout Shares will vest when the volume-weighted average price (“VWAP”) of the New
TriSalus Common Stock price equals or exceeds $15.00 per share for at least 20 trading days during any 30 trading-day period, one- fourth
of the Sponsor Earnout Shares will vest when the VWAP of the New TriSalus Common Stock price equals or exceeds $20.00 for at least 20
trading days during any 30 trading-day period, one- fourth of the Sponsor Earnout Shares will vest when the VWAP of the New TriSalus Common
Stock price equals or exceeds $25.00 for at least 20 trading days during any 30 trading-day period, and the remaining one-fourth will
vest when the VWAP equals or exceeds $30.00 for at least 20 trading days during any 30 trading-day period. Additionally, the Sponsor Earnout
Shares will vest if there is a change in control of New TriSalus on or before the 5th anniversary of the Closing Date that results in
the holders of New TriSalus Common Stock receiving a price per share equal to or in excess of the applicable earnout targets.
The accounting for
the Sponsor Earnout Shares was evaluated under ASC Topic 480, Distinguishing Liabilities from Equity, and ASC Subtopic 815-40,
Derivatives and Hedging — Contracts in Entity’s Own Equity, to determine if the Sponsor Earnout Shares should be classified
as a liability or within equity. As part of that preliminary analysis, it was determined that the Sponsor Earnout Shares subject to vesting
are freestanding from other shares of common stock held by the Sponsor and do not meet the criteria in ASC 815-40 to be considered indexed
to the New TriSalus Common Stock. As a result, the Sponsor Earnout Shares will be classified as a liability. Therefore, an adjustment
to recognize a liability related to the Sponsor Earnout Shares has been applied to the unaudited pro forma combined financial information.
Accounting for the Preferred Stock PIPE
Investment
In connection with
closing of the Business Combination, MTAC issued 4,015,002 shares of New TriSalus’ Series A Convertible Preferred Stock, with
a par value of $0.0001 per share (the “Series A Convertible Preferred Stock”), at a purchase price of $10.00 per share,
for gross proceeds of approximately $40.2 million. The Series A Convertible Preferred Stock will initially be convertible into shares
of New TriSalus Common Stock at $10.00 per share, subject to customary adjustments and a conversion price reset feature, at any time at
the option of the holder. The Series A Convertible Preferred Stock will also automatically convert into shares of New TriSalus Common
Stock, at the then-applicable conversion price, upon the four- year anniversary of the Business Combination.
The Series A Convertible
Preferred Stock accrues cumulative dividends at 8.0% per annum, which will be paid upon declaration by the board of directors, upon liquidation,
or upon conversion. It will also participate in any dividends or distributions (other than dividends paid in the form of New TriSalus
Common Stock, convertible securities, or options) made to the common stockholders on an as-converted basis. Dividends may be paid in cash
or, at the election of the New TriSalus, by delivery of shares of the New TriSalus Common Stock.
The accounting for
the Series A Convertible Preferred Stock is currently under evaluation. A preliminary analysis was performed whereby ASC Topic 480,
Distinguishing Liabilities from Equity, ASC Subtopic 815-15, Derivatives and Hedging — Embedded Derivatives and ASC Subtopic 815-40,
Derivatives and Hedging — Contracts in Entity’s Own Equity were considered in determining whether the Series A Convertible
Preferred Stock should be classified as a liability or within equity. As part of that analysis, it was preliminarily determined that the
Series A Convertible Preferred Stock does not meet the criteria in ASC 480 to be classified as a liability, rather, it meets the
criteria in ASC 815-40 to be considered indexed to the New TriSalus Common Stock and classified as equity. Further, as part of the preliminary
analysis, it was determined that there aren’t any embedded features that require bifurcation or result in a classification outside
of permanent equity. As a result, the Series A Convertible Preferred Stock will be classified as equity for purposes of the pro forma
financial information, and an adjustment to recognize the expected cash proceeds and issuance of Series A Convertible Preferred Stock
has been applied to the unaudited pro forma combined financial information.
Other Financing and Related Events
MTAC — Final Redemption
As described
in the proxy statement/prospectus, MTAC provided holders of its shares of Class A Common Stock with the opportunity to have all or
a portion of their shares redeemed for cash upon the closing of the Business Combination. On August 8, 2023, MTAC held a special
meeting of stockholders, at which, holders of an aggregate of 890,499 shares of MTAC’s
Class A Common Stock elected to exercise their right to redeem their shares for a pro rata portion of the funds in the Company’s
trust account (the “Trust Account”). As a result, approximately $9.4 million (approximately $10.58 per redeemed
share) was removed from the Trust Account to pay such holders.
Basis of Pro Forma Presentation
The historical financial
information has been adjusted to give pro forma effect to the transaction accounting required for the Business Combination. The adjustments
in the unaudited pro forma condensed combined financial information have been identified and presented to provide relevant information
necessary for an accurate understanding of the post-combination entity upon the Effective Time.
The unaudited pro forma condensed
combined financial information is for illustrative purposes only.
The financial results may have been different
had the companies always been combined. You should not rely on the unaudited pro forma condensed combined financial information as being
indicative of the historical results that would have been achieved had the companies always been combined or the future results that the
post-combination entity will experience. Legacy TriSalus and MTAC have not had any historical relationship prior to the Business Combination.
Accordingly, no pro forma adjustments were required to eliminate activities between the companies.
Accounting Policies
Following consummation
of the Business Combination, management is performing a comprehensive review of Legacy TriSalus’ and MTAC’s accounting policies.
As a result of the review, management may identify differences between the accounting policies of the two entities which, when conformed,
could have a material impact on the financial statements of New TriSalus. Based on its initial analysis, management did not identify any
differences that would have a material impact on the unaudited pro forma condensed combined financial information. As a result, the unaudited
pro forma condensed combined financial information does not assume any differences in accounting policies.
Unaudited Pro Forma Condensed
Combined Balance Sheet
As of June 30, 2023
(in thousands)
|
|
TriSalus
Historical |
|
|
MTAC
Historical |
|
|
Subsequent
Event
Adjustments |
|
|
Financing
Adjustments |
|
|
Transaction
Adjustments |
|
|
Pro
Forma
Combined |
|
ASSETS |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
3,904 |
|
|
$ |
104 |
|
|
|
— |
|
|
|
$ |
40,150 |
|
(B) |
|
$ |
2,655 |
|
(C) |
|
$ |
40,128 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(685 |
) |
(E) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(6,000 |
) |
(F) |
|
|
|
|
Accounts receivable |
|
|
2,094 |
|
|
|
— |
|
|
|
— |
|
|
|
|
— |
|
|
|
— |
|
|
|
2,094 |
|
Inventory, net |
|
|
1,522 |
|
|
|
— |
|
|
|
— |
|
|
|
|
— |
|
|
|
— |
|
|
|
1,522 |
|
Prepaid expenses |
|
|
4,859 |
|
|
|
57 |
|
|
|
— |
|
|
|
|
— |
|
|
|
(4,233 |
) |
(E) |
|
|
683 |
|
Total current assets |
|
|
12,379 |
|
|
|
161 |
|
|
|
— |
|
|
|
|
40,150 |
|
|
|
(8,263 |
) |
|
|
44,427 |
|
Property and equipment, net |
|
|
1,885 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1,885 |
|
Right-of-use asset |
|
|
1,322 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1,322 |
|
Intangible assets, net |
|
|
858 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
858 |
|
Other assets |
|
|
367 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
367 |
|
Investments held in Trust Account |
|
|
— |
|
|
|
12,076 |
|
|
|
(9,421 |
) |
(A) |
|
|
— |
|
|
|
(2,655 |
) |
(C) |
|
|
— |
|
Total assets |
|
$ |
16,811 |
|
|
$ |
12,237 |
|
|
$ |
(9,421 |
) |
|
$ |
40,150 |
|
|
$ |
(10,918 |
) |
|
$ |
48,859 |
|
LIABILITIES, TEMPORARY EQUITY AND SHAREHOLDERS’ EQUITY (DEFICIT) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Trade payables |
|
$ |
4,297 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
4,297 |
|
Accrued expenses |
|
|
9,106 |
|
|
|
2,670 |
|
|
|
— |
|
|
|
— |
|
|
|
(2,170 |
) |
(F) |
|
|
9,606 |
|
Series B-2 tranche liabilities |
|
|
959 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(959 |
) |
(G) |
|
|
— |
|
Series B-3 warrant liabilities |
|
|
17,190 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(17,190 |
) |
(G) |
|
|
— |
|
Short-term lease liabilities |
|
|
384 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
384 |
|
Convertible note |
|
|
— |
|
|
|
1,500 |
|
|
|
— |
|
|
|
— |
|
|
|
(1,500 |
) |
(K) |
|
|
— |
|
Promissory note – related party |
|
|
— |
|
|
|
1,573 |
|
|
|
— |
|
|
|
— |
|
|
|
(1,573 |
) |
(F) |
|
|
— |
|
Other current liabilities |
|
|
253 |
|
|
|
288 |
|
|
|
— |
|
|
|
— |
|
|
|
(257 |
) |
(F) |
|
|
284 |
|
Total current liabilities |
|
|
32,189 |
|
|
|
6,031 |
|
|
|
— |
|
|
|
— |
|
|
|
(23,649 |
) |
|
|
14,571 |
|
Long-term lease liabilities |
|
|
1,410 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1,410 |
|
Warrant liabilities |
|
|
262 |
|
|
|
531 |
|
|
|
— |
|
|
|
— |
|
|
|
(262 |
) |
(H) |
|
|
573 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
42 |
|
(K) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred underwriting fee payable |
|
|
— |
|
|
|
8,750 |
|
|
|
— |
|
|
|
— |
|
|
|
(8,750 |
) |
(F) |
|
|
— |
|
Other long-term liabilities |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
24,499 |
|
(I) |
|
|
24,499 |
|
Total liabilities |
|
|
33,861 |
|
|
|
15,312 |
|
|
|
— |
|
|
|
— |
|
|
|
(8,120 |
) |
|
|
41,053 |
|
Commitments and contingencies |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class A common stock subject to possible redemption |
|
|
— |
|
|
|
12,046 |
|
|
|
(9,421 |
) |
(A) |
|
|
|
|
|
|
(2,625 |
) |
(D) |
|
|
— |
|
Convertible preferred stock |
|
|
181,313 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
17,190 |
|
(G) |
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(198,503 |
) |
(H) |
|
|
|
|
Shareholders’ equity (deficit) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible preferred stock |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Common stock |
|
|
18 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(16 |
) |
(H) |
|
|
2 |
|
Class B Common stock, $0.0001 par value |
|
|
— |
|
|
|
1 |
|
|
|
— |
|
|
|
— |
|
|
|
(1 |
) |
(I) |
|
|
— |
|
Additional paid-in capital |
|
|
13,200 |
|
|
|
— |
|
|
|
— |
|
|
|
40,150 |
|
(B) |
|
|
2,625 |
|
(D) |
|
|
221,734 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1,610 |
) |
(E) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,750 |
|
(F) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
198,781 |
|
(H) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(24,498 |
) |
(I) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(15,122 |
) |
(J) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,458 |
|
(K) |
|
|
|
|
Accumulated deficit |
|
|
(211,581 |
) |
|
|
(15,122 |
) |
|
|
— |
|
|
|
— |
|
(B) |
|
|
(3,308 |
) |
(E) |
|
|
(213,930 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
959 |
|
(G) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15,122 |
|
(J) |
|
|
|
|
Total shareholders’ equity (deficit) |
|
|
(198,363 |
) |
|
|
(15,121 |
) |
|
|
— |
|
|
|
40,150 |
|
|
|
181,140 |
|
|
|
7,806 |
|
Total liabilities, temporary equity and shareholders’ equity (deficit) |
|
$ |
16,811 |
|
|
$ |
12,237 |
|
|
$ |
(9,421 |
) |
|
$ |
40,150 |
|
|
$ |
(10,918 |
) |
|
$ |
48,859 |
|
Unaudited
Pro Forma Condensed Combined Statement of Operations
For the
Six Months Ended June 30, 2023
(in thousands, except share
and per share data)
|
|
TriSalus
Historical |
|
|
MTAC
Historical |
|
|
Transaction
Adjustments |
|
|
Pro
Forma
Combined |
|
Revenue |
|
$ |
7,596 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
7,596 |
|
Cost of goods sold |
|
|
1,434 |
|
|
|
— |
|
|
|
— |
|
|
|
1,434 |
|
Gross profit |
|
|
6,162 |
|
|
|
— |
|
|
|
— |
|
|
|
6,162 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
|
12,504 |
|
|
|
— |
|
|
|
— |
|
|
|
12,504 |
|
Sales and marketing |
|
|
6,741 |
|
|
|
— |
|
|
|
— |
|
|
|
6,741 |
|
General and administrative |
|
|
8,472 |
|
|
|
2,273 |
|
|
|
— |
|
|
|
10,745 |
|
Loss from operations |
|
|
(21,555 |
) |
|
|
(2,273 |
) |
|
|
— |
|
|
|
(23,828 |
) |
Interest income |
|
|
71 |
|
|
|
369 |
|
|
|
(369 |
) |
(AA) |
|
71 |
|
Interest expense |
|
|
(9 |
) |
|
|
— |
|
|
|
— |
|
|
|
(9 |
) |
Loss on equity issuance |
|
|
(4,189 |
) |
|
|
— |
|
|
|
— |
|
|
|
(4,189 |
) |
Change in fair value of warrant and tranche liabilities |
|
|
3,491 |
|
|
|
531 |
|
|
|
(3,753 |
) |
(BB) |
|
269 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income and expense, net |
|
|
(43 |
) |
|
|
— |
|
|
|
— |
|
|
|
(43 |
) |
(Loss) income before income taxes |
|
|
(22,234 |
) |
|
|
(1,373 |
) |
|
|
(4,122 |
) |
|
|
(27,729 |
) |
Income tax expense |
|
|
8 |
|
|
|
70 |
|
|
|
— |
|
|
|
78 |
|
Net (loss) income |
|
$ |
(22,242 |
) |
|
$ |
(1,443 |
) |
|
$ |
(4,122 |
) |
|
$ |
(27,807 |
) |
Net (loss) income per share: |
|
|
|
|
|
|
2,024,925 |
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding of Class A common stock, basic and diluted |
|
|
|
|
|
$ |
(0.18 |
) |
|
|
|
|
|
|
|
|
Basic and diluted net income per share, Class A common stock |
|
|
|
|
|
|
6,111,111 |
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding of Class B common stock, basic and diluted |
|
|
|
|
|
$ |
(0.18 |
) |
|
|
|
|
|
|
|
|
Basic and diluted net income per share, Class B common stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding of common stock, basic and diluted |
|
|
17,068,505 |
|
|
|
|
|
|
|
|
|
|
|
23,191,681 |
|
Basic and diluted net loss per share, common stock |
|
$ |
(1.48 |
) |
|
|
|
|
|
|
|
|
|
$ |
(1.27 |
) |
Unaudited Pro Forma Condensed
Combined Statement of Operations
For the Year Ended December
31, 2022
(in thousands, except
share and per share data)
|
|
TriSalus
Historical |
|
|
MTAC
Historical |
|
|
Transaction
Adjustments |
|
|
Pro Forma
Combined |
|
Revenue |
|
$ |
12,398 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
12,398 |
|
Cost of goods sold |
|
|
2,258 |
|
|
|
— |
|
|
|
— |
|
|
|
2,258 |
|
Gross profit |
|
|
10,140 |
|
|
|
— |
|
|
|
— |
|
|
|
10,140 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
|
21,358 |
|
|
|
— |
|
|
|
— |
|
|
|
21,358 |
|
Sales and marketing |
|
|
12,738 |
|
|
|
— |
|
|
|
— |
|
|
|
12,738 |
|
General and administrative |
|
|
12,483 |
|
|
|
2,746 |
|
|
|
— |
|
|
|
15,229 |
|
Loss from operations |
|
|
(36,439 |
) |
|
|
(2,746 |
) |
|
|
— |
|
|
|
(39,185 |
) |
Interest income |
|
|
180 |
|
|
|
3,019 |
|
|
|
(3,019 |
) |
(CC) |
|
180 |
|
Interest expense |
|
|
(1 |
) |
|
|
— |
|
|
|
— |
|
|
|
(1 |
) |
Change in fair value of warrant and tranche liabilities |
|
|
(2,186 |
) |
|
|
5,837 |
|
|
|
2,208 |
|
(DD) |
|
5,859 |
|
Loss on equity issuance |
|
|
(8,312 |
) |
|
|
— |
|
|
|
— |
|
|
|
(8,312 |
) |
Other income and expense, net |
|
|
(420 |
) |
|
|
— |
|
|
|
(22 |
) |
(DD) |
|
(6,291 |
) |
|
|
|
|
|
|
|
|
|
|
|
(8,266 |
) |
(EE) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,458 |
|
(FF) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
959 |
|
(GG) |
|
|
|
(Loss) income before income taxes |
|
|
(47,178 |
) |
|
|
6,110 |
|
|
|
(6,682 |
) |
|
|
(47,750 |
) |
Income tax expense |
|
|
9 |
|
|
|
571 |
|
|
|
— |
|
|
|
580 |
|
Net (loss) income |
|
$ |
(47,187 |
) |
|
$ |
5,539 |
|
|
$ |
(6,682 |
) |
|
$ |
(48,330 |
) |
Net (loss) income per share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding of Class A common stock, basic and diluted |
|
|
|
|
|
|
23,358,326 |
|
|
|
|
|
|
|
|
|
Basic and diluted net income per share, Class A common stock |
|
|
|
|
|
$ |
0.19 |
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding of Class B common stock, basic and diluted |
|
|
|
|
|
|
6,250,000 |
|
|
|
|
|
|
|
|
|
Basic and diluted net income per share, Class B common stock |
|
|
|
|
|
$ |
0.19 |
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding of common stock, basic and diluted |
|
|
12,526,248 |
|
|
|
|
|
|
|
|
|
|
|
23,191,681 |
|
Basic and diluted net loss per share, common stock |
|
$ |
(3.99 |
) |
|
|
|
|
|
|
|
|
|
$ |
(2.22 |
) |
NOTES TO UNAUDITED PRO FORMA CONDENSED
COMBINED FINANCIAL INFORMATION
The pro forma adjustments
have been prepared as if the Business Combination had been consummated on June 30, 2023, in the case of the unaudited pro forma condensed
combined balance sheet, and as if the Business Combination had been consummated on January 1, 2022, the beginning of the earliest
period presented, in the case of the unaudited pro forma condensed combined statements of operations.
The unaudited pro forma
condensed combined financial information has been prepared assuming the following methods of accounting in accordance with GAAP.
The Business Combination
will be accounted for as a reverse recapitalization in accordance with GAAP. Accordingly, for accounting purposes, the Business Combination
will be treated as the equivalent of TriSalus issuing stock for the net assets of MTAC, accompanied by a recapitalization. The net assets
of MTAC will be stated at historical cost, with no goodwill or other intangible assets recorded. The financial statements of New TriSalus
will represent a continuation of the financial statements of TriSalus.
The unaudited pro forma
condensed combined financial statements were prepared in accordance with Article 11 of SEC Regulation S-X, as amended by the final
rule, Release No. 33-10786, Amendments to Financial Disclosures about Acquired and Disposed Businesses. Release No. 33-10786
replaces the existing pro forma adjustment criteria with simplified requirements to depict the accounting for the Business Combination
and related transactions (“Transaction Accounting Adjustments”). The unaudited pro forma condensed combined financial information
does not give effect to any anticipated synergies, operating efficiencies, tax savings, or cost savings that may be associated with the
Business Combination.
The unaudited pro forma
condensed combined financial information does not give effect to any tax impacts associated with the pro forma adjustments as such pro
forma adjustments result in the generation of additional net operating losses offset by a full valuation allowance recorded on such net
operating losses as it is more likely than not that the net operating losses will not be utilized.
The
pro forma adjustments reflecting the completion of the Business Combination and related transactions are based on currently
available information and assumptions and methodologies that management believes are reasonable under the circumstances. The pro
forma adjustments, which are described in the accompanying notes, may be revised as additional information becomes available and is
evaluated. Therefore, it is likely that the actual adjustments will differ from the pro forma adjustments, and it is possible the
difference may be material. Management believes that its assumptions and methodologies provide a reasonable basis for presenting all
of the significant effects of the Business Combination and related transactions based on information available to management at the
current time and that the pro forma adjustments give appropriate effect to those assumptions and are properly applied in the
unaudited pro forma condensed combined financial information.
The unaudited pro forma
condensed combined financial information is not necessarily indicative of what the actual results of operations and financial position
would have been had the Business Combination and related transactions taken place on the dates indicated, nor are they indicative of the
future consolidated results of operations or financial position of New TriSalus. They should be read in conjunction with the historical
financial statements and notes thereto of Legacy TriSalus and MTAC.
2. | Transaction Accounting Adjustments and Assumptions to the Unaudited Pro Forma Condensed Combined Balance Sheet as of June 30,
2023 |
The adjustments included
in the unaudited pro forma condensed combined balance sheet as of June 30, 2023, are as follows:
| (A) | Represents the adjustment to record the redemption of shares of MTAC’s Class A Common Stock on August 10, 2023. See
“Other Financing and Related Events” section above. |
| (B) | Represents the pro forma adjustment to record the gross proceeds of $40.2 million from the issuance of 4,015,002 shares of Series A
Convertible Preferred Stock to the Preferred Stock PIPE Investors. The gross proceeds were not reduced by Preferred Stock PIPE Investment
related transaction costs, which were estimated at $1.6 million, as they were settled by the Sponsor on the Closing Date. Pursuant to
the Sponsor Support Agreement, the Sponsor is solely responsible for the payment of MTAC transaction costs in excess of the MTAC Transaction
Expenses Cap, which, for the purposes of this adjustment, was exceeded from transaction costs captured in Adjustment (F). As a result,
Additional paid in capital was increased by a total of $40.2 million, resulting from the $38.6 million of additional paid in capital,
net of transaction costs, from the issuance of the Series A Convertible Preferred Stock, in addition to the Sponsor’s $1.6
million noncash contribution for transaction costs related to the Preferred Stock PIPE Investment. |
| (C) | Represents the reclassification of cash and investments held in the Trust Account remaining as of June 30, 2023. The cash held
in the Trust Account became available in conjunction with the closing of the Business Combination. |
| (D) | Reflects the reclassification of New TriSalus Common Stock of the $2.6 million of MTAC Class A Common Stock, subject to possible
redemption. |
| (E) | Represents the payment of estimated Legacy TriSalus transaction
costs of $4.9 million in non-recurring costs incurred in connection with the Business Combination,
which are primarily related to legal and accounting fees. Such transaction costs are allocated
to additional paid-in capital of $1.6 million and accumulated deficit of $3.3 million based
on the relative fair value of the acquired Sponsor Earnout Shares and the outstanding New
TriSalus Common Stock at the Effective Time in connection with the Business Combination. |
| (F) | Represents the adjustments associated with the estimated MTAC transaction costs and the MTAC related party promissory notes either
settled by MTAC or settled by the Sponsor on the Closing Date. Pursuant to the Sponsor Support Agreement, the Sponsor is solely responsible
for the payment of MTAC transaction costs in excess of the MTAC Transaction Expenses Cap, which for the purposes of this adjustment, is
$6.0 million as the Available Closing MTAC Cash was less than $70 million. The MTAC Transaction Expenses Cap also includes the payment
of any promissory notes and convertible notes, if not converted into warrants, in favor of the Sponsor as well as MTAC transaction costs
incurred from transactions prior to the Business Combination and, to the extent not waived, the deferred underwriting fee that would otherwise
be due on the Closing Date. On November 11, 2022 MTAC and Raymond James amended the underwriting agreement to provide for a waiver
by Raymond James of the $8.8 million deferred underwriting fee in its entirety if the proposed Business Combination between MTAC and TriSalus
is consummated. As a result of the consummation of the Business Combination, the deferred underwriting fee payable of $8.8 million as
of June 30, 2023 was eliminated with an offsetting adjustment to additional paid-in-capital and is not included in the MTAC Transaction
Expenses Cap. Further, as discussed in adjustment (K), the MTAC convertible notes were converted into MTAC Warrants at the Effective Time.
As a result, the MTAC convertible notes are not included in the MTAC Transaction Expenses Cap. This adjustment reflects $7.1 million of
MTAC estimated transaction costs to be settled on the Closing Date, of which $6.7 million relates to the legal and financial advisory
costs in connection with the Business Combination and $0.4 million relates to transaction costs from a prior transaction. In addition,
the adjustment reflects the settlement of the MTAC related promissory and extension notes outstanding of $1.6 million and $0.3 million,
respectively, as of June 30, 2023. |
The following table
reconciles the cash outflow related to MTAC transaction costs and promissory and extension notes on the Closing Date (in thousands):
| |
Amount | |
Total MTAC transaction costs and
promissory and extension notes settled on the Closing
Date | |
$ | 8,958 | |
Less:
Portion settled by Sponsor | |
| (2,958 | ) |
MTAC
transaction costs and promissory notes paid via MTAC cash | |
$ | 6,000 |
The following table
reconciles total MTAC transaction costs and promissory and extension notes settled on the Closing Date to MTAC transaction costs expensed
on the Closing Date (in thousands):
| |
Amount | |
Total
MTAC transaction costs and promissory notes settled on the Closing Date | |
$ | 8,958 | |
Less: MTAC promissory
notes outstanding as of 6/30/23 and settled on the Closing Date | |
| (1,573 | ) |
Less: MTAC extension
note outstanding as of 6/30/23 and settled on the Closing Date | |
| (257 | ) |
Less:
MTAC transaction costs related to Business Combination accrued as of 6/30/23 and paid on the Closing Date | |
| (1,811 | ) |
Less: MTAC transaction
costs related to prior transaction accrued as of 6/30/23 and paid on the Closing Date | |
| (359 | ) |
MTAC transaction
costs expensed on the Closing Date | |
$ | 4,958 | |
As the MTAC transaction
costs would have been initially recognized on the MTAC pre-closing balance sheet immediately prior to the Effective Time and the accumulated
deficit of MTAC would be reclassified to additional paid in capital at the Effective Time (see adjustment (J)), for purpose of this adjustment,
the MTAC transaction expenses are recorded directly to additional paid-in capital. The following presents the adjustment to additional
paid in capital as a result of the MTAC transaction costs (in thousands):
| |
Amount | |
Sponsor non-cash contribution from payment
of MTAC transaction costs on behalf of MTAC | |
$ | 2,958 | |
Plus: Waiver of deferred underwriting fee | |
| 8,750 | |
Less: MTAC transaction costs expensed on the Closing Date | |
| (4,958 | ) |
MTAC transaction costs – additional paid in capital adjustment | |
$ | 6,750 | |
|
(G) | Represents the gain on expiration of the Series B-2 tranche liabilities and the automatic conversion of unexercised Series B-3
Warrants into Series B-3 preferred stock on a cashless basis upon consummation of the Business Combination. The expiration of the
Series B-2 tranche liabilities resulted in a decrease in the Series B-2 tranche liabilities and a decrease in Accumulated deficit,
for a gain on expiration, of $1.0 million. The automatic conversion of unexercised Series B-3 Warrants into Series B-3 preferred
stock resulted in a decrease in the Series B-3 warrant liabilities and increase in Convertible preferred stock of $17.2 million. |
|
(H) | Represents the issuance of 21,999,886 shares of New TriSalus Common Stock to Legacy TriSalus stockholders (including Legacy TriSalus
common stockholders who received their shares upon conversion of the Legacy TriSalus Preferred Stock and automatic exercise of the Legacy
TriSalus Warrants) as consideration for the reverse recapitalization. |
|
(I) | Prior to the Effective Time, the Sponsor held 6,249,999 shares of MTAC’s Class A Common Stock and 1 share of Class B Common Stock. At
the Effective Time, 2,187,500 of these shares were forfeited and cancelled; 3,125,000 became Sponsor Earnout Shares; and 937,500 were
reclassified as New TriSalus Common Stock. The Sponsor Earnout Shares will be accounted for as a liability. See section “Accounting
for the Sponsor Earnout Shares” for further discussion. |
The preliminary estimated fair value of
the Sponsor Earnout Shares is $24.5 million. The pro forma value of the Sponsor Earnout Shares was estimated using a Monte Carlo simulation
model. The significant assumptions utilized in estimating the fair value of the Sponsor Earnout Shares include the following: (i) starting
share value of $10.00; (ii) a dividend yield of 0.0%; (iii) a risk-free rate of 4.18%; and (iv) expected equity volatility
of 65.0%.
|
(J) | Reflects the elimination of MTAC’s historical accumulated deficit. |
|
(K) | Represents the conversion of MTAC’s related party convertible notes into MTAC Warrants (which have the same terms and conditions
as the Private Placement Warrants) at the Effective Time, which was convertible at the option of the convertible note holder. Based on
the outstanding balance as of June 30, 2023 of $1.5 million, the MTAC convertible notes were converted into 1,000,000 MTAC Warrants
based on a $1.50 conversion price. The fair value of the 1,000,000 MTAC Warrants issued upon conversion is $42 thousand. A gain on conversion
of $1.46 million of the MTAC convertible note is recorded to additional paid-in capital as a result of the elimination of MTAC’s
historical accumulated deficit at the Effective Time (see adjustment (J)). |
3. | Transaction Accounting Adjustments and Assumptions to the Unaudited Pro Forma Condensed Combined Statement of Operations for the
Six Months Ended June 30, 2023 |
The adjustments included
in the unaudited pro forma condensed combined statement of operations for the six months ended June 30, 2023, are as follows:
| (AA) | Reflects the elimination of interest earned on investments held
in the Trust Account. |
| (BB) | Reflects the elimination of the change in fair value of Legacy
TriSalus Warrant liabilities as a result of the settlement of the Legacy TriSalus Warrants at or immediately prior to the Effective Time. |
4. | Transaction Accounting Adjustments and Assumptions to the Unaudited Pro Forma Condensed Combined Statement of Operations for the
Year Ended December 31, 2022 |
The adjustments included
in the unaudited pro forma condensed combined statement of operations for the year ended December 31, 2022, are as follows:
| (CC) | Reflects the elimination of interest earned on investments held
in the Trust Account. |
| (DD) | Reflects the elimination of the change in fair value of Legacy
TriSalus Warrant liabilities as a result of the settlement of the Legacy TriSalus Warrants at or immediately prior to the Effective Time. |
| (EE) | Represents the pro forma adjustment to record the nonrecurring
expense related to $3.3 million of Legacy TriSalus transaction costs and $5.0 million of MTAC transaction costs, discussed further at
adjustments (E) and (F). |
|
(FF) | Represents the gain on conversion upon the expected conversion of MTAC convertible notes into MTAC Warrants (which would have the
same terms and conditions as the Private Placement Warrants) at the Effective Time, discussed further at adjustment (K). |
|
(GG) | Represents the pro forma adjustment to record the nonrecurring expense related to the gain on expiration of the Series B-2 tranche
liabilities upon the Business Combination; as discussed further at adjustment (G). |
The pro forma weighted
average shares calculations have been calculated for the six months ended June 30, 2023 using the historical weighted average shares
outstanding, and the issuance of additional shares in connection with the Business Combination, assuming the Business Combination occurred
on January 1, 2022. As the Business Combination is being reflected as if it had occurred at the beginning of the periods presented,
the calculation of weighted average shares outstanding for both basic and diluted net loss per share assumes that the shares issuable
relating to the Business Combination have been outstanding for the entire periods presented. Holders of Legacy TriSalus Common Stock received
shares of New TriSalus Common Stock in an amount determined by application of the Exchange Ratio.
The 3,125,000 Sponsor
Earnout Shares are not considered outstanding from an accounting perspective. Further, due to the fact that the Sponsor Earnout Shares
are contingently issuable for accounting purposes based upon New TriSalus Common Stock share price reaching specified thresholds that
have not yet been achieved, the Sponsor Earnout Shares have been excluded from basic and diluted pro forma net loss per share.
The following potential
outstanding securities were excluded from the computation of pro forma net loss per share, basic and diluted, because their effect would
have been anti-dilutive, or issuance of such shares is contingent upon the satisfaction of certain conditions which were not satisfied
by the end of the period:
|
|
Number of Shares |
|
Sponsor Earnout Shares |
|
|
3,125,000 |
|
Stock Options (formerly TriSalus Options) |
|
|
1,759,366 |
|
Restricted Stock Units (“RSU’s") (formerly TriSalus RSU’s) |
|
|
184,018 |
|
Public Warrants |
|
|
8,333,272 |
|
Private Placement Warrants |
|
|
4,933,333 |
|
Series A Convertible Preferred Stock |
|
|
4,015,002 |
|
Additional MTAC Warrants (adjustment (K)) |
|
|
1,000,000 |
|
The unaudited pro forma
condensed combined net loss per share has been prepared for the six months ended June 30, 2023 and the year ended December 31,
2022 (in thousands, except for share and per share data):
|
|
For the Six Months
Ended June 30, 2023 |
|
|
For the Year Ended
December 31, 2021 |
|
|
|
Combined
Pro Forma |
|
|
Combined
Pro Forma |
|
Numerator |
|
|
|
|
|
|
|
|
Pro forma net loss – basic and diluted |
|
$ |
(27,807 |
) |
|
$ |
(48,330 |
) |
Less: Annual 8% cumulative dividend for Convertible Preferred Shareholders |
|
|
(1,606 |
) |
|
|
(3,212 |
) |
Net loss attributable to common Stockholder |
|
|
(29,413 |
) |
|
|
(51,542 |
) |
Denominator |
|
|
|
|
|
|
|
|
Pro forma weighted average shares of common stock outstanding – basic and diluted (1) |
|
|
23,191,681 |
|
|
|
23,191,681 |
|
Pro forma basic and diluted net loss per share(1) |
|
$ |
(1.27 |
) |
|
$ |
(2.22 |
) |
(1) | Excludes the effects of potentially dilutive shares from Sponsor Earnout Shares, Series A Convertible Preferred Stock, stock
options, public warrants, and Private Placement Warrants from the computation of diluted net loss per share because including them would
have had an antidilutive effect. |
Exhibit 99.4
TriSalus Life Sciences Completes Merger with
MedTech Acquisition Corporation
Advances TriSalus’ Platform Focused on
Improving Outcomes for Patients with Liver and Pancreatic Cancer
Expected to Advance Technology Development and
Sales Growth
Advancing SD-101 Into Phase 2 Clinical Trial
in Uveal Melanoma, Phase 1 Trial in Pancreatic Cancer and Continuing Clinical Trials in HCC and Cholangiocarcinoma
Provides Cash Runway through Mid-2024 to Fund
Key Milestones
TriSalus’ Common Stock Expected to Begin
Trading on the Nasdaq under Symbol "TLSI" on August 11, 2023
DENVER, Co. and FORT LAUDERDALE, Fla., August 11, 2023 –
TriSalus Life Sciences® Inc., (TriSalus or the Company), an oncology company integrating its novel delivery technology with immunotherapy
to transform treatment for patients with liver and pancreatic tumors, today announced the completion of its previously announced
merger with MedTech Acquisition Corporation (Nasdaq: MTAC) (MedTech). TriSalus’ common stock and warrants are expected to commence
trading on the Nasdaq Global Market under the ticker symbols “TLSI” and “TLSIW,” respectively, on August 11, 2023.
“Completing our merger with MedTech marks an important milestone
in our efforts to bring to market innovative approaches to treating liver and pancreatic tumors,” said Mary Szela, President and
CEO of TriSalus. “Over the last several months we have advanced our device business and generated positive clinical data that supports
the potential of our immunotherapeutic program. We are moving forward with the financial resources needed to grow our commercial organization
and fund our key milestones through mid-2024. We believe that we are poised to create shareholder value as we continue our work to bring
hope and improved treatments to the lives of patients. Finally, I want to especially thank our MTAC and TriSalus shareholders for trusting
us to create value for them. I also want to thank our employees, interventional radiologists, and clinical investors and particularly
our patients for their unwavering support that has been instrumental in helping us to achieve this milestone.”
“We are excited to complete this merger with TriSalus and support
the growth of its innovative devices and treatments,” said Chris Dewey, CEO of MedTech. “We believe that TriSalus has significant
near and long-term value creation opportunities through its commercialization strategy and the potential to deploy SD-101 into multiple
indications across several lines of therapy. We have full confidence that Mary and the experienced TriSalus team will continue working
to meet significant unmet medical needs and delivering value to shareholders.”
The Company’s new board of directors consists of Mats Wahlstrom,
Mary Szela, Sean Murphy, Kerry Hicks, Dr. Anil Singhal, Dr. Andrew C. von Eschenbach, Kelly Martin, David J. Matlin and Dr. Arjun (“JJ”)
Desai.
Szela continued, “We welcome Andy, Kelly, JJ and David to the
Board and look forward to benefiting from their experience across the medical technology, pharmaceutical, healthcare and financial industries.
Innovative Device Technology Combined with Immunotherapeutic Platform
Creates Significant Upside Potential
| · | Fast-Growing Core Device Business: TriSalus' commercial stage, FDA cleared TriNav® Infusion System includes the proprietary
SmartValve technology. SmartValve enables precision delivery of therapeutics to tumors using the Pressure-Enabled Drug Delivery™
(PEDD) approach. The PEDD approach has been shown to modulate pressure and flow, increasing therapeutic delivery to the tumor while decreasing
exposure in normal tissue – an important goal for interventional radiologists focused on better outcomes with less toxicity. PEDD
brings the potential to improve patient outcomes and also brings additional expansion opportunities through the delivery of a wide variety
of therapeutics. TriNav achieved $8.4 million and $12.4 million in net sales in 2021 and 2022, respectively, and is on track to generate
approximately $19.2 million in net sales in 2023. |
| · | Robust Device Pipeline: TriSalus' technology pipeline includes a range of devices that use technology expected to substantially
improve therapeutic delivery. An FDA cleared delivery system for infusing immunotherapy into pancreatic adenocarcinoma patients is currently
under study at MD Anderson Cancer Center. The pipeline also includes a full suite of devices that allows interventional radiologists to
optimize therapy delivery across the broad range of solid tumor types, vessel sizes, and with greater precision using intra-procedural
flow dynamic data. The first new device expected in the expanded toolkit is the TriNav LV device, designed to optimally address larger
vessel sizes, which received 510(k) clearance by the FDA in May 2023 and is targeted for commercial launch in the first half of 2024. |
To accelerate TriSalus’ strategy, James “Jim”
Alecxih was recently appointed as President, Device Technology Business. Jim will oversee the development and expansion of the Company’s
portfolio of innovative infusion technologies.
| · | Therapeutic Platform in Clinical Development: TriSalus is developing SD-101, an investigational immunotherapeutic designed
to improve patient outcomes by treating the immunosuppressive environment created by many tumors – an environment that can make
current immunotherapies ineffective in the liver and pancreas. SD-101 is a class C TLR9 agonist with a dual mechanism of action and a
differentiated profile versus other TLR agonists. In solid tumors, the drug alters the tumor microenvironment by reducing immunosuppressive
myeloid-derived suppressor cells (MDSC) while simultaneously stimulating multiple immune cell types. |
Patient data generated during Pressure-Enabled Regional Immuno-Oncology™
(PERIO) clinical trials support the hypothesis that SD-101 delivered via PEDD may have favorable immune effects within the liver and systemically.
Currently SD-101 is being studied in three clinical trials for patients with uveal melanoma with liver metastases, intrahepatic cholangiocarcinoma,
hepatocellular carcinoma, and pancreatic ductal adenocarcinoma.
In the studies reported to date, SD-101 in combination with
systemic checkpoint inhibition and delivered with PEDD, achieved high concentrations in the liver with minimal systemic exposure and was
well tolerated based on a low SD-101 treatment related serious adverse event rate of 5%, and resulted in immune cell activation and natural
killer cell expansion. The immune effects in liver metastases and the blood are consistent with broad tumor microenvironment modulation
and the ability of SD-101 to deplete MDSCs in the liver. These findings were highlighted during an oral discussion session at ASCO 2023.
Additional Phase 1 data readouts for the PERIO clinical trial
program are planned in the fourth quarter of 2023 and a Phase 2 trial is scheduled to be initiated in the second half of 2023.
| · | Well Positioned with Cash Runway: Proceeds raised in connection with the merger with MedTech, including proceeds from the recently
closed private placement transaction and amounts remaining in the MedTech trust account, along with cash on hand, provides a cash runway
through mid-2024 to fund key milestones. |
Advisors
Cooley LLP is acting as legal counsel to
TriSalus. Raymond James is acting as exclusive financial advisor to MedTech and as the sole placement agent on the convertible offering,
and Paul Hastings LLP is serving as legal counsel to the placement agent. Foley & Lardner LLP is acting as legal counsel to MedTech.
For Patients
To learn more about the
clinical trial treatment protocol and enrollment, visit
http://www.periotrial.com or http://www.clinicaltrials.gov and search NCT04935229, NCT05220722, and NCT05607953.
Media Contact:
press@trisaluslifesci.com
Investor
Contact:
Aaron Palash / Allison Sobel
Joele Frank, Wilkinson Brimmer Katcher
+1 212 355 4449
About TriSalus Life Sciences
TriSalus Life Sciences® is an oncology company integrating
novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors.
The Company’s platform includes devices that utilize a proprietary
drug delivery technology and a clinical stage investigational immunotherapy. The Company’s two FDA-cleared devices use its proprietary
Pressure-Enabled Drug Delivery™ (PEDD) approach to deliver a range of therapeutics: the TriNav® Infusion System for
hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD is a novel
delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas. The PEDD approach modulates pressure
and flow in a manner that delivers more therapeutic to the tumor and is designed to reduce undesired delivery to normal tissue, bringing
the potential to improve patient outcomes. SD-101, the Company’s investigational immunotherapeutic candidate, is designed to improve
patient outcomes by treating the immunosuppressive environment created by many tumors and which can make current immunotherapies ineffective
in the liver and pancreas. Patient data generated during Pressure-Enabled Regional Immuno-Oncology™ (PERIO) clinical trials support
the hypothesis that SD-101 delivered via PEDD may have favorable immune effects within the liver and systemically.
In partnership with leading cancer centers across the country –
and by leveraging deep immuno-oncology expertise and inventive technology development – TriSalus is committed to
advancing innovation that improves outcomes for patients. Learn more at trisaluslifesci.com and follow
us on Twitter @TriSalusLifeSci and LinkedIn.
Forward-Looking Statements
Certain statements in this communication may be considered forward-looking
statements, including but not limited to statements regarding the Company’s revenue expectations for 2023, the Company’s expectations
that the proceeds from the business combination and related transactions provide a cash runway through 2024 and the potential to deploy
SD-101 into multiple indications across multiple lines of therapy. Forward-looking statements generally relate to future events and can
be identified by terminology such as “aim”, “may”, “should”, “could”, “might”,
“plan”, “possible”, “project”, “strive”, “budget”, “forecast”,
“expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”,
“predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar
terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to
differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon
estimates and assumptions that, while considered reasonable by MedTech and its management, and TriSalus and its management, as the case
may be, are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, but are
not limited to: the risk that the Business Combination disrupts current plans and operations of TriSalus; the outcome of any legal proceedings
that may be instituted against TriSalus or MedTech related to the Merger Agreement, or the Business Combination; changes in business,
market, financial, political and legal conditions; unfavorable changes in the reimbursement environment for TriSalus’ products;
TriSalus’ product candidates not achieving success in preclinical or clinical trials or not being able to obtain regulatory approval,
either on a timely basis or at all or subject to any conditions that negatively impact TriSalus’ ability to commercialize the applicable
product candidates; TriSalus being unable to continue to grow TriNav sales; the size of the addressable markets for TriNav and SD-101,
if successfully developed and approved by the applicable regulatory authorities, being less than TriSalus currently estimates; TriSalus’
ability to successfully commercialize any product candidates that it successfully develops and that are approved by applicable regulatory
authorities; TriSalus’ ability to continue to fund preclinical and clinical trials for SD-101; TriSalus’ ability to partner
with other companies; future economic and market conditions; the development, effects and enforcement of laws and regulations affecting
TriSalus’ business or industry; TriSalus’ ability to manage future growth; TriSalus’ ability to maintain and grow its
market share; the effects of competition on TriSalus’ business; the ability to implement business plans, forecasts and other expectations,
and identify and realize additional opportunities; the failure to realize the anticipated benefits of the Business Combination or to realize
estimated pro forma results and the underlying assumptions; and other risks and uncertainties set forth in the section entitled “Risk
Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the registration on Form S-4 and other documents
filed by the Company from time to time with the Securities and Exchange Commission. The foregoing list of factors is not exclusive. These
filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from
those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned
not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise
these forward-looking statements. The Company does not give any assurance that it will achieve its expectations.
v3.23.2
Cover
|
Aug. 10, 2023 |
Entity Addresses [Line Items] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Aug. 10, 2023
|
Current Fiscal Year End Date |
--12-31
|
Entity File Number |
001-39813
|
Entity Registrant Name |
TRISALUS
LIFE SCIENCES, INC.
|
Entity Central Index Key |
0001826667
|
Entity Tax Identification Number |
85-3009869
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
6272
W. 91st Ave.
|
Entity Address, City or Town |
Westminster
|
Entity Address, State or Province |
CO
|
Entity Address, Postal Zip Code |
80031
|
City Area Code |
888
|
Local Phone Number |
321-5212
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
Common Stock [Member] |
|
Entity Addresses [Line Items] |
|
Title of 12(b) Security |
Common
Stock, $0.0001 par value per share
|
Trading Symbol |
TLSI
|
Security Exchange Name |
NASDAQ
|
Warrant [Member] |
|
Entity Addresses [Line Items] |
|
Title of 12(b) Security |
Warrants,
each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 per share
|
Trading Symbol |
TLSIW
|
Security Exchange Name |
NASDAQ
|
Former Address [Member] |
|
Entity Addresses [Line Items] |
|
Entity Address, Address Line One |
MedTech
Acquisition Corporation
|
Entity Address, Address Line Two |
48
Maple Avenue
|
Entity Address, City or Town |
Greenwich
|
Entity Address, State or Province |
CT
|
Entity Address, Postal Zip Code |
06830
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEnd date of current fiscal year in the format --MM-DD.
+ References
+ Details
Name: |
dei_CurrentFiscalYearEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gMonthDayItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
dei_EntityAddressesLineItems |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
TriSalus Life Sciences (NASDAQ:TLSI)
Historical Stock Chart
From Aug 2024 to Sep 2024
TriSalus Life Sciences (NASDAQ:TLSI)
Historical Stock Chart
From Sep 2023 to Sep 2024